

EAU17 | LONDON

24-28 March 2017



Why do we form stones and how can we prevent them?

Poster Session 01

Friday, 24 March
09:00 - 10:30

Location: Room Milan, North Hall (Level 1)

Chairs: G. Gambaro, Rome (IT)
A. Rodgers, Cape Town (ZA)
A. Skolarikos, Athens (GR)

Aims and objectives of this presentation

The stone is not the disease! Unraveling the epidemiology and pathomechanisms of renal stone formation should be the aim of stone research. A thorough understanding of why crystals are retained is necessary to improve preventive concepts.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- 1 **Geographical and prevalence trends in urolithiasis in England: A ten-year review**
By: Ni Raghallaigh H., [Ellis D.](#), Symes A.
Institutes: Brighton & Sussex Univeristy Hospitals Nhs Trust, Dept. of Urology, Brighton, United Kingdom
- 2 **24-hour urine parameters and body mass index in a large cohort of high risk renal stone formers patients**
By: [Esperto E.](#)¹, Marangella M.², Miano R.³, Trinchieri A.⁴
Institutes:¹Sapienza University, Sant'andrea Hospital, Dept. of Urology, Rome, Italy, ²Mauritian's Order Hospital, Dept. of Nephrology, Turin, Italy, ³Policlinico Tor Vergata Foundation, University of Rome Tor Vergata, Dept. of Urology, Rome, Italy, ⁴Lecco's Hospital, Dept. of Urology, Lecco, Italy
- 3 **Twelve-hour overnight urine as a new tool to assess the urinary crystallization risk: Preliminary results**
By: [Casasayas Carles P.](#)¹, Rodriguez Garcia N.¹, Rodriguez A.², Saez-Torres C.², Gutierrez-Sanz-Gadea C.¹, Grases F.²
Institutes:¹Hospital Son Llatzer, Dept. of Urology, Palma De Mallorca, Spain, ²Universitat De Les Illes Balears, Laboratory of Kidney Stone Research. University Institute of Health Science Research (IUNICS-IdISP), Palma De Mallorca, Spain
- 4 **Hyperuricemia or uric-acid stone; which increase the risk of renal function deterioration**
By: [Tanaka T.](#), Htakeyama S., Terayama Y., Saitoh F., Saitoh H., Yamamoto H., Imai A., Yoneyama T., Hashimoto Y., Koie T., Ohyama C.
Institutes: Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan
- 5 **Urolithiasis is an independent risk factor for fracture: A nation-wide population-based and with an 8-year follow-up study**
By: [Chung H.J.](#)¹, Lin A.T-L.¹, Huang Y.H.¹, Lin C.C.¹, Chen T.J.², Chen K.K.¹
Institutes:¹Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan, ²Taipei Veterans General Hospital, Dept. of Family Medicine, Taipei, Taiwan
- 6 **Seeking explanations for the pathogenesis of kidney stones in studies of a relatively stone-free race group**
By: [Rodgers A.](#)
Institutes: University of Cape Town, Dept. of Chemistry, Cape Town, South Africa
- 7 **Endoscopic description of renal papillary abnormalities in stone disease by flexible ureteroscopy:**

A proposed classification of severity and type

By: Almeras C.¹, Daudon M.², Ploussard G.³, Gautier J.R.³, Salin A.³, Traxer O.⁴, Meria P.⁵

Institutes:¹Clinique Saint Jean Languedoc, Dept. of Urology, Toulouse, France, ²Tenon Hospital, Dept. of Functional Explorations, Paris, France, ³Clinique Saint Jean Languedoc, Dept of Urology, Toulouse, France, ⁴Tenon Hospital, Dept of Urology, Paris, France, ⁵Saint Louis Hospital, Dept of Urology, Paris, France

8

Calcium oxalate stone formation: Microstructural evaluation of Randall plaque and the plaque/stone interface

By: Wendt-Nordahl G.¹, Sethmann I.², Enzmann F.³, Simon L.³, Knoll T.¹, Klebe H.-J.²

Institutes:¹Klinikum Sindelfingen-Böblingen, Dept. of Urology, Sindelfingen, Germany, ²Technical University Darmstadt, Institut für Angewandte Geowissenschaften, Darmstadt, Germany, ³University Mainz, Institut für Geowissenschaften, Mainz, Germany

9

Association between polymorphisms in osteopontin gene (SPP1) and first episode calcium oxalate urolithiasis

By: Safarinejad M.R.

Institutes:Clinical Center for Urological Disease Diagnosis and Private Clinic Specialized In Urological and An, Dept. of Urology, Tehran, Iran

10

The association between the gene polymorphisms in the calcium-sensing receptor and calcium nephrolithiasis in Jiangxi Gannan area

By: Guoxi Z., Qingming Z., Xiaofeng Z., Quanliang L., Yijun X., Gengqing W., Xiaoning W., Bo J.

Institutes:Institute of Urology, Gannan Medical University, Dept. of Urology, First Affiliated Hospital of Gannan Medical University, Ganzhou, China

11

Characterizing the association between toll-like receptor types and nephrolithiasis with renal inflammation in an animal model

By: Ölçücü M.T.¹, Teke K.², Yalcin S.², Olcucuoglu E.³, Caner V.⁶, Turk N.S.⁵, Tuncay O.L.⁴

Institutes:¹Agri State Hospital, Dept. of Urology, Agri, Turkey, ²Agri State Hospital, Dept. of Urology, Agri, Turkey, ³Türkiye Yuksek Ihtisas Education and Research Hospital, Dept. of Urology, Ankara, Turkey, ⁴Pamukkale University School of Medicine, Dept. of Urology, Denizli, Turkey, ⁵Pamukkale University School of Medicine, Dept. of Pathology, Denizli, Turkey, ⁶Pamukkale University School of Medicine, Dept. of Genetics, Denizli, Turkey

13

Optimal management of cystine stone formers: 21-year retrospective follow-up study

By: Moore S.¹, Somani B.¹, Cook P.²

Institutes:¹University Hospital Southampton, Dept. of Urology, Southampton, United Kingdom, ²University Hospital Southampton, Dept. of Biochemical Pathology, Southampton, United Kingdom

14

Adherence of cystinuric patients to medical prevention treatment and its impact on clinical outcomes

By: Young G.², Kampantais S.¹, Stasinou T.², Bourdoumis A.³, Chow K.²

Institutes:¹Southend University Hospital, Dept. of Urology, Southend On Sea, United Kingdom, ²University Hospital of South Manchester, Dept. of Urology, Manchester, United Kingdom, ³Pennine Acute Hospitals NHS Trust, Dept. of Urology, Manchester, United Kingdom

15

Environmental melamine exposure increase renal tubular injury in patients with calcium urolithiasis: The possible mechanism of melamine associated urolithiasis formation

By: Liu C-C.¹, Wu C-F.², Hsieh T-J.³, Tsai Y-C.⁴, Huang S-P.⁵, Lee Y-C.⁵, Huang T-Y.⁵, Chou Y-H.⁵, Shen J-T.⁶, Huang C-N.⁵, Wu W-J.⁵, Wu M-T.⁷

Institutes:¹Kaohsiung Medical University Hospital, Kaohsiung Medical University, PingTung Hospital, Dept. of Urology, Kaohsiung/PingTung, Taiwan, ²Kaohsiung Medical University, Dept. of Public Health, College of Health Sciences, Kaohsiung, Taiwan, ³Kaohsiung Medical University, Graduate Institute of Medicine, Kaohsiung, Taiwan, ⁴Kaohsiung Medical University Hospital, Division of Nephrology, Dept. of Internal Medicine, Kaohsiung, Taiwan, ⁵Kaohsiung Medical University Hospital, Kaohsiung Medical University, Dept. of Urology, Kaohsiung, Taiwan, ⁶Kaohsiung Municipal Hsiao-Kang Hospital, Dept. of Urology, Kaohsiung, Taiwan, ⁷Kaohsiung

Treatment of high risk and oligo-metastatic prostate cancer

Poster Session 02

Friday, 24 March
09:00 - 10:30

Location: Room Amsterdam, North Hall (Level 1)

Chairs: B.J. Challacombe, London (GB)
S. Egawa, Tokyo (JP)
R.J. Karnes, Rochester (US)

Aims and objectives of this presentation

The aim of this session is to evaluate outcomes of treatments in high risk and oligo-metastatic prostate cancer

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- 17 **Attempted nerve sparing in high risk prostate cancer: Does it have an impact on oncological and functional outcomes? A retrospective long-term single center study**
By: [Furrer M.A.](#)¹, Gross T.¹, Nguyen D.P.¹, Boxler S.¹, Genitsch V.², Burkhard F.¹, Thalmann G.¹
Institutes:¹University Hospital Bern, Dept. of Urology, Bern, Switzerland, ²University Hospital Bern, Institute of Pathology, Bern, Switzerland
- 18 **Impact of preoperative risk on metastatic progression and cancer specific death in patients with adverse pathology at radical prostatectomy**
By: [Boehm K.](#)¹, Leyh-Bannurah S-R.², Rosenbaum C.², Budäus L.³, Graefen M.³, Haferkamp A.¹, Tilki D.³
Institutes:¹University Medical Center, Johannes Gutenberg University, Dept. of Urology and Pediatric Urology, Mainz, Germany, ²University Medical Center, Dept. of Urology, Hamburg, Germany, ³University Medical Center, Martini-Clinic, Hamburg, Germany
- 19 **Low rate of positive surgical margins are not associated with improved the biochemical recurrence in high-risk prostate cancer patients**
By: [Srougi V.](#)¹, Sanchez-Salas R.¹, Secin F.², Baghdadi M.¹, Nunes-Silva I.¹, Garcia-Barreras S.¹, Rembeyo G.¹, Rozet F.¹, Galiano M.¹, Barret E.¹, Cathelineau X.¹
Institutes:¹Institut Montsouris, Dept. of Urology, Paris, France, ²CEMIC and San Lazaro Foundation, Dept. of Urology, Buenos Aires, Argentina
- 20 **Association between type 2 diabetes and curative treatment in men with intermediate and high risk localised prostate cancer**
By: [Crawley D.](#)¹, Garmo H.¹, Rudman S.², Stattin P.³, Zethelius B.⁴, Holmberg L.¹, Adolfsson J.⁴, Van Hemelrijck M.¹
Institutes:¹King's College London, Dept. of Cancer Epidemiology, London, United Kingdom, ²Guy's and St Thomas NHS Foundation Trust, Dept. of Medical Oncology, London, United Kingdom, ³Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden, ⁴Karolinska Institute, Dept. of Clinical Science, Intervention and Technology, Stockholm, Sweden
- 21 **Improved recurrence-free survival in locally advanced prostate cancer after robot-assisted radical prostatectomy with 3D-cancer mapping constructed by MRI/US fusion biopsy**
By: [Kamoi K.](#), Okihara K., Hongo F., Naitoh Y., Iwata A., Kanazawa M., Ushijima S., Ukimura O.
Institutes:Kyoto Prefectural University of Medicine, Dept. of Urology, Kyoto, Japan
- 22 **Assessing the 20-year outcomes of radical prostatectomy for high risk prostate cancer: Results from a large, multi-institutional series**
By: [Bianchi M.](#)¹, Colicchia M.³, Gandaglia G.², Munegato S.⁴, Fossati N.², Bandini M.², Stabile A.²,

Dell'oglio P.², Suardi N.², Gontero P.⁴, Karnes J.³, Joniau S.⁵, Spahn M.⁶, Montorsi F.², Briganti A.²
Institutes:¹Magna Graecia University, Dept. of Urology, Catanzaro, Italy, ²Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ³Mayo Clinic, Dept. of Urology, Rochester, United States of America, ⁴Molinette Hospital, Dept. of Urology, Torino, Italy, ⁵University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ⁶University Hospital of Bern, Dept. of Urology, Bern, Switzerland

- 23 **Oncological and functional outcomes after RP for high or very high-risk prostate cancer – European validation of the current NCCN guideline**
By: Pompe R.S.¹, Gild P.², Chun F.², Salomon G.¹, Leyh-Bannurah S-R.¹, Huland H.¹, Graefen M.¹, Karakiewicz P.³, Tilki D.¹
Institutes:¹Universitätsklinikum Hamburg-Eppendorf, Martini Clinic and Dept. of Urology, Hamburg, Germany, ²Universitätsklinikum Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ³University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada
- 24 **Freedom from androgen deprivation and radiotherapy therapy after upfront minimally invasive surgery for high-risk prostate cancer**
By: Servián Vives P., Patel A., Winkler M.
Institutes:Imperial College Nhs Trust, Dept. of Urology, London, United Kingdom
- 25 **Survival associated with radical prostatectomy versus radiotherapy for high-risk prostate cancer: A contemporary, nationwide observational analysis**
By: Jindal T., Dalela D., Karabon P., Vetterlein M., Seisen T., Sood A., Trinh Q-D., Jeong W., Menon M., Abdollah F.
Institutes:Henry Ford Hospital, Dept. of Urology, Detroit, United States of America
- 26 **Impact of additional radiation and/or androgen deprivation therapy on functional outcomes after radical prostatectomy**
By: Tennstedt P.¹, Adam M.², Tilki D.¹, Steuber T.¹, Haese A.¹, Salomon G.¹, Petersen C.³, Huland H.¹, Graefen M.¹, Huber W.⁴, Schlomm T.¹
Institutes:¹University Medical Center Eppendorf, Martini-Klinik, Hamburg, Germany, ²University of Tuebingen, Dept. of Urology, Tuebingen, Germany, ³University Medical Center Eppendorf, Dept. of Radiooncology, Hamburg, Germany, ⁴European Molecular Biology Laboratory (EMBL), Genome Biology Unit, Hamburg, Germany
- 27 **Extended pelvic lymph node dissection for intermediate-high risk prostate cancer: Frequency and distribution of nodal metastases**
By: Roscigno M.¹, Nicolai M.¹, Naspro R.¹, Pellucchi F.¹, Cornaghi L.B.¹, Angiolilli D.¹, Chinaglia D.², Da Pozzo L.F.¹
Institutes:¹ASST Papa Giovanni XXIII, Dept. of Urology, Bergamo, Italy, ²ASST Papa Giovanni XXIII, Dept. of Pathology, Bergamo, Italy
- 28 **Predictors of early cancer specific and other cause mortality in high risk prostate cancer patients after radical prostatectomy: Results from a large, multi-institutional analysis**
By: Bianchi M.¹, Gandaglia G.¹, Fossati N.¹, Dell'oglio P.¹, Joniau S.², Colicchia M.³, Munegato S.⁴, Bandini M.⁵, Spahn M.⁶, Scattoni V.⁵, Gontero P.⁷, Karnes J.³, Montorsi F.⁵, Briganti A.⁵
Institutes:¹Vita-Salute University San Raffaele; Magna Graecia University, Dept. of Urology, Milan, Italy, ²University Hospital of Leuven, Dept. of Urology, Leuven, Belgium, ³Mayo Clinic, Dept. of Urology, Rochester, United States of America, ⁴University of Turin, Dept. of Urology, Turin, Italy, ⁵Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ⁶University Hospital of Bern, Dept. of Urology, Bern, Switzerland, ⁷University of Turin, Dept. of Urology, Turin, Switzerland
- 29 **Cytoreductive radical prostatectomy (cRP) is feasible in men with hormone-naive, metastatic prostate cancer (mPCA)**
By: Heidenreich A.¹, Briganti A.², Karnes J.³, Fossati N.², Gandaglia G.², Montorsi F.², Suardi N.², Colicchia M.³, Shariat S.⁴, Pfister D.¹
Institutes:¹Uniklinik Köln, Dept. of Urology, Cologne, Germany, ²Vita Salute San Raffaele University, Urological Research Institute, Milan, Italy, ³Mayo Clinic, Dept. of Urology, Rochester, United States

of America, ⁴Universitätsklinik Wien, Dept. of Urology, Vienna, Austria

31

Observation of preliminary clinical effect and analysis of perioperative complications of radical prostatectomy for patients with oligo-metastatic prostate cancer

By: Li G., Dai B., Ye D.

Institutes: Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

Joint Session of the European Association of Urology (EAU) and the Confederación Americana de Urología (CAU)

Urology beyond Europe

Friday, 24 March
09:30 - 13:00

Location: Room London, North Hall (Level 1)

Chairs: J. Gutierrez, Winston Salem (US)
J. Palou, Barcelona (ES)

09:30 - 09:35

Welcome and introduction

J. Gutierrez, Winston Salem (US)
J. Palou, Barcelona (ES)

09:55 - 10:15

Focal therapy for prostate cancer, is it ready for prime time?

R.E. Sanchez-Salas, Paris (FR)

09:35 - 09:55

High risk localised prostate cancer, radical prostatectomy versus radiotherapy

A. Briganti, Milan (IT)

10:15 - 10:35

Active surveillance for prostate cancer, whom and how?

C.H. Bangma, Rotterdam (NL)

10:35 - 10:55

Cytoreductive nephrectomy in kidney cancer, is still important?

P.F.A. Mulders, Nijmegen (NL)

10:55 - 11:15

Has robotic surgery made a real difference in cystectomy?

O. Castillo, Santiago (CL)

11:15 - 11:35

Upper tract tumour conservative management: New insights

A. Breda, Barcelona (ES)

11:35 - 11:55

Testosterone controversy, current guidelines

M. Sotomayor de Zavaleta, Mexico (MX)

11:55 - 12:15

Male LUTS: Which pills for what?

M.J. Drake, Bristol (GB)

12:15 - 12:35

Overactive Bladder: Differential diagnosis for appropriate management

J. Angulo Cuesta, Madrid (ES)

12:35 - 12:55

Complex stone cases, guidelines base discussion

12:35 - 12:55

Presenter:

J. Gutierrez, Winston Salem (US)

12:35 - 12:55

Discussants:

N. Bernardo, Buenos Aires (AR)
M. Cepeda, Valladolid (ES)

12:55 - 13:00

EAU Información a Pacientes

J.L. Vásquez, Copenhagen (DK)

Joint Session of the European Association of Urology (EAU) and World Chinese Urologists (CUA/TUA)

Urology beyond Europe

Friday, 24 March
09:30 - 13:00

Location: Room 7, Capital suite (level 3)

Chairs: T-L. Lin, Taipei (TW)
F. Montorsi, Milan (IT)
Y-H. Sun, Shanghai (CN)

Aims and objectives of this presentation

To promote the scientific exchange and collaboration between Chinese urologists and European urologists.

To provide better care for urological patients.

09:30 - 09:35

Welcome and introduction

T-L. Lin, Taipei (TW)
F. Montorsi, Milan (IT)
Y-H. Sun, Shanghai (CN)

09:35 - 09:45

EAU patient information - Chinese translation

T. Bach, Hamburg (DE)

09:45 - 10:15

Management of renal stones

Moderators: O. Traxer, Paris (FR)
K-H. Tsui, Taipei (TW)

To be confirmed

09:45 - 09:55

Innovative concepts in percutaneous nephrolithotomy: Lessons learned from 1200 cases

C-H. Shen, Chiayi (TW)

09:55 - 10:05

Complications after RIRS

L. Villa, Milan (IT)

10:05 - 10:15

Super-Mini PCNL for the treatment of renal stone

G-H. Zeng, Guangzhou (CN)

10:15 - 10:20

Discussion

10:20 - 10:55

Uro-oncology

Moderators: S. Shariat, Vienna (AT)
W-J. Wu, Kaohsiung (TW)
L-P. Xie, Hangzhou (CN)

10:20 - 10:30

The emergence of common actionable targets for cancer metastasis evolution: Precision medicine in urological cancer

T.-L. Cha, Taipei (TW)

10:30 - 10:40

Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing

M. Gerlinger, London (GB)

10:40 - 10:50

2017: Updates in China prostate cancer consortium

To be confirmed

10:50 - 10:55

Discussion

10:55 - 11:35

Endourology

Moderators:

To be confirmed

E. Liatsikos, Patras (GR)

C.T. Wu, Keelung (TW)

10:55 - 11:05

Laparoendoscopic Single-Site (LESS) retroperitoneal approach for nephroureterectomy

E.Y-H. Huang, Taipei (TW)

11:05 - 11:15

Retroperitoneal versus anterior approach in kidney cancer: When and why

G. Carrieri, Foggia (IT)

11:15 - 11:25

Sun's Tip Flexible Ureteroscope in the application of upper urinary tract surgeries

To be confirmed

11:25 - 11:35

Discussion

11:35 - 12:15

Urothelial cancer/Renal cancer

Moderators:

A. Alcaraz, Barcelona (ES)

Y.S. Pu, Taipei (TW)

To be confirmed

11:35 - 11:45

2017: Updates on aristolochic acid carcinogenesis

C. Chen, Taipei (TW)

11:45 - 11:55

Renal biopsy: More dogma belied

U. Capitanio, Milan (IT)

11:55 - 12:05

2017: Updates in Upper Urothelial Cancer in China

To be confirmed

12:05 - 12:15

Discussion

12:15 - 12:55

Functional Urology

Moderators:

Y.C. Chuang, Kaohsiung (TW)

M. Lazzeri, Florence (IT)

K-X. Xu, Beijing (CN)

12:15 - 12:25

Urinating in the standing position: A feasible alternative for women with knee osteoarthritis or detrusor underactivity

C.L. Chou, Taichung (TW)

12:25 - 12:35

Intradetrusor onabotulinumtoxinA injections: The best technique

T.M. Kessler, Zurich (CH)

12:35 - 12:45

Transperineal bulbo-prostatic anastomosis in patients with simple traumatic posterior urethral strictures: A 15 years retrospective study from a referral urethral center

F. Qiang, Shanghai (CN)

12:45 - 12:55

Discussion

12:55 - 13:00

Conclusion

T.L. Lin, Taipei (TW)

F. Montorsi, Milan (IT)

Y-H. Sun, Shanghai (CN)

4th ESO Prostate Cancer Observatory: Innovation and care in the next 12 months

Special session

Friday, 24 March
10:00 - 11:45

Location: Room Vienna, North Hall (Level 1)

Chairs: H. Van Poppel, Leuven (BE)
R. Valdagni, Milan (IT)

Aims and objectives of this presentation

ESO Observatories are high level sessions organized during major international congresses with the aim of providing the audience with updated and unbiased information on a given topic. An ESO Observatory lasts about 1 hour and half and concentrates on a forecast given by a panel of experts of what is expected to happen in their own field in the coming 12 months. The Panel includes distinguished clinicians and scientists and a patient advocate.

The forecast by each panelist is given in the form of take-home concise message with a 7 minute presentation followed by 3 minutes of discussion. The forecast will be discussed by the panel.

10:00 - 10:05

Introduction

H. Van Poppel, Leuven (BE)
R. Valdagni, Milan (IT)

10:05 - 10:15

The researcher's perspective

N. Zaffaroni, Milan (IT)

10:15 - 10:25

The urologist's perspective on surgery

D. Tilki, Hamburg (DE)

10:25 - 10:35

The urologist's perspective on active surveillance

S. Joniau, Leuven (BE)

10:35 - 10:45

The imaging specialist's perspective on MRI

C. Moore, London (GB)

10:45 - 10:55

The pathologist's perspective

T. Van der Kwast, Toronto (CA)

10:55 - 11:05

The radiation oncologist's perspective

M. Bolla, Grenoble (FR)

11:05 - 11:15

The medical oncologist's perspective

M. De Santis, Coventry (GB)

11:15 - 11:25

The imaging specialist's perspective on PSMA

U. Haberkorn, Heidelberg (DE)

11:25 - 11:35

The patient's perspective

L. Denis, Antwerp (BE)

11:35 - 11:45

Discussion and take home messages

Special session of the Prostate Cancer Prevention Group

Special session

Friday, 24 March
10:00 - 16:00

Location: Room Stockholm, North Hall (Level 1)

Chairs: To be confirmed
A. Stenzl, Tübingen (DE)
M. Wirth, Dresden (DE)

Aims and objectives of this presentation

Focus on how best to identify individuals for active surveillance and what the follow up protocols should be

10:00 - 10:05

Welcome and introduction

To be confirmed
A. Stenzl, Tübingen (DE)
M. Wirth, Dresden (DE)

10:05 - 11:00

Early detection

Moderator: J. Cuzick, London (GB)

10:05 - 10:20

Protect

F.C. Hamdy, Oxford (GB)

10:20 - 10:35

ERSPC

J. Hugosson, Göteborg (SE)

10:35 - 10:50

PLCO

To be confirmed

10:50 - 11:00

Question and answers

11:00 - 12:50

Risk factors and biomarkers for screening and triage

Moderator: A. Stenzl, Tübingen (DE)

11:00 - 11:15

Familial and genetic factors: New SNPs and panels

R.A. Eeles, London (GB)

11:15 - 11:30

Dietary and lifestyle factors

T. Key, Oxford (GB)

11:30 - 11:45

The role of miRNA in oncogenesis and progression

M. Wirth, Dresden (DE)

11:45 - 11:55

Questions and answers (Risk factors)

| | |
|---------------|---|
| 11:55 - 12:10 | Blood and urine based biomarkers J.A. Schalken, Nijmegen (NL) |
| 12:10 - 12:25 | Tissue-based biomarkers: CCP J. Cuzick, London (GB) |
| 12:25 - 12:40 | Imaging-based biomarkers: mpMRI P. Albers, Düsseldorf (DE) |
| 12:40 - 12:50 | Questions and answers (Biomarkers) |
| <hr/> | |
| 12:50 - 13:20 | Break |
| <hr/> | |
| 13:20 - 15:00 | Management of low-risk cancer and preventive therapy Moderator: M. Wirth, Dresden (DE) |
| 13:20 - 13:35 | Observation or active surveillance or curative treatment: What do PIVOT data tell us? To be confirmed |
| 13:35 - 13:50 | Observation or active surveillance or curative treatment: What do SPCG-4 data tell us? To be confirmed |
| 13:50 - 14:05 | Prospective validation of active surveillance: PRIAS C.H. Bangma, Rotterdam (NL) |
| 14:05 - 14:15 | Questions and answers (Management of low risk cancer) |
| 14:15 - 14:30 | 5-α reductase inhibitors: Do they prevent only low-grade disease and increase high-grade disease? C.G. Roehrborn, Dallas (US) |
| 14:30 - 14:40 | Aspirin M. Thorat, London (GB) |
| 14:40 - 14:50 | Nutraceuticals V. Fradet, Quebec (CA) |
| 14:50 - 15:00 | Questions and answers (Preventive therapy) |
| <hr/> | |
| 15:00 - 16:00 | Consensus panel discussion Moderator: J. Cuzick, London (GB) |

Joint Session of the European Association of Urology (EAU) and the Arab Association of Urology (AAU)

Urology beyond Europe

Friday, 24 March
10:30 - 13:00

Location: Room Munich, North Hall (Level 1)

Chairs: H. Abol-Enein, Mansoura (EG)
Y. Farahat, Tanta (EG)
M. Wirth, Dresden (DE)

Aims and objectives of this presentation

After this session the audience will gain the knowledge about some hot topics touching the clinical practice. How to treat stress incontinence in females without the need to implant a synthetic material and how to make the successful implantation of a penile prosthesis. Management of small renal mass needs to be outlined, Locally advanced prostate cancer became a curable disease, post prostatectomy incontinence need to be verified. How posterior urethroplasty is performed successfully. Organ sparing strategy is getting wider acceptance and lastly the use of ileum in reconstructive urological procedure.

10:30 - 10:40

Welcome and introduction

To be confirmed
M. Wirth, Dresden (DE)

10:40 - 11:20

Session I: Andrology and female urology

10:40 - 11:00

Stress urinary incontinence: I treat it without synthetic materials

C.R. Chapple, Sheffield (GB)

11:00 - 11:20

Penile prosthesis: How I do it to be successful

A. Shamsodini Takhtei, Doha - Waab (QA)

11:20 - 12:05

Session II: Reconstructive urology

11:20 - 11:35

Use of ileum in urology

H. Abol-Enein, Mansoura (EG)

11:35 - 11:50

Posterior urethroplasty: How I do it

To be confirmed

11:50 - 12:05

Postprostatectomy incontinence: How to avoid and how to manage

D.M. Castro Díaz, La Laguna Santa Cruz Tenerife (ES)

12:05 - 12:50

Session III: Oncology

12:05 - 12:20

Management of small renal mass

P.F.A. Mulders, Nijmegen (NL)

12:20 - 12:35

Organ sparing surgeries (kidney, ureter, bladder)

K. Al Othman, Riyadh (SA)

12:35 - 12:50

Locally advanced prostate cancer is a treatable disease
M. Wirth, Dresden (DE)

12:50 - 13:00

Discussion and closure

Joint Session of the European Association of Urology (EAU) and the Maghreb Union Countries

Urology beyond Europe

Friday, 24 March
10:30 - 13:00

Location: Room 4, Capital suite (level 3)

Chairs: A. Belaidi, Boufarik Blida (DZ)
A. Bouker, Tunis (TN)
F. Cruz, Porto (PT)
H.A. El Alj, Rabat (MA)

Aims and objectives of this presentation

As every year , this session is a very important opportunity which is aimed at meeting between experts EAU and Maghreb countries, for exchanging and enriching our knowledge around a very interesting scientific program of actuality..

Thanks a lot for the invitation.

Thank you for the organizers.

Dr . Abdelkader. Belaidi (Algerie)

10:30 - 10:35

Welcome and introduction

F. Cruz, Porto (PT)
H.A. El Alj, Rabat (MA)

10:35 - 11:00

BPH

10:35 - 10:50

TURP: Is the gold standard treatment of benign prostatic obstruction free of complications?

C. Djefal, Annaba (DZ)

10:50 - 11:00

Is laser prostatectomy ready to prime time in BPH surgery?

C. Llorente, Madrid (ES)

11:00 - 11:30

Bladder cancer

11:00 - 11:15

When to switch for a cystectomy in MNIBC?

M. Marzouk, Rabat (MA)

11:15 - 11:30

Lymphadenectomy in the treatment of invasive bladder tumour: Technique, extent, and oncological value

M. Babjuk, Prague 5 (CZ)

11:30 - 12:00

Stones

11:30 - 11:45

Epidemiology of urinary stones in Maghreb countries

K. Atallah, Tunis (TN)

11:45 - 12:00

Will flexible ureteroscopy replace PCNL?

O. Traxer, Paris (FR)

12:00 - 12:30

Kidney cancer

12:00 - 12:15

Which are my limits for a partial nephrectomy in a kidney tumour?

M. Lezrek, Meknes (MA)

12:15 - 12:30

The role of percutaneous biopsy in the management of renal tumours

A. Volpe, Novara (IT)

12:30 - 12:55

OAB male LUTS

12:30 - 12:40

Current management of OAB

To be confirmed

12:40 - 12:55

What to do if my BPH patient maintains bothersome storage LUTS

T. Antunes Lopes, Porto (PT)

12:55 - 13:00

Conclusions

F. Cruz, Porto (PT)

To be confirmed

Joint Session of the European Association of Urology (EAU) and the Pakistan Association of Urological Surgeons (PAUS)

Urology beyond Europe

Friday, 24 March
10:30 - 13:00

Location: Room 11, Capital suite (level 3)

Chairs: I. Korneyev, St. Petersburg (RU)
M. Sheriff, Gillingham, Kent (GB)

Aims and objectives of this presentation

In this session EAU & PAUS will collaboratively endeavour to provide an overview of the latest developments in these two important areas of Urological practice. The aim is to discuss ethical challenges and latest technical advances in renal transplantation and management of prostate cancer which is increasing in Pakistan.

10:30 - 10:35

Welcome and introduction

A. Mumtaz, Rahimyar Khan (PK)
C.R. Chapple, Sheffield (GB)

10:35 - 11:25

Renal transplantation

Moderators: A. Mahmood, Rawalpindi (PK)
J.D. Olsburgh, London (GB)

10:35 - 10:45

Technological advances in renal transplantation

J.D. Olsburgh, London (GB)

10:45 - 10:55

Donor nephrectomy: Transition to laparoscopy in Pakistan

To be confirmed

10:55 - 11:05

Current immunosuppressive regimens in renal transplantation

J.M. Campistol, Barcelona (ES)

11:05 - 11:15

Ethical challenges in organ transplantation: Where are we in Pakistan?

A. Rizvi, Karachi (PK)

11:15 - 11:25

State-of-the-art lecture: Postgraduate Urological Training in Pakistan & Europe: What can we learn from each other?

M.S. Khan, Orpington (GB)

11:25 - 11:40

Discussion

11:40 - 12:25

Prostate cancer

Moderators: To be confirmed
F. Montorsi, Milan (IT)

11:40 - 11:55

Management of prostate cancer: Update

F. Montorsi, Milan (IT)

11:55 - 12:10

Prostate cancer in Pakistan: Challenges in the management of an emerging problem

F. Abbas, Karachi (PK)

12:10 - 12:25

Discussion

12:25 - 12:55

Joint EAU-PAUS case discussion

12:25 - 12:55

Panel:

H. Ather, Karachi (PK)

F. Montorsi, Milan (IT)

Z. Qamar , Rawalpindi (PK)

12:25 - 12:40

Case 1

12:40 - 12:55

Case 2

12:55 - 13:00

Conclusion

To be confirmed

I. Korneyev, St. Petersburg (RU)

Joint Session of the European Association of Urology (EAU) and the Federation of ASEAN Urological Associations (FAUA)

Urology beyond Europe

Friday, 24 March
10:30 - 13:00

Location: Room 14, Capital suite (level 3)

Chairs: C.C.M. Lei, Kuching (MY)
J.W. Thüroff, Mannheim (DE)

Aims and objectives of this presentation

This session represents the best from FAUA (Federation of ASEAN Urological Associations), which was first formed in Kuala Lumpur in 1993. The ASEAN community is very diverse, with many areas under-served but with top of the range technology and expertise in the capital cities. The EAU – FAUA session is an excellent forum for ASEAN to collaborate not only with EAU but the rest of the world!

10:30 - 10:35

Welcome and introduction by chairs

10:35 - 10:45

Intraoperative tele-conferencing and tele-referral with smartphones: Evolution and current application in the Philippines

E.A. Arada III, Metro Manila (PH)

10:45 - 10:55

First 100 cases of robotic cystectomy: Hospital Kuala Lumpur, Malaysia

M. Sundram, Petaling Jaya (MY)

10:55 - 11:05

Choice of urinary diversion after radical cystectomies

V.L. Chuyen, Ho Chi Minh City (VN)

11:05 - 11:20

EAU Lecture: Continent urinary diversion: What lessons have we Learned?

J.W. Thüroff, Mannheim (DE)

11:20 - 11:25

Discussion

11:25 - 11:35

Contemporary management of elusive genitourinary tuberculosis: Asian perspective

T. Lwin, Yangon (MM)

11:35 - 11:45

RIRS to treat large kidney stones

E. Chotikawanich, Khonkaen (TH)

11:45 - 11:55

Pyeloplasty for UPJ obstruction, laparoscopy or robotic assisted

H.D. Ngo, Ho Chi Min City (VN)

11:55 - 12:05

Urethral stricture in a 100 million motorcycles-country: A multicentre study

K. Adi, Bandung (ID)

12:05 - 12:10

Discussion

12:10 - 12:20

EAU lecture: Surgery for high risk and oligometastatic prostate cancer

M. Wirth, Dresden (DE)

| | |
|---------------|---|
| 12:20 - 12:30 | Updates on metastatic prostate cancer treatment and their utility in Asia E. Chiong, Singapore (SG) |
| 12:30 - 12:45 | Prostate health index for prostate cancer detection and aggressiveness in Asian patients with the 4.0 to 10.0 ng/mL range B. Lojanapiwat, Chiang Mai (TH) |
| 12:45 - 12:55 | Discussion |
| 12:55 - 13:00 | Closing remarks by chairs |

Extracorporeal shock wave lithotripsy

Poster Session 03

Friday, 24 March
10:45 - 12:15

Location: Room Milan, North Hall (Level 1)

Chairs: To be confirmed
To be confirmed
To be confirmed

Aims and objectives of this presentation

ESWL has been the method of first choice in stone treatment for two decades. Endourology has now taken this role of many indications. However, the idea of (almost) no-touch stone disintegration is convincing and new technological developments may turn back the clock.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- 32 **CT texture analysis of ex vivo renal stones predicts ease of fragmentation with shock wave lithotripsy**
By: [Devlies W.](#)², [Cui H.](#)¹, [Ravenscroft S.](#)³, [Heers H.](#)⁴, [Freidin A.](#)⁵, [Cleveland R.](#)⁵, [Turney B.](#)¹
Institutes:¹University of Oxford, Oxford Stone Group, Oxford, United Kingdom, ²KU Leuven, Faculty of Medicine, Leuven, Belgium, ³University of Oxford, Medical Sciences Division, Oxford, United Kingdom, ⁴Philipps-Universität Marburg, Dept. of Urology and Paediatric Urology, Marburg, Germany, ⁵University of Oxford, Kennedy Institute of Rheumatology, Oxford, United Kingdom
- 33 **Predictive factors of the outcome of extracorporeal shockwave lithotripsy in the treatment of upper urinary tract stones: Evidence from a prospective study**
By: [Quaresima L.](#), [Pretore E.](#), [Moroni L.](#), [Galosi A.B.](#)
Institutes:Polytechnic University of The Marche Region, Dept. of Urology, Ancona, Italy
- 34 **Prediction for success rate of shock wave lithotripsy using mean stone density-stone heterogeneity index ratio calculating Hounsfield unit on non-contrast computed tomography**
By: [Jeong W.S.](#), [Kang D.H.](#), [Cho K.S.](#), [Ham W.S.](#), [Choi Y.D.](#), [Lee J.Y.](#)
Institutes:Severance Hospital, Urological Science Institute, Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea
- 35 **Ultrasonography is not inferior to fluoroscopy to guide extracorporeal shock waves during treatment of renal and upper ureteric calculi: A randomized prospective cohort study**
By: [Van Besien J.](#), [Uvin P.](#), [Merckx L.](#)
Institutes:AZ Sint Lucas Ghent, Dept. of Urology, Ghent, Belgium
- 36 **Pretreatment with low energy shockwaves and a 3-minute pause reduces markers of renal injury in patients undergoing extracorporeal shockwave lithotripsy**
By: [Ilyas R.](#), [Young G.](#), [Chow K.](#)
Institutes:University Hospital of South Manchester NHS Foundation Trust, Dept. of Urology, Manchester, United Kingdom
- 37 **Ultraslow High Power SWL, versus slow power ramping SWL in stones with high attenuation value**
By: [Al-Dessoukey A.](#), [Abdallah M.](#), [Sayed O.](#), [Abdallah R.](#), [Moussa A.](#), [Massoud A.](#)
Institutes:Beni Suef University, Dept. of Urology, Cairo, Egypt
- 38 **Dual shockwave and using high-flow oxygen administration by nasal cannula (HFONC) may improve lithotripsy results**
By:

- Gatkin M., Sopotov A., Raikin I.
Institutes:Zdorovie Center, Dept. of Urology, Barnaul, Russia
- 39 **Ureteral stenting can be a negative predictor for successful outcome following shock wave lithotripsy in patients with ureteral stones**
By: Oh K.T., Kang D.H., Cho K.S., Ham W.S., Chung D.Y., Kwon J.K., Choi Y.D., Lee J.Y.
Institutes:Severance Hospital, Urological Science Institute, Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea
- 40 **Impact of pretreatment hydronephrosis on the success rate of shock wave lithotripsy in patients with ureteral calculi**
By: Chang K.D., Lee J.Y., Ham W.S., Kang D.H., Cho K.S.
Institutes:Severance Hospital, Urological Science Institute, Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea
- 41 **Adjuvant alpha blockers to extracorporeal shock wave lithotripsy: A randomized controlled trial**
By: Lanchon C., Ronna M., Descotes J-L., Rambeaud J-J., Fiard G., Thuillier C., Terrier N., Pic G., Boillot B., Long J-A.
Institutes:Grenoble University Hospital, Dept. of Urology, Grenoble Cedex 9, France
- 43 **Does previous stone surgery affect the outcome of SWL treatment in adults with kidney stones?**
By: Gültekin M.H.¹, Turegun F.A.¹, Ozkan B.², Tansu N.¹, Kendigelen P.³, Erozcenci A.¹, Onal B.¹
Institutes:¹Cerrahpasa Medical Faculty, Dept. of Urology, Istanbul, Turkey, ²Acibadem University, Dept. of Urology, Istanbul, Turkey, ³Cerrahpasa Medical Faculty, Dept. of Anesthesiology, Istanbul, Turkey
- 44 **Does shockwave lithotripsy impair urine pH? Results of the prospective Swiss Kidney Stone Cohort register**
By: Skuginna V.¹, Mohebbi N.², Fuster D.¹, Kim M-J.³, Wagner C.², Wuerzner G.⁴, Dhayat N.², Bonny O.⁵, Roth B.¹
Institutes:¹University Hospital Bern, Dept. of Urology and Nephrology, Bern, Switzerland, ²University Hospital Zürich, Dept. of Urology and Nephrology, Zürich, Switzerland, ³University Hospital Basel, Dept. of Urology and Nephrology, Basel, Switzerland, ⁴University Hospital Geneva, Dept. of Urology and Nephrology, Geneva, Switzerland, ⁵University Hospital Lausanne, Dept. of Urology and Nephrology, Lausanne, Switzerland
- 45 **Extracorporeal shock-wave lithotripsy (ESWL) for renal stones is associated with decreased kidney function after long term follow-up**
By: Fankhauser C.¹, Grogg J.¹, Holenstein A.¹, Zhong Q.², Steurer J.³, Hermanns T.¹, Sulser T.¹, Poyet C.¹
Institutes:¹University Hospital of Zurich, Dept. of Urology, Zurich, Switzerland, ²University Hospital of Zurich, Dept. of Pathology of Molecular Pathology, Zurich, Switzerland, ³University Hospital of Zurich, Horten Centre for Patient Oriented Research and Knowledge Transfer, Zurich, Switzerland
- 46 **Extracorporeal shock wave lithotripsy (ESWL) monotherapy in children; predictors of successful outcome**
By: Alsagheer G., Abdel-Kader M., Hasan A., Mohamed O., Atef F., Mahmoud O., Abolyosr A.
Institutes:South Valley University, Dept. of Urology, Qena, Egypt
- 47 **Urinary tract infections raise risk for renal hematoma after shock-wave lithotripsy**
By: Schregel C., John H., Keller I., Randazzo M.
Institutes:Kantonsspital Winterthur, Dept. of Urology, Winterthur, Switzerland

Renal and adrenal complex surgery

Video Session 01

Friday, 24 March
10:45 - 12:15

Location: Room Paris, North Hall (Level 1)

Chairs: To be confirmed
G. Janetschek, Salzburg (AT)
M. Musquera Felip, Barcelona (ES)

Aims and objectives of this presentation

This session focuses mainly on different indications for and techniques of robot assisted laparoscopic surgery. Robotic partial nephrectomy is close to become standard. Adrenalectomy, one of the first and best indications for standard laparoscopy, is increasingly performed by means of robot-assisted surgery – including partial adrenalectomy and the transdiaphragmatic approach – and this session will show the advantages. Caval thrombus due to RCC is one of the few indications where open surgery remains indispensable; the technique is presented.

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

- V01 **Robotic nephroureterectomy without undocking or patient repositioning: Surgical technique**
By: [Hugues G.](#), Pillot P., Delpech P.O., Bernardeau S., Charles T., Celhay O.
Institutes: Poitiers University Hospital, Dept. of Urology, Poitiers, France
- V02 **Da Vinci Xi robot-assisted adrenalectomy for masses larger than 4 cm: Experience from a single high volume centre**
By: [Buffi N.](#)¹, Lughezzani G.², Lista G.², Maffei D.², Pescechera R.², Benetti A.¹, Pasini L.¹, Zandegiacomo S.¹, Forni G.¹, Lazzeri M.¹, Casale P.¹, Saita A.¹, Hurle R.¹, Bozzini G.³, Taverna G.³, Guazzoni G.⁴
Institutes: ¹Humanitas University, Dept. of Urology, Milan, Italy, ²Istituto clinico Humanitas, IRCCS, Dept. of Urology, Milan, Italy, ³Humanitas Mater Domini, Dept. of Urology, Castellanza, Italy, ⁴Istituto Clinico Humanitas, IRCCS, Humanitas University, Dept. of Urology, Castellanza, Italy
- V03 **Robot-assisted laparoscopic partial adrenalectomy for aldosterone-producing adenomas**
By: [Spahn M.](#), Metzger T., Boxler S., Thalmann G.
Institutes: Inselspital - Universitätsspital Bern, Dept. of Urology, Bern, Switzerland
- V04 **Robotic-assisted thoracoscopic transdiaphragmatic adrenalectomy (RATTA) for metastatic renal cell carcinoma**
By: Russell C.¹, [Salami S.](#)¹, Lebastchi A.¹, Lagisetty K.², Hafez K.¹, Reddy R.¹, Weizer A.¹
Institutes: ¹University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ²University of Michigan, Dept. of Surgery, Ann Arbor, United States of America
- V05 **A simplified approach of robotic partial nephrectomy**
By: [Peyronnet B.](#), Alimi Q., Fardoun T., Mathieu R., Verhoest G., Bensalah K.
Institutes: CHU Rennes, Dept. of Urology, Rennes, France
- V06 **Clampless robot-assisted laparoscopic partial nephrectomy for large renal masses**
By: [Brassetti A.](#)¹, Del Vecchio G.², Emiliozzi P.², Martini M.², Pansadoro A.², Scarpone P.², Pansadoro V.²
Institutes: ¹Sant'andrea Hospital, Dept. of Urology, Rome, Italy, ²Laparoscopic and Oncological Urology Centre, "Pio IX" Hospital, Fondazione Vincenzo Pansadoro, Dept. of Urology, Rome, Italy

V08

Transmesocolic laparoscopic partial nephrectomy for RCC in a horseshoe kidney

By: Kochkin A.¹, Gallyamov E.², Martov A.³, Sevryukov F.¹, Knutov A.¹, Sergeev V.³, Novikov A.⁴

Institutes:¹Urological Center of Russian Railways Hospital, Dept. of Urology, Nizhny Novgorod, Russia, ²Aleksandr Evdokimov Moscow State University of Medicine and Dentistry, Dept. of Urology, Moscow, Russia, ³Avetik Burnazian Federal Scientific Medical Biophysical Center FMBA, Dept. of Urology, Moscow, Russia, ⁴Medical Center of Bank of Russia, Dept. of Urology, Moscow, Russia

Treatment of advanced prostate cancer - If, when and what?

Poster Session 04

Friday, 24 March
10:45 - 12:15**Location:** Room Amsterdam, North Hall (Level 1)**Chairs:** S. Bracarda, Arezzo (IT)
P. Cornford, Liverpool (GB)
A.S. Merseburger, Lübeck (DE)**Aims and objectives of this presentation**

Data about new and available approaches for systemic treatment of prostate cancer and management of nodal disease will be presented. Differential indication of hormone ablation versus other forms of systemic treatments will be discussed together with long – term effects of androgen deprivation therapy.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- 48 **Improved survival in patients diagnosed with metastatic prostate cancer – a nationwide analysis**
By: [Helgstrand J.T.](#)¹, Klemann N.¹, Toft B.², Vainer B.², Brasso K.¹, Brooks J.³, Iversen P.¹, Røder M.¹
Institutes:¹Copenhagen University Hospital, Rigshospitalet, Copenhagen Prostate Cancer Center, Dept. of Urology, Copenhagen, Denmark, ²Copenhagen University Hospital, Rigshospitalet, Dept. of Pathology, Copenhagen, Denmark, ³Stanford University Hospital, Dept. of Urology, Stanford, United States of America
- 49 **Testing the external validity of ProtecT trial results in North American men with clinically localized prostate cancer (PCa)**
By: [Abdollah F.](#)¹, Nocera L.¹, Sood A.¹, Dalela D.¹, Karabon P.¹, Rogers C.¹, Peabody J.¹, Briganti A.², Montorsi F.², Menon M.¹
Institutes:¹Henry Ford Hospital / Health System, Dept. of Urology, Detroit, United States of America, ²IRCCS San Raffaele, Dept. of Urology, Milan, Italy
- 50 **What is the optimal post-operative management of men with lymph node recurrent prostate cancer after salvage lymph node dissection? Results from a large, multi-institutional series**
By: [Briganti A.](#)¹, Fossati N.¹, Suardi N.¹, Bandini M.¹, Colicchia M.⁶, Karnes J.R.⁶, Haidl F.⁷, Pfister D.⁷, Porres D.⁷, Heidenreich A.⁷, Herlemann A.⁹, Gratzke C.⁹, Stief C.⁹, Battaglia A.⁴, Everaerts W.⁴, Joniau S.⁴, Van Poppel H.⁴, Aksenov A.V.⁸, Osmonov D.K.⁸, Juenemann K.P.⁸, Abreu A.D.L.³, Almeida F.³, Fay C.², Gill I.², Mottrie A.M.⁵, Montorsi F.¹
Institutes:¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²Keck School of Medicine, University of Southern California, USC Institute of Urology, Los Angeles, United States of America, ³Phoenix Imaging Center, Dept. of Urology, Phoenix, United States of America, ⁴University Hospitals Leuven, Dept of Development and Regeneration, Leuven, Belgium, ⁵OLV Ziekenhuis Aalst, Dept. of Urology, Melle, Belgium, ⁶Mayo Clinic, Dept. of Urology, Rochester, United States of America, ⁷University of Cologne, Dept. of Urology, Cologne, Germany, ⁸University Hospital Schleswig Holstein, Dept. of Urology and Pediatric Urology, Campus Kiel, Germany, ⁹Ludwig-Maximilians-University, Dept. of Urology, Munich, Germany
- 51 **Salvage lymph node dissection in nodal recurrent prostate cancer is not devoid of complications: Results from a single tertiary referral center**
By: [Dell'Oglio P.](#)¹, Gandaglia G.¹, Stabile A.¹, Fossati N.¹, Bianchi M.², Bravi C.¹, Zaffuto E.¹, Bandini M.¹, Fallara G.¹, Gallina A.¹, Suardi N.¹, Rigatti P.³, Montorsi F.¹, Briganti A.¹
Institutes:¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²Magna Graecia University, Dept. of Urology, Catanzaro, Italy, ³Advanced Urotechnology Center, Scientific Institute "Istituto Auxologico Italiano", Dept. of Urology, Milan, Italy

- 52 **Phase III study of intermittent monotherapy versus continuous combined androgen deprivation**
By: [Calais Da Silva Junior F.](#)¹, Calais Da Silva Senior F.¹, Gonçalves F.², Kliment J.³, Santos A.⁴, Pastidis S.⁵, Queimadelos A.⁶, Robertson C.⁷
Institutes:¹CHLC - Hospital de São José, Dept. of Urology, Lisbon, Portugal, ²CUIMED A Saint Michal Hospital, Dept. of Urology, Bratislava, Slovakia, ³Jessenius Schooll of Medicine, Dept. of Urology, Martin, Slovakia, ⁴Hospital De Braga, Dept. of Urology, Braga, Portugal, ⁵Amalia Fleming Hospital, Dept. of Urology, Athens, Greece, ⁶Policlinica La Rosaleda, Dept. of Urology, Santiago Compostela, Spain, ⁷University of Stracthclyde, Dept. of Urology, Glasgow, United Kingdom
- 53 **Chemical castration decreased the risk of dementia in patient with prostate cancer - From 13368 patients, Taiwan national health insurance research database**
By: [Hong J.](#), Liao C., Huang C., Lu Y.
Institutes:National Taiwan University Hospital, Dept. of Urology, Taipei, Taiwan
- 54 **Testosterone recovery after long time androgen deprivation therapy: The role of duration of deprivation in combination with other predictive factors**
By: [Borque Fernando A.](#)¹, Estrada-Domínguez F.², Esteban L.³, Gil Sanz M.J.⁴, Sanz Saiz G.⁵
Institutes:¹Hospital Universitario Miguel Servet, Dept. of Uology, Zaragoza, Spain, ²Hospital Universitario "Miguel Servet" (IIS Aragón), Dept. of Urology, Zaragoza, Spain, ³Universidad De Zaragoza, Escuela Universitaria Politécnica De La Almunia, Zaragoza, Spain, ⁴Hospital Universitario Miguel Servet, Dept. of Urology, Zaragoza, Spain, ⁵Universidad De Zaragoza, Dept. of Statistical Methods, Zaragoza, Spain
- 55 **Survival following primary androgen deprivation therapy or watchful waiting among older men with localized prostate cancer**
By: [Seikkula H.](#)¹, Boström P.², Rantanen M.³, Pitkäniemi J.³, Malila N.³, Kaipia A.⁴
Institutes:¹Central Hospital of Central Ostrobothnia, Dept. of Urology, Kokkola, Finland, ²Turku University Hospital, Dept. of Urology, Turku, Finland, ³Finnish Cancer Registry, Institute For Statistical and Epidemiological Cancer Research, Helsinki, Finland, ⁴Satakunta Hospital District, Dept. of Urology, Pori, Finland
- 56 **Does prostate cancer represent the main cause of death in all node positive prostate cancer patients? The impact of competing causes of mortality according to tumor characteristics and recurrence status**
By: [Dell'Oglio P.](#)¹, Zaffuto E.¹, Stabile A.¹, Gandaglia G.¹, Colicchia M.², Fossati N.¹, Capitanio U.¹, Dehò F.¹, Colombo R.¹, Bertini R.¹, Montorsi F.¹, Karnes J.³, Briganti A.¹
Institutes:¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²Mayo Clinic, Dept. of Urology, Rochester, United States of America, ³Mayo Clinic, Dept. of Urology, Rochester, Mn, United States of America
- 57 **Radium-223 (Ra-223) in sequence or in concurrent use with abiraterone acetate (AA) or enzalutamide (E) in metastatic castration resistant prostate cancer (mCRPC) patients treated in an international early access program (iEAP)**
By: [Saad F.](#)¹, Heinrich D.², Gillessen S.³, O'sullivan J.⁴, Carles J.⁵, Wirth M.⁶, Miller K.⁷, Huang L.⁸, Seger M.⁹, Nilsson S.¹⁰, Heidenreich A.¹¹
Institutes:¹University of Montreal Hospital Center, Dept. of GU Oncology, Montréal, Canada, ²Akershus University Hospital,, Dept. of Oncology, Lørenskog, Norway, ³Kantonsspital St Gallen,, Dept. of Oncology, St Gallen, Switzerland, ⁴The Northern Ireland Cancer Centre, Dept. of Radiation Oncology, Belfast, United Kingdom, ⁵Vall D' Hebron University Hospital,, Dept. of Medical Oncology, Barcelona, Spain, ⁶University Hospital Carl-Gustav Carus, Dept. of Urology, Dresden, Germany, ⁷Charité University Medicine Berlin, Dept. of Urology, Berlin, Germany, ⁸Pharmaceutical Division of Bayer, Dept. of Statistics, Whippany, United States of America, ⁹Pharmaceutical Division of Bayer, Dept. of Global Medical Affairs, Whippany, United States of America, ¹⁰Karolinska University Hospital, Dept. of Oncology, Stockholm, Sweden, ¹¹University Hospital Cologne, Dept. of Urology, Cologne, Germany
- 58 **The importance of imaging studies to monitor treatment with novel AR-targeted agents in**

metastatic castration resistant prostate cancer (mCRPC)

By: Heidegger L., Kohl T., Pfister D., Friederike H., Paffenholz P., Heidenreich A.

Institutes: Uniklinik Köln, Dept. of Urology, Köln, Germany

59

Does nadir testosterone at the end of long term androgen deprivation therapy predict outcomes in high risk prostate cancer? Data from a phase III trial

By: Nabid A.¹, Garant M-P.², Martin A-G.³, Souhami L.⁴, Duclos M.⁴, Bahary J-P.⁵, Lemaire C.⁶, Vass S.⁷, Archambault R.⁸, Vincent F.⁹, Bahoric B.¹¹, Bettahar R.¹⁰

Institutes:¹Centre Hospitalier Universitaire De Sherbrooke, Dept. of Radio-Oncology, Sherbrooke, Canada, ²Centre Hospitalier Universitaire De Sherbrooke, Biostatistical Services, Sherbrooke, Canada, ³Centre Hospitalier Universitaire De Québec, Dept. of Radio-Oncology, Québec, Canada, ⁴Centre Universitaire De Santé McGill, Dept. of Radio-Oncology, Montréal, Canada, ⁵Centre Hospitalier Universitaire De Montréal, Dept. of Radio-Oncology, Montréal, Canada, ⁶Hôpital Maissonneuve-Rosemont, Dept. of Radio-Oncology, Montréal, Canada, ⁷Centre De Santé Et Services Sociaux De Chicoutimi, Dept. of Radio-Oncology, Chicoutimi, Canada, ⁸Hôpital De Gatineau, Dept. of Radio-Oncology, Gatineau, Canada, ⁹Centre Hospitalier Régional De Trois-Rivières, Dept. of Radio-Oncology, Trois-Rivières, Canada, ¹⁰Centre Hospitalier Régional De Rimouski, Dept. of Radio-Oncology, Rimouski, Canada, ¹¹Hôpital Général Juif de Montréal, Dept. of Radio-Oncology, Montreal, Canada

60

Semi-ecologic, nationwide, population-based study of GnRH agonists, orchiectomy and risk of cardiovascular disease

By: Stattin P.¹, Thomsen F.B.², Sandin F.³, Garmo H.⁴, Ahlgren G.⁵, Lissbrant I.F.⁶, Van Hemelrijck M.⁴, Adolfsson J.⁷, Robinson D.⁸

Institutes:¹Uppsala University Hospital, Dept. of Surgical Sciences, Uppsala, Sweden, ²Rigshospitalet, University of Copenhagen, Copenhagen Prostate Cancer Center, Dept. of Urology, Copenhagen, Denmark, ³Uppsala University Hospital, Regional Cancer Centre Uppsala Örebro, Uppsala, Sweden, ⁴King's College London, School of Medicine, Dept. of Cancer Studies, Cancer Epidemiology Group, London, United Kingdom, ⁵SUS Malmö, Dept. of Urology, Malmö, Sweden, ⁶University of Gothenburg, Dept. of Oncology, Gothenburg, Sweden, ⁷Karolinska Institutet, CLINTEC-Dept, Stockholm, Sweden, ⁸Umeå University Hospital, Dept. of Surgical and Perioperative Sciences, Umeå, Sweden

12:00 - 12:10

Advanced prostate cancer - A wide range of treatment options and challenges

A.S. Merseburger, Lübeck (DE)

New technologies in minimal invasive techniques and new imaging techniques

Poster Session 05

Friday, 24 March
10:45 - 12:15

Location: Room Berlin, North Hall (Level 1)

Chairs: T. Ahlering, Orange (US)
H. Fukushima, Tokyo (JP)
F. Greco, Crotone (IT)

Aims and objectives of this presentation

To assess the horizon for new technologies for minimal invasive treatments and intraoperative imaging

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- 61 **Prognostic value of vibrational infrared micro-imaging spectroscopy in renal clear cell adenocarcinoma with a metastasis predictive algorithm in a big data spectral model**
By: [El-Bakri A.](#)¹, [Vuible V.](#)¹, [Nguyen Q.](#)¹, [Eymard J-C.](#)³, [Larré S.](#)², [Piot O.](#)¹
Institutes:¹Médian Biophotonique Et Technologies Pour La Santé, Université De Reims Champagne-Ardenne, Urca Umr Cnrs 7369 Medyc, Reims, France, ²Robert Debré Teaching Hospital, Dept. of Urology, Reims, France, ³Institut Jean Godinot, Dept. of Oncology, Reims, France
- 62 **Initial assessment of clinical feasibility, safety and efficacy of NanoKnife irreversible electroporation (IRE) in the focal treatment of localized renal cell carcinoma (RCC) with delayed interval tumor resection (IRENE trial)**
By: [Wendler J.J.](#)¹, [Ricke J.](#)², [Pech M.](#)², [Fischbach F.](#)², [Jürgens J.](#)², [Porsch M.](#)¹, [Janitzky A.](#)³, [Baumunk D.](#)³, [Siedentopf S.](#)⁴, [Köllermann J.](#)⁵, [Schostak M.](#)³, [Liehr U-B.](#)³
Institutes:¹University Magdeburg, Dept. of Urology, Magdeburg, Germany, ²University Magdeburg, Dept. of Radiology, Magdeburg, Germany, ³University Magdeburg, Dept. of Urology, Magdeburg, Germany, ⁴University Magdeburg, Dept. of Pathology, Magdeburg, Germany, ⁵Sana Medical Center, Dept. of Pathology, Offenbach, Germany
- 63 **Novel three-dimensional bone 'mapping' software can help assess progression of osseous prostate cancer metastases from routine CT**
By: [Thurtle D.](#)¹, [Treece G.](#)², [Barrett T.](#)³, [Gnanapragasam V.](#)¹
Institutes:¹University of Cambridge, Dept. of Urology, Cambridge, United Kingdom, ²University of Cambridge, Dept. of Engineering, Cambridge, United Kingdom, ³University of Cambridge, Dept. of Radiology, Cambridge, United Kingdom
- 64 **Percutaneous unroofing-less invasive approach for renal cyst management**
By: [Hu J.](#), [Yu X.](#), [Wang S.](#), [Ye Z.](#)
Institutes:Tongji Hospital, Tongji Medical College, Huazhong University Of Science And Technology, Dept. of Urology, Wuhan, China
- 65 **Transurethral en bloc resection of bladder tumor with a dual channelized flexible cystoscope using an Impact Shooter: Preliminary results in human cadavers embalmed by Thiel's model**
By: [Morizane S.](#)¹, [Maeda T.](#)², [Nishikawa R.](#)¹, [Honda M.](#)¹, [Ikebuchi Y.](#)³, [Matsumoto K.](#)³, [Ueki M.](#)⁴, [Masumori N.](#)², [Fujimiya M.](#)⁵, [Takenaka A.](#)¹
Institutes:¹Tottori University, Faculty of Medicine, Dept. of Urology, Yonago, Japan, ²Sapporo Medical University School of Medicine, Dept. of Urology, Sapporo, Japan, ³Tottori University, Faculty of Medicine, Dept. of Gastroenterology, Yonago, Japan, ⁴Tottori University Hospital, Center for Promoting Next-Generation Highly Advanced Medicine, Yonago, Japan, ⁵Sapporo Medical University School of Medicine, Dept. of Anatomy, Sapporo, Japan

- 66 **3D prostate MRI reconstruction for cognitive robot assisted radical prostatectomy: Is it able to reduce the positive surgical margin rate?**
By: Porpiglia E., Manfredi M., Checcucci E., Mele F., Bertolo R., De Luca S., Garrou D., Cattaneo G., Amparore D., Fiori C.
Institutes: San Luigi Hospital, Dept. of Urology, Turin, Italy
- 67 **Evaluation of ex-vivo and in-vivo biomarkers in different stages of prostatic cancer**
By: Theil G., Schietinger C., Kersten K., Schumann A., Fornara P.
Institutes: Clinic of Urology and Kidney Transplantation Center, Dept. of Martin-Luther University, Halle/ Saale, Germany
- 68 **Hypothermic nerve-sparing radical prostatectomy facilitates earlier recovery of potency at one year**
By: Ko Y-H., Skarecky D., Huynh L., Ahlering T.
Institutes: University of California, Irvine, Dept. of Urology, Orange, United States of America
- 69 **Novel ex vivo endoscopic near infrared fluorescence imaging method using pHLIP®/ICG in patients undergoing radical cystectomy for urothelial carcinoma of the bladder**
By: Brito J.¹, Golijanin B.¹, Tran T.¹, Moshnikova A.², Gershman B.¹, Engelman D.³, Reshetnyak Y.², Andreev O.², Amin A.⁴, Golijanin D.¹
Institutes: ¹Rhode Island Hospital and The Miriam Hospital, Dept. of Urology, Providence, United States of America, ²University of Rhode Island, Dept. of Physics, Kingston, United States of America, ³Yale University, Molecular Biophysics and Biochemistry, New Haven, United States of America, ⁴Rhode Island Hospital and The Miriam Hospital, Dept. of Pathology, Providence, United States of America
- 70 **Application of the radio-guided occult lesion localization (ROLL) technique for renal lumpectomy (RE-ROLL): From the laboratory to the patient**
By: Vera Donoso C.D.¹, Betancourt-Hernandez J.¹, Martinez-Sarmiento M.¹, Monserrat-Monfort J.J.¹, Avargues-Pardo A.¹, Vera-Pinto V.², Sopena-Novales P.², Torres-Espallardo I.², Bello-Jarque P.², Boronat-Tormo F.¹
Institutes: ¹La Fe, University and Polytechnic Hospital, Dept. of Urology, Valencia, Spain, ²La Fe, University and Polytechnic Hospital, Dept. of Nuclear Medicine, Valencia, Spain
- 71 **Mini-laparoscopic single-site partial nephrectomy with early unclamped technique for renal tumors with intermediate PADUA score (IDEAL phase 2a)**
By: Greco E.¹, Alba S.², Bottone F.², Mohammed N.¹, Kawan F.¹, Mirone V.³, Fornara P.¹
Institutes: ¹Martin-Luther University, Dept. of Urology, Halle Saale, Germany, ²Romolo Hospital, Dept. of Urology, Rocca Di Neto, Italy, ³Federico II University, Dept. of Urology, Naples, Italy
- 73 **Thulium laser vapo-enucleation of the prostate according to the mushroom technique: Preliminary results**
By: Kara N., Cudas Duarte R., Fassy Fehri H.
Institutes: Hôpital Édouard-Herriot, Dept. of Urology, Lyon, France
- 74 **Utility of diffusion-weighted magnetic resonance imaging of testes in azoospermia: Correlation between apparent diffusion coefficient and histological patterns of spermatogenesis**
By: Han B.H.¹, Park S.B.², Choe J.H.³, Seo J.T.⁴, Chun Y.K.⁵
Institutes: ¹Cheil General Hospital, Dankook University College Of Medicine, Dept. of Radiology, Seoul, South Korea, ²Chung-Ang University College of Medicine, Dept. of Radiology, Seoul, South Korea, ³Cheil General Hospital, Dankook University College Of Medicine, Dept. of Urology, Seoul, South Korea, ⁴Cheil General Hospital, Dankook University College of Medicine, Dept. of Urology, Seoul, South Korea, ⁵Cheil General Hospital, Dankook University College of Medicine, Dept. of Pathology, Seoul, South Korea

EAU Patient Information Project: Setting standards in cooperation and care

Special session

Friday, 24 March
12:15 - 13:30

Location: Room 1, Capital suite (level 3)

Chair: T. Bach, Hamburg (DE)

Aims and objectives of this presentation

Aim:

- To promote knowledge about the project to a wide audience
- To highlight the cooperative character and worldwide expansion
- To encourage usage of EAU patient information by patients and doctors
- To disseminate the information of our GL to our patients through the doctors and patient groups

Target group:

Urologists, patient groups, national societies and nurses.

12:15 - 12:20

Welcome and introduction

T. Bach, Hamburg (DE)

12:20 - 12:30

The society's perspective – What can EAU Patient Information do for you, why do we need to translate GL for patients?

C.R. Chapple, Sheffield (GB)

12:30 - 12:40

The residents/doctors perspective: How I use EAU Patient Information to get my patients informed

G. Patruno, Rome (IT)

12:40 - 12:50

The patients' perspective: What a patient fears and needs

A. Winterbottom, Chinnor (GB)

12:50 - 13:00

The nurses perspective: Things patients do not ask or do not dare to ask their doctors

C.N. Tillier, Amsterdam (NL)

13:00 - 13:10

The international view: Why is it important to have patient information in the native language

C. Llorente, Madrid (ES)

13:10 - 13:20

The future of EAU patient information in daily practice: Demonstration of "The Patient Information App"

T. Bach, Hamburg (DE)

13:20 - 13:25

Discussion

13:25 - 13:30

Conclusion

T. Bach, Hamburg (DE)

Infectious challenges of urology

Poster Session 06

Friday, 24 March
12:30 - 14:00

Location: Room Milan, North Hall (Level 1)

Chairs: R. Bartoletti, Pisa (IT)
B. Köves, Budapest (HU)
P. Tenke, Budapest (HU)

Aims and objectives of this presentation

Infectious aspects in Urology presents the latest information for the care of your patients.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- 75 **Morbidity and mortality outcomes in urosepsis compared according to new sepsis definitions: A prospective multinational observational study –systemic inflammatory response syndrome protects is value**
By: [Tandoi du Z.](#)¹, Koves B.², Cai T.³, Platz A.⁴, Wagenlehner F.⁴, Bjerklund Johansen T.E.⁵
Institutes:¹Oslo University, Institute of Clinical Medicine, Oslo, Norway, ²South Pest Teaching Hospital, Dept. of Urology, Budapest, Hungary, ³Santa Chiara Hospital, Dept. of Urology, Trento, Italy, ⁴Universitätsklinikum Gießen und Marburg GmbH, Pediatric Urology and Andrology, Giessen, Germany, ⁵Oslo University, Dept. of Urology and Institute of Clinical Medicine, Oslo, Norway
- 76 **Risk factors for mortality in patients with urosepsis**
By: [Fukunaga A.](#), Kawakita M.
Institutes:Kobe City Medical Center General Hospital, Dept. of Urology, Kobe, Japan
- 77 **The comparison of MDR and ESBL patterns among causative pathogens of UTI in hospitalized patients in two different ICUs in Loghman hospital**
By: [Pooya M.](#)¹, Saleh M.¹, Mir-Marashi F.¹, Bouzari S.¹, Mardani M.²
Institutes:¹Pasteur Institute Of Iran, Dept. Of Molecular Biology, Tehran, Iran, ²Shahid Beheshti University of Medical Sciences, Loghman Hakim Hospital, Tehran, Iran
- 78 **A novel predictive tool for Asian Fournier's gangrene: 40 cases and 15-year-experience of a tertiary center**
By: [Lin Y-H.](#)¹, Lu Y-C.², Hong J-H.², Liao C-H.¹, Huang K-H.², Huang C-Y.², Liu S-P.², Pu Y-S.²
Institutes:¹Cardinal Tien Hospital, Division of Urology, Dept. of Surgery, New Taipei City, Taiwan, ²National Taiwan University Hospital, Dept. of Urology, Taipei, Taiwan
- 80 **Five-year prospective study evaluating healthcare-associated infections (HAIs) in a urology ward: Risk factors, microbiological characteristics and resistance patterns**
By: [Medina Polo J.](#), Sopena-Sutil R., Benitez-Sala R., Lara-Isa A., Alonso-Isa M., Gil-Moradillo J., Justo-Quintas J., Garcia-Rojo E., González-Padilla D.A., González-Díaz A., Abad-López P., Passas-Martínez J.B., Tejido-Sánchez A.
Institutes:Hospital Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain
- 81 **Quick SOFA score might be inadequate as initial sepsis screening system in UTI patients**
By: [Fujita S.](#), Naito S, Ichyanagi O, Kanno H, Yamagishi A, Yagi M, Kurota Y, Sakurai T, Nishida H, Shibasaki T, Kawazoe H, Kato T, Nagaoka A, Tsuchiya N
Institutes:Yamagata University, School Of Medicine, Dept. of Urology, Yamagata City, Japan
- 82 **Detecting bacterial resistance in urine at the point of care via a custom tailored LAMP panel**
By:

Fritzenwanker M.¹, Imirzalioglu C.¹, Wagenlehner F.², Chakraborty T.¹

Institutes:¹Justus-Liebig-Universität, Institut Für Medizinische Mikrobiologie, Giessen, Germany, ²Justus-Liebig-Universität, Klinik Für Urologie, Kinderurologie Und Andrologie, Giessen, Germany

83 **Establishment of a 3D organotypic urothelial cell culture model as infection model system for BK polyomavirus – viral lifecycle and identification of new therapeutic targets**

By: Schneidewind L.¹, Knerr-Rupp K.¹, Feld P.¹, Janssen M.², Keiser M.³, Smola S.¹

Institutes:¹University of The Saarland Medical Center, University of The Saarland, Dept. of Virology, Homburg, Germany, ²University of The Saarland Medical Center, University of The Saarland, Dept. of Urology and Paediatric Urology, Homburg, Germany, ³University Medicine Greifswald, Dept. of Pharmacology, Greifswald, Germany

84 **Antimicrobial resistance patterns and risk factors for ciprofloxacin in Enterococcus faecalis isolates from expressed prostatic secretions of patients with chronic bacterial prostatitis**

By: Lee G.¹, Seo Y.¹, Song J.²

Institutes:¹Dankook University Medical College, Dept. of Urology, Cheonan, South Korea, ²Yonsei University Wonju College of Medicine, Dept. of Urology, Wonju, South Korea

85 **Withdrawn**

By:

Institutes:

86 **Prostatic secretion microbiota and chronic bacterial prostatitis symptoms or signs: Is there a connection?**

By: Kogan M.I.¹, Naboka J.², Gudima I.², Ibishev H.¹

Institutes:¹Rostov State Medical University, Dept. of Urology, Rostov-On-Don, Russia, ²Rostov State Medical University, Dept. of Microbiology, Rostov-On-Don, Russia

87 **Does micropattern (sharklet) on urinary catheter surface reduce urinary tract infections? Results from phase I randomized open label interventional trial**

By: Magyar A.¹, Arthanareeswaran V.K.A.¹, Soós L.¹, Nagy K.¹, Dobák A.², Szilágyi I.M.³, Justh N.³, Chandra A.R.¹, Köves B.¹, Tenke P.¹

Institutes:¹Jahn Ferenc Dél-pesti Kórház, Dept. of Urology, Budapest, Hungary, ²Corden International, Dept. of Microbiology, Budapest, Hungary, ³University of Technology and Economics, BME, Budapest, Hungary

88 **How to overcome gram-positive bacterial identification in matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for complicated urinary tract infection-causative bacteria?**

By: Shigemura K.¹, Kitagawa K.², Yamamichi F.³, Nakano Y.¹, Tokimatsu I.⁴, Fujisawa M.¹

Institutes:¹Kobe University Graduate School of Medicine, Dept. of Urology, Kobe, Japan, ²Kobe University Graduate School of Medicine, Dept. of Internal Related, Kobe, Japan, ³Hyogo Prefectural Amagasaki General Medical Center, Dept. of Urology, Amagasaki, Japan, ⁴Kobe University Hospital, Infection Control Team, Kobe, Japan

89 **The adherence to european association of urology guidelines on urological infection in a tertiary referral hospital is the right way for increasing the antimicrobial stewardship among general practitioners**

By: Cai T.¹, Mazzoli S.², Verze P.³, Migno S.⁴, Tiscione D.¹, Luciani L.¹, Lanzafame P.⁵, Eccher C.¹, Malossini G.¹, Bartoletti R.⁶, Mirone V.³, Wagenlehner F.⁷, Bjerklund Johansen T.⁸

Institutes:¹Santa Chiara Hospital, Dept. of Urology, Trento, Italy, ²Santa Maria Annunziata Hospital, Sexually Transmitted Disease Centre, Florence, Italy, ³University of Naples, Federico II, Dept. of Urology, Naples, Italy, ⁴Santa Chiara Hospital, Dept. of Gynaecology and Obstetrics, Trento, Italy, ⁵Santa Chiara Hospital, Department of Microbiology, Trento, Italy, ⁶University of Pisa, Dept. of Urology, Pisa, Italy, ⁷Universita`tsklinikum Giessen Und Marburg GmbH, Justus-Liebig-Universita`t, Giessen, Klinik Und Poliklinik Fu`r Urologie, Kinderurologie Und Andrologie, Giessen, Germany, ⁸University of Oslo, Dept. of Urology, Oslo, Norway

Challenging retroperitoneal surgery

Video Session 02

Friday, 24 March
12:30 - 14:00

Location: Room Paris, North Hall (Level 1)

Chairs: R.K. Ahlawat
M.C. Ferriero, Rome (IT)
R.J.A. Van Moorselaar, Amsterdam (NL)

Aims and objectives of this presentation

The aim during the session would be to conduct the scientific discussions smoothly, and effective leadership

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

- V09 **First laparoscopic kidney transplantation in Turkey**
By: Özden E.¹, Yakupoglu Y.K.¹, Oner S.¹, Dilek M.², Bostanci Y.¹, Sarikaya S.¹
Institutes:¹Ondokuz Mayıs University, Dept. of Urology, Samsun, Turkey, ²Ondokuz Mayıs University, Dept. of Nephrology, Samsun, Turkey
- V10 **Laparoscopic radical left nephrectomy with inferior vena cava thrombectomy: Step-by-step**
By: Bogomolov O.¹, Shkolnik M.¹, Belov A.¹, Rutkin I.², Andabekov T.¹, Sidorova S.¹
Institutes:¹FSBI Russian Research Centre For Radiology and Surgical Technologies, Dept. of Urology, Saint-Petersburg, Russia, ²FSBI Russian Research Centre For Radiology and Surgical Technologies, Dept. of Surgery, Saint-Petersburg, Russia
- V11 **Ex vivo repair and autotransplantation for complex renal artery aneurysms**
By: Bouye S.¹, Rizk J.¹, Azzaoui R.², Flamand V.¹
Institutes:¹Lille University Hospital, Dept. of Urology, Lille, France, ²Lille University Hospital, Dept. of Vascular Surgery, Lille, France
- V12 **Robotic assisted kidney auto-transplantation in a porcine skill training model**
By: Tiong H.-Y.¹, Goh B.¹, Tan L.¹, Chiong E.¹, Vathsala A.²
Institutes:¹National University Hospital, Dept. of Urology, Singapore, Singapore, ²National University Hospital, National Center For Organ Transplantation, Singapore, Singapore
- V13 **New surgical technique of renal artery control during nephrectomy with tumor thrombus removal**
By: Lesovoy V., Shchukin D., Garagatiy I., Polyakov M., Khareba G.
Institutes:Kharkiv National Medical University, Dept. of Urology, Nephrology and Andrology, Kharkiv, Ukraine
- V14 **Laparoscopic inter-aorto-caval lymph-node dissection for RCC**
By: Bass R., Sidi A., Tsivian A.
Institutes:E. Wolfson M. C., Dept. of Urologic Surgery, Holon, Israel
- V15 **Robotic en-bloc radical nephrectomy and retro-caval lymphadenectomy**
By: Percot M., Allenet C., Michiels C., Deslandes M., Queruel V., Capon G., Robert G., Pasticier G., Bensadoun H., Ferriere J.-M., Bernhard J.-C.
Institutes:University Hospital Center, Dept. of Urology, Bordeaux, France
- V16 **Post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) nerve sparing left side**
By: Lusch A., Albers P.
Institutes:Düsseldorf University, Dept. of Urology, Düsseldorf, Germany

Epigenetics and novel signaling pathways in prostate carcinogenesis

Poster Session 07

Friday, 24 March
12:30 - 14:00

Location: Room Amsterdam, North Hall (Level 1)

Chairs: C.P. Evans, Sacramento (US)
G. Jenster, Rotterdam (NL)
S. Perner, Bonn (DE)

Aims and objectives of this presentation

Invasion and metastasis in prostate cancer are regulated by different signaling molecules. In this session, the pathway of Wnt/beta-catenin and its interaction with other signaling cascaded in prostate tumorigenesis and progression will be highlighted. In addition, novel findings about regulation of the key transcription factor ERG will be presented.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- 90 **The prostate cancer-bone environment causes upregulation of the pentose phosphate pathway**
By: Whitburn J.¹, Rao S.¹, Tabata S.², Hirayama A.², Soga T.², Hamdy F.¹, Edwards C.¹
Institutes:¹University of Oxford, Nuffield Dept. of Surgical Sciences, Oxford, United Kingdom, ²Keio University, Institute for Advanced Biosciences, Tsuruoka, Japan
- 91 **A novel epigenetic crosstalk between ERG and EZH2 leads to prostate cancer progression**
By: Zoma M.¹, Curti L.¹, Shinde D.¹, Mitra A.¹, Albino D.¹, Rossi S.¹, Civenni G.¹, Losa M.¹, Thalmann G.², Chiorino G.³, Catapano C.V.¹, Carbone G.M.¹
Institutes:¹IOR Institute of Oncology Research, Tumor Biology and Experimental Therapeutic, Bellinzona, Switzerland, ²University of Bern, Inselspital, Dept. of Urology, Bern, Switzerland, ³Fondo Edo Tempia, Laboratory of Cancer Genomics, Biella, Italy
- 92 **Stage-specific embryonal antigen 4 expressing human prostate stem cells have enhanced regenerative potential in vivo**
By: Höfner T.¹, Klein C.², Eisen C.², Rigo-Watermeier T.², Haferkamp A.¹, Sprick M.²
Institutes:¹University Hospital Mainz, Dept. of Urology, Mainz, Germany, ²Heidelberg Institute for Stem Cell Technology and Experimental Medicine, HI-STEM GGmbH, Heidelberg, Germany
- 93 **Cell surface GRP78 activation by anti-GRP78 autoantibodies confers prostate tumour growth via tissue factor activation**
By: Al-Hashimi A., Hoogenes J., Shayegan B., Austin R.
Institutes:McMaster University, Dept. of Medicine, Hamilton, Canada
- 94 **MALT1 is a downstream gene of WNT/ β -catenin inducing cell proliferation and invasion potential via the upregulation of NF κ B activity in human prostate carcinoma cells**
By: Juang H-H.¹, Tsui K-H.²
Institutes:¹Chang Gung University, Dept. of Anatomy, Tao-yuan, Kwei-shan, Taiwan, ²Chang Gung Memorial Hospital, Dept. of Urology, Tao-yuan, Kwei-shan, Taiwan
- 95 **SE-cadherin stimulates integrin-mediated chemotaxis in prostate cancer**
By: Tsaur I.¹, Maxeiner S.², Rutz J.², Thomas C.¹, Jüngel E.¹, Blaheta R.A.²
Institutes:¹University Medicine Mainz, Dept. of Urology and Pediatric Urology, Mainz, Germany, ²University Hospital Frankfurt, Dept. of Urology and Pediatric Urology, Frankfurt, Germany
- *96 **Compartmentalized β -catenin driven by genomic rearrangement in prostate cancer dictates growth factor dependent, intratumoral cell fate and behavior**

By: [Lu Q.](#)¹, Li M-C.¹, Zhang J.², Chen Y-H.², Boykins C.¹, Du J.³, Ai X.⁵, Chen B-A.⁶, Jiang Y-G.⁴
Institutes:¹Brody School Of Medicine At East Carolina University, Dept. of Anatomy and Cell Biology, Greenville, United States of America, ²Brody School Of Medicine At East Carolina University, Dept. of Anatomy And Cell Biology, Greenville, United States of America, ³Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing An Zhen Hospital, Capital Medical University, Beijing, China, ⁴Beijing An Zhen Hospital, Capital Medical University, Dept. of Urology, Beijing, China, ⁵PLA Army General Hospital, Dept. of Urology, Beijing, China, ⁶Southeast University School of Clinical Medicine, Dept. of Hematology and Oncology, Nanjing, China

*97

Expression of checkpoint receptors in tumor-infiltrated T-cells of renal cell and prostate carcinomas

By: [Bedke J.](#)¹, Zelba H.², Hennenlotter J.¹, Zettl M.³, Rammensee H-G.², Stenzl A.¹, Gouttefangeas C.²

Institutes:¹University of Tübingen, Dept. of Urology, Tübingen, Germany, ²University of Tübingen, Dept. of Immunology, Tübingen, Germany, ³Boehringer Ingelheim RCV GmGH & CoKG, NBE Discovery, Vienna, Austria

*98

Evaluation of systematic alterations in the proteome by androgen receptor stimulation and blockade in prostate cancer

By: [Molokwu C.](#)¹, Kristensen A.², Zhang F.³, Saxena N.³, Shrestha R.⁴, Bell R.⁴, Hach F.⁴, Collins C.⁵, Sorensen P.⁶, Gleave M.⁵

Institutes:¹Bradford Royal Infirmary, Dept. of Urology, Bradford, United Kingdom, ²British Columbia Cancer Research Centre, Proteomics Unit, Vancouver, Canada, ³Vancouver Prostate Centre, Tumour Biology Group, Vancouver, Canada, ⁴Vancouver Prostate Centre, Bioinformatics Group, Vancouver, Canada, ⁵University of British Columbia, Dept. of Urological Sciences, Vancouver, Canada, ⁶University of British Columbia, Dept. of Pathology & Laboratory Medicine, Vancouver, Canada

*99

Description of the dimerization surface for the ligand-binding domain of the androgen receptor and its role in transcriptional control by agonists and antagonists

By: [Claessens F.](#)¹, Nadal M.², Prekovic S.¹, Gallastegui N.², Helsen C.¹, Abella M.², Zielinska K.², Gay M.³, Vilaseca M.³, Taules M.⁴, Houtsmuller A.⁵, Van Royen M.⁵, Fuentes-Prior P.², Estebanez-Perpina E.²

Institutes:¹KU Leuven, Molecular Endocrinology Laboratory, Leuven, Belgium, ²Institute of Biomedicine of The University of Barcelona, Dept. of Biochemistry and Molecular Biomedicine, Barcelona, Spain, ³Parc Cientific De Barcelona, Mass Spectrometry Core Facility, Barcelona, Spain, ⁴Centres Cientifics I Tecnològics, Unitat De Citometria, Barcelona, Spain, ⁵Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands

*100

Bone morphogenic protein-6 and retinoblastoma expression: an inverse relationship in prostate cancer progression?

By: [McCormick K.](#)¹, Leiblich A.¹, Stevens D.¹, Alves C.¹, Fan S-J.¹, Carr K.¹, Morris J.¹, Harris A.², Wilson C.¹, Hamdy F.³, Goberdhan D.¹

Institutes:¹University of Oxford, Dept. of Physiology, Anatomy and Genetics, Oxford, United Kingdom, ²University of Oxford, The Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom, ³University of Oxford, Nuffield Department of Surgical Sciences, John Radcliffe Hospital, Oxford, United Kingdom

*101

Expression of stromal elements of prostatic adenocarcinoma in different Gleason grades

By: Osorio C., Gallo C., Costa W., [Sampaio F.](#)

Institutes:State University of Rio de Janeiro, Urogenital Research Unit, Rio De Janeiro, Brazil

*102

Induction of neuroendocrine differentiation in prostate cancer cells by Dovitinib (TKI-258) and associated therapeutic implications

By: [Yadav S.](#), Li J., Stockert J.A.S., Herzog B.H., O'connor J.O., Tewari A.K.T., Yadav K.K.Y.

Institutes:Icahn School Of Medicine At Mount Sinai, Dept. of Urology, New York, United States of America

13:49 - 13:56

Epigenetics in prostate cancer

G. Jenster, Rotterdam (NL)

How LUTS function and grows?

Poster Session 08

Friday, 24 March
12:30 - 14:00

Location: Room Berlin, North Hall (Level 1)

Chairs: C. Gratzke, Munich (DE)
R. Hamid, London (GB)

Aims and objectives of this presentation

Basic insight in the LUT functioning will be discussed during this session

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *103 **Depletion of peripheral serotonin synthesis induces benign prostatic growth in mice: More evidence for the new neuroendocrine theory in BPH etiology**
By: [Mota P.M.](#)¹, [Carvalho-Dias E.](#)¹, [Miranda A.](#)², [Martinho O.](#)², [Nogueira-Silva C.](#)³, [Alenina N.](#)⁴, [Bader M.](#)⁴, [Autorino R.](#)¹, [Lima E.](#)¹, [Correia-Pinto J.](#)⁵
Institutes:¹Surgical Sciences Research Domain, Life and Health Sciences Research Institute, ICVS/3B's - PT Gover, Dept. of CUF Urology and Service of Urology - Hospital of Braga, Braga, Portugal, ²Life and Health Sciences Research Institute, ICVS/3B's - PT Government Associate Laboratory, The Cli, Surgical Sciences Research Domain, Braga, Portugal, ³Surgical Sciences Research Domain, Life and Health Sciences Research Institute, ICVS/3B's - PT Gover, Dept. of Obstetrics and Gynecology, Braga, Portugal, ⁴Max Delbrück Center For Molecular Medicine, Robert-Rössle-Str. 10, Berlin 13125, Germany, Berlin Institute of Health, Berlin, Germany, ⁵Surgical Sciences Research Domain, Life and Health Sciences Research Institute, ICVS/3B's - PT Gover, Dept. of Pediatric Surgery - Hospital of Braga, Braga, Portugal
- *104 **Impacts of apolipoprotein A-1 and alpha-fetoprotein on the development of benign prostatic hyperplasia and lower urinary tract symptoms: Results from a high-volume health check-up database**
By: [Lee K.S.](#), [Kim D.K.](#), [Koo K.C.](#), [Heo J.E.](#), [Oh K.T.](#), [Chung B.H.](#)
Institutes:Gangnam Severance Hospital, Yonsei University Health System, Dept. of Urology, Seoul, South Korea
- *105 **Impairment of autophagy is associated with obesity and inflammation in patients with benign prostatic hyperplasia and lower urinary tract symptoms**
By: [De Nunzio C.](#)¹, [Giglio S.](#)², [Cirombella R.](#)², [Mallel G.](#)², [Nacchia A.](#)¹, [Lombardo R.](#)¹, [Presicce F.](#)¹, [Tubaro A.](#)¹, [Vecchione A.](#)²
Institutes:¹Sant' Andrea Hospital - Sapienza University, Dept. of Urology, Rome, Italy, ²Sant' Andrea Hospital - Sapienza University, Dept. of Molecular Pathology, Rome, Italy
- *106 **Myogenic tone is significantly increased in benign prostatic hyperplasia and can be attenuated by sildenafil and tamsulosin, with outcome associated to patient age and prostate volume**
By: [Lee S.](#)¹, [Chakrabarty B.](#)², [Papargiris M.](#)¹, [Ryan A.](#)³, [Frydenberg M.](#)⁴, [Lawrentschuk N.](#)⁵, [Middendorff R.](#)⁶, [Risbridger G.](#)¹, [Ellem S.](#)¹, [Exintaris B.](#)⁷
Institutes:¹Monash University, Dept. of Anatomy and Developmental Biology, Clayton, Australia, ²Monash University, Drug Discovery Biology, Parkville, Australia, ³TissuePath, Dept. of Pathology, Melbourne, Australia, ⁴Monash University, Dept. of Surgery, Melbourne, Australia, ⁵Melbourne University, Dept. of Surgery, Melbourne, Australia, ⁶Justus-Liebig-University, Institute of Anatomy and Cell Biology, Giessen, Germany, ⁷Monash University, Dept. of Drug Discovery Biology, Parkville, Australia

- *107 **Detection of Rac activity and inhibition of smooth muscle contraction by EHT1864 in the human trigone: Expanding the role of Rac GTPase in the lower urinary tract outflow region**
 By: Wang Y., Gratzke C., Rutz B., Yu Q., Strittmatter F., Herlemann A., Rutz B., Stief C., Hennenberg M.
 Institutes: LMU Munich, Dept. of Urology, München, Germany
- *108 **Inhibition of prostate smooth muscle contraction by the LIM kinase inhibitor, SR-7826: A new anticontractile strategy and implications for a role of LIM kinases in the control of prostate smooth muscle tone**
 By: Yu Q., Gratzke C., Wang Y., Rutz B., Herlemann A., Strittmatter F., Stief C., Hennenberg M.
 Institutes: LMU-Klinikum der Universität München, Dept. of Urology, Munich, Germany
- *109 **The anticontractile inhibitor, secinH3 inhibits ARF6, but not Rac or RhoA GTPase activities in the human prostate: A new role for ARF6 in smooth muscle contraction?**
 By: Hennenberg M., Wang Y., Herlemann A., Yu Q., Strittmatter F., Rutz B., Stief C., Gratzke C.
 Institutes: LMU Munich, Dept. of Urology, Munich, Germany
- *110 **The oxidants/antioxidants balance in patients with benign prostatic hyperplasia before and after the treatment with dutasteride**
 By: Ene C.V.¹, Nicolae I.², Ene C.D.³, Geavlete B.¹, Geavlete P.¹, Georgescu S.⁴
 Institutes: ¹St John Hospital Bucharest, Dept. of Urology, Bucharest, Romania, ²Clinical Hospital of Tropical and Infectious Diseases "Victor Babes", Dept. of Research, Bucharest, Romania, ³Clinical Hospital of Nephrology "Carol Davila", Dept. of Nephrology, Bucharest, Romania, ⁴Clinical Hospital of Tropical and Infectious Diseases "Victor Babes", Dept. of Dermato-Venerology, Bucharest, Romania
- *111 **Restraint stress induces nocturia in mice**
 By: Ihara T.¹, Mitsui T.¹, Nakamura Y.², Imai Y.¹, Kira S.¹, Nakagomi H.¹, Sawada N.¹, Nakao A.², Takeda M.¹
 Institutes: ¹University of Yamanashi, Dept. of Urology, Yamanashi, Japan, ²University of Yamanashi, Dept. of Immunology, Yamanashi, Japan
- *112 **The vitamin D analogue BXL-628 improves contraction development ex vivo in bladders of aged mice**
 By: Hohnen B.¹, Rademakers K.², Den Hartog G.³, Meriaux C.¹, Van Koevinge G.²
 Institutes: ¹Maastricht University, Dept. of Neuroscience, Maastricht, The Netherlands, ²Maastricht University Medical Center, Dept. of Urology, Maastricht, The Netherlands, ³Maastricht University, Dept. of Pharmacology and Toxicology, Maastricht, The Netherlands
- *113 **Effects of litoxetine on urethral pressure and detrusor overactivity in anesthetized female rats**
 By: Méen M.¹, Guérard M.¹, Gamé X.², Lluel P.¹
 Institutes: ¹Urosphere, Dept. of Pharmacology, Toulouse, France, ²CHU Rangueil, Dept. of Urology, Toulouse, France
- *114 **Effects of the receptor antagonist picotamide on endothelin-1-, -2- and -3-induced contractions in human prostate smooth muscle**
 By: Hennenberg M., Tamalunas A., Strittmatter F., Stief C., Gratzke C.
 Institutes: LMU Munich, Dept. of Urology, Munich, Germany
- *115 **Two microRNA clusters may determine the biological functions of microRNA-regulated pathways in underactive bladder**
 By: Hashemi Gheinani A.¹, Burkhard F.², Monastyrskaya K.²
 Institutes: ¹Urology Research Laboratory, Dept. of Clinical Research, Bern, Switzerland, ²University Hospital Bern, Dept. of Urology, Bern, Switzerland
- *116 **Detrusor bioengineering using compressed collagen, adipose-derived stem cells and smooth muscle cells**
 By: Smolar J.¹, Horst M.², Eberli D.¹

Institutes:¹University Hospital Zurich, Dept. of Urology, Zürich, Switzerland, ²University Children's Hospital, Dept. of Pediatric Urology, Zürich, Switzerland

The last rites for cystoscopy?

Poster Session 09

Friday, 24 March
12:30 - 14:00**Location:** Room Vienna, North Hall (Level 1)**Chairs:** P. Black, Vancouver (CA)
R.T. Bryan, Birmingham (GB)
G. Gakis, Tuebingen (DE)**Aims and objectives of this presentation**

understand where TCC molecular diagnostics is heading. Ready for prime time or more hype then hope?

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

*117

Validation of a mRNA-based urine test for bladder cancer detection in patients with hematuria**By:** Van Valenberg F.J.P.¹, Bridge J.A.², Mayne D.³, Beqaj S.⁴, Sexton W.J.⁵, Lotan Y.⁶, Weizer A.Z.⁷, Jansz G.K.⁸, Stenzl A.⁹, Danella J.F.¹⁰, Shepard B.R.¹¹, Cline K.J.¹², Williams M.B.¹³, Montgomery T.¹⁴, David R.D.¹⁵, Harris R.G.¹⁶, Klein E.W.¹⁷, Bradford T.J.¹⁸, Wolk F.N.¹⁹, Westenfelder K.R.²⁰, Trainer A.F.²¹, Richardson T.A.²², Witjes J.A.¹**Institutes:**¹Radboudumc, Urology, Nijmegen, The Netherlands, ²University of Nebraska Medical Center, Departments of Pathology/Microbiology, Pediatrics and Orthopaedic Surgery, Omaha, United States of America, ³Sacred Heart Hospital, Molecular Laboratory, Pensacola, United States of America, ⁴Pathology Inc., Clinical Laboratory, Torrance, United States of America, ⁵Moffitt Cancer Center, Genitourinary Oncology and Oncologic Sciences, Tampa, United States of America, ⁶University of Texas Southwestern, Urology, Dallas, United States of America, ⁷University of Michigan Hospital, Urology, Ann Arbor, United States of America, ⁸G. Kenneth Jansz MPC, Private Practice, Burlington, Canada, ⁹University of Tuebingen, Urology, Tuebingen, Germany, ¹⁰Geisinger Health System, Urology, Danville, United States of America, ¹¹Urological Surgeons of Long Island, PLLC, Private Practice, Garden City, United States of America, ¹²Regional Urology, Private Practice, Shreveport, United States of America, ¹³Urology of Virginia, Private Practice, Virginia Beach, United States of America, ¹⁴Kansas City Urology Care, Private Practice, Overland Park, United States of America, ¹⁵Skyline Urology, Private Practice, Torrance, United States of America, ¹⁶UroPartners, Private Practice, Melrose Park, United States of America, ¹⁷Idaho Urologic Institute, Private Practice, Meridian, United States of America, ¹⁸Virginia Urology, Private Practice, Richmond, United States of America, ¹⁹Skyline Urology, Private Practice, Sherman Oaks, United States of America, ²⁰Five Valleys Urology, Private Practice, Missoula, United States of America, ²¹Adult and Pediatric Urology & Urogynecology, Private Practice, Omaha, United States of America, ²²Wichita Urology Group, Private Practice, Wichita, United States of America

*118

Does smoking influence the performance of urine markers in the diagnosis of urothelial carcinoma?**By:** Schnürer S., Hennenlotter J., Dockter K., Rausch S., Stenzl A., Todenhöfer T.**Institutes:** Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany

*119

Performance characteristics of a mRNA-based urine test for the detection of bladder cancer recurrence**By:** Van Valenberg F.¹, Bridge J.², Mayne D.⁴, Beqaj S.⁵, Sexton W.⁶, Lotan Y.⁷, Weizer A.⁸, Jansz G.⁹, Stenzl A.¹⁰, Danella J.³, Shepard B.¹¹, Cline K.¹², Williams M.¹³, Montgomery T.¹⁴, David R.¹⁵, Harris R.¹⁶, Klein E.¹⁷, Bradford T.¹⁸, Wolk F.¹⁹, Westenfelder K.²⁰, Trainer A.²¹, Richardson T.²², Witjes J.¹**Institutes:**¹Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, ²University of Nebraska Medical Center, Dept. of Pathology/Microbiolog, Pediatrics and Orthopaedic Surgery, Omaha, United States of America, ³Geisinger Health System, Dept. of Urology, Danville, United States of

America, ⁴Sacred Heart Hospital, Molecular Laboratory, Pensacola, United States of America, ⁵ Pathology Inc., Clinical Laboratory, Torrance, United States of America, ⁶Moffitt Cancer Center, Genitourinary Oncology and Oncologic Sciences, Tampa, United States of America, ⁷University of Texas Southwestern, Dept. of Urology, Dallas, United States of America, ⁸University of Michigan Hospital, Dept. of Urology, Ann Arbor, United States of America, ⁹G. Kenneth Jansz MPC, Burlington, Canada, ¹⁰University of Tuebingen, Dept. of Urology, Tuebingen, Germany, ¹¹Urological Surgeons of Long Island, PLLC, Garden City, United States of America, ¹²Regional Urology, Shreveport, United States of America, ¹³Urology of Virginia, Virginia Beach, United States of America, ¹⁴Kansas City Urology Care, Overland Park, United States of America, ¹⁵Skyline Urology, Torrance, United States of America, ¹⁶UroPartners, Melrose Park, United States of America, ¹⁷Idaho Urologic Institute, Meridian, United States of America, ¹⁸Virginia Urology, Richmond, United States of America, ¹⁹Skyline Urology, Sherman Oaks, United States of America, ²⁰Five Valleys Urology, Missoula, United States of America, ²¹Adult and Pediatric Urology & Urogynecology, Omaha, United States of America, ²²Wichita Urology Group, Wichita, United States of America

- *120 **Non invasive prediction of recurrences in bladder cancer by detecting TERT promoter mutations in urine**
By: [Kara N.](#)¹, Descotes F.², Decaussin Petrucci M.², Piaton E.², Geiguer F.², Rodriguez-Lafrasse C.², Terrier J.E.³, Lopez J.², Ruffion A.³
Institutes:¹Centre Hospitalier Lyon-Sud, Dept. of Urology, Pierre-bénite, France, ²Centre Hospitalier Lyon-Sud, Dept. of Molecular Biology and Biochemistry, Pierre-Bénite, France, ³Centre Hospitalier Lyon-Sud, Dept. of Urology, Pierre-Bénite, France
- *121 **Multiplex proximity extension assay of 425 candidate biomarkers in the sera of bladder cancer patients: Correlation with stage and outcome**
By: [Ward D.](#)¹, Gordon N.¹, Abbotts B.², James N.³, Zeegers M.⁴, Cheng K.K.⁵, Bryan R.¹
Institutes:¹University of Birmingham, Institute of Cancer and Genomic Sciences, Birmingham, United Kingdom, ²University of Birmingham, Institute Of Cancer And Genomic Sciences, Birmingham, United Kingdom, ³University of Warwick, Clinical Trials Unit, Warwick, United Kingdom, ⁴University of Maastricht, Dept. of Complex Genetics, Birmingham, United Kingdom, ⁵University of Birmingham, School of Health and Population Sciences, Birmingham, United Kingdom
- *122 **Non-invasive diagnosis and monitoring of bladder cancer utilizing high-throughput genome sequencing on urine sediment**
By: [Liu H.](#), Lin T., He W., Wang B., Xu K., Han J., Zheng J., Huang J.
Institutes:Sun Yat-Sen Memorial Hospital, Dept. of Urology, Guangzhou, China
- *123 **Method of detecting bladder cancer by optical analysis of bodily fluids**
By: [Rabah D.](#)
Institutes:College of Medicine, King Saud University, Dept. of Surgery, Riyadh, Saudi Arabia
- *124 **Urethral wash cytology accuracy in the diagnosis of asymptomatic urethral recurrence after radical cystectomy for urothelial bladder cancer**
By: Manica M.¹, Naspro R.¹, [Pellucchi F.](#)¹, Rocchini L.¹, Roscigno M.¹, Chinaglia D.², Da Pozzo L.F.¹
Institutes:¹Papa Giovanni Xxiii Hospital, Dept. of Urology, Bergamo, Italy, ²Papa Giovanni Xxiii Hospital, Dept. of Pathology, Bergamo, Italy
- *125 **Diagnosis and prediction of recurrent bladder cancer by urinary DNA methylation analysis: Multicenter prospective study**
By: [Shindo T.](#)¹, Shimizu T.¹, Nishiyama N.¹, Niinuma T.², Kitajima H.², Kai M.², Shinkai N.¹, Itoh N.³, Tanaka T.¹, Suzuki H.², Masumori N.¹
Institutes:¹Sapporo Medical University School of Medicine, Dept. of Urology, Sapporo, Japan, ²Sapporo Medical University School of Medicine, Dept. of Molecular Biology, Sapporo, Japan, ³NTT East Corporation Sapporo Hospital, Dept. of Urology, Sapporo, Japan
- *126 **Urine-based diagnostics of bladder tumours through volatile organic compounds: A pilot study comparing two detection systems**

By: Heers H.¹, Gut J.¹, Hegele A.¹, Hofmann R.¹, Boeselt T.², Hattesoehl A.², Baumbach J.³, Koczulla A.R.²

Institutes:¹Philipps-Universität Marburg, Dept. of Urology and Paediatric Urology, Marburg, Germany, ²Philipps-Universität Marburg, Dept. of Pneumology, Marburg, Germany, ³Reutlingen University, Dept. of Applied Chemistry, Reutlingen, Germany

*128

Molecular tumour grading and classification of non muscle invasive bladder cancer based on whole transcriptome analysis

By: Zlotta A.R.¹, Shen J.², Noon A.³, Jiang H.⁴, Kuk C.¹, Ni R.⁵, Sukhu B.⁵, Chan K.², Erlich A.¹, Roupret M.⁶, Seisen T.⁶, Comparat E.⁷, Sweet J.⁸, Kulkarni G.S.⁹, Fleshner N.E.⁹, Azad A.⁵, Van Der Kwast T.H.⁸, Wrana J.L.²

Institutes:¹Mount Sinai Hospital, Dept. of Surgery (urology), Toronto, Canada, ²Mount Sinai Hospital, Lunenfeld-Tanenbaum Research Institute, Toronto, Canada, ³University of Sheffield, Dept. of Urology, Sheffield, United Kingdom, ⁴University Health Network, Dept. of Statistics, Toronto, Canada, ⁵Mount Sinai Hospital, Dept. of Pathology and Laboratory Medicine, Toronto, Canada, ⁶Groupe Hospitalier La Pitié-Salpêtrière, Université Pierre Et Marie Curie, Dept. of Urology, Paris, France, ⁷Groupe Hospitalier La Pitié-Salpêtrière, Université Pierre Et Marie Curie, Dept. of Pathology, Paris, France, ⁸Toronto General Hospital, University Health Network, Dept. of Pathology, Toronto, Canada, ⁹Princess Margaret Cancer Centre, University Health Network, Dept. of Surgical Oncology, Urology, Toronto, Canada

*129

Significance of serum n-glycan profiling as a diagnostic biomarker in urothelial carcinoma

By: Oikawa M.¹, Hatakeyama S.¹, Yoneyma T.², Tobisawa Y.¹, Narita T.¹, Yamamoto H.¹, Hashimoto Y.², Koie T.¹, Narita S.³, Sasaki A.⁴, Tsuchiya N.⁵, Habuchi T.³, Takahashi I.⁶, Nakaji S.⁶, Ohyama C.¹

Institutes:¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Hirosaki University Graduate School of Medicine, Dept. of Advanced Transplant and Regenerative Medicine, Hirosaki, Japan, ³Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan, ⁴Tsugaru General Hospital, Dept. of Urology, Tsugaru, Japan, ⁵Yamagata University Graduate School of Medicine, Dept. of Urology, Yamagata, Japan, ⁶Hirosaki University School of Medicine, Dept. of Social Medicine, Hirosaki, Japan

*130

Concurrent bladder tumours in patients undergoing photodynamic diagnostic ureterorenoscopy: How many lesions are missed under white light?

By: Zreik A.¹, Kata S.G.², Ahmad S.², Chlosta P.L.³, Aboumarzouk O.M.¹

Institutes:¹Queen Elizabeth University Hospital, Dept. of Urology, Glasgow, United Kingdom, ²Ninewells Hospital, Dept. of Urology, Dundee, United Kingdom, ³Jagiellonian University, Dept. of Urology, Cracow, Poland

13:49 - 13:56

Last word on the last rite

P. Black, Vancouver (CA)

Joint Session of the European Association of Urology (EAU) and the Iranian Urological Association (IUA)

Urology beyond Europe

Friday, 24 March
13:15 - 15:45

Location: Room London, North Hall (Level 1)

Chairs: A. Basiri, Tehran (IR)

S.J. Hosseini, Tehran (IR)

13:15 - 13:20

Welcome by chairmen

13:20 - 14:05

Renal Transplantation

13:20 - 13:35

Case Presenter

To be confirmed

13:35 - 13:50

IUA Lecture

G. Pourmand, Tehran (IR)

13:50 - 14:05

EAU Lecture

G. Janetschek, Salzburg (AT)

14:05 - 14:50

Urinary stone

14:05 - 14:20

Case Presenter

To be confirmed

14:20 - 14:35

IUA Lecture

A. Basiri, Tehran (IR)

14:35 - 14:50

EAU Lecture

To be confirmed

14:50 - 15:35

Infertility

14:50 - 15:05

Case Presenter

S.J. Hosseini, Tehran (IR)

15:05 - 15:20

IUA Lecture

To be confirmed

14:20 - 15:35

EAU Lecture

N. Sofikitis, Ioannina (GR)

15:35 - 15:45

Discussion and closing remarks

Joint Session of the European Association of Urology (EAU) and the Société Internationale d'Urologie (SIU)

Urology beyond Europe

Friday, 24 March
13:15 - 15:45

Location: Room Munich, North Hall (Level 1)

Chairs: P. Coloby, Cergy Pontoise (FR)
A. Stenzl, Tübingen (DE)

Aims and objectives of this presentation

To introduce and discuss around the world: The management of pelvic stone with ureteropelvic obstruction, the updated prevention and treatment of penile cancer and the updated treatment of BPH.

13:15 - 13:20

Welcome and introduction

P. Coloby, Cergy Pontoise (FR)
A. Stenzl, Tübingen (DE)

13:20 - 14:05

Urolithiasis

Moderator: O. Traxer, Paris (FR)

13:20 - 13:30

New technology development

O. Traxer, Paris (FR)

13:30 - 14:05

Round table discussion: Management of pelvic stone with ureteropelvic obstruction

13:30 - 14:05

Panel:

N. Bernardo, Buenos Aires (AR)
M.R. Desai, Naidad (IN)
R. El Khoury, Beirut (LB)
O. Traxer, Paris (FR)

13:30 - 13:35

Clinical case

O. Traxer, Paris (FR)

13:35 - 13:43

PCNL

M.R. Desai, Naidad (IN)

13:43 - 13:51

FURS

N. Bernardo, Buenos Aires (AR)

13:51 - 13:59

Laparoscopy

R. El Khoury, Beirut (LB)

13:59 - 14:05

Discussion

O. Traxer, Paris (FR)

14:05 - 14:50

Penile cancer

Moderator: To be confirmed

14:05 - 14:20

Risk factors and prevention

To be confirmed

14:20 - 14:35

Lymph node Imaging and surgical treatment

To be confirmed

14:35 - 14:50

New development in the treatment of localised penile cancer

E. Solsona, Valencia (ES)

14:50 - 15:35

BPH

Moderator: S. Gravas, Larissa (GR)

14:50 - 15:05

Holistic approach to BPH for individualised and personalised care

K.T. Foo, Singapore (SG)

15:05 - 15:20

New development in non surgical treatment

S. Gravas, Larissa (GR)

15:20 - 15:35

Pharmacology of the lower urinary tract: What to observe in the medical treatment of lower urinary tract dysfunction

To be confirmed

15:35 - 15:45

Take home messages

P. Coloby, Cergy Pontoise (FR)

A. Stenzl, Tübingen (DE)

Joint Session of the European Association of Urology (EAU) and the Japanese Urological Association (JUA)

Urology beyond Europe

Friday, 24 March
13:15 - 15:45

Location: Room 7, Capital suite (level 3)

Chairs: C.R. Chapple, Sheffield (GB)
S. Egawa, Tokyo (JP)

Aims and objectives of this presentation

To discuss debatable issues in urological practice through case discussions

13:15 - 13:20

Welcome and introduction

C.R. Chapple, Sheffield (GB)
S. Egawa, Tokyo (JP)

13:20 - 14:05

Prostate Cancer

Moderators: D.J. Rosario, Sheffield (GB)
S. Horie, Tokyo (JP)

13:20 - 13:40

Extending the use of androgen receptor targeted drugs in men with nmCRPC

13:20 - 13:30

Yes

T. Kimura, Tokyo (JP)

13:30 - 13:40

No

A. Briganti, Milan (IT)

13:40 - 14:05

Panel discussion on clinical cases: What is your choice of treatment?

13:40 - 14:05

Panel:

D.J. Rosario, Sheffield (GB)
S. Maruyama, Sapporo (JP)
Y. Matsui, Kyoto (JP)
H.G. Van Der Poel, Amsterdam (NL)

14:05 - 14:50

Renal cell carcinoma

Moderators: M.J. Ribal, Barcelona (ES)
Y. Tomita, Niigata (JP)

14:05 - 14:25

Second line treatment for metastatic or unresectable RCC with nivolumab

14:05 - 14:15

Yes

B. Mellado, Barcelona (ES)

14:15 - 14:25

No
M. Takahashi, Tokushima (JP)

14:25 - 14:50

Panel discussion on clinical cases: How to approach this situation?

14:25 - 14:50

Panel:
B. Mellado, Barcelona (ES)
A.S. Merseburger, Lübeck (DE)
M.J. Ribal, Barcelona (ES)
R. Takata, Morioka (JP)
To be confirmed
Y. Tomita, Niigata (JP)
H.G. Van Der Poel, Amsterdam (NL)

14:50 - 15:35

Underactive bladder/Detrusor underactivity

Moderators: C.R. Chapple, Sheffield (GB)
N. Sekido, Tokyo (JP)

14:50 - 15:00

Animal model of underactive bladder/ detrusor underactivity
N. Sekido, Tokyo (JP)

15:00 - 15:10

Current definition and emerging therapy of underactive bladder/detrusor underactivity
C.R. Chapple, Sheffield (GB)

15:10 - 15:35

Panel discussion on clinical cases: How do you treat this patient? Differences in approach to underactive bladder

15:10 - 15:35

Panel:
Y. Matsukawa, Nagoya (JP)
T. Mitsui, Sapporo (JP)
M. Oelke, Hanover (DE)
G. Van Koeveringe, Maastricht (NL)

15:35 - 15:45

Conclusion
M. Fujisawa, Kobe (JP)

Joint Session of the European Association of Urology (EAU) and the Urological Society of India (USI)

Urology beyond Europe

Friday, 24 March
13:15 - 15:45

Location: Room 9, Capital suite (level 3)

Chairs: D.M. Castro Díaz, La Laguna Santa Cruz Tenerife (ES)
P.N. Dogra, New Delhi (IN)

Aims and objectives of this presentation

The contents of this EAU-USI joint session will provide an update on those current hot topics from the perspective of both societies. Recognized experts working in India and Europe will openly discuss recent developments in Peyronie’s disease, Microbiome and LUTS, Minimally invasive management of BPH, Bladder cancer, Prostate cancer and the use of meshes Reconstructive Urology.

13:15 - 13:20

Welcome and introduction

D.M. Castro Díaz, La Laguna Santa Cruz Tenerife (ES)
P.N. Dogra, New Delhi (IN)

13:20 - 13:45

Current trends in the management of Peyronie's disease

13:20 - 13:30

Indian perspective

To be confirmed

13:30 - 13:40

European perspective

I. Moncada, Madrid (ES)

13:40 - 13:45

Discussion

13:45 - 14:05

Etiopathogenesis of LUTS: Current update

13:45 - 13:55

Contemporary views

To be confirmed

13:55 - 14:05

Role of microbiome in the development of LUTS

J.P.F.A. Heesakkers, Nijmegen (NL)

14:05 - 14:30

Minimally invasive therapy for BPH: What is the current gold standard?

14:05 - 14:15

Indian perspective

S. Basu, Kolkata (IN)

14:15 - 14:25

European perspective

M. Oelke, Hanover (DE)

14:25 - 14:30

Discussion

14:30 - 14:55 **Current approach to prostate cancer castration resistance**

14:30 - 14:40 **Indian perspective**
S.K. Raghunath, Bangalore (IN)

14:40 - 14:50 **European perspective**
P. Cornford, Liverpool (GB)

14:50 - 14:55 **Discussion**

14:55 - 15:20 **Timing of radical cystectomy in NMIBC**

14:55 - 15:05 **Indian perspective**
P.N. Dogra, New Delhi (IN)

15:05 - 15:15 **European perspective**
M. Babjuk, Prague 5 (CZ)

15:15 - 15:20 **Discussion**

15:20 - 15:40 **What, why, when, whom and how on the use of meshes for reconstructive urology**

15:20 - 15:30 **Indian perspective**
S. Raina, Mumbai (IN)

15:30 - 15:40 **European perspective**
D.M. Castro Díaz, La Laguna Santa Cruz Tenerife (ES)

15:40 - 15:45 **Discussion and conclusion**

Joint Session of the European Association of Urology (EAU) and the Korean Urological Association (KUA)

Urology beyond Europe

Friday, 24 March
13:15 - 15:45

Location: Room 4, Capital suite (level 3)

Chairs: J.H. Hong, Seoul (KR)
H. Van Poppel, Leuven (BE)

Aims and objectives of this presentation

The attendants will get an update on active surveillance and management of renal cell carcinoma in Van Hippel Lindau disease, discussed in the following case presentation. Next, the actual place of surgery in oligometastatic prostate cancer will be highlighted. The second part of the session will treat with the difficulties encountered in the management of overactive bladder and interstitial cystitis, also supported by a vivid case discussion. Finally challenges in urolithiasis management and stone surgery are presented and solved.

13:15 - 13:20

Welcome and introduction

To be confirmed
H. Van Poppel, Leuven (BE)

13:20 - 14:05

Session I: Renal cell carcinoma

Moderators: C-S. Kim, Seoul (KR)
H. Van Poppel, Leuven (BE)

13:20 - 13:35

Active surveillance of renal cell carcinoma: European experience

A. Volpe, Novara (IT)

13:35 - 13:50

Management of renal cell carcinoma in patients with von Hippel-Lindau disease

To be confirmed

13:50 - 14:05

Case discussion

13:50 - 14:05

Case presenter:

S.H. Choi, Daegu (KR)

13:50 - 14:05

Panel:

T. Klatte, Wien (AT)
To be confirmed
To be confirmed
A. Volpe, Novara (IT)

14:05 - 14:20

Role of surgery for oligometastatic prostate cancer

Moderators: J.H. Hong, Seoul (KR)
H. Van Poppel, Leuven (BE)

14:05 - 14:20

Speaker:

F.K-H. Chun, Hamburg (DE)

14:20 - 15:05

Session II: Advanced management of functional bladder disease

Moderators: J-N.L. Cornu, Rouen (FR)
J.C. Kim, Bucheon (KR)

14:20 - 14:35

Update on bladder pain syndrome/interstitial cystitis

M. Cervigni, Rome (IT)

14:35 - 14:50

Botox injection for idiopathic overactive bladder symptoms

J.H. Bae, Seoul (KR)

14:50 - 15:05

Case discussion

14:50 - 15:05

Case presenter:

H. Yoon, Seoul (KR)

14:50 - 15:05

Panel:

J.H. Bae, Seoul (KR)
M. Cervigni, Rome (IT)
D.K. Kim, Daejeon (KR)
F. Van Der Aa, Leuven (BE)

15:05 - 15:40

Session III: Urolithiasis

Moderators: K. Sarica, Istanbul (TR)
I.Y. Seo, Iksan-shi (KR)

15:05 - 15:20

How to manage urolithiasis in challenging cases

O. Wiseman, Cambridge (GB)

15:20 - 15:35

Perioperative changes in renal function during renal stone surgery

S.Y. Cho, Seoul (KR)

15:35 - 15:40

Discussion

15:40 - 15:45

Closing remarks

To be confirmed
H. Van Poppel, Leuven (BE)

Joint Meeting of the European Association of Urology (EAU) and the Caucasus/Central Asia

Urology beyond Europe

Friday, 24 March
13:15 - 15:45

Location: Room 11, Capital suite (level 3)

Chairs: To be confirmed
To be confirmed

13:15 - 13:20

Welcome and introduction by chairs

13:20 - 14:25

Urolithiasis

Moderator: A. Chkhotua, Tbilisi (GE)

13:20 - 13:35

The diagnostic workup of frequent stone formers

K. Sarica, Istanbul (TR)

13:35 - 13:50

Sandwich technique

T. Knoll, Sindelfingen (DE)

13:50 - 14:05

Complications of endoscopic procedures on urolithiasis

B. Ayubov, Tashkent (UZ)

To be confirmed

S. Giyasov, Tashkent (UZ)

14:05 - 14:20

Percutaneous nephroscopic surgery: Using tranexamic acid to prevent intraoperative bleeding

Y. Iskakov, Astana (KZ)

To be confirmed

To be confirmed

14:20 - 14:25

Discussion

14:25 - 15:00

Prostate cancer

Moderator: To be confirmed

14:25 - 14:40

Modern trends in surgical treatment of prostate cancer: The progressive shift from open to lap to robot

P. Verze, Naples (IT)

14:40 - 14:55

The outcome of nerve-sparing robotic radical prostatectomy with full pelvic anatomy preservation

A.M. Grabsky, Yerevan (AM)

M. Mosoyan, St. Petersburg (RU)

14:55 - 15:00

Discussion

15:00 - 15:35

Urethral strictures

Moderator: S.M. Javad-Zada, Baku (AZ)

15:00 - 15:15

Workup of urethral stricture patients

To be confirmed

Z. Tchanturaia, Tbilisi (GE)

15:15 - 15:30

Surgical treatment of urethral strictures

To be confirmed

15:30 - 15:45

Closing remarks

Meeting of the Young Academic Urologists (YAU)

Special session

Friday, 24 March
13:15 - 16:00

Location: Room 14, Capital suite (level 3)

Chairs: To be confirmed
M.S. Silay, Istanbul (TR)

Aims and objectives of this presentation

The Young Academic Urologists (YAU) is a group of talented and already renowned European young urologists. We aim to promote high-quality studies in order to provide strong evidence for the best urological practice. In this session, both scientific and educational context will be discussed among the members of YAU and the leaders of European Urology.

13:15 - 13:25

YAU after 5 years: YAU's perspective
M.S. Silay, Istanbul (TR)

13:25 - 13:35

YAU after 5 years: EAU Executive's perspective
F. Montorsi, Milan (IT)

13:35 - 13:45

Overview of the non-oncology group's achievements
P. Verze, Naples (IT)

13:45 - 13:55

Overview of the oncology group's achievements
E. Xylinas, Paris (FR)

13:55 - 14:00

Awards of the YAU: Best paper published in 2016 by a YAU group and Best poster presented at EAU 2017 by a YAU group

14:00 - 14:30

Key studies of the year

14:00 - 14:10

Robot versus open RP trial

14:00 - 14:10

Presenter
T.A.T. Marcelissen, Maastricht (NL)

14:00 - 14:10

Discussant
To be confirmed

14:10 - 14:20

ESWL vs URS for renal lithiasis

14:10 - 14:20

Presenter
P. Kallidonis, Patras (GR)

14:10 - 14:20

Discussant
O. Traxer, Paris (FR)

14:20 - 14:30

PROTECT trial

| | |
|---------------|--|
| 14:20 - 14:30 | Presenter G. Gandaglia, Milan (IT) |
| 14:20 - 14:30 | Discussant F.C. Hamdy, Oxford (GB) |
| 14:30 - 14:45 | Establishing a professional career at a European level: Motivational talk by Crystal Matula Award Winner To be confirmed |
| <hr/> | |
| 14:45 - 15:30 | Challenge the expert session: YAU versus key opinion leaders |
| | Moderators: S.D. Brookman-May, Munich (DE) G. Ploussard, Toulouse (FR) E. Xylinas, Paris (FR) |
| 14:45 - 15:00 | Adjuvant therapy for high-risk RCC |
| 14:45 - 14:52 | Pro I. Ouzaid, Paris Cedex 18 (FR) |
| 14:53 - 15:00 | Con A. Bex, Amsterdam (NL) |
| 15:00 - 15:15 | Adjuvant radiation therapy for prostate cancer |
| 15:00 - 15:07 | Pro P. Ost, Ghent (BE) |
| 15:08 - 15:15 | Con A. Heidenreich, Cologne (DE) |
| 15:15 - 15:30 | Adjuvant chemotherapy for bladder cancer |
| 15:15 - 15:22 | Pro R. Seiler, Bern (CH) |
| 15:23 - 15:30 | Con To be confirmed |
| <hr/> | |
| 15:30 - 16:00 | YAU meets sections: How to improve the collaboration? |
| | Moderators: T.A.T. Marcelissen, Maastricht (NL) F. Sanguedolce, London (GB) |
| 15:30 - 15:40 | Urological imaging J. Walz, Marseille (FR) |
| 15:40 - 15:50 | Urological research K. Junker, Homburg (DE) |

15:50 - 16:00

Transplantation
E. Lledó García, Madrid (ES)

Clinical aspects of infections in urology

Poster Session 10

Friday, 24 March
14:15 - 15:45

Location: Room Milan, North Hall (Level 1)

Chairs: F. Bruyere, Tours (FR)
T. Cai, Trento (IT)
F.M.E. Wagenlehner, Giessen (DE)

Aims and objectives of this presentation

Presentation of clinical infectious aspects in urology patients

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

14:38 - 14:48

Guidelines for the treatment of urinary tract infections

F.M.E. Wagenlehner, Giessen (DE)

*131

Risk factors in urosepsis associated with time to recovery: A prospective multinational observational study

By: Tandoi du Z.¹, Koves B.², Cai T.³, Platz A.⁴, Bjerklund Johansen T.E.⁵, Wagenlehner F.⁶

Institutes:¹Oslo University, Institute of Clinical Medicine, Oslo, Norway, ²South Pest Teaching Hospital, Dept. of Urology, Budapest, Hungary, ³Santa Chiara Hospital, Dept. of Urology, Trento, Italy, ⁴Universitätsklinikum Gießen und Marburg GmbH, Dept. of Children Urology and Andrology, Giessen, Germany, ⁵Oslo University, Dept. of Urology, Oslo, Norway, ⁶Universitätsklinikum Gießen und Marburg GmbH - Standort Gießen, Dept. of Children Urology and Andrology, Giessen, Germany

*132

Cirpofloxacin infusion versus 3rd generation cephalosporin as a surgical prophylaxis for percutaneous nephrolithotomy: randomized study

By: Omar M.K.M., El Sheirf E., El Shazly M., Sultan S.

Institutes: Menoufia University, Dept. of Urology, shibin el kom, Egypt

*133

Targeted antibiotic prophylaxis can prevent febrile urinary tract infection after removal of ureteral stents in radical cystectomy patients with intestinal urinary diversion

By: Nasu Y.¹, Murata T.¹, Sugimoto M.², Takamoto A.², Ono N.³

Institutes:¹Okayama Rosai Hospital, Dept. of Urology, Okayama, Japan, ²Okayama University Hospital, Dept. of Urology, Okayama, Japan, ³Kochi Health Sciences Center, Dept. of Urology, Kochi, Japan

*134

Efficacy and safety of different dosages of phosphomycin as antimicrobial prophylaxis in transrectal biopsy of the prostate: A pilot study

By: D'Elia C.¹, Emanuela T.¹, Ladurner C.¹, Saleh O.², Cai T.³, Palermo S.¹, Tischler T.¹, Spoladore G.⁴, Mian P.⁴, Pycha A.¹

Institutes:¹Bolzano General Hospital, Dept. of Urology, Bolzano, Italy, ²University of Florence, Dept. of Urology, Florence, Italy, ³Santa Chiara Hospital, Dept. of Urology, Trento, Italy, ⁴Bolzano General Hospital, Dept. of Infectious Diseases, Bolzano, Italy

*135

Rectal culture-guided targeted antimicrobial prophylaxis significantly reduces the incidence of post-operative infectious complications in men at high risk for infections submitted to transrectal ultrasound prostate biopsy –results of a cross-sectional study

By: Boeri L.¹, Fontana M.¹, Gallioli A.¹, Zanetti S.P.¹, Catellani M.², De Lorenzis E.¹, Palmisano F.¹, Longo F.¹, Montanari E.¹

Institutes:¹Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Dept. of Urology, Milan, Italy, ²Istituto Europeo Di Oncologia, Dept. of Urology, Milan, Italy

- *136 **Transurethral resection of the prostate: Are we following the guidelines? Outcomes from the global prevalence of infections in urology (GPIU) side study 2006-2009**
By: Köves B.¹, Tandogdu Z.², Cai T.³, Bogenhard F.⁴, Tenke P.¹, Wullt B.⁵, Naber K.⁶, Bartoletti R.⁷, Cek M.⁸, Kulchavenya E.⁹, Perepanova T.¹⁰, Pilatz A.¹¹, Bjerklund Johansen T-E.¹², Wagenlehner F.¹¹
Institutes:¹Jahn Ferenc South Pest Teaching Hospital, Dept. of Urology, Budapest, Hungary, ²Newcastle University, Northern Institute For Cancer Research, Newcastle Upon Tyne, United Kingdom, ³Santa Chiara Regional Hospital, Dept. of Urology, Trento, Italy, ⁴Technische Hochschule Mittelhessen, Dept. of Bioinformatics, Giessen, Germany, ⁵Lund University, Dept. of Microbiology, Immunology and Glycobiology, Lund, Sweden, ⁶Technical University of Munich, Dept. of Urology, Munich, Germany, ⁷University of Florence, Dept. of Experimental and Clinical Medicine, Florence, Italy, ⁸Trakya Medical School, Dept. of Urology, Edirne, Turkey, ⁹TB Research Institute, Novosibirsk, Russia, ¹⁰S.R. Urology Institute, Moscow, Russia, ¹¹Justus-Liebig-University, Dept. of Urology, Paediatric Urology and Andrology, Gießen, Germany, ¹²Oslo University, Dept. of Urology, Oslo, Norway
- *137 **Therapeutic effect of indoleamine 2,3-dioxygenase inhibitor in epididymitis**
By: Ohira S.¹, Hara R.¹, Tone S.², Kin S.¹, Shimizu S.¹, Fukumoto K.¹, Fujii T.¹, Miyaji Y.¹, Nagai A.¹
Institutes:¹Kawasaki Medical School, Dept. of Urology, Kurashiki City, Japan, ²Graduate School of Tokyo Denki University, Dept. of Life Science and Engineering, Hatoyama-Cho, Japan
- *138 **Canephron N reduced immune cell recruitment in experimental cystitis**
By: Nausch B.¹, Röhrl J.¹, Koeberle A.², Harler U.³, Joannidis M.³, Werz O.², Künstle G.¹
Institutes:¹Bionorica SE, Preclinical R&D, Neumarkt, Germany, ²Friedrich-Schiller-University Jena, Institute of Pharmacy, Jena, Germany, ³Medical University of Innsbruck, Intensive Care and Emergency Medicine Department, Innsbruck, Austria
- *139 **Alternative therapy for acute uncomplicated cystitis**
By: Kulchavenya E., Shevchenko S., Brizhatyuk E.
Institutes:Novosibirsk Research TB Institute, Dept. of Urogenital, Novosibirsk, Russia
- *141 **The reduction of escherichia coli resistance against ciprofloxacin is a microbiological parameter for asymptomatic bacteriuria predicting: Results from a cross-sectional study**
By: Cai T.¹, Mazzoli S.², Meacci F.², Tiscione D.¹, Malossini G.¹, Bartoletti R.³
Institutes:¹Santa Chiara Hospital, Dept. of Urology, Trento, Italy, ²Santa Maria Annunziata Hospital, Sexually Transmitted Disease Centre, Florence, Italy, ³University of Pisa, Dept. of Urology, Pisa, Italy
- *142 **Efficacy of antibiotic prophylaxis and cleaning/disinfection devices in flexible cystoscopy to prevent positive urinary culture after procedure**
By: Felip E.², Arzo Fabregas M.¹, Martinez Rodriguez R.H.¹, Juventeny N.², Ibarz Servio L.¹
Institutes:¹Hospital Universitari Germans Trias i Pujol, Dept. of Urology, Badalona, Spain, ²Hospital Universitari Germans Trias i Pujol, Dept. of Urology Nurse, Badalona, Spain
- *143 **A retrospective study of immunotherapy treatment with Uro-Vaxom® (OM-89) for prophylaxis of recurrent urinary tract infections**
By: Brodie A., Jour I., Charlotte F., Hanbury D.
Institutes:Lister Hospital, Dept. of Urology, Stevenage, United Kingdom

Options in intracorporeal neobladder reconstruction

Video Session 03

Friday, 24 March
14:15 - 15:45

Location: Room Paris, North Hall (Level 1)

Chairs: J.W. Collins, Stockholm (SE)
F.D. D'Hondt, Aalst (BE)

Aims and objectives of this presentation

Intracorporeal reconstructive surgery is challenging. The aims and objectives of this session are to present different approaches to intracorporeal neobladder reconstruction. Different centres of excellence will present their standardised approach and we will discuss the potential advantages (and disadvantages) from these different techniques and examining the current evidence.

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

- *V17 **Laparoscopic robot-assisted intracorporeal modified studer orthotopic neobladder following radical cystectomy**
By: [John H.](#)¹, Padevit C.¹, Horton K.¹, Hosseini A.², Wiklund P.²
Institutes:¹Kantonsspital Winterthur, Dept. of Urology, Winterthur, Switzerland, ²Karolinska Institutet, Dept. of Urology, Stockholm, Sweden
- *V18 **Laparoscopic radical cystectomy with intracorporeal heterotopic urinary diversion in a female patient with solitary kidney**
By: Nosov A., [Reva S.](#), Berkut M., Petrov S.
Institutes: N.N.Petrov Research Institute of Oncology, Dept. of Oncurology, Saint-Petersburg, Russia
- *V21 **Laparoscopic intracorporeal orthotopic ileal neobladder with double afferent isoperistaltic limbs**
By: [Xing N.](#)
Institutes: Beijing Chao-Yang Hospital, Capital Medical University, Dept. of Urology, Beijing, China
- *V22 **Robot-assisted radical cystectomy with totally intracorporeal orthotopic ileal neobladder: Preliminary Experience**
By: [Minervini A.](#), Vanacore D., Sessa F., Chini T., Sforza S., Campi R., Mari A., Vielli D., Cini C., Sebastianelli A., Tuccio A., Siena G., Carini M.
Institutes: University of Florence, Dept. of Urology, Florence, Italy

Prostate cancer progression, epithelial to mesenchymal transition and nuclear receptors

Poster Session 11

Friday, 24 March
14:15 - 15:45

Location: Room Amsterdam, North Hall (Level 1)

Chairs: A. Bjartell, Malmö (SE)
G. Carbone, Bellinzona (CH)
M. Puhr, Innsbruck (AT)

Aims and objectives of this presentation

Cellular events during prostate cancer progression are controlled by transcription factors, miRNA, and nuclear receptors. Several contributions highlight the role of miRNA in different prostate cell types and show causal relationship with prostate cancer progression and stemness. These novel regulatory networks will be discussed in the session.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *145 **Functional high-throughput screening and expression analysis identify microRNAs sharing the AAGUGC seed sequence as key regulators of epithelial-mesenchymal transition in prostate cancer**
By: [Bao S.](#)¹, Howarth A.², Kratschmer P.¹, Snaith A.¹, Haire A.¹, Yapp C.¹, Ebner D.², Hamdy F.¹, Edwards C.¹
Institutes:¹University of Oxford, Nuffield Dept. of Surgical Sciences, Oxford, United Kingdom, ²University of Oxford, Nuffield Dept. of Medicine, Oxford, United Kingdom
- *146 **MicroRNA-424 promotes STAT3 activation and prostate cancer progression**
By: Dallavalle C.¹, Albino D.¹, Civenni G.¹, Merulla J.¹, Mello-Grand M.², Ostano P.², Losa M.¹, Thalmann G.³, Chiorino G.², Catapano C.¹, [Carbone G.](#)¹
Institutes:¹IOR Institute of Oncology Research, Tumor Biology and Experimental Therapeutic, Bellinzona, Switzerland, ²Fondo Edo Tempia, Laboratory of Cancer Genomics, Biella, Italy, ³University of Bern, Inselspital, Dept. of Urology, Bern, Switzerland
- *147 **Characterization and personalized treatment response in primary and metastatic prostate canceroids**
By: [Karkampouna S.](#)¹, La Manna F.², Zoni E.¹, Beimers L.³, Kloen P.⁴, Wetterwald A.¹, Grosjean J.¹, Klima I.¹, Cecchini M.¹, Spahn M.⁵, Thalmann G.⁵, Kruithof-De Julio M.¹
Institutes:¹Urology Research Laboratory, Dept. of Clinical Research, Bern, Switzerland, ²Leiden University Medical Center, Dept. of Urology, Leiden, The Netherlands, ³Slotervaart Medical Centre, Dept. of Orthopaedic Surgery, Amsterdam, The Netherlands, ⁴Academic Medical Centre, Dept. of Orthopaedic Trauma Surgery, Amsterdam, The Netherlands, ⁵University Hospital Bern, Dept. of Urology, Bern, Switzerland
- *148 **MCAM supports the aggressive phenotype in human prostate cancer**
By: [Zoni E.](#)¹, Astrologo L.¹, Melsen J.², Klima I.¹, Grosjean J.¹, Van Der Pluijm G.², Cecchini M.¹, Kruithof-De Julio M.¹, Thalmann G.³
Institutes:¹Urology Research Laboratory, Dept. of Clinical Research, Bern, Switzerland, ²Leiden University Medical Center, Urology Research Laboratory, Leiden, The Netherlands, ³University Hospital Bern, Dept. of Urology, Bern, Switzerland
- *149 **Epigenetic mechanisms and therapeutic opportunities in metastatic castration resistant prostate cancer**

By: [Ruggero K](#)¹, [Giacobbe A](#)², [Mitrofanova A](#)³, [Calvet A](#)¹, [Palomero L](#)¹, [Pujana M.A](#)¹, [Califano A](#)⁴, [Abate-Shen C](#)², [Aytes A](#)¹

Institutes:¹Idibell, Dept. of Procure, Ico, Barcelona, Spain, ²Institute of Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, Dept. of Urology, Medicine, Systems Biology, and Pathology and Cell Biology, New York, United States of America, ³Rutgers, Dept. of Health Informatics, Newark, United States of America, ⁴Center For Computational Biology and Bioinformatics, Institute of Cancer Genetics, Herbert Irving Co, Dept. of Systems Biology, Biomedical Informatics, and Biochemistry and Molecular Biophysics, New York, United States of America

*150

EMT status within M1 diagnostic prostate biopsies correlate with stem like phenotype and loss of AR signalling

By: [Hiew K](#)¹, [Bokobza S](#)², [Hart C](#)³, [Elliott T](#)⁴, [Smith N](#)², [Brown M](#)³, [Clarke N](#)⁵

Institutes:¹Salford Royal NHS Foundation Trust, Dept. of Urology, Salford, United Kingdom, ²AstraZeneca, R&D, Oncology IMed, Macclesfield, United Kingdom, ³The University of Manchester, Genito Urinary Cancer Research Group, Division of Molecular & Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, Manchester, United Kingdom, ⁴Christie Hospital NHS Foundation Trust, Dept. of Oncology, Manchester, United Kingdom, ⁵Christie Hospital NHS Foundation Trust, Dept. of Urology, Manchester, United Kingdom

*151

Steroid hormone receptors are differently expressed in prostate cancer depending on Gleason grade and presence of disease recurrence

By: [Gevaert T](#)¹, [Vandenbroeck T](#)¹, [Van Poppel H](#)¹, [Claessens F](#)², [Salmon I](#)³, [Rorive S](#)³, [Decaestecker C](#)⁴, [Van Eycke Y](#)⁴, [De Ridder D](#)¹, [Joniau S](#)¹

Institutes:¹UZ Leuven, Dept. of Urology, Leuven, Belgium, ²KU Leuven, Dept. of Molecular and Cellular Medicine, Leuven, Belgium, ³Université Libre De Bruxelles, Dept. of Pathology, Bruxelles, Belgium, ⁴Université Libre De Bruxelles, DIAPath - Center For Microscopy and Molecular Imaging, Gosselies, Belgium

*152

Characterizing androgen receptor blockade- and metabolic stress-induced tunneling nanotube formation supporting stress adaptivity in prostate cancer

By: [Kretschmer A](#)¹, [Zhang F](#)¹, [Tse C](#)¹, [Leachman L](#)¹, [Gleave A](#)¹, [Somasekharan S.P](#)¹, [Sorensen P](#)², [Gleave M](#)¹

Institutes:¹Vancouver Prostate Centre, Dept. of Urologic Sciences, Vancouver, Canada, ²BC Cancer Research Centre, Dept. of Pathology, Vancouver, Canada

*153

Neoadjuvant hormonal therapies induce the expression of AR transcript variants

By: [Tammela T](#)¹, [Kallio H](#)², [Annala M](#)², [Brofeldt A](#)², [Hieta R](#)², [Kivinummi K](#)², [Nykter M](#)², [Lilja H](#)², [Bova G](#)², [Visakorpi T](#)²

Institutes:¹Tampere University Hospital, Dept. of Surgery, Tampere, Finland, ²University of Tampere, Biomeditech, Tampere, Finland

*154

Galectin-3 is involved in the progression of castration-resistant prostate cancer through the regulation of tumor invasion, angiogenesis and androgen receptor signaling

By: [Fukumori T](#)¹, [Dondoo T-O](#)¹, [Daizumoto K](#)², [Fukawa T](#)², [Yamamoto Y](#)², [Yamaguchi K](#)², [Takahashi M](#)², [Kanayama H-O](#)²

Institutes:¹Tokushima University, Dept. Of Urology, Tokushima, Japan, ²Tokushima University, Dept. of Urology, Tokushima, Japan

*156

Semaphorin/plexin signalling promotes trafficking of glucocorticoid receptor and androgen receptor to the nucleus

By: [Magali Williamson M](#)

Institutes:Kings College London, Randall Division, London, United Kingdom

15:34 - 15:41

Epithelial to mesenchymal transition in prostate cancer

G. Carbone, Bellinzona (CH)

Evolving knowledge in neuro-urology

Poster Session 12

Friday, 24 March
14:15 - 15:45

Location: Room Berlin, North Hall (Level 1)

Chairs: S. Charalampous, Limassol (CY)
T.M. Kessler, Zurich (CH)
T.L.C. Kuo, Singapore (SG)

Aims and objectives of this presentation

Neurological diseases can cause considerable urological problems. In this session recent advances are discussed.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *157 **The use of mirabegron in the treatment of overactive bladder in patients affected by Parkinson's disease**
By: Gubbiotti M., Rossi De Vermandois J., Turco M., Giannantoni A.
Institutes:University of Perugia, Dept. of Surgical and Biomedical Sciences, Perugia, Italy
- *158 **Comparison of intradetrusor injections of botulinum toxin A in adult patients with spina bifida and in patients with spinal cord injury: A multicenter study**
By: Peyronnet B.¹, Hascoet J.¹, Roumiguie M.², Castel-Lacanal E.³, Marque P.³, Manunta A.¹, Game X.²
Institutes:¹CHU Rennes, Dept. of Urology, Rennes, France, ²CHU Toulouse, Dept. of Urology, Toulouse, France, ³CHU Toulouse, Dept. of Physical Medicine and Rehabilitation, Toulouse, France
- *159 **Clinical profile of amyotrophic lateral sclerosis patients with lower urinary tract symptoms and neurogenic bladder: A cross-sectional study**
By: Arlandis S.¹, Vázquez-Costa J.F.², Martínez-Cuenca E.¹, Hervás D.³, Sevilla T.², Broseta Rico E.¹
Institutes:¹La Fe, University and Polytechnic Hospital, Dept. of Urology, Valencia, Spain, ²La Fe, University and Polytechnic Hospital, Dept. of Neurology, Valencia, Spain, ³Instituto De Investigación Sanitaria La Fe, Dept. of Biostatistics, Valencia, Spain
- *160 **Frontal lobe function correlates with one-year incidence of urinary incontinence in elderly with Alzheimer disease**
By: Yoshida M.¹, Sugimoto T.², Ono R.³, Murata S.³, Saji N.², Niida S.⁴, Toba K.², Sakurai T.²
Institutes:¹National Center For Geriatrics and Gerontology, Dept. of Urology, Obu, Japan, ²National Center For Geriatrics and Gerontology, Center For Comprehensive Care and Research On Memory Disorders, Obu, Japan, ³Kobe University, Graduate School of Health Sciences, Dept. of Community Health Sciences, Kobe, Japan, ⁴National Center For Geriatrics and Gerontology, Medical Genome Center, Obu, Japan
- *161 **Feasibility, morbidity and functional results of robotic supratrigonal cystectomy with augmentation ileocystoplasty**
By: Madec F.-X., Hedhli O., Perrouin-Verbe M.-A., Robine E., Le Clerc Q.-C., Branchereau J., Le Normand L., Rigaud J.
Institutes:Nantes University Hospital, Dept. of Urology, Nantes, France
- *162 **Intra detrusor injections of botulinum toxin type A in children with spina bifida: A multicenter study**
By: Hascoet J.¹, Forin V.², Baron M.³, Capon G.⁴, Prudhomme T.⁵, Allenet C.⁴, Tournier S.², Maurin

C.⁶, Bouali O.⁷, Peycelon M.⁸, Fremond B.⁹, Renaux-Petel M.¹⁰, Manunta A.¹, Liard A.¹⁰, Karsenty G.⁶, Arnaud A.⁹, Cornu J.-N.³, Game X.⁵, Peyronnet B.¹

Institutes:¹Rennes University Hospital, Dept. of Urology, Rennes, France, ²Trousseau Hospital, Dept. of Pediatric Physic, Paris, France, ³Rouen University Hospital, Dept. of Urology, Rouen, France, ⁴Bordeaux University Hospital, Dept. of Urology, Bordeaux, France, ⁵Toulouse University Hospital, Dept. of Urology, Toulouse, France, ⁶AP-HM Conception, Dept. of Urology, Marseille, France, ⁷Toulouse University Hospital, Dept. of Pediatric Surgery, Toulouse, France, ⁸Trousseau Hospital, Dept. of Pediatric Surgery, Paris, France, ⁹Rennes University Hospital, Dept. of Pediatric Surgery, Rennes, France, ¹⁰Rouen University Hospital, Dept. of Pediatric Surgery, Rouen, France

*163

Comparison between different dosages of intradetrusor botulinum toxin to treat neurogenic detrusor overactivity

By: Spinelli M., Guerrer C., Citeri M., Zanollo L., Tamarelle B., Rizzato L.

Institutes:Hospital Niguarda Milan, Alberto Zanollo Center, Spinal Unit, Milan, Italy

*164

Long-term outcome of adenosine A2A receptor antagonist on lower urinary tract symptoms in male Parkinson's disease patients

By: Kitta T.¹, Yabe I.², Kanno Y.¹, Ouchi M.¹, Moriya K.¹, Takahashi I.², Matsushima M.², Sasaki H.², Shinohara N.¹

Institutes:¹Hokkaido University School of Medicine, Dept. of Urology, Sapporo, Japan, ²Hokkaido University School of Medicine, Dept. of Neurology, Sapporo, Japan

*165

Can we avoid bladder augmentation in case of failure of a first intradetrusor botulinum toxin injections in patients with spinal dysraphism?

By: Peyronnet B.¹, Amarenco G.², De Seze M.³, Schurch B.⁴, Even A.⁵, Verrando A.², Capon G.⁶, Hascoet J.¹, Castel-Lacanal E.⁷, Lenormand C.⁸, Maurin C.⁹, Biardeau X.¹⁰, Monleon L.¹¹, Marcelli F.¹⁰, Perrouin-Verbe M-A.⁸, Baron M.¹², Allenet C.⁶, Cornu J-N.¹², Mouracade P.¹³, Boutin J-M.¹¹, Saussine C.¹³, Grise P.¹², Lenormand L.⁸, Kerdraon J.¹⁴, Chartier-Kastler E.¹⁵, Karsenty G.⁹, Denys P.⁵, Manunta A.¹, Game X.⁷

Institutes:¹CHU Rennes, Dept. of Urology, Rennes, France, ²Tenon Hospital, Dept. of Neurourology, Paris, France, ³Clinique Saint-Augustin, Dept. of Neurourology, Bordeaux, France, ⁴CHU Lausanne, Dept. of Neurourology, Lausanne, France, ⁵Raymond Poincaré Hospital, Dept. of Neurourology, Garches, France, ⁶CHU Bordeaux, Dept. of Urology, Bordeaux, France, ⁷CHU Toulouse, Dept. of Urology, Toulouse, France, ⁸CHU Nantes, Dept. of Urology, Nantes, France, ⁹CHU Marseille, Dept. of Urology, Marseille, France, ¹⁰CHU Lille, Dept. of Urology, Lille, France, ¹¹CHU Tours, Dept. of Urology, Tours, France, ¹²CHU Rouen, Dept. of Urology, Rouen, France, ¹³CHU Strasbourg, Dept. of Urology, Strasbourg, France, ¹⁴CHU Rennes, Dept. of Physical Medicine and Rehabilitation, Rennes, France, ¹⁵Pitié Salpêtrière Hospital, Dept. of Urology, Paris, France

*166

Combined treatment of DDAVP and mirabegron represents an effective treatment of neurogenic detrusor overactivity in patients with multiple sclerosis

By: Zachariou A.¹, Filiponi M.², Dimitriadis F.¹, Takenaka A.³, Sofikitis N.¹

Institutes:¹Ioannina University School of Medicine, Dept. of Urology, Ioannina, Greece, ²Elpis Hospital, Dept. of Urology, Volos, Greece, ³Tottori University School of Medicine, Dept. of Urology, Tottori, Japan

*167

Detrusor acontractility after acute spinal cord injury: Myth or reality

By: Bywater M., Tornic J., Mehnert U., Kessler T.

Institutes:University Hospital Balgrist, Dept. of Neuro Urology, Zürich, Switzerland

*168

High EDSS can predict risk for upper urinary tract damage in patients with multiple sclerosis

By: Schneider M.P.¹, Ineichen B.¹, Hagenbuch N.², Linnebank M.³, Kessler T.⁴

Institutes:¹University Hospital of Zürich, Dept. of Neuro-Urology, Zürich, Switzerland, ²Biostatistics and Prevention Institute, Dept. of Biostatistics, Zürich, Switzerland, ³University Hospital Zürich, Dept. of Neurology, Zürich, Switzerland, ⁴Balgrist University Hospital, Dept. of Neuro-Urology, Zürich, Switzerland

*169

Influence of botulinum toxin type A on urodynamic parameters and sexual function in men with

neurogenic detrusor overactivity

By: Sivkov A.¹, Romikh V.², Panteleev V.², Zakharchenko A.², Arkhireev A.², Apolikhin O.¹, Kaprin A.³

Institutes:¹Research Institute of Urology and Interventional Radiology N.a. Lopatkin - Branch of Fsbj Nmrrc, Moscow, Russia, ²Research Institute of Urology and Interventional Radiology N.a. Lopatkin - Branch of Fsbj Nmrrc, Neurourology and Urodynamics, Moscow, Russia, ³Fsbj Nmrrc, Moscow, Russia

Perioperative chemotherapy and advanced disease - increasing experience and new aspects

Poster Session 13

Friday, 24 March
14:15 - 15:45

Location: Room Vienna, North Hall (Level 1)

Chairs: P. Patel, Birmingham (GB)
C.N. Sternberg, Rome (IT)
J.A. Witjes, Nijmegen (NL)

Aims and objectives of this presentation

This session will highlight new data on systemic perioperative therapy and advanced bladder cancer, including chemotherapy, immunotherapy and prediction of outcome.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*170

Pembrolizumab produces clinically meaningful responses as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from subgroup analyses of KEYNOTE-052

By: Powles T.¹, Bellmunt J.², Castellano D.³, O'donnell P.⁴, Grivas P.⁵, Vuky J.⁶, Plimack E.⁷, Hahn N.⁸, Balar A.⁹, Pang L.¹⁰, Savage M.¹⁰, Perini R.¹⁰, Keefe S.¹⁰, Bajorin D.¹¹, De Wit R.¹²

Institutes:¹Barts Cancer Institute, Queen Mary University of London, Dept. of Experimental Cancer Medicine, London, United Kingdom, ²Dana-Farber Cancer Institute, Dept. of Genitourinary Oncology, Boston, United States of America, ³Hospital Universitario 12 De Octubre, Dept. of Medicine, Madrid, Spain, ⁴The University of Chicago Medical Centre, Dept. of Medicine, Chicago, United States of America, ⁵Cleveland Clinic, Dept. of Hematology and Oncology, Cleveland, United States of America, ⁶Oregon Health & Science University, Dept. of Oncology, Portland, United States of America, ⁷Fox Chase Cancer Center, Dept. of Hematology and Oncology, Philadelphia, United States of America, ⁸Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Dept. of Oncology and Urology, Baltimore, United States of America, ⁹Perlmutter Cancer Center, NYU Langone Medical Center, Dept. of Medicine, New York, United States of America, ¹⁰Merck & Co., Inc., Dept. of Clinical Oncology, Kenilworth, United States of America, ¹¹Memorial Sloan Kettering Cancer Center, Dept. of Medical Oncology, New York, United States of America, ¹²Erasmus MC Cancer Institute, Dept. of Urology and Oncology, Rotterdam, The Netherlands

*171

Updated meta-analysis (MA) of salvage therapy for metastatic urothelial cancer (mUC): Comparing outcomes of immunotherapy (IT) vs. single agent and doublet chemotherapy (CT)

By: Necchi A.¹, Raggi D.¹, Sonpavde G.², Giannatempo P.³, Mariani L.⁴, Galsky M.⁵, Bellmunt J.⁶, Miceli R.⁴

Institutes:¹Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, ²UAB Comprehensive Cancer Center, Dept. of Medical Oncology & Hematology, Birmingham, United States of America, ³Fondazione IRCCS Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, ⁴Fondazione IRCCS Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy, ⁵Mount Sinai School of Medicine, Tisch Cancer Institute, Dept. of Medical Oncology, New York, United States of America, ⁶Dana-Farber Cancer Institute and Harvard Medical School, Dept. of Medical Oncology, Boston, United States of America

*172

Adjuvant chemotherapy vs. observation following radical cystectomy for pT3-4 and/or pN+ urothelial carcinoma of the bladder previously treated with neoadjuvant chemotherapy

By: Seisen T.¹, Jamzadeh A.², Vetterlein M.¹, Von Landenberg N.¹, Gild P.¹, Menon M.², Rouprêt M.³, Sun M.¹, Choueiri T.⁴, Bellmunt J.⁴, Trinh Q.-D.¹

Institutes:¹Brigham and Women's Hospital, Harvard Medical School, Division of Urological Surgery and Center For Surgery and Public Health, Boston, United States of America, ²Henry Ford Health

System, VUI Center For Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Detroit, United States of America, ³Pitié-Salpêtrière, APHP, University Paris VI, Department of Urology, Paris, France, ⁴Dana Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America

- *173 **Comparative effectiveness of selective adjuvant versus systematic neoadjuvant chemotherapy-based strategy for muscle-invasive urothelial carcinoma of the bladder**
By: Seisen T.¹, Sonpavde G.², Kachroo N.³, Lipsitz S.⁴, Leow J.¹, Menon M.³, Gild P.¹, Von Landenberg N.¹, Rouprêt M.⁵, Kibel A.¹, Sun M.¹, Pal S.⁶, Bellmunt J.⁷, Choueiri T.⁷, Trinh Q-D.¹
Institutes:¹Brigham and Women's Hospital, Harvard Medical School, Division of Urological Surgery and Center For Surgery and Public Health, Boston, United States of America, ²University of Alabama At Birmingham, Division of Hematology-Oncology, Department of Medicine, Birmingham, United States of America, ³Henry Ford Health System, VUI Center for Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Detroit, United States of America, ⁴Brigham and Women's Hospital, Harvard Medical School and Harvard T.H. Chan School of Public Health, Center for Surgery and Public Health, Boston, United States of America, ⁵Pitié-Salpêtrière, APHP, University Paris VI, Dept. of Urology, Paris, France, ⁶City of Hope Comprehensive Cancer Center, Dept. of Medical Oncology & Experimental Therapeutics, Duarte, United States of America, ⁷Dana Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America
- *174 **Neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) for muscle-invasive urothelial bladder cancer (MIUBC): Final results and translational findings of an open-label, single-arm, phase 2 study**
By: Necchi A.¹, Lo Vullo S.², Raggi D.¹, Giannatempo P.¹, Nicolai N.³, Piva L.³, BIASONI D.³, Catanzaro M.³, Torelli T.³, Stagni S.³, Calareso G.⁴, Togliardi E.⁵, Colecchia M.⁶, Busico A.⁶, Perrone F.⁶, Pennati M.⁷, Zaffaroni N.⁷, Mariani L.², Salvioni R.³
Institutes:¹Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, ²Fondazione IRCCS - Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy, ³Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, ⁴Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Radiology, Milan, Italy, ⁵Fondazione IRCCS - Istituto Nazionale Dei Tumori, Pharmacy Unit, Milan, Italy, ⁶Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Pathology, Milan, Italy, ⁷Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Experimental Oncology and Molecular Medicine, Milan, Italy
- *175 **Is neoadjuvant chemotherapy beneficial before radical cystectomy? Examining the external validity of the swog-8710 trial**
By: Hanna N.¹, Trinh Q.-D.¹, Sammon J.², Seisen T.¹, Vetterlein M.¹, Moreira R.³, Preston M.¹, Lipsitz S.¹, Bellmunt J.³, Menon M.², Choueiri T.³, Abdollah F.²
Institutes:¹Brigham and Women's Hospital, Harvard Medical School, Dept. of Urology, Boston, United States of America, ²Henry Ford Hospital, Dept. of Urology, Detroit, United States of America, ³Dana-Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America
- *176 **An inconvenient truth: Difference between patient-reported and doctor-reported outcomes in advanced urothelial carcinoma**
By: Hamano I.¹, Hatakeyama S.¹, Narita T.¹, Fukushi K.¹, Yamamoto H.¹, Soma O.¹, Matsumoto T.¹, Tobisawa Y.¹, Yoneyama T.², Imai A.¹, Yoneyama T.¹, Hashimoto Y.², Koie T.¹, Ohyama C.¹
Institutes:¹Hirosaki University School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Hirosaki University School of Medicine, Dept. of Advanced Transplant and Regenerative Medicine, Hirosaki, Japan
- *177 **Survival benefit of neoadjuvant chemotherapy for muscle invasive bladder cancer in elderly patients**
By: Hamano I.¹, Hatakeyama S.¹, Oikawa M.¹, Narita T.¹, Hagiwara K.¹, Tanaka T.¹, Noro D.¹, Yuki T.¹, Yamamoto H.¹, Yoneyama T.², Imai A.¹, Yoneyama T.¹, Hashimoto Y.², Koie T.¹, Ohyama C.¹
Institutes:¹Hirosaki University School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Hirosaki University School of Medicine, Dept. of Advanced Transplant and Regenerative Medicine, Hirosaki, Japan

- *178 **The pathological and clinical response of the luminal and basal subtypes of muscle-invasive bladder cancer to neoadjuvant cisplatin-based chemotherapy and radical cystectomy depend on the immunohistochemical classification system**
By: Zhang R.¹, Chen H.¹, Xia J.², Shi O.³, Cao M.¹, Jin D.¹, Li C.⁴, Zhuang G.⁵, Liu Q.², Xue W.¹, Radvanyi F.⁶, Allory Y.⁷, Huang Y.¹
Institutes:¹Shanghai Renji Hospital, Dept. of Urology, Shanghai, China, ²Shanghai Renji Hospital, Dept. of Pathology, Shanghai, China, ³Shanghai Jiao Tong University School of Medicine, Dept. of Epidemiology and Statistics, Shanghai, China, ⁴Chinese Academy of Sciences, Chinese Academy of Sciences Protein Science Core Facility Center, Institute of Biophysics, Beijing, China, ⁵Renji-Med X Clinical Stem Cell Research Center, Renji Hospital, State Key Laboratory of Oncogenes and Related Genes, Shanghai, China, ⁶Institut Curie, CNRS, UMR 144, Paris, France, ⁷AP-HP, Hôpitaux Universitaires Henri-Mondor, Dept. of Pathology, Créteil, France
- *179 **Impact of adjuvant chemotherapy in patients with pT3NanyM0 upper tract urothelial cancer following radical nephroureterectomy**
By: Song W., Choi Y.H., Chung H.W., Lee C.U., Na J.P., Sung H.H., Jeon H.G., Jeong B.C., Seo S.I., Jeon S.S., Choi H.Y., Lee H.M.
Institutes:Samsung Medical Center, Sungkyunkwan University School of Medicine, Dept. of Urology, Seoul, South Korea
- *180 **Multimodal bladder preservation technique for muscle invasive bladder cancer: Results from a prospective trial**
By: Inamoto T.¹, Takahara K.², Ibuki N.², Takai T.², Uchimoto T.³, Saito K.², Tanda N.², Yoshikawa Y.², Minami K.², Hirano H.², Nomi H.², Azuma H.², Yamamoto K.⁴, Shinbo T.⁴, Yamamoto K.⁴, Narumi Y.⁴
Institutes:¹Osaka Medical College, Osaka, Japan, ²Osaka Medical College, Dept. of Urology, Osaka, Japan, ³Osaka Medical College Mishima-Minami Hospital, Dept. of Urology, Osaka, Japan, ⁴Osaka Medical College, Dept. of Radiology, Osaka, Japan
- 15:26 - 15:36 **Aspects on perioperative chemotherapy**
 C.N. Sternberg, Rome (IT)

'Sleepless nights': Would you do the same again?

Plenary session 01

Saturday, 25 March
08:30 - 10:00

Location: eURO Auditorium (Level 0)

Chairs: T.S. O'Brien, London (GB)
B. Leigh, London (GB)

Aims and objectives of this presentation

To explore controversies in Renal cancer management through the prism of the law court. If events didn't go to plan, would the decisions you made stand up to scrutiny by a lawyer? Expert urological surgeons will discuss the evidence for why they managed the case in the way they did; they will then be cross examined by legal counsel.

During the plenary sessions, French and Spanish translation will be provided. Please collect your headset in the session room prior to the start of the session and return it after the session.

Meet the speakers of the plenary session:

Delegates are able to meet the speakers of the plenary session immediately at the end of the session in the foyer of the eURO Auditorium (Level 0). Do not miss this opportunity to meet and greet the speakers and to consult them for any questions you may have.

08:30 - 09:00

Case presentation 3 cm mass in a 70 year old

08:30 - 08:32

Case presenter
T.S. O'Brien, London (GB)

08:32 - 08:42

Urologist in the dock
A. Bex, Amsterdam (NL)

08:42 - 08:52

Cross examination
B. Leigh, London (GB)

08:52 - 09:00

Discussion

09:00 - 09:30

Case presentation 4.5 cm mass in a 50 year old

09:00 - 09:02

Case presenter
T.S. O'Brien, London (GB)

09:02 - 09:12

Urologist in the dock
C.K. Bensalah, Rennes (FR)

09:12 - 09:22

Cross examination
B. Leigh, London (GB)

09:22 - 09:30

Discussion

09:30 - 10:00

Case presentation 12 cm mass with lung metastases

09:30 - 09:32

Case presenter

T.S. O'Brien, London (GB)

09:32 - 09:42

Urologist in the dock

V. Matveev, Moscow (RU)

09:42 - 09:52

Cross examination

B. Leigh, London (GB)

09:52 - 10:00

Discussion

Hot topics in andrology

Plenary session 02

Saturday, 25 March
08:30 - 10:00

Location: Room Copenhagen, North Hall (Level 1)

Chairs: F. Montorsi, Milan (IT)
H. Van Poppel, Leuven (BE)

Aims and objectives of this presentation

The aim of this session is to give the urologist insight into gold standards, controversies, and future developments within andrology. This plenary session will include state-of-the art lectures from key opinion leaders in the field of andrology and will focus on the management of patients with erectile dysfunction, premature ejaculation, male infertility, and hypogonadism.

During the plenary sessions, French and Spanish translation will be provided. Please collect your headset in the session room prior to the start of the session and return it after the session.

Meet the speakers of the plenary session:

Delegates are able to meet the speakers of the plenary session immediately at the end of the session in the foyer of the Room Copenhagen (North Hall, Level 1). Do not miss this opportunity to meet and greet the speakers and to consult them for any questions you may have.

08:30 - 08:45

State-of-the-art lecture Testosterone therapy in men with prostate cancer
P.B. Ostergren, Copenhagen (DK)

08:45 - 09:00

State-of-the-art lecture Scrotal pain: The optimal treatment algorithm
Y. Reisman, Amstelveen (NL)

09:00 - 09:15

State-of-the-art lecture Penile implants in Peyronie's disease and priapism: When and how?
D.J. Ralph, London (GB)

09:15 - 09:30

State-of-the-art lecture From impaired testicular development to poor male reproductive function
S. Kliesch, Münster (DE)

09:30 - 09:45

State-of-the-art lecture Is every man fertile?
M. Shabbir, London (GB)

09:45 - 10:00

State-of-the-art lecture Male contraception: Where are we going?
F. Fusco, Napoli (IT)

Special session of the History office

Special session

Saturday, 25 March
08:30 - 11:30

Location: Room 9, Capital suite (level 3)

Chair: P.E. Van Kerrebroeck, Maastricht (NL)

Aims and objectives of this presentation

This sessions is divided in two parts. The first part deals with the evolution of British Urology, presenting interesting highlights of the long history of Urology in the United Kingdom. The second part will discuss some important aspects of Urology during the Nazi time

08:30 - 08:35

Welcome and introduction

P.E. Van Kerrebroeck, Maastricht (NL)
P.M. Thompson, London (GB)

08:30 - 10:30

The evolution of British urology

Moderators: P.M. Thompson, London (GB)
P.E. Van Kerrebroeck, Maastricht (NL)

08:35 - 08:55

From stonecutters to science: The early days in the evolution in British urology

P. Kumar, Coventry (GB)

08:55 - 19:15

Sir Henry Thompson, the first British urologist

P.M. Thompson, London (GB)

09:15 - 09:35

St Peters Hospital, the first Urology Hospital

P. Worth, London (GB)

09:35 - 09:55

Peter Freyer, the First Leader of British urology

To be confirmed

09:55 - 10:15

Terrence Millin, his impact on British urology

J.C. Goddard, Leicester (GB)

10:15 - 10:35

The role of the RSM and BAUS in the development of British urology

R. Kirby, London (GB)

10:35 - 11:30

Research Project: Urology under the Swastika

Moderators: D. Schultheiss, Giessen (DE)
P.E. Van Kerrebroeck, Maastricht (NL)

10:35 - 11:05

Urology under the Swastika: A global issue

D. Schultheiss, Giessen (DE)

11:05 - 11:30

Urology under the Swastika: The British perspective

To be confirmed

ESU/ESFFU Hands-on Training course in OnabotulinumtoxinA administration for OAB

HOT15

Saturday, 25 March
09:30 - 11:00

Location: Room Europe, Exhibition Hall (Level 1)

Chair: H. Hashim, Bristol (GB)

Aims and objectives of this presentation

Botulinum toxin type A administration in Urology has become common practice over the last two decades. Following the completion of Phase 3 registration trials in OAB, OnabotulinumtoxinA received marketing approval for this indication and now has a standardised injection paradigm. This course is procedure-focused, and will teach attendees the practicalities of OnabotulinumtoxinA administration through short lectures, videos and hands-on demonstrations using bladder models. Attendees will learn how to reconstitute the product and see different types of equipment available.

R. Inman, Sheffield (GB)

M.S. Rahnama'i, Heerlen (NL)

A. Sahai, London (GB)

ESU/ESFFU Hands-on Training in Urodynamics

HOT05

Saturday, 25 March
09:30 - 12:30

Location: Room North America, Exhibition Hall (Level 1)

Chair: G. Van Koeveringe, Maastricht (NL)

Aims and objectives of this presentation

This course aims to provide a practical course offering an interactive “hands-on” environment for doctors, nurses and technicians to improve their skills in urodynamics.

Programme:

Plenary Session How to perform CMG, VCMG, AmbCMG, UPP and RLPP

Station 1 Urodynamics: The principles of pressure and flow measurements. The limitation and advantages of each approach, potential artefacts and their mitigations will also be discussed

Station 2 Male case studies: characteristic traces of filling voiding and voiding phase traces as well as fluoroscopy images of outlet obstruction

Station 3 Female case studies: characteristic filling voiding and voiding phase traces as well as fluoroscopy images of outlet obstruction and with emphasis on the assessment of stress urinary incontinence

Station 4 Neuropathic case studies: special considerations of performing urodynamics in this cohort as well as characteristic traces and images will be discussed

E. Finazzi Agrò, Rome (IT)

R. Kirschner-Hermanns, Aachen (DE)

T. McKinney, Fort Lauderdale (US)

To be confirmed

P.F.W.M. Rosier, Nijmegen (NL)

To be confirmed

ESU/ESUT Hands-on Training in Basic laparoscopic skills

HOT01

Saturday, 25 March
09:45 - 10:45

Location: Room South America, Exhibition Hall (Level 1)

Aims and objectives of this presentation

In this course basic laparoscopic and suturing skills can be learned and trained. Psychomotor skills such as depth perception and bimanual dexterity are trained by the validated exercises of the European Basic Laparoscopic Urological Skills (E-BLUS) training programme.

Experienced laparoscopist-tutors will guide you to master such basic laparoscopy skills as instrument handling, pattern cutting and intracorporal suturing. This course can be used as an additional training to prepare for the E-BLUS examination. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

Kidney transplant and urological cancer

Meeting of the EAU Section of Transplantation Urology (ESTU), in cooperation with the EAU Section of Oncological Urology (ESOU)

Saturday, 25 March
10:00 - 14:00

Location: Room Berlin, North Hall (Level 1)

Chairs: M. Brausi, Modena (IT)
E. Lledó García, Madrid (ES)

Aims and objectives of this presentation

Malignancy has become one of the three major causes of death after transplantation in the past decade and is thus increasingly important in all organ transplant programs. The objective of this session is to update real incidence and therapeutically aspects of urological cancers in both candidates and kidney transplant receptors.

10:00 - 10:05

Welcome and introduction

M. Brausi, Modena (IT)
E. Lledó García, Madrid (ES)

10:05 - 10:40

Prostate cancer in donors and KT candidates

Moderator: P. Ditonno, Bari (IT)

10:05 - 10:15

Screening of prostate cancer in donors: When?

A. Chkhotua, Tbilisi (GE)

10:15 - 10:25

The receptor: Time to wait after the diagnosis and treatment. Any place for observational management?

G. Karam, Nantes (FR)

10:25 - 10:35

Main surgical considerations in pre-transplant treatment of prostate cancer

A. Breda, Barcelona (ES)

10:35 - 10:40

Conclusions

10:40 - 11:15

Prostate cancer in KT receptors

Moderator: F.J. Burgos Revilla, Madrid (ES)

10:40 - 10:50

PSA screening in KT recipients

A.J. Figueiredo, Coimbra (PT)

10:50 - 11:00

Main surgical considerations in radical prostatectomy in KT receptors

X.P.C. Tillou, Caen (FR)

11:00 - 11:10

Role of focal therapy in KT receptors

J.I. Martínez Salamanca, Madrid (ES)

11:10 - 11:15

Conclusions

11:15 - 11:35

Oligometastatic prostate cancer in ESRD and KT patients

Moderator: C. Hernández Fernández, Madrid (ES)

M. Brausi, Modena (IT)

11:35 - 11:55

Key technical aspects in the surgical approach of big retroperitoneal masses with vascular invasion

Moderator: F.J. González García, Madrid (ES)

G. Ciancio, Miami (US)

11:55 - 12:05

Special considerations in immunosuppressive protocols in KT patients with urological tumours

Moderator: F. Kleinclauss, Besançon (FR)

K. Budde, Berlin (DE)

12:05 - 12:30

Renal cancer

Moderator: J.D. Olsburgh, London (GB)

12:05 - 12:15

How to deal with the small tumour in kidney donors?

M. Musquera Felip, Barcelona (ES)

12:15 - 12:25

Management of kidney graft tumours in KT recipients: Sparing treatment versus radical surgery - Key aspects and indications

V. Hevia Palacios, Madrid (ES)

12:25 - 12:30

Conclusions

12:30 - 13:05

Urothelial cancer

Moderator: A. Alcaraz, Barcelona (ES)

12:30 - 12:40

An algorithm of management of non-muscle invasive urothelial cancer in kidney transplant receptors

O. Rodríguez Faba, Barcelona (ES)

12:40 - 12:50

Management of muscle invasive urothelial cancer in kidney transplant receptors: Key aspects

J. Palou, Barcelona (ES)

12:50 - 13:00

ESRD patient with history of urothelial cancer: Criteria to access the transplant waiting-list

R.J.M.J. Boissier, Marseille (FR)

13:00 - 13:05

Conclusions

13:05 - 13:20

Presentation of the collaboration project for international specialisation in kidney transplant: ESTU-EAU and Jackson Memorial Hospital (Miami, USA)

G. Guerra, Miami (US)

G. Ciancio, Miami (US)

E. Lledó García, Madrid (ES)

13:20 - 13:35

Presentation of the Renal Transplant Textbook (ESTU-EAU)

A.J. Figueiredo, Coimbra (PT)

E. Lledó García, Madrid (ES)

To be confirmed

13:50 - 13:55

Rene Küss Award 2017

E. Lledó García, Madrid (ES)

13:55 - 14:00

Conclusions

M. Brausi, Modena (IT)

E. Lledó García, Madrid (ES)

New challenges in urogenital infections and andrological urology

Joint meeting of the EAU Section of Andrological Urology (ESAU) and the EAU Section of Infections in Urology (ESIU)

Saturday, 25 March
10:00 - 14:00

Location: Room Stockholm, North Hall (Level 1)

Chairs: N. Sofikitis, Ioannina (GR)
F.M.E. Wagenlehner, Giessen (DE)

Aims and objectives of this presentation

Infections have acute and chronic sequelae. In the acute phase antibiotic resistance is one of the major problems in patient care. The spectrum ranges from benign localised infections to life threatening sepsis with organ dysfunction.

In chronic infections there is a significant overlap between infections and andrological diseases, which will be addressed in this ESAU / ESIU joint symposium. In addition, selected andrological urology topics concerning the fields of erectile dysfunction and male infertility, will be discussed. Furthermore, recent news from andrology and EAU guidelines updates from urogenital infections will be presented.

10:00 - 10:05

Welcome and introduction

N. Sofikitis, Ioannina (GR)
F.M.E. Wagenlehner, Giessen (DE)

10:05 - 10:20

An ESAU-EAA lecture

Moderators: S. Kliesch, Münster (DE)
F.M.E. Wagenlehner, Giessen (DE)

10:05 - 10:20

Male accessory genital gland infections and infertility

To be confirmed

10:20 - 11:30

Urogenital infections: Pathogenesis and mechanisms responsible for andrological consequences

Moderators: T.E. Bjerklund Johansen, Stavern (NO)
G.R. Dohle, Rotterdam (NL)

10:20 - 10:35

Epididym-orchitis and obstruction (functional and anatomical)

A. Pilatz, Gießen (DE)

10:35 - 10:50

Seminal pathway obstruction: Parameters influencing the urologist's decision for reconstructive surgery or Assisted Reproductive Technology (ART)

T. Diemer, Giessen (DE)

10:50 - 11:05

The role of microorganisms in urogenital pain syndromes

V. Smelov, Lyon (FR)

11:05 - 11:20

Connective links between LUTS and erectile dysfunction: Biological factors and epidemiological observations

C. Bettocchi, Bari (IT)

11:20 - 11:30

Discussion

11:30 - 12:20

Male infertility and sexual dysfunction

Moderators: R. Bartoletti, Pisa (IT)
A. Giwercman, Malmö (SE)

11:30 - 11:45

The immunological basis of Peyronie's disease

D.J. Ralph, London (GB)

11:45 - 12:00

Is there a cause-effect mechanism between varicocele and male infertility?

F. Fusco, Napoli (IT)

12:00 - 12:15

Sexual dysfunction in male cancer survivors: The role of surgical treatment

A. Kadioglu, Istanbul (TR)

12:15 - 12:20

Discussion

12:20 - 13:15

Urosepsis and its consequences

Moderators: T. Perepanova, Moscow (RU)
A. Salonia, Milan (IT)

12:20 - 12:35

Epidemiology of urosepsis

Z. Tandoi du, Newcastle Upon Tyne (GB)

12:35 - 12:50

Definition and pathophysiology of sepsis/urosepsis

S.E. Geerlings, Amsterdam (NL)

12:50 - 13:05

Current management of urosepsis

F. Bruyere, Tours (FR)

13:05 - 13:15

Discussion

13:15 - 13:35

Recent news from andrology (Snapshots)

Moderators: S.S. Minhas, London (GB)
P. Tenke, Budapest (HU)

13:15 - 13:25

Infertility

P. Verze, Naples (IT)

13:25 - 13:35

Erectile dysfunction and penile surgery

Z. Kopa, Budapest (HU)

13:35 - 13:55

EAU Guidelines update from urogenital infections (snapshots)

Moderators: G. Bonkat, Basel (CH)
M. Dinkelman-Smit, Breda (NL)

13:35 - 13:45

Current management of urethritis

B. Köves, Budapest (HU)

13:45 - 13:55

Antibiotic prophylaxis in prostate biopsy

T. Cai, Trento (IT)

13:55 - 14:00

Closing remarks

N. Sofikitis, Ioannina (GR)

F.M.E. Wagenlehner, Giessen (DE)

From formation to removal: A comprehensive update of stone disease from different aspects

Meeting of the EAU Section of Urolithiasis (EULIS) in cooperation with the EAU Section of Uro-Technology (ESUT)

Saturday, 25 March
10:15 - 14:45

Location: Room Copenhagen, North Hall (Level 1)

Chair: K. Sarica, Istanbul (TR)

Aims and objectives of this presentation

Modern management of stone disease has changed significantly, particularly in the last two decades, due to the rapid technological developments. A complete evaluation, appropriate preparation and close follow-up of every case has become more important in an attempt to bring patients to a stone-free status with minimal complications.

Minimal invasive procedures have gained more importance than ever but application of these procedures must proceed in a standardised manner, following an appropriate training program which will enable residents to shorten the learning curves. Moreover, the impact of stone disease itself (as well as the procedures performed) on the quality of life of patients, should be kept in mind during follow-up as well as management of particularly recurrent and complex cases.

Thus, in this EULIS session, in addition to taking a close look at the recent developments (particularly on the pathophysiology and epidemiology of stone disease), we will try to focus on the importance of new treatment modalities and their possible effects on the changing concepts in both medical and surgical management of urolithiasis. This will be done largely with video presentations as presented by the experts in this specific field of urology.

10:15 - 10:20

Welcome and introduction

K. Sarica, Istanbul (TR)

10:20 - 11:15

Etiopathogenesis and epidemiology of stone disease: An update

Moderators: D.J. Kok, Rotterdam (NL)
J.M. Reis Santos, Lisbon (PT)
R.J. Unwin, London (GB)

10:20 - 10:35

Etiopathogenesis of stone formation: An update in the era of endourological advancements

H-G. Tiselius, Stockholm (SE)

10:35 - 10:50

Epidemiology of stone disease: What has changed in the last 25 years?

W.G. Robertson, Over, Cambridge (GB)

10:50 - 11:05

The importance and quality of stone analysis in Europe

R. Siener, Bonn (DE)

11:05 - 11:15

Discussion

11:15 - 12:00

Panel discussion: Nightmare cases in endourology

Moderator: T. Knoll, Sindelfingen (DE)

11:15 - 12:00

Panel:

S. Lahme, Pforzheim (DE)
P.J.S. Osther, Fredericia (DK)
A. Skolarikos, Athens (GR)

12:00 - 12:40

Video Session: Management of impacted upper ureteral stones - Which technique and why?

Moderators: E. Montanari, Milan (IT)
A. Papatsoris, Marousi - Athens (GR)
O. Traxer, Paris (FR)

12:00 - 12:10

Antegrade percutaneous approach

A. Hoznek, Creteil (FR)

12:10 - 12:20

Semi-rigid and/or flexible URS

P.A. Geavlete, Bucharest (RO)

12:20 - 12:30

Laparoscopic ureterolithotomy

G. Wendt-Nordahl, Sindelfingen (DE)

12:30 - 12:40

Discussion

12:40 - 12:45

"One more thing" - The EAU patient information app on urinary stones

T. Bach, Hamburg (DE)

12:45 - 13:15

Controversial issues in stone management

Moderators: A.Y. Muslumanoglu, Istanbul (TR)
I. Saltirov, Sofia (BG)
M. Straub, Munich (DE)

12:45 - 12:55

The new anticoagulants in endourology: Do they let us for a safe intervention?

H-M. Fritsche, Regensburg (DE)

12:55 - 13:05

Cost-effectiveness of endourologic management of stones

W.L. Strohmaier, Coburg (DE)

13:05 - 13:15

Management of stent related problems

A. Trinchieri, Lecco (IT)

13:15 - 14:00

Training, assessment and follow-up in stone disease

Moderators: K.H. Andreassen, Frederiksberg (DK)
C.C. Seitz, Vienna (AT)
A. Szendrői, Budapest (HU)

13:15 - 13:30

Learning curves for urolithiasis surgery - What do we know so far?

K. Ahmed, London (GB)

13:30 - 13:45

Development of a master questionnaire for stone disease

T. Bach, Hamburg (DE)

13:45 - 14:00

How should we follow the patients after endourological management?

G. Gambaro, Rome (IT)

14:00 - 14:40

New treatment modalities and their impact on our current approaches

Moderators:

C.M. Scoffone, Turin (IT)

C. Türk, Vienna (AT)

G-H. Zeng, Guangzhou (CN)

14:00 - 14:10

Micro URS

J. Galan Llopis, Alicante (ES)

14:10 - 14:20

Robotic FURS

K. Sarica, Istanbul (TR)

14:20 - 14:30

Disposable URS

N.N-P. Buchholz, Dubai (AE)

14:30 - 14:40

Miniaturisation in PNL: How did it affect our approaches in stone treatment?

S. Hayek, Cambridge (GB)

14:40 - 14:45

Announcements and final remarks

K. Sarica, Istanbul (TR)

Critical review of robotic surgery in Uro-oncology

Meeting of the EAU Section of Oncological Urology (ESOU) in cooperation with the EAU Robotic Urology Section (ERUS) and with the ESSO, ESTRO, EUOG, EORTC and SUO

Saturday, 25 March
10:15 - 14:45

Location: Room Madrid, North Hall (Level 1)

Chairs: M. Brausi, Modena (IT)

10:15 - 10:40

The European Society of Surgical Oncology (ESSO)

10:15 - 10:35

Lymphadenectomy in uro-oncological pelvic surgery

F. Lista Mateos, Madrid (ES)

10:35 - 10:40

Discussion

10:40 - 11:05

The European Organisation for Research and Treatment of Cancer Genito-Urinary Cancer Group (EORTC GUCC)

10:40 - 11:00

The role of surgery in metastatic renal cancer

A. Bex, Amsterdam (NL)

11:00 - 11:05

Discussion

11:05 - 11:30

The European Society for Radiotherapy & Oncology (ESTRO)

11:05 - 11:25

Bladder sparing procedures for muscle invasive bladder cancer: A real advancement?

A. Kiltie, Oxford (GB)

11:25 - 11:30

Discussion

11:30 - 11:55

The European Uro-Oncology Group (EUOG)

11:30 - 11:50

Circulating tumour cells in prostate cancer: A marker?

S. Osanto, Leiden (NL)

11:50 - 11:55

Discussion

11:55 - 12:15

Patrick Walsh Lecture: What's new at Hopkins - AS, PSMA scans, AR-V7

P.C. Walsh, Baltimore, MD (US)

12:15 - 12:35

Society for Urologic Oncology (SUO)

| | |
|---------------|--|
| 12:15 - 12:35 | The argument for surgical management of high risk prostate cancer C.P. Evans, Sacramento (US) |
| 12:35 - 15:15 | Critical review of robotic surgery in URO-Oncology: ESOU-ERUS perspectives |
| 12:35 - 13:10 | Debate on prostate cancer surgery: Radical prostatectomy should be performed with robot |
| 12:35 - 12:50 | Pro: Radical prostatectomy should be performed with robot H.G. Van Der Poel, Amsterdam (NL) |
| 12:50 - 13:05 | Con: Radical prostatectomy should be performed with robot S. Joniau, Leuven (BE) |
| 13:05 - 13:10 | Discussion |
| 13:10 - 13:45 | Debate on bladder cancer surgery: Open radical cystectomy is still the way |
| 13:10 - 13:25 | Pro: Open radical cystectomy is still the way M. Brausi, Modena (IT) |
| 13:25 - 13:40 | Con: Open radical cystectomy is still the way N.P. Wiklund, Stockholm (SE) |
| 13:40 - 13:45 | Discussion |
| 13:45 - 14:20 | Debate on kidney cancer: Partial nephrectomy/tumour enucleation is better done by robot |
| 13:45 - 14:00 | Pro: Partial nephrectomy/tumour enucleation is better done by robot A. Larcher, Milan (IT) |
| 14:00 - 14:15 | Con: Partial nephrectomy/tumour enucleation is better done by robot H. Van Poppel, Leuven (BE) |
| 14:15 - 14:20 | Discussion |
| 14:20 - 14:35 | Quality of life after robotic, lap and open surgery: Real different? W. Artibani, Verona (IT) |
| 14:35 - 14:40 | Discussion |
| 14:40 - 14:45 | Closure by chairs |

YUORDay17 (EAU Young Urologists Office & European Society of Residents in Urology ESRU)

Special session

Saturday, 25 March
10:15 - 17:15

Location: Room Milan, North Hall (Level 1)

Chairs: S. Sarikaya, Ankara (TR)
J.P.M. Sedelaar, Nijmegen (NL)

Aims and objectives of this presentation

The main aim of this session is to introduce ESRU, to present our projects and to announce our upcoming activities. ESRU is one of the most active working groups within the EAU and there are lots of issues to present during YUORDay Sessions. Also there will be specific presentations about YUO, YAU, EUSP, EBU and ESU. The lectures were especially designed for resident education. During YUORDay, there will be Campbell Quiz and also awards. We are waiting all the residents and urologists to attend this fruitful program and join us to be informed about recent issues.

S. Sarikaya, Ankara (TR)
J.P.M. Sedelaar, Nijmegen (NL)

10:20 - 11:00

What residents need to know about the EAU organization

Moderators: P. Panayotopoulos, Angers (FR)
A. Ürkmez, Istanbul (TR)

10:20 - 10:30

European Board of Urology (EBU)

J.D. Nawrocki, Brighton (GB)

10:30 - 10:40

European School of Urology (ESU)

J. Palou, Barcelona (ES)

10:40 - 10:50

Young Academics Urologist (YAU)

M.S. Silay, Istanbul (TR)

10:50 - 11:00

EAU Patient Information Project

M. Sochaj, Gorzow Wielkopolski (PL)

11:00 - 12:30

European Urology Scholarship Programme (EUSP)

Moderators: V.G. Mirone, Naples (IT)
J.P.M. Sedelaar, Nijmegen (NL)

11:00 - 11:10

From resident to president: Developing a successful career

J.P.M. Sedelaar, Nijmegen (NL)

11:10 - 11:20

A great research opportunity for young urologists

M.J. Ribal, Barcelona (ES)

11:20 - 11:30

Discussion

11:30 - 11:40

How to write a successful European Urology Scholarship Programme (EUSP) application

J.A. Schalken, Nijmegen (NL)

11:40 - 11:50

Experience of an Urology Scholarship Programme (EUSP) scholar

F. Castiglione, Cologno Monzese (IT)

11:50 - 12:00

Discussion

12:00 - 12:15

Everything you always wanted to know about the European Urology Scholarship Programme (EUSP) (but were afraid to ask)

G. Patruno, Rome (IT)

12:15 - 12:30

Best Scholar Award Winner

V.G. Mirone, Naples (IT)

S. Joniau, Leuven (BE)

12:30 - 13:15

Simulation and training

Moderators:

P.B. Ostergren, Copenhagen (DK)

M.E. Rodríguez Socarrás, Vigo (ES)

12:30 - 12:45

Anatomy learning in urology

F. Dal Moro, Padova (IT)

12:45 - 13:00

Simulation and new technologies

D. Veneziano, Reggio Calabria (RC) (IT)

13:00 - 13:15

Future of training/residency in urology

To be confirmed

13:15 - 14:35

Surgery: Tips and tricks

Moderators:

D. Duijvesz, Rotterdam (NL)

J.L. Vásquez, Copenhagen (DK)

13:15 - 13:35

En bloc Transurethral resection of the bladder

B. Malavaud, Toulouse (FR)

13:35 - 13:55

Vesicoureteral reflux

M.S. Silay, Istanbul (TR)

13:55 - 14:15

How to handle iatrogenic lesions

V. Ficarra, Udine (IT)

14:15 - 14:35

Penile curvature

D.J. Ralph, London (GB)

14:35 - 15:15

Translational medicine: From basics to clinical practice

Moderators:

G. Patruno, Rome (IT)

S. Sarikaya, Ankara (TR)

14:35 - 14:55

Epigenetic based prostate cancer markers: How far are we?

J. Angulo Cuesta, Madrid (ES)

14:55 - 15:15

Translating new erectile dysfunction therapies

M. Albersen, Leuven (BE)

15:15 - 15:45

Building up a career in urology

Moderators: S. Boret
F. Esperto, Rome (IT)

15:15 - 15:25

How to become a robotic surgeon?

A. Mottrie, Aalst (BE)

15:25 - 15:35

How to become an endourologist?

O. Traxer, Paris (FR)

15:45 - 16:30

Pros and cons: Controversies in urology

Moderators: M. Stepanchenko, Chernivtsi (UA)
Z. Zotter, Budapest (HU)

15:45 - 16:00

Partial nephrectomy in T2 tumours: Where is the limit?

A.J. Figueiredo, Coimbra (PT)

16:00 - 16:15

Immediate radical cystectomy for high-risk non-muscle invasive bladder cancer

E. Xylinas, Paris (FR)

16:15 - 16:30

MUS versus Colpo/AFS

R. Hamid, London (GB)

16:30 - 17:00

Campbell Quiz Challenge

Moderators: J. Gómez Rivas, Madrid (ES)
M. Waterschoot, Sinaai (BE)
M.J. Ribal, Barcelona (ES)

17:00 - 17:15

Prizes and awards

Moderator: S. Sarikaya, Ankara (TR)

Biomarkers and tumour heterogeneity: Friends or enemies for differential therapy?

Joint meeting of the EAU Section of Urological Pathology (ESUP) and the EAU Section of Urological Research (ESUR)

Saturday, 25 March
10:15 - 14:00

Location: Room Paris, North Hall (Level 1)

Chairs: K. Junker, Homburg (DE)
R. Montironi, Ancona (IT)

Aims and objectives of this presentation

Major advances have been made in understanding the mechanisms of primary and acquired resistance to current agents in urogenital cancer, as well as in the identification and validation of relevant molecular targets. The integration of clinic-pathologic data with emerging techniques of molecular profiling-based treatment will represent the future of personalised therapeutic approach for urogenital cancer.

10:15 - 10:20

Welcome and introduction

K. Junker, Homburg (DE)

10:20 - 10:50

Biomarkers: Introduction

Moderators: L. Kiemeny, Nijmegen (NL)
R. Montironi, Ancona (IT)

10:20 - 10:35

Biomarkers: Definition, requirements, pitfalls

L. Kiemeny, Nijmegen (NL)

10:35 - 10:50

Best biomarkers in body fluids: CTC's, free DNA/RNA or exosomes?

K. Pantel, Hamburg (DE)

10:50 - 11:40

Bladder cancer

Moderators: M. Knowles, Leeds (GB)
A. Lopez-Beltran, Lisbon (PT)
A. Vlahou, Athens (GR)

10:50 - 11:00

Histopathological subtypes: Prognostic relevance

A. Lopez-Beltran, Lisbon (PT)

11:00 - 11:10

Basal/luminal signature: Identification of aggressive subtypes

Y. Allory, Creteil (FR)

11:10 - 11:20

Non-muscle invasive cancer: BCG therapy prediction

A.M. Kamat, Houston (US)

11:20 - 11:30

Muscle-invasive cancer: Can we predict the response to systematic therapy?

To be confirmed

11:30 - 11:40

Introduction of new markers to clinical guidelines and practice: Requirements and roadmap

B.W.G. Van Rhijn, Amsterdam (NL)

11:40 - 12:30

Kidney cancer

Moderators: Y. Allory, Creteil (FR)
V. Ficarra, Udine (IT)
H. Moch, Zurich (CH)

11:40 - 11:50

Relevance of histopathological subtypes: Which are the bad guys?
H. Moch, Zurich (CH)

11:50 - 12:00

Prognostic markers: Ready to use?
K. Junker, Homburg (DE)

12:00 - 12:10

Predictive markers
E. Oosterwijk, Nijmegen (NL)

12:10 - 12:20

Genetic heterogeneity: What is relevant concerning marker development?
S. Turajlic, London (GB)

12:20 - 12:30

Heterogeneity: The urologist's view
V. Ficarra, Udine (IT)

12:30 - 13:00

Penile and testicular cancer

Moderators: G.J. Netto, Baltimore (US)
S. Horenblas, Amsterdam (NL)

12:30 - 12:40

Biomarkers for testicular cancer: What we have and what we need
L. Looijenga, Rotterdam (NL)

12:40 - 12:50

The new 2016 WHO classification of penile cancer
M. Colecchia, Milan (IT)

12:50 - 13:00

Penile cancer: What we need and what we have - The urologist's view
S. Horenblas, Amsterdam (NL)

13:00 - 13:50

Prostate cancer

Moderators: H.Y. Leung, Glasgow (GB)
To be confirmed
R. Montironi, Ancona (IT)

13:00 - 13:10

Implementation of the new 'prostate cancer grading system'
R. Montironi, Ancona (IT)

13:10 - 13:20

Tumour heterogeneity: The evolutionary history of lethal metastatic cancer
To be confirmed

13:20 - 13:30

Tumour heterogeneity: The urologist's view
A. Bjartell, Malmö (SE)

13:30 - 13:40

Predictive markers in prostate cancer: Tissue based markers
G.J. Netto, Baltimore (US)

13:40 - 13:50

Predictive markers in prostate cancer: Liquid biopsy

G. Attard, Sutton (GB)

13:50 - 14:00

Conclusion

R. Montironi, Ancona (IT)

How to manage metastatic castration-resistant prostate cancer in an office setting

Meeting of the EAU Section of Urologists in Office (ESUO)

Saturday, 25 March
10:15 - 13:15

Location: Room Amsterdam, North Hall (Level 1)

Chairs: H. Brenneis, Pirmasens (DE)
H. Haas, Heppenheim (DE)

Aims and objectives of this presentation

Do patients with mHR prostate cancer have to be treated exclusively in the hospital? This session aims to show that a save and effective treatment is possible in an office setting too. Two experienced office urologists discuss cases together with a clinical specialist and the audience. This represents the first session of the newly formed EAU Section of Urologists in Office (ESUO). Based on previous experience with such expert courses at national meetings, the ESUO wants to demonstrate the value of such workshops on an European level.

10:15 - 13:15

Expert:
To be confirmed

Revisiting management of LUTS in neurogenic and non-neurogenic patients

Meeting of the EAU Section of Female and Functional Urology (ESFFU)

Saturday, 25 March
10:15 - 14:00

Location: Room Vienna, North Hall (Level 1)

Chair: F. Cruz, Porto (PT)

Aims and objectives of this presentation

LUTS are highly prevalent in both genders above 40 years of age. In the western population more than 70% of males and females report at least one lower urinary tract symptom and half is considerably bothered by them.

LUTS are even more common among patients with neurogenic bladder dysfunctions, in whom bladder control assumes one of the most important objectives necessary to improve quality of life. Last decade witnessed the introduction of new forms of treatment for LUTS, either in neurogenic and non-neurogenic patients, the outcomes of which need now critical reevaluation.

10:15 - 10:20

Welcome and introduction

F. Cruz, Porto (PT)

10:20 - 11:35

Management of common neuro-urological problems

Moderators: D.J.M.K. De Ridder, Leuven (BE)
H. Madersbacher, Innsbruck (AT)

10:20 - 10:35

LUTS in MS patients

E. Chartier-Kastler, Paris (FR)

10:35 - 10:50

LUTS in Parkinson's disease male

K-D. Sievert, Salzburg (AT)

10:50 - 11:05

LUTS in CVA patients

S. Arlandis Guzman, Valencia (ES)

11:05 - 11:20

LUTS in Alzheimer disease

M. Lazzeri, Florence (IT)

11:20 - 11:35

Discussion of clinical cases

D.J.M.K. De Ridder, Leuven (BE)
H. Madersbacher, Innsbruck (AT)

11:35 - 11:55

State-of-the-art lecture: Spinal cord regeneration and axon re-growth. Which options tested in the bench progressed into clinical trials?

T.M. Kessler, Zurich (CH)

11:55 - 12:15

ICS lecture: Underactive bladder: A clinical problem or a new research field?

E. Kocjancic, Chicago (US)

| | |
|---------------|---|
| 12:15 - 12:30 | Prize winner 5th international neuro-urology meeting |
| 12:15 - 12:20 | Introduction T.M. Kessler, Zurich (CH) |
| 12:20 - 12:30 | Lecture of prize winner |
| <hr/> | |
| 12:30 - 14:00 | LUTS |
| | Moderators: F.C. Burkhard, Berne (CH) S. Charalampous, Limassol (CY) |
| 12:30 - 12:45 | What works and what does not work in the management of nocturia? K. Everaert, Ghent (BE) |
| 12:45 - 13:00 | What is new in the management of BPS/IC? P. Dinis Oliveira, Porto (PT) |
| 13:00 - 13:15 | Do alpha-blockers relieve benign prostatic obstruction or are they only good for LUTS improvement? Y. Igawa, Tokyo (JP) |
| 13:15 - 13:30 | How I solve the early and late complications of Mid Urethral Slings (MUS)? T. Tarcan, Istanbul (TR) |
| 13:30 - 13:45 | What does the evidence tell us about the use of urodynamics in females with SUI? E. Costantini, Perugia (IT) |
| 13:45 - 14:00 | Urgency incontinence: Are all treatment options equally effective? H. Hashim, Bristol (GB) |
| <hr/> | |
| 14:00 - 14:00 | Closure of the meeting F. Cruz, Porto (PT) |

How to get the most out of prostate cancer imaging?

Meeting of the EAU Section of Urological Imaging (ESUI) in cooperation with the EAU Section of Urological Research (ESUR) and the European Society of Nuclear Medicine (EANM)

Saturday, 25 March
10:15 - 14:00

Location: Room London, North Hall (Level 1)

Chair: J. Walz, Marseille (FR)

Aims and objectives of this presentation

The 2017 meeting of the ESUI addresses the hottest topic in urological imaging, that of prostate cancer imaging. The aim of the session is to provide an extensive and critical overview on the evolutions and developments in the different imaging tools available, such as multiparametric MRI and ultrasound based imaging techniques. Important and essential issues such as standardization and quality control as well as practical problems will be addressed. Moreover, current controversies will be explored and debated in point and counterpoint sessions followed by interactive discussions. Detailed knowledge of the performance and limitations of new imaging technologies seems mandatory when using them effectively and beneficially in clinical practice. At the end, the EAU prostate cancer guidelines will give their point of view on how imaging can be integrated into clinical practice without over stressing limited resources.

During the session, the prize giving ceremony for the 2017 ESUI vision award will be held, followed by the presentation of the awarded study. The aim of the ESUI vision award is to highlight the most innovative imaging study published during the last year in urology.

10:15 - 10:20

Introduction

J. Walz, Marseille (FR)

10:20 - 11:40

Prostate cancer detection

Moderators: B.M. Carey, Leeds (GB)
B.A. Hadaschik, Heidelberg (DE)
T. Loch, Flensburg (DE)

10:20 - 10:28

Controversies in prostate cancer detection - Multiparametric MRI is a must

J.J. Futterer, Nijmegen (NL)

10:28 - 10:36

Controversies in prostate cancer detection - Biparametric MRI is enough

To be confirmed

10:36 - 10:40

Discussion

10:40 - 10:48

Alternatives to MRI: Where are we with ultrasound based imaging?

To be confirmed

10:48 - 10:52

Discussion

10:52 - 11:00

Lessons learned from mammography: The way to certification

To be confirmed

11:00 - 11:04

Discussion

11:04 - 11:12 **To fuse or not to fuse: Is software fusion mandatory?**
C. Kastner, Cambridge (GB)

11:12 - 11:16 **Discussion**

11:16 - 11:24 **Multiparametric ultrasound: Reality or fiction?**
H. Wijkstra, Amsterdam (NL)

11:24 - 11:28 **Discussion**

11:28 - 11:36 **PI-RADS 3 lesion: Biopsy or not?**
V. Scattoni, Milan (IT)

11:36 - 11:40 **Discussion**

11:40 - 12:36 **Staging of prostate cancer**

Moderators: L. Budäus, Hamburg (DE)
T. Maurer, Munich (DE)
R. Schiavina, Bologna (IT)

11:40 - 11:48 **Controversies: What helps more to characterise the disease? - Imaging**
T. Maurer, Munich (DE)

11:48 - 11:56 **Controversies: What helps more to characterise the disease? - Biomarkers and gen profiling**
G. Jenster, Rotterdam (NL)

11:56 - 12:00 **Discussion**

12:00 - 12:08 **How to define 'significant' disease on targeted biopsy**
H.U. Ahmed, London (GB)

12:08 - 12:12 **Discussion**

12:12 - 12:20 **PSMA at initial staging**
To be confirmed

12:20 - 12:24 **Discussion**

12:24 - 12:32 **EANM lecture: Is choline PET outdated?**
S. Fanti, Bologna (IT)

12:32 - 12:36 **Discussion**

12:36 - 12:46 **ESUI Vision Award 2017**

12:43 - 12:46

Discussion

12:46 - 13:55

Active surveillance and curative treatment: Get the most out of imaging

Moderators: M. Ritter, Mannheim (DE)
A. Villers, Lille (FR)
J. Walz, Marseille (FR)

12:46 - 12:54

Controversies - Focal therapy and the concept of the index lesion: Sense
J.J.M.C.H. De La Rosette, Amsterdam (NL)

12:54 - 13:02

Controversies - Focal therapy and the concept of the index lesion: Nonsense
A. Briganti, Milan (IT)

13:02 - 13:06

Discussion

13:06 - 13:14

When and how to include MRI into active surveillance protocols?
C.H. Bangma, Rotterdam (NL)

13:14 - 13:18

Discussion

13:18 - 13:26

Does imaging improve safety and efficacy of primary and salvage radiotherapy?
P. Ost, Ghent (BE)

13:26 - 13:30

Discussion

13:30 - 13:38

Does imaging improve surgery?
M. Graefen, Hamburg (DE)

13:38 - 13:42

Discussion

13:42 - 13:50

The EAU Guidelines Office point of view: How to get the most out of limited resources in prostate cancer imaging?
N. Mottet, Saint-Étienne (FR)

13:50 - 13:55

Discussion

13:55 - 14:00

Summary
J. Walz, Marseille (FR)

Advancements in genito-urinary reconstruction

Meeting of the EAU Section of Genito-Urinary Reconstructive Surgeons (ESGURS)

Saturday, 25 March
10:15 - 15:45

Location: Room Munich, North Hall (Level 1)

Chair: R. Djinovic, Belgrade (RS)

Aims and objectives of this presentation

Uro-Genital Reconstructive Surgery is still evolving through the world and did not achieve standard approach in treatment. During our Section Meeting we will try to present newest advancement by the top experts and to cover all fields of reconstructive urology – upper and lower tract, urethral, genital surgery, sex reassignment, incontinence, penile implant, but also to share experience in latest breakthrough – penile transplant. We hope that the program we made will be equally interesting to both beginners to learn basic techniques and experts to broaden their knowledge.

10:15 - 10:20

Welcome and introduction

R. Djinovic, Belgrade (RS)

10:20 - 10:50

Uro-genital congenital anomalies: Tips and tricks

Moderators: E. Kocjancic, Chicago (US)
I. Moncada, Madrid (ES)

10:20 - 10:30

Crippled penis post hypospadias: What can we do?

To be confirmed

10:30 - 10:40

Epispadais-extrophy complex in males: Genital and urinary tract reconstruction

R. Djinovic, Belgrade (RS)

10:40 - 10:50

Vaginal prolapse and pregnancy in extrophy patients

D.N. Wood, London (GB)

10:50 - 11:30

Anterior urethra reconstruction

Moderators: L. Martínez-Piñero, Madrid (ES)
O. Shenfeld, Jerusalem (IL)

10:50 - 11:00

BXO (Balanitis Xerotica Obliterans): Treatment of urethral stricture and external genitalia

E. Palminteri, Arezzo (IT)

11:00 - 11:10

Two-stage buccal mucosa urethroplasty: Reliable solution for pendular urethra strictures

A. Zhivov, Moscow (RU)

11:10 - 11:20

Urethral diverticula/fistula

M. Fisch, Hamburg (DE)

11:20 - 11:30

Bulbar urethroplasty: Where are we in 2017?

To be confirmed

11:30 - 12:10

Posterior urethra reconstruction

Moderators: To be confirmed
R. Dahlem, Hamburg (DE)

11:30 - 11:40

Post TURP membranous urethra stricture: Sphincter-preserving technique
R. Gomez, Santiago (CL)

11:40 - 11:50

Delayed urethroplasty after failed realignment in the treatment of pelvic fracture related injuries: Easier or not?
N. Lumen, Ghent (BE)

11:50 - 12:00

New generation urethral and ureteral stents: The best solution for the worst scenarios?
O.R. Sedigh, Torino (IT)

12:00 - 12:10

Recto-urethral fistula after radiotherapy for prostate cancer
L. Gómez Pérez, San Juan De Alicante (ES)

12:10 - 12:45

Penile transplant: Genito-urinary trauma/Penile cancer

Moderators: R. Djinovic, Belgrade (RS)
To be confirmed
D.J. Ralph, Chesham (GB)
L. Schechter, Morton Grove, IL (US)

12:10 - 12:20

Penile transplant: Evolution of vascularized composite
To be confirmed

12:20 - 12:25

Discussion

12:25 - 12:35

Battlefield injuries: Reconstructing of the blast injured perineum
P. Anderson, Dorridge (GB)

12:35 - 12:45

Pelvic fracture with bladder neck/posterior urethra injuries
A.R. Mundy, London (GB)

12:45 - 13:25

Upper tract reconstruction

Moderators: S. Deger, Ostfildern (DE)
M. Gallucci, Rome (IT)

12:45 - 12:55

Intra-corporeal urinary diversions: Technique, outcomes and robotic management of late complications
G. Simone, Rome (IT)

12:55 - 13:05

Robotic/laparoscopic ureteral reimplantation versus open ureteral reimplantation
M.S. Silay, Istanbul (TR)

13:05 - 13:15

Continent urinary diversion for severe bladder dysfunction
M.A.B. Fahmy, Cairo (EG)

13:15 - 13:25

Neobladder complications: How to solve them?
V. Pansadoro, Rome (IT)

13:25 - 14:05

Transgender surgery

Moderators: N. Morel Journal, Lyon (FR)
J. Romero-Otero, Madrid (ES)

13:25 - 13:35

M2F surgery: How to solve problems after primary surgery?

K-D. Sievert, Salzburg (AT)

13:35 - 13:45

The use of ileum in case of neovaginal stenosis: Functional outcome

C. Trombetta, Trieste (IT)

13:45 - 13:55

F2M – Radial forearm flap total phalloplasty: Plastic surgeon's point of view

L. Schechter, Morton Grove, IL (US)

13:55 - 14:05

Management of neo-urethral complications after total phalloplasty

E. Kocjancic, Chicago (US)

14:05 - 14:55

Penile implant surgery

Moderators: To be confirmed
To be confirmed

14:05 - 14:15

Real penile enlargement with penile implant

S. Sansalone, Rome (IT)

14:15 - 14:25

Glans necrosis post penile prosthesis: What to do?

A. Shamsodini Takhtei, Doha - Waab (QA)

14:25 - 14:35

Prosthesis infection: Remove it or not?

R. Olianias, Voegelsen (DE)

14:35 - 14:45

Penile implant: Reservoir problems

G. Garaffa, London (GB)

14:45 - 14:55

Penile implant in unusual cases: How to place it properly?

J. Romero-Otero, Madrid (ES)

14:55 - 15:25

Peyronies surgery: Tips and tricks

Moderators: To be confirmed
A. Zucchi, Perugia (IT)

14:55 - 15:05

Grafting in peyronies: Why does it fail so often?

D.J. Ralph, Chesham (GB)

15:05 - 15:15

Peyronies treatment: Tunical expansion with implant without grafting

P. Egydio, São Paulo (BR)

15:15 - 15:25

Penile implant in peyronies: Modeling versus grafting

I. Moncada, Madrid (ES)

15:25 - 15:45

Incontinence surgery: Tips and tricks

Moderators: I. Moncada, Madrid (ES)
N. Tomada, Porto (PT)

15:25 - 15:35

Comparison of AUS: Advantages and disadvantages

T.S. Pottek, Hamburg (DE)

15:35 - 15:45

Post-prostatectomy incontinence with bulbar/panurethral stricture with: How to treat?

R. Dahlem, Hamburg (DE)

Technology at its best

Meeting of the EAU Section of Uro-Technology (ESUT), in cooperation with the EAU Robotic Urology Section (ERUS) and the EAU Section of Urolithiasis (EULIS)

Saturday, 25 March
10:30 - 17:45

Location: eURO Auditorium (Level 0)

Chair: E. Liatsikos, Patras (GR)

Aims and objectives of this presentation

Following a more than 10-year tradition of Live-surgery sessions, the EAU-Section of Uro-Technology (ESUT) presents an ambitious programme focussing on novel techniques in percutaneous, endourological, laparoscopic and robotic-assisted procedures. This year, we want to focus on novel technology improving the performance of video-assisted surgery and diagnostics in all fields of Endourology. This session is conducted in collaboration with the the EAU Robotic Urology Section (ERUS) and the EAU Section of Urolithiasis (EULIS). In the laparoscopic and robot-assisted cases, we will focus on the developments of imaging as well as new instruments and devices (laser) improving the ergonomics of laparoscopy and endourology. The latest digital developments for flexible endoscopy of the upper urinary tract for diagnosis and treatment of tumours and calculi are demonstrated.

ESUT-faculty consists of internationally well-known experts serving as surgeons and moderators. The different surgical procedures will be transmitted from Guy's Hospital in London in high-definition and 3D-quality. Traditionally, the format of ESUT-Live Surgery will allow all delegates to directly communicate with the surgeons to ask questions and to discuss every aspect of the procedure. Moreover, the ESUT session will be available on-line.

10:30 - 17:45

Live broadcasts from Guy's Hospital, London (UK)

Coordinators at eURO Auditorium

A. Breda, Barcelona (ES)
A.J. Gross, Hamburg (DE)

Coordinator at Guy's Hospital, London (UK)

B.J. Challacombe, London (GB)

Patient Advocates

To be confirmed
M. Brown, Ardross (AU)
To be confirmed
J.M. Glass, Ealing (GB)
To be confirmed
S. Malde, Uxbridge (GB)
R. Thurai raja, Harpenden (GB)

Endourology coordinator

M. Bultitude, London (GB)

Laparoscopic and robotic coordinator

P. Cathcart, Cardiff (GB)

10:30 - 10:35

Welcome and introduction

E. Liatsikos, Patras (GR)

10:35 - 10:40

Ethics of Live-Surgery: Cases from last year

M. Straub, Munich (DE)

10:40 - 12:20

Live-Surgery Part I

Moderators:

C. Anderson, London (GB)

A. Breda, Barcelona (ES)

R.E. Sanchez-Salas, Paris (FR)

P. Tenke, Budapest (HU)

P.J. Zondervan, Amsterdam (NL)

10:40 - 11:00

3D-4K Nerve sparing extraperitoneal radical prostatectomy

J-U. Stolzenburg, Leipzig (DE)

11:00 - 11:20

Robotic neurosafe radical prostatectomy

A. Haese, Hamburg (DE)

11:20 - 11:40

Robotic radical cystectomy using Da Vinci Si

N.P. Wiklund, Stockholm (SE)

11:40 - 11:50

Bipolar bladder tumour resection with PDD

To be confirmed

11:50 - 12:05

MIP: A novel concept of PCNL

M. Bultitude, London (GB)

H. Ratan, Nottingham (GB)

12:05 - 12:20

Supine Endoscopic Combined Intrarenal Surgery (ECIRS)

S.J. Gordon, Brighton (GB)

B.K. Somani, Southampton (GB)

12:20 - 14:05

Live-Surgery Part II

Moderators:

A.E. Canda, Ankara (TR)

T. Knoll, Sindelfingen (DE)

F. Montorsi, Milan (IT)

To be confirmed

D. Veneziano, Reggio Calabria (RC) (IT)

12:20 - 12:30

Pre-recorded video: Upper tract TCC

A. Breda, Barcelona (ES)

12:30 - 12:40

Pre-recorded video: FURS tumour NBI

M. Brehmer, Aarhus N (DK)

To be confirmed

12:40 - 12:50

Pre-recorded video: En-Bloc resection of bladder tumour with HD-PDD

A. Karl, Munich (DE)

12:50 - 13:00

Pre-recorded video: Bipolar enucleation of prostate

T.R.W. Herrmann, Hannover (DE)

13:00 - 13:10

Pre-recorded video: Electromagnetic guided percutaneous puncture

E.A.R. Lima, Braga (PT)

13:10 - 13:30

Robotic partial nephrectomy using Da Vinci XI

A. Mottrie, Aalst (BE)

13:30 - 13:50

3D-4K Laparoscopic partial nephrectomy

A. Alcaraz, Barcelona (ES)

13:50 - 14:05

Prone percutaneous nephrolithotripsy

E. Liatsikos, Patras (GR)

14:05 - 15:55

Live-Surgery Part III

Moderators:

To be confirmed
P. Dasgupta, London (GB)
F. Gomez Sancha, Madrid (ES)
To be confirmed
N. Peter, Budapest (HU)
B. Turna, Izmir (TR)

14:05 - 14:25

Robotic neobladder reconstruction

J. Kelly, London (GB)

14:25 - 14:40

Holmium prostate enucleation

To be confirmed

14:40 - 14:55

Single use flexible ureteroscopic lithotripsy

O. Wiseman, Cambridge (GB)

14:55 - 15:05

Pre-recorded video: Bipolar enucleation of the prostate

T. Bach, Hamburg (DE)

15:05 - 15:15

Pre-recorded video: 50W Holmium prostate enucleation

C.M. Scoffone, Turin (IT)

15:15 - 15:25

Pre-recorded video: NBI-assisted resection of bladder tumour

B. Malavaud, Toulouse (FR)

15:25 - 15:35

Pre-recorded video: Monopolar prostate enucleation

To be confirmed

15:35 - 15:55

ICG-guided laparoscopic partial nephrectomy

F. Porpiglia, Turin (IT)

15:55 - 17:45

Live-Surgery Part IV

Moderators:

T. Bach, Hamburg (DE)
A.Y. Muslumanoglu, Istanbul (TR)
P.J.S. Osther, Fredericia (DK)
A. Papatsoris, Marousi - Athens (GR)
K. Sarica, Istanbul (TR)
O. Traxer, Paris (FR)

15:55 - 16:10

Flexible ureteroscopic lithotripsy with Boa Vision

C.C. Seitz, Vienna (AT)

16:10 - 16:25

Digital flexible ureteroscopic lithotripsy

L. Ajayi, London (GB)

16:25 - 16:35

Pre-recorded video: Robotic renal transplantation

M. Stöckle, Homburg (DE)

16:35 - 16:45

Pre-recorded video: Flexible URS (FURS) using digital Cobra

M. Straub, Munich (DE)

16:45 - 16:55

Pre-recorded video: Holmium prostate vaporisation

To be confirmed

16:55 - 17:05

Pre-recorded video: Prostate enucleation using low energy pulsed thulium laser with preservation of ejaculation

J. Roche, Bordeaux (FR)

17:05 - 17:15

Pre-recorded video: Aquablation

To be confirmed

17:15 - 17:25

Pre-recorded video: Thulium prostate enucleation

G. Muto, Roma (IT)

17:25 - 17:35

Pre-recorded video: Urolift under local anesthesia

T.A. McNicholas, Herts (GB)

17:35 - 17:45

Pre-recorded video: Isiris Single use stent removal system

To be confirmed

How to write an introduction and material and methods

ESU Course 01

Saturday, 25 March
11:00 - 13:00

Location: Room 10, Capital suite (level 3)

Chair: To be confirmed

Paediatric urology for the adult urologist - 1

ESU Course 02

Saturday, 25 March
11:00 - 14:00

Location: Room 11, Capital suite (level 3)

Chair: J.M. Nijman, Groningen (NL)

Aims and objectives of this presentation

Many children with congenital anomalies will present to the adult urologist with long-term sequelae. It is important to know what has been done in terms of surgical procedures so that the adult urologist knows what he can do in the future. It is also important to know how the urological follow-up of these patients should be done. The most common pediatric conditions will be reviewed, while long-term complications will be explored by short interactive case presentations.

- Many children born with hydronephrosis may not require surgical intervention, but need close follow-up until after puberty
- Penile and urethral reconstruction, such as hypospadias may have serious implications for transurethral procedures in the future
- The clinical presentation of congenital anomalies of the urinary tract is changing but some of these may still present in the adult patient
- Obstructive uropathy and VUR are not always surgical anomalies, but may be functional in nature: the treatment modalities and long-term outcomes depend on the pathophysiology

11:00 - 14:00

Prenatal hydronephrosis / prenatal intervention and post natal management

J.M. Nijman, Groningen (NL)

11:00 - 14:00

Vesico-ureteral reflux: Longterm outcome and complications

S. Tekgül, Ankara (TR)

11:00 - 14:00

Obstructive uropathy: Megaureter, posterior urethral valves and the valve bladder: A life-long dilemma

D.N. Wood, London (GB)

11:00 - 14:00

Discussion

Robot-assisted laparoscopic prostatectomy

ESU Course 04

Saturday, 25 March
11:00 - 14:00

Location: Room 14, Capital suite (level 3)

Chair: P-T. Piéchaud, Bordeaux (FR)

11:00 - 14:00

Introduction

P-T. Piéchaud, Bordeaux (FR)

11:00 - 14:00

General principles of robotic radical prostatectomy

W. Artibani, Verona (IT)
P. Dasgupta, London (GB)

11:00 - 14:00

Anatomical and oncological supports of radical prostatectomy

11:00 - 14:00

Bladder neck preservation: Useful? Dangerous?

P-T. Piéchaud, Bordeaux (FR)

11:00 - 14:00

Neurovascular bundle dissection: Anatomical reminders of the peri prostatic fascia and space of dissection

P. Dasgupta, London (GB)

11:00 - 14:00

Tips and tricks around vesico uretral anastomosis (Rocco, anterior suspension...)

W. Artibani, Verona (IT)

11:00 - 14:00

Step by step operative procedure; How I do it

W. Artibani, Verona (IT)
P. Dasgupta, London (GB)
P-T. Piéchaud, Bordeaux (FR)

11:00 - 14:00

Questions from participants about operative protocols

11:00 - 14:00

Lymphadenectomy

W. Artibani, Verona (IT)

11:00 - 14:00

Specific situations

P-T. Piéchaud, Bordeaux (FR)

11:00 - 14:00

Postoperative complications

P. Dasgupta, London (GB)

11:00 - 14:00

Anatomical and functional results

W. Artibani, Verona (IT)

11:00 - 14:00

Conclusion

P-T. Piéchaud, Bordeaux (FR)

Adrenalectomy

ESU Course 06

Saturday, 25 March
11:00 - 14:00

Location: Room 16, Capital suite (level 3)

Chair: A.S. Gözen, Heilbronn (DE)

Aims and objectives of this presentation

To teach all about the adrenal gland minimal invasive approach; starting with the correct indications for surgery and preoperative medical preparation. The different approaches and new equipment will be shown including special instructions. The operations will be given step by step in high quality videos in detail with tips and tricks. The complication videos and intraoperative management will be discussed interactively with the experts.

11:00 - 14:00

Indications and patient preparation (medical and surgical)

H. Langenhuijsen, Nijmegen (NL)

11:00 - 14:00

Surgical anatomy

F. Porpiglia, Turin (IT)

11:00 - 14:00

How I do it; step by step operative procedure, technical tips and tricks

11:00 - 14:00

Transperitoneal

H. Langenhuijsen, Nijmegen (NL)

11:00 - 14:00

Retroperitoneal and prone

A.S. Gözen, Heilbronn (DE)

11:00 - 14:00

Mini-laparoscopic

F. Porpiglia, Turin (IT)

11:00 - 14:00

Complications and management

A.S. Gözen, Heilbronn (DE)

11:00 - 14:00

Discussion and interaction

A.S. Gözen, Heilbronn (DE)
H. Langenhuijsen, Nijmegen (NL)
F. Porpiglia, Turin (IT)

ESU/ESUT Hands-on Training in Basic laparoscopic skills

HOT02

Saturday, 25 March
11:00 - 12:00

Location: Room South America, Exhibition Hall (Level 1)

Aims and objectives of this presentation

In this course basic laparoscopic and suturing skills can be learned and trained. Psychomotor skills such as depth perception and bimanual dexterity are trained by the validated exercises of the European Basic Laparoscopic Urological Skills (E-BLUS) training programme.

Experienced laparoscopist-tutors will guide you to master such basic laparoscopy skills as instrument handling, pattern cutting and intracorporal suturing. This course can be used as an additional training to prepare for the E-BLUS examination. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

ESU/ESFFU Hands-on Training course in OnabotulinumtoxinA administration for OAB

HOT16

Saturday, 25 March
11:30 - 13:00

Location: Room Europe, Exhibition Hall (Level 1)

Chair: H. Hashim, Bristol (GB)

Aims and objectives of this presentation

Botulinum toxin type A administration in Urology has become common practice over the last two decades. Following the completion of Phase 3 registration trials in OAB, OnabotulinumtoxinA received marketing approval for this indication and now has a standardised injection paradigm. This course is procedure-focused, and will teach attendees the practicalities of OnabotulinumtoxinA administration through short lectures, videos and hands-on demonstrations using bladder models. Attendees will learn how to reconstitute the product and see different types of equipment available.

R. Inman, Sheffield (GB)
M.S. Rahnama'i, Heerlen (NL)
A. Sahai, London (GB)

EAU Research Foundation Meeting

Special session

Saturday, 25 March
12:00 - 14:15

Location: Room 9, Capital suite (level 3)

Chair: P.F.A. Mulders, Nijmegen (NL)

Aims and objectives of this presentation

Introduction of EAU research foundation and its activity in the urology research community

12:00 - 12:10

Welcome

P.F.A. Mulders, Nijmegen (NL)

12:10 - 12:25

Lecture by EAU career track fellow [Castration resistant PC: Causal mechanisms and novel therapeutic targets after androgen receptor blockade failure](#)

A. Aytes, Barcelona (ES)

12:25 - 12:40

Active surveillance of patients with incidental small renal masses. EAU Research Foundation project 'EASE'

A. Volpe, Novara (IT)

12:40 - 12:55

The role of image guidance in the diagnosis of PCa. EAU Research Foundation project 'PRECISION'

V. Kasivisvanathan, London (GB)

12:55 - 13:25

Designing, conducting and communicating 'Investigator Initiated Research' at the EAU Research Foundation.

W.P.J. Witjes, Arnhem (NL)

13:10 - 13:25

Selection of male patients for minimal invasive therapy of stress urinary incontinence. EAU Research Foundation project 'SATURN'

R. Hamid, London (GB)

13:25 - 13:40

The continuing challenge of antibiotic resistance in Urinary Tract Infections. EAU Research Foundation project 'GPIU/SERPENS'

T.E. Bjerklund Johansen, Stavern (NO)

13:40 - 13:55

Patient selection for adjuvant treatment of high risk NMIBC. EAU Research Foundation project 'NIMBUS'

M. Colombel, Lyon (FR)

13:55 - 14:10

Adjuvant treatment of MIBC: Results and lessons learned from the MAGNOLIA study. EAU Research Foundation project 'MAGNOLIA'

P.F.A. Mulders, Nijmegen (NL)

14:10 - 14:15

Closure and farewell

P.F.A. Mulders, Nijmegen (NL)

How to proceed with hematuria

ESU Course 03

Saturday, 25 March
12:00 - 14:00

Location: Room 12, Capital suite (level 3)

Chair: S. Boorjian, Rochester (US)

Aims and objectives of this presentation

Hematuria is one of the most common indications for urologic evaluation, and is recognized as a sign of potentially important illness. Therefore, knowledge of the differential diagnosis, principles of evaluation, and strategies for management of hematuria is critical. This course is designed for the practicing urologist, to provide a guidelines-based and case-oriented approach to the evaluation and management of hematuria.

After attending the course, participants will:

- Understand guideline recommendations for initial evaluation of asymptomatic microscopic hematuria
- Describe existing data regarding hematuria screening
- Recognize intravesical treatment regimens and associated side effect profiles for hemorrhagic cystitis
- Create strategies for treating refractory hemorrhagic cystitis, upper urinary tract, and prostate-related bleeding

12:00 - 14:00

Course introduction and background to hematuria

S. Boorjian, Rochester (US)

12:00 - 14:00

Review of microscopic hematuria

H. Mostafid, Guildford (GB)

12:00 - 14:00

AUA guidelines (and beyond) on microscopic hematuria

S. Boorjian, Rochester (US)

12:00 - 14:00

Cases and questions focusing on microhematuria

S. Boorjian, Rochester (US)

H. Mostafid, Guildford (GB)

12:00 - 14:00

Evaluation and management of gross hematuria and hemorrhagic cystitis

S. Boorjian, Rochester (US)

H. Mostafid, Guildford (GB)

12:00 - 14:00

Prostate/Urethral/Upper urinary tract bleeding

H. Mostafid, Guildford (GB)

12:00 - 14:00

Cases and questions focusing on gross hematuria

S. Boorjian, Rochester (US)

H. Mostafid, Guildford (GB)

Surgery for renal cancer beyond minimally invasive approaches: Opportunities and limits

ESU Course 05

Saturday, 25 March
12:00 - 14:00

Location: Room 15, Capital suite (level 3)

Chair: M. Kuczyk, Hanover (DE)

Aims and objectives of this presentation

Addressing patients with locally advanced renal cell cancer with / without intraval tumour thrombosis usually not being considered candidates for laparoscopy, the current course presents tips and tricks for the surgical management of these cases. In addition, the indication for and the potential clinical value of metastasectomy, cytoreductive nephrectomy and lymph node dissection in the aforementioned clinical situation is revisited.

- Tips and tricks for the surgical management of locally advanced renal cancer with / without intracaval tumor thrombosis
- What is the indication for and the value of metastasectomy in renal cancer patients?
- Can we define the ideal candidate for cytoreductive nephrectomy?
- Is there any value of a more extended lymph node dissection during nephrectomy?

12:00 - 14:00

The role of metastasectomy in metastatic renal cancer

M. Kuczyk, Hanover (DE)

12:00 - 14:00

The role of cytoreductive nephrectomy in metastatic renal cancer

M. Kuczyk, Hanover (DE)

12:00 - 14:00

Tips and tricks for the surgical management of patients with advanced renal cell cancer not suitable for a minimally invasive approach

A. Bex, Amsterdam (NL)

12:00 - 14:00

The surgical strategy for the management of renal cancer with intracaval thrombosis

A. Bex, Amsterdam (NL)

12:00 - 14:00

The role of lymphadenectomy during the surgical treatment of RCC patients

M. Kuczyk, Hanover (DE)

ESU/ESUT Hands-on Training in Basic laparoscopic skills

HOT03

Saturday, 25 March
12:15 - 13:15

Location: Room South America, Exhibition Hall (Level 1)

Aims and objectives of this presentation

In this course basic laparoscopic and suturing skills can be learned and trained. Psychomotor skills such as depth perception and bimanual dexterity are trained by the validated exercises of the European Basic Laparoscopic Urological Skills (E-BLUS) training programme.

Experienced laparoscopist-tutors will guide you to master such basic laparoscopy skills as instrument handling, pattern cutting and intracorporal suturing. This course can be used as an additional training to prepare for the E-BLUS examination. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

ESU/ESFFU Hands-on Training in Urodynamics

HOT06

Saturday, 25 March
13:00 - 16:00

Location: Room North America, Exhibition Hall (Level 1)

Chair: G. Van Koeveringe, Maastricht (NL)

Aims and objectives of this presentation

This course aims to provide a practical course offering an interactive “hands-on” environment for doctors, nurses and technicians to improve their skills in urodynamics.

Programme:

Plenary Session How to perform CMG, VCMG, AmbCMG, UPP and RLPP

Station 1 Urodynamics: The principles of pressure and flow measurements. The limitation and advantages of each approach, potential artefacts and their mitigations will also be discussed

Station 2 Male case studies: characteristic traces of filling voiding and voiding phase traces as well as fluoroscopy images of outlet obstruction

Station 3 Female case studies: characteristic filling voiding and voiding phase traces as well as fluoroscopy images of outlet obstruction and with emphasis on the assessment of stress urinary incontinence

Station 4 Neuropathic case studies: special considerations of performing urodynamics in this cohort as well as characteristic traces and images will be discussed

E. Finazzi Agrò, Rome (IT)

R. Kirschner-Hermanns, Aachen (DE)

T. Mckinney, Fort Lauderdale (US)

To be confirmed

P.F.W.M. Rosier, Nijmegen (NL)

To be confirmed

ESU/ESFFU Hands-on Training course in OnabotulinumtoxinA administration for OAB

HOT17

Saturday, 25 March
13:30 - 15:00

Location: Room Europe, Exhibition Hall (Level 1)

Chair: To be confirmed

Aims and objectives of this presentation

Botulinum toxin type A administration in Urology has become common practice over the last two decades. Following the completion of Phase 3 registration trials in OAB, OnabotulinumtoxinA received marketing approval for this indication and now has a standardised injection paradigm. This course is procedure-focused, and will teach attendees the practicalities of OnabotulinumtoxinA administration through short lectures, videos and hands-on demonstrations using bladder models. Attendees will learn how to reconstitute the product and see different types of equipment available.

A. Garcia Mora, Mexico City (MX)

R. Hamid, London (GB)

M.S. Rahnama'i, Heerlen (NL)

Optimising laparoscopic partial nephrectomy

Video Session 04

Saturday, 25 March
14:15 - 15:45

Location: Room Paris, North Hall (Level 1)

Chairs: A. Carbone, Latina (IT)
B. Guillonnet, Paris (FR)
C. Schwentner, Stuttgart (DE)

Aims and objectives of this presentation

To present novel techniques and technical features of minimally-invasive partial nephrectomy. Laparoscopic partial nephrectomy approaches to minimize kidney damage while maintaining oncological safety are current reality.

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

- *V25 **Preliminary kidney parenchymal ligation to achieve trifecta in zero-ischemia laparoscopic partial nephrectomy**
By: [Komai Y.](#)¹, Gotohda N.², Sakai Y.¹, Ito M.¹
Institutes:¹National Cancer Center Hospital East, Dept. of Urology, Chiba, Japan, ²National Cancer Center Hospital East, Dept. of Hepatobiliary and Pancreatic Surgery, Chiba, Japan
- *V27 **Off-clamp laparoscopic partial nephrectomy for hilar renal cell carcinoma: Surgical description**
By: [Al Salhi Y.](#)¹, Fuschi A.¹, Velotti G.¹, Leto A.¹, Pastore A.L.¹, Palleschi G.¹, Carbone A.¹, Falsaperla M.²
Institutes:¹Sapienza University of Rome, Dept. of Medico-Surgical Sciences and Biotechnologies, Urology Unit, Latina, Italy, ²Hospital Vittorio Emanuele, Dept. of Urology, Catania, Italy
- *V29 **Selective calmping of terziary arterial branch during laparoscopic partial nephrectomy thanks to 3d reconstruction of the vascular pedicle**
By: [Varca V.](#), Benelli A., Gregori A.
Institutes:Ospedale Salvini, Dept. of Urology, Garbagnate Milanese, Italy
- *V30 **Kidney mobilization and rotation during laparoscopic partial nephrectomy for access to dorsal and/or upper pole tumors**
By: [Macek P.](#), Novak K., Pesl M.
Institutes:General University Hospital and Medical Faculty of Charles University In Prague, Dept. of Urology, Prague, Czech Republic
- *V31 **Laparoscopic extraperitoneal renal tumor enucleation (LERTE) with renal hypotension on demand for endophitic masses**
By: [Cochetti G.](#), Barillaro F., D'amico F., Boni A., Pohja S., Mearini E.
Institutes:University of Perugia, Dept. of Surgical and Biomedical Sciences, Division of Urological, Andrological Surgery and Minimally-Invasive Techniques, Perugia, Italy
- *V32 **Laparoscopic partial nephrectomy for a small renal mass on an allograft kidney**
By: [Ozden E.](#), Oner S., Yakupoglu Y.K., Bostanci Y., Yilmaz A.F., Sarikaya S.
Institutes:Ondokuz Mayıs University, Dept. of Urology, Samsun, Turkey

Finding and applying the best technology to treat BPO

Poster Session 14

Saturday, 25 March
14:15 - 15:45

Location: Room Amsterdam, North Hall (Level 1)

Chairs: A. Bachmann, Basel (CH)
L. Carmignani, Milan (IT)
G.Y. Robert, Bordeaux CEDEX (FR)

Aims and objectives of this presentation

Invasive, including minimally invasive treatment modalities will be discussed

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *181 **Comparative effectiveness of transurethral resection techniques for benign prostatic hyperplasia – analysis of an all payer in patient discharge database**
By: Meyer C.¹, Gild P.¹, Von Landenberg N.¹, Friedlander D.¹, Eswara J.¹, Menon M.², Chun F.³, Fisch M.³, Sun M.¹, Chung B.⁴, Chang S.¹, Trinh Q-D.¹
Institutes:¹Brigham and Women's Hospital, Harvard Medical School, Division of Urological Surgery and Center For Surgery and Public Health, Boston, United States of America, ²Henry Ford Health System, VUI Center For Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Detroit, United States of America, ³University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ⁴Stanford Medical Center, Dept. of Urology, Stanford, United States of America
- *182 **Greenlight laser (XPS) 180W photoselective vaporization (PVP) vs. plasma kinetic vaporization of the prostate (PKVP) for treatment of small to moderate sized benign prostatic hyperplasia. A randomized controlled trial**
By: Ghobrial E., Elshal A., Laymon M., El-Tabey N., Shoma A., Nabeeh A., Shokeir A.
Institutes:Urology and Nephrology Center, Dept. of Urology, Elmansoura, Egypt
- *184 **TUR-P for large prostates using a pressure-controlled suprapubic suction device - a comparative study on long-term results in prostates smaller vs. bigger than 70cc**
By: Wilhelm K., Cazana M., Schoenthaler M., Schoeb D., Katzenwadel A., Wetterauer U., Miernik A.
Institutes:Faculty of Medicine, University of Freiburg, Germany, Clinic for Urology, Freiburg, Germany
- *185 **Vaporize, anatomically vaporize or enucleate the prostate? The flexible use of the GreenLight Laser**
By: Cindolo L.¹, Ruggera L.², Destefanis P.³, Dadone C.⁴, Schips L.¹, Marchioni M.⁵, Ferrari G.⁶
Institutes:¹Asl Abruzzo 02, Dept. of Urology, Chieti, Italy, ²Santa Maria Degli Angeli Hospital, Dept. of Urology, Pordenone, Italy, ³Azienda Ospedaliera Città Della Salute E Della Scienza Di Torino – Sede Molinette, Dept. of Urology, Torino, Italy, ⁴Santa Croce E Carle Hospital, Dept. of Urology, Cuneo, Italy, ⁵SS. Annunziata Hospital G.D'Annunzio University of Chieti, Dept. of Urology, Chieti, Italy, ⁶Hesperia Hospital, Dept. of Urology, Modena, Italy
- *186 **5-year outcome following pure bipolar plasma vaporization of the prostate: Results from a prospective 3D ultrasound volumetry study**
By: Kranzbühler B., Gross O., Fankhauser C., Wettstein M., Grossmann N., Keller E., Eberli D., Sulser T., Poyet C., Hermanns T.
Institutes:University Hospital Zurich, Dept. of Urology, Zurich, Switzerland

- *187 **A prospective study in 506 patients about the safety of omitting AB-prophylaxis in TURP in patients without pre-operative bacteriuria/catheter**
 By: [Baten E.](#)¹, Orye C.², Cartuyvels R.³, Van Renterghem K.¹
 Institutes:¹Jessa Ziekenhuis, Dept. of Urology, Hasselt, Belgium, ²UZLeuven, Dept. of Urology, Leuven, Belgium, ³Jessa Ziekenhuis, Dept. of Microbiology, Hasselt, Belgium
- *188 **Learning curves and perioperative outcomes after endoscopic enucleation of the prostate: A comparison between GreenLight 532-nm and holmium lasers**
 By: [Peyronnet B.](#)¹, Robert G.², Comat V.², Roupret M.³, Gomez-Sancha F.⁴, Cornu J-N.⁵, Misrai V.⁶
 Institutes:¹University of Rennes, Dept. of Urology, Rennes, France, ²University of Bordeaux, Dept. of Urology, Bordeaux, France, ³Pitie Salpetriere Hospital, Dept. of Urology, Paris, France, ⁴CUA - Clínica CEMTRO, Dept. of Urology, Madrid, Spain, ⁵University of Rouen, Dept. of Urology, Rouen, France, ⁶Clinique Pasteur, Dept. of Urology, Toulouse, France
- *189 **Incidental prostate cancer (pT1a-pT1b) detection at bph surgery in the modern era - are we modifying the detection rate?**
 By: [Capogrosso P.](#)¹, Capitanio U.¹, Ventimiglia E.¹, Cazzaniga W.¹, Pederzoli F.¹, Boeri L.², Oreggia D.¹, Moretti D.¹, Briganti A.¹, Cathelineau X.³, Montorsi F.¹, Salonia A.¹
 Institutes:¹IRCCS San Raffaele Hospital/ University Vita-Salute San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, ²IRCCS Cà Granda, Hospital Maggiore Policlinico, Dept. of Urology, Milan, Italy, ³Institut Mutualiste Montsouris, Dept. of Urology, Paris, France
- *190 **Holmium laser enucleation of the prostate: A single centre case series of 1000 patients with 13 years of follow-up**
 By: [Whiting D.](#), Penev B., Cynk M.
 Institutes:Maidstone and Tunbridge Wells Nhs Trust, Dept. of Urology, Maidstone, United Kingdom
- *191 **50 Watt HoLEP: How efficiently can a low power holmium laser enucleate prostates?**
 By: [Khan E.](#)¹, Saleemi M.¹, Barrass B.¹, Taneja S.¹, Alam A.¹, Mohammed A.¹, Nunney I.²
 Institutes:¹Luton and Dunstable Hospital NHS Foundation Trust, Dept. of Urology, Luton, United Kingdom, ²Norwich Medical School, University of East Anglia, Dept. of Medical Statistics, Norwich, United Kingdom
- *192 **Long term (5 Year) results from the largest, prospective, randomized, controlled study of the minimally invasive prostatic urethral lift (PUL)**
 By: [Roehrborn C.](#)¹, Gange S.², Shore N.³, Giddens J.⁴, Bolton D.⁵, Cowan B.⁶, Cantwell A.⁷, Mcvary K.⁸, Chin P.⁹, Te A.¹⁰, Gholami S.¹¹, Rashid P.¹², Moseley W.¹³, Tutrone R.¹⁴, Freedman S.¹⁵, Incze P.¹⁶, Coffield K.¹⁷, Borges F.¹⁸, Rukstalis D.¹⁹
 Institutes:¹UT Southwestern Medical School, Dept. of Urology, Dallas, United States of America, ²Western Urological Clinic, Dept. of Urology, Salt Lake City, United States of America, ³Carolina Urologic Research Center, Dept. of Urology, Myrtle Beach, United States of America, ⁴Jonathan Giddens Medicine Professional Corporation, Dept. of Urology, Brampton, Canada, ⁵Austin Health, Dept. of Urology, Heidelberg, Australia, ⁶Urology Associates of Denver, Dept. of Urology, Englewood, United States of America, ⁷Advanced Urology Institute, Dept. of Urology, Daytona Beach, United States of America, ⁸Southern Illinois University, Dept. of Urology, Springfield, United States of America, ⁹Illawarra Urology, Dept. of Urology, Figtree, Australia, ¹⁰Weill Cornell Medical Center, Dept. of Urology, New York, United States of America, ¹¹Urology Associates of Silicon Valley, Dept. of Urology, San Jose, United States of America, ¹²Urology Centre, Dept. of Urology, Port Macquarie, Australia, ¹³Genesis Research LLC, Dept. of Urology, San Diego, United States of America, ¹⁴Chesapeake Urology Research Associates, Dept. of Urology, Baltimore, United States of America, ¹⁵Sheldon J. Freedman, M.D., Ltd., Dept. of Urology, Las Vegas, United States of America, ¹⁶The Fe/Male Health Centres, Dept. of Urology, Oakville, Canada, ¹⁷Scott and White Healthcare, Dept. of Urology, Temple, United States of America, ¹⁸Pinellas Urology Inc., Dept. of Urology, St. Petersburg, United States of America, ¹⁹Wake Forest Baptist Health, Dept. of Urology, Winston Salem, United States of America

15:30 - 15:38

Associated video presentation Robot-assisted simple prostatectomy (RASP) step by step

procedure and results

P. Umari, Duino-Aurisina (TS) (IT)

Receptors and targets in functional urology

Poster Session 15

Saturday, 25 March
14:15 - 15:45

Location: Room Berlin, North Hall (Level 1)

Chairs: C. Cruz, Porto (PT)
DM Daly, Lancashire (GB)
K. Monastyrskaya, Bern (CH)

Aims and objectives of this presentation

The search for new pharmacological targets continues. Receptors and new mechanisms are being discussed in this session

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*193 **Estradiol releasing hydrogel as a proangiogenic substitute for fat flaps used in urogenital reconstruction**

By: Eke G.², [Mangir N.](#)¹, Hasirci N.³, Chapple C.⁴, Hasirci V.⁵, Macneil S.¹

Institutes:¹Kroto Research Institute, Dept. of Materials Science and Engineering, Sheffield, United Kingdom, ²Middle East Technical University (METU), Dept. of Biotechnology & BIOMATEN, METU Center of Excellence In Biomaterials and Tissue Engineering, Ankara, Turkey, ³METU, Dept. of Biotechnology, Chemistry & BIOMATEN, METU Center of Excellence In Biomaterials and Tissue Engineering, Ankara, Turkey, ⁴Royal Hallamshire Hospital, Dept. of Urology, Sheffield, United Kingdom, ⁵METU, Dept. of Biotechnology, Biological Sciences & BIOMATEN, METU Center of Excellence In Biomaterials and Tissue Engineering, Ankara, Turkey

Associated video presentation

*194 **9-Phenanthrol modifies rat bladder function independent of TRPM4**

By: [Deruyver Y.](#)¹, Uvin P.¹, Pinto S.², Van Ranst N.², Franken J.¹, Gevaert T.¹, Everaerts W.¹, Voets T.², De Ridder D.¹, Vennekens R.²

Institutes:¹KU Leuven, Laboratory of Experimental Urology, Leuven, Belgium, ²KU Leuven, Laboratory of Ion Channel Research, Leuven, Belgium

Associated video presentation

*195 **Supraspinal effects of dopamine uptake inhibitor on the micturition reflex in rats**

By: Honda M.¹, Yoshimura N.², [Kimura Y.](#)¹, Kawamoto B.¹, Tsounapi P.¹, Hikita K.¹, Shimizu S.³, Shimizu T.³, Saito M.³, Chancellor M.⁴, Takenaka A.¹

Institutes:¹Tottori University Faculty of Medicine, Dept. of Urology, Yonago, Japan, ²University of Pittsburgh, Dept. of Urology, Pittsburgh, United States of America, ³Kochi Medical School, Dept. of Pharmacology, Nankoku, Japan, ⁴William Beaumont Hospital, Dept. of Urology, Royal Oak, United States of America

Associated video presentation

*196 **Role of supraspinal and spinal group III metabotropic glutamate receptor in micturition reflex in urethane-anesthetized rats**

By: [Honda M.](#)¹, Kimura Y.¹, Kawamoto B.¹, Tsounapi P.¹, Hikita K.¹, Saito M.², Takenaka A.¹

Institutes:¹Tottori University Faculty of Medicine, Dept. of Urology, Yonago, Japan, ²Kochi Medical School, Dept. of Pharmacology, Nankoku, Japan

Associated video presentation

- *197 **KPR-2579, a novel TRPM8 antagonist, inhibits hyperactivity of the primary bladder afferent nerves induced by acetic acid in rats**
 By: [Aizawa N.](#)¹, Fujimori Y.², Kobayashi J.², Nakanishi O.², Hirasawa H.², Homma Y.³, Igawa Y.¹
Institutes:¹The University of Tokyo Graduate School of Medicine, Dept. of Continence Medicine, Tokyo, Japan, ²Kissei Pharmaceutical Co., Ltd., Discovery Research R&D, Azumino, Japan, ³The University of Tokyo Graduate School of Medicine, Dept. of Urology, Tokyo, Japan

Associated video presentation

- *198 **Does TRP channel play a role in cooling-induced contraction of human detrusor smooth muscle?**
 By: [Kajioka S.](#), Maki T., Lee K., Takahashi R., Ito M.
Institutes: Kyushu University, Dept. of Urology, Fukuoka, Japan

Associated video presentation

- *199 **Novel three-mRNA and three-miRNA signatures accurately identify urodynamically-defined bladder phenotypes and correspond to functional improvement after deobstruction**
 By: [Moltzahn F.](#)¹, Burkhard F.¹, Hashemi Gheinani A.², Koeck I.², Monastyrskaya K.²
Institutes:¹University Hospital Bern, Dept. of Urology, Bern, Switzerland, ²Urology Research Laboratory, Dept. of Clinical Research, Bern, Switzerland

Associated video presentation

- *200 **Inflamamsome is an important mediator of chronic bladder inflammation in spontaneously hypertensive rats**
 By: [Mizoguchi S.](#), Mori K., Sato F., Hiromitsu M.
Institutes: Oita University, Dept. of Urology, Yuhu, Japan

Associated video presentation

- *201 **The water avoidance stress induces bladder pain due to a prolonged adrenergic (alpha1A) stimulation of the bladder**
 By: Matos R.¹, Serrão P.², Rodrigues L.³, Birder L.A.⁴, Cruz F.⁵, [Charrua A.](#)⁶
Institutes:¹Faculty of Medicine of University of Porto, Dept. of Biomedical Science, Porto, Portugal, ²University of Porto, Dept. of Pharmacology & Therapeutics and MedInUP, Porto, Portugal, ³University of Southern California, Dept. of Urology and Obstetrics and Gynecology, Los Angeles, United States of America, ⁴University of Pittsburgh School of Medicine, Dept. of Medicine and Pharmacology-Chemical Biology, Pittsburgh, United States of America, ⁵University of Porto and CHSJ, Dept. of Biomedical Science and I3S-IBMC, Porto, Portugal, ⁶University of Porto, Dept. of Biomedical Science and I3S-IBMC, Porto, Portugal

Associated video presentation

- *202 **Validation of TNF- α as the top upstream regulator of bladder remodelling during outlet obstruction-induced lower urinary tract dysfunction**
 By: Koeck I.¹, Hashemi Gheinani A.¹, Burkhard F.², [Monastyrskaya K.](#)²
Institutes:¹Urology Research Laboratory, Dept. of Clinical Research, Bern, Switzerland, ²University Hospital Bern, Dept. of Urology, Bern, Switzerland

Associated video presentation

- *203 **Morphological and functional restoration comparison between a novel bilayer chitosan and bladder acellular matrix graft as scaffolds in a rat bladder augmentation model**
 By: Xiao D.¹, Wang Q.², Zhang M.¹, Zhou Z.¹, [Lu M.](#)¹
Institutes:¹Renji Hospital, Dept. of Urology and Andrology, Shanghai, China, ²Shanghai 9th

People's Hospital, Dept. of Urology, Shanghai, China

Associated video presentation

*204

Effects of litoxetine on acetic acid-induced detrusor overactivity and striated anal sphincter functions in rabbits: Comparison with duloxetine

By: Pérez-Martínez F.², Lluel P.¹, Vela-Navarrete R.²

Institutes:¹Urosphere, Dept of Pharmacology, Toulouse, France, ²Universidad Autónoma De Madrid, Dept. of Urology, Madrid, Spain

Associated video presentation

*205

The stem cell growth factor receptor KIT is not expressed on interstitial cells in bladder

By: Gevaert T.¹, Vanstreels E.², Daelemans D.², Everaerts W.¹, Van Der Aa F.¹, Pintelon I.³, Timmermans J-P.³, Roskams T.⁴, Steiner C.⁵, Neuhaus J.⁵, De Ridder D.¹

Institutes:¹UZ Leuven, Dept. of Urology, Leuven, Belgium, ²KU Leuven, Rega Institute For Medical Research, Leuven, Belgium, ³University of Antwerp, Dept. of Veterinary Sciences, Antwerp, Belgium, ⁴KU Leuven, Dept. of Pathology, Leuven, Belgium, ⁵University of Leipzig, Klinik Und Poliklinik Für Urologie, Leipzig, Germany

Associated video presentation

Ongoing prospective trials

Poster Session 16

Saturday, 25 March
14:15 - 15:45

Location: Room Vienna, North Hall (Level 1)

Chairs: J. Bellmunt, Barcelona (ES)
M. Retz, Munich (DE)
S. Shariat, Vienna (AT)

Aims and objectives of this presentation

To show what is currently going on in oncologic urology and other fields in urology regarding multi center prospective randomized studies

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

14:38 - 14:48

Overview on systematic reviews/meta analysis

S. Shariat, Vienna (AT)

*206

A phase 3 randomized, double-blind, placebo-controlled trial of ODM-201 vs. placebo in combination with standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer (ARASENS)

By: Smith M.¹, Saad F.², Hussain M.³, Sternberg C.⁴, Fizazi K.⁵, Crawford D.⁶, Yamada K.⁷, Kappeler C.⁸, Kuss I.⁸, Tombal B.⁹

Institutes:¹Massachusetts General Hospital Cancer Center and Harvard Medical School, Dept. of Urologic Oncology, Boston, United States of America, ²University of Montreal, University of Montreal Hospital Center/CRCHUM, Montreal, Canada, ³Northwestern University Feinberg School of Medicine, Dept. of Hematology/Oncology, Chicago, United States of America, ⁴San Camillo and Forlanini Hospitals, Dept. of Medical Oncology, Rome, Italy, ⁵Gustave Roussy, University of Paris Sud, Cancer Medicine, Villejuif, France, ⁶University of Colorado, Dept. of Urologic Oncology, Aurora, United States of America, ⁷Bayer Pharmaceuticals, Dept. of Oncology, Whippany, United States of America, ⁸Bayer Pharma AG, Dept. of Oncology, Berlin, Germany, ⁹Cancer Centre, Catholic University of Louvain (UCL), Dept. of Urology, Brussels, Belgium

*207

Prostate cancer intra-tumoral heterogeneity: Correlation between clinical parameters, mpMRI and biomarkers

By: Carmona Echeverria L.M.¹, Johnston E.², Shanmugabavan Y.³, Rowan A.⁴, Goh G.⁵, Scott R.³, Hung M.³, Gelinger M.⁶, Arya M.³, Emberton M.³, Freeman A.⁷, Punwani S.², Barrat D.⁸, Yipeng H.⁸, Attard G.⁹, Whitaker H.¹, Linch M.⁵, De Bono J.⁹, Swanston C.⁴, Ahmed H.³

Institutes:¹University College London, Dept. of Surgery and Interventional Science - Centre For Molecular Intervention, London, United Kingdom, ²University College London, UCL Centre For Medical Imaging, London, United Kingdom, ³University College London, Dept. of Surgery and Interventional Science, London, United Kingdom, ⁴Cancer Research UK, Translational Cancer Therapeutics Laboratory, London, United Kingdom, ⁵University College London, Cancer Institute, London, United Kingdom, ⁶Institute of Cancer Research, Centre For Evolution and Cancer, London, United Kingdom, ⁷University College London, Dept. of Research Pathology, London, United Kingdom, ⁸University College London, UCL Centre For Medical Image Computing, London, United Kingdom, ⁹Institute of Cancer Research, Dept. of Clinical Studies, London, United Kingdom

*208

KEYNOTE-365: Phase 1b/2 trial of pembrolizumab combination therapy for metastatic castration-resistant prostate cancer (mCRPC)

By: Yu E.Y.², Wu H.¹, Schloss C.¹

Institutes:¹Merck & Co., Inc., Dept. of Clinical Oncology, Kenilworth, United States of America, ²Seattle Cancer Care Alliance, Dept. of Medicine, Seattle, United States of America

- *209 **Multi-institutional validation and assessment of training modalities in robotic surgery (the MARS project)**
 By: [Raison N.](#)¹, Ahmed K.¹, Aydin A.², Van Der Poel H.³, Mottrie A.⁴, Dasgupta P.²
 Institutes:¹King's College London, Mrc Centre For Transplantation, London, United Kingdom, ²King's College London, MRC Centre For Transplantation, London, United Kingdom, ³Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ⁴OLV Clinic, Dept. of Urology, Aalst, Belgium
- *210 **The effects of the human fetal estrogen estetrol (E4) in healthy men to estimate its potential use for the treatment of prostate cancer**
 By: [Dutman E.](#), Zimmerman Y., Coelingh-Bennink H.
 Institutes:Pantarhei Oncology BV, Zeist, The Netherlands
- *211 **PURE01: An open label, single-arm, phase 2 study of the anti-programmed death (PD)-1 monoclonal antibody (moAb) pembrolizumab for neoadjuvant therapy of muscle-invasive urothelial bladder carcinoma (miUBC)**
 By: [Necchi A.](#)¹, Mariani L.², Anichini A.³, Giannatempo P.¹, Raggi D.¹, Togliardi E.⁴, Calareso G.⁵, Nicolai N.⁶, Crippa F.⁷, Biononi D.⁶, Torelli T.⁶, Catanzaro M.⁶, Stagni S.⁶, Piva L.⁶, Salvioni R.⁶
 Institutes:¹Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, ²Fondazione IRCCS - Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy, ³Fondazione IRCCS - Istituto Nazionale Dei Tumori, Human Tumors Immunobiology Unit, Milan, Italy, ⁴Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Pharmacy Unit, Milan, Italy, ⁵Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Radiology, Milan, Italy, ⁶Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, ⁷Fondazione IRCCS - Istituto Nazionale Dei Tumori, Nuclear Medicine and PET Unit, Milan, Italy
- *212 **IMvigor010, a Phase III study of adjuvant atezolizumab vs observation in patients (pts) with muscle-invasive urothelial carcinoma (UC)**
 By: [Gschwend J.](#)¹, Bellmunt J.², Castellano D.³, Daneshmand S.⁴, Hussain M.⁵, Nishiyama H.⁶, Powles T.⁷, Degaonkar V.⁸, Nguyen Duc A.⁹, Culine S.¹⁰
 Institutes:¹Technical University of Munich, Dept. of Urology, München, Germany, ²Bladder Cancer Center, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, United States of America, ³Hospital Universitario 12 De Octubre, Dept. of Oncology, Madrid, Spain, ⁴University of Southern California, Dept. of Oncology, Los Angeles, United States of America, ⁵Northwestern University, Dept. of Oncology, Chicago, United States of America, ⁶University of Tsukuba, Dept. of Oncology, Ibaraki, Japan, ⁷Barts Cancer Institute, Queen Mary University of London, London, United Kingdom, ⁸Genentech, Inc., Dept. of Oncology, South San Francisco, United States of America, ⁹Roche, Dept. of Oncology, Basel, Switzerland, ¹⁰Hôpital Saint-Louis, Dept. of Oncology, Paris, France
- *213 **Phase 3 randomized trial of intravenous mannitol versus placebo prior to renal ischemia during partial nephrectomy: Impact on renal functional outcomes**
 By: [Spaliviero M.](#), Power N., Murray K., Sjoberg D., Benfante N., Bernstein M., Wren J., Russo P., Coleman J.
 Institutes:Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America
- *214 **A phase 2 trial of lenvatinib in combination with everolimus in patients with advanced or metastatic non-clear cell renal cell carcinoma**
 By: [Hutson T.](#)¹, Xing D.², Dutcus C.², Baig M.², Fishman M.³
 Institutes:¹Texas Oncology, Dallas, United States of America, ²Eisai, Woodcliff Lake, United States of America, ³H. Lee Moffitt, Cancer and Research Center, Tampa, United States of America
- *215 **A national, prospective, non-interventional study (NIS) of nivolumab (BMS-936558) in patients with advanced renal cell carcinoma after prior therapy**
 By: [Grimm M.-O.](#), Grünwald V., Bedke J.
 Institutes:Jena University Hospital, Dept. of Urology, Jena, Germany

- *216 **APACHE: An open label, randomized, phase 2 study of the anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab (D, MEDI4736), alone or in combination with Tremelimumab (T), in patients (pts) with advanced germ cell tumors (GCT)**
By: [Necchi A.](#)¹, [Mariani L.](#)², [Anichini A.](#)³, [Giannatempo P.](#)¹, [Raggi D.](#)¹, [Togliardi E.](#)⁴, [Calareso G.](#)⁵, [Nicolai N.](#)⁶, [Crippa F.](#)⁷, [Salvioni R.](#)⁶
Institutes:¹Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, ²Fondazione IRCCS - Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy, ³Fondazione IRCCS - Istituto Nazionale Dei Tumori, Human Tumors Immunobiology Unit, Milan, Italy, ⁴Fondazione IRCCS - Istituto Nazionale Dei Tumori, Pharmacy Unit, Milan, Italy, ⁵Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Radiology, Milan, Italy, ⁶Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, ⁷Fondazione IRCCS - Istituto Nazionale Dei Tumori, Nuclear Medicine and PET Unit, Milan, Italy
- *217 **An effective and acceptable cleaning method for re-use of catheters for intermittent catheterisation (IC)**
By: [Wilks S.](#)¹, [Morris N.](#)², [Delgado D.](#)², [Prieto J.](#)¹, [Moore K.](#)³, [Macaulay M.](#)⁴, [Fader M.](#)¹
Institutes:¹University of Southampton, Dept. of Health Sciences, Southampton, United Kingdom, ²Bristol Urological Institute, Dept. of Learning and Research, Bristol, United Kingdom, ³University of Alberta, Faculty of Nursing, Alberta, Canada, ⁴University College London, Continence & Skin Technology Group, London, United Kingdom
- 15:36 - 15:43 **Summary**
J. Bellmunt

Ureteroscopy: Tools and techniques

Poster Session 17

Saturday, 25 March
14:15 - 15:45

Location: Room London, North Hall (Level 1)

Chairs: Y. Farahat, Dubai (AE)
B. Geavlete, Bucharest (RO)
Y-H. Sun, Shanghai (CN)

Aims and objectives of this presentation

Ureteroscopy has become the working horse in stone management. A huge number of different scopes and disposables are available – which are really needed and why?

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *218 **Ultra-low X-ray exposure during flexible ureteroscopy in nephrolithiasis patients – How far can we go?**
By: [Hein S.](#)¹, [Schoenthaler M.](#)¹, [Wilhelm K.](#)¹, [Schoeb D.S.](#)¹, [Schlager D.](#)¹, [Adams F.](#)¹, [Vach W.](#)², [Miernik A.](#)¹
Institutes:¹Medical Centre - University of Freiburg, Dept. of Urology - Division of Urotechnology, Freiburg, Germany, ²University of Freiburg, Centre For Medical Biometry and Medical Informatics, Freiburg, Germany
- *219 **Which flexible ureteroscopes (digital vs optical) can easily reach the difficult lower pole calyces and have better end-tip deflection?**
By: [Drago L.B.](#)¹, [Buttice S.](#)², [Sener E.T.](#)³, [Proietti S.](#)⁴, [Ploumidis A.](#)⁵, [Iacobaie C.](#)⁶, [Doizi S.](#)⁶, [Berg J.](#)⁶, [Somani B.](#)⁷, [Traxer O.](#)⁶
Institutes:¹Spitalul Clinic Judeean de Urgen "Pius Branzu" Timisoara, Dept. of Urology, Timisoara, Romania, ²Università Degli Studi Di Messina, Dept. of Urology, Messina, Italy, ³Marmara University, Dept. of Urology, Istanbul, Turkey, ⁴Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ⁵Athens Medical Center, Dept. of Urology, Athens, Greece, ⁶Hopital Tenon, Université Pierre Et Marie Curie - Paris VI, Dept. of Urology, Paris, France, ⁷University Hospital Southampton NHS Trust, Dept. of Urology, Southampton, United Kingdom
- *220 **A comparison of the effects of ureteroscopy and micro ureteroscopy on renal vascularization and intrapelvic pressure**
By: [Caballero-Romeu J-P.](#)¹, [Galán-Llopis J-A.](#)², [Soria F.](#)³, [Morcillo-Martín E.](#)³, [Caballero-Pérez P.](#)⁴, [De La Cruz-Conty J-E.](#)³, [Romero-Maroto J.](#)⁵
Institutes:¹Fisabio-Isabial, Dept. of Urology, Alicante, Spain, ²Universitary Hospital of Vinalopó, Dept. of Urology, Alicante, Spain, ³Jesús Usón Minimally Invasive Surgery Center, Endoscopy Unit, Cáceres, Spain, ⁴University of Alicante, Dept. of Community Nursing, Preventive Medicine and Public Health and History, Alicante, Spain, ⁵University Clinical Hospital of San Juan, Dept. of Urology, Alicante, Spain
- *221 **Predictive factors of insertion failure of ureteral access sheath for flexible ureteroscopy: A study about 594 procedures**
By: [Forzini T.](#), [Lecuelle D.](#), [Alezra E.](#), [Becquart N.](#), [Saint F.](#), [De Sousa P.](#)
Institutes:Amiens University Hospital, Dept. of Urology and Transplantation, Amiens, France
- *222 **Comparison of Holmium laser fibers: Evaluation of fiber durability and flexibility**
By: [Haddad M.](#)¹, [Berthe L.](#)², [Doizi S.](#)¹, [Traxer O.](#)¹
Institutes:¹Sorbonne Universités, UPMC Univ Paris 06, Ap-Hp, Grc N°20, Groupe De Recherche Clinique Sur La Lithi, Dept. of Urology, Tenon Hospital, Paris, France, ²Ecole Nationale Supérieure

Des Arts & Métiers, Process and Engineering In Mechanics and Materials Laboratory (Pimm), Umr Cnrs/Ensam 8006, Paris, France

- *223 **Impact of the curve diameter and laser setting on laser fiber fracture**
By: Haddad M.¹, Emiliani E.¹, Doizi S.¹, Rouchausse Y.², Coste F.², Berthe L.², Traxer O.¹
Institutes:¹Tenon Hospital, Dept. of Urology, Paris, France, ²Ecole Nationale Des Arts Et Métiers, PIMM Laboratory, Paris, France
- *224 **How to perform the dusting technique for calcium oxalate stones during Ho:YAG lithotripsy**
By: Lee J.W.¹, Park J.², Cho M.C.², Jeong H.², Son H.², Cho S.Y.², Oh J.K.³
Institutes:¹Dongguk University Ilsan Hospital, Dept. of Urology, Goyang, South Korea, ²Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Dept. of Urology, Seoul, South Korea, ³Gachon University Gil Medical Center, Gachon University College of Medicine, Dept. of Urology, Incheon, South Korea
- *225 **Laser vaporization of urinary stones during retrograde intrarenal surgery (rirs) is associated with the bacteria spread into the irrigation fluid but not with bacteraemia**
By: Cai T.¹, Tiscione D.¹, Meacci F.², Mazzoli S.², Lanzafame P.³, Malossini G.¹, Bartoletti R.⁴
Institutes:¹Santa Chiara Hospital, Dept. of Urology, Trento, Italy, ²Santa Maria Annunziata Hospital, Sexually Transmitted Disease Centre, Florence, Italy, ³Santa Chiara Hospital, Dept. of Microbiology, Trento, Italy, ⁴University of Pisa, Dept. of Urology, Pisa, Italy
- *226 **Comparison between the possibilities of Holmium and Thulium Laser in Lithotripsy in vitro**
By: Glybochko P.¹, Altshuler G.², Vinarov A.¹, Rapoport L.¹, Enikeev M.¹, Grigoriev N.¹, Enikeev D.¹, Sorokin N.¹, Dymov A.¹, Sukhanov R.¹, Taratkin M.¹, Zamyatina V.³
Institutes:¹First Moscow State Medical University of I.M. Sechenov, Research Institute of Urology and Reproductive Health, Moscow, Russia, ²IPG Medical, Dept. of Photonics, Oxford, United States of America, ³NTO IRE-Polus, Dept. of Photonics, Moscow, Russia
- *227 **Evaluation of the New Moses technology of Holmium laser lithotripsy: Initial clinical experience**
By: Ibrahim A., Carrier S., Andonian S., Elhilali M.
Institutes:McGill University Health Center, Dept. of Urology, Montreal, Canada
- *228 **Withdrawn**
By:
Institutes:
- *229 **Viability and biocompatibility of an adhesive system for intrarenal embedding and endoscopic removal of small residual fragments in minimally-invasive stone treatment in an in vivo pig model**
By: Hein S.¹, Schoenthaler M.¹, Schoeb D.S.¹, Grunwald I.², Richter K.², Brandmann M.², Haberstroh J.³, Bronsert P.⁴, Wetterauer U.⁵, Miernik A.¹
Institutes:¹Medical Centre - University of Freiburg, Dept. of Urology - Division of Urotechnology, Freiburg, Germany, ²Fraunhofer Institute For Manufacturing Technology and Advanced Materials IFAM, Bremen, Germany, Dept. of Adhesive Bonding Technology and Surfaces, Bremen, Germany, ³Medical Centre - University of Freiburg, Dept. of Experimental Surgery, CEMT-FR, Freiburg, Germany, ⁴Medical Centre - University of Freiburg, Institute of Pathology, Freiburg, Germany, ⁵Medical Centre - University of Freiburg, Dept. of Urology, Freiburg, Germany
- *230 **Development and validation of a novel abrasion-based method to assess biofilms on ureteral stents**
By: Buhmann M.³, Abt D.¹, Altenried S.², Betschart P.¹, Zumstein V.¹, Schmid H.-P.¹, Maniura-Weber K.², Ren Q.²
Institutes:¹Kantonsspital St. Gallen, Dept. of Urology, St. Gallen, Switzerland, ²Swiss Federal Laboratories For Materials Science and Technology, Dept. of Materials Meet Life, Laboratory for Biointerfaces, St. Gallen, Switzerland, ³Swiss Federal Laboratories for Materials Science and Technology, Dept. of Materials Meet Life, Laboratory for Biointerfaces, St. Gallen, Switzerland
- *231 **A Likert analysis about double J stent related urinary symptoms assessed by the Ureteric Stent**

Symptoms Questionnaire (USSQ) after semirigid and flexible ureteroscopy (RIRS)

By: Bosio A., Alessandria E., Peretti D., Dalmasso E., Destefanis P., Passera R., Gontero P.

Institutes: Città Della Salute E Della Scienza Di Torino - Molinette Hospital, Dept. of Urology, Turin, Italy

*232

Initial experience with Allium™ & Uventa™ Stent for the management of ureteric strictures and leak

By: Suntharasivam T.¹, Samuel M¹, Thomas D¹, Rix D.¹, Haslam P.², William R.², Shaw M.¹, Rogers A.¹

Institutes:¹Freeman Hospital, Dept. of Urology, Newcastle Upon Tyne, United Kingdom, ²Freeman Hospital, Dept. of Radiology, Newcastle Upon Tyne, United Kingdom

*233

Intestinal colonization resistance is associated with hyperoxaluria in the patients with recurrent pyelonephritis

By: Stepanova N., Stashevskaya N., Driyanska V., Kolesnyk M.

Institutes: State Institution Institute of Nephrology of The National Academy of Medical Sciences, Dept. of Nephrology, Kyiv, Ukraine

Screening and early detection of prostate cancer: PSA and beyond

Poster Session 18

Saturday, 25 March
14:15 - 15:45

Location: Room Stockholm, North Hall (Level 1)

Chairs: F. Abdollah, Detroit (US)
F.C. Hamdy, Oxford (GB)
M.J. Roobol, Rotterdam (NL)

Aims and objectives of this presentation

The session is aimed at addressing the multi-variable risk assessment to optimize the use of screening and early detection strategies in prostate cancer

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*234

An evaluation of a selective prostate cancer screening program using family history as a supplementary screening tool to PSA: Results from the ProtecT trial

By: Johnston T.¹, Lamb A.¹, Vowler S.², Xiong T.¹, Moore A.¹, Holding P.³, Herbert P.¹, Davis M.⁴, Lane A.⁴, Donovan J.⁴, Hamdy F.⁵, Neal D.¹

Institutes:¹University of Cambridge, Academic Urology Group, Cambridge, United Kingdom, ²Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, United Kingdom, ³University of Oxford, Nuffield Dept. of Surgical Sciences, Oxford, United Kingdom, ⁴University of Bristol, School of Social and Community Medicine, Bristol, United Kingdom, ⁵University of Oxford, Nuffield Department of Surgical Sciences, Oxford, United Kingdom

*235

At what age should a PSA-based screening program start? 20-year results from the Göteborg randomized population-based prostate cancer screening study

By: Carlsson S.¹, Arnsrud Godtman R.², Holmberg E.³, Lilja H.⁴, Månsson M.², Stranne J.², Hugosson J.²

Institutes:¹Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, ²Sahlgrenska Academy, Dept. of Urology, Gothenburg, Sweden, ³Sahlgrenska Academy, Dept. of Oncology, Gothenburg, Sweden, ⁴Memorial Sloan Kettering Cancer Center, Dept. of Surgery, Malmö, Sweden

*236

Malignancies in male BRCA mutation carriers – results from a prospectively screened cohort of patients enrolled to a dedicated male BRCA clinic

By: Margel D.¹, Mano R.¹, Benjaminov O.², Kedar I.³, Ozalvo R.¹, Sela S.¹, Ber Y.¹, Baniel J.¹

Institutes:¹Rabin Medical Center, Dept. of Urology, Petah Tikva, Israel, ²Rabin Medical Center, Dept. of Imaging, Petah Tikva, Israel, ³Rabin Medical Center, The Raphael Recanati Genetics Institute, Petah Tikva, Israel

*237

Is further screening of Asian men with low baseline prostate-specific antigen levels (≤ 1.0 ng/ml) worthwhile?

By: Urata S., Kitagawa Y., Mizokami A.

Institutes:Kanazawa University, Dept. of Urology, Kanazawa, Japan

*238

The use of prostate-specific antigen screening in purchased versus direct care settings: Data from the TRICARE military database

By: Gild P.¹, Von Landenberg N.¹, Cole A.¹, Jiang W.², Lipsitz S.², Learn P.³, Sun M.¹, Choueiri T.⁴, Nguyen P.⁵, Chun F.⁶, Fisch M.⁶, Kibel A.¹, Menon M.⁷, Sammon J.⁷, Koehlmoos T.⁸, Haider A.², Trinh Q-D.¹

Institutes:¹Brigham and Women's Hospital, Harvard Medical School, Division of Urological Surgery

and Center For Surgery and Public Health, Boston, United States of America, ²Brigham and Women's Hospital, Center for Surgery and Public Health, Boston, United States of America, ³Uniformed Services University of The Health Sciences, Dept. of Surgery, Bethesda, United States of America, ⁴Dana-Farber Cancer Institute and Brigham and Women's Hospital, Dept. of Medical Oncology, Boston, United States of America, ⁵Dana-Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America, ⁶University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ⁷Henry Ford Health System, VUI Center for Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Detroit, United States of America, ⁸Uniformed Services University of The Health Sciences, Dept. of Preventive Medicine and Biostatistics, Bethesda, United States of America

- *239 **Prostate cancer screening in high risk families: Should PSA testing be performed yearly in first degree relatives with baseline PSA \geq 1ng/ml?**
By: [Callerot P.](#)¹, Moineau M-P.², Cussenot I.³, Baschet F.³, L'Her J.¹, Doucet L.¹, Cancel-Tassin G.³, Cormier L.⁴, Mangin P.³, Cussenot O.⁵, Fournier G.¹, Valeri A.¹
Institutes:¹Brest University Hospital, Dept. of Urology, Brest, France, ²Brest University Hospital, Nuclear Medicine Laboratory, Brest, France, ³Tenon University Hospital, CeRePP (Centre De Recherche Sur Les Pathologies Prostatiques), Paris, France, ⁴Dijon University Hospital, Dept. of Urology, Dijon, France, ⁵Tenon University Hospital, Dept. of Urology, Paris, France
- *240 **Risk of prostate-cancer death at 20 years stratified by midlife PSA and a panel of four kallikrein markers from a representative cohort of 11,506 healthy unscreened men aged 45-74**
By: Sjoberg D.D.², Vickers A.J.², Assel M.², Dahlin A.³, Carlsson S.¹, Poon B.Y.², Ulmert D.¹, [Lilja H.G.](#)¹
Institutes:¹Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, ²Memorial Sloan Kettering Cancer Center, Dept. of Biostatistics, New York, United States of America, ³Lund University, Clinical Microbiology, Malmo, Sweden
- *241 **Inclusion of mpMRI into the European randomized study of screening for prostate cancer (ERSPC) risk calculator: A new proposal to improve the accuracy of prostate cancer detection**
By: [Dell'Oglio P.](#)¹, Stabile A.¹, Gandaglia G.¹, Brembilla G.², Maga T.¹, Cristel G.², Kinzikeeva E.¹, Losa A.¹, Esposito A.², Cardone G.², De Cobelli F.², Del Maschio A.², Gaboardi F.¹, Montorsi F.¹, Briganti A.¹
Institutes:¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²Vita-Salute University San Raffaele, Dept. of Radiology, Milan, Italy
- *242 **Head-to-head comparison of commonly used international prostate cancer risk calculators for prostate biopsy**
By: Pereira-Azevedo N.¹, [Verbeek J.](#)¹, Nieboer D.², Steyerberg E.², Roobol M.¹
Institutes:¹Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, ²Erasmus MC, Dept. of Public Health, Rotterdam, The Netherlands
- *243 **Outcomes of PSA-based prostate cancer screening among men using non-steroidal anti-inflammatory drugs**
By: [Murtola T.](#)¹, Vettenranta A.², Talala K.³, Taari K.⁴, Stenman U.-H.⁵, Tammela T.¹, Auvinen A.⁶
Institutes:¹Tampere University Hospital, Dept. of Urology, Tampere, Finland, ²University of Tampere, School of Medicine, Tampere, Finland, ³Finnish Cancer Registry, Dept. of Research, Helsinki, Finland, ⁴Helsinki University, School of Medicine, Helsinki, Finland, ⁵Helsinki University Hospital, Dept. of Biochemistry, Helsinki, Finland, ⁶University of Tampere, School of Health Sciences, Tampere, Finland
- *244 **Decreasing screening efficacy with increasing age: Results from a population-based screening trial - Swiss ERSPC (Aarau)**
By: [Prause L.](#)¹, Wyler S.¹, Moltgen T.¹, Huber A.², Grobholz R.³, Manka L.⁴, Recker F.¹, Kwiatkowski M.¹
Institutes:¹Cantonal Hospital Aarau, Dept. of Urology, Aarau, Switzerland, ²Cantonal Hospital Aarau, Dept. of Laboratory Medicine, Aarau, Switzerland, ³Cantonal Hospital Aarau, Dept. of Pathology, Aarau, Switzerland, ⁴Academic Hospital Braunschweig, Dept. of Urology, Braunschweig, Germany

- *245 **Stage distribution of prostate cancer at a tertiary care oncology centre in India-Reflections of an unscreened population**
By: [Prakash G.](#)¹, Bakshi G.¹, Shinde R.², Bhamre R.², Murthy V.³, Rent E.⁴, Pal M.¹, Mahantshetty U.³, Menon S.⁵
Institutes:¹Tata Memorial Hospital, Dept. of Surgical Oncology(urooncology), Mumbai, India, ²Tata Memorial Hospital, Dept. of Surgical Oncology, Mumbai, India, ³Tata Memorial Hospital, Dept. of Radiation Oncology, Mumbai, India, ⁴AJ Shetty Hospital, Dept. of Surgical Oncology, Mangalore, India, ⁵Tata Memorial Hospital, Dept. of Surgical Pathology, Mumbai, India
- *246 **The diverse genomic landscape of low-risk prostate cancer**
By: [Cooperberg M.](#)¹, Erho N.², Chan J.³, Feng F.³, Cowan J.³, Simko J.³, Ong K.², Alshalalfa M.², Kolisnik T.², Margrave J.², Aranes M.², Du Plessis M.², Buerki C.², Zhao S.², Tenggara I.³, Davicioni E.², Carroll P.³
Institutes:¹University of California, Dept. of Urology, San Francisco, United States of America, ²GenomeDx, San Diego, United States of America, ³UCSF, Dept. of Urology, San Francisco, United States of America
- *247 **A positive digital rectal examination (DRE) does not predict prostate cancer in 45 yr old men - results from the German risk-adapted PCA Screening Trial (PROBASE)**
By: [Arsov C.](#)¹, Becker N.², Herkommer K.³, Gschwend J.³, Imkamp F.⁴, Kuczyk M.⁴, Hadaschik B.⁵, Hohenfellner M.⁵, Siener R.⁶, Kristiansen G.⁷, Antoch G.⁸, Albers P.¹
Institutes:¹University of Düsseldorf, Dept. of Urology, Düsseldorf, Germany, ²German Cancer Research Center Heidelberg, Division of Cancer Epidemiology (C020), Heidelberg, Germany, ³Technische Universitaet Muenchen, Dept. of Urology, Munich, Germany, ⁴Hanover Medical School, Dept. of Urology, Hanover, Germany, ⁵University of Heidelberg, Dept. of Urology, Heidelberg, Germany, ⁶University of Bonn, Dept. of Urology, Bonn, Germany, ⁷University of Bonn, Dept. of Pathology, Bonn, Germany, ⁸University of Düsseldorf, Dept. of Diagnostic and Interventional Radiology, Düsseldorf, Germany

Men's sexual health: Focus on ED, LiSWT and testosterone replacement therapy

Poster Session 19

Saturday, 25 March
14:15 - 15:45

Location: Room 7, Capital suite (level 3)

Chairs: A. Salonia, Milan (IT)
E.C. Serefoglu, Ankara (TR)
R. Tal, Haifa (IL)

Aims and objectives of this presentation

This session will provide the audience with the most recent clinical evidence from short-term randomized trials regarding low-intensity shockwave therapy (LiSWT) for erectile dysfunction. In addition the session will focus on testosterone replacement therapy.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *248 **Virtual cavernoscopy – a unique modality for visualizing cavernosal arteries independent of blood flow**
By: Izumi K., Shiozaki K., Miyake T., Sasaki Y., Kishimoto T., Yamanaka M., Kawanishi Y.
Institutes: Takamatsu Red Cross Hospital, Dept. of Urology, Takamatsu, Japan
- *249 **The role of chitosan membranes application on the neurovascular bundles during robot-assisted radical prostatectomy: Preliminary results of a phase II study**
By: Porpiglia F., Bertolo R., De Cillis S., Manfredi M., Mele F., Amparore D., Garrou D., Checcucci E., Cattaneo G., Fiori C.
Institutes: San Luigi Hospital, Dept. of Urology, Turin, Italy
- *251 **Role of penile low intensity shock wave therapy in the treatment of refractory erectile dysfunction: A prospective, randomized, placebo-controlled study**
By: Vinay J., Moreno D., Vives A., Rajmil O., Ruiz-Castane E., Sanchez-Curbelo J.
Institutes: Fundació Puigvert, Dept. of Andrology, Barcelona, Spain
- *252 **Low intensity shock wave treatment (LiSWT) improves erectile function in a session-dependent manner: Results of a randomized trial comparing two treatment protocols**
By: Kalyvianakis D., Mykoniatis I., Memmos D., Hatzichristou D.
Institutes: Aristotle University of Thessaloniki, Dept. of Urology, Thessaloniki, Greece
- *253 **Association between erectile dysfunction, testosterone levels and prediction of 10-year cardiovascular mortality**
By: Kratiras Z.¹, Makarounis K.¹, Ioakimidis N.², Spapis V.¹, Kapogiannis F.¹, Angelis A.², Sidiropoulos D.¹, Vlacopoulos C.², Tousoulis D.², Fasoulakis C.¹
Institutes: ¹Hippokraton General Hospital Athens, Dept. of Urology, Athens, Greece, ²Hippokraton General Hospital Athens, Medical School, University of Athens, Dept. of Cardiology, Athens, Greece
- *254 **Which patients with non-symptomatic late onset hypogonadism are suitable for testosterone replacement therapy?**
By: Park H.J.¹, Park N.C.¹, Nam J.K.¹, Kim T.N.¹, Moon D.G.²
Institutes: ¹Pusan National University Hospital, Dept. of Urology, Busan, South Korea, ²Korean University Hospital, Dept. of Urology, Seoul, South Korea
- *256 **Adverse effects of testosterone replacement therapy for men, a matched cohort study**
By:

Hanske J.¹, Von Landenberg N.¹, Gild P.¹, Cole A.¹, Jiang W.², Lipsitz S.², Kathrins M.³, Learn P.⁴, Menon M.⁵, Noldus J.⁶, Sun M.¹, Trinh Q-D.¹

Institutes:¹Brigham and Women's Hospital, Harvard Medical School, Division of Urological Surgery and Center For Surgery and Public Health, Boston, United States of America, ²Brigham and Women's Hospital, Harvard Medical School, Center For Surgery and Public Health, Boston, United States of America, ³Brigham and Women's Hospital, Harvard Medical School, Division of Urologic Surgery and Center For Surgery and Public Health, Boston, United States of America, ⁴Uniformed Services University of The Health Sciences, Dept. of Surgery, Bethesda, United States of America, ⁵Uniformed Services University of The Health Sciences, Dept. of Surgery, Detroit, United States of America, ⁶Marienhospital Herne, Ruhr University Bochum, Dept. of Urology, Herne, Germany

*257 **Acceptance and safety of axillary testosterone gel (Axiron®) in patients with symptomatic hypogonadism**

By: Probst K.A., Groenewold F., Janssen M., Stoeckle M., Siemer S.

Institutes:Saarland University Medical Center, Dept. of Urology, Homburg, Germany

*258 **Does calculated free testosterone overcome total testosterone in protecting from sexual symptoms impairment? Findings of a cross-sectional study**

By: Boeri L.¹, Capogrosso P.², Ventimiglia E.², Cazzaniga W.², Pederzoli F.², Oreggia D.², Frego N.², Moretti D.³, Montanari E.¹, Gaboardi F.³, Mirone V.⁴, Montorsi F.², Salonia A.²

Institutes:¹Irccs Fondazione Ca' Granda - Ospedale Maggiore Policlinico, Dept. Of Urology, Milan, Italy, ²IRCCS San Raffaele Hospital/University Vita-Salute San Raffaele, Division of Oncology/Unit of Urology; URI, Milan, Italy, ³IRCCS San Raffaele Hospital, Division of Oncology/Unit of Urology; URI, Milan, Italy, ⁴University of Naples Federico II, Dept. of Urology, Naples, Italy

*259 **Efficacy of tadalafil for treating chronic prostatitis/chronic pelvic pain syndrome in patients without erectile dysfunction**

By: Park H.J.¹, Park N.C.¹, Moon D.G.², Kim T.N.³, Nam J.K.³, Park S.W.³

Institutes:¹Busan National University Hospital, Dept. of Urology, Busan, South Korea, ²Korea University Hospital, Dept. of Urology, Seoul, South Korea, ³Busan National University Yangsan Hospital, Dept. of Urology, Yangsan, South Korea

*260 **A survey on Korean urologists practice pattern in surgical management of premature ejaculation**

By: Kim J.W., Ahn S.T., Jeong H.G., Chae J.Y., Oh M.M., Park H.S., Kim J.J., Moon D.G.

Institutes:Korea University Guro Hospital, Dept. of Urology, Seoul, South Korea

15:34 - 15:41

Summary

A. Salonia, Milan (IT)

ESU/ESUT Hands-on Training in Basic laparoscopic skills

HOT04

Saturday, 25 March
14:15 - 15:15

Location: Room South America, Exhibition Hall (Level 1)

Aims and objectives of this presentation

In this course basic laparoscopic and suturing skills can be learned and trained. Psychomotor skills such as depth perception and bimanual dexterity are trained by the validated exercises of the European Basic Laparoscopic Urological Skills (E-BLUS) training programme.

Experienced laparoscopist-tutors will guide you to master such basic laparoscopy skills as instrument handling, pattern cutting and intracorporal suturing. This course can be used as an additional training to prepare for the E-BLUS examination. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

Screening and active surveillance – where are we now

ESU Course 07

Saturday, 25 March
14:30 - 17:30

Location: Room 10, Capital suite (level 3)

Chair: A.R. Zlotta, Toronto (CA)

Aims and objectives of this presentation

- Prostate cancer presents a global public. While the ERSPC has showed a reduction in prostate cancer mortality, the potential for negative effects from over-diagnosis and treatment cannot be ignored. This is why the evidence for and against prostate cancer screening remains controversial.
- Today's challenges include the age when to start screening, screening intervals and the optimal use of "intelligent screening" which would incorporate many factors other than PSA such as Family history, Ethnicity and Genetic factors.
- Active surveillance is now widely accepted as a management strategy for low risk prostate cancer with definitive treatment used if there is evidence that the patient is at increased risk for disease progression. Multiple studies consistently found a low rate of progression to metastatic disease or death from prostate cancer with active surveillance; in addition, the majority of patients did not require definitive therapy.
- Clinical and pathological factors influencing the risk of disease progression in patients with low risk prostate cancer under active surveillance, surveillance strategy, role of repeat biopsy, inclusion criteria, use of MRI will be discussed.

14:30 - 17:30

Screening

J. Hugosson, Göteborg (SE)

14:30 - 17:30

Active surveillance

A.R. Zlotta, Toronto (CA)

Advanced course on urethral stricture surgery

ESU Course 08

Saturday, 25 March
14:30 - 17:30

Location: Room 11, Capital suite (level 3)

Chair: R. Inman, Sheffield (GB)

Aims and objectives of this presentation

To update on latest advances and evidence for treatment for male urethral stricture disease including

- Investigations and assessment
- Minimally invasive and endoscopic treatment
- Urethroplasty for anterior urethral strictures (Penile and bulbar strictures)
- Surgery for posterior urethral strictures (Pelvic fracture injuries)

The course will consist of lectures, reviews of the evidence regarding treatment of strictures and interactive case discussions to illustrate decision making.

14:30 - 17:30

Introduction

R. Inman, Sheffield (GB)

14:30 - 17:30

Basic principles, anatomy and minimally invasive management of urethral stricture disease

P. Nyirády, Budapest (HU)

14:30 - 17:30

Management of anterior urethral stricture disease

R. Inman, Sheffield (GB)

14:30 - 17:30

Urethroplasty for posterior urethral injuries

L. Martínez-Piñero, San Sebastián de los Reyes (ES)

14:30 - 17:30

Female strictures

R. Inman, Sheffield (GB)

14:30 - 17:30

Interesting cases and final questions

R. Inman, Sheffield (GB)

L. Martínez-Piñero, San Sebastián de los Reyes (ES)

P. Nyirády, Budapest (HU)

Management of BPO: From medical to surgical treatment

ESU Course 09

Saturday, 25 March
14:30 - 17:30

Location: Room 12, Capital suite (level 3)

Chair: V.A.C. Ramani, Manchester (GB)

Aims and objectives of this presentation

- To help delegates understand the principles and evidence behind the assessment and medical management of a BPO patient.
- To summarise / review the evidence base for electro surgery and lasers for surgical management of BPO.
- Tips and Tricks to improve outcomes and avoid complications.
- To help delegates understand the factors that influence the patient's and surgeon's choice of treatment modalities

14:30 - 17:30

Introduction/scene setting BPO 2016

V.A.C. Ramani, Manchester (GB)

14:30 - 17:30

Assessment and medical management

V.A.C. Ramani, Manchester (GB)

14:30 - 17:30

Surgical management – Electrosurgery

T.R.W. Herrmann, Hannover (DE)

14:30 - 17:30

Surgical management – Lasers and less invasive options

S.A. Ahyai, Göttingen (DE)

14:30 - 17:30

Case presentations

S.A. Ahyai, Göttingen (DE)

T.R.W. Herrmann, Hannover (DE)

Retropubic radical prostatectomy – Tips, tricks and pitfalls

ESU Course 10

Saturday, 25 March
14:30 - 17:30

Location: Room 14, Capital suite (level 3)

Chair: H. Van Poppel, Leuven (BE)

Aims and objectives of this presentation

In many parts of Europe, open retropubic radical prostatectomy is still the gold standard for treating localised prostate cancer. The competition with radiotherapy and novel techniques like cryosurgery and HIFU, should encourage urologists to optimally perform the surgical resection .

This teaching course is a must for the elder resident and the younger urologist but well trained urologists who do not treat many patients with localised prostate cancer, will benefit.

14:30 - 17:30

Introduction

H. Van Poppel, Leuven (BE)

14:30 - 17:30

Surgical anatomy

O.W. Hakenberg, Rostock (DE)

14:30 - 17:30

Step by step radical retropubic prostatectomy

H. Van Poppel, Leuven (BE)

14:30 - 17:30

Tips, tricks and pitfalls

O.W. Hakenberg, Rostock (DE)

14:30 - 17:30

Treatment of complications

H. Van Poppel, Leuven (BE)

14:30 - 17:30

Discussion and interaction

Urinary tract and genital trauma

ESU Course 11

Saturday, 25 March
14:30 - 17:30

Location: Room 15, Capital suite (level 3)

Chair: N.D. Kitrey, Ramat Gan (IL)

Aims and objectives of this presentation

Trauma is a leading cause of death and morbidity in civilian populations. All Urologists will have to manage trauma patients and need to understand basic principles. The EAU Guidelines Group prepare guidelines in order to assist in the management of urological trauma and these principles will be followed for the specific organ systems and in the context of polytrauma.

- Urological trauma is usually associated with other injuries. The role of the urologist in polytrauma is important to understand.
- Modern diagnostic imaging and interventional radiology techniques has resulted in a greater understanding of organ injury and treatment
- Increasing use is made of non-operative or delayed surgical intervention with a resulting higher rate of organ preservation.
- Minimising long term morbidity is an important role for injuries that are usually not life threatening.

14:30 - 17:30

Introduction

D.M. Sharma, London (GB)

14:30 - 17:30

General trauma considerations

D.M. Sharma, London (GB)

14:30 - 17:30

Blunt and penetrating renal trauma

N.D. Kitrey, Ramat Gan (IL)

14:30 - 17:30

Ureteric injuries – diagnosis and treatment

D.M. Sharma, London (GB)

14:30 - 17:30

Bulbar and bulbomembranous urethral trauma

N.D. Kitrey, Ramat Gan (IL)

14:30 - 17:30

Bladder, penile and testicular trauma

D.M. Sharma, London (GB)

14:30 - 17:30

Case presentations

D.M. Sharma, London (GB)

N.D. Kitrey, Ramat Gan (IL)

Prolapse management and female pelvic floor problems

ESU Course 12

Saturday, 25 March
14:30 - 17:30

Location: Room 16, Capital suite (level 3)

Chair: D.J.M.K. De Ridder, Leuven (BE)

Aims and objectives of this presentation

This course gives practical information about prolapse management by urologists. From anatomy to mesh implant, the recent revival of native tissue repairs and the management of complications. Also laparoscopic and robotic approaches will be evaluated.

14:30 - 17:30

Vaginal surgical anatomy for urologists

E. Kocjancic, Chicago (US)

14:30 - 17:30

Investigations and imaging for POP

D.J.M.K. De Ridder, Leuven (BE)

14:30 - 17:30

Vaginal Native tissue repair

D.J.M.K. De Ridder, Leuven (BE)

14:30 - 17:30

Vaginal Mesh repair

E. Kocjancic, Chicago (US)

14:30 - 17:30

Open/laparoscopic/robotic repair

H. Hashim, Bristol (GB)

14:30 - 17:30

Classification and Management of complications & case discussion

H. Hashim, Bristol (GB)

E. Kocjancic, Chicago (US)

How to write results and discussion

ESU Course 13

Saturday, 25 March
14:30 - 16:30

Location: Room 17, Capital suite (level 3)

ESU/ESFFU Hands-on Training course in OnabotulinumtoxinA administration for OAB

HOT18

Saturday, 25 March
15:30 - 17:00

Location: Room Europe, Exhibition Hall (Level 1)

Chair: To be confirmed

Aims and objectives of this presentation

Botulinum toxin type A administration in Urology has become common practice over the last two decades. Following the completion of Phase 3 registration trials in OAB, OnabotulinumtoxinA received marketing approval for this indication and now has a standardised injection paradigm. This course is procedure-focused, and will teach attendees the practicalities of OnabotulinumtoxinA administration through short lectures, videos and hands-on demonstrations using bladder models. Attendees will learn how to reconstitute the product and see different types of equipment available.

E. Chartier-Kastler, Paris (FR)
A. Garcia Mora, Mexico City (MX)
M.S. Rahnama'i, Heerlen (NL)

BLEXIT - best perioperative outcomes from cystectomy

Poster Session 20

Saturday, 25 March
16:00 - 17:30

Location: Room Copenhagen, North Hall (Level 1)

Chairs: P. Anderson, Melbourne (AU)
P. Gontero, Turin (IT)
J. McGrath, Exeter (GB)

Aims and objectives of this presentation

understand how to optimize perioperative outcomes in cystectomy

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *261 **Postoperative psoas muscle loss and nutritional deterioration after radical cystectomy for patients with invasive bladder cancer**
By: [Miyake M.](#)¹, Morizawa Y.¹, Hori S.¹, Marugami N.², Shimada K.³, Gotoh D.¹, Tatsumi Y.¹, Nakai Y.¹, Anai S.¹, Tanaka N.¹, Fujimoto K.¹
Institutes:¹Nara Medical University, Dept. of Urology, Nara, Japan, ²Nara Medical University, Dept. of Radiology, Nara, Japan, ³Nara City Hospital, Dept. of Pathology, Nara, Japan
- *262 **Robot-assisted laparoscopic cystectomy vs. open mini-laparotomy cystectomy: Evaluation of anti-inflammatory potential of CO2-pneumoperitoneum in a randomized porcine study**
By: [Kingo P.S.](#)¹, Rasmussen T.M.¹, Jakobsen L.K.¹, Palmfeldt J.², Borre M.¹, Nørregaard R.², Jensen J.B.¹
Institutes:¹Aarhus University Hospital, Skejby, Dept. of Urology, Aarhus N, Denmark, ²Aarhus University Hospital, Skejby, Dept. of Clinical Medicine, Aarhus N, Denmark
- *263 **Can pre-operative functional status (FS) or gait velocity (GV) replace cardiopulmonary exercise testing (CPET) as an independent predictor of survival and complications following radical cystectomy (RC)?**
By: [Nair R.](#), Downs C., Parsons B., Fynmore T., Omar K., Thurairaja R., Khan M.S.
Institutes:Guy's and St Thomas' NHS Foundation Trust, Dept. of Urology, London, United Kingdom
- *264 **20-gene expression signature to predict lymph node positive disease at radical cystectomy for muscle-invasive bladder cancer: Not validated**
By: [Van Kessel K.](#)¹, Van De Werken H.², Lurkin I.¹, Ziel – Van Der Made A.¹, Zwarthoff E.¹, Boormans J.³
Institutes:¹Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands, ²Erasmus MC, Cancer Computational Biology Center (CCBC), Rotterdam, The Netherlands, ³Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands
- *265 **The use of antibiotic prophylaxis in patients undergoing radical cystectomy for bladder cancer**
By: [Haider M.](#)¹, Mayr R.¹, Fritsche H-M.¹, Ladurner C.², Pycha A.², Comploj E.², Lemire F.³, Lacombe L.³, Fradet Y.³, Lodde M.³
Institutes:¹University of Regensburg, Dept. of Urology, Regensburg, Germany, ²General Hospital of Bolzano, Dept. of Urology, Bolzano, Italy, ³Laval University, Dept. of Urology, Québec, Canada
- *266 **Can radical cystectomy be performed safely in the metastatic setting? Location of metastatic bladder cancer as a determinant of in-hospital mortality**
By: [Zaffuto E.](#)¹, Moschini M.¹, Leyh-Bannurah S-R.², Gazdovich S.³, Dell'Oglio P.¹, Pompe R.², Shariat S.⁴, Montorsi F.¹, Briganti A.¹, Saad F.⁵, Karakiewicz P.³
Institutes:¹IRCCS Ospedale San Raffaele, Division of Oncology/Unit of Urology; URI, Milan, Italy, ²

Prostate Cancer Center Hamburg-Eppendorf, Martini-Clinic, Hamburg, Germany, ³University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada, ⁴Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁵University of Montreal Health Center, Dept. of Urology, Montreal, Canada

- *267 **Increasing use of incontinent urinary diversion: A total population analysis of radical cystectomies in Germany from 2006 to 2013**
By: Groeben C.¹, Koch R.², Baunacke M.¹, Wirth M.¹, Huber J.¹
Institutes:¹TU Dresden, Medical Faculty Carl Gustav Carus, Dept. of Urology, Dresden, Germany, ²TU Dresden, Medical Faculty Carl Gustav Carus, Dept. of Medical Statistics and Biometry, Dresden, Germany
- *268 **Incidence and risk factors for venous thromboembolism after transurethral resection of bladder tumor: A population-based analysis**
By: Zaffuto E.¹, Pompe R.², Moschini M.¹, Bondarenko H.D.³, Dell'Oglio P.¹, Fossati N.¹, Gandaglia G.¹, Gallina A.¹, Shariat S.F.⁴, Montorsi F.¹, Briganti A.¹, Karakiewicz P.I.⁵
Institutes:¹IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy, ²Prostate Cancer Center Hamburg-Eppendorf, Martini-Clinic, Hamburg, Germany, ³University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada, ⁴Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁵University of Montreal Health Center, Dept. of Cancer Prognostics and Health Outcomes, Montreal, Canada
- *269 **Diarrhea as a limiting factor of quality of life after radical cystectomy: Results from a cross-sectional study evaluating long-term bowel issues in bladder cancer patients**
By: Hupe M.C.¹, Vahlensieck W.², Hennig M.¹, Ozimek T.¹, Struck J.¹, Tezval H.³, Merseburger A.¹, Kuczyk M.³, Kramer M.¹
Institutes:¹University Hospital Schleswig-Holstein, Campus Luebeck, Dept. of Urology, Luebeck, Germany, ²Kurpark-Klinik, Dept. of Urology, Bad Nauheim, Germany, ³Hannover Medical School, Dept. of Urology, Hannover, Germany
- *270 **Low psoas muscle volume indicates long hospitalization after radical cystectomy**
By: Kawahara T., Saitoh Y., Miyoshi Y., Uemura H.
Institutes:Yokohama City University Medical Center, Dept. of Urology and Renal Transplantation, Yokohama, Japan
- *272 **The BAUS radical cystectomy audit 2014/2015 - an update on current practice and an analysis of the effect of centre and surgeon case volume**
By: Khadhoury S.¹, Miller C.¹, Cresswell J.², Rowe E.³, Fowler S.⁴, Hounsom L.⁵, Mcgrath J.S.¹
Institutes:¹Royal Devon and Exeter Hospital, Dept. of Urology, Exeter, United Kingdom, ²South Tees NHS Trust, Dept. of Urology, Middlesbrough, United Kingdom, ³North Bristol NHS Trust, Dept. of Urology, Bristol, United Kingdom, ⁴BAUS, Dept. of Surgery, London, United Kingdom, ⁵Public Health England, Dept. of Public Health, London, United Kingdom
- *273 **Pure but not mixed histological variants are associated with poor survival at radical cystectomy in bladder cancer patients**
By: Moschini M.¹, Colombo R.¹, Gandaglia G.¹, Di Trapani E.¹, Burgio G.¹, Damiano R.², Mattei A.³, Shariat S.⁴, Salonia A.¹, Briganti A.¹, Montorsi F.¹, Gallina A.¹
Institutes:¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²Magna Graecia University of Catanzaro, Dept. of Urology, Catanzaro, Italy, ³Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, ⁴Medical University of Vienna, Dept. of Urology, Vienna, Austria
- *274 **Comparative effectiveness of trimodal therapy versus radical cystectomy for localized muscle-invasive urothelial carcinoma of the bladder**
By: Seisen T.¹, Sun M.¹, Lipsitz S.², Abdollah F.³, Leow J.¹, Menon M.³, Von Landenberg N.¹, Gild P.¹, Rouprêt M.⁴, Preston M.¹, Harshman L.⁵, Kibel A.S.¹, Nguyen P.⁶, Bellmunt J.⁵, Choueiri T.⁵, Trinh Q.-D.¹
Institutes:¹Brigham and Women's Hospital, Harvard Medical School, Division of Urological Surgery and Center For Surgery and Public Health, Boston, United States of America, ²Brigham and

Women's Hospital, Harvard Medical School, Division of Urological Surgery and Center For, Boston, United States of America, ³Henry Ford Health System, VUI Center For Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Detroit, United States of America, ⁴Pitié-Salpêtrière, APHP, University Paris VI, Dept. of Urology, Paris, France, ⁵Dana Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America, ⁶Brigham and Women's Hospital, Harvard Medical School, Dept. of Radiation Oncology, Boston, United States of America

17:19 - 17:26

Summary

J. McGrath, Exeter (GB)

Complex conditions for urogenital reconstructions

Poster Session 21

Saturday, 25 March
16:00 - 17:30

Location: Room Madrid, North Hall (Level 1)

Chairs: R. Djinovic, Belgrade (RS)

N. Watkin, London (GB)

Aims and objectives of this presentation

Complex conditions in reconstructive patient care is presented

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *275 **Open repair of bladder neck contractures (BNC) with or without adjuvant radiotherapy – our experience in 42 patients**
By: [Ivaz S.](#), Bugeja S., Frost A., Dragova M., Andrich D., Mundy A.
Institutes: UCLH NHS Foundation Trust, Dept. of Urology, London, United Kingdom
- *276 **The T-plasty as a modified YV-plasty for the treatment of highly recurrent bladder neck stenosis: High success and patient's satisfaction rates**
By: [Rosenbaum C.](#), Reiss P., Engel O., Kluth L., Fisch M., Dahlem R.
Institutes: Universitätsklinikum Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany
- *277 **The effect of radiotherapy on the outcome of the repair of urorectal fistulae**
By: [Ivaz S.](#), Frost A., Dragova M., Bugeja S., Andrich D., Mundy A.
Institutes: UCLH NHS Foundation Trust, Dept. of Reconstructive Urology, London, United Kingdom
- *278 **The longer-term results of non-transecting bulbar urethroplasty**
By: [Frost A.](#), Ivaz S., Bugeja S., Dragova M., Andrich D., Mundy A.
Institutes: UCLH NHS Foundation Trust, Dept. of Reconstructive Urology, London, United Kingdom
- *279 **Comparative assessment of postoperative erectile function and quality of life in male one-stage onlay vs. inlay buccal mucosal graft urethroplasty**
By: [Vetterlein M.](#), Rosenbaum C., Gild P., Meyer C., Ludwig T., Loewe C., Aziz A., Engel O., Dahlem R., Fisch M., Kluth L.
Institutes: University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany
- *280 **Re-do urethroplasty after unsuccessful urethral reconstruction with buccal mucosa graft**
By: [Pandey A.](#), Borisenkov M., Barta-Kelemen A., Keller H.
Institutes: Sana Klinikum Hof GmbH, Dept. of Urology, Hof, Germany
- *281 **Characteristics and predictors of complications after urethroplasty: Effect of operative duration, length of stay, and use of tissue transfer**
By: Lacy J.², Dugan A.³, [Gupta S.](#)¹
Institutes: ¹University of Kentucky, Dept. of Urology, Lexington, United States of America, ²University of Tennessee, Dept. of Urology, Knoxville, United States of America, ³University of Kentucky, Dept. of Surgery, Lexington, United States of America
- *282 **UREThRAL Stricture Score can predict surgical outcome of urethral reconstruction in patients with anterior urethral stricture**
By: [Mitsui Y.](#), Tamura K., Tai T., Nagata M., Yamabe F., Suzuki K., Kobayashi H., Nakajima K.,

Nagao K.

Institutes:Toho University Faculty Of Medicine, Dept. of Urology, Ohta, Japan

*283

Surgical outcomes of primary and recurrent female urethral diverticula

By: Ko K.J.¹, Chung H.W.¹, Lee C.U.¹, Na J.P.¹, Sung H.H.¹, Choi S.M.², Lee K-S.¹

Institutes:¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Dept. of Urology, Seoul, South Korea, ²Gyeongsang National University H, Dept. of Urology, Jinju, South Korea

*284

Midterm follow up of patients performed fold-back perineoscrotal flap plus penile inversion vaginoplasty for male-to-female gender reassignment surgery

By: Tavakkoli Tabassi K., Ghoreifi A., Hosseini E., Eghtesadi M., Moradian S.

Institutes:Mashhad University of Medical Sciences, Dept. of Urology, Mashhad, Iran

*285

Evaluation of success rate, functional outcome, comorbidity and quality of life in patients with one-stage ventral onlay buccal mucosa graft urethroplasty for urethral stricture disease after radiotherapy using a validated patient-reported outcome measure (PROM)

By: Körner-Riffard K., Gild P., Vetterlein M., Rosenbaum C., Loewe C., Dahlem R., Fisch M., Kluth L.

Institutes:University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany

*287

De novo penile deviation after urethroplasty with oral mucosa: A relevant problem?

By: Pandey A., Raita C., Beier J.

Institutes:Sana Klinikum Hof GmbH, Dept. of Urology, Hof, Germany

*288

Evaluation of the single-incision system to treat pelvic organ prolapse: Follow-up from 24 to 96 months of first 178 patients

By: Castroviejo Royo F.¹, Martinez-Sagara Ocejia J.M.¹, Conde Redondo C.¹, Rodríguez Toves L.A.¹, Gonzalez Tejero C.², Marina García Tuñón C.², Tapia Herrero A.¹, García Viña A.¹, Poza Del Val M.¹, Miralles Ayuso S.¹

Institutes:¹Rio Hortega University Hospital, Dept. of Urology, Valladolid, Spain, ²Rio Hortega University Hospital, Dept. of Gynecology, Valladolid, Spain

Evolving trends in prostate cancer surgery

Video Session 05

Saturday, 25 March
16:00 - 17:30

Location: Room Paris, North Hall (Level 1)

Chairs: W.L.M. Everaerts, Kessel-Lo (BE)
R. Gaston, Bordeaux (FR)
F. Gómez Veiga, Salamanca (ES)

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

- *V33 **Anatomical extended pelvic lymph node dissection**
By: Branger N.¹, Mortier P.¹, Koskas Y.¹, Thomassin-Piana J.², Salem N.³, Gravis G.⁴, Pignot G.¹, Walz J.¹
Institutes:¹Institut Paoli Calmettes, Dept. of Urology, Marseille, France, ²Institut Paoli Calmettes, Dept. of Pathology, Marseille, France, ³Institut Paoli Calmettes, Dept. of Radiation Oncology, Marseille, France, ⁴Institut Paoli Calmettes, Dept. of Oncology, Marseille, France
- *V34 **P.L.E.A.T. -preventing lymphocele ensuring absorption transperitoneally: A novel technique**
By: Dal Moro E., Zattoni F.
Institutes:University of Padova, Dept. of Surgery, Oncology and Gastroenterology - Urology, Padova, Italy
- *V38 **Single-port robotic assisted radical prostatectomy is feasible and safe**
By: Gaboardi F., Grillo M., Giovannalberto P., Smelzo S., Passaretti G., Rosso M., Kinzikeeva E., Saitta G., Suardi N.
Institutes:San Raffaele Turro Hospital, Dept. of Urology, Milan, Italy
- *V39 **Combining antegrade and retrograde dissection during salvage robotic radical prostatectomy**
By: Ferriero M., Simone G., Mastroianni R., Tuderti G., Misuraca L., Minisola F., Guaglianone S., Gallucci M.
Institutes:Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy
- *V40 **Radical prostatectomy after vascular targeted photodynamic therapy Tookad® Soluble: Feasibility, short and long term results**
By: Pierrard V.¹, Lebdai S.², Terrier J.E.³, Azzouzi A-R.², Kleinclauss F.⁴, Joniau S.⁵, Van Der Poel H.⁶, Salomon G.⁷, Casanova J.⁸, Medina R.⁹, Potiron E.¹⁰, Rigaud J.¹¹, Barret E.¹², Gaillac B.¹³, Ruffion A.³
Institutes:¹Hospital Center Lyon Sud, Dept. of Urology, Lyon, France, ²Hospital Center, Dept. of Urology, Angers, France, ³Centre Hospitalier Lyon Sud, Dept. of Urology, Lyon, France, ⁴Hospital Center, Dept. of Urology, Besançon, France, ⁵Hospital Center, Dept. of Urology, Leuven, Belgium, ⁶Antoni Van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ⁷Spire Portsmouth Hospital, Dept. of Urology, Hamburg, Germany, ⁸Hospital Center, Dept. of Urology, Valencia, Spain, ⁹Hospital Center, Dept. of Urology, Sevilla, Spain, ¹⁰Clinique Atlantis, Dept. of Urology, Nantes, France, ¹¹Centre Hospitalier, Dept. of Urology, Nantes, France, ¹²Institut Mutualiste Montsouris, Dept. of Urology, Paris, France, ¹³Institut STEBA, Dept. of Urology, Paris, France

Outcome in minimally invasive surgery for BPO

Poster Session 22

Saturday, 25 March
16:00 - 17:30

Location: Room Amsterdam, North Hall (Level 1)

Chairs: T. Hermanns, Zürich (CH)
J.Y. Park, Gangneung (KR)
C.G. Roehrborn, Dallas (US)

Aims and objectives of this presentation

The results from the complications perspective will be discussed

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *290 **Treatment failure and perioperative complications after GreenLight laser vaporisation of the prostate**
By: Calandriello M., Abbinante M., De Giorgi G., [Giannarini G.](#), Crestani A., Ficarra V.
Institutes: Academic Medical Centre Hospital Santa Maria Della Misericordia, Dept. of Urology, Udine, Italy
- *291 **Postoperative dysuria after high- and low-power en-bloc no-touch HoLEP**
By: [Cracco C.M.](#), Ingrosso M., Russo N., Scoffone C.M.
Institutes: Ospedale Cottolengo, Dept. of Urology, Torino, Italy
- *292 **One-fourth of patients may report impairment of erectile function after holmium laser enucleation of the prostate (HoLEP)**
By: [Marquette T.](#), Comat V., Capon G., Pasticier G., Bernhard J., Bensadoun H., Ferriere J., Robert G.
Institutes: CHU bordeaux, Dept. of Urology, Bordeaux, France
- *293 **Can preoperative detrusor underactivity have an impact on surgical outcomes of laser prostatectomy: Comparison in serial 3-year follow-up outcomes between 120-W lithium triborate photoselective vaporization of the prostate (PVP) and holmium laser enucleation of the prostate (HoLEP)**
By: Park J.¹, [Ahn C.H.](#)², Sun D.Y.², Cho S.Y.¹, Baik S.³, Chun S.J.⁴, You K.H.⁵, Cho M.C.¹, Park K.², Jeong H.¹, Kim S.W.², Paick J-S.², Son H.¹
Institutes: ¹Boramae Medical Center, Dept. of Urology, Seoul, South Korea, ²Seoul National University, Dept. of Urology, Seoul, South Korea, ³Chosun University School of Medicine, Dept. of Urology, Gwangju, South Korea, ⁴Gwangju Veterans Hospital, Dept. of Urology, Gwangju, South Korea, ⁵Gwanmyeong Sungae Hospital, Dept. of Urology, Gwanmyeong, South Korea
- *294 **Results of laser Greenlight® 180-W XPS vaporization for benign prostatic obstruction in patients with antithrombotic therapy or platelet aggregation inhibitors: A multicentric study**
By: [Lefevre M.](#)¹, Huet R.¹, Lebdaï S.², Ouzaid I.³, Fontenil A.², Gerbaud F.³, Ravery V.³, Azzouzi A-R.², Peyronnet B.¹, Bensalah K.¹, Verhoest G.¹, Vincendeau S.¹, Mathieu R.¹
Institutes: ¹Rennes University Hospital, Dept. of Urology, Rennes, France, ²University Hospital of Angers, Dept. of Urology, Angers, France, ³Bichat-Claude Bernard Hospital, Dept. of Urology, Paris, France
- *295 **Photoselective vaporization of the prostate with Greenlight laser XPS 180W, Green laser enucleation of the prostate and open prostatectomy for benign prostatic obstruction: A comparative analysis of perioperative and short term results**
By: [Huet R.](#)¹, Vincendeau S.¹, Sebe P.², Peyronnet B.¹, Guillé F.¹, Colau A.², Verhoest G.¹, Bensalah K.¹, Guillonnet B.², Mathieu R.¹

Institutes:¹CHU Rennes, Dept. of Urology, Rennes, France, ²Les Diaconesses Croix St Simon Hospital, Dept. of Urology, Paris, France

- *296 **Thulium vapoenucleation of the prostate versus holmium laser enucleation of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a prospective randomized trial**
By: [Netsch C.](#)¹, Becker B.¹, Tiburtius C.¹, Moritz C.¹, Venneri Becci A.¹, Herrmann T.², Gross A.¹
Institutes:¹Asklepios Klinik Barmbek, Dept. of Urology, Hamburg, Germany, ²MHH Medical School of Hanover, Dept. of Urology, Hannover, Germany
- *297 **Holmium laser enucleation of the prostate (HoLEP) does not prevent from all bleeding complications in patients on anti-coagulant therapy**
By: [Comat V.](#), Marquette T., Capon G., Bernhard J-C., Pasticier G., Bensadoun H., Ferrière J-M., Robert G.
Institutes:Chu Bordeaux, Dept. of Urologie, Bordeaux, France
- *299 **Prospective randomized study comparing monopolar with bipolar transurethral resection of prostate on a large cohort of patients with benign prostatic obstruction: Long term outcomes**
By: [Pastore A.L.](#), Palleschi G., Al Rawashdah S., Fuschi A, Velotti G., Leto A., Al Salhi Y., Petrozza V., Carbone A.
Institutes:Sapienza University of Rome, Dept. of Medico Surgical Sciences and Biotechnologies, Latina, Italy
- *300 **Low-power versus high-power en-bloc no-touch HoLEP: Comparing feasibility, safety and efficacy**
By: [Cracco C.M.](#), Ingrosso M., Russo N., Scoffone C.M.
Institutes:Ospedale Cottolengo, Dept. of Urology, Torino, Italy
- *301 **Convective radiofrequency water vapor energy ablation effectively treats lower urinary tract symptoms due to benign prostatic enlargement regardless of obesity while preserving erectile and ejaculatory function: Results of a multicenter, randomized, controlled trial**
By: [Gupta N.](#), Köhler T., Mcvary K.
Institutes:Southern Illinois University, Dept. of Urology, Springfield, United States of America
- *302 **Suprapubic catheter insertion: What is the harm?**
By: [Donaldson J.](#), Murray I., Janjua K., Mitchell I.
Institutes:Victoria Hospital, Dept. of Urology, Kirkcaldy, United Kingdom
- 17:15 - 17:25 **Complications in minimally invasive surgery for LUTS**
 C.G. Roehrborn, Dallas (US)

Basic science in functional urology: Where do we stand?

Poster Session 23

Saturday, 25 March
16:00 - 17:30

Location: Room Berlin, North Hall (Level 1)

Chairs: D. Eberli, Zürich (CH)

S. Poletajew, Warszawa Wesola (PL)

Aims and objectives of this presentation

Cell based therapy, genetics, receptors and channels...the story continues

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *303 **The inhibitory effect of neuropeptide Y Y1 receptor agonist on micturition reflex in rats**
By: [Honda M.](#)¹, Yoshimura N.², Kimiura Y.¹, Kawamoto B.¹, Tsounapi P.¹, Hikita K.¹, Shimizu S.³, Shimizu T.³, Saito M.³, Chancellor M.⁴, Takenaka A.¹
Institutes:¹Tottori University Faculty of Medicine, Dept. of Urology, Yonago, Japan, ²University of Pittsburgh, Dept. of Urology, Pittsburgh, United States of America, ³Kochi Medical School, Dept. of Pharmacology, Nankoku, Japan, ⁴William Beaumont Hospital, Dept. of Urology, Royal Oak, United States of America
- *304 **Development of neurogenic detrusor overactivity is prevented by early bladder afferent desensitization in spinal cord injured rats**
By: [Oliveira R.](#)¹, Coelho A.¹, Cruz F.², Cruz C.¹
Institutes:¹Faculty of Medicine, University of Porto, Institute For Innovation and Health Research, Dept. of Biomedicine, Translational NeuroUrology Group, Porto, Portugal, ²Hospital São João, Porto, Institute For Innovation and Health Research, Translational NeuroUrology Group, Porto, Portugal
- *305 **Effects of neurotrophins and bladder tissue on neurite outgrowth in cultured mouse pelvic ganglia**
By: [Zhu B.](#)¹, Ekman M.¹, Zeng J.², Swärd K.¹, Uvelius B.³
Institutes:¹Lund University, Dept. of Experimental Medical Science, Lund, Sweden, ²The Sixth Affiliated Hospital of Guangzhou Medical University, Dept. of Urology, Qingyuan, China, ³Lund University, Dept. of Urology, Clinical Sciences, Lund, Sweden
- *306 **Corresponding microRNA and mRNA expression profiles in a mouse model of bladder outlet obstruction and human patients' biopsies**
By: [Monastyrskaya K.](#)¹, Köck I.², Vasquez E.³, Hashemi Gheinani A.², Baumgartner U.⁴, Sack B.³, Lukianov S.³, Burkhard F.¹, Adam R.³
Institutes:¹University Hospital Bern, Dept. of Urology, Bern, Switzerland, ²Urology Research Laboratory, Dept. of Clinical Research, Bern, Switzerland, ³Urological Diseases Research Center, Boston Children's Hospital, Boston, United States of America, ⁴Institute of Pathology, Dept. of Molecular Pathology, Bern, Switzerland
- *307 **Imaging human skeletal muscle regeneration after stem cell application for sphincter reconstruction using diffusion tensor imaging (DTI) and magnetisation transfer (MT) measurements**
By: Keller D.¹, Eberhardt C.², Rottmar M.², Haralampieva D.¹, Sulser T.¹, Boss A.², [Eberli D.](#)¹
Institutes:¹University Hospital Zurich, Dept. of Urology, Zürich, Switzerland, ²University Hospital Zurich, Institute for Diagnostic and Interventional Radiology, Zürich, Switzerland

- *308 **In vivo evaluation of the effectiveness of an innovative technology for the recovery of erectile dysfunction after radical prostatectomy**
 By: Skoufias S.¹, Adamakis I.¹, Levis P.¹, Stergiopoulos N.², Araujo Fraga Da Silva R.², Constantinides C.¹
 Institutes:¹Laiko Hospital, Dept. of Urology, Goudi - Athens, Greece, ²Ecole Polytechnique Federale De Lausanne, Institute of Bioengineering, Lausanne, Switzerland
- *309 **Serotonin paraneuronal cells in the urethral epithelium of human and rodents: Expression and function**
 By: Coelho A.², Oliveira R.², Cavaleiro H.², Cruz C.D.², Cruz F.¹
 Institutes:¹Hospital S. Joao, IBMC and I3S, University of Porto, Dept. of Urology, Porto, Portugal, ²Faculty of Medicine, IBMC and I3S, University of Porto, Dept. of Biomedicine, Porto, Portugal
- *310 **Expression of programmed death ligand 1 in interstitial cystitis patients is correlated with bladder pain degree and hydrodistension outcome**
 By: Chen Y., Yu W., Yang Y., Fan Y., Wu S., Jin J.
 Institutes:Peking University First Hospital, Dept. of Urology, Beijing, China
- *311 **Understanding the role of stem cells in urinary bladder regeneration - a preclinical study in a large animal model**
 By: Pokrywczynska M.¹, Jundzill A.¹, Buhl M.¹, Balcerczyk D.¹, Rasmus M.¹, Warda K.¹, Buchholz L.¹, Tworkiewicz J.³, Kwiecinski P.², Drewa T.³
 Institutes:¹Nicoalus Copernicus University, Dept. of Regenerative Medicine, Bydgoszcz, Poland, ²Vetlab, Brudzew, Poland, ³Nicoalus Copernicus University, Dept. of Regenerative Medicine, Bydgoszcz, Poland
- *312 **Effects of cell transport medium, temperature, period, density and container type for retention of therapeutic potency of mesenchymal stem cells**
 By: Ha Y-S., Lee Y.J., Chung J-W., Choi S.H., Lee J.N., Kim B.S., Kim H.T., Kim T-H., Yoo E.S., Kwon T.G., Chung S.K., Kim B.W.
 Institutes:Kyungpook National University Medical Center, Dept. of Urology, Daegu, South Korea
- *313 **Urinary bladder regenerate by recruiting developmental hedgehog signaling pathway**
 By: Pokrywczynska M., Jundzill A., Rasmus M., Warda K., Buchholz L., Drewa T.
 Institutes:Nicoalus Copernicus University, Dept. of Regenerative Medicine, Bydgoszcz, Poland
- *314 **Uncovering links between metabolic syndrome and lower urinary tract symptoms suggestive of BPH at molecular level: First evidence for an involvement of the ghrelin system**
 By: Wang Y., Gratzke C., Yu Q., Ciotkowska A., Rutz B., Strittmatter F., Stief C., Hennenberg M.
 Institutes:LMU Munich, Dept. of Urology, Munich, Germany
- *315 **Pathophysiological roles of TRPA1 channel in lipopolysaccharide (LPS)-induced bladder inflammatory nociception and hypersensitivity in mice**
 By: Kamei J.¹, Aizawa N.¹, Nakagawa T.², Kaneko S.³, Homma Y.⁴, Igawa Y.¹
 Institutes:¹The University of Tokyo Graduate School of Medicine, Dept. of Continence Medicine, Tokyo, Japan, ²Kyoto University Hospital, Dept. of Pharmacy, Kyoto, Japan, ³Kyoto University, Graduate School of Pharmaceutical Sciences, Dept. of Molecular Pharmacology, Kyoto, Japan, ⁴The University of Tokyo Graduate School of Medicine, Dept. of Urology, Toyko, Japan
- *316 **The neurotransmitters in the periaqueductal grey matter, involved in bladder function**
 By: Zare A.², Jahanshahi A.², Rahnama'i M.S.¹, Celine M.², Van Koeveeringe G.¹
 Institutes:¹Maastricht UMC+, Dept. of Urology, Maastricht, The Netherlands, ²Maastricht University, Dept. of Neuroscience, Maastricht, The Netherlands

Improving exploration and surgical management of adrenal tumours

Poster Session 24

Saturday, 25 March
16:00 - 17:30

Location: Room Vienna, North Hall (Level 1)

Chairs: C.K. Bensalah, Rennes (FR)
P. Fornara, Petersberg / OT Sennewitz (DE)

Aims and objectives of this presentation

Tumours of the adrenal gland are a heterogeneous group of lesions that arise from either the adrenal cortex or the medulla. These tumours are extremely rare and exhibit an average annual age-adjusted incidence of 0.29 cases per 100,000 individuals. They include several subtypes of lesions that can be either malignant or benign. Some of these tumours are functional and produce hormonal and metabolic syndromes that can lead to their discovery. Other adrenal tumours (up to 50% of tumours, depending on the histologic subtype) are silent and are only discovered when they attain a large size and produce localised abdominal symptoms or metastases. However, the discovery of adrenal incidentalomas is becoming increasingly frequent due to the widespread use of abdominal ultrasonography, computed tomography and magnetic resonance imaging.

Most of these tumours are sporadic, and their aetiology remains unknown. However, several syndromes have been associated with an increased risk of adrenal tumours, and the underlying molecular defects of these syndromes have advanced our understanding of the molecular pathways involved in the tumourigenesis of adrenal tumours. The aim of this session is to focus on the most recent studies examining differences in the incidence, prognosis, work-up, and modern surgical management of different subtypes of adrenal tumours.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*317

Adrenal vein sampling vs. CT scan to determine treatment in primary aldosteronism: An outcome-based randomised diagnostic trial

By: Dekkers T.², Prejbisz A.³, Schultze Kool L.J.⁴, Groenewoud J.M.M.⁵, Velema M.², Spiering W.⁶, Koł odziejczyk-Kruk S.³, Arntz M.⁴, Kł dziela J.¹¹, [Langenhuijsen J.F.](#)¹, Kerstens M.N.⁷, Van Den Meiracker A.H.⁸, Van Den Born B.J.⁹, Sweep F.C.G.J.¹⁰, Hermus A.R.M.M.², Januszewicz A.³, Lighthart-Naber A.F.², Makai P.⁵, Van Der Wilt G-J.⁵, Lenders J.W.M.², Deinum J.²

Institutes:¹University Medical Center Nijmegen, Dept. of Urology, Nijmegen, The Netherlands, ²University Medical Center Nijmegen, Dept. of Internal Medicine, Nijmegen, The Netherlands, ³Institute of Cardiology, Dept. of Hypertension, Warsaw, Poland, ⁴University Medical Center Nijmegen, Dept. of Radiology, Nijmegen, The Netherlands, ⁵University Medical Center Nijmegen, Dept. of Health Evidence, Nijmegen, The Netherlands, ⁶University Medical Center Utrecht, Dept. of Vascular Medicine, Utrecht, The Netherlands, ⁷University Medical Center Groningen, Dept. of Endocrinology, Groningen, The Netherlands, ⁸Erasmus Medical Center, Dept. of Internal Medicine, Rotterdam, The Netherlands, ⁹Academic Medical Center, Dept. of Internal and Vascular Medicine, Amsterdam, The Netherlands, ¹⁰University Medical Center Nijmegen, Dept. of Laboratory Medicine, Nijmegen, The Netherlands, ¹¹Institute of Cardiology, Dept. of Interventional Cardiology and Angiology, Warsaw, Poland

*318

Longitudinal evaluation of health related quality of life following laparoscopic adrenalectomy: Impact of adrenalectomy on cortisol-producing adenoma

By: [Inoue S.](#), Kurimura Y., Fukuoka K., Ueno T., Kitano H., Goto K., Shinmei S., Hieda K., Hayashi T., Teishima J., Matsubara A.

Institutes:Hiroshima University, Dept. of Urology, Hiroshima, Japan

- *319 **Nutlin-3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation**
By: [Feng C.](#), Chen S.
Institutes:Huashan Hospital Fudan University, Dept. of Urology, Shanghai, China
- *320 **Programmed death-ligand 1 expression in pheochromocytoma**
By: [Yasuhiro H.](#), Tanaka T., Imai A., Hatakeyama S., Yoneyama T., Koie T., Ohyama C.
Institutes:Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan
- *321 **Visualization of aldosterone-related steroids on adrenal frozen sections**
By: [Nishimoto K.](#)¹, Higashi T.², Nishikawa T.³, Seki T.⁴, Oyama M.¹, Kosaka T.⁶, Oya M.⁶, Suematsu M.⁵, Sugiura Y.⁵
Institutes:¹Saitama Medical University International Medical Center, Dept. of Uro-Oncology, Hidaka, Japan, ²Tokyo University of Science, Dept. of Faculty of Pharmaceutical Sciences, Noda, Japan, ³Yokohama Rosai Hospital, Endocrinology & Diabetes Center, Yokohama, Japan, ⁴California University of Science and Medicine, School of Medicine, Dept. of Medical Education, Colton, United States of America, ⁵Keio University School of Medicine, Dept. of Biochemistry, Shinjuku, Japan, ⁶Keio University School of Medicine, Dept. of Urology, Shinjuku, Japan
- *322 **Ten minutes rapid measurement of aldosterone and active renin concentration may change the diagnosis and treatment of primary aldosteronism**
By: [Sato H.](#)¹, Morimoto R.², Ono Y.², Tezuka Y.⁴, Omata K.⁴, Nezu M.², Iwakura Y.², Igarashi Y.², Kudo M.², Arai Y.³, Ito S.²
Institutes:¹Tohoku University Graduate School Of Medicine, Division Of Clinical Hypertension, Endocrinology & Metabolism, Sendai, Japan, ²Tohoku University Hospital, Division of Nephrology, Endocrinology and Vascular Medicine, Sendai, Japan, ³Tohoku University Hospital, Dept. of Urology, Sendai, Japan, ⁴Tohoku University Graduate School of Medicine, Division of Clinical Hypertension, Endocrinology & Metabolism, Sendai, Japan
- *323 **Prognosis of patients with malignant adrenal pheochromocytomas: A conditional probability analysis**
By: [Wenjun X.](#), Zhu Y., Ye D.
Institutes:Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China
- *324 **Partial laparoscopic adrenalectomy as a method of surgical management of adrenal tumors**
By: [Knežević N.](#)¹, Milas I.¹, Kulić T.¹, Penezić L.¹, El Saleh A.¹, Baćak Kocman I.², Kačelan Z.²
Institutes:¹University Hospital Zagreb, Dept. of Urology, Zagreb, Croatia, ²University Hospital Zagreb, Dept. of Anesthesiology, Zagreb, Croatia
- *325 **Predictive factors of hypertension persistence after adrenalectomy in Conn adenoma**
By: [Prudhomme T.](#)¹, Becquart N.², Cordonnier C.², Duly Bouhanick B.³, Bennet A.⁴, Thoulouzan M.¹, Soulié M.¹, Saint F.², Huyghe E.¹
Institutes:¹CHU Rangueil, Dept. of Urology, Toulouse, France, ²CHU D'Amiens, Dept. of Urology, Amiens, France, ³CHU Rangueil, Dept. of Arterial Hypertension, Toulouse, France, ⁴CHU Larrey, Dept. of Endocrinology, Toulouse, France
- *326 **Comparative study of laparoscopic (216 cases) and robotic (40 cases) posterior retroperitoneal anatomical adrenalectomy**
By: [Wang G-X.](#), Fu B., Liu W., Zhang C., Zhou X.
Institutes:The First Affiliated Hospital of Nanchang University, Dept. of Urology, Nanchang, China
- *327 **Outcomes of adrenalectomy for adrenal metastasis of renal cell carcinoma in the era of adrenal-sparing radical nephrectomy: A multicenter study**
By: [Peyronnet B.](#)¹, Schoentgen N.², Betari R.³, Gryn A.⁴, Goujon A.¹, Grevez T.⁵, Oumakhlouf S.⁶, Thoulouzan M.⁴, Brichart N.⁷, Pradere B.⁵, Beauval J-B.⁴, Rammal A.⁸, Soulie M.⁹, Fournier G.², Bruyere F.⁵, Grise P.⁶, Joulin V.², Nouhaud F-X.⁶, Manunta A.¹, Huyghe E.⁴, Bensalah K.¹
Institutes:¹CHU Rennes, Dept. of Urology, Rennes, France, ²CHU Brest, Dept. of Urology, Brest,

France, ³CHU Amiens, Dept. of Urology, Amiens, France, ⁴CHU Toulouse, Dept. of Urology, Toulouse, France, ⁵CHU Tours, Dept. of Urology, Tours, France, ⁶CHU Rouen, Dept. of Urology, Rouen, France, ⁷CHU Orleans, Dept. of Urology, Orleans, France, ⁸CH Orleans, Dept. of Urology, Orleans, France, ⁹CH Toulouse, Dept. of Urology, Toulouse, France

17:13 - 17:20

Summary

To be confirmed

Ureteroscopy: Clinical outcomes

Poster Session 25

Saturday, 25 March
16:00 - 17:30

Location: Room London, North Hall (Level 1)

Chairs: S.D. Kim, Busan (KR)

G-H. Zeng, Guangzhou (CN)

Aims and objectives of this presentation

Retrograde intrarenal stone surgery became easier with the availability of new technologies. Have we reached 100% stone free rate?

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *329 **ScorDiS-RIRS: A proposal for a new scoring system to predict difficult retrograde intra-renal surgery for renal stones**
By: Dal Moro F., Beltrami P., Mandato F.G., Bettin L., Borso C., Iafrate M., Ruggera L., Zattoni F.
Institutes: University of Padova, Dept. of Surgery, Oncology and Gastroenterology - Urology, Padova, Italy
- *330 **External validation of Imamura nomogram as preoperative predictive system for semi-rigid ureterolithotripsy outcomes**
By: De Nunzio C.¹, Bellangino M.¹, Voglino O.A.¹, Baldassarri V.¹, Presicce F.¹, Pignatelli M.², Tema G.¹, Berardi E.², Cremona A.², Tubaro A.¹
Institutes: ¹Sant' Andrea Hospital - Sapienza University, Dept. of Urology, Rome, Italy, ²Sant' Andrea Hospital - Sapienza University, Dept. of Radiology, Rome, Italy
- *331 **Tailoring antibiotic prophylaxis for ureteroscopic procedures based on local resistance profiles may lead to reduced rates of infections and urosepsis**
By: Zisman A., Badaan S., Kastin A., Kravtsov A., Kakiashvili D., Amiel G., Mullerad M.
Institutes: Rambam Health Care Campus, Technion Faculty of Medicine, Dept. of Urology, Haifa, Israel
- *332 **Impact of preoperative α -adrenergic antagonists on ureteral access sheath insertion force and the upper limit of force to avoid ureteral mucosal injury: A randomized-controlled study**
By: Koo K.C.¹, Lee D.H.³, Yoon J.H.², Park N.-C.², Lee K.S.¹, Kim D.K.¹, Kim J.C.¹, Oh K.T.¹, Heo J.E.¹, Cho K.S.¹, Hong C.H.¹, Chung B.H.¹
Institutes: ¹Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, ²Yonsei University, School of Mechanical Engineering, Seoul, South Korea, ³Pusan National University Hospital, Pusan National University College of Medicine, Dept. of Urology, Pusan, South Korea
- *333 **Preoperative ureteral wall thickness predicts the presence of impacted stone in patients with ureteral stone undergoing ureteroscopic lithotripsy**
By: Takashi Y.¹, Inoue T.², Murota T.², Kinoshita H.², Matsuda T.²
Institutes: ¹Kansai Medical University, Dept. of Urology and Andrology, Hirakata, Japan, ²Kansai Medical University, Dept. of Urology and Andrology, Osaka, Japan
- *334 **Use of post-ureteroscopy lesion scale for the evaluation of ureteral damage: Does it need a learning curve?**
By: Polo Hernández R.¹, Caballero Romeu J.P.¹, Galán Llopis J.A.², Soria F.³, Caballero Pérez P.⁴, Morcillo Martín E.³, De La Cruz Conty J.³, Garcés Valverde M.¹, Romero Maroto J.⁵
Institutes: ¹Fisabio-Isabial, Dept. of Urology, Alicante, Spain, ²Universitary Hospital of Vinalopó,

Dept. of Urology, Alicante, Spain, ³Jesús Usón Minimally Invasive Surgery Centre - Endoscopy Unit, Dept. of Urology, Cáceres, Spain, ⁴University of Alicante, Dept. of Community Nursing, Preventive Medicine and Public Health and History, Alicante, Spain, ⁵University Clinical Hospital of San Juan, Dept. of Urology, Alicante, Spain

- *335 **Preliminary results of a prospective randomized trial of safety guidewire use in ureteroscopic stone surgery: To use or not to use**
 By: Tanidir Y., Bahadir S., Sener T.E., Sulukaya M., Sekerci C.A., Tinay I., Simsek F.
 Institutes: Marmara University School of Medicine, Dept. of Urology, Istanbul, Turkey
- *336 **Lithiasic size estimation according to the image technique**
 By: Parra-López M., Antón-Eguía B.T., Argüelles-Salido E., Campoy-Martínez P., Medina-López R.A.
 Institutes: Virgen Del Rocío University Hospital. Seville Biomedicine Institute (ibis)., Dept. of Urology and Nephrology., Seville, Spain
- *337 **Effects of flexible ureteroscopy on renal blood flow**
 By: Sener T.E.¹, Bin Hamri S.², Sever I.H.³, Ozdemir B.³, Tanidir Y.¹, Traxer O.⁴
 Institutes: ¹Marmara University School of Medicine, Dept. of Urology, Istanbul, Turkey, ²King Abdulaziz National Guard Hospital, Dept. of Urology, Riyadh, Saudi Arabia, ³Marmara University School of Medicine, Dept. of Radiology, Istanbul, Turkey, ⁴Pierre & Marie Curie University, Tenon University Hospital, Dept. of Urology, Paris, France
- *338 **Secondary signs on preoperative CT as predictive factors of febrile urinary tract infection**
 By: Lee J.N., Lee Y.J., Chung J-W., Ha Y-S., Choi S.H., Kim B.S., Kim H.T., Kim T-H., Yoo E.S., Kwon T.G., Chung S.K., Kim B.W.
 Institutes: Kyungpook National University School of Medicine, Dept. of Urology, Daegu, South Korea
- *339 **A prospective, observational study to investigate change of separate renal function in patients who underwent minimally invasive renal stone surgery according to the preoperative differential renal function**
 By: Choo M.S.¹, Ryu K.H.³, Park J.², Cho M.C.², Son H.², Jeong H.², Cho S.Y.²
 Institutes: ¹Hallym University Dongtan Sacred Heart Hospital, Dept. of Urology, Hwaseong-Si, South Korea, ²SMG-SNU Boramae Medical Center, Dept. of Urology, Seoul, South Korea, ³Gwangmyeong Sungae Hospital, Dept. of Urology, Gwangmyeong-City, South Korea
- *340 **Endoscopic recognition of kidney lithiasis: Validation of first intra-operative imaging**
 By: Estrade V.¹, Benmeziani R.¹, Jour I.², Daudon M.³, Traxer O.⁴
 Institutes: ¹Centre Hospitalier d'Angoulême, Dept. of Urology, Angoulême, France, ²Lister Hospital, Dept. of Urology, Stevenage, United Kingdom, ³Hopitaux Universitaires Est Parisien Tenon, Multidisciplinary Functional Explorations, Paris, France, ⁴Hopitaux Universitaires Est Parisien Tenon, Dept. of Urology, Paris, France
- *341 **Retrograde intrarenal surgery in the elderly: Is it feasible and safe?**
 By: Berardinelli F.¹, De Francesco P.¹, Marchioni M.¹, Cera N.², Proietti S.³, Hennessey D.⁴, Dalpiaz O.⁵, Cracco C.⁶, Scoffone C.⁶, Giusti G.³, Cindolo L.¹, Schips L.¹
 Institutes: ¹S. Pio Da Pietrelcina Hospital, Dept. of Urology, Vasto, Italy, ²University of Porto, Faculty of Psychology and Educational Sciences, Porto, Portugal, ³Urological Research Institute, IRCCS Ospedale San Raffaele, Ville Turro Division, Dept. of Urology, Milan, Italy, ⁴Austin Health, Dept. of Urology, Melbourne, Australia, ⁵Medizinische Universität Graz, Urologische Klinik, Graz, Austria, ⁶Ospedale Cottolengo, Dept. of Urology, Torino, Italy
- *342 **Secondary intervention due to symptomatic ureteral stones is not necessary in the majority of patients after previous stenting**
 By: Stojkova E., Moltzahn F., Burkhard F., Thalmann G., Roth B.
 Institutes: University Hospital Bern, Dept. of Urology, Bern, Switzerland

Novel methods to improve detection and outcomes of prostate cancer

Poster Session 26

Saturday, 25 March
16:00 - 17:30

Location: Room Stockholm, North Hall (Level 1)

Chairs: A. Rannikko, Helsinki (FI)
P. Stattin, Uppsala (SE)
L-P. Xie, Hangzhou (CN)

Aims and objectives of this presentation

The aim of this session is to update on novel approach to improve detection and outcomes of prostate cancer

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *344 **Repeat prostate-specific antigen tests before prostate biopsy: A decreasing in PSA values is associated with a reduced risk of cancer and particularly high grade cancer**
By: De Nunzio C., Lombardo R., Presicce F., Deroma M., Tema G., Cancrini F., Tubaro A.
Institutes: Sant' Andrea Hospital - Sapienza University, Dept. of Urology, Rome, Italy
- *345 **Atorvastatin before prostatectomy and prostate cancer - A randomized, double-blind, placebo controlled clinical trial**
By: Murtola T.¹, Riikonen J.¹, Syväälä H.², Tolonen T.³, Koskimäki J.¹, Pakarainen T.¹, Kaipia A.⁴, Isotalo T.⁵, Kujala P.³, Tammela T.¹
Institutes:¹Tampere University Hospital, Dept. of Urology, Tampere, Finland, ²University of Tampere, School of Medicine, Tampere, Finland, ³Fimlab Laboratories, Dept. of Pathology, Tampere, Finland, ⁴Satakunta Central Hospital, Dept. of Urology, Pori, Finland, ⁵Päijät-Häme Central Hospital, Dept. of Urology, Lahti, Finland
- *346 **The effect of metformin use and the incidence of prostate cancer in type 2 diabetes mellitus patients: A nationwide population-based study**
By: Yun S.J.¹, Kim S.Y.², Park J-H.³, Cho I-C.⁴, Jeong P.⁵, Kang H.W.⁵, Ha Y-S.⁶, Kim W.T.⁵, Kim Y-J.⁵, Lee S.C.⁵, Kim W-J.⁵
Institutes:¹Chungbuk National University, Dept. of Urology, Cheongju, South Korea, ²Chungbuk National University Hospital, Office of Public Health, Cheongju, South Korea, ³College of Medicine, Chungbuk National University, Dept. of Preventive Medicine, Cheongju, South Korea, ⁴National Police Hospital, Dept. of Urology, Seoul, South Korea, ⁵Chungbuk National University College of Medicine, Dept. of Urology, Cheongju, South Korea, ⁶Kyungpook National University Medical Center, Dept. of Urology, Daegu, South Korea
- *347 **An automated-microcapillary electrophoresis-based immunoassay system may improve diagnostic accuracy of prostate cancer and be a good indicator of biopsy Gleason score**
By: Ishikawa T.¹, Yoneyama T.¹, Tobisawa Y.¹, Hatakeyama S.¹, Kurosawa T.², Nakamura K.², Koie T.¹, Hashimoto Y.¹, Ohyama C.¹
Institutes:¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Wako Pure Chemical Industries, Ltd., Diagnostics Research Laboratories, Amagasaki, Japan
- *348 **Association between single nucleotide polymorphisms, gene expression and prostate cancer risk at the moment of diagnosis**
By: Puche Sanz I.¹, Robles-Fernández I.², Pascual-Geler M.¹, Martínez-Gonzalez L.², Lorente J.A.², Cózar-Olmo J.M.¹, Álvarez-Cubero M.J.²
Institutes:¹Complejo Hospitalario Universitario Granada, Dept. of Urology, Granada, Spain, ²Pfizer-

University of Granada-Junta De Andalucía Centre For Genomics and Oncological Research (GENYO), Dept. of Genomics, Granada, Spain

- *349 **Clinical usefulness of eight novel monoclonal antibodies against Prostate-Specific Antigen (PSA) to differentiate prostate cancer and benign prostate hyperplasia. Measurement of different PSA molecular forms with specific immunoassays**
By: Navarro S.², Royo M.², Martos L.², Vera Donoso C.D.¹, Martinez-Sarmiento M.¹, Alapont J.M.¹, Ramon L.A.², Oto J.², España F.², Medina-Badenes P.²
Institutes:¹La Fe, University and Polytechnic Hospital, Dept. of Urology, Valencia, Spain, ²Instituto De Investigación Sanitaria La Fe, Grupo De Hemostasia, Trombosis, Arteriosclerosis Y Biología Vasculard, Valencia, Spain
- *350 **Defining a cohort of men who may not require repeat prostate biopsy based on PCA3 and MRI: The double negative effect**
By: Perlis N.¹, Al-Kasab T.¹, Ahmad A.¹, Goldberg E.¹, Fadak K.¹, Sayyid R.¹, Finelli A.¹, Kulkarni G.¹, Hamilton R.¹, Zlotta A.², Fleshner N.¹
Institutes:¹University of Toronto, University Health Network, Dept. of Surgical Oncology, Division of Urology, Toronto, Canada, ²University of Toronto, University Health Network and Sinai Health System, Dept. of Surgical Oncology, Division of Urology, Toronto, Canada
- *351 **Circulating tumor cells as a marker of bone metastases in patients with high-risk prostate cancer**
By: Cieřlikowski W.A.¹, Ida A.¹, Hrab M.¹, Budna J.², ĩwierczewska M.², Jankowiak A.², Zabel M.², Antczak A.¹
Institutes:¹Poznań University of Medical Sciences, Dept. of Urology, Poznań, Poland, ²Poznań University of Medical Sciences, Dept. of Histology and Embryology, Poznań, Poland
- *352 **Clinical validation of a 17-gene genomic prostate score (GPS) assay as a predictor of distant metastases in men with prostate cancer (PCa) treated with radical prostatectomy (RP) in a community setting**
By: Van Den Eeden S.¹, Zhang N.⁴, Shan J.¹, Quesenberry C.¹, Han J.², Tsiatis A.³, Lu R.⁴, Lawrence J.⁵, Febbo P.⁵, Presti J.⁶
Institutes:¹Kaiser Permanente Northern California, Dept. of Research, Oakland, United States of America, ²Kaiser Oakland Medical Center, Dept. of Pathology, Oakland, United States of America, ³Genomic Health, Dept. of Pathology, Redwood City, United States of America, ⁴Genomic Health, Dept. of Biostatistics, Redwood City, United States of America, ⁵Genomic Health, Medical Department, Redwood City, United States of America, ⁶Kaiser Oakland Medical Center, Dept. of Urology, Oakland, United States of America
- *353 **Serum miRNA-supported transrectal MRI-Ultrasound fusion-guided biopsy of the prostate enhances tumor prediction and classification**
By: Keck B., Wach S., Pöllmann J., Jansen T., Kahlmeyer A., Taubert H., Wullich B.
Institutes:University Hospital Erlangen, Dept. of Urology, Erlangen, Germany
- *354 **The influence of physical activity on prostate cancer diagnosis: A multicenter biopsy cohort analysis**
By: De Nunzio C.¹, Cindolo L.², Sountoulidis P.³, Toutziaris C.⁴, Gacci M.⁵, Presicce F.¹, Cancrini F.¹, Schips L.², Serni S.⁵, Tubaro A.¹
Institutes:¹Sant'Andrea Hospital - Sapienza University, Dept. of Urology, Rome, Italy, ²Padre Pio Da Pietrelcina Hospital, Dept. of Urology, Vasto, Italy, ³General Hospital of Veria, Dept. of Urology, Veria, Greece, ⁴Aristotle University of Thessaloniki, Dept. of Urology, Thessaloniki, Greece, ⁵Careggi Hospital, Dept. of Urology, Florence, Italy
- *356 **Germline mutations in the Kallikrein 6 region and predisposition for aggressive prostate cancer**
By: Briollais L.², Ozcelik H.², Xu J.², Kwiatkowski M.³, Lalonde E.⁴, Sendorek D.⁴, Fleshner N.⁵, Recker F.³, Kuk C.⁶, Olkhov-Mitsel E.², Savas S.⁷, Hanna S.⁸, Juvet T.⁵, Hunter G.⁴, Friedlander M.², Li H.², Chadwick K.⁵, Prassas I.⁹, Soosaipillai A.⁹, Randazzo M.³, Trachtenberg J.⁵, Toi A.⁵, Shiah Y-J.⁴, Fraser M.¹⁰, Van Der Kwast T.¹¹, Bristow R.¹⁰, Bapat B.², Diamandis E.⁹, Boutros P.⁴, Zlotta A.¹
Institutes:¹Mount Sinai Hospital, Dept. of Surgery (urology), Toronto, Canada, ²Mount Sinai

Hospital, Lunenfeld-Tanenbaum Research Institute, Toronto, Canada, ³Cantonal Hospital Aarau, Dept. of Urology, Aarau, Switzerland, ⁴Ontario Institute For Cancer Research, Informatics & Biocomputing Program, Toronto, Canada, ⁵Princess Margaret Hospital, University Health Network, Dept. of Surgical Oncology, Urology, Toronto, Canada, ⁶Mount Sinai Hospital, Dept. of Surgery and Urology, Toronto, Canada, ⁷Memorial University, Craig L. Dobbin Genetics Research Centre, Discipline of Genetics, Faculty of Medicine, St. John's, Canada, ⁸Mount Sinai Hospital, Dept. of Surgery, Urology, Toronto, Canada, ⁹Mount Sinai Hospital, Dept. of Pathology and Laboratory Medicine, Toronto, Canada, ¹⁰Princess Margaret Hospital, University Health Network, Ontario Cancer Institute, Toronto, Canada, ¹¹Toronto General Hospital, University Health Network, Dept. of Pathology, Toronto, Canada

17:17 - 17:24

Summary

A. Rannikko, Helsinki (FI)

New therapeutic approaches in RCC

Poster Session 27

Saturday, 25 March
16:00 - 17:30

Location: Room Munich, North Hall (Level 1)

Chairs: U. Capitanio, Milan (IT)
T. Klatte, Wien (AT)

Aims and objectives of this presentation

To demonstrate various types of new therapeutic approaches in renal tumors

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *357 **Proposal and validation of a dynamic criterion for patient inclusion in kidney cancer active surveillance protocols**
By: Larcher A.¹, Muttin F.¹, Ripa F.¹, Stabile A.¹, Trevisani F.¹, Nini A.¹, La Croce G.¹, Carezzi C.¹, Mottrie A.², Salonia A.¹, Briganti A.¹, Montorsi F.¹, Bertini R.¹, Capitanio U.¹
Institutes:¹Irccs Ospedale San Raffaele, Urological Research Institute, Division of Oncology, Unit of Urology, Milan, Italy, ²Onze Lieve Vrouw Hospital, Dept. of Urology, Aalst, Belgium
- *358 **The natural history of observed large renal masses**
By: Touma N.¹, Leslie R.¹, Ho L.¹, Siemens R.¹, Menard A.²
Institutes:¹Queen's University, Dept. of Urology, Kingston, Canada, ²Queen's University, Dept. of Radiology, Kingston, Canada
- *359 **Renal warm ischemia time and glomerular loss: An experimental study in a pig model**
By: Damasceno-Ferreira J., Abreu L., Bechara G., Costa W., Pereira-Sampaio M., Sampaio F., De Souza D.
Institutes:Rio De Janeiro State University, Urogenital Research Unit, Rio De Janeiro, Brazil
- *360 **Renal function after selective internal radiation therapy (SIRT) with yttrium-90 (Y-90) resin microspheres in patients with primary renal cell carcinoma (RCC): The RESIRT study**
By: Aslan P.¹, Clark W.², Patel M.³, Vass J.⁴, Cade D.⁵, De Silva S.J.⁶, De Souza P.⁷
Institutes:¹Waratah Private Hospital, Dept. of Urology, Hurtsville, Australia, ²St George Hospital, Dept. Of Urology, Sydney, Australia, ³Westmead Hospital, Dept. Of Urology, Westmead, Australia, ⁴Royal North Shore Hospital, Sydney and Macquarie University Hospital, North Ryde, Australia, ⁵Sirtex Medical Ltd, Sydney, Australia, ⁶Sutherland Hospital, Sydney, Australia, ⁷Western Sydney University, School of Medicine, Sydney, Australia
- *361 **Better nephron sparing option for patients with cT1 stage renal masses: Comparison of open, laparoscopic partial nephrectomy and radiofrequency ablation**
By: Alekseev B., Kalpinskiy A., Nyushko K., Vorobiev N., Taraki H., Muhomedyarova A., Sundui Y., Kaprin A.
Institutes:National Medical Research Radiological Center, Dept. of Oncurology, Moscow, Russia
- *362 **Percutaneous ablation of small renal tumours: A multi-centre experience**
By: Yeap S.H.A.¹, Yeow S.Y.¹, Lohan R.², Pua U.³, Teo C.⁴, Png K.S.⁵
Institutes:¹Khoo Teck Puat Hospital, Tan Tock Seng Hospital, Dept. of Urology, Singapore, Singapore, ²Khoo Teck Puat Hospital, Dept. of Radiology, Singapore, Singapore, ³Tan Tock Seng Hospital, Dept. of Radiology, Singapore, Singapore, ⁴Khoo Teck Puat Hospital, Dept. of Urology, Singapore, Singapore, ⁵Tan Tock Seng Hospital, Dept. of Urology, Singapore, Singapore

- *363 **Minimally invasive conservative treatment of localized renal tumors: A single center experience on percutaneous ablations and robot-assisted partial nephrectomy**
By: [Grassano Y.](#)¹, Cornelis F.², Grenier N.², Michiels C.¹, Capon G.¹, Bensadoun H.¹, Pasticier G.¹, Robert G.¹, Ferriere J-M.¹, Bernhard J-C.¹
Institutes:¹Groupe hospitalier Pellegrin, Dept. of Urology, Bordeaux, France, ²Groupe hospitalier Pellegrin, Dept. of Radiology, Bordeaux, France
- *364 **Laparoscopic versus percutaneous cryoablation for T1 renal masses: An Italian multicentric study**
By: De Concilio B.¹, Cicero C.², [Zeccolini G.](#)¹, Laganà F.³, Balestreri L.⁴, Casarrubea G.⁵, Zattoni F.⁶, Merlo F.⁷, Siracusano S.⁸, Celia A.¹
Institutes:¹San Bassiano Hospital, Dept. of Urology, Bassano del Grappa, Italy, ²San Bassiano Hospital, Dept. of Radiology, Bassano del Grappa, Italy, ³Dolo Hospital, Dept. of Urology, Dolo, Italy, ⁴C.R.O. Aviano Hospital, Dept. of Oncology, Aviano, Italy, ⁵Padova University Hospital, Dept. of Radiology, Padua, Italy, ⁶Padova University Hospital, Dept. of Urology, Padua, Italy, ⁷Mestre Hospital, Dept. of Urology, Mestre, Italy, ⁸Verona University Hospital, Dept. of Urology, Verona, Italy
- *365 **Microwave ablation versus radiofrequency ablation for small renal lesions; a comparison of efficacy and safety**
By: [Evans R.](#), Abusanade O., Thwaini A., Keane J., Loan W.
Institutes:Belfast City Hospital, Dept. of Urology, Belfast, United Kingdom
- *366 **CO2 laser dissection (COLD) knife robotic partial nephrectomy for solid renal pseudotumors in a porcine model: Idea, development, exploration, assessment, long-term monitoring (IDEAL) stage 0 study**
By: [Alruwaily A.](#)¹, Rohde J.², Garneys L.², Palapattu G.¹, Ghani K.¹
Institutes:¹University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ²Intuitive Surgical, Atlanta, United States of America
- *367 **Histopathologic analysis of tumor bed after in vitro tumor enucleation on radical nephrectomy specimen**
By: [Lu Q.](#)¹, Ji C.¹, Zhao X.¹, Guo S.², Liu G.¹, Zhang S.¹, Li X.¹, Gan W.¹, Guo H.¹
Institutes:¹Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Dept. of Urology, Nanjing, China, ²Nanjing Medical University, School of Public Health, Nanjing, China

17:07 - 17:15 **Associated video presentation Combined robot-assisted salvage partial nephrectomy and cryotherapy after radiofrequency failure on a solitary kidney**
 C. Michiels, Bordeaux (FR)

17:15 - 17:22 **Summary**
 To be confirmed

Men's sexual health: Focus on treatment of erectile dysfunction and Peyronie's disease

Poster Session 28

Saturday, 25 March
16:00 - 17:30

Location: Room 7, Capital suite (level 3)

Chairs: M. Fode, Herlev (DK)
D.G. Hatzichristou, Thessaloniki (GR)
J. Romero-Otero, Madrid (ES)

Aims and objectives of this presentation

This session will provide the audience with the most recent clinical evidence on the treatment of erectile dysfunction and Peyronie's disease. The main aim is to leave the audience with ideas which can be implemented in the every day clinical practice.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*368

Safety and potential effect of a single intracavernous injection of autologous adipose-derived regenerative cells in patients with erectile dysfunction following radical prostatectomy: 12-month follow-up

By: Haahr M.¹, Jensen C.H.², Sørensen J.A.³, Sheikh S.P.⁴, Lund L.¹

Institutes:¹Odense University Hospital, Dept. of Urology, Odense, Denmark, ²Odense University Hospital, Dept. of Clinical Biochemistry and Pharmacology, Odense, Denmark, ³Odense University Hospital, Dept. of Plastic Surgery, Odense, Denmark, ⁴Odense University Hospital, Dept. of Clinical Biochemistry and Pharmacology, Odense, Denmark

*369

A pilot study on the safety and feasibility of VL#FIA3-30 -a newly developed topical agent for treating erectile dysfunction

By: Appel B., Massarwa O., Gruenwald I.

Institutes:Rambam Health Care Campus, Dept. of Urology, Haifa, Israel

*370

Multicenter investigation of the microorganisms involved in penile prosthesis infection: An analysis of the efficacy of the AUA and EAU guidelines for penile prosthesis prophylaxis

By: Gross M.¹, Phillips E.², Carrasquillo R.³, Thornton A.⁴, Greenfield J.⁵, Levine L.⁶, Alukal J.⁷, Conners W.⁸, Glina S.⁹, Tanrikut C.¹⁰, Honig S.¹¹, Becher E.¹², Bennett N.¹³, Wang R.¹⁴, Perito P.¹⁵, Stahl P.¹⁶, Rosselló Gayá M.¹⁷, Rosselló Barbará M.¹⁷, Cedeno J.¹⁸, Gheiler E.¹⁸, Kalejaiye O.¹⁹, Ralph D.¹⁹, Köhler T.²⁰, Stember D.²¹, Carrion R.²², Maria P.²³, Brant W.²⁴, Bickell M.²⁵, Garber B.²⁵, Pineda M.²⁶, Burnett A.²⁶, Eid J.F.²⁷, Henry G.²⁸, Munarriz R.³

Institutes:¹Dartmouth-Hitchcock Medical Center, Dept. of Urology, Lebanon, United States of America, ²CentraCare Health, Dept. of Urology, St. Cloud, United States of America, ³Boston University Medical Center, Dept. of Urology, Boston, United States of America, ⁴Boston University Medical Center, Dept. of Medicine, Boston, United States of America, ⁵Urology Associates of North Texas, Dept. of Urology, Arlington, United States of America, ⁶Rush University Medical Center, Dept. of Urology, Chicago, United States of America, ⁷NYU Langone Medical Center, Dept. of Urology, New York City, United States of America, ⁸Beth Israel Deaconess Medical Center, Dept. of Urology, Boston, United States of America, ⁹Faculdade de Medicina Do ABC/Instituto H. Ellis, Dept. of Urology, São Paulo, Brazil, ¹⁰Massachusetts General Hospital, Dept. of Urology, Boston, United States of America, ¹¹Yale School of Medicine, Dept. of Urology, New Haven, United States of America, ¹²University of Buenos Aires, Dept. of Urology, Buenos Aires, Argentina, ¹³Northwestern Memorial Hospital, Dept. of Urology, Chicago, United States of America, ¹⁴The University of Texas Health Science Center At Houston, Dept. of Urology, Houston, United States of America, ¹⁵Perito Urology, Dept. of Urology, Miami, United States of America, ¹⁶Columbia University College of

Physicians & Surgeons, Dept. of Urology, New York City, United States of America, ¹⁷Hospital Quirón Palmaplanas Salud, Dept. of Urology, Palma de Mallorca, Spain, ¹⁸Urology Specialists, Dept. of Urology, Hialeah, United States of America, ¹⁹University College London Hospital, Dept. of Urology, London, United Kingdom, ²⁰SIU School of Medicine, Dept. of Urology, Springfield, United States of America, ²¹Mount Sinai Hospital, Dept. of Urology, New York City, United States of America, ²²USF Morsani College of Medicine, Dept. of Urology, Tampa, United States of America, ²³Albert Einstein College of Medicine, Dept. of Urology, New York City, United States of America,

²⁴University of Utah Hospital, Dept. of Urology, Salt Lake City, United States of America, ²⁵Hahnemann University Hospital, Dept. of Urology, Philadelphia, United States of America, ²⁶Johns Hopkins University School of Medicine, Dept. of Urology, Baltimore, United States of America, ²⁷Advanced Urological Care, Dept. of Urology, New York City, United States of America, ²⁸Regional Urology, Dept. of Urology, Shreveport, United States of America

*371 **Penile prosthesis implantation preserves and may increase penile size irrespective of implant type**
By: [Giona S.](#)¹, Habous M.², Abdelwahab O.³, Laban O.⁴, Mahmoud S.², Nassar M.⁵, Tealab A.⁶, Binsaleh S.⁷, Mulhall J.⁸, Muir G.¹

Institutes:¹King's College Hospital, Dept. of Urology, London, United Kingdom, ²Elaj Medical Centers, Dept. of Urology, Jeddah, Saudi Arabia, ³Benha University, Dept. of Urology, Benha, Egypt, ⁴King Khaled Hospital, Dept. of Urology, Tabouk, Saudi Arabia, ⁵Elaj Medical Centers, Dept. of Urology, Madina, Saudi Arabia, ⁶Zagazig University, Dept. of Urology, Zagazig, Egypt, ⁷King Saud University, Dept. of Urology, Riyadh, Saudi Arabia, ⁸Memorial Sloan Kettering Cancer Center, Sexual and Reproductive Medicine, New York, United States of America

*372 **Distal corporal anchoring stitch, a technique to address distal corporal crossovers and impending lateral extrusions of a penile prosthesis**

By: [Busetto G.M.](#)¹, Antonini G.¹, Del Giudice F.¹, De Berardinis E.¹, Perito P.²

Institutes:¹Sapienza Rome University, Dept. of Urology, Rome, Italy, ²Coral Gable Hospital, Dept. of Urology, Miami, United States of America

*373 **The role of the tachosil and SIS as grafts after inflatable penile prosthesis implantation and plaque incision: Surgical and functional outcomes in a single center prospective comparative study**

By: Falcone M.¹, [Timpano M.](#)¹, Ceruti C.¹, Omid S.¹, Sibona M.¹, Gillo A.², Oderda M.¹, Cocci A.³, Gontero P.¹, Rolle L.¹

Institutes:¹University of Turin, Dept. of Urology, Turin, Italy, ²Ospedale Parini, Dept. of Urology, Aosta, Italy, ³University of Florence, Dept. of Urology, Florence, Italy

*374 **Small intestinal submucosa graft in the treatment of Peyronie's disease: Long term patient-reported outcomes and satisfaction**

By: [Ribeiro Morgado L.A.](#)¹, Ribeiro Morgado M.², Pacheco-Figueiredo L.¹, Tomada N.¹, Cruz F.¹

Institutes:¹Centro Hospitalar São João, Dept. of Urology, Porto, Portugal, ²Faculdade de Medicina da Universidade do Porto, Dept. of Renal, Infectious and Urologic Diseases, Porto, Portugal

*376 **Safety and effectiveness of collagenase clostridium histolyticum (CCH) (Xiapex®) in the treatment of peyronie's disease using a new shortened protocol**

By: [Abdel Raheem A.](#), Capece M., Kalejaiye A., Falcone M., Mubasher A., Parnham A., Garaffa G., Christopher N., Ralph D.

Institutes:University College London Hospital, Dept. of Andrology, London, United Kingdom

*377 **Intralesional verapamil versus ialuronic acid for the treatment of Peyronie's disease: A randomized single-blinded study**

By: Favilla V.¹, [Russo G.I.](#)¹, Zucchi A.², Siracusa G.³, Privitera S.¹, Cimino S.¹, Madonia M.³, Cai T.⁴, Cavallini G.⁵, Liguori G.⁶, Silvani M.⁷, Dachille G.⁸, Franco G.⁹, Verze P.¹⁰, Palmieri A.¹⁰, Mirone V.¹⁰, Morgia G.¹

Institutes:¹University of Catania, Urology Section, Dept. of Surgery, Catania, Italy, ²University of Perugia, Dept. of Urology, Perugia, Italy, ³University of Sassari, Dept. of Urology, Sassari, Italy, ⁴Santa Chiara Regional Hospital, Dept. of Urology, Trento, Italy, ⁵Outpatient Clinic of Ferrara, Medicitalia Andrology Section, Ferrara, Italy, ⁶Urology Unit, Cattinara Hospital, Trieste, Italy, ⁷

Hospital Degli Infermi, Dept. of Urology, Biella, Italy, ⁸San Giacomo Hospital, Dept. of Urology, Monopoli, Italy, ⁹University La Sapienza, Dept. of Urology, Roma, Italy, ¹⁰University of Naples, Federico II, Dept. of Urology, Napoli, Italy

*378

Daily tadalafil therapy: A new treatment option for Peyronie's disease?

By: [Park H.J.](#)¹, Park N.C.¹, Kim T.N.¹, Nam J.K.¹, Moon D.G.²

Institutes:¹Pusan National University Hospital, Dept. of Urology, Busan, South Korea, ²Korea University Hospital, Dept. of Urology, Seoul, South Korea

*379

Penile enlargement with the Elist silicone implant: Safety and efficiency after 500 operations

By: Elist J.J.², [Lemperle H.G.](#)¹

Institutes:¹University of California, Dept. of Plastic Surgery, San Diego, United States of America, ²Beverly Hills, Urology practice, Los Angeles, United States of America

17:15 - 17:22

Summary

M. Fode, Herlev (DK)

Redefining and optimising contemporary bladder cancer care

Plenary session 03

Sunday, 26 March
07:30 - 10:30

Location: eURO Auditorium (Level 0)

Chairs: J. Palou, Barcelona (ES)
M. Rouprêt, Paris (FR)

Aims and objectives of this presentation

Bladder cancer is a frequently occurring disease with a high mortality rate despite optimal treatment. This session will highlight the proper management of non muscle invasive bladder cancer, including ongoing debate about conservative management in T1 tumor or the rhythm of follow-up in low grade tumor . Additionally the therapeutic impact of the extent of lymphadenectomy during radical cystectomy will be stated.. Potential indications and contraindications, such as comorbidity, are related to treatment choice. The implementation of fast-track programs of rehabilitation to enhance postsurgical recovery after cystectomy and the quality of life after urinary diversion will be discussed.

During the plenary sessions, French and Spanish translation will be provided. Please collect your headset in the session room prior to the start of the session and return it after the session.

Meet the speakers of the plenary session:

Delegates are able to meet the speakers of the plenary session immediately at the end of the session in the foyer of the eURO Auditorium (Level 0). Do not miss this opportunity to meet and greet the speakers and to consult them for any questions you may have.

07:30 - 08:00

EAU Consensus highlights

08:00 - 09:00

Case discussion Perfect management of T1 bladder cancer

Moderator: G.N. Thalmann, Bern (CH)

08:00 - 08:04

Case presentation

G.N. Thalmann, Bern (CH)

08:04 - 08:18

Perfect transurethral resection

M. Babjuk, Prague 5 (CZ)

08:18 - 08:32

Perfect pathology report

R. Montironi, Ancona (IT)

08:32 - 08:46

Adjuvant treatment

J.A. Witjes, Nijmegen (NL)

08:46 - 09:00

Perfect decision re cystectomy

A.M. Kamat, Houston (US)

09:00 - 09:30

Debate Do we need a follow-up in low grade bladder tumour after 12 months?

Moderator: M. Brausi, Modena (IT)

09:00 - 09:15

Yes (EAU Guidelines)
M. Burger, Regensburg (DE)

09:15 - 09:30

No (NICE Guidelines)
H. Mostafid, Guildford (GB)

09:30 - 10:00

State-of-the-art lecture The evidence for the extent of lymphadenectomy in TCC

09:30 - 09:45

Presenter
J.E. Gschwend, München (DE)

09:45 - 10:00

Discussant
S. Lerner, Houston (US)

10:00 - 10:15

State-of-the-art lecture Enhanced Recovery After Surgery (ERAS) for bladder cancer: Non-surgical options to improve outcomes of cystectomy
J.W.F. Catto, Sheffield (GB)

10:15 - 10:30

State-of-the-art lecture What determines QoL after urinary diversion and how to measure it?
W. Artibani, Verona (IT)

Benign Prostatic Enlargement (BPE): Evaluation, drugs, surgery or new interventional treatment

Plenary session 04

Sunday, 26 March
08:00 - 10:30

Location: Room Copenhagen, North Hall (Level 1)

Chairs: C.R. Chapple, Sheffield (GB)
P. Radziszewski, Warsaw (PL)

Aims and objectives of this presentation

The clinical scene for benign prostatic enlargement diagnosis and treatment is changing rapidly. The old paradigms regarding who should get drugs and who should be operated are no longer valid. During the session participants will be updated with modern patophysiological concepts of BPE. This will be followed by a debate on urodynamics and a vigorous case discussion on dilemna related to treatment choice accordingly to the prostate size. New emerging techniques will be discussed and the session will be concluded with drug management of LUTS and BPE as well as with unresolved diagnostic and therapeutic problems. The session aims not only to deliver the new knowledge, but also to stimulate discussion.

Objectives

During this session participants are expected to learn about BPE patophysiology, diagnostics , pharmacological and surgical treatment. The session should stimulate exchange of experience and growth of new ideas.

During the plenary sessions, French and Spanish translation will be provided. Please collect your headset in the session room prior to the start of the session and return it after the session.

Meet the speakers of the plenary session:

Delegates are able to meet the speakers of the plenary session immediately at the end of the session in the foyer of the Room Copenhagen (North Hall, Level 1). Do not miss this opportunity to meet and greet the speakers and to consult them for any questions you may have.

08:00 - 08:15

State-of-the-art lecture Inflammation in BPE: Does it change the treatment?

M. Gacci, Florence (IT)

08:15 - 08:45

Debate Is there still a role for urodynamics in BPE in 2017?

Moderator: H. Woo, Sydney (AU)

08:15 - 08:30

Pro

M. Oelke, Hanover (DE)

08:30 - 08:45

Con

N. Thiruchelvam, Cambridge (GB)

08:45 - 09:15

Case discussion LUTS due to BPE: When to operate and when to avoid surgery

08:45 - 09:15

Case presenter and moderator

A. Tubaro, Rome (IT)

08:45 - 08:55

Case related to: Small prostate dilemmas

08:55 - 09:05

Case related to: Very large prostate and storage LUTS

09:05 - 09:15

Case related to: Very large prostate and voiding LUTS

08:45 - 09:15

Discussants

A. De La Taille, Créteil (FR)

M. Speakman, Taunton (GB)

09:15 - 09:30

State-of-the-art lecture Guidelines and emerging technologies

S. Gravas, Larissa (GR)

09:30 - 10:00

Debate Emerging techniques in surgery: Light, electricity or water?

Moderator: C. Gratzke, Munich (DE)

09:30 - 09:40

Electricity

T.R.W. Herrmann, Hannover (DE)

09:40 - 09:50

Light

C.M. Scoffone, Turin (IT)

09:50 - 10:00

Water

N. Barber, Camberley (GB)

10:00 - 10:15

State-of-the-art lecture Contemporary management of voiding symptoms following surgery for bladder outlet obstruction

K. Everaert, Ghent (BE)

10:15 - 10:30

American Urological Association (AUA) lecture LUTS and BPE: Unresolved diagnostic and therapeutic issues

C.G. Roehrborn, Dallas (US)

Office management of male sexual dysfunction

ESU Course 14

Sunday, 26 March
08:30 - 11:30

Location: Room 10, Capital suite (level 3)

Chair: C. Stief, Munich (DE)

Aims and objectives of this presentation

The course is aimed at providing practical advice on how to diagnose and treat a patient with Premature ejaculation or ED. It will allow

- An up-to-date understanding of the aetiology of ED and EP
- An adequate work up enabling an individually adopted regimen
- Currently available treatment options as topical and oral drugs, testosterone and devices
- Post-prostatectomy ED with various approaches

08:30 - 11:30

Introduction

C. Stief, Munich (DE)

08:30 - 11:30

Diagnostics - What is necessary?

I. Eardley, Leeds (GB)

08:30 - 11:30

Testosterone replacement

C. Stief, Munich (DE)

08:30 - 11:30

Oral therapy for ED

I. Eardley, Leeds (GB)

08:30 - 11:30

Therapy of ED when pills fail

D.J. Ralph

08:30 - 11:30

Medical therapy for premature ejaculation

I. Eardley, Leeds (GB)

08:30 - 11:30

Surgical topics: Penile implants, priapism, Peyronie's

D.J. Ralph

08:30 - 11:30

What to do after radical prostatectomy?

C. Stief, Munich (DE)

Update on stone disease

ESU Course 15

Sunday, 26 March
08:30 - 11:30

Location: Room 11, Capital suite (level 3)

Chair: A. Patel, London (GB)

Aims and objectives of this presentation

The previously devastating burden of urinary tract urolithiasis has been reduced by modern stone therapy. Complex branched stones are rare, and therapy has moved largely to the outpatient setting. Nevertheless, successful management requires competence in all aspects of stone management. After a brief review of new developments in present treatment strategies, these will be further explored by interactive case presentations.

- Stone disease aetiology is multi-factorial, relating in large part to genetics, diet (salt, calorie and protein intake), hydration status factors and ageing.
- The clinical presentation is changing with a growing base of elderly and obese patient cohorts in developed nations.
- Today's challenge is employing the ideal initial and salvage approaches for specific situations – individuals, including judicious selection of prevention strategies.
- Patients should be given choices and counselled about the risk benefits and potential outcomes of all appropriate reasonable approaches.

08:30 - 11:30

Introduction

A. Patel, London (GB)

08:30 - 11:30

Medical aspects of urinary stones

M. Straub, Munich (DE)

08:30 - 11:30

SWL

M. Straub, Munich (DE)

08:30 - 11:30

Uretero-Renoscropy

A. Breda, Barcelona (ES)

08:30 - 11:30

Percutaneous nephrolithotomy and questions and answers

A. Patel, London (GB)

08:30 - 11:30

Interactive case discussion

A. Patel, London (GB)

Focal treatment in prostate cancer

ESU Course 16

Sunday, 26 March
08:30 - 11:30

Location: Room 12, Capital suite (level 3)

Chair: E. Barret, Paris (FR)

Aims and objectives of this presentation

Focal treatment is about eradicating the cancer lesion within the prostate while preserving genitourinary function. This interactive course offers delegates

- understanding of the rationale for focal treatment and patient selection criteria
- update on principles, outcome and side effects of focal technologies
- a thorough discussion of biopsy strategies and imaging in diagnostic work-up and follow-up
- information about existing registries

As men with prostate cancer are getting younger the side effects of whole gland treatment are getting more important. With several new technologies available a significant development of focal treatment is expected in the coming years.

A. Govorov, Moscow (RU)

J.P.M. Sedelaar, Nijmegen (NL)

Lower urinary tract dysfunction and urodynamics

ESU Course 17

Sunday, 26 March
08:30 - 11:30

Location: Room 14, Capital suite (level 3)

Chair: P. Abrams, Bristol (GB)

Aims and objectives of this presentation

Having attended the course, the attendee should:

- Understand the basic physical principles referable to urodynamics
- Be able to assess the quality of a urodynamic trace
- Recognise common artefacts and know how to correct them
- Know the indications for urodynamic studies in men, women and neurological patients.

08:30 - 11:30

Urodynamics: Philosophy, scientific basis and technique

P. Abrams, Bristol (GB)

08:30 - 11:30

Urodynamics in neurourology

J.L.H.R. Bosch, Utrecht (NL)

08:30 - 11:30

Urodynamics in female urology

P. Abrams, Bristol (GB)

08:30 - 11:30

Urodynamics in men

J.L.H.R. Bosch, Utrecht (NL)

Advanced course on laparoscopic nephrectomy

ESU Course 18

Sunday, 26 March
08:30 - 11:30

Location: Room 15, Capital suite (level 3)

Chair: V. Pansadoro, Rome (IT)

Aims and objectives of this presentation

Minimally invasive surgery has steadily improved over the last years. Today one can approach with confidence new, difficult and challenging situations.

The course is structured to evaluate and explore the increasing indications and possible complications of Laparoscopic and Robotic kidney surgery.

This course will focus upon common and uncommon complications and how to manage and prevent them.

In addition, special situations such as single port inguinal approach, zero ischemia time, cava thrombus, accidental splenectomy and living donor nephrectomy will be presented.

08:30 - 11:30

Introduction

R. Bollens, Lomme (FR)
V. Pansadoro, Rome (IT)

08:30 - 11:30

Transperitoneal approach

V. Pansadoro, Rome (IT)

08:30 - 11:30

Retroperitoneal approach

R. Bollens, Lomme (FR)
V. Pansadoro, Rome (IT)

08:30 - 11:30

Single port inguinal approach

R. Bollens, Lomme (FR)

08:30 - 11:30

Intraoperative complications

R. Bollens, Lomme (FR)
V. Pansadoro, Rome (IT)

08:30 - 11:30

Difficult nephrectomies

R. Bollens, Lomme (FR)

08:30 - 11:30

Partial nephrectomy

R. Bollens, Lomme (FR)
V. Pansadoro, Rome (IT)

08:30 - 11:30

Special cases

R. Bollens, Lomme (FR)
V. Pansadoro, Rome (IT)

Chronic pelvic pain in men and women

ESU Course 19

Sunday, 26 March
08:30 - 11:30

Location: Room 16, Capital suite (level 3)

Chair: E.J. Messelink, Groningen (NL)

Aims and objectives of this presentation

The urologist is often dealing with patients having Chronic Pelvic Pain. This course will offer the urologist practical guidance in treating these patients. In the case discussion the participants will have the opportunity to help outlining the problem. In the lectures theoretical knowledge will be translated into daily guidelines for diagnostics and treatment of patients with pelvic pain.

At the end of this course the participant will

- Know the basic principles of treating patients with chronic pelvic pain.
- Know how to rule out well known causes.
- Have knowledge of the myofascial and psychological aspects.
- Be able to refer patients at the right time to the right team.

08:30 - 11:30

Chronic pelvic pain, the basics: Mechanisms and terminology
E.J. Messelink, Groningen (NL)

08:30 - 11:30

Chronic pelvic pain in men: Case presentation and discussion
D.S. Engeler, St. Gallen (CH)

08:30 - 11:30

Chronic pelvic pain in men: Practical guidelines on diagnostics and treatment
D.S. Engeler, St. Gallen (CH)

08:30 - 11:30

Chronic pelvic pain in women: Case presentation and discussion
E.J. Messelink, Groningen (NL)

08:30 - 11:30

Chronic pelvic pain in women: Practical guidelines on diagnostics and treatment
E.J. Messelink, Groningen (NL)

08:30 - 11:30

The interdisciplinary approach: Team members and organisation
D.S. Engeler, St. Gallen (CH)
E.J. Messelink, Groningen (NL)

Surgical anatomy

ESU Course 20

Sunday, 26 March
08:30 - 11:30

Location: Room 17, Capital suite (level 3)

Chair: J-U. Stolzenburg, Leipzig (DE)

Aims and objectives of this presentation

This course addresses comprehensively important anatomical considerations for open and minimally invasive radical prostatectomy and partial nephrectomy. Key technical aspects such access, port placement, robotic docking and each step of the procedures will be discussed. Additionally interfascial and intrafascial of nerve-sparing surgery will be discussed. In partial nephrectomy the focus is on pedicle control, tumour excision, how to achieve adequate haemostasis and how to shorten ischemia time.

J-U. Stolzenburg, Leipzig (DE)

08:30 - 11:30

Surgical anatomy for laparoscopic/robotic assisted radical cystectomy

J. Cresswell, Middlesbrough (GB)

08:30 - 11:30

Port placement and robot docking-principles for pelvic laparoscopy

J. Cresswell, Middlesbrough (GB)

To be confirmed

08:30 - 11:30

Prostate, bladder and urethral sphincter anatomy. How to preserve urinary continence

J. Cresswell, Middlesbrough (GB)

To be confirmed

08:30 - 11:30

Surgical anatomy for nerve sparing surgery

J. Cresswell, Middlesbrough (GB)

08:30 - 11:30

Boundaries and technique of pelvic lymph node dissection for radical prostatectomy (standard, extended PLNA, risk stratified access) and radical cystectomy

J. Cresswell, Middlesbrough (GB)

08:30 - 11:30

Summary and take home messages

J. Cresswell, Middlesbrough (GB)

08:30 - 11:30

Quiz

To be confirmed

E-BLUS Exam

HOT09

Sunday, 26 March
09:45 - 10:45

Location: Room South America, Exhibition Hall (Level 1)

Aims and objectives of this presentation

The European training in basic laparoscopic urological skills (E-BLUS) is a programme offered to residents and urologists who want to improve the basic skills in laparoscopy. It is a unique opportunity to train with international experts in laparoscopy. The E-BLUS programme includes:

- Hands-on Training (HOT) courses of different levels carried out under the guidance of experienced tutors
- A set of training-box exercises developed and validated by the Dutch project Training in Urology (TiU) to train basic skills needed in urological laparoscopy
- E-BLUS examination and certification
- An online theoretical course

Personalised medicine in urological oncology

Thematic session 01

Sunday, 26 March
10:30 - 12:00

Location: Room Madrid, North Hall (Level 1)

Chairs: Z. Culig, Innsbruck (AT)
J.A. Schalken, Nijmegen (NL)

Aims and objectives of this presentation

Individualized therapy in prostate cancer should be based on our knowledge about overexpressed oncogenes. The session will highlight importance of the transcription factor ERG and cytokines which may be targeted in experimental models and in clinical settings. Furthermore, the speakers will address issues related to scientific background of radiation therapy in prostate cancer.

10:30 - 10:50

State-of-the-art lecture **How to select prostate cancer patients for radiation therapy?**
A. Dubrovskaya, Dresden (DE)

10:50 - 11:10

State-of-the-art lecture **Personalised approach to antagonising ERG in prostate cancer**
G. Carbone, Bellinzona (CH)

11:10 - 11:30

State-of-the-art lecture **Individualisation of anti-cytokine treatment in prostate cancer**
A. Bjartell, Malmö (SE)

11:30 - 11:45

Panel discussion **Using translational research to optimise treatment for patients with prostate cancer**

Panel: A. Bjartell, Malmö (SE)
G. Carbone, Bellinzona (CH)
A. Dubrovskaya, Dresden (DE)

11:45 - 12:00

Associated abstract presentations

*754

Systems pharmacology and quantitative proteomics for developing targeted triple therapy

By: [Ehardt H.A.](#)¹, [Root A.](#)², [Beizaei A.](#)¹, [Liu Y.](#)³, [Gauthier N.](#)⁴, [Sander C.](#)⁴, [Aebersold R.](#)³

Institutes:¹University College Dublin, Systems Biology Ireland, Dublin, Ireland, ²Memorial Sloan-Kettering Cancer Center, Weill Cornell Graduate School of Medical Sciences, New York City, United States of America, ³ETH Zurich, Institute of Molecular Systems Biology, Zurich, Switzerland, ⁴Dana-Farber Cancer Institute, CBio Center At Dana-Farber, Boston, United States of America

State-of-the-art lecture

*747

Targeting enzalutamide-resistant prostate cancer using the novel androgen receptor inhibitor ODM-201

By: [Borgmann H.](#), [Ozistanbullu D.](#), [Beraldi E.](#), [Dalal K.](#), [Fazli L.](#), [Gleave M.](#)

Institutes: Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada

State-of-the-art lecture

Expert challenges expert

Thematic session 02

Sunday, 26 March
10:30 - 12:00

Location: Room Milan, North Hall (Level 1)

Chairs: B. Djavan, Vienna (AT)
G. Janetschek, Salzburg (AT)

Aims and objectives of this presentation

Salvage prostatectomy is technically more difficult than primary prostatectomy, and the complication rate is higher. The videos demonstrate that it can be performed by either open surgery or robot-assisted laparoscopy. The advantages and disadvantages of either technique will be discussed.

EPLND – the gold standard – has a false negative rate of at least 10%. This rate can be decreased by super extended PLND, but the price is decreased specificity, longer operative time, and possibly a higher complication rate. The solution may be targeted PLND such as sentinel PLND which allows to increase specificity, sensitivity and accuracy. Two different concepts of sentinel PLND will be presented.

10:30 - 11:15 **Salvage prostatectomy - How I do it?**

10:30 - 10:50 **Open salvage prostatectomy**

10:30 - 10:50 **Presenter**
A. Heidenreich, Cologne (DE)

10:30 - 10:50 **Discussant**
D. Murphy, Melbourne (AU)

10:50 - 11:10 **Robotic salvage prostatectomy**

10:50 - 11:10 **Presenter**
D. Murphy, Melbourne (AU)

10:50 - 11:10 **Discussant**
A. Heidenreich, Cologne (DE)

11:10 - 11:15 **Discussion**

11:15 - 12:00 **Extent of primary lymph node dissection**

11:15 - 11:35 **Sentinel node**

11:15 - 11:35 **Presenter**
H.G. Van Der Poel, Amsterdam (NL)

11:15 - 11:35 **Discussant**

N. Fossati, Milan (IT)

11:35 - 11:55

Extended lymph node dissection

11:35 - 11:55

Presenter

N. Fossati, Milan (IT)

11:35 - 11:55

Discussant

H.G. Van Der Poel, Amsterdam (NL)

11:55 - 12:00

Discussion

Urogenital reconstructions

Thematic session 03

Sunday, 26 March
10:30 - 12:00

Location: Room Paris, North Hall (Level 1)

Chairs: R. Djinovic, Belgrade (RS)
A.R. Mundy, London (GB)

Aims and objectives of this presentation

This session deals with some acuter urological traumatic issues. The first is a classic and will deal with the moment of reconstruction of posterior urethral injuries.

The debate highlights when it is imperative to insert a suprapubic catheter in the acute phase of a pelvic fracture related urethral injury. In addition, it will discuss when suprapubic catheter is preferred above or can be considered as alternative to direct realignment. The state of the art lectures deal with possible reconstruction after Fournier's gangrene and after penile cancer.

10:30 - 11:10

Debate Acute management of a posterior urethral injury after pelvic fracture

10:30 - 10:50

Direct alignment

F. Campos Juanatey, Santander (ES)

10:50 - 11:10

Suprapubic catheter first

N. Lumen, Ghent (BE)

11:10 - 11:30

State-of-the-art lecture Fournier's gangrene: Treatment and surgical reconstruction

To be confirmed

11:30 - 11:50

State-of-the-art lecture Penile reconstruction after trauma and cancer

M. Ninkovic, Munich (DE)

11:50 - 12:00

Associated abstract presentation

*279

Comparative assessment of postoperative erectile function and quality of life in male one-stage onlay vs. inlay buccal mucosal graft urethroplasty

By: Vetterlein M., Rosenbaum C., Gild P., Meyer C., Ludwig T., Loewe C., Aziz A., Engel O., Dahlem R., Fisch M., Kluth L.

Institutes: University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany

State-of-the-art lecture

OAB: What matters in diagnosis and treatment

Thematic session 04

Sunday, 26 March
10:30 - 12:00

Location: Room Amsterdam, North Hall (Level 1)

Chairs: J-N.L. Cornu, Rouen (FR)
F. Cruz, Porto (PT)

Aims and objectives of this presentation

OAB is a common symptom complex that includes urgency, frequency, nocturia and urgency incontinence. Despite the fact that it is highly prevalent in both genders, its cause is still unclear. Tests that may help clinicians to identify the origin of OAB symptoms are still uncertain but need to be explored if the more specific treatments are to be discovered and prescribed. The better cause by OAB symptoms is crucial for planning a correct management of the condition and this may call for the use of patient reported outcomes

10:30 - 10:45

State-of-the-art lecture Multiple comorbidity and OAB: What matters to patients and GP's?
J-N.L. Cornu, Rouen (FR)

10:45 - 11:00

State-of-the-art lecture Which urodynamic parameters correlate with OAB severity?
M.J. Drake, Bristol (GB)

11:00 - 11:15

State-of-the-art lecture Biomarkers for OAB
K. Monastyrskaya, Bern (CH)

11:15 - 11:45

Case discussion Outcomes for medical treatment in OAB

11:15 - 11:30

OAB: What outcomes are important?
K. Rademakers, Maastricht (NL)

11:30 - 11:45

Patient Reported Outcome Measures (PROMs) in OAB: What are we measuring?
C. Kelleher, London (GB)

11:45 - 12:00

State-of-the-art lecture Innovation in neuromodulation
S. Elneil, London (GB)

Adrenal disorders

Thematic session 05

Sunday, 26 March
10:30 - 12:00

Location: Room Berlin, North Hall (Level 1)

Chairs: To be confirmed
J.P.F.A. Heesakkers, Nijmegen (NL)

Aims and objectives of this presentation

Adrenal surgery is not that common in urological practice. Is it done for endocrine pathologies but also for malignant indications. Experts in the field will share their experience on diagnostics, indications and assessment of the adrenal glands. To boost the interest in adrenal surgery a high quality submitted abstract was selected that will be presented by a young colleague.

10:30 - 10:50

State-of-the-art lecture Adrenal cortical carcinoma
F. Porpiglia, Turin (IT)

10:50 - 11:10

State-of-the-art lecture Management of adrenal incidentalomas
To be confirmed

11:10 - 11:30

State-of-the-art lecture Indications for partial adrenalectomy
A.S. Gözen, Heilbronn (DE)

11:30 - 11:50

State-of-the-art lecture Open, laparoscopic or robotic treatment of adrenal tumours?
H. Langenhuijsen, Nijmegen (NL)

11:50 - 12:00

Associated abstract presentation

Immuno-oncology: Changing treatment paradigms in renal and urothelial cancer

Thematic session 06

Sunday, 26 March
10:30 - 12:00

Location: Room Vienna, North Hall (Level 1)

Chairs: M. De Santis, Coventry (GB)
M. Kuczyk, Hanover (DE)

Aims and objectives of this presentation

This session deals with new immunotherapeutical approaches at renal and bladder cancer. For renal cancer, insights the mechanisms of action, the efficacy of these treatment modalities in comparison with established TKI therapy for different indications including the application within a sequential setting should be delivered. For bladder cancer, it should become obvious to what extent and for which indications immunotherapeutic approaches can be expected to replace conventional approaches at the treatment of metastatic disease.

10:30 - 10:40

State-of-the-art lecture Immunotherapy - Impact from oncologist's point of view
J. Larkin, London (GB)

11:10 - 11:25

State-of-the-art lecture Biomarkers for treatment selection
S. Shariat, Vienna (AT)

11:25 - 11:40

State-of-the-art lecture Is there still a role for chemotherapy?
A. Bamias, Athens (GR)

10:40 - 10:50

State-of-the-art lecture Immunotherapy - Impact from surgeon's point of view
F-C.E. Von Rundstedt, Jena (DE)

11:40 - 11:55

State-of-the-art lecture How will immunotherapy change the treatment paradigm?
R. Jones, Glasgow (GB)

10:50 - 11:00

State-of-the-art lecture Immunotherapy - Open questions and trials
L. Albiges, Villejuif (FR)

11:00 - 11:10

Discussion

11:10 - 12:00

Urothelial cancer

11:55 - 12:00

Discussion

Paediatric urology

Thematic session 07

Sunday, 26 March
10:30 - 12:00

Location: Room London, North Hall (Level 1)

Chairs: G. Bogaert, Leuven (BE)
W.F.J. Feitz, Nijmegen (NL)

Aims and objectives of this presentation

Paediatric Urology 2017 session will give you the latest update in the field of pediatric urology and life long care developments for patients with congenital urological anomalies.

10:30 - 10:45

State-of-the-art lecture **Dartos and androgens in congenital penile malformations**
A-F. Spinoit, Gent (BE)

10:45 - 11:00

State-of-the-art lecture **Recent advances in the surgical treatment of pediatric stone disease**
M.S. Silay, Istanbul (TR)

11:00 - 11:15

State-of-the-art lecture **Varicocele aspects in children and adolescence**
G. Bogaert, Leuven (BE)

11:15 - 11:30

State-of-the-art lecture **Functional assessment and challenges of revision surgery following surgery in childhood**
J.M. Nijman, Groningen (NL)

11:30 - 11:45

State-of-the-art lecture **The quest for normality - Thoughts on congenital urological anomalies and how we manage patient expectations**
D.N. Wood, London (GB)

11:45 - 12:00

State-of-the-art lecture **Long-term outcome of pediatric urology anomalies and future prospects**
S. Tekgöl, Ankara (TR)

Challenges in urinary tract reconstruction

Thematic session 08

Sunday, 26 March
10:30 - 12:00

Location: Room Stockholm, North Hall (Level 1)

Chairs: H. Botto, Suresnes (FR)
K.G.W. Månsson, Lund (SE)

Aims and objectives of this presentation

This session will analyze the causes of some problems seen after urinary diversion and suggest techniques how to solve them. Pros and cons of some methods for diversion will be discussed.

10:30 - 10:45

State-of-the-art lecture **Management of idiopathic retroperitoneal fibrosis**
A. Fernando, London (GB)

10:45 - 11:15

Case discussion **Tips and tricks for stomal hernia**

10:45 - 10:55

How to avoid
M. Gallucci, Rome (IT)

10:55 - 11:15

How to fix
J.P. Bedke, Tübingen (DE)

11:15 - 11:30

State-of-the-art lecture **Catheterisable stoma in adults: Facts and fiction**
E. Chartier-Kastler, Paris (FR)

11:30 - 12:00

Debate **Cutaneous ureterostomy**

11:30 - 11:45

This is a good technique and should be used
A. Pycha, Bolzano (IT)

11:45 - 12:00

This is a complication-filled technique and we should think about something else
C. Llorente, Madrid (ES)

Individualised treatment for prostate cancer

Thematic session 09

Sunday, 26 March
10:30 - 12:00

Location: Room Munich, North Hall (Level 1)

Chairs: C.H. Bangma, Rotterdam (NL)
J. N'Dow, Aberdeen (GB)

Aims and objectives of this presentation

In low risk prostate cancer various factors may influence the decisions to commit to active surveillance or not. In this session we aim to illustrate the relative contribution of imaging and biomarkers to identify the best individuals to follow an AS protocol. The audience will be able to decide themselves if it is useful, and when, to introduce new diagnostic modalities, or not to start AS at all for a single patient.

10:30 - 10:45

State-of-the-art lecture **Comorbidity assessment and clinical patient profiles in decision making**
P. Mongiat-Artus, Paris (FR)

10:45 - 11:15

Case discussion **Can MRI replace the use of repeat biopsy in active surveillance?**

10:45 - 10:55

Case presenter
M. Valerio, London (GB)

10:55 - 11:05

Pro
C. Moore, London (GB)

11:05 - 11:15

Con
G. Giannarini, Udine (IT)

11:15 - 11:30

State-of-the-art lecture **Using biomarkers in the era of MRI**
Y. Fradet, Quebec (CA)

11:30 - 11:45

State-of-the-art lecture **Genetic markers: Worth the effort and the cost?**
P.J. Boström, Turku (FI)

11:45 - 12:00

Conclusions

Surgery-in-Motion-School Session

European Urology session

Sunday, 26 March
10:45 - 12:45

Location: Room Copenhagen, North Hall (Level 1)

10:45 - 11:15

Male cystectomy

N.P. Wiklund, Stockholm (SE)
J.W.F. Catto, Sheffield (GB)
A. Mottrie, Aalst (BE)
J. Palou, Barcelona (ES)

11:15 - 11:45

Female cystectomy

N.P. Wiklund, Stockholm (SE)
J.W.F. Catto, Sheffield (GB)
A. Mottrie, Aalst (BE)
J. Palou, Barcelona (ES)

11:45 - 12:15

Ileal conduit

N.P. Wiklund, Stockholm (SE)
J.W.F. Catto, Sheffield (GB)
A. Mottrie, Aalst (BE)
J. Palou, Barcelona (ES)

12:15 - 12:45

Neobladder

N.P. Wiklund, Stockholm (SE)
J.W.F. Catto, Sheffield (GB)
A. Mottrie, Aalst (BE)
J. Palou, Barcelona (ES)

E-BLUS Exam

HOT10

Sunday, 26 March
11:00 - 12:00

Location: Room South America, Exhibition Hall (Level 1)

Aims and objectives of this presentation

The European training in basic laparoscopic urological skills (E-BLUS) is a programme offered to residents and urologists who want to improve the basic skills in laparoscopy. It is a unique opportunity to train with international experts in laparoscopy. The E-BLUS programme includes:

- Hands-on Training (HOT) courses of different levels carried out under the guidance of experienced tutors
- A set of training-box exercises developed and validated by the Dutch project Training in Urology (TiU) to train basic skills needed in urological laparoscopy
- E-BLUS examination and certification
- An online theoretical course

What has changed in the non-oncology guidelines

ESU Course 21

Sunday, 26 March
12:00 - 14:00

Location: Room 10, Capital suite (level 3)

Chair: S. Gravas, Larissa (GR)

Aims and objectives of this presentation

At the end of this course, participants should be able to:

- Explain how the recommendations of Guidelines are formulated
- Understand how Guidelines are updated and the importance and limitations of scope search
- Review the clinical problems and the academic questions that clinical research tried to address in the Guidelines
- Be familiar with the strength of the evidence of the current Guidelines and the aspects that still need to be researched
- Highlight the changes and the gaps of the different guidelines discussed at the course
- Apply knowledge gained in this course to develop an evidence-based practice in the management of patients

A. Tubaro, Rome (IT)

G. Bonkat, Basel (CH)

UTUC: Diagnosis and management

ESU Course 22

Sunday, 26 March
12:00 - 14:00

Location: Room 11, Capital suite (level 3)

Chair: S. Shariat, Vienna (AT)

Aims and objectives of this presentation

This course will address contemporary concepts and controversies in UTUC such as

- Accurate staging and its role in clinical decision making/risk stratification
- Risks, benefits, and side effects of current and novel therapeutic approaches including endoscopic and minimal-invasive surgery
- Optimal management of the bladder cuff as well as indication and extent of lymphadenectomy
- Systemic therapy for high-risk and metastatic patients

12:00 - 14:00

Epidemiology, diagnosis, evaluation

M. Rouprêt, Paris (FR)

12:00 - 14:00

Prognostic and predictive factors, pathology

S. Shariat, Vienna (AT)

12:00 - 14:00

Treatment of low risk cancer (high grade Ta, T1 and CIS)

M. Rouprêt, Paris (FR)

12:00 - 14:00

Treatment of localized high risk (invasive) and metastatic cancer

S. Shariat, Vienna (AT)

Laparoscopy for beginners

ESU Course 23

Sunday, 26 March
12:00 - 14:00

Location: Room 12, Capital suite (level 3)

Chair: X. Cathelineau, Paris (FR)

Aims and objectives of this presentation

With the large widespread of mini-invasive surgery, improving knowledge of practical aspects of laparoscopy is mandatory.

Knowledge of:

- Indications and contra-indications of laparoscopic approach
- How to choose and use the instrumentation, in order to optimize the procedure and minimize adverse effects
- Air insufflations parameters and optimal access in laparoscopic urology
- How to prevent, recognize and manage complications

This course aims to provide all this knowledge in an interactive and practical way (video clip, open discussion), in order to assist beginners in laparoscopy shortening their learning curve and optimizing the success of their laparoscopic procedures.

- Laparoscopic surgery: For which patients and which procedures?
- Masterize the armentarium
- Tips and tricks to optimize the procedure
- New potential and future evolutions

12:00 - 14:00

Indications for laparoscopy

B.S.E.P. Van Cleynenbreugel, Wolfsdonk (BE)

12:00 - 14:00

Instrumentation and haemostatis

X. Cathelineau, Paris (FR)

12:00 - 14:00

Peritoneal access and effects of pneumoperitoneum

B.S.E.P. Van Cleynenbreugel, Wolfsdonk (BE)

12:00 - 14:00

Avoiding complications

X. Cathelineau, Paris (FR)

Basic surgical and endo urological skills

ESU Course 24

Sunday, 26 March
12:00 - 14:00

Location: Room 14, Capital suite (level 3)

Chair: L. Henningsohn, Stockholm (SE)

Aims and objectives of this presentation

The course is designed to apply basic surgical knowledge and principles in the initial development of urological training. It aims to provide learners with valuable basic skills in developing a safe and methodological approach to application of surgical knowledge.

- To familiarize oneself with all the basic surgical and endourological procedures.
- To understand the importance of previous medical history, anatomy and surgical technique for basic Urological procedures.
- To review indications, technical details and possible complications and management in basic surgical and endourological procedures.

12:00 - 14:00

Physical examination of the genitourinary tract

L. Henningsohn, Stockholm (SE)
R.E. Sanchez-Salas, Paris (FR)

12:00 - 14:00

Penile surgery

L. Henningsohn, Stockholm (SE)

12:00 - 14:00

Scrotal surgery

R.E. Sanchez-Salas, Paris (FR)

12:00 - 14:00

Basic endoscopic procedures (urethral catheterization, cystoscopy, nephrostomy)

L. Henningsohn, Stockholm (SE)
R.E. Sanchez-Salas, Paris (FR)

Testicular cancer

ESU Course 25

Sunday, 26 March
12:00 - 14:00

Location: Room 15, Capital suite (level 3)

Chair: P. Albers, Düsseldorf (DE)

Aims and objectives of this presentation

The ESU Course on Testicular Cancer will cover all important issues in the diagnosis and treatment of patients with germ cell cancer. There will be time for discussion during and after the presentations. Case reports will be discussed to highlight special situations of controversy. In addition, short video clips will be presented to demonstrate surgical techniques in retroperitoneal residual tumor resection.

In brief, following items will be presented and discussed:

- EAU Guideline recommended staging procedures and classifications like IGCCCG
- Stage-by-stage treatment of low stage disease including TIN
- Chemotherapy and indication of post chemotherapy surgery according to EAU guidelines
- Recommended follow-up investigations, long-term toxicities, 2nd malignancies

12:00 - 14:00

Testis cancer – early stages

N.W. Clarke, Manchester (GB)

12:00 - 14:00

Testis cancer – case discussion

N.W. Clarke, Manchester (GB)

12:00 - 14:00

Testis cancer - advanced stages

P. Albers, Düsseldorf (DE)

12:00 - 14:00

Testis cancer - case discussion

P. Albers, Düsseldorf (DE)

Management and outcome in invasive and locally advanced bladder cancer

ESU Course 26

Sunday, 26 March
12:00 - 14:00

Location: Room 16, Capital suite (level 3)

Chair: B. Malavaud, Toulouse (FR)

Aims and objectives of this presentation

MIBC is a multifaceted entity where one size no longer fits all, supporting the development of personalized and, in selected cases, organ-preserving strategies.

Are the advances in imaging, molecular biology, conservative surgery; medical oncology and radiotherapy strong enough to shift the current pre-eminence of the ablative approach toward a more integrated and conservative perspective? If yes, what are the ideal candidates?

- One size does not fit all and urologists are central to the development of personalized treatment in MIBC
- Patients selection is critical and based on advances in imaging, resection techniques and pathology
- Organ preservation is feasible in a significant proportion of patients
- Radical cystectomy and pre-emptive chemotherapy are essential to optimize results in aggressive conditions.

12:00 - 14:00

Cystectomy in the management of bladder invasive and locally advanced bladder cancer

M. Burger, Regensburg (DE)

12:00 - 14:00

Case discussion on cystectomy in the management of bladder invasive and locally advanced bladder cancer

B. Malavaud, Toulouse (FR)

12:00 - 14:00

Bladder sparing approaches to muscle invasive bladder cancer

M. Burger, Regensburg (DE)

12:00 - 14:00

Case discussion on bladder sparing approaches to muscle invasive bladder cancer

B. Malavaud, Toulouse (FR)

12:00 - 14:00

Cytotoxic chemotherapy in bladder cancer: Neoadjuvant and adjuvant setting and treatment of metastatic disease

B. Malavaud, Toulouse (FR)

Evaluation of risk in comorbidity in onco-urology

ESU Course 27

Sunday, 26 March
12:00 - 14:00

Location: Room 17, Capital suite (level 3)

Chair: N. Mottet, Saint-Étienne (FR)

Aims and objectives of this presentation

Senior adults represent a growing population with specific problems. Individual life expectancy is a key decision driver . . . provided it is approachable.

The key points to be covered are the following

- Age by itself is usually irrelevant, unlike comorbidities
- Survival predictive factor exist, combined in practical tools
- Reliable screening tools for geriatrician referral exist
- A multidisciplinary program with geriatricians is key

12:00 - 14:00

Introduction: Who we are, objectives

N. Mottet, Saint-Étienne (FR)

12:00 - 14:00

Senior adults: A growing population

S. O'Hanlon

12:00 - 14:00

Senior adults are undertreated

N. Mottet, Saint-Étienne (FR)

12:00 - 14:00

Age is not a key factor regarding major surgery (muscle invasive bladder experience)

N. Mottet, Saint-Étienne (FR)

12:00 - 14:00

Clinical cases (to set the scene): Evaluation of comorbidities in practice / individual life expectancy

N. Mottet, Saint-Étienne (FR)

S. O'Hanlon

12:00 - 14:00

How to evaluate individual life expectancy in practice

S. O'Hanlon

12:00 - 14:00

How to evaluate individual comorbidities in practice

S. O'Hanlon

12:00 - 14:00

An example of the added value of a dedicated program and its prerequisites / what to do in real life

S. O'Hanlon

12:00 - 14:00

Conclusion

N. Mottet, Saint-Étienne (FR)

Awards and prostate cancer targeted diagnosis and treatment

Video Session 06

Sunday, 26 March
12:15 - 13:45

Location: eURO Auditorium (Level 0)

Chairs: M. Emberton, London (GB)
A. Messas, Paris (FR)
C. Stief, Munich (DE)

Aims and objectives of this presentation

This session will be divided into two parts.

During the first part, we will see several communications concerning fusion biopsies, through different methods.

Then, we will go further with videos concerning focal treatment of prostate cancer.

In the Second part will show the videos and reward the authors for the 3 best videos presented during the congress. Don't miss these amazing video communications that will be exclusively presented during this award session.

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

*V41

MRI/US fusion transperineal prostate biopsies under local anesthesia

By: [Bianco F.](#)¹, Debruyne F.², Martinez-Ballesteros C.³, Lozano-Kaplun S.⁴, Cedeno J.³, Kaufman A.⁴, Carballido J.³, Scher J.⁴, Martinez-Salamanca J.³

Institutes:¹Urological Research Network, Dept. of Urology, Miami Lakes, United States of America, ²Andros Institute, Dept. of Urology, Netherlands, The Netherlands, ³Universidad Autonoma Madrid, Dept. of Urology, Madrid, Spain, ⁴Urological Research Network, Dept. of Urology, Miami, United States of America

*V43

Single setting 3D MRI-US guided frozen section and focal cryoablation of the index lesion: Proof of principle and initial series

By: Lugnani F.¹, Misuraca L.¹, Ferriero M.¹, Panebianco V.², Del Monte M.², Sentinelli S.³, Gallucci M.¹, [Simone G.](#)¹

Institutes:¹Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ²Sapienza University of Rome, Dept. of Radiology, Rome, Italy, ³Regina Elena National Cancer Institute, Dept. of Pathology, Rome, Italy

*V44

Focal therapy with HIFU FocalOne device with MRI target fusion biopsy by KOELIS

By: [Potiron E.](#), Nevoux P., Rousseau T., Le Goguic G., Lacoste J.

Institutes:Clinique Urologique Nantes Atlantis, Nantes, France

*V45

Multiparametric magnetic resonance imaging in fusion with transrectal ultrasound fusion biopsy with the BioJet™ System for the detection of clinically significant prostate cancer. Technical details and initial results

By: [Russo A.](#)¹, Kinzikeeva E.¹, Maga T.¹, Losa A.¹, Pini G.¹, Cardone G.², Salonia A.³, Montorsi F.³, Briganti A.³, Suardi N.¹, Gaboardi F.¹

Institutes:¹Ospedale San Raffaele Turro, Dept. of Urology, Milan, Italy, ²Ospedale San Raffaele Turro, Dept. of Radiology, Milan, Italy, ³Urological Research Institute, IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy

*V46

MRI/US fusion office-based targeted cryoablation with local anesthesia

By: [Bianco F.](#), Lozano-Kaplun S., Cedeno J., Barashi N., Scher J., Kaufman A., Lopez A., Nicholson M.

Institutes:Urological Research Network, Dept. of Urology, Miami Lakes, United States of America

*V48

Robot assisted radical nephrectomy and inferior vena cava thrombectomy: Surgical technique, perioperative and oncologic outcomes

By: Simone G.¹, Misuraca L.¹, Hatcher D.², Ferriero M.¹, Minisola F.¹, Tuderti G.¹, Guaglianone S.¹, De Castro Abreu A.L.², Aron M.², Desai M.², Gill I.S.², Gallucci M.¹

Institutes:¹Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ²Keck School of Medicine, University of Southern California, Dept. of Urology, Los Angeles, United States of America

*V49

Trimodal (18) F-choline-PET/mpMRI/TRUS targeted prostate biopsies: First clinical experience

By: Bonnal J.L.¹, Marien A.¹, Rock A.¹, El Maadarani K.¹, Francois C.¹, Delebarre A.², Berssard D.², Mauroy B.¹, Gosset P.³, Blaire T.⁴

Institutes:¹Hopital Saint Philibert, Dept. of Urology, Lomme, France, ²Hopital Saint Philibert, Dept. of Radiology, Lomme, France, ³Hopital Saint Vincent, Dept. of Pathology, Lille, France, ⁴Hopital Saint Philibert, Dept. of Nuclear Medicine, Lomme, France

Modern tools and new evidence in staging of urothelial carcinomas

Poster Session 29

Sunday, 26 March
12:15 - 13:45

Location: Room Madrid, North Hall (Level 1)

Chairs: M.J. Ribal, Barcelona (ES)
D.J. Rosario, Sheffield (GB)
T. Seisen, Paris (FR)

Aims and objectives of this presentation

The proper diagnostic pathway, including demands for pathology and imaging, is an ongoing debate in bladder cancers.

Non muscle invasive papillary tumours confined to the mucosa and invading the lamina propria are classified as stage Ta and T1, respectively, according to the Tumour, Node, Metastasis (TNM) classification system. Flat, high-grade tumours that are confined to the mucosa are classified as CIS (Tis). New molecular biology techniques and clinical experience can pinpoint the highly malignant potential of selected CIS and T1 lesions. In muscle invasive bladder cancer both computed tomography (CT) and magnetic resonance imaging (MRI) may be used to detect T3b or higher disease. However, assessment of lymph node metastases with CT or MRI based on size and morphology has its limitations. This session aims to highlight new insights in the work-up of these tumors.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

*380

Prognostic impact of a 12-gene progression score in non-muscle invasive bladder cancer: A prospective multicenter validation study

By: Dyrskjöt L.², Reinert T.², Algaba F.³, Christensen E.², Nieboer D.⁴, Hermann G.⁵, Morgensen K.⁵, Marquez M.⁶, Segersten U.⁷, Hoyer S.⁸, Ulhøj B.⁸, Hartmann A.⁹, Stöhr R.⁹, Wach S.¹⁰, Nawroth R.¹¹, Beukers W.²⁰, Schwamborn K.¹², Tulic C.¹³, Simic T.¹⁴, Junker K.¹⁵, Harving N.¹⁶, Petersen A.C.¹⁷, Jensen J.B.¹⁸, Keck B.¹⁰, Horstmann M.¹, Maurer T.¹⁹, Steyerberg E.⁴, Zwarthoff E.²⁰, Real F.⁶, Malats N.²¹, Malmström P-U.⁷, Ørntoft T.F.²

Institutes:¹Friedrich Schiller University of Jena, Dept. of Urology, Jena, Germany, ²Aarhus University Hospital, Dept. of Molecular Medicine, Aarhus, Denmark, ³University Autònoma de Barcelona, Section of Pathology, Fundació Puigvert, Barcelona, Spain, ⁴Erasmus MC, Dept. of Public Health, Rotterdam, The Netherlands, ⁵Frederiksberg Hospital, Dept. of Urology, Frederiksberg, Denmark, ⁶Spanish National Cancer Research Centre, CNIO, Madrid, Spain, ⁷Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden, ⁸University of Aarhus, Dept. of Pathology, Aarhus, Denmark, ⁹University Hospital of Erlangen, Dept. of Pathology, Erlangen-Nürnberg, Germany, ¹⁰University Hospital Erlangen, Dept. of Urology, Erlangen, Germany, ¹¹Klinikum Rechts Der Isar, Technical University of Munich, Dept. of Urology, Munich, Germany, ¹²Klinikum Rechts Der Isar, Technical University of Munich, Dept. of Pathology, Munich, Germany, ¹³Faculty of Medicine, University of Belgrade, Dept. of Urology, Belgrade, Serbia, ¹⁴Faculty of Medicine, University of Belgrade, Institute of Medical and Clinical Biochemistry, Belgrade, Serbia, ¹⁵Saarland University, Dept. of Urology, Homburg, Germany, ¹⁶Aalborg University Hospital, Dept. of Urology, Aalborg, Denmark, ¹⁷Aalborg University Hospital, Dept. of Pathology, Aalborg, Denmark, ¹⁸Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, ¹⁹Klinikum Rechts Der Isar, Technical University of Munich, Dept. of Urology, Munich, Germany, ²⁰Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands, ²¹Universitat Pompeu Fabra, Dept. of Experimental Science, Barcelona, Spain

*381

11C-acetate PET-MRI in bladder cancer staging

By: Salminen A.¹, Jambor I.², Merisaari H.³, Ettala O.¹, Virtanen J.², Koskinen I.⁴, Veskimäe E.⁵, Sairanen J.⁴, Minn H.⁶, Kempainen J.⁷, Boström P.¹

Institutes:¹Turku University Hospital, Dept. of Urology, Turku, Finland, ²Turku University Hospital,

Dept. of Diagnostic Radiology, Turku, Finland, ³University of Turku, Dept. of Information Technology, Turku, Finland, ⁴Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, ⁵Tampere University Hospital, Dept. of Urology, Tampere, Finland, ⁶Turku University Hospital, Dept. of Clinical Oncology, Turku, Finland, ⁷Turku University Hospital, Dept. of Clinical Physiology, Nuclear Medicine and PET Imaging, Turku, Finland

- *382 **Metric sub-stage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer**
By: Fransen Van De Putte E.¹, Van Der Kwast T.², Bertz S.³, Denzinger S.⁴, Manach Q.⁵, Compérat E.⁶, Boormans J.⁷, Jewett M.⁸, Stoehr R.³, Zlotta A.⁹, Hendricksen K.¹, Rouprêt M.⁵, Otto W.⁴, Burger M.⁴, Hartmann A.³, Van Rhijn B.¹
Institutes:¹Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ²University of Toronto, Princess Margaret Cancer Center, Dept. of Pathology, Toronto, Canada, ³University of Erlangen, Dept. of Pathology, Erlangen, Germany, ⁴University of Regensburg, Caritas Krankenhaus St. Joseph, Dept. of Urology, Regensburg, Germany, ⁵Hôpital Universitaire Pitié-Salpêtrière, Dept. of Urology, Paris, France, ⁶Hôpital Universitaire Pitié-Salpêtrière, Dept. of Pathology, Paris, France, ⁷Erasmus Medical Center, Dept. of Urology, Rotterdam, The Netherlands, ⁸University of Toronto, Princess Margaret Cancer Center, Dept. of Surgery (Urology), Toronto, Canada, ⁹University of Toronto, Mount Sinai Hospital, Dept. of Surgery (Urology), Toronto, Canada
- *383 **A panel of micro-RNA signature as a tool for predicting survival of patients with urothelial carcinoma of the bladder**
By: Inamoto T.¹, Takahara K.², Ibuki N.², Takai T.², Uchimoto T.², Saito K.², Tanda N.², Yoshikawa Y.², Minami K.², Hirano H.², Nomi H.², Azuma H.²
Institutes:¹Osaka Medical College, Osaka, Japan, ²Osaka Medical College, Dept. of Urology, Osaka, Japan
- *384 **Using the EORTC risk tables & the CUETO scoring model for predicting recurrence and progression in non-muscle invasive bladder cancer: A local single centre experience**
By: Lee S.L., Lim S.K., Ng K.K., Ng F.C.
Institutes:Changi General Hospital, Dept. of Urology, Singapore, Singapore
- *385 **Using liquid biopsy to assess the genomic landscape of metastatic urothelial carcinoma**
By: Todenhöfer T.¹, Vandekerckhove G.², Struss W.², Annala M.², Beja K.², Eigl B.², Mischinger J.¹, Stenzl A.¹, Black P.², Wyatt A.²
Institutes:¹Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany, ²University of British Columbia, Vancouver Prostate Centre, Vancouver, Canada
- *386 **Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) and morphological imaging in recurrent urothelial carcinomas: A retrospective, multi-center study**
By: Zattoni F.¹, Ficarra V.², Briganti A.³, Colicchia M.⁴, Fanti S.⁵, Karnes R.J.⁴, Incerti E.⁶, Lowe V.⁷, Moschini M.³, Panareo S.⁸, Picchio M.⁶, Rambaldi I.⁹, Schiavina R.¹⁰, Zattoni F.¹², Evangelista L.¹¹
Institutes:¹University of Padua, Dept. of Surgery, Oncology and Gastroenterology, Padua, Italy, ²University of Udine, Dept. of Experimental and Clinical Medical Sciences, Udine, Italy, ³Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, ⁴Mayo Clinic, Dept. of Urology, Rochester, United States of America, ⁵Sant'Orsola-Malpighi Hospital, Dept. of Nuclear Medicine, Bologna, Italy, ⁶IRCCS Ospedale San Raffaele, Dept. of Nuclear Medicine, Milan, Italy, ⁷Mayo Clinic, Dept. of Nuclear Medicine, Rochester, United States of America, ⁸University Hospital of Ferrara, Dept. of Diagnostic Imaging E Laboratory Medicine, Ferrara, Italy, ⁹University Hospital of Ferrara, Nuclear Medicine Unit, Diagnostic Imaging E Laboratory Medicine Department, Ferrara, Italy, ¹⁰Sant'Orsola-Malpighi Hospital, Dept. of Urology, Bologna, Italy, ¹¹Veneto Institute of Oncology IOV – IRCCS, Nuclear Medicine and Molecular Imaging Unit, Padua, Italy, ¹²University of Padua, Dept. of Surgery, Oncology, and Gastroenterology, Padua, Italy
- *387 **Prognostic impact of immunohistochemical classification of bladder cancer according to luminal (Uroplakin III) and basal (Cytokeratin 5/6) markers**

By: Hayashi T.¹, Sentani K.², Kakumoto S.¹, Oo H.Z.³, Sakamoto N.², Mutaguchi K.⁴, Kobatake K.¹, Goto K.¹, Inoue S.¹, Teishima J.¹, Yasui W.², Black P.C.³, Matsubara A.¹
Institutes:¹Hiroshima University, Dept. of Urology, Hiroshima, Japan, ²Hiroshima University, Dept. of Molecular Pathology, Hiroshima, Japan, ³Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada, ⁴Nakatsu Daiichi Hospital, Dept. of Urology, Nakatsu, Japan

*388

Validation of preoperative thrombocytosis as adverse prognostic factor in advanced bladder cancer (BCA) after radical cystectomy (RC)

By: Foerster B.¹, Moschini M.¹, Abufaraj M.¹, Soria F.¹, Lotan Y.², Karakiewicz P.³, Briganti A.⁴, Babjuk M.⁵, Rink M.⁶, Kluth L.⁶, John H.⁷, Shariat S.¹

Institutes:¹Medical University of Vienna, Dept. of Urology, Vienna, Austria, ²University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ³University of Montreal, Dept. of Urology, Montreal, Canada, ⁴Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, ⁵Faculty Hospital Motol, Second Faculty of Medicine, Charles University In Praha, Dept. of Urology, Prague, Czech Republic, ⁶University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ⁷Kantonsspital Winterthur, Dept. of Urology, Winterthur, Switzerland

*389

Preoperative hemoglobin to platelet ratio as a predictor of survival after radical cystectomy due to bladder cancer, synergic effect of anemia and thrombocytosis

By: La Croce G.¹, Moschini M.¹, Dell'oglio P.¹, Nini A.¹, Bandini M.¹, Capogrosso P.¹, Ventimiglia E.¹, Sanchez-Salas R.², Salonia A.¹, Briganti A.¹, Montorsi F.¹, Gallina A.¹, Colombo R.¹

Institutes:¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²L'Institut Mutualiste Montsouris, Dept. of Urology, Paris, France

*390

Tumor regression grading after neoadjuvant chemotherapy in bladder cancer: Validation in an independent cohort

By: Seiler R., Oo H.Z., Todenhöfer T., Fazli L., Daugaard M., Black P.

Institutes:University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada

*391

ADC value as a predictive marker for regional lymphnode metastasis of bladder cancer

By: Masaaki E.¹, Sakamoto S.², Sekita N.¹, Sato H.¹, Kono H.¹, Nishikawa R.¹, Takeuchi N.², Suzuki H.³, Mikami K.⁴, Ichikawa T.²

Institutes:¹Chibaken Saiseikai Narashino Hospital, Dept. of Urology, Narashino, Japan, ²Chiba University, Dept. of Urology, Chiba, Japan, ³Toho University Medical Center, Sakura Hospital, Dept. of Urology, Sakura, Japan, ⁴Chibaken Saiseikai Narashino Hospital, Dept. of Urology, Sakura, Japan

*392

The effects of 18f-fdg pet/ct on the management and prognosis of patients with bladder cancer (bca) and upper urinary tract urothelial carcinoma (utuc)

By: Zattoni F.¹, Briganti A.², Colicchia M.³, Castellucci P.⁴, Ficarra V.⁵, Karnes R.J.³, Fallanca F.⁶, Lowe V.⁷, Massari F.⁸, Gallina A.², Bartolomei M.⁹, Picchio M.⁶, Ippolito C.¹⁰, Schiavina R.¹¹, Zattoni F.¹², Evangelista L.¹³

Institutes:¹University of Padua, Dept. of Surgery, Oncology, and Gastroenterology, Padova, Italy, ²URI, IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, ³Mayo Clinic, Dept. of Urology, Rochester, Mn, United States of America, ⁴Sant'Orsola-Malpighi Hospital, Dept. of Nuclear Medicine, Bologna, Italy, ⁵University of Udine, Dept. of Experimental and Clinical Medical Sciences, Udine, Italy, ⁶IRCCS Ospedale San Raffaele, Milan, Italy, Dept. of Nuclear Medicine, Milan, Italy, ⁷Mayo Clinic, Dept. of Nuclear Medicine, Rochester, Mn, United States of America, ⁸S. Orsola-Malpighi Hospital, Dept. of Medical Oncology, Bologna, Italy, ⁹University Hospital of Ferrara, Dept. of Diagnostic Imaging E Laboratory Medicine, Ferrara, Italy, ¹⁰University- Hospital of Ferrara, Dept. of Surgery, Ferrara, Italy, ¹¹Sant'Orsola-Malpighi Hospital, Dept. of Urology, Bologna, Italy, ¹²University of Padua, Dept. of Surgery, Oncology, and Gastroenterology, Padua, Italy, ¹³Veneto Institute of Oncology IOV – IRCCS, Nuclear Medicine and Molecular Imaging Unit, Padua, Italy

13:30 - 13:37

Summary

D.J. Rosario, Sheffield (GB)

Insights into epidemiology and pathophysiology of LUTS

Poster Session 30

Sunday, 26 March
12:15 - 13:45

Location: Room Milan, North Hall (Level 1)

Chairs: C. De Nunzio, Rome (IT)
M. Gacci, Florence (IT)
T. Matsuo, Nagasaki (JP)

Aims and objectives of this presentation

The aims and objectives of this session is to achieve new data on pathophysiology of non neurogenic LUTS, with a special focus on metabolic syndrome as new target for behavioural treatments of LUTS, including diet and lifestyle

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *393 **The prevalence and progression of lower urinary tract symptoms in an ageing population – results from the European Randomized study of Screening for Prostate Cancer (Rotterdam)**
By: [Venderbos L.](#), Bangma C., Roobol M.
Institutes:Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands
- *394 **Management of LUTS in men in a nationwide cohort with 10 years follow-up: Lessons from clinical practice**
By: [Cornu J-N.L.](#)¹, Vicaut E.², Portal J-J.², Gabbas M.³, Tuppin P.³, Doizi S.⁴, Lukacs B.⁴
Institutes:¹CHU de Rouen - Hôpital Charles Nicolle, Dept. of Urology, Rouen, France, ²Fernand Widal Hospital, Dept. of Biostatistics and Clinical Research, Paris, France, ³National Health Insurance, Data Management, Paris, France, ⁴Tenon Hospital, Dept. of Urology, Paris, France
- *395 **Who is likely to be safe on conservative management for LUTS-BPH?**
By: [Rosier P.](#)
Institutes:UMC Utrecht, Dept. of Urology, Utrecht, The Netherlands
- *396 **Development of an electronic bladder diary app for smart-phone: A pilot study**
By: [Mateu Arrom L.](#)¹, Peri L.², Franco A.², López-Fando L.³, Alcaraz A.²
Institutes:¹Hospital Clínic Barcelona - Hospital Plató, Dept. of Urology, Barcelona, Spain, ²Hospital Clínic Barcelona, Dept. of Urology, Barcelona, Spain, ³Hospital Ramón Y Cajal, Dept. of Urology, Madrid, Spain
- *397 **Analysis of the relationship between benign prostatic hyperplasia/lower urinary tract symptoms and total serum testosterone level**
By: [De Nunzio C.](#), Presicce F., Lombardo R., Tema G., Bellangino M., Cancrini F., Nacchia A., Tubaro A.
Institutes:Sant' Andrea Hospital - Sapienza University, Dept. of Urology, Rome, Italy
- *398 **Metabolic syndrome and smoking are associated with an increased risk of nocturia in male patients with benign prostatic enlargement**
By: [De Nunzio C.](#), Presicce F., Bellangino M., Cancrini F., Tema G., Brassetti A., Proietti F., Esperto F., Deroma M., Lombardo R., Tubaro A.
Institutes:Sant' Andrea Hospital - Sapienza University, Dept. of Urology, Rome, Italy
- *399 **Effect of restricted salt intake on nocturia**
By:

Tomohiro M., Nakamura Y., Yasuda T., Ohba K., Miyata Y., Sakai H.

Institutes:Nagasaki University School of Medicine, Dept. of Urology, Nagasaki, Japan

*400

Effect of weight reduction in lower urinary tract symptoms among men who underwent bariatric surgery

By: Yee C-H., Liu S.Y-W., Teoh J.Y-C., Chiu P.K-F., Chan E.S-Y., Chan C-K., Hou S-M., Wong S.K-H., Ng E.K-W., Ng C-F.

Institutes:Prince of Wales Hospital, The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, Hong Kong

*401

Patients with nocturnal polyuria presented a different night-time and daytime bladder capacity: Implication for nocturia

By: Presicce E., De Nunzio C., Puccini F., Melchionna A., Lombardo R., Tubaro A.

Institutes:Sant' Andrea Hospital - Sapienza University, Dept. of Urology, Rome, Italy

*402

Urgency is a conclusive target for nocturia in male patients with lower urinary tract symptoms: Results from a multicenter prospective study

By: Kiuchi H., Ueda N., Soda T., Fukuhara S., Takao T., Tsujimura A., Miyagawa Y., Nonomura N.

Institutes:Osaka University, Dept. of Urology, Suita, Japan

*403

Lower urinary tract symptoms in patients with Parkinson's disease in a prospective study: Symptoms, urodynamics and considerations

By: Chunsong J., Cui X., Yan H., Wang Q., Li J., Cui B., Chen X., Ou T.

Institutes:Xuanwu Hospital Capital Medical University, Dept. of Urology, Beijing, China

*404

Studying the effect of Diabetes Mellitus type 2 on prostate related parameters: A prospective single institutional study

By: Elabbady A., Hashad M.M.E., Kotb A., Ghanem A.

Institutes:University of Alexandria, Dept. of Urology, Alexandria, Egypt

*405

Thyroid hormones and benign prostatic hyperplasia

By: Lee J-H.

Institutes:National Police Hospital, Dept. of Urology, Seoul, South Korea

*406

The association between lower urinary tract symptoms and cardiovascular risk factors in men

By: Yee C-H., Yip S-Y., Teoh J.Y-C., Chiu P.K-F., Chan C-K., Chan E.S-Y., Hou S-M., Ng C-F.

Institutes:Prince of Wales Hospital, The Chinese University of Hong Kong, Dept. of Surgery, Hong Kong, Hong Kong

Tailored stone treatment

Poster Session 31

Sunday, 26 March
12:15 - 13:45

Location: Room Paris, North Hall (Level 1)

Chairs: E. Montanari, Milan (IT)
P.J.S. Osther, Fredericia (DK)
A. Petřík, České Budějovice (CZ)

Aims and objectives of this presentation

ESWL, ureteroscopy, percutaneous nephrolithotomy or even laparoscopy? A tailored, individualized treatment plan should be the aim, although all modalities can be used for most stones.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *407 **Asymptomatic renal stones: long term follow up from a tertiary hospital**
By: [Darrad M.](#), Agyei M., Yallappa S., Subramonian K.
Institutes: Queen Elizabeth Hospital, Dept. of Urology, Birmingham, United Kingdom
- *408 **Follow-up care after ED visits for kidney stones – a missed opportunity**
By: [Hollingsworth J.](#), Yan P.L., Hollenbeck B.K., Ghani K.R.
Institutes: University of Michigan, Dept. of Urology, Ann Arbor, United States of America
- *409 **Acute renal colic, urinary tract infection and leucocytosis – Is there any relationship? A prospective trial**
By: [Schnabel M.J.](#), Rosenhammer B., Fritsche H.-M.
Institutes: Caritas Krankenhaus St. Josef, University of Regensburg, Dept. of Urology, Regensburg, Germany
- *410 **A multi-centre cohort study evaluating the role of inflammatory markers in patient's presenting with acute ureteric colic (MIMIC)**
By: [Shah T.](#)¹, O' Keeffe A.², Lamb B.¹, Cashman S.¹, Nambiar A.¹, Cumberbatch M.¹, Pang K.¹, Akman J.¹, Pickard R.³, Erotocritou P.⁴, Smith D.⁵, Kasivisvanathan V.¹
Institutes:¹British Urology Researchers In Surgical Training (BURST) Research Collaborative, Dept. of Urology, London, United Kingdom, ²University College London, Dept. of Statistical Science, London, United Kingdom, ³Newcastle University, Dept. of Urology, Newcastle, United Kingdom, ⁴Whittington Hospital, Dept. of Urology, London, United Kingdom, ⁵University College London Hospital, Dept. of Urology, London, United Kingdom
- *411 **Oral dissolution therapy (ODT) for lucent renal calculi; can we predict the outcome?**
By: Elsayy A., [Elshal A.](#), El-Nahas A., Abdel-Basset M., Farag H., Shokeir A.
Institutes: Mansoura University, Dept. of Urology, Mansoura, Egypt
- *412 **Day-case ureteroscopy (DC-URS) for stone disease: Outcomes from an university hospital**
By: [Ghosh A.](#)¹, Oliver R.¹, Way C.², White L.², Somani B.¹
Institutes:¹University Hospital Southampton NHS FT, Dept. of Urology, Southampton, United Kingdom, ²University Hospital Southampton NHS FT, Dept. of Anaesthesiology, Southampton, United Kingdom
- *413 **Comparison of success and complication rates between extracorporeal shock wave lithotripsy (ESWL) and flexible ureterorenoscopy (URS) for untreated renal calculi**
By:

Fankhauser C.¹, Hermanns T.¹, Lieger L.¹, Diethelm O.¹, Müntener M.², Umbehr M.², Luginbühl T.³, Sulser T.¹, Poyet C.¹

Institutes:¹University Hospital, University of Zurich, Dept. of Urology, Zurich, Switzerland, ²City Hospital Triemli of Zurich, Dept. of Urology, Zurich, Switzerland, ³Spital Uster, Dept. of Urology, Uster, Switzerland

- *414 **Ureteroscopy in pregnant women with complicated colic pain: A two center-matched retrospective study**
By: Buttice S.², ener T.E.¹, Laganà A.S.³, Vitale S.G.³, Netsch C.⁴, Tanidir Y.¹, Pappalardo R.², Magno C.²
Institutes:¹Marmara University School of Medicine, Dept. of Urology, Istanbul, Turkey, ²University of Messina, Dept. of Human Pathology, Section of Urology, Messina, Italy, ³University of Messina, Unit of Gynecology and Obstetrics, Department of Human Pathology In Adulthood and Childhood "G. Barresi", Messina, Italy, ⁴Asklepios Hospital Barmbek, Dept. of Urology, Hamburg, Germany
- *415 **Comparison of three surgical modalities for 20-25mm size lower pole stones: Retrograde intrarenal surgery (RIRS) vs mini-percutaneous nephrolithotomy (MPCNL) vs. percutaneous nephrolithotomy (PCNL), which is preferred?**
By: Choi J.Y., Ko Y.H., Song P.H., Moon K.H., Jung H.C.
Institutes:Yeungnam University College of Medicine, Dept. of Urology, Daegu, South Korea
- *416 **Retrograde intrarenal surgery and micro-percutaneous nephrolithotomy for renal lithiasis smaller than 2 cm**
By: Cepeda M., Amón J.H., Mainez J.A., De La Cruz B., Rodríguez V., Poza M., Alonso D., Martínez-Sagarra J.M.
Institutes:Río Hortega University Hospital, Dept. of Urology, Valladolid, Spain
- *417 **Transperitoneal laparoscopic ureterolithotomy vs. percutaneous antegrade ureteroscopy in the treatment of large proximal ureteral calculi: A prospective randomized comparative study**
By: El Harrech Y., Abaka N., Ghoundale O., Touiti D.
Institutes:Military Hospital Avicenne, Dept. of Urology, Marrakech, Morocco
- *418 **Retroperitoneal laparoscopic ureterolithotomy versus semi rigid URS with laser lithotripsy in management of upper ureteric stone 2 cm or more: A prospective comparative study**
By: Sakr A., Omran M., Fawzi A., Desoky E., Youssef M., Seleem M., Elgalaly H., Eliwa A., Ragab A., Elkady E.
Institutes:Zagazig University Hospital, Dept. of Urology, Zagazig, Egypt
- *419 **Transperitoneal laparoscopic pyelolithotomy versus retrograde intrarenal surgery for treatment of renal pelvis stones in horseshoe kidneys: A prospective randomized study**
By: Fawzi A.M., Sakr A., Eliwa A., Omran M., Youssef M., Desoky E., Seleem M.
Institutes:Zagazig University, Dept. of Urology, Zagazig, Egypt
- *420 **Live surgical demonstrations do not compromise patients safety: Results from a 5 year experience in 151 urinary stone cases**
By: Zanetti S.P.¹, Legemate J.², Kamphuis G.², Beard J.², Montanari E.¹, Traxer O.³, De La Rosette J.²
Institutes:¹Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico, Dept. of Urology, Milan, Italy, ²AMC Academic Hospital, Dept. of Urology, Amsterdam, The Netherlands, ³Hôpital Tenon, Dept. of Urology, Paris, France
- *421 **The usefulness of limited field low-dose noncontrast computerized tomography for monitoring ureteral stones**
By: Cho D.S.¹, Kim S.I.², Kim S.J.²
Institutes:¹Bundang Jesaeng General Hospital, Dept. of Urology, Seongnam, South Korea, ²Ajou University School of Medicine, Dept. of Urology, Suwon, South Korea
- *423 **What are the benefits and harms of ureteroscopy (URS) compared with shock-wave lithotripsy**

(SWL) in the treatment of upper ureteral stones: A systematic review

By: Drake T.

Institutes: Royal Bournemouth Hospital, Dept. of Urology, Bournemouth, United Kingdom

Pelvic pain and bladder pain syndrome

Poster Session 32

Sunday, 26 March
12:15 - 13:45

Location: Room Amsterdam, North Hall (Level 1)

Chairs: A. Apostolidis, Thessaloniki (GR)
R. Dmochowski, Nashville (US)
A. Giannantoni, Perugia (IT)

Aims and objectives of this presentation

Pain has a serious impact on the quality of life of patients with bladder pain syndromes. Where do we stand?

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *424 **Efficacy of botulinum toxin A for the treatment of interstitial cystitis to improve quality of life: A systematic review**
By: [Ochoa Vargas D.C.](#)¹, Garcia Perdomo H.A.²
Institutes:¹Hospital Universitari Germans Trias i Pujol, Dept. of Urology, Barcelona, Spain, ²Universidad Del Valle, Dept. of Urology, Cali, Colombia
- *425 **Quetiapine fumarate extended release in the treatment of bladder painful syndrome with nonurological associated conditions: An exploratory study**
By: [Giannantoni A.](#), Gubbiotti M., Rossi De Vermandois J.A., Turco M., Quadrini F., Salvini E.
Institutes:University of Perugia, Dept. of Surgical and Biomedical Sciences, Urology and Andrology Section, Perugia, Italy
- *426 **Increased mRNA expression of transient receptor potential channels in the urothelium of patients with interstitial cystitis: Possible biomarker**
By: [Mitsui T.](#), Tsuchiya S., Sawada N., Ihara T., Kira S., Nakagomi H., Takeda M.
Institutes:University of Yamanashi, Dept. of Urology, Chuo-City, Japan
- *427 **Efficacy of treatment with Hyaluril in females with urethral syndrome: A prospective analysis comparing naive patients with subjects who experienced previous ineffective treatments**
By: [Palleschi G.](#), Carbone A., Leto A., Fuschi A., Salhi Y., Velotti G., Pajoncini C., Nallo S., Pastore A.L.
Institutes:Sapienza University of Rome, Dept. of Medico Surgical Sciences and Biotechnologies, Urology Unit, Latina, Italy
- *428 **Comparison of intravesical chondroitin sulfate and combined hyaluronic acid/chondroitin sulfate for interstitial cystitis/bladder pain syndrome**
By: Arslan B.¹, [Onuk O.](#)², Ozkan A.¹, Eroglu A.¹, Cetin B.¹, Hazar A.I.¹, Aydin M.¹
Institutes:¹Gop Taksim Training and Research Hospital, Dept. of Urology, Istanbul, Turkey, ²Yeniüyzyil University, Dept. of Urology, Istanbul, Turkey
- *429 **Multidisciplinary self-management telecare system may improve quality of life in patients with interstitial cystitis/bladder pain syndrome (IC/BPS) – A Randomized Controlled Study**
By: [Lee M-H.](#), Wu H-C., Chen W-C.
Institutes:Feng-Yuan Hospital, Dept. of Urology, Taichung, Taiwan
- *431 **Long term outcome following bladder neck artificial urinary sphincter implantation**
By: [Bugeja S.](#), Ivaz S., Frost A., Dragova M., Andrich D.E, Mundy A.R

Institutes:UCLH NHS Foundation Trust, University College London Hospital, London, United Kingdom

- *432 **The role of depression on the risk of urinary incontinence in women: A pooled analysis of RCT and cohorts**
By: Chang Xu X., [Tong-Zu L.](#)
Institutes:Wuhan University Zhongnan Hospital, Dept. of Urology, Wuhan, China
- *433 **High serum concentration of estradiol may be a risk factor of prostate volume**
By: [Ding X.](#), Jun Q., Yu W.
Institutes:Xinhua Hospital Affiliated To Shanghai Jiaotong University School Of Medicine, Dept. of Urology, Shanghai, China
- *434 **Effects of perioperative complications on favorable outcomes after primary artificial urinary sphincter implantation: Results from a European multi-centre study**
By: [Kretschmer A.](#)¹, Hüscher T.², Thomsen F.³, Kronlachner D.³, Obaje A.⁴, Anding R.⁵, Pottek T.⁶, Rose A.⁷, Olanas R.⁸, Friedl A.⁹, Hübner W.¹⁰, Homberg R.¹¹, Pfitzenmaier J.¹², Queissert F.¹³, Naumann C.M.¹⁴, Schweiger J.¹⁵, Wotzka C.¹⁶, Nyarangi-Dix J.¹⁷, Hofmann T.¹⁸, Buchner A.¹, Haferkamp A.², Bauer R.M.¹
Institutes:¹LMU-Klinikum der Universität München, Dept. of Urology, Munich, Germany, ²University Hospital Mainz, Dept. of Urology, Mainz, Germany, ³University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany, ⁴St. Bernward Hospital, Dept. of Urology, Hildesheim, Germany, ⁵University Hospital Bonn, Dept. of Urology, Bonn, Germany, ⁶Asklepios Hospital West Hamburg, Dept. of Urology, Hamburg, Germany, ⁷Helios Hospital Duisburg, Dept. of Urology, Duisburg, Germany, ⁸Hospital Lüneburg, Dept. of Urology, Lüneburg, Germany, ⁹Hospital Göttlicher Heiland, Dept. of Urology, Vienna, Austria, ¹⁰Hospital Weinviertel, Dept. of Urology, Korneuburg, Austria, ¹¹St. Barbara Hospital, Dept. of Urology, Hamm, Germany, ¹²Evangelic Hospital Bielefeld, Dept. of Urology, Bielefeld, Germany, ¹³University Hospital Münster, Dept. of Urology, Münster, Germany, ¹⁴University Hospital Kiel, Dept. of Urology, Kiel, Germany, ¹⁵Catholic Hospital St. Johann Nepomuk, Dept. of Urology, Erfurt, Germany, ¹⁶Diakonie Hospital Stuttgart, Dept. of Urology, Stuttgart, Germany, ¹⁷University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, ¹⁸Diakonie Hospital Schwäbisch Hall, Dept. of Urology, Schwäbisch Hall, Germany
- *435 **Laparoscopic sacrocolpopexy in advanced age women: Influence of age in surgical and perioperative outcomes**
By: [López-Fando Lavalle L.](#), Carracedo Calvo D., Sánchez Gallego M.D., Jiménez Cidre M.A., Gómez De Vicente J.M., Lorca Alvaro J., Burgos Revilla F.J.
Institutes:Hospital Universitario Ramón y Cajal, Dept. of Urology, Madrid, Spain
- *436 **Visual prostatic symptom score provides better correlation with urinary flow studies compared with international prostatic symptom score in males from low and high sociocultural status**
By: [Torres-Anguiano J.R.](#)¹, Kocjancic E.², Maldonado-Alcaraz E.¹, Moreno-Palacios J.¹, León-Mar R.¹, López-Sámano V.A.¹, Montoya-Martínez G.¹, Torres-Mercado L.O.¹, Serrano-Brambila E.A.¹
Institutes:¹Hospital De Especialidades Del Centro Médico Nacional Siglo Xxi, Dept. of Urology, Mexico City, Mexico, ²University of Illinois At Chicago, Dept. of Urology, Chicago, United States of America
- *437 **Spatially resolved Raman spectroscopy using conventional cystoscopy optics: Proof-of-principle**
By: [Miernik A.](#)¹, Wilhelm K.¹, Hein S.¹, Schoenthaler M.¹, Lemke N.², Kuehn M.², Wetterauer U.¹, Roth M.³, Moralejo B.⁴, Schmaelzlin E.⁴
Institutes:¹Universitätsklinikum Freiburg, Dept. of Urology, Freiburg, Germany, ²Schoelly Fibreoptics GmbH, Advanced Technologies, Denzlingen, Germany, ³University of Potsdam, Institute of Physics and Astronomy, Potsdam, Germany, ⁴Leibniz-Institut For Astrophysics Potsdam (AIP), Multiplex Raman Spectroscopy, Potsdam, Germany
- *438 **Evaluation of penile compression devices for physiological impact and user acceptability**
By: [Lemmens J.](#)¹, Broadbridge J.¹, Macaulay M.², Bader D.¹, Fader M.¹
Institutes:¹University of Southampton, Faculty of Health Sciences, Southampton, United Kingdom, ²

Infertility: Clinical

Poster Session 33

Sunday, 26 March
12:15 - 13:45

Location: Room Berlin, North Hall (Level 1)

Chairs: A. Kadioglu, Istanbul (TR)
D.A. Ohl, Ann Arbor (US)
N. Sofikitis, Ioannina (GR)

Aims and objectives of this presentation

The aim of the session is to provide the audience with up-to-date knowledge on onco-infertility and outcomes of surgical sperm retrieval, vasoepididymostomy and varicocelectomy. In addition cross-sectional data on male infertility related to hypogonadism and insulin resistance will be presented.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *439 **Prevalence and characteristics of infertile men reporting previous cancer history**
By: Cazzaniga W.¹, Capogrosso P.¹, Pederzoli F.¹, Ventimiglia E.¹, Boeri L.², Frego N.¹, Alfano M.³, Dehò F.³, Gaboardi F.³, Mirone V.⁴, Montorsi F.¹, Salonia A.¹
Institutes:¹IRCCS San Raffaele Hospital/ University Vita-Salute San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, ²IRCCS Cà Granda, Hospital Maggiore Policlinico, Dept. of Urology, Milan, Italy, ³IRCCS San Raffaele Hospital, Division of Oncology, Unit of Urology, Milan, Italy, ⁴University of Naples Federico II, Dept. of Urology, Naples, Italy
- *440 **Preserving fertility in patients with testicular tumours: Result from a monocentric observational study**
By: Gadda F.¹, Palmisano F.¹, Paffoni A.², Serino A.¹, Ferrari S.², Boeri L.¹, Spinelli M.G.¹, Serrago M.¹, De Lorenzis E.¹, Dell'orto P.G.¹, Montanari E.¹
Institutes:¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Dept. of Urology, Clinical Sciences and Community, Milan, Italy, ²Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Infertility Center, Milan, Italy
- *441 **Infertility due to non obstructive azoospermia (NOA): What's the chance of take home baby?**
By: Conca Baenas M.A., Marzullo Zuchett L., Rogel Bertó R., Luján Marco S., Boronat Tormo F.
Institutes:La Fe, University and Polytechnic Hospital, Dept. of Urology, Valencia, Spain
- *442 **The combined trifocal and microsurgical testicular sperm extraction enhances retrieval rate in low-chance retrieval nonobstructive azoospermia**
By: Ishida M., Falcone M., Timpano M., Ceruti C., Sedigh O., Preto M., Sibona M., Gontero P., Frea B., Rolle L.
Institutes:Città Della Salute E Della Scienza, University of Torino, Dept. of Urology, Torino, Italy
- *443 **Microdissection TESE (mTESE) outcomes following orchidopexy for intra-abdominal and inguinal testicles in adults**
By: Christodoulidou M.¹, Ziada M.¹, Parnham A.¹, Williamson E.¹, Freeman A.², Kelly J.D.¹, Dawas K.¹, Muneer A.¹
Institutes:¹University College Hospitals London, Dept. of Urology, London, United Kingdom, ²University College Hospitals London, Dept. of Pathology, London, United Kingdom
- *444 **Salvage mTESE after previous failed mTESE: Results and predictors for success**
By: Moubasher A., Kalejaiye O., Raheem A.A., Chiriaco G., Capece M., Sangstar P., Christopher N., Muneer A., Garaffa G., Ralph D.

Institutes:University College Hospital London, Dept. of Urology, London, United Kingdom

*445 **The feasibility of repeat microdissection testicular sperm extraction less than 6 months for patients with non-obstructive azoospermia testes**

By: Tai M-C., Huang W., Lin A., Chen K.

Institutes:Taipei Veterans General Hospital, Dept. of Urology, Taipei City, Taiwan

*446 **Men with insulin resistance are at increased risk of azoospermia: Results from a cross-sectional study**

By: Cazzaniga W.¹, Ventimiglia E.¹, Capogrosso P.², Pederzoli F.¹, Frego N.¹, Boeri L.³, Alfano M.⁴, Dehò F.⁴, Gaboardi F.⁴, Mirone V.⁵, Piemonti L.⁶, Montorsi F.⁷, Salonia A.⁷

Institutes:¹IRCCS San Raffaele Hospital/University Vita-Salute San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, ²IRCCS San Raffaele Hospital/University Vita-Salute San Raffaele, Division of Oncology, Unit of Urology of Urology; URI, Milan, Italy, ³IRCCS Cà Granda, Hospital Maggiore Policlinico, Dept. of Urology, Milan, Italy, ⁴IRCCS San Raffaele Hospital, Division of Oncology, Unit of Urology, Milan, Italy, ⁵University of Naples Federico II, Dept. of Urology, Naples, Italy, ⁶IRCCS San Raffaele Scientific Institute, Diabetes Research Institute, Milan, Italy, ⁷IRCCS San Raffaele Hospital/ University Vita-Salute San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy

*447 **Primary, secondary, and compensated hypogonadism: A novel risk stratification for infertile men**

By: Ventimiglia E.¹, Capogrosso P.¹, Boeri L.², Cazzaniga W.¹, Pederzoli F.¹, Frego N.¹, Oreggia D.¹, Dehò F.³, Gaboardi F.³, Mirone V.⁴, Montorsi F.¹, Salonia A.¹

Institutes:¹IRCCS San Raffaele Hospital/University Vita-Salute San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, ²IRCCS Cà Granda, Hospital Maggiore Policlinico, Dept. of Urology, Milan, Italy, ³IRCCS San Raffaele Hospital, Division of Oncology, Unit of Urology, Milan, Italy, ⁴University of Naples Federico II, Dept. of Urology, Naples, Italy

*448 **Pregnancy and live birth rates of microsurgical vasoepididymostomy for azoospermic patients with epididymal obstruction in the era of intracytoplasmic sperm injection and possible factors affecting the outcomes**

By: Peng J., Zhang Z., Yuan Y., Cui W., Tang Y.

Institutes:Peking University First Hospital, Andrology Center, Beijing, China

*449 **Withdrawn**

By:

Institutes:

*450 **Embolization of clinical varicocele: Long term effects on semen quality, complication rates and satisfaction**

By: Freire M.J.¹, Sousa A.P.², Sousa L.¹, Ramalho-Santos J.³, Parada B.¹, Almeida-Santos T.², Figueiredo A.¹

Institutes:¹Coimbra Hospital and University Centre, Dept. of Urology and Renal Transplantation, Coimbra, Portugal, ²Coimbra Hospital and University Centre, Dept. of Reproductive Medicine, Coimbra, Portugal, ³University of Coimbra, Centre For Neuroscience and Cell Biology, Coimbra, Portugal

*451 **Effect of antioxidant supplementation on sperm parameters in oligo-astheno-teratozoospermia, with and without varicocele: A double blind place controlled (dbpc) study**

By: Busetto G.M.¹, Virmani A.², Antonini G.¹, Ragonesi G.¹, Del Giudice F.¹, Gentile V.¹, De Berardinis E.¹

Institutes:¹Sapienza Rome University, Dept. of Urology, Rome, Italy, ²Sigma-Tau HealthScience, Dept. of Nutraceuticals, Utrecht, The Netherlands

13:30 - 13:37

Summary

N. Sofikitis, Ioannina (GR)

Benign but difficult - the surgical management of ureteric obstruction

Poster Session 34

Sunday, 26 March
12:15 - 13:45

Location: Room Vienna, North Hall (Level 1)

Chairs: O. Apolikhin, Moscow (RU)
M. Bultitude, London (GB)
J. Galan Llopis, Elche (ES)

Aims and objectives of this presentation

explore a range of challenging diseases and scenarios in upper urinary tract obstruction

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *462 **Endometriosis – urinary tract involvement and predictive factors for major surgery**
By: Freire M.J.¹, Dinis P.J.¹, Medeiros R.², Sousa L.¹, Águas F.², Figueiredo A.¹
Institutes:¹Coimbra Hospital and University Centre, Dept. of Urology and Renal Transplantation, Coimbra, Portugal, ²Coimbra Hospital and University Centre, Dept. of Gynaecology, Coimbra, Portugal
- *452 **Long term outcome of ureterolysis and omental wrapping for idiopathic retroperitoneal fibrosis**
By: Zahran M., Osman Y., Soltan M., Elhussein Abolazm A., Ghazy M., Harraz A., Shokeir A., Ali-El-Dein B., Abol-Enein H.
Institutes:Urology and Nephrology Center, Dept. of Urology, Mansoura, Egypt
- *453 **Surgical management for radiation induced distal ureteral obstruction**
By: Polyakov N., Keshishev N., Kachmazov A., Grigorieva M., Serebryany S., Kazachenko A., Apolikhin O., Alekseev B., Kaprin A.
Institutes:N.Lopatkin Scientific Research Institute of Urology and Interventional Radiology, Dept. of Reconstructive Urology, Moscow, Russia
- *454 **Laparoscopic ureteroneocystostomy for deep infiltrating ureteral endometriosis: Outcomes of 138 consecutive cases from a third level national referral centre**
By: Caleffi G.¹, Molinari A.¹, Ceccarello M.², Scarperi S.², Ballario R.¹, Pastorello M.¹, Ceccaroni M.², Cavalleri S.¹
Institutes:¹Sacred Heart Hospital, Dept. of Urology, Negrar, Italy, ²Sacred Heart Hospital, Dept. of Obstetrics and Gynaecology, Negrar, Italy
- *457 **Ureter stricture rate after robot-assisted radical cystectomy with a totally intracorporeal urinary diversion**
By: Hosseini A.¹, Dey L.¹, Ebbing J.², Adding C.¹, Laurin O.¹, Collins J.¹, Wiklund P.¹
Institutes:¹Karolinska University Hospital, Dept. of Urology, Stockholm, Sweden, ²University Hospital Basel, Dept. of Urology, Basel, Switzerland
- *458 **An alternative technique for treating long mid-ureteral strictures and defects**
By: Palermo S.M., Trenti E., D'elia C., Comploj E., Ladurner C., Huqi D., Mian C., Schuster H., Pycha A.
Institutes:General Hospital of Bolzano, Dept. of Urology, Bolzano, Italy
- *459 **Outcomes following first-line endourological management of ureteroenteric anastomotic strictures after urinary diversion: A single-center study**
By: Gomez F., Thomas A., Sempels M., Nechifor V., Hubert C., Leruth J., Waltregny D.

Institutes:CHU Liège, Dept. of Urology, Liege, Belgium

*460

Long-term outcome and complications after ileal ureter replacement – a contemporary high-volume single-center experience

By: Herout R., Martini A., Borkowetz A., Zastrow S, Oehlschläger S., Leike S., Fröhner M., Wirth M.P.

Institutes:Technical University Dresden, Dept. of Urology, Dresden, Germany

*461

Can we improve them? Experience in the management of relatively poorly functioning obstructed kidneys

By: Johnstone C.¹, Gkentzis A.², Kimuli M.², Cartledge J.², Biyani C.²

Institutes:¹Royal Liverpool Hospital, Dept. of Urology, Liverpool, United Kingdom, ²St James Hospital, Dept. of Urology, Liverpool, United Kingdom

*463

Upper urinary tract decompression using ileal ureter replacement (IUR) in comparison to endoureteral thermoexpandable Stent [Memokath 051]

By: Akbarov I., Al-Mahmid M., Pfister D., Heidenreich A.

Institutes:University Hospital of Cologne, Dept. of Urology, Uro-Oncology and Robot Assisted Surgery, Cologne, Germany

*465

Evaluation of urinary neutrophil gelatinase-associated lipocalin as a biomarker in pediatric and adult patients with ureteropelvic junction obstruction

By: Talibzade F., Kaya C., Sahin B., Tanidir Y., Sekerci C.A., Akbal C., Simsek F.

Institutes:Marmara University School of Medicine, Dept. of Urology, Istanbul, Turkey

Paediatric urology 1

Poster Session 35

Sunday, 26 March
12:15 - 13:45

Location: Room London, North Hall (Level 1)

Chairs: J.M. Nijman, Groningen (NL)
S. Tekgül, Ankara (TR)
D.N. Wood, London (GB)

Aims and objectives of this presentation

Paediatric Urology 1 session will update you on the latest insights and new aspects in the care for your paediatric patients

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *466 **Early one stage passerini-glazel feminizing genitoplasty for congenital adrenal hyperplasia: What happens at puberty?**
By: [Lesma A.](#)¹, Montorsi F.²
Institutes:¹IRCCS Ospedale San Raff, Dept. of Urology, Milan, Italy, ²University Vita-Salute San Raffaele, I, Dept. of Urology, Milan, Italy
- *467 **Renal cyst evolution in childhood: A contemporary observational study**
By: [Rediger C.](#), Wayne C., Reddy D., Ksara S., Keays M., Guerra L., Leonard M.
Institutes:Children's Hospital of Eastern Ontario, Dept. of Surgery - Division of Urology, Ottawa, Canada
- *468 **Paediatric kidney transplantation: A single-centre experience of 16 years**
By: [Bañuelos Marco B.](#)¹, Koch T-M.², Friedersdorff F.¹, Goranova I.¹, Lingnau A.¹
Institutes:¹Charité - Universitätsmedizin Berlin, Dept. of Urology, Berlin, Germany, ²Charité - Universitätsmedizin Berlin, Dept. of Paediatric Nephrology, Berlin, Germany
- *469 **The impact of donor age, HLA matching and panel reactivity antibodies in pediatric kidney transplant**
By: [Bañuelos Marco B.](#)¹, Koch T-M.², Friedersdorff F.¹, Goranova I.¹, Lingnau A.¹
Institutes:¹Charité - Universitätsmedizin Berlin, Dept. of Urology, Berlin, Germany, ²Charité - Universitätsmedizin Berlin, Dept. of Pediatric Nephrology, Berlin, Germany
- *470 **Adult follow up of major dysfunctional voiding in children**
By: [Sandri S.](#)
Institutes:Hospital G. Fornaroli, Dept. of Urology, Magenta, Italy
- *472 **Evaluation of urologic problems in anorectal malformations and effect of anorectoplasty on lower urinary tract function**
By: [Abou Hashem S.](#)¹, Mostafa S.²
Institutes:¹Zagazig University Hospital, Zagazig, Egypt, ²Zagazig University Hospital, Dept. of Pathology, Zagazig, Egypt
- *473 **Pelvic osteotomy in the newborn classic bladder exstrophy closure: Complications and outcomes**
By: Sullivan B.¹, Friedlander D.², Di Carlo H.², Sponseller P.¹, [Gearhart J.](#)²
Institutes:¹Johns Hopkins, Division of Pediatric Orthopaedics, Baltimore, United States of America, ²Johns Hopkins, Jeffs Division of Pediatric Urology, Baltimore, United States of America

- *474 **Primary closure of bladder exstrophy in children above 1 month, is it important to do bilateral osteotomies? A pilot study**
By: About Ela M. Nabil W., [Ghoneima W.E.](#), Abdelwahhab M., Shouman A., Shokry A., El Sheemy M., El Ghoniemy M., Badawy H.
Institutes: Kasr Al Ainy Hospital Cairo University, Dept. of Pediatric Urology, Cairo, Egypt
- *475 **Bladder exstrophy: Which quality of life? About 15 cases**
By: [Ben Ahmed Y.](#), Landolsi M., Chibani I., Charieg A., Noura F., Jouini R., Jlidi S.
Institutes: Children Hospital Bachir Hamza, Dept. of Pediatric Surgery, Tunis, Tunisia
- *476 **The value of urinary BDNF levels on assessment of the botulinum toxin type A treatment for neurogenic detrusor overactivity in children with myelodysplasia**
By: Sekerci C.A.¹, [Tanidir Y.](#)², Top T.², Basok B.I.³, Isman F.⁴, Simsek F.¹, Akbal C.¹, Tarcan T.¹
Institutes:¹Marmara University School of Medicine, Dept. of Urology and Pediatric Urology, Istanbul, Turkey, ²Marmara University School of Medicine, Dept. of Urology, Istanbul, Turkey, ³Tepecik Training and Research Hospital, Dept. of Biochemistry, Izmir, Turkey, ⁴Medeniyet University School of Medicine, Dept. of Biochemistry, Istanbul, Turkey
- *477 **SNM in children: The best response in congenital and acquired neurogenic bladder**
By: [Lopes Mendes A.L.](#)¹, Jansen I.², Zaccara A.M.³, Capitanucci M.L.³, De Gennaro M.³, Mosiello G.³
Institutes:¹Paediatric Hospital Bambino Gesù, Dept. of Robotic Surgery and Urodynamic Unit, Rome, Italy, ²AMC University Hospital, Dept. of Urology and Department of Biomedical Engineering and Physics, Amsterdam, The Netherlands, ³Paediatric Hospital Bambino Gesù, Dept. of Robotic Surgery and Urodynamic Unit, Rome, Italy
- *478 **Histological features of the testicular nubbin in the vanishing testis: Is surgical exploration necessary?**
By: Ha J.Y., Shin T.J., Jung W.H., Kim B.H., Park C.H., [Kim C.I.](#)
Institutes: Keimyung University School of Medicine, Dept. of Urology, Daegu, South Korea
- *479 **Variation of dysgenetic gonads and tumor risk in patients with 45,X/46,XY mosaicism**
By: [Matsumoto F.](#), Okusa T., Matsuyama S., Matsui F., Yazawa K.
Institutes: Osaka Medical Center & Research Institute, Dept. of Urology, Osaka, Japan
- *480 **Current preferences in primary hypospadias repair: Results of a web-based survey from the Pediatric Section from the European Association of Urology (EAU) Young Academic Urologists (YAU)**
By: [Spinoit A-F.](#)¹, Silay M.S.², Radford A.³, Hoebeke P.¹, Haid B.⁴
Institutes:¹Universitair ziekenhuis Gent, Dept. of Urology, Gent, Belgium, ²Medeniyet Göztepe Etilim University, Dept. of Urology, Istanbul, Turkey, ³Leeds Children's Hospital, NHS, Dept. of Pediatric Urology, Leeds, United Kingdom, ⁴Sisters of The Charity Clinic, Dept. of Pediatric Urology, Linz, Austria

Biomarkers in diagnosis and progression of castration resistant prostate cancer

Poster Session 36

Sunday, 26 March
12:15 - 13:45

Location: Room Stockholm, North Hall (Level 1)

Chairs: I.T.R. Cavarretta, Milan (IT)
C. Jeronimo, Porto (PT)

Aims and objectives of this presentation

Use of validated prostate cancer biomarkers is important for selection of patients who are on risk to develop aggressive disease and also for monitoring castration therapy resistance. Novel approaches to analyze markers in multifocal prostate cancer will be presented.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*481

Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death

By: Na R.¹, Zheng S.L.², Han M.³, Yu H.², Jiang D.², Shah S.², Ewing C.³, Zhang L.³, Novakovic K.⁴, Petkewicz J.², Gulukota K.⁵, Helseth D.⁵, Quinn M.², Humphries E.³, Wiley K.³, Isaacs S.³, Wu Y.¹, Liu X.², Zhang N.¹, Wang C-H.², Khandekar J.⁵, Hulick P.⁶, Shevrin D.⁶, Cooney K.⁷, Shen Z.¹, Partin A.³, Carter H.B.³, Carducci M.⁸, Eisenberger M.⁸, Denmeade S.⁸, Mcguire M.⁴, Walsh P.³, Helfand B.⁴, Brendler C.⁴, Ding Q.¹, Xu J.², Isaacs W.³

Institutes:¹Huashan Hospital, Fudan University, Dept. of Urology, Shanghai, China, ²NorthShore University HealthSystem, Program for Personalized Cancer Care, Evanston, United States of America, ³Johns Hopkins University School of Medicine, Dept. of Urology and The James Buchanan Brady Urologic Institute, Baltimore, United States of America, ⁴NorthShore University HealthSystem, Dept. of Surgery, Evanston, United States of America, ⁵NorthShore University HealthSystem, Center for Molecular Medicine, Evanston, United States of America, ⁶NorthShore University HealthSystem, Dept. of Medicine, Evanston, United States of America, ⁷University of Utah, Dept. of Internal Medicine, Salt Lake City, United States of America, ⁸Johns Hopkins Medical Institutions, Sidney Kimmel Comprehensive Cancer Center, Baltimore, United States of America

*482

Comprehensive molecular dissection of multi-focal prostate cancer and concomitant lymph node metastasis: Implications for tissue based prognostic biomarkers

By: Salami S.¹, Hovelson D.², Mathieu R.³, Kaplan J.², Susani M.⁴, Rioux-Leclercq N.⁵, Shariat S.³, Tomlins S.², Palapattu G.¹

Institutes:¹University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ²University of Michigan, Dept. of Pathology, Ann Arbor, United States of America, ³Medical University Vienna, Dept. of Urology, Vienna, Austria, ⁴Medical University Vienna, Dept. of Pathology, Vienna, Austria, ⁵Rennes University Hospital, Dept. of Pathology, Rennes, France

*483

A genomic analysis of metastases-prone localized prostate cancer in a European, high-risk population

By: Van Den Broeck T.¹, Gevaert T.¹, Prekovic S.², Ong K.³, Tosco L.¹, Moris L.², Smeets E.², Lehrer J.³, Haddad Z.³, Helsen C.², Margrave J.³, Van Poppel H.¹, Everaerts W.¹, Erho N.³, Buerki C.³, Davicioni E.³, Joniau S.¹, Claessens F.²

Institutes:¹UZ Leuven, Dept. of Urology, Leuven, Belgium, ²KU Leuven, Laboratory of Molecular Endocrinology, Leuven, Belgium, ³GenomeDx, GenomeDx Biosciences, Vancouver, Canada

*484

Analysing circulating tumour cells with epithelial and mesenchymal features for prostate cancer prognosis

By: Xu L.¹, Mao X.², Guo T.², Chan P.Y.³, Shaw G.⁴, Hines J.⁴, Wang Y.², Oliver T.², Ahmad A.⁵, Berney D.², Shamash J.³, Lu Y.-J.²

Institutes:¹Zhongshan Hospital Fudan University, Barts Cancer Institute, Dept. of Urology, Shanghai, China, ²Barts Cancer Institute, Centre for Molecular Oncology, London, United Kingdom, ³Barts Health NHS, Dept. of Medical Oncology, London, United Kingdom, ⁴Barts Health NHS, Dept. of Urology, London, United Kingdom, ⁵Wolfson Institute of Preventive Medicine, Centre for Cancer Prevention, London, United Kingdom

*485

Decipher test impacts decision-making among patients considering adjuvant and salvage treatment following radical prostatectomy: Interim results from the multicenter prospective PRO-IMPACT study

By: Gore J.¹, Du Plessis M.², Santiago-Jimenez M.³, Yousefi K.³, Thompson D.⁴, Karsh L.⁵, Lane B.⁶, Franks M.⁷, Chen D.⁸, Bandyk M.⁹, Bianco Jr. F.¹⁰, Brown G.¹¹, Clark W.¹², Kibel A.¹³, Kim H.¹⁴, Lowrance W.¹⁵, Manoharan M.¹⁶, Maroni P.¹⁷, Perrapato S.¹⁸, Sieber P.¹⁹, Trabulsi E.²⁰, Waterhouse R.²¹, Davicioni E.²², Lotan Y.²³, Lin DW¹

Institutes:¹University of Washington, Seattle Cancer Care Alliance, Seattle, United States of America, ²GenomeDx Biosciences, Clinical Development, Vancouver, Canada, ³GenomeDx Biosciences, Dept. of Biostatistics, Vancouver, Canada, ⁴Emmes Canada, Dept. of Biostatistics, Burnaby, Canada, ⁵The Urology Center of Colorado, Dept. of Urology, Colorado, United States of America, ⁶Spectrum Health Medical Group, Dept. of Urology, Grand Rapids, United States of America, ⁷Virginia Urology, Dept. of Urology, Richmond, United States of America, ⁸Fox Chase Cancer Center, Surgical Oncology, Philadelphia, United States of America, ⁹Lakeland Regional Cancer Center, Dept. of Urology, Lakeland, United States of America, ¹⁰Nova Southeastern University, Urological Research Network, Miami, United States of America, ¹¹Delaware Valley Urology, LLC, Dept. of Urology, Voorhees, United States of America, ¹²Alaska Clinical Research Center, Dept. of Urology, Anchorage, United States of America, ¹³Brigham and Womens Hospital, Dept. of Urology, Boston, United States of America, ¹⁴Cedars-Sinai Medical Center, Dept. of Urology, Los Angeles, United States of America, ¹⁵University of Utah, Huntsman Cancer Institute, Salt Lake City, United States of America, ¹⁶University of Miami, Miller School of Medicine, Miami, United States of America, ¹⁷University of Colorado, Anschutz Medical Campus, Aurora, United States of America, ¹⁸University of Vermont Medical Center, Dept. of Urology, Burlington, United States of America, ¹⁹Lancaster Urology, Dept. of Urology, Lancaster, United States of America, ²⁰Thomas Jefferson University, Sidney Kimmel Medical College, Philadelphia, United States of America, ²¹Carolina Urology Partners, Dept. of Urology, Gastonia, United States of America, ²²GenomeDx Biosciences, Bioinformatics, San Diego, Canada, ²³UT Southwestern Medical Center, Dept. of Urology, Dallas, United States of America

*486

The occurrence and therapeutic consequences of androgen receptor copy number gain in prostate cancer patients using Droplet Digital PCR

By: Buelens S.¹, Claeys T.¹, Kumps C.¹, Poelaert F.¹, Dhondt B.¹, Vandesompele J.², Nurten Y.², Vynck M.³, Thas O.³, Lumen N.¹

Institutes:¹Ghent University Hospital, Dept. of Urology, Gent, Belgium, ²Ghent University, Dept. of Pediatrics and Medical Genetics, Gent, Belgium, ³Ghent University, Dept. of Mathematical Modelling, Statistics and Bio-Informatics, Gent, Belgium

*487

Identification of a CTC-based prognostic signature in mCRPC driven by Aurora Kinase A and Wnt signaling

By: Morgan T.¹, Singhal U.¹, Wang Y.¹, Henderson J.¹, Niknafs Y.², Qiao Y.², Taichman R.³, Zaslavsky A.¹, Feng F.⁴, Palapattu G.¹, Chinnaiyan A.², Tomlins S.²

Institutes:¹University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ²University of Michigan, Dept. of Pathology, Ann Arbor, United States of America, ³University Of Michigan, School of Dentistry, Ann Arbor, United States of America, ⁴University of California San Francisco, Dept. of Radiation Oncology, San Francisco, United States of America

*488

Delineation of human prostate cancer evolution identifies chromothripsis as a polyclonal event selecting for FKBP4 driven castration resistance

By: Gsponer J.², Quintavalle C.², Müller D.¹, Lorber T.², Juskevicius D.², Lenkiewicz E.³, Zellweger T.⁴, Barrett M.³, Bubendorf L.², Ruiz C.², Rentsch C.¹

Institutes:¹University Hospital Basel, Dept. of Urology, Basel, Switzerland, ²University Hospital Basel, Institute for Pathology, Basel, Switzerland, ³Mayo Clinic Arizona, Dept. of Research, Scottsdale, United States of America, ⁴St. Claraspital, Dept. of Urology, Basel, Switzerland

*490 **Cell free DNA methylation markers as predictors of treatment response and prognosis for castration-resistant prostate cancer**

By: Hendriks R.¹, Dijkstra S.¹, Smit F.², Vandersmissen J.², Van De Voorde H.², Mulders P.¹, Van Oort I.¹, Van Criekinge W.³, Schalken J.¹

Institutes:¹Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, ²MDxHealth, Dept. of Research and Development, Irvine, United States of America, ³Ghent University, Dept. of Statistics and Bio-Informatics, Ghent, Belgium

*491 **Expression of neuropilin 2 as predictor for tumour-related death in patients with prostate cancer**
By: Borkowetz A.¹, Toma M.², Fuessel S.¹, Erdmann K.¹, Hoenscheid P.², Froehner M.¹, Muders M.², Wirth M.¹

Institutes:¹TU Dresden, Dept. of Urology, Dresden, Germany, ²TU Dresden, Dept. of Pathology, Dresden, Germany

*492 **Calcium signaling remodeling as a predictive factor of systemic recurrence after radical prostatectomy**

By: Perrouin Verbe M.A.¹, Talagas M.², Garlantezec R.³, Schoentgen N.⁴, Uguen A.², Doucet L.², Rosec S.⁵, Nicot M.C.², Gobin E.², Marcorelles P.², Fournier G.⁴, Valeri A.⁴, Mignen O.⁶

Institutes:¹Pitié Salpêtrière Academic Hospital, Dept. of Urology, Paris, France, ²Brest University Hospital, Dept. of Pathology, Brest, France, ³University Rennes 1, INSERM U1085-IRSET, Rennes, France, ⁴Brest University Hospital, Dept. of Urology, Brest, France, ⁵Brest University Hospital, INSERM U 1412, Centre D'Investigation Clinique, Brest, France, ⁶University of Brest, INSERM U 1078, Brest, France

13:30 - 13:37

Circulating tumor cells in prostate cancer

To be confirmed

Prostate cancer: Impact of MRI on biopsies

Poster Session 37

Sunday, 26 March
12:15 - 13:45

Location: Room Munich, North Hall (Level 1)

Chairs: C. Arsov, Düsseldorf (DE)
O. Rouviere, Lyon, Cedex (FR)
J. Walz, Marseille (FR)

Aims and objectives of this presentation

This session will highlight the optimal use of MRI for the stratification of men undergoing prostatic biopsies

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *493 **Clinical outcome following a low-suspicious multiparametric prostate MRI or benign MRI-targeted biopsies for prostate cancer detection: A 3-year follow-up study of men with prior negative transrectal ultrasound guided biopsies**
By: [Boesen L.](#)¹, Nørgaard N.¹, Løgager V.², Thomsen H.²
Institutes:¹Herlev University Hospital, Dept. of Urology, Herlev, Denmark, ²Herlev University Hospital, Dept. of Radiology, Herlev, Denmark
- *494 **Multi-parametric magnetic resonance imaging combined with prostate-specific antigen velocity can predict the probability of prostate cancer in patients after initial negative biopsy**
By: [Song G.](#), Huang C., Ji G., Zhou L.
Institutes:Peking University First Hospital, Dept. of Urology, Beijing, China
- *495 **Evaluation of negative predictive value of multiparametric MRI for prostate cancer: Retrospective analysis after 5 years of clinical experience**
By: [Barchetti G.](#)¹, Del Monte M.¹, Salvo V.¹, Grompone M.¹, Sciarra A.², Panebianco V.¹
Institutes:¹Sapienza University of Rome, Dept. of Radiology, Rome, Italy, ²Sapienza University of Rome, Dept. of Urology, Rome, Italy
- *496 **PSA-density based patient selection for MRI-targeted prostate biopsy could reduce unnecessary biopsy procedures in men on active surveillance for low-grade prostate cancer**
By: [Alberts A.](#)¹, Roobol M.¹, Drost F.-J.², Van Leenders G.³, Bokhorst L.¹, Bangma C.¹, Schoots I.²
Institutes:¹Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, ²Erasmus MC, Dept. of Radiology, Rotterdam, The Netherlands, ³Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands
- *497 **Improving accuracy of prostate cancer risk prediction in prostate biopsy naïve patients with suspicious PSA and/or digital rectal examination through implementation of multiparametric MRI obtained parameters**
By: [Musch M.](#)¹, Roggenbuck U.², Malik-Patsalis A.B.³, Lehmann N.², Ebel T.⁴, Koch J.-A.³, Krege S.¹, Kroepfl D.¹
Institutes:¹Kliniken Essen-Mitte, Dept. of Urology, Paediatric Urology and Urologic Oncology, Essen, Germany, ²University of Duisburg-Essen, Institute For Medical Informatics, Biometry and Epidemiology, Essen, Germany, ³Kliniken Essen-Mitte, Dept. of Diagnostic and Interventional Radiology, Essen, Germany, ⁴Zentrum Für Pathologie Essen-Mitte, Centre For Pathology, Essen, Germany
- *498 **Combined clinical parameters and multiparametric MRI for advanced risk modeling of prostate**

cancer -patient-tailored risk stratification can reduce unnecessary biopsies

By: Radtke J.P.¹, Bonekamp D.², Kesch C.¹, Freitag M.², Alt C.³, Celik K.¹, Distler F.⁴, Roth W.⁵, Wieczorek K.⁶, Duensing S.¹, Roethke M.², Teber D.¹, Schlemmer H-P.², Hohenfellner M.¹, Hadaschik B.¹

Institutes:¹University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, ²German Cancer Research Center, Dept. of Radiology, Heidelberg, Germany, ³University Hospital Düsseldorf, Dept. of Interventional and Diagnostic Radiology, Düsseldorf, Germany, ⁴Paracelsus University Nürnberg, Dept. of Urology, Nürnberg, Germany, ⁵University Medicine Mainz, Dept. of Pathology, Mainz, Germany, ⁶University of Heidelberg, Dept. of Pathology, Heidelberg, Germany

*499

Added value of pre-biopsy prostate multiparametric MRI in biopsy-naïve patients: Preliminary results of the MRI-FIRST trial

By: Rouviere O.¹, Puech P.²¹, Renard Penna R.¹⁹, Claudon M.¹⁰, Roy C.², Mege Lechevallier F.³⁰, Decaussin-Petrucci M.³¹, Rabilloud M.²⁸, Schott Pethelaz A.M.²⁹, Dubreuil Chambardel M.¹, Magaud L.³², Cros F.¹, Barry Delongchamps N.¹⁶, Boutier R.¹³, Bratan F.¹, Brunelle S.⁴, Camparo P.²⁵, Colin P.²⁴, Correas J.M.¹⁷, Cornélis F.⁶, Cornud F.¹⁵, Descotes J.L.²⁶, Eschwege P.¹¹, Fiard G.²⁶, Fendler J.P.¹², Habchi H.¹⁸, Hallouin P.⁹, Khairoune A.¹⁷, Lang H.³, Lebras Y.⁶, Malavaud B.¹⁴, Moldovan P.¹, Mottet N.¹⁸, Mozer P.²⁰, Nevoux P.⁸, Pagnoux G.¹, Pasticier G.⁷, Portalez D.¹⁴, Potiron E.⁸, Timsit M-O.³⁴, Villers A.²³, Walz J.⁵, Colombel M.²⁷, Ruffion A.³³, Crouzet S.²⁷, Lemaitre L.²², Grenier N.⁶

Institutes:¹Hôpital Edouard Herriot, Dept. of Imaging, Lyon, France, ²CHU De Strasbourg, Dept. of Radiology, Strasbourg, France, ³CHU De Strasbourg, Dept. of Urology, Strasbourg, France, ⁴Institut Paoli-Calmettes, Dept. of Imaging, Marseille, France, ⁵Institut Paoli-Calmettes, Dept. of Surgery Oncology, Marseille, France, ⁶CHU Pellegrin, Dept. of Radiology, Bordeaux, France, ⁷CHU Pellegrin, Dept. of Urology, Bordeaux, France, ⁸Clinique Nantes Atlantis, Dept. of Urology, Saint Herblain, France, ⁹Cabinet De Radiologie, Nantes, France, ¹⁰CHRU Nancy-Brabois, Dept. of Radiology, Nancy, France, ¹¹CHRU Nancy-Brabois, Dept. of Urology, Nancy, France, ¹²Centre Hospitalier St Joseph St Luc, Dept. of Urology, Lyon, France, ¹³Centre Hospitalier St Joseph St Luc, Dept. of Radiology, Lyon, France, ¹⁴IUCT-ONCOPOLE, Dept. of Uro-Oncology, Toulouse, France, ¹⁵Hôpital COCHIN, Dept. of Radiology, Paris, France, ¹⁶Hôpital COCHIN, Dept. of Urology, Paris, France, ¹⁷Groupe Hospitalier Necker Enfants Malades, Dept. of Radiology, Paris, France, ¹⁸CHU Hôpital Nord, Dept. of Urology, St Etienne, France, ¹⁹UPMC APHP - Hôpitaux Tenon-Pitié Salpêtrière, Dept. of Imaging, Paris, France, ²⁰UPMC APHP - Hôpital Pitié Salpêtrière, Dept. of Urology, Paris, France, ²¹Université Lille, CHU De Lille, Dept. of Radiology, Lille, France, ²²Univ. Lille, CHU De Lille, Dept. of Genito-Urinary Radiology, Lille, France, ²³Univ. Lille, CHU De Lille, Dept. of Urology, Lille, France, ²⁴Hôpital Privé La Louvière, Ramsay Générale De Santé, Dept. of Urology, Lille, France, ²⁵Centre De Pathologie, Amiens, France, ²⁶CHU De Grenoble, Dept. of Urology, Grenoble, France, ²⁷Hôpital Edouard Herriot, Dept. of Urology, Lyon, France, ²⁸Centre Hospitalier Lyon Sud, Dept. of Biostatic Service, Pierre Benite, France, ²⁹Université Lyon 1, Dept. of Training and Research in Human Biology, Lyon, France, ³⁰Hôpital Edouard Herriot, Dept. of Pathological Anatomy and Cytology, Lyon, France, ³¹Centre Hospitalier Lyon Sud, Laboratoire D'anatomie Et Cytologie Pathologiques, Pierre Benite, France, ³²Hospices Civils De Lyon, Medical Information Division, Research Evaluation and Scientific Publication Support, Lyon, France, ³³Centre Hospitalier Lyon Sud, Dept. of Urology, Pierre Bénite, France, ³⁴Hôpital Européen Georges Pompidou, Dept. of Urology, Paris, France

*500

A randomized controlled trial to assess and compare the outcomes of AI-US-CT guided biopsy, transrectal ultrasound guided 12-core systematic biopsy, and mpMRI assisted 12-core systematic biopsy

By: Xie L-P., Wang X., Zheng X-Y., Liu B., Li J-F., Wang S.

Institutes:¹st Affiliated Hospital, College of Medicine, Zhejiang University, Dept. of Urology, Hangzhou, China

*501

Value of magnetic resonance imaging in population-based prostate cancer screening: Comparison of 3 biopsy strategies in the 5th screening round of the ERSPC Rotterdam

By: Alberts A.¹, Schoots I.², Drost F-J.², Bokhorst L.¹, Van Leenders G.³, Dwarkasing R.², Barentsz J.⁴, Schröder F.¹, Bangma C.¹, Roobol M.¹

Institutes:¹Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, ²Erasmus MC, Dept. of Radiology, Rotterdam, The Netherlands, ³Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands, ⁴Radboud MC, Dept. of Radiology, Nijmegen, The Netherlands

- *502 **A prospective randomized study comparing standard prostate biopsy and a new diagnostic path with MRI and fusion biopsy: Results after two years**
By: [Porpiglia E.](#), Mele F., Manfredi M., De Luca S., Checcucci E., Bertolo R., Garrou D., Cattaneo G., Amparore D., Bollito E., Russo F., Gned D., De Pascale A., Cirillo S., Fiori C.
Institutes: San Luigi Hospital, Dept. of Urology, Turin, Italy
-
- 13:22 - 13:30 **Associated video presentation Focal therapy with HIFU FocalOne device with MRI target fusion biopsy by KOELIS**
 To be confirmed
- *503 **Transcriptome wide analysis of MRI-targeted biopsy and matching surgical specimens from high-risk prostate cancer patients treated with radical prostatectomy**
By: [Hadaschik B.](#)¹, Takha M.², Radtke J.P.¹, Bonekamp D.³, Du Plessis M.², Buerki C.², Erho N.², Ong K.², Davicioni E.²
Institutes: ¹University of Heidelberg, Medical Faculty Heidelberg, Dept. of Urology, Heidelberg, Germany, ²GenomeDx Biosciences Inc., Research and Development, Vancouver, Canada, ³German Cancer Research Center, Dept. of Radiology, Heidelberg, Germany
- Associated video presentation**
- *504 **Prostate MRI for predicting capsular invasion prior to robot-assisted radical prostatectomy. Lesson learned after 400 cases**
By: [Porpiglia E.](#), Manfredi M., Mele F., Bertolo R., Amparore D., Cattaneo G., Garrou D., Checcucci E., Bollito E., Volante M., Veltri A., De Pascale A., Gned D., Russo F., Regge F., Regge D., Cirillo S., Fiori C.
Institutes: San Luigi Hospital, Dept. of Urology, Turin, Italy
- Associated video presentation**
- *505 **Concordance between biopsy and radical prostatectomy Gleason score: evaluation of determinants in a large-scale study of patients undergoing RALP in Belgium**
By: [Soenens C.](#)¹, Ameye F.¹, De Kuyper P.¹, De Coster G.², Van Damme N.², Vandervorst L.², Quackels T.³, Roumequère T.³, Joniau S.⁴, Van Cleynenbreugel B.⁴
Institutes: ¹Az Maria Middelaes, Dept. of Urology, Gent, Belgium, ²Belgian Cancer Registry, Belgian Cancer Registry, Brussels, Belgium, ³Erasmus Hospital, Dept. of Urology, Brussels, Belgium, ⁴University Hospital of Leuven, Dept. of Urology, Leuven, Belgium
- Associated video presentation**
- *506 **Does the inclusion of non-index lesions at biopsy improve our ability to predict adverse pathologic outcomes at radical prostatectomy? Implications for targeted plus systematic biopsy schemes**
By: [Gandaglia G.](#)¹, Bandini M.¹, Dell'oglio P.¹, Fossati N.¹, Pellegrino F.¹, Fallara G.¹, Zaffuto E.¹, Bravi C.A.¹, Nocera L.¹, Damiano R.², Freschi M.³, Montironi R.⁴, Montorsi F.¹, Briganti A.¹
Institutes: ¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²Magna Graecia University, Dept. of Urology, Catanzaro, Italy, ³Vita-Salute University San Raffaele, Dept. of Pathology, Milan, Italy, ⁴Polytechnic University of The Marche Region, Section of Pathological Anatomy, Ancona, Italy
- Associated video presentation**

History of urology

Poster Session 38

Sunday, 26 March
12:15 - 13:45

Location: Room 7, Capital suite (level 3)

Chairs: D. Schultheiss, Giessen (DE)
P.M. Thompson, London (GB)
P.E. Van Kerrebroeck, Maastricht (NL)

Aims and objectives of this presentation

This session presents several aspects of the history of Urology

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

*507 **Bilbao republican urologists prosecuted by Franco's regimen after Spanish Civil War**

By: [Angulo J.](#)¹, Guimon J.², Gondra J.³, Pérez-Yarza G.⁴, Ercoreka A.³

Institutes:¹Hospital Universitario de Getafe, Dept. of Urology, Getafe, Spain, ²Universidad Del Pais Vasco, Dept. of Psichiatry, Bilbao, Spain, ³Universidad Del Pais Vasco, Museum of History of Medicine, Bilbao, Spain, ⁴Universidad Del Pais Vasco, Dept. of Physiology, Bilbao, Spain

Associated video presentation

*508 **Correspondence of Dr Joaquin Albarran and Spanish Prime Minister Antonio Maura (1907-1908): An inside into the renal stone disease of Maura's wife Constanca Gamazo, and into Spanish and European Urology of the time**

By: [Fariña-Pérez L.A.](#)¹, Fernández-Arias M.²

Institutes:¹Hospital Povisa, Dept. of Urology, Vigo, Spain, ²History Office, University of Medical Sciences and Cuban Society of History of Medicine, Havana, Cuba

Associated video presentation

*510 **Reynaldo dos Santos (1880-1970), a great master of urology, abdominal imaging and history of art, made links between Portuguese and Spanish urology in the first half of the 20th century**

By: [Fariña-Pérez L.A.](#)¹, Cunha T.²

Institutes:¹Hospital Povisa, Dept. of Urology, Vigo, Spain, ²House-Museum Reynaldo dos Santos, Parede-Cascais, Portugal

Associated video presentation

*511 **Lithotomia Douglassiana; the book, the operation and the fight**

By: [Goddard J.](#)

Institutes:University Hospitals of Leicester NHS Trust, Dept. of Urology, Leicester, United Kingdom

Associated video presentation

*512 **Carl Posner (1854-1928): Pioneer of urology and sexology**

By: [Krischel M.](#), Moll F., Fangerau H.

Institutes:Heinrich Heine University Düsseldorf, Dept. of The History, Philosophy, and Ethics of Medicine, Düsseldorf, Germany

Associated video presentation

- *513 **Recent discovery of phallic depictions in prehistoric cave art in Asia minor**
By: [Verit A.](#)
Institutes: Fsm Hospital, Urology, Istanbul, Turkey
- Associated video presentation**
- *514 **Phallic representations in pre-Columbian Central and South America**
By: [Angulo J.](#)¹, [Figueroa C.](#)²
Institutes: ¹Hospital Universitario de Getafe, Dept. of Urology, Getafe, Spain, ²Urologia Integral, Dept. of Urology, Ciudad De Guatemala, Guatemala
- Associated video presentation**
- *515 **Withdrawn**
By:
Institutes:
- Associated video presentation**
- *516 **A tribute to the life and accomplishments of a true Yorkshireman "Leslie Norman Pyrah"**
By: [Khan F.](#), Kimuli M., Biyani C.S., Cartledge J.
Institutes: St James University Hospital, Dept. of Urology, Leeds, United Kingdom
- Associated video presentation**
- *517 **Constantine Dimopoulos: The renovator of Greek urology**
By: [Poulakou-Rebelakou E.](#)¹, Tsiamis C.², Karamanou M.¹, Rempelakos A.³, Chrisofos M.⁴
Institutes: ¹Athens University, Medical School, Dept. History of Medicine, Athens, Greece, ²Athens University, Medical School, Dept. Microbiology, Athens, Greece, ³Bioclinic of Athens, Athens, Greece, ⁴Athens University, Medical School, Dept. of Urology, Athens, Greece
- Associated video presentation**
- *518 **Godfather of modern renal surgery; a Novick**
By: [Sogaolu O.](#), Calleary J.
Institutes: Pennine Acute Trust, Dept. of Urology, Manchester, United Kingdom
- Associated video presentation**

Best Posters Regional Meetings

Sunday, 26 March
12:15 - 13:45

Location: Room 9, Capital suite (level 3)

Chairs: B. Djavan, Vienna (AT)
J. Rassweiler, Heilbronn (DE)

Aims and objectives of this presentation

This poster session includes the top poster which have been presented during the three different Regional Meetings 2016. Base on this, the delegates will be able to learn on a single spot all about interesting new scientific developments in Baltic, Central and South-eastern Europe. We are aiming to discuss each poster intensively counting on the active participation of the audience.

12:18 - 12:18

RM01: Validation of risk nomogram to predict lymph node invasion in prostate cancer patients undergoing lymph node dissection

D. Milonas, Kaunas (LT)

12:18 - 12:18

RM03: Long-term functional outcomes of nephron sparing surgery for renal masses in the solitary kidney

L. Suslov, Minsk (BY)

12:18 - 12:18

RM04: Transition of NMIBC grading system from 1973 to 2004 WHO classification in Tartu 2010-2013

R. Ots, Tartu (EE)

12:18 - 12:18

RM06: Are small renal masses always harmless and large ones threatening?

M. Jakubovskis, Riga (LV)

12:18 - 12:18

RM08: Resurfacing and reconstruction of the glans penis after partial penile amputation - initial experience and cosmetic results

O. Ivanovski, Skopje (MK)

12:18 - 12:18

RM09: Complications of en-block resection of bladder tumors with bipolar hook cutting electrode

S. Hawlina, Ljubljana (SI)

12:18 - 12:18

RM12: Histopathologic and molecular comparative analyses of intravesical aurora kinase A inhibitor with bacillus Calmette-Guerin in precursor lesions of non-muscle invasive bladder cancer in vivo model: Preliminary results

K. Teke, Kocaeli (TR)

12:18 - 12:18

RM13: Robotic (Avicenna) flexible ureteroscopy in renal stones

B. Geavlete, Bucharest (RO)

12:18 - 12:18

RM14: Are we ready for the watchful waiting and focal therapy in treatment of prostate cancer? Analysis of histological material after radical prostatectomy

F. Kowalski, Bydgoszcz (PL)

12:18 - 12:18

RM15: Risk of malignancy in complex cystic renal masses (Bosniak category III-IV)

C. Mirvald, Bucuresti (RO)

12:18 - 12:18

RM16: Genomic aspects regarding prostate cancer aggressiveness

B. Cheorpeaca, Bucharest (RO)

12:18 - 12:18

RM19: Laparoscopic repair of ileal conduit parastomal hernia using the modified Sugarbaker technique (video)

D. Garcia Rojo, Barcelona (ES)

E-BLUS Exam

HOT11

Sunday, 26 March
12:15 - 13:15

Location: Room South America, Exhibition Hall (Level 1)

Aims and objectives of this presentation

The European training in basic laparoscopic urological skills (E-BLUS) is a programme offered to residents and urologists who want to improve the basic skills in laparoscopy. It is a unique opportunity to train with international experts in laparoscopy. The E-BLUS programme includes:

- Hands-on Training (HOT) courses of different levels carried out under the guidance of experienced tutors
- A set of training-box exercises developed and validated by the Dutch project Training in Urology (TiU) to train basic skills needed in urological laparoscopy
- E-BLUS examination and certification
- An online theoretical course

Endourology and complex stone management

Video Session 07

Sunday, 26 March
14:00 - 15:30

Location: eURO Auditorium (Level 0)

Chairs: P.A. Geavlete, Bucharest (RO)
J-T. Klein, Ulm (DE)
R. Miano, Rome (IT)

Aims and objectives of this presentation

To view the latest on surgical management of complex stone by RIRS and PCNL with particular attention to the indications, the percutaneous access technique and the techniques of lithotripsy. New technologies are important to develop without to forget the main aims: safety and efficacy of the procedures.

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

- *V50 **Asynchronous bilateral PCNL in horseshoe kidney with high stone burden: Review of demanding aspects**
By: [Agudelo J.A.](#)¹, Arias E.¹, Chirinos J.¹, Ktech N.¹, Urdaneta L.², Riveros M.², Bustamante J.²
Institutes:¹Hospital Coromoto De Maracaibo, Dept. of Urology, Maracaibo, Venezuela, ²Hospital Universitario De Maracaibo, Dept. of Urology, Maracaibo, Venezuela
- *V51 **Dusting utilizing suction technique (DUST) for percutaneous nephrolithotomy: Use of a dedicated laser handpiece to treat a staghorn stone**
By: [Ghani K.R.](#), Roberts W.W.
Institutes:University of Michigan, Dept. of Urology, Ann Arbor, United States of America
- *V52 **PCNL at home**
By: [Carballo Quintá M.](#)¹, López García S.¹, Castro Iglesias M.¹, Rivas Dangel G.², Almúster Domínguez S.¹, Rodríguez Socarrás M.E.¹, Montero Fabuena R.¹, Pérez Schoch M.¹, López Díez E.¹, Ojea Calvo A.¹
Institutes:¹Complejo Hospitalario Universitario De Vigo, Dept. of Urology, Vigo, Spain, ²Complejo Hospitalario Universitario De Vigo, Dept. of Ophtalmology, Vigo, Spain
- *V54 **Intraoperative stone free status using Dyna CT Artis Zeego in complex retrograde intrarenal surgeries**
By: [Susaeta R.](#), Guzman S., Zambrano N., Fulla J., Mercado A., Kerkebe M., Campero J.M., Ramos C.
Institutes:Clinica las Condes S.A., Dept. of Urology, Santiago, Chile
- *V55 **Hydroxyadenine urolithiasis presenting as anuria in 9 month old female: Diagnostic and therapeutic dilemma**
By: [Malpani A.](#), Ganpule A., Sabnis R., Desai M.
Institutes:Muljibhai Patel Urological Hospital, Dept. of Urology, Nadiad, India
- *V56 **New experience with robotic flexible ureteroscopy in renal stones (report of 200 cases)**
By: [Geavlete P.A.](#)¹, Saglam R.², Georgescu D.³, Multescu R.³, Mirciulescu V.³, Kabakci A.S.⁴, Geavlete B.³
Institutes:¹Sanador Hospital, Dept. of Urology, Bucharest, Romania, ²Medicana International Hospital, Dept. of Urology, Ankara, Turkey, ³Saint John Clinical Hospital, Dept. of Urology, Bucharest, Romania, ⁴Hacettepe University, Dept. of Bioengineering, Ankara, Turkey

*V57

Hybrid technique to determine the site of skin puncture, angle and depth of puncture in fluroscopically guided percutaneous renal puncture in prone position

By: Sharma G.¹, Sharma A.²

Institutes:¹Chitale Clinic Pvt. Ltd., Dept. of Urology, Solapur, India, ²Chitale Clinic Pvt. Ltd., Dept. of Radiology, Solapur, India

Robotic surgery in urology

3DHD Live surgery

Sunday, 26 March
14:00 - 17:00

Location: Room Copenhagen, North Hall (Level 1)

Moderators: P. Dasgupta, London (GB)
J-U. Stolzenburg, Leipzig (DE)
N.P. Wiklund, Stockholm (SE)

14:00 - 15:30

Live 3DHD da Vinci Si © with Firefly™ Fluorescence Imaging Partial Nephrectomy
B.J. Challacombe, London (GB)

15:30 - 17:00

Live 3DHD da Vinci Xi © Nephro ureterectomy and Integrated Table Motion
C. Vaessen, Paris Cedex 13 (FR)

Experimental approaches in personalized medicine in urothelium tumors

Poster Session 39

Sunday, 26 March
14:00 - 15:30

Location: Room Madrid, North Hall (Level 1)

Chairs: To be confirmed
M. Knowles, Leeds (GB)
M. Sanchez-Carbayo, Vitoria-Gasteiz (ES)

Aims and objectives of this presentation

Natural course of bladder cancer could be affected by many factors. In order to predict course of the disease, it is important to analyze multiple parameters. Studies presented in this session will focus also on exosomes and miRNA.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *519 **Tumor-associated exosomes of urothelial bladder cancer cells affect tumor-promoting processes in normal bladder fibroblasts and support tumorigenesis**
By: [Baumgart S.](#)¹, [Heinzelmann J.](#)¹, [Krause E.](#)², [Stoeckle M.](#)¹, [Stampe Ostenfeld M.](#)³, [Junker K.](#)¹
Institutes:¹Saarland University Medical Center, Dept. of Urology, Homburg, Germany, ²Saarland University Medical Center, Dept. of Physiology, Homburg, Germany, ³University Hospital Aarhus, Dept. of Molecular Medicine, Aarhus, Denmark
- *520 **Cancer-associated fibroblasts secreted exosomal miR-146a promotes bladder cancer progression**
By: [Zhuang J.](#)¹, [Shen L.](#)², [Yan J.](#)², [Guo H.](#)¹
Institutes:¹Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital, Dept. of Urology, Nanjing, China, ²MOE Key Laboratory of Model Animals For Disease Study, Model Animal Research Center, Dept. of Tumor Biology, Nanjing, China
- *521 **Genomic landscape of upper urinary tract urothelial carcinoma**
By: [Fuji Y.](#)¹, [Sato Y.](#)¹, [Suzuki H.](#)², [Shiozawa Y.](#)², [Yoshizato T.](#)², [Yoshida K.](#)², [Shiraishi Y.](#)³, [Nakagawa T.](#)¹, [Kume H.](#)¹, [Nishimatsu H.](#)⁴, [Okaneya T.](#)⁵, [Sanada M.](#)⁶, [Makishima H.](#)², [Miyano S.](#)³, [Ogawa S.](#)², [Homma Y.](#)¹
Institutes:¹The University Of Tokyo Hospital, Dept. of Urology, Bunkyo, Japan, ²Graduate School of Medicine Kyoto University, Dept. of Pathology and Tumor Biology, Kyoto, Japan, ³Institute of Medical Science The University of Tokyo, Laboratory of DNA Information Analysis, Human Genome Center, Minato, Japan, ⁴The Fraternity Memorial Hospital, Dept. of Urology, Sumida, Japan, ⁵Toranomon Hospital, Dept. of Urology, Minato, Japan, ⁶Nagoya Medical Center, Advanced Diagnosis, Clinical Reserach Center, Nagoya, Japan
- *522 **Molecular subtype classification of advanced bladder cancer and matched lymph-node metastases by integrative immunohistochemistry, gene expression, and mutation analyses**
By: [Sjödahl G.](#)¹, [Eriksson P.](#)², [Lövgren K.](#)², [Liedberg F.](#)¹, [Höglund M.](#)²
Institutes:¹Translational Medicine, Dept. of Urologic Research, Lund, Sweden, ²Clinical Sciences, Dept. of Oncology and Pathology, Lund, Sweden
- *524 **Urine based DNA methylation biomarkers for monitoring bladder cancer**
By: [Van Der Heijden A.](#)², [Mengual L.](#)¹, [Ingelmo-Torres M.](#)¹, [Lozano J.](#)³, [Van Rijt-Van De Westerlo C.](#)⁴, [Santos P.](#)¹, [Geavlete B.](#)⁵, [Moldoveanu C.](#)⁵, [Ene C.](#)⁵, [Dinney C.](#)⁶, [Czerniak B.](#)⁷, [Schalken J.](#)⁴, [Kiemeneý L.](#)⁸, [Ribal M.](#)¹, [Witjes J.](#)², [Alcaraz A.](#)¹
Institutes:¹Hospital Clinic, IDIBAPS, Dept. of Urology, Barcelona, Spain, ²Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, ³Hospital Clinic, CIBERehd, IDIBAPS, Barcelona, Spain, ⁴

Radboudumc, Dept. of Experimental Urology, Nijmegen, The Netherlands, ⁵Saint John Emergency Clinical Hospital, Dept. of Urology, Bucharest, Romania, ⁶MD Anderson Cancer Center, Dept. of Urology, Houston, Texas, United States of America, ⁷MD Anderson Cancer Center, Dept. of Pathology, Houston, Texas, United States of America, ⁸Radboudumc, Dept. of Health Evidence, Nijmegen, The Netherlands

- *525 **Utilization of next-generation sequencing techniques to investigate markers for chemosensitivity in bladder cancer patients treated with neoadjuvant chemotherapy prior to radical cystectomy**
By: Boström P.¹, Fey V.², Kaikkonen E.³, Lamminen T.¹, Laitinen A.¹, Mirtti T.⁴, Koskinen I.⁵, Salminen A.¹, Taimen P.⁶, Schleutker J.³
Institutes:¹Turku University Hospital, Dept. of Urology, Turku, Finland, ²University of Turku, Institution of Biotechnology, Turku, Finland, ³Turku University, Dept. of Medical Biochemistry and Genetics, Turku, Finland, ⁴Helsinki University Hospital and Finnish Institute For Molecular Medicine, University of Helsinki, Dept. of Pathology (HUSLAB), Helsinki, Finland, ⁵Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, ⁶Turku University Hospital, Dept. of Pathology, Turku, Finland
- *526 **Bladder cancer-secreted extracellular vesicles destroy vascular endothelial barriers**
By: Yoneyama M.S.¹, Hatakeyama S.², Funyu T.³, Tsuboi S.¹, Ohyama C.²
Institutes:¹Oyokyo Kidney Research Institute, Dept. of Cancer Immunology and Cell Biology, Hirosaki, Japan, ²Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ³Oyokyo Kidney Research Institute, Dept. of Urology, Hirosaki, Japan
- *527 **KRT5 and KRT20 expression predicts recurrence and progression of stage pT1 non-muscle-invasive bladder cancer (NMIBC)**
By: Breyer J.¹, Wirtz R.², Denzinger S.¹, Erben P.³, Kriegmair M.³, Stoehr R.⁴, Eckstein M.⁴, Burger M.¹, Otto W.¹, Hartmann A.⁴
Institutes:¹University of Regensburg, Dept. of Urology, Regensburg, Germany, ²Stratifyer Molecular Pathology GmbH, Cologne, Germany, ³University Hospital Mannheim, Dept. of Urology, Mannheim, Germany, ⁴University of Erlangen-Nuremberg, Institute of Pathology, Erlangen, Germany
- *528 **Cell-free DNA from urine samples – a valuable source for bladder cancer biomarkers?**
By: Salomo K., Moritz S., Füssel S., Wirth M.
Institutes:Universitätsklinikum Carl Gustav Carus, Dept. of Urology, Dresden Johannstadt Nord, Germany
- *529 **SMYD3 drives IGF-1R-AKT pathway activation in bladder cancer**
By: Liu L.¹, Fan Y.², Wang K.², Yan K.², Liu C.²
Institutes:¹Shandong University, School of Nursing, Jinan, China, ²Shandong University Qilu Hospital, Dept. of Urology, Jinan, China
- *530 **Her2 alterations in muscle-invasive bladder cancer: There is more than protein expression in patient selection for targeted therapy**
By: Kiss B.², Wyatt A.¹, Douglas J.³, Skuginna V.², Mo F.¹, Anderson S.¹, Rotzer D.², Fleischmann A.⁴, Genitsch V.⁴, Hayashi T.⁵, Neuenschwander M.⁴, Bürki C.⁶, Davicioni E.⁶, Collins C.¹, Thalman G.², Black P.¹, Seiler R.¹
Institutes:¹University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ²University of Bern, Dept. of Urology, Bern, Switzerland, ³University Hospital of Southampton, Dept. of Urology, Hampshire, United Kingdom, ⁴University of Bern, Institute of Pathology, Bern, Switzerland, ⁵Hiroshima University, Dept. of Urology, Hiroshima, Japan, ⁶GenomeDx, Biosciences, Vancouver, Canada
- 15:15 - 15:25 **Molecular subtypes urothelial cancer**
M. Sanchez-Carbayo, Vitoria-Gasteiz (ES)

News in LUTS pharmacotherapy

Poster Session 40

Sunday, 26 March
14:00 - 15:30

Location: Room Milan, North Hall (Level 1)

Chairs: J.C. Nickel, Kingston (CA)
P. Nyirády, Budapest (HU)
N. Thiruchelvam, Cambridge (GB)

Aims and objectives of this presentation

CSS

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *531 **Impact of 5-Alpha reductase inhibitors for treatment of benign prostatic hyperplasia on erectile dysfunction, treated depression, gynecomastia, and breast cancer: A real world 20 year observational study**
By: Hagberg K.W.², Divan H.A.³, Persson R.², Fang S.C.³, Jick S.S.², Nickel J.C.¹
Institutes:¹Queen's University, Dept. of Urology, Kingston, Canada, ²Boston University School of Public Health, Boston Collaborative Drug Surveillance Program, Lexington, United States of America, ³New England Research Institutes, NERI, Watertown, United States of America
- *532 **Phosphodiesterase inhibitors for BPH-LUTS: Is the benefit worth?**
By: Pattanaik S.¹, Mavuduru R.², Panda A.³, Mathew J.⁴, Aggarwal M.⁵, Singh S.², Mandal A.²
Institutes:¹Postgraduate Institute of Medical Education and Research, Dept. of Pharmacology, Chandigarh, India, ²Postgraduate Institute of Medical Education and Research, Dept. of Urology, Chandigarh, India, ³CMC, Dept. of Urology, Vellore, India, ⁴Postgraduate Institute of Medical Education and Research, Dept. of Pediatrics, Chandigarh, India, ⁵NMC Specialty Hospital, Dept. of Urology, Abudhabi, United Arab Emirates
- *533 **Antimuscarinic use in the elderly: A poisoned apple?**
By: Meyer C.¹, Pucheril D.², Karabon P.², Gild P.¹, Von Landenberg N.¹, Atiemo H.², Menon M.², Chughtai B.³, Fisch M.⁴, Chun F.⁴, Trinh Q-D.¹
Institutes:¹Brigham and Women's Hospital, Harvard Medical School, Division of Urological Surgery and Center For, Division of Urologic Surgery and Center For Surgery and Public Health, Boston, United States of America, ²Henry Ford Health System, VUI Center for Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Detroit, United States of America, ³Weil Cornell Medical College/New York Presbyterian Hospital, Dept. of Urology, New York, United States of America, ⁴University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany
- *534 **A 52-week randomized comparative study of a triple therapy (tamsulosin, dutasteride, and imidafenacin) versus a dual therapy (tamsulosin and dutasteride) in benign prostatic hyperplasia patients with overactive bladder (Direct Study)**
By: Yamanishi T.¹, Asakura H.², Seki N.³, Tokunaga S.⁴
Institutes:¹Dokkyo Medical University, Dept. of Urology, Tochigi, Japan, ²Saitama Medical University Hospital, Dept. of Urology, Saitama, Japan, ³Kyushu Central Hospital, Dept. of Urology, Fukuoka, Japan, ⁴Kyushu University Hospital, Medical Information Center, Fukuoka, Japan
- *535 **Comparison between tadalafil 5 mg vs. Serenoa repens/selenium/lycopene for the treatment of benign prostatic lower urinary tract symptoms secondary to benign prostatic hyperplasia. A phase IV, randomized, multicenter, non-inferiority clinical study. SPRITE study**

By: Morgia G.¹, Vespasiani G.², Reale G.¹, Di Mauro M.¹, Pareo R.³, Voce S.⁴, Madonia M.⁵, Fedelini P.⁶, Veneziano P.⁷, Carini M.⁸, Salvia G.⁹, Santaniello F.¹⁰, Ginepri A.¹¹, Bitelli M.¹², Terrone C.¹³, Gentile M.¹⁴, Giannantoni A.¹⁵, Blefari F.¹⁶, Beatrice V.¹⁷, Polledro P.¹⁸, La Rosa P.¹⁹, Arnone S.²⁰, Santelli G.²¹, Russo G.I.¹

Institutes:¹University of Catania, Urology Section, Dept. of Surgery, Catania, Italy, ²University of Tor Vergata, Dept. of Urology, Rome, Italy, ³Hospital Nuovo Regina Margherita Roma, Dept. of Urology, Rome, Italy, ⁴Ravenna Hospital, Dept. of Urology, Ravenna, Italy, ⁵University of Sassari, Dept. of Urology, Sassari, Italy, ⁶Cardarelli Hospital, Dept. of Urology, Naples, Italy, ⁷Riuniti Hospital, Dept. of Urology, Reggio Calabria, Italy, ⁸University of Firenze, Dept. of Urology, Florence, Italy, ⁹ASP Acireale, Dept. of Urology, Acireale, Italy, ¹⁰Riuniti Hospital, Dept. of Urology, Ancona, Italy, ¹¹Figlie Di San Camillo Hospital, Dept. of Urology, Rome, Italy, ¹²Frascati Hospital, Dept. of Urology, Frascati, Italy, ¹³University of Piemonte Orientale, Dept. of Urology, Novara, Italy, ¹⁴Avellino Hospital, Dept. of Urology, Avellino, Italy, ¹⁵University of Perugia, Dept. of Urology, Perugia, Italy, ¹⁶Hospital of Prato, Dept. of Urology, Prato, Italy, ¹⁷S. Croce Hospital, Dept. of Urology, Ancona, Italy, ¹⁸SS. Annunziata Di Savigliano Hospital, Dept. of Urology, Cuneo, Italy, ¹⁹Garibaldi Hospital, Dept. of Urology, Catania, Italy, ²⁰Lugo of Romagna Hospital, Dept. of Urology, Ravenna, Italy, ²¹Lucca Hospital, Dept. of Urology, Lucca, Italy

*536

A randomized, open-label, multicenter study evaluating efficacy of switch from dutasteride to tadalafil in benign prostatic hyperplasia patient with lower urinary tract symptoms (D-to-T trial)

By: Matsumoto T.¹, Hatakeyama S.¹, Yoshikawa K.², Fukui K.³, Yanagisawa T.⁴, Kawaguchi T.⁵, Imai A.¹, Yoneyama T.¹, Hashimoto Y.¹, Koie T.¹, Saito H.⁶, Yamaya K.⁶, Funyu T.⁶, Ohyama C.¹

Institutes:¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Mutsu General Hospital, Dept. Of Urology, Mutsu, Japan, ³Fukui Urology Clinic, Dept. of Urology, Aomori, Japan, ⁴Aomori Rosai Hospital, Dept. of Urology, Hachinohe, Japan, ⁵Aomori Prefectural Central Hospital, Dept. of Urology, Aomori, Japan, ⁶Oyokyo Kidney Research Institute, Dept. of Urology, Hirosaki, Japan

*538

Impact of Vesomni™ on quality of life of men with lower urinary tract symptoms associated with benign prostatic hyperplasia in routine clinical practice: Interim results from the EUROPA study

By: Rees J.¹, Arbe E.⁷, Rosa Arias J.², Skoumal R.³, Walters C.⁴, Yavuz Y.⁵, De Wachter S.⁶

Institutes:¹Tyntesfield Medical Group, Brockway Medical Centre, Nailsea, United Kingdom, ²Hospital "Santiago Apóstol", Dept. of Urology, Miranda De Ebro, Spain, ³Urocentrum Brno, Dept. of Urology, Brno, Czech Republic, ⁴Astellas Pharma Europe Ltd, Medical and Clinical Operations, Chertsey, United Kingdom, ⁵Astellas Pharma Global Development, Dept. of Data Sciences, Leiden, The Netherlands, ⁶University Hospital Antwerpen, University Antwerpen, Dept. of Urology, Edegem, Belgium, ⁷Astellas Pharma Europe Ltd, Dept. of Medical Affairs, Chertsey, United Kingdom

*539

Post-operative continuous use of antimuscarinics in BPH patients with storage symptoms requiring antimuscarinics before surgery – A nationwide population-based study

By: Huang E.Y.-H., Chung H.-J., Lin C.-C., Peng R.-S., Chang Y.-H., Lin A.T.-L., Chen K.-K.

Institutes:Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan

*541

Testosterone therapy (TTh) improves urinary function and reduces major adverse cardiovascular events (MACE) in hypogonadal men with type 2 diabetes (T2DM) treated up to 8 years in comparison to an untreated control group

By: Haider A.¹, Haider K.¹, Doros G.², Traish A.³

Institutes:¹Private Urology Practice, Dept. of Urology, Bremerhaven, Germany, ²Boston University School of Public Health, Dept. of Epidemiology and Statistics, Boston, United States of America, ³Boston University School of Medicine, Dept. of Urology and Biochemistry, Boston, United States of America

*542

The effect of non-steroidal anti-inflammatory drugs on risk of benign prostatic hyperplasia

By: Murtola T.¹, Nygård L.², Talala K.³, Taari K.⁴, Tammela T.¹, Auvinen A.⁵

Institutes:¹Tampere University Hospital, Dept. of Urology, Tampere, Finland, ²University of Tampere, School of Medicine, Tampere, Finland, ³Finnish Cancer Registry, Dept. of Research, Helsinki, Finland, ⁴Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, ⁵University of Tampere, School of Health Sciences, Tampere, Finland

- *543 **The effect of statins on the risk of receiving transurethral resection of prostate in the outpatients of genitourinary clinic - a study by applying nation-wide population based database**
By: [Lin C-C.](#)¹, Chung H.J.¹, Lin A.T.L.¹, Huang Y.H.¹, Chen T.Z.²
Institutes:¹Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan, ²Taipei Veterans General Hospital, Dept. of Family Medicine, Taipei, Taiwan
- *544 **The comparison in the efficacy of the two combination therapies with an anticholinergic agent and an α 1-blocker versus a α 3-adrenoceptor agonist and an α 1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: A randomized, prospective trial using a urodynamic study**
By: [Matsukawa Y.](#), Matsuo K., Majima T., Narita H., Kato M., Yamamoto T., Gotoh M.
Institutes:Nagoya University Graduate School of Medicine, Dept. of Urology, Nagoya, Japan

Percutaneous nephrolithotomy

Poster Session 41

Sunday, 26 March
14:00 - 15:30

Location: Room Paris, North Hall (Level 1)

Chairs: T. Bach, Hamburg (DE)
M.R. Desai, Naidad (IN)
G. Giusti, Basiglio (IT)

Aims and objectives of this presentation

PCNL seems to be on the rise again, after two decades of ESWL and URS. The evolution of techniques and instruments have optimized the outcome and minimalized the morbidity

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *545 **Value of CROES, S.T.O.N.E nomograms and guy's stone score as preoperative predictive system for percutaneous nephrolithotomy (PCNL) outcomes**
By: [De Nunzio C.](#)¹, Bellangino M.¹, Voglino O.A.¹, Baldassarri V.¹, Pignatelli M.², Berardi E.², Tema G.¹, Cremona A.², Tubaro A.¹
Institutes:¹Sant'Andrea Hospital - Sapienza University, Dept. of Urology, Rome, Italy, ²Sant'Andrea Hospital - Sapienza University, Dept. of Radiology, Rome, Italy
- *546 **External validation and comparison of the scoring systems (S.T.O.N.E, GUY, CROES, S-ReSC) for predicting percutaneous nephrolithotomy outcomes: A single center experience with 506 cases**
By: [Yarimoglu S.](#), Bozkurt I.H., Aydogdu O., Yonguc T., Gunlusoy B., Degirmenci T.
Institutes:Izmir Bozyaka Training and Research Hospital, Dept. of Urology, Izmir, Turkey
- *547 **Can Guy's and S.T.O.N.E. scores predict the outcome of percutaneous nephrolithotomy in children?**
By: [Elshal A.](#), El-Nahas A., Shoma A., Elsayy A., Abouelkheir R., El-Kenawy M., Nabeeh M., Shokeir A.
Institutes:Mansoura University, Dept. of Urology, Mansoura, Egypt
- *548 **Preoperative predictors of infection complications in PCNL surgery. A prospective study**
By: [Ordaz Jurado D.D.G.](#), Lorenzo L., Budia A., López-Acón D., Bahilo P., Trassierra M., Boronat F.
Institutes:La Fe, University and Polytechnic Hospital, Dept. of Urology, Valencia, Spain
- *549 **Validation of automated kidney stone volumetry in low dose computed tomography**
By: [Wilhelm K.](#)¹, Hein S.¹, Schlager D.¹, Adams F.¹, Miernik A.¹, Schoenthaler M.¹, Hesse A.², Neubauer J.³
Institutes:¹Faculty of Medicine and Medical Center - University of Freiburg, Center For Surgery Department of Urology, Freiburg, Germany, ²University of Bonn, Department of Urology, Division of Experimental Urology, Bonn, Germany, ³Faculty of Medicine and Medical Center - University of Freiburg, Department of Radiology, Freiburg, Germany
- *550 **Safety and efficacy of percutaneous nephrolithotripsy (PNL) in supine versus prone position: A randomized controlled trial**
By: [Abouelgreed A.](#)¹, Elgendy M.², Abdelaal M.², Shebl S.², Sabry K.², Ibrahim S.²
Institutes:¹Gulf Medical University, Dept. of Urology, Ajman, Egypt, ²Alazhar University, Dept. of Urology, Cairo, Egypt
- *551 **Papillary versus non papillary puncture in percutaneous nephrolithotomy: A prospective randomized trial**

By: Kallidonis P., Kyriazis I., Kotsiris D., Ntasiotis P., Koutava A., Panagopoulos V., Kamal W., Liatsikos E.

Institutes: University of Patras University Hospital, Dept. of Urology, Patra, Greece

*552

Supra-costal access for percutaneous nephrolithotomy in modified supine position: Feasibility, safety and efficacy

By: El Harrech Y.¹, Zaini R.², Ghoundal O.¹, Touiti D.¹

Institutes:¹Military Hospital Avicenne, Dept. of Urology, Marrakech, Morocco, ²Military Hospital, Dept. of Urology, Guelmim, Morocco

*554

In vitro assessment of the hydrodynamic clearance of stone fragments and dust in percutaneous nephrolithotomy instruments

By: Mager R.¹, Balzereit C.², Herrmann T.³, Nagele U.⁴, Haferkamp A.¹, Schilling D.⁵

Institutes:¹University Medical Center Mainz, Dept. of Urology, Mainz, Germany, ²ExperTeach GmbH, Dept. of Physics, Dietzenbach, Germany, ³Hannover Medical School, Dept. of Urology and Urologic Oncology, Hannover, Germany, ⁴General Hospital Hall, Dept. of Urology and Andrology, Hall In Tyrol, Austria, ⁵Isarkliniken Munich, Dept. of Urology, Munich, Germany

*556

Outcome of mini versus standard percutaneous nephrolithotomy for renal stones

By: Elmarakbi A.², Ghoneima W.¹, Elsheemy M.¹, Ibrahim H.³, Habib E.¹, Khadgi S.⁴, Shrestha S.⁴, Al-Kandari A.⁵

Institutes:¹Cairo University, Dept. of Urology, Cairo, Egypt, ²Bani Swaif University, Dept. of Urology, Bani Swaif, Egypt, ³Fayoum University, Dept. of Urology, Fayoum, Egypt, ⁴Vayodah and Venus International Hospitals, Dept. of Urology, Kathmandu, Nepal, ⁵Kuwait University, Dept. of Surgery and Urology, Kuwait, Kuwait

*559

CT-controlled stone-free-rate after minimal-invasive percutaneous nephrolitholapaxy (MIP) in correlation with instrument-size

By: Schachtner J.R.¹, Tokas T.¹, Kitzbichler G.¹, Habicher M.¹, Herrmann T.², Nagele U.¹

Institutes:¹Landeskrankenhaus Hall, Dept. of Urology and Andrology, Hall in Tirol, Austria, ²Hannover Medical School (MHH), Urology and Urooncology, Hannover, Germany

OAB and nocturia

Poster Session 42

Sunday, 26 March
14:00 - 15:30

Location: Room Amsterdam, North Hall (Level 1)

Chairs: M.J. Drake, Bristol (GB)
M. Oelke, Hanover (DE)
A.J. Wein, Philadelphia (US)

Aims and objectives of this presentation

OAB and nocturia remain important clinical challenges in an aging population. What is new?

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *561 **Development of TANGO: A novel screening tool to identify co-existing causes of nocturia**
By: Bower W.¹, Rose G.², Whishaw D.⁵, Ervin C.³, Khan F.², Goldin J.⁴
Institutes:¹Melbourne Health, Dept. of Rehabilitation and Sub-Acute Community Services, Parkville, Australia, ²Melbourne Health, Dept. of Rehabilitation Services, Parkville, Australia, ³Melbourne Health, Dept. of Sub-Acute Community Services, Parkville, Australia, ⁴Melbourne Health, Dept. of Respiratory and Sleep Medicine, Parkville, Australia, ⁵Melbourne Health, Dept. of Aged Care Services and Urology, Parkville, Australia
- *562 **Effects of imidafenacin on urine production, voided volume, and hours of undisturbed sleep in overactive bladder patients with nocturnal polyuria – post hoc analysis of two clinical trials**
By: Yokoyama O.¹, Takeda M.², Gotoh M.³, Yoshida M.⁴, Kakizaki H.⁵, Takahashi S.⁶, Masumori N.⁷
Institutes:¹University of Fukui, Dept. of Urology, Fukui, Japan, ²University of Yamanashi, Dept. of Urology, Yamanashi, Japan, ³Nagoya University Graduate School of Medicine, Dept. of Urology, Nagoya, Japan, ⁴National Center For Geriatrics and Gerontology, Dept. of Urology, Obu, Japan, ⁵Asahikawa Medical University, Dept. of Renal and Urologic Surgery, Asahikawa, Japan, ⁶Nihon University School of Medicine, Dept. of Urology, Tokyo, Japan, ⁷Sapporo Medical University School of Medicine, Dept. of Urology, Sapporo, Japan
- *563 **Influence of urinary calcium excretion on urinary symptoms such as nocturia**
By: Tomohiro M.
Institutes:Nagasaki University, School of Medicine, Dept. of Urology, Nagasaki, Japan
- *564 **Disruption of adaptation in bladder capacity for urine production rate during night time in aged men with nocturia: Analysis of the data of frequency volume chart**
By: Kira S., Mitsui T., Miyamoto T., Ihara T., Nakagomi H., Sawada N., Takeda M.
Institutes:University of Yamanashi, Dept. of Urology, Chuo, Japan
- *565 **Overnight ambulatory urodynamics findings in patients with nocturia and/or nocturnal enuresis**
By: Solomon E., Ecclestone H., Duffy M., Malde S., Pakzad M., Hamid R., Greenwell T., Ockrim J.
Institutes:University College Hospital London, Dept. of Urology, London, United Kingdom
- *566 **Reduction of nocturia in patients treated with C-PAP for obstructive sleep apnea syndrome**
By: Degalliers S.¹, De Vries P.¹, Ewoldt T.², Rahnama'i S.²
Institutes:¹Zuyderland Medical Center Heerlen, Dept. of Urology, Heerlen, The Netherlands, ²Maastricht University, Dept. of Urology, Maastricht, The Netherlands
- *567 **Association between age and low risk of clean intermittent catheterisation with onabotulinumtoxinA in overactive bladder patients with corresponding improvements in urinary**

symptoms and quality of life

By: [Drake M.](#)¹, Everaert K.², Rovner E.³, Dmochowski R.⁴, Ginsberg D.⁵, Radomski S.⁶, Nitti V.⁷, Aboushwareb T.⁸, Chang C-T.⁹, Chapple C.R.¹⁰

Institutes:¹Bristol Urological Institute, Dept. of Urology, Bristol, United Kingdom, ²Ghent University Hospital, Dept. of Uro-Gynaecology, Ghent, Belgium, ³Medical University of South Carolina, Dept. of Urology, Charleston, United States of America, ⁴Vanderbilt University Medical Center, Dept. of Urologic Surgery, Nashville, United States of America, ⁵USC Institute of Urology, Dept. of Urology, Los Angeles, United States of America, ⁶University of Toronto, Dept. of Urology, Toronto, Canada, ⁷New York University, Dept. of Urology, New York, United States of America, ⁸Allergan Plc, Dept. of Urology, Irvine, California, United States of America, ⁹Allergan Plc, Dept. of Statistics, Bridgewater, United States of America, ¹⁰The Royal Hallamshire Hospital, Sheffield Teaching Hospitals, NHS Foundation Trust, Dept. of Urology, Sheffield, United Kingdom

*568 **Randomised crossover-controlled evaluation of simultaneous-bilateral transcutaneous electrostimulation of nervus tibialis posterior during urodynamics**

By: Fritsche H-M., Girtner F., Huber T., [Mayr R.](#), Burger M.

Institutes:University of Regensburg, Dept. of Urology, Regensburg, Germany

*569 **Development of an overactive bladder assessment tool: A potential alternative to the bladder diary**

By: [Kelleher C.](#)¹, Chapple C.², Johnson N.³, Payne C.⁴, Homma Y.⁵, Hakimi Z.⁶, Siddiqui E.⁷, Kopp Z.³, Evans C.³

Institutes:¹Guy's and St Thomas' Hospitals, Dept. of Obstetrics and Gynecology, London, United Kingdom, ²Sheffield University, Dept. of Urology Research, Sheffield, United Kingdom, ³Endpoint Outcomes, Dept. of Outcomes Research, Boston, United States of America, ⁴Vista Urology & Pelvic Pain Partners, Dept. of Urology, San Jose, United States of America, ⁵University of Tokyo, Dept. of Urology, Tokyo, Japan, ⁶Astellas, Dept. of Medical Affairs, Leiden, The Netherlands, ⁷Astellas Pharma Europe Ltd, Dept. of Medical Affairs, Chertsey, United Kingdom

*570 **Long-term comparison of adherence to drug therapy in 1,917 patients with overactive bladder**

By: [Keishi K.](#), Kanao K., Morinaga S., Muramatsu H., Saiki H., Kobayashi I., Nishikawa G., Kato Y., Watanabe M., Nakamura K., Sumitomo M.

Institutes:Aichi Medical University, Dept. of Urology, Nagakute, Japan

*571 **Three-months results of implant driven tibial nerve stimulation for the treatment of overactive bladder syndrome**

By: [Van Breda J.](#), Martens F., Tromp J., Heesakkers J.

Institutes:Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands

*572 **New novel chronic tibial neuromodulation (CTNM) treatment option for oab significantly improves urgency (ui)/urge urinary incontinence (uui) and normalizes sleep patterns: Initial results**

By: [Sievert K-D.](#)¹, Milinovic L.², Foditsch E.¹, Dewachter S.⁴, Knupfer S.³, Kozomara M.³, Roggenkemp A.², Kessler T.³

Institutes:¹Paracelsus Private Medical University of Salzburg, Dept. of Scitrecs, Salzburg, Austria, ²SALK, Dept. of Urology, Salzburg, Austria, ³Balgrist, Dept. of Neuro-Urology, Zurich, Switzerland, ⁴University of Antwerpen, Dept. of Urology, Antwerpen, Belgium

*573 **Do patients with OAB experience different bladder sensations?**

By: [Herrewegh A.](#), Vrijens D., Marcelissen T., Van Koeveringe G.

Institutes:Maastricht Universitair Medisch Centrum+, Dept. of Urology, Maastricht, The Netherlands

*574 **Affective symptoms and quality of life in patients with voiding or storage dysfunction -results before and after sacral neuromodulation**

By: [Jairam R.](#), Drossaerts J., Schilders I., Vrijens D., Van Koeveringe G., Van Kerrebroeck P.

Institutes:Maastricht UMC+, Dept. of Urology, Maastricht, The Netherlands

Infertility: Basic to clinical

Poster Session 43

Sunday, 26 March
14:00 - 15:30

Location: Room Berlin, North Hall (Level 1)

Chairs: G.R. Dohle, Rotterdam (NL)
Z. Kopa, Budapest (HU)
P. Verze, Naples (IT)

Aims and objectives of this presentation

This session will introduce the audience to the newest pre-clinical and clinical developments in male factor infertility.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *575 **Single nucleotide polymorphisms within the novel testis-specific Haspin gene encoding a serine/threonine protein kinase in human male infertility**
By: Miyagawa Y.¹, Soda T.¹, Ueda N.¹, Fukuhara S.¹, Kiuchi H.¹, Tsujimura A.², Tanaka H.³, Nonomura N.¹
Institutes:¹Osaka University Graduate School of Medicine, Dept. of Urology, Suita, Japan, ²Juntendo University Urayasu Hospital, Dept. of Urology, Urayasu, Japan, ³Nagasaki International University, Faculty of Pharmaceutical Sciences, Sasebo, Japan
- *576 **Does detection of DDX4 mRNA in cell free seminal plasma represents a reliable non-invasive germ cell marker in patients with non-obstructive azoospermia?**
By: Abdallah W.², Hashad D.³, Abdelmaksoud R.², Hashad M.M.E.¹
Institutes:¹University of Alexandria, Dept. of Urology, Alexandria, Egypt, ²University of Alexandria, Dept. of Dermatology, Venereology and Andrology, Alexandria, Egypt, ³University of Alexandria, Dept. of Clinical Pathology, Alexandria, Egypt
- *577 **Therapeutic effect of RIPK1 inhibitor in testicular ischemia-reperfusion**
By: Ohira S.¹, Hara R.¹, Tone S.², Nagai A.¹
Institutes:¹Kawasaki Medical School, Dept. of Urology, Kurashiki City, Japan, ²Graduate School of Tokyo Denki University, Dept. of Life Science and Engineering, Hatoyama-Cho, Japan
- *578 **Formation of the human sperm reservoir and its major players**
By: Bour S.¹, Paschold R.¹, Alba-Alejandre I.², Becker A.¹, Stief C.¹, Koelle S.³, Trottmann M.¹
Institutes:¹University of Munich, Dept. of Urology, Munich, Germany, ²University of Munich, Dept. of Gynecology, Munich, Germany, ³University College Dublin, Dept. of Developmental Biology, Dublin, Ireland
- *579 **Effect of electromagnetic wave from cellular phone on the spermatogenesis: Development of an experimental model**
By: Oh J.J., Kim K., Kook H.R., Kim T.J., Lee I.J., Song B.D., Jung Y.S., Lee D.H., Byun S-S., Lee S.E., Lee S., Hong S.K.
Institutes:Seoul National University Bundang Hospital, Dept. of Urology, Seongnam, South Korea
- *580 **Effects of smoking on the glycocalyx of human spermatozoa**
By: Paschold R., Bour S., Becker A., Stief C., Trottmann M.
Institutes:Ludwig-Maximilians-University Munich, Dept. of Urology, Munich, Germany
- *581 **Oxidative stress alterations in the epididymis and testis in a nicotine-exposed rat model**

By: Tsounapi P.¹, Honda M.¹, Dimitriadis F.², Shimizu S.³, Kawamoto B.¹, Kimura Y.¹, Hikita K.¹, Saito M.³, Sofikitis N.², Takenaka A.¹

Institutes:¹Tottori University Faculty of Medicine, Dept. of Urology, Yonago, Japan, ²University of Ioannina School of Medicine, Dept. of Urology, Ioannina, Greece, ³Kochi Medical School, Dept. of Pharmacology, Nankoku, Japan

*582

Heavy cigarette smoking is the most detrimental factor for sperm dna fragmentation – results of a cross-sectional study in primary infertile men

By: Boeri L.¹, Pederzoli F.², Ventimiglia E.², Capogrosso P.², Cazzaniga W.², Frego N.², Oreggia D.², Scano R.³, Montanari E.¹, Gaboardi F.³, Montorsi F.², Salonia A.²

Institutes:¹IRCCS Fondazione Ca' Granda - Ospedale Maggiore Policlinico, Dept. of Urology, Milan, Italy, ²IRCCS San Raffaele Hospital/ University Vita-Salute San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, ³IRCCS San Raffaele Hospital, Division of Oncology, Unit of Urology, Milan, Italy

*583

Clinical and experimental studies suggest a novel cause of male infertility: Deficiency in expression of sperm phospholipase C

By: Dimitriadis F.¹, Tsounapi P.², Vlachopoulou E.³, Matthaïou I.³, Zachariou A.³, Giannakis J.³, Takenaka A.², Sofikitis N.³

Institutes:¹Aristotle University, Dept. of Urology, Thessaloniki, Greece, ²Tottori University, Dept. of Urology, Yonago, Japan, ³Ioannina University, Dept. of Urology, Ioannina, Greece

*584

The evolving profile of comorbidities in infertile men: Results from a 10-years follow-up cohort study

By: Ventimiglia E.¹, Cazzaniga W.¹, Pederzoli F.¹, Frego N.¹, Chierigo F.¹, Capogrosso P.¹, Boeri L.², Alfano M.³, Scano R.³, Mirone V.⁴, Montorsi F.¹, Salonia A.¹

Institutes:¹IRCCS San Raffaele Hospital/ University Vita-Salute San Raffaele, Dept. of Oncology and Urology; URI, Milan, Italy, ²IRCCS Ca' Granda Hospital Maggiore Policlinico, Dept. of Urology, Milan, Italy, ³IRCCS San Raffaele Hospital, Dept. of Oncology and Urology; URI, Milan, Italy, ⁴University of Naples Federico II, Dept. of Urology, Naples, Italy

*585

Male infertility is a risk for depression and low self-esteem: Prospective, case-control, clinical study

By: Basar M.M.², Kendirci M.¹, Alkan E.², Semiz A.², Sirin H.³, Balbay D.²

Institutes:¹Istinye University, Faculty of Medicine, Liv Hospital Ulus, Dept. of Urology, Istanbul, Turkey, ²Memorial Sisli Hospital, Dept. of Urology, Istanbul, Turkey, ³Arnavutköy State Hospital, Dept. of Urology, Istanbul, Turkey

*586

Male infertility is associated with altered treatment course of men with cancer

By: Eminaga O.¹, Shufeng L.², Brooks J.², Eisenberg M.²

Institutes:¹Univeristy Hospital of Cologne, Dept. of Urology, Cologne, Germany, ²Stanford University, School of Medicine, Stanford, United States of America

*587

How realistic is endoscopic vasectomy? An ex-vivo study on feasibility and certainty of endoluminal occlusion of porcine vas deferens

By: Schlager D.¹, Maas J.M.¹, Spittau B.², Leiber C.¹, Wetterauer U.¹, Diemer T.³, Weidner W.³, Schönthaler M.¹, Miernik A.¹

Institutes:¹University Medical Center Freiburg, Dept. of Urology, Freiburg, Germany, ²University Medical Center Freiburg, Dept. of Anatomy, Freiburg, Germany, ³University Hospital Giessen, Dept. of Urology, Pediatric Urology and Andrology, Giessen, Germany

15:17 - 15:24

Summary

Z. Kopa, Budapest (HU)

Improving recovery and reducing complication rate after urological surgery

Poster Session 44

Sunday, 26 March
14:00 - 15:30

Location: Room Vienna, North Hall (Level 1)

Chairs: J. Bjerregaard Jensen, Aarhus N (DK)
I. Korneyev, St. Petersburg (RU)

Aims and objectives of this presentation

This session presents the recent advances and evidence about enhanced recovery after surgery programs, as well as new data regarding peri-operative care in patients undergoing major urological surgery.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *588 **Enhanced recovery enhances reduction of length of stay in patients treated with robotic assisted radical cystectomy with intracorporeal urinary diversion**
By: [Tan W.S.](#)¹, Lamb B.², Tan M-Y.³, Sridhar A.², Mohammed A.², Baker H.², Briggs T.², Tan M.⁴, Kelly J.¹
Institutes:¹University College London, Dept. of Surgery and Interventional Science, London, United Kingdom, ²University College London Hospitals, Dept. of Urology, London, United Kingdom, ³University of Glasgow, School of Medicine, London, United Kingdom, ⁴University College London Hospitals, Dept. of Anaesthesia and Perioperative Medicine, London, United Kingdom
- *589 **The application of ERAS pathways to radical cystectomy: Outcomes from 482 consecutive cases**
By: [Pang K.](#)¹, Groves R.², Noon A.¹, Catto J.¹
Institutes:¹University of Sheffield, Dept. of Oncology and Academic Urology Unit, Sheffield, United Kingdom, ²Royal Hallamshire Hospital, Dept. of Anaesthesia, Sheffield, United Kingdom
- *590 **A prospective randomized single-centre trial evaluating an ERAS protocol versus a standard protocol for patients treated with radical cystectomy and urinary diversion for bladder cancer**
By: [Frees S.](#), Aning J., Black P., Struss W., Bell R., Gleave M., So A.
Institutes:Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada
- *591 **Factors influencing the length of hospital stay after robotic radical cystectomy; is 4 days hospital stay feasible?**
By: [Moschonas D.](#), Soares R., Roodhouse A., Jones C., Mostafid H., Woodhams S., Swinn M., Perry M., Patil K.
Institutes:The Royal Surrey County Hospital, Dept. of Urology, Guildford, United Kingdom
- *592 **Enhanced recovery protocol after radical cystectomy is safe and accelerates bowel function recovery compared to standard perioperative care**
By: Palumbo V.², [Giannarini G.](#)¹, Lami V.², Rossanese M.¹, Crestani A.¹, Ficarra V.¹
Institutes:¹Academic Medical Centre Hospital Santa Maria Della Misericordia, Dept. of Urology, Udine, Italy, ²University of Padua, Dept. of Urology, Padua, Italy
- *593 **Enhanced recovery after radical cystectomy – Results of the first 18 months after implementation of a full ERAS program using the EIAS database**
By: [Müller S.](#), Lilleaasen G., Davami J., Axcrona K.
Institutes:Akershus Universitetssykehus, Dept. of Urology, Lørenskog, Norway
- *594 **Validation of the Clavien-Dindo grading system in urology by the EAU guidelines ad hoc panel**

By: Mitropoulos D.², Jensen J.B.¹, Artibani W.³, Biyani C.S.⁴, Rouprêt M.⁵, Truss M.⁶
Institutes:¹Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, ²University of Athens Medical School, Dept. of Urology, Athens, Greece, ³University of Verona, Dept. of Surgery, Verona, Italy, ⁴St. James's University Hospital, Dept. of Urology, Leeds, United Kingdom, ⁵Pitié-Salpêtrière Hospital, AP-HP, Academic Dept. of Urology, Paris, France, ⁶Klinikum Dortmund GmbH, Dept. of Urology, Dortmund, Germany

*595 **Spinal analgesia versus intravenous opioid for robot-assisted radical prostatectomy: A retrospective analysis of 200 cases**

By: Kim L.¹, Brammer K.¹, Jay A.¹, Kasivisvanathan R.², Cahill D.¹

Institutes:¹Royal Marsden Hospital Nhs, Dept. of Urology, London, United Kingdom, ²Royal Marsden Hospital Nhs, Dept. of Anaesthesia, London, United Kingdom

*596 **Can pre-operative gait velocity (GV) replace cardiopulmonary exercise testing (CPET) as an independent predictor of survival and complications following radical cystectomy (RC)?**

By: Fynmore T.¹, Abdunnassir L.¹, Parsons B.², Nair R.², Khan S.², Thurairaja R.²

Institutes:¹Guy's & St Thomas Nhs Foundation Trust, Dept. of Urology and Physiotherapy, London, United Kingdom, ²Guy's & St Thomas Nhs Foundation Trust, Dept. of Urology, London, United Kingdom

*597 **Procedure-specific risks of thrombosis and bleeding in urological cancer surgery: Systematic reviews and meta-analyses**

By: Tikkinen K.¹, Craigie S.², Agarwal A.³, Violette P.⁴, Novara G.⁵, Cartwright R.⁶, Naspro R.⁷, Siemieniuk R.⁸, Ali B.⁹, Eryuzlu L.³, Geraci J.⁹, Winkup J.⁹, Yoo D.³, Gould M.¹⁰, Sandset P.M.¹¹, Guyatt G.¹²

Institutes:¹University of Helsinki, Dept. of Urology and Public Health, Helsinki, Finland, ²McMaster University, Michael G. DeGroote National Pain Center, Hamilton, Canada, ³University of Toronto, School of Medicine, Toronto, Canada, ⁴Woodstock General Hospital, Dept. of Surgery, Division of Urology, Woodstock, Canada, ⁵University of Padua, Dept. of Surgical, Oncological, and Gastroenterological Sciences, Urology Clinic, Padua, Italy, ⁶Imperial College London, Dept. of Epidemiology and Biostatistics, London, United Kingdom, ⁷ASST Papa Giovanni XXIII, Dept. of Urology, Bergamo, Italy, ⁸University of Toronto, Dept. of Medicine, Toronto, Canada, ⁹McMaster University, Dept. of Clinical Epidemiology and Biostatistics, Hamilton, Canada, ¹⁰Kaiser Permanente Southern California, Dept. of Research and Evaluation, Pasadena, United States of America, ¹¹University of Oslo, Institute of Clinical Medicine, Oslo, Norway, ¹²McMaster University, Dept. of Medicine, Hamilton, Canada

*598 **NOACs in urology: The surgeon's guide to perioperative management**

By: Rahim S.¹, Datta S.¹, Wood M.², Maan Z.¹

Institutes:¹Colchester Hospital University Nhs Foundation Trust, Dept. of Urology, Colchester, United Kingdom, ²Colchester Hospital University Nhs Foundation Trust, Dept. of Haematology, Colchester, United Kingdom

*599 **Prediction of postoperative complications after radical nephrectomy, based on patient comorbidity preoperatively**

By: Fragkiadis E., Alamanis C., Mitropoulos D., Constantinides C.A.

Institutes:Laiko Hospital, Urology, Zografou-Athens, Greece

*600 **The feasibility of day case robotic-assisted laparoscopic prostatectomy**

By: Coomer W.¹, Jefferies M.¹, Ravi J.¹, Colmsee M.², Tozer J.², Carter A.¹, Wilson J.¹

Institutes:¹The Royal Gwent Hospital, Dept. of Urology, Newport, United Kingdom, ²The Royal Gwent Hospital, Dept. of Anaesthetics, Newport, United Kingdom

15:15 - 15:22

Summary

To be confirmed

Paediatric urology 2

Poster Session 45

Sunday, 26 March
14:00 - 15:30

Location: Room London, North Hall (Level 1)

Chairs: To be confirmed
M.S. Silay, Istanbul (TR)
To be confirmed

Aims and objectives of this presentation

Paediatric urology 3 involves new aspects in penile and testicular aspects as well as special items of care for children.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *601 **Effects of sex hormones during the prenatal period on behavioral sexual dimorphism in school-aged children**
By: Mitsui T.¹, Araki A.², Miyashita C.², Ito S.², Kitta T.³, Moriya K.³, Cho K.⁴, Morioka K.⁴, Takeda M.¹, Shinohara N.³, Kishi R.², Nonomura K.³
Institutes:¹University of Yamanashi, Dept. of Urology, Chuo-City, Japan, ²Hokkaido University, Center for Environmental and Health Sciences, Sapporo, Japan, ³Hokkaido University, Dept. of Urology, Sapporo, Japan, ⁴Hokkaido University, Dept. of OB-GYN, Sapporo, Japan
- *602 **Prune-belly syndrome. Is penile structures similar to normal fetuses?**
By: Gallo C., Costa W., Favorito L., Sampaio F.
Institutes:State University of Rio De Janeiro, Urogenital Research Unit, Rio De Janeiro, Brazil
- *603 **The incidence of isolated penile torsion in North India: A study of 5,018 male neonates**
By: Bhat M.¹, Bhat A.², Kumar V.⁴, Bhat A.³, Goyal S.²
Institutes:¹M.G. Medical College Jaipur, Dept. of Urology, Jaipur, India, ²Dr. S.N. Medical College Jodhpur, Dept. of Urology, Jodhpur, India, ³S.P. Medical College Bikaner, Dept. of Surgery, Bikaner, India, ⁴S.P. Medical College Bikaner, Dept. of Urology, Bikaner, India
- *604 **The prevalence and clinical features of spinal dysraphism in children with hypospadias**
By: Chi B.H., Moon Y.T., Myung S.C., Kim K.D., Kim K., Chang I.H., Kim J.W.
Institutes:Chung-Ang University Hospital, Dept. of Urology, Seoul, South Korea
- *605 **Our modifications in Glassberg–Duckette technique to prevent fistula and stricture at proximal anastomosis of inner prepuce flap tube and urethra in severe hypospadias**
By: Bhat A.¹, Bhat M.², Tomar V.S.³, Singh V.³, Bhat A.⁴, Goyal S.³
Institutes:¹Dr. S.N. Medical College Jodhpur, Dept. of Urology, Jodhpur, India, ²M. G. Medical College Jaipur, Dept. of Surgery, Jaipur, India, ³Dr S.N Medical College Jodhpur, Dept. of Urology, Jodhpur, India, ⁴S.P. Medical College Bikaner, Dept. of Surgery, Bikaner, India
- *606 **TIPU in concealed hypospadias/megameatus intact prepuce**
By: Bhat A.², Bhat M.¹, Upadhayay R.⁴, Bhat A.³, Goyal S.²
Institutes:¹M.G. College Jaipur, Dept. of Surgery, Bikaner, India, ²Dr. S.N. Medical College Jodhpur, Dept. of Urology, Jodhpur, India, ³S.P. Medical College Bikaner, Dept. of Surgery, Bikaner, India, ⁴S.P. Medical College Bikaner, Dept. of Urology, Bikaner, India
- *607 **Incidence of undescended testes in preterm labor and factors associated with spontaneous descent**
By:

Kim S-O., Cho Y.H., Chung H.S., Oh K.J., Hwang E.C., Jung S.I., Kang T.W., Park K., Kwon D.D.
Institutes:Chonnam National University Medical School, Dept. of Urology, Gwangju, South Korea

- *608 **The impact of early orchiopexy on undescended testes: Analysis of testicular growth rate ratio**
By: Tseng C-S., Huang K-H., Pu Y-S., Chiang I-N.
Institutes:National Taiwan University, Dept. of Urology, Taipei, Taiwan
- *610 **Is diagnostic laparoscopy justified for the initial management of unilateral non-palpable testis?**
By: Matsuyama S., Matsumoto F., Matsui F., Yazawa K., Okusa T.
Institutes:Osaka Medical Center & Research Institut, Dept. of Urology, Osaka, Japan
- *611 **Other than duration of symptoms, is there a predictive factor for testicular viability following testicular torsion in children?**
By: Song P.H., Choi J.Y., Ko Y.H., Moon K.H., Jung H.C.
Institutes:Yeungnam University, College of Medicine, Dept. of Urology, Daegu, South Korea
- *613 **The activity and discussion points of #Circumcision through Twitter; a microblogging platform**
By: Ucar T., Çulpan M., Caskurlu T., Silay M.S.
Institutes:Medeniyet Universitesi Goztepe Egitim Arastirma Hastanesi, Dept. of Urology, Istanbul, Turkey
- *614 **Complications of male circumcision over 10 years: Single center experience**
By: Sakr A., Omran M., Fawzi A., Youssef K., Desoky E., Elkady E., Seleem M., Eliwa A., Elgalaly H., Elsayed E., Khalil S.
Institutes:Zagazig University Hospital, Dept. of Urology, Zagazig, Egypt
- *615 **Transitional care practice amongst paediatric urologists and surgeons in the UK**
By: Faure Walker N.¹, Smeulders N.², Wood D.³, Couchman A.¹
Institutes:¹Kingston Hospital, Dept. of Urology, Kingston Upon Thames, United Kingdom, ²Great Ormond Street Hospital For Children, Dept. of Urology, London, United Kingdom, ³University College London Hospital, Dept. of Urology, London, United Kingdom

Prostate cancer biomarkers: Technical advances and clinical implications

Poster Session 46

Sunday, 26 March
14:00 - 15:30

Location: Room Stockholm, North Hall (Level 1)

Chairs: M.G.K. Cumberbatch, Sheffield (GB)
S. Füssel, Dresden Johannstadt Nord (DE)
K. A. Tasken, Oslo (NO)

Aims and objectives of this presentation

Investigations on circulating tumor cells have been widely used in prostate cancer biomarker studies. Further improvements in biomarker assessment include application of MRI. New technical tools will be presented in the session.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *616 **Molecular characterization of magnetic resonance imaging visible and invisible prostate cancer: Biological insights and therapeutic implications**
By: [Salami S.](#)¹, Hovelson D.², Udager A.², Lee M.¹, Curci N.³, Kaplan J.², George A.¹, Davenport M.³, Tomlins S.², Palapattu G.¹
Institutes:¹University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ²University of Michigan, Dept. of Pathology, Ann Arbor, United States of America, ³University of Michigan, Dept. of Radiology, Ann Arbor, United States of America
- *617 **A combination of new protein biomarkers reduces unneeded prostate biopsies and improves the detection of prostate cancer: Findings of a recent study**
By: [Steuber T.](#)¹, Tennstedt P.¹, Macagno A.², Golding B.², Schiess R.², Gillissen S.³
Institutes:¹Universitätsklinikum Hamburg-Eppendorf, Martini-Clinic, Prostate Cancer Center, Hamburg, Germany, ²Proteomedix, Dept. of Biotechnology, Schlieren, Switzerland, ³Cantonal Hospital St. Gallen, Dept. of Oncology, St. Gallen, Switzerland
- *618 **Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence**
By: [Braadland P.R.](#)¹, Giskeødegård G.², Guldvik I.J.³, Sandsmark E.², Bertilsson H.⁴, Euceda L.², Hansen A.², Grytli H.H.³, Katz B.⁵, Svindland A.⁵, Berge V.⁶, Eri L.M.⁶, Nygård S.⁷, Bathen T.², Tasken K.A.¹, Tessem M-B.²
Institutes:¹Oslo University Hospital and University of Oslo, Institute of Cancer Research and Institute of Clinical Medicine, Oslo, Norway, ²Norwegian University of Science and Technology (NTNU), Dep. of Circulation and Medical Imaging, Trondheim, Norway, ³Oslo University Hospital, Institute of Cancer Research, Oslo, Norway, ⁴St.Olav's Hospital and Norwegian University of Science and Technology (NTNU), Dep. of Urology and Dep. of Circulation and Medical Imaging, Trondheim, Norway, ⁵Oslo University Hospital, Dep. of Pathology, Oslo, Norway, ⁶Oslo University Hospital, Dep. of Urology, Oslo, Norway, ⁷Oslo University Hospital, Institute of Informatics, Oslo, Norway
- *619 **Incidence rates and cancer control outcomes of contemporary primary neuroendocrine prostate cancer: Analysis of SEER database**
By: [Zaffuto E.](#)¹, Zanaty M.², Bondarenko H.D.², Pompe R.³, Dell'oglio P.¹, Gandaglia G.¹, Fossati N.¹, Stabile A.¹, Zorn K.C.⁴, Montorsi F.¹, Briganti A.¹, Karakiewicz P.I.²
Institutes:¹IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology; URI, Milan, Italy, ²University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada, ³Prostate Cancer Center Hamburg-Eppendorf, Martini-Clinic, Hamburg, Germany, ⁴University of Montreal Health Center, Dept. of Surgery, Section of Urology, Montreal, Canada

- *620 **Identification of tumour specific biomarkers associated to serum lactate dehydrogenase levels for predicting clinical responses to docetaxel chemotherapy in mCRPC**
By: [Hiew K.](#)¹, Hart C.A.², Bokobza S.³, Elliott T.⁴, Smith N.³, Brown M.², Clarke N.⁵
Institutes:¹Salford Royal NHS Foundation Trust, Dept. of Urology, Salford, United Kingdom, ²The University of Manchester, Genito Urinary Cancer Research Group, Manchester, United Kingdom, ³AstraZeneca, R&D, Oncology IMed, Macclesfield, United Kingdom, ⁴Christie Hospital NHS Foundation Trust, Dept. of Oncology, Manchester, United Kingdom, ⁵Christie Hospital NHS Foundation Trust, Dept. of Urology, Manchester, United Kingdom
- *621 **Elevated preoperative neutrophil–lymphocyte ratio predicts upgrading at radical prostatectomy**
By: [Özsoy M.](#)¹, Moschini M.¹, Fajkovic H.¹, Soria F.¹, Seitz C.¹, Klatte T.¹, Kilian G.¹, Briganti A.², Karakiewicz P.³, Roupret M.⁴, Kramer G.¹, Shariat S.¹
Institutes:¹Medical University of Vienna, Dept. of Urology, Vienna, Austria, ²Vita-Salute University, San Raffaele Scientific Institute, Urological Research Institute, Milan, Italy, ³University of Montreal, Health Centre, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada, ⁴Pitié-Salpêtrière Hospital, Dept. of Urology, Paris, France
- *622 **Perioperative search for circulating tumor cells in patients undergoing prostate brachytherapy for clinically nonmetastatic prostate cancer**
By: [Tsumura H.](#)¹, Satoh T.¹, Tabata K-I.¹, Ishiyama H.², Takenaka K.², Sekiguchi A.², Kitano M.², Hayakawa K.², Iwamura M.¹
Institutes:¹Kitasato University School of Medicine, Dept. of Urology, Sagamihara, Japan, ²Kitasato University School of Medicine, Dept. of Radiology and Radiation Oncology, Sagamihara, Japan
- *623 **Purification of urinary extracellular vesicles for uro-oncological biomarker studies using an iodixanol (Optiprep™) density gradient**
By: [Dhondt B.](#)¹, Claeys T.¹, Poelaert F.¹, Buelens S.¹, Vergauwen G.², Van Deun J.², Geurickx E.², Hendrix A.², De Wever O.², Lumen N.¹
Institutes:¹Universitair Ziekenhuis Gent, Dept. of Urology, Gent, Belgium, ²Universitair Ziekenhuis Gent, Dept. of Radiation Oncology and Experimental Cancer Research, Gent, Belgium
- *624 **Prostate cancer genomics: Identification of prognostic markers from the bone marrow**
By: [Bier S.](#)¹, Hennenlotter J.¹, Haerle U.², Karpatsi E.¹, Stenzl A.¹, Todenhoefer T.¹, Schmees C.²
Institutes:¹Eberhard-Karls-University Tuebingen, Dept. of Urology, Tübingen, Germany, ²Natural and Medical Sciences Institute, Dept. of Tumor Biology, Tübingen, Germany
- *625 **Increased CCR4-positive regulatory T cells in biopsy specimens of poor prognostic prostate cancer**
By: [Watanabe M.](#)¹, Kanao K.¹, Suzuki S.², Muramatsu H.¹, Morinaga S.¹, Kajikawa K.¹, Kobayashi I.¹, Nishikawa G.¹, Kato Y.¹, Nakamura K.¹, Yoshikawa K.³, Ueda R.², Sumitomo M.¹
Institutes:¹Aichi Medical University, Dept. of Urology, Nagakute, Japan, ²Aichi Medical University, Dept. of Tumor Immunology, Nagakute, Japan, ³Aichi Medical University, Division of Advanced Research Promotion, Nagakute, Japan
- *626 **Identification and validation of a novel blood-based biomarker of aggressive prostate cancer**
By: [Guldvik I.J.](#)¹, Grytli H.², Zuber V.³, Thiede B.⁴, Saatcioglu F.⁴, Gislefoss R.⁵, Kvåle R.⁵, George A.⁶, Gnanapragasam V.⁷, Grönberg H.⁸, Wiklund F.⁸, Neal D.⁹, Mills I.¹⁰, Taskén K. A.²
Institutes:¹Oslo University Hospital/Centre For Molecular Medicine Norway, Dept. of Prostate Cancer, Oslo, Norway, ²Oslo University Hospital, Dept. of Tumorbiology, Oslo, Norway, ³Centre For Molecular Medicine (Norway), University of Oslo and Oslo University Hospital, Dept. of Prostate Cancer, Oslo, Norway, ⁴University of Oslo, Dept. of Biosciences, Oslo, Norway, ⁵Oslo University Hospital, Dept. of Cancer Registry of Norway, Oslo, Norway, ⁶University of Cambridge, Dept. of Surgery, Cambridge, United Kingdom, ⁷University of Cambridge, Translational Prostate Cancer Group, Cambridge, United Kingdom, ⁸Karolinska Institute, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, ⁹University of Oxford, Dept. of Surgical Sciences, Oxford, United Kingdom, ¹⁰Queen's University Belfast/Centre For Molecular Medicine Norway, Dept. of Prostate Cancer UK/Movember Centre of Excellence For Prostate Cancer Research, Centre For Cancer

Research and Cell Biology, Belfast, Ireland

15:11 - 15:21

New protein biomarkers in prostate cancer
S. Füssel, Dresden Johannstadt Nord (DE)

Prostate biopsy: Improving safety, quality and efficacy

Poster Session 47

Sunday, 26 March
14:00 - 15:30

Location: Room Munich, North Hall (Level 1)

Chairs: S. Kruck, Tübingen (DE)
R. Montironi, Ancona (IT)
R.F. Van Velthoven, Brussels (BE)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *627 **Comparison of patient experience after transperineal template prostate biopsy with prior transrectal ultrasound guided prostate biopsy**
By: [Bhatt N.](#), Haroon U., Akram M., Drumm J., Flood H., Giri S.
Institutes:University Hospital Limerick, Dept. of Urology, Limerick, Ireland
- *628 **Complications following extended transperineal template mapping MRI/TRUS fusion biopsy of the prostate – initial experience from 421 procedures**
By: [Gross O.](#), Kaufmann B., Mortezaei A., Maerzendorfer O., Sulser T., Eberli D.
Institutes:University Hospital Zurich, Dept. of Urology, Zürich, Switzerland
- *629 **Absence of learning curve impact may let MRI-TRUS fusion guided biopsy up for early diagnosis of prostate cancer**
By: [Lista G.](#)¹, Lughezzani G.¹, Lazzeri M.¹, Bini V.², Hurle R.¹, Buffi N.¹, Cardone P.¹, Casale P.¹, Pasini L.¹, Zandegiacomo Dezorzi S.¹, Peschechera R.¹, Bozzini G.³, Maffei D.⁴, Guazzoni G.⁴
Institutes:¹Istituto Clinico Humanitas, Irccs, Dept. of Urology, Milan, Italy, ²Università Degli Studi Di Perugia, Dept. of Medicine, Perugia, Italy, ³Humanitas Mater Domini, Dept. of Urology, Varese, Italy, ⁴Istituto Clinico Humanitas, Irccs, Humanitas University, Dept. of Urology, Milan, Italy
- *630 **Prospective comparison of a 1.5T fast magnetic resonance imaging (MRI) protocol and the 3T multi-parametric MRI ESUR protocol as triage test for men with an elevated PSA**
By: [Vannieuwenhove S.](#)², Thiry S.¹, Annet L.², Butoescu V.¹, Lecouvet F.², Tombal B.¹
Institutes:¹Cliniques Universitaires Saint-Luc, Dept. of Urology, Brussels, Belgium, ²Cliniques Universitaires Saint-Luc, Dept. of Radiology, Brussels, Belgium
- *631 **Antimicrobial lubricant reduces rectal bacteria at transrectal prostate biopsy. Results from a large prospective randomized trial**
By: Salomon G.², Prues S.², Saul J.², Budäus L.², Tilki D.², Graefen M.², Haferkamp A.¹, [Boehm K.](#)¹
Institutes:¹University Medical Center, Johannes Gutenberg University, Dept. of Urology and Pediatric Urology, Mainz, Germany, ²University Medical Center, Martini-Clinic, Hamburg, Germany
- *632 **Rectal swab cultures and targeted prophylactic antimicrobial regimes do not reduce the risk of sepsis following transrectal prostate biopsy**
By: [Mulhem W.](#), Hadjipavlou M., Eragat M., Kenny C., Cooke A., Hammadeh M.
Institutes:Queen Elizabeth Hospital, Woolwich, Dept. of Urology, London, United Kingdom
- *633 **A prospective randomized trial of povidone-iodine suppository before transrectal ultrasound guided prostate biopsy**
By: [Lee I.J.](#), Lee S., Lee S.E., Chung Y.S., Song B.D., Hong S.K., Lee H., Kim T.J.
Institutes:Seoul National University Bundang Hospital, Dept. of Urology, Seongnam-Si, South Korea

- *634 **Prevalence and significance of fluoroquinolone-resistant bacteria carriage in patients undergoing trans rectal ultra-sonography prostate biopsy**
By: [Pourmand G.](#)¹, Hasanzadeh A.², Pourmand M.R.², Alizadeh A.³
Institutes:¹Tehran University of Medical Sciences, Urology Research Center, Tehran, Iran, ²Tehran University of Medical Sciences, Dept. of Pathobiology, Tehran, Iran, ³Tehran University of Medical Sciences, Dept. of Epidemiology and Biostatistics, Tehran, Iran
- *635 **Cribriform pattern is highly predictive factor of biochemical recurrence in positive surgical margin patients**
By: [Ku J.Y.](#), Lee C.H., Lee K., Kim K.H., Baek S.R., Park J.H., Lee J.Z., Park H.J., Han S.H., Jeong I.Y., Kwon M.J., Ha H.K.
Institutes:Pusan National University Hospital, Dept. of Urology, Busan, South Korea
- *636 **Role of dynamic contrast-enhanced (DCE) sequences in mpMRI prostate cancer diagnosis evaluated by 5 radiology residents**
By: Callaris G.¹, [Marra G.](#)¹, Oderda M.¹, Giglio J.², Misischi F.², Cimpoesu P.², Gentile F.², Bergamasco L.³, Molinaro L.⁴, Frea B.¹, Faletti R.², Fonio P.², Gontero P.¹
Institutes:¹University of Turin, Dept. of Surgical Sciences, Urology, Turin, Italy, ²University of Turin, Dept. of Surgical Sciences, Radiology Unit, Turin, Italy, ³University of Turin, Dept. of Surgical Sciences, Turin, Italy, ⁴University of Turin, Dept. of Medical Sciences, Pathology Unit, Turin, Italy
- *637 **Cost-effectiveness analysis of magnetic resonance imaging-ultrasound fusion biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer**
By: [Ingham M.](#), Mossanen M., Wang Y., Chang S.
Institutes:Brigham and Women's Hospital, Harvard Medical School, Dept. of Urology, Boston, United States of America
- *638 **Diagnostic performance of multiparametric MRI in prostate cancer: Per core analysis of three prospective ultrasound/MRI fusion biopsy datasets**
By: [Ferriero M.](#)¹, Giacobbe A.², Papalia R.³, Collura D.², Altobelli E.³, Mastroianni R.³, Tuderti G.¹, Minisola F.¹, Misuraca L.¹, Guaglianone S.¹, Muto G.³, Gallucci M.¹, Simone G.¹
Institutes:¹Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ²San Giovanni Bosco Hospital, Dept. of Urology, Turin, Italy, ³Campus Bio-Medico University, Dept. of Urology, Rome, Italy
- *639 **Withdrawn**
By:
Institutes:

15:15 - 15:23 **Associated video presentation Robotic MRI/US fusion transperineal biopsy using the iSR'obot Mona Lisa: Technique, safety and accuracy**
A. Patel, London (GB)

Predictive and prognostic factors in RCC

Poster Session 48

Sunday, 26 March
14:00 - 15:30

Location: Room 7, Capital suite (level 3)

Chairs: A. Mattei, Lucerne (CH)
M. Oya, Tokyo (JP)
B. Peyronnet, Rennes (FR)

Aims and objectives of this presentation

To discuss various predictive and prognostic factors.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

*640

Predictive factor of lymph node metastases in patients with non-metastatic renal cell carcinoma; multi-center study

By: Kim K.S.¹, Kim H.W.², Kim J.C.³, Kwak C.⁴, Kim Y-J.⁵, Kang S.H.⁶, Byun S-S.⁷, Kim S.H.¹, Hong S-H.⁸

Institutes:¹Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Dept. of Urology, Incheon, South Korea, ²St. Paul's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Dept. of Urology, Seoul, South Korea, ³Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea., Dept. of Urology, Bucheon, South Korea, ⁴Seoul National University College of Medicine, Seoul, Korea, Dept. of Urology, Seoul, South Korea, ⁵Chungbuk National University College of Medicine, Cheongju, Korea, Dept. of Urology, Cheongju, South Korea, ⁶Korea University School of Medicine, Seoul, Korea, Dept. of Urology, Seoul, South Korea, ⁷Seoul National University Bundang Hospital, Seongnam, Korea, Dept. of Urology, Seongnam, South Korea, ⁸College of Medicine, The Catholic University of Korea, Seoul, Korea, Dept. of Urology, Seoul, South Korea

Associated video presentation

*641

Long-term assessment of mortality patterns after surgical treatment for non-metastatic kidney cancer: A competing risk analysis

By: Larcher A.¹, Muttin F.¹, Nini A.¹, Trevisani F.¹, Ripa F.¹, Cianflone F.¹, Carezzi C.¹, Dell'oglio P.¹, Rigatti P.², Dehó F.¹, Montorsi F.¹, Capitanio U.¹, Bertini R.¹

Institutes:¹IRCCS Ospedale San Raffaele, Urological Research Institute, Division of Oncology, Unit of Urology, Milan, Italy, ²Scientific Institute Istituto Auxologico Italiano, Department of Urology, Advanced Urotechnology Center, Milan, Italy

Associated video presentation

*642

External validation of the Mayo Clinic Stage, Size, Grade, and Necrosis score in patients with renal cell carcinoma and venous tumor thrombus

By: Lorentz C.¹, Tai C.², Capitanio U.³, Carballido J.⁴, Ciancio G.⁵, Daneshmand S.⁶, Evans C.⁷, Gontero P.⁸, Haferkamp A.⁹, Hohenfellner M.¹⁰, Huang W.¹¹, Espinós E.¹², Martínez-Salamanca J.⁴, Mckiernan J.¹³, Montorsi F.³, Pahernik S.¹⁰, Palou J.¹⁴, Pruthi R.¹⁵, Russo P.¹⁶, Scherr D.¹⁷, Spahn M.¹⁸, Terrone C.¹⁹, Tilki D.⁷, Donoso C.²⁰, Vergho D.¹⁸, Wallen E.¹⁵, Zigeuner R.²¹, Libertino J.²², Master V.¹

Institutes:¹Emory University School of Medicine, Dept. of Urology, Atlanta, United States of America, ²University of California, Dept. of Epidemiology and Biostatistics, San Francisco, United States of America, ³University Vita-Salute, Dept. of Urology, Milan, Italy, ⁴Universidad Autónoma De Madrid, Dept. of Urology, Madrid, Spain, ⁵University of Miami, Dept. of Urology, Miami, United States of America, ⁶University of Southern California, Dept. of Urology, Los Angeles, United States

of America, ⁷University of California-Davis, Dept. of Urology, Sacramento, United States of America, ⁸University of Turin, Dept. of Urology, Turin, Italy, ⁹University of Frankfurt, Dept. of Urology, Frankfurt, Germany, ¹⁰University of Heidelberg, Dept. of Urology, Heidelberg, Germany, ¹¹New York University School of Medicine, Dept. of Urology, New York, United States of America, ¹²Hospital Universitario Infanta Sofía, Dept. of Urology, Madrid, Spain, ¹³Columbia University College of Physicians and Surgeons, Dept. of Urology, New York, United States of America, ¹⁴Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ¹⁵University of North Carolina, Dept. of Urology, Chapel Hill, United States of America, ¹⁶Memoria Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, ¹⁷Weill Cornell Medical Center, Dept. of Urology, New York, United States of America, ¹⁸University of Würzburg, Dept. of Urology, Würzburg, Germany, ¹⁹University of Eastern Piedmont, Dept. of Urology, Novara, Italy, ²⁰Hospital Universitario Y Politécnico La Fe, Dept. of Urology, Valencia, Spain, ²¹Medical University of Graz, Dept. of Urology, Graz, Austria, ²²Lahey Clinic, Dept. of Urology, Burlington, United States of America

Associated video presentation

*643

The prevalence of renal cancer detected by abdominal ultrasonography in asymptomatic individuals: A systematic review and meta-analysis to inform the case for a screening study

By: Rossi S.¹, Hsu R.¹, Blick C.², Goh V.³, Hanbury D.⁴, Nathan P.⁵, Nicol D.⁶, Fleming S.⁷, Sweeting M.⁸, Watson C.⁹, Wilson E.¹⁰, Stewart G.¹

Institutes:¹Addenbrooke's Hospital, Dept. of Urology, Cambridge, United Kingdom, ²Royal Berkshire Hospital, Dept. of Urology, Reading, United Kingdom, ³Guy's & St Thomas' Hospitals NHS Trust, Dept. of Radiology, London, United Kingdom, ⁴Lister Hospital, Dept. of Urology, Stevenage, United Kingdom, ⁵Mount Vernon Cancer Centre, Dept. of Oncology, Northwood, United Kingdom, ⁶Royal Marsden Hospital, Dept. of Urology, London, United Kingdom, ⁷Ninewells Hospital, Centre for Forensic and Legal Medicine, Dundee, United Kingdom, ⁸University of Cambridge, Dept. of Public Health and Primary Care, Cambridge, United Kingdom, ⁹National Cancer Research Institute, Renal and Bladder Cancer Clinical Studies Group, London, United Kingdom, ¹⁰University of Cambridge, Cambridge Centre for Health Services Research, Cambridge, United Kingdom

Associated video presentation

*644

Predictive and prognostic effect of inflammatory lymphadenopathies in renal cell carcinoma

By: Pecoraro A.¹, Larcher A.¹, Nini A.¹, Muttin F.¹, Stabile A.¹, Di Trapani E.¹, Carezzi C.¹, Trevisani F.¹, De Cobelli F.², Gaboardi F.¹, Guazzoni G.³, Briganti A.¹, Montorsi F.¹, Bertini R.¹, Capitanio U.¹

Institutes:¹IRCCS Ospedale San Raffaele, Urological Research Institute, Dept. of Oncology and Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Radiology, Milan, Italy, ³Humanitas Clinical and Research Centre, Dept. of Urology, Milan, Italy

Associated video presentation

*645

Prognostic significance of Fuhrman grade and age for cancer-specific and overall survival in patients with papillary renal cell carcinoma: Results of an international multi-institutional study on 2189 patients

By: Scavuzzo A.⁴, Wolff I.⁵, Jimenez Rios M.A.⁴, Capitanio U.⁶, Dell'Oglio P.⁶, Krabbe L-M.⁷, Herrmann E.⁷, Klatt T.³, Shariat S.³, Borgmann H.¹, Haferkamp A.¹, Ecke T.⁸, Vergo D.⁹, Riedmiller H.⁹, Wagener N.¹⁰, Huck N.¹⁰, Pahernik S.¹¹, Zastrow S.¹², Wirth M.¹², Musquera M.², Surcel C.¹³, Mirvald C.¹³, Kalusova K.¹⁴, Hutterer G.¹⁵, Zigeuner R.¹⁵, May M.¹⁶, Gilfrich C.¹⁶, Stief C.G.¹⁷, Brookman-May S.¹⁷

Institutes:¹University Hospital Mainz, Dept. of Urology, Mainz, Germany, ²University Hospital Barcelona, Dept. of Urology, Barcelona, Spain, ³Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁴Instituto Nacional De Cancerologia, Dept. of Urology, Mexico, Mexico, ⁵Carl-Thiem-Klinikum Cottbus, Dept. of Urology, Cottbus, Germany, ⁶Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, ⁷University of Muenster Medical Center, Dept. of Urology, Muenster, Germany, ⁸Hospital Bad Saarow, Dept. of Urology, Bad Saarow, Germany, ⁹Julius-Maximilians-University Medical Centre of Würzburg, Dept. of Urology, Würzburg, Germany, ¹⁰University Hospital Mannheim, Dept. of Urology, Mannheim, Germany, ¹¹University Hospital

Heidelberg, Dept. of Urology, Heidelberg, Germany, ¹²University Hospital Carl Gustav Carus, Dept. of Urology, Dresden, Germany, ¹³Fundeni Clinical Institute, Centre of Urological Surgery, Dialysis and Renal Transplantation, Bucharest, Romania, ¹⁴Charles University In Pilsen, Dept. of Urology, Pilsen, Czech Republic, ¹⁵Medical University Graz, Dept. of Urology, Graz, Austria, ¹⁶Klinikum St. Elisabeth Straubing, Dept. of Urology, Straubing, Germany, ¹⁷Ludwig-Maximilians-University, Dept. of Urology, Munich, Germany

Associated video presentation

*646

Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease

By: Wagener N.¹, Edelmann D.², Benner A.², Huck N.¹, Hutterer G.³, Zigeuner R.³, Borgmann H.⁴, Haferkamp A.⁴, Pahernik S.⁵, Wolff I.⁶, Krabbe L.M.⁷, Herrmann E.⁷, Verghe D.⁸, Mirvald C.⁹, Surcel C.⁹, Musquera M.¹⁰, Ecke T.¹¹, Prochazkova K.¹², Scavuzzo A.¹³, Dell'Oglio P.¹⁴, Capitanio U.¹⁴, Klatte T.¹⁵, Shariat S.¹⁵, Zastrow S.¹⁶, Wirth M.¹⁶, Cindolo L.¹⁷, May M.¹⁸, Gilfrich C.¹⁸, Stief C.¹⁹, Brookman-May S.D.¹⁹

Institutes:¹Mannheim Medical Center, University of Heidelberg, Germany, Dept. of Urology, Mannheim, Germany, ²German Cancer Research Center, Heidelberg, Germany, Dept. of Biostatistics, Heidelberg, Germany, ³Medical University of Graz, Austria, Dept. of Urology, Graz, Austria, ⁴University Medical Center, University of Mainz, Germany, Dept. of Urology, Mainz, Germany, ⁵Klinikum Nuernberg, University Hospital Paracelsus University, Nuernberg, Germany, Dept. of Urology, Nuernberg, Germany, ⁶Carl-Thiem-Klinikum Cottbus, Germany, Dept. of Urology, Cottbus, Germany, ⁷University of Muenster Medical Center, Muenster, Germany, Dept. of Urology, Muenster, Germany, ⁸Julius-Maximilians-University Medical Center Wuerzburg, Germany, Dept. of Urology, Wuerzburg, Germany, ⁹Fundeni Clinical Institute, Bucharest, Romania, Center of Urological Surgery, Dialysis and Renal Transplantation, Bucharest, Romania, ¹⁰Hospital Clinic, University of Barcelona, Spain, Dept. of Urology, Barcelona, Spain, ¹¹HELIOS Hospital, Bad Saarow, Germany, Dept. of Urology, Bad Saarow, Germany, ¹²Faculty Hospital Plzen and Faculty of Medicine Plzen, Charles University, Prague, Czech Republic, Dept. of Urology, Prague, Czech Republic, ¹³Instituto Nacional De Cancerologia (INCan), Mexico City, Mexico, Dept. of Urology, Mexico City, Mexico, ¹⁴San Raffaele Scientific Institute, Milan, Italy, Unit of Urology and Division of Experimental Oncology, Urological Research Institute (URI), Milan, Italy, ¹⁵Medical University of Vienna, Austria, Dept. of Urology, Vienna, Austria, ¹⁶University Hospital Carl Gustav Carus, Technical University of Dresden, Germany, Dept. of Urology, Dresden, Germany, ¹⁷San Pio Da Pietrelcina Hospital, Vasto, Italy, Dept. of Urology, Vasto, Italy, ¹⁸St. Elisabeth-Hospital Straubing, Germany, Dept. of Urology, Straubing, Germany, ¹⁹Ludwig-Maximilians-University, Munich, Germany, Dept. of Urology, Munich, Germany

Associated video presentation

*647

Non-metastatic renal cell carcinoma follow-up, recurrences and outcomes – a RECUR database analysis

By: Dabestani S.¹, Beisland C.², Gudmundsson E.³, Stewart G.⁴, Lam T.⁵, Gietzmann W.⁶, Zakikhani P.⁶, Marconi L.⁷, Powles T.⁸, Van Werkhoven E.⁹, Meijer R.P.¹², Ljungberg B.¹¹, Bex A.¹⁰

Institutes:¹Lund University, Dept. of Clinical Sciences, Malmö, Sweden, ²Haukeland University Hospital, Dept. of Urology, Bergen, Norway, ³Landspítali University Hospital, Dept. of Urology, Reykjavik, Iceland, ⁴University of Cambridge, Academic Urology Group, Cambridge, United Kingdom, ⁵University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, ⁶Aberdeen Royal Infirmary, Dept. of Urology, Aberdeen, United Kingdom, ⁷Coimbra University Hospital, Dept. of Urology, Coimbra, Portugal, ⁸Queen Mary University of London, Barts Cancer Institute, London, United Kingdom, ⁹The Netherlands Cancer Institute, Dept. of Bioinformatics and Statistics, Amsterdam, The Netherlands, ¹⁰The Netherlands Cancer Institute, Division of Surgical Oncology, Department of Urology, Amsterdam, The Netherlands, ¹¹Umeå University, Dept. of Surgical and Perioperative Sciences, Umeå, Sweden, ¹²University Medical Center Utrecht, Dept. of Urology, Utrecht, The Netherlands

Associated video presentation

*648

Contemporary incidence and epidemiologic trends of brain metastases at renal cell carcinoma diagnosis

By: [Gild P.](#)¹, Von Landenberg N.¹, Sun M.¹, Develasco G.², Brastianos P.³, Menon M.⁴, Fisch M.⁵, Chun F.⁵, Nguyen P.⁶, Trinh Q-D.¹, Choueiri T.²

Institutes:¹Brigham and Women's Hospital, Center For Surgery and Public Health and Division of Urologic Surgery, Boston, United States of America, ²Dana-Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America, ³Dana-Farber Cancer Institute, Dept. of Cancer Biology, Boston, United States of America, ⁴Henry Ford Hospital, VUI Center For Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Detroit, United States of America, ⁵University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ⁶Dana-Farber Cancer Institute and Brigham and Women's Hospital, Dept. of Medical Oncology, Boston, Germany

Associated video presentation

*649 **Utilization and outcomes of T2 partial nephrectomy: A US population based analysis of the national cancer database**

By: Hamilton Z., Fero K., Bloch A., Field C., Han D., [Derweesh I.](#)

Institutes: Moores Cancer Center, Dept. of Urology, La Jolla, United States of America

Associated video presentation

*650 **Contact with renal sinus is a significant risk factor for metastasis in pT1 clear cell renal cell carcinoma**

By: [Izumi K.](#)¹, Saito K.¹, Nakayama T.¹, Fukuda S.², Fukushima H.³, Uehara S.⁴, Koga F.³, Yonese J.⁴, Kageyama Y.², Kihara K.⁵, Fujii Y.⁵

Institutes:¹Tokyo Medical And Dental Graduate School, Dept. of Urology, Tokyo, Japan, ²Saitama Cancer Center, Dept. of Urology, Saitama, Japan, ³Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Dept. of Urology, Tokyo, Japan, ⁴Cancer Institute Hospital, Dept. of Urology, Tokyo, Japan, ⁵Tokyo Medical and Dental Graduate School, Dept. of Urology, Tokyo, Japan

Associated video presentation

*651 **Utility of chest x-ray in follow-up of pT1 renal cell carcinoma**

By: [Rizzo M.](#)¹, Umari P.¹, Pavan N.¹, Liguori G.¹, Verzotti E.¹, Cancellieri L.¹, Mottrie A.², Minervini A.³, Trombetta C.³

Institutes:¹Cattinara Hospital; University of Trieste, Dept. of Urology, Trieste, Italy, ²Onze-Lieve-Vrouwziekenhuis, Dept. of Urology, Aalst, Belgium, ³University Hospital Careggi, Dept. of Urology, Florence, Italy

Associated video presentation

*652 **Organ confined renal cell carcinoma - are the current guidelines sufficient?**

By: Frees S.¹, Kamal M.¹, Nestler S.², Bidnur S.³, Levien P.¹, Neisius A.¹, Jaeger W.¹, Thomas C.¹, Thueroff J.⁴, [Roos F.](#)¹

Institutes:¹University Medical Center, Dept. of Urology, Mainz, Germany, ²Hochtaunus Hospital Bad Homburg, Dept. of Urology, Bad Homburg, Germany, ³Vancouver Prostate Center, Dept. of Urology, Vancouver, Canada, ⁴University Medical Center, Dept. of Urology, Mannheim, Germany

Associated video presentation

*654 **Hospital activity and costs following partial nephrectomy: A comparison of surgical modalities using UK data**

By: Camp C.¹, O'hara J.¹, Hughes D.¹, [Adshead J.](#)²

Institutes:¹Hcd Economics, Dept. of Economics, Daresbury, United Kingdom, ²Hertfordshire and Bedfordshire Urological Cancer Centre, Lister Hospital, Dept. of Urology, Stevenage, United Kingdom

Associated video presentation

E-BLUS Exam

HOT12

Sunday, 26 March
14:15 - 15:15

Location: Room South America, Exhibition Hall (Level 1)

Aims and objectives of this presentation

The European training in basic laparoscopic urological skills (E-BLUS) is a programme offered to residents and urologists who want to improve the basic skills in laparoscopy. It is a unique opportunity to train with international experts in laparoscopy. The E-BLUS programme includes:

- Hands-on Training (HOT) courses of different levels carried out under the guidance of experienced tutors
- A set of training-box exercises developed and validated by the Dutch project Training in Urology (TiU) to train basic skills needed in urological laparoscopy
- E-BLUS examination and certification
- An online theoretical course

Advanced course on upper tract laparoscopy (kidney, UPJ, adrenal and stones)

ESU Course 28

Sunday, 26 March
14:30 - 17:30

Location: Room 10, Capital suite (level 3)

Chair: G. Janetschek, Salzburg (AT)

Aims and objectives of this presentation

Surgery of the kidney and adrenal gland by means of laparoscopy is standard of care.

Approach: Transperitoneal, retroperitoneoscopy, posterior approach, direct approach through the mesentery of the colon. Each has specific advantages.

Procedures: Virtually all ablative procedures concerning the adrenal, kidney and ureter, but also reconstruction. Rarely but effectively stone surgery.

Presentation: power-point, interactive, videos, analysis of complications.

-For surgery of the kidney and adrenal, the da Vinci robot is often overkill. Therefore standard laparoscopy should be mastered in addition.

– Choice of the perfect approach makes the respective surgery easier and safer.

Standard laparoscopy is greatly facilitated by 3D vision.

– When mastering both laparoscopic surgical skills and the surgical concept of the respective procedure complications can either be avoided or managed appropriately.

14:30 - 17:30

Approach: Transperitoneal, Retroperitoneoscopy

G. Janetschek, Salzburg (AT)

14:30 - 17:30

Nephrectomy, nephroureterectomy

A. Alcaraz, Barcelona (ES)

14:30 - 17:30

Pyeloplasty: Indication – technique – problems

H. Baumert, Paris (FR)

14:30 - 17:30

Stone surgery

A. Alcaraz, Barcelona (ES)

14:30 - 17:30

Adrenalectomy: Total and partial

H. Baumert, Paris (FR)

14:30 - 17:30

Complication management

G. Janetschek, Salzburg (AT)

14:30 - 17:30

Questions and discussion

A. Alcaraz, Barcelona (ES)

H. Baumert, Paris (FR)

G. Janetschek, Salzburg (AT)

Flexible ureterorenoscopy and retrograde intrarenal surgery: Instrumentation, technique, tips and tricks, indications

ESU Course 29

Sunday, 26 March
14:30 - 17:30

Location: Room 11, Capital suite (level 3)

Chair: O. Traxer, Paris (FR)

Aims and objectives of this presentation

The aims and objectives of this course is to provide a complete overview of instruments, endoscopes, indications, technique and special tips and tricks concerning Retrograde IntraRenal Surgery (RIRS) using flexible ureterorenoscopes and Holmium YAG lasers. At the end the participants will know the equipment and the technique to perform flexible ureterorenoscopy in the best conditions.

- To learn about equipment
- To learn about technique and indications
- To learn how to use an Holmium Laser
- To learn tips and tricks for special circumstances

14:30 - 17:30

Welcome message and introduction of the course

O. Traxer, Paris (FR)

14:30 - 17:30

Instrumentation: Endoscopes

O. Traxer, Paris (FR)

14:30 - 17:30

Instrumentation: Laser and lithotripsy devices

M. Grasso, New York (US)

14:30 - 17:30

Instrumentation: Disposable (wires, retrieving devices, UAS, irrigation devices and others)

P.J.S. Osther, Fredericia (DK)

14:30 - 17:30

Technique: Stones

O. Traxer, Paris (FR)

14:30 - 17:30

Technique: Urothelial tumours and strictures

M. Grasso, New York (US)

14:30 - 17:30

Tips and tricks and special circumstances

O. Traxer, Paris (FR)

14:30 - 17:30

Indications (guidelines) and clinical cases

P.J.S. Osther, Fredericia (DK)

14:30 - 17:30

Conclusions

O. Traxer, Paris (FR)

Penile diseases

ESU Course 30

Sunday, 26 March
14:30 - 17:30

Location: Room 12, Capital suite (level 3)

Chair: S.S. Minhas, London (GB)

Aims and objectives of this presentation

This novel course will give a state of the art update on the variety of penile diseases that Urologists will encounter in everyday clinical practice. The faculty consists of a group of internationally renowned experts in this field.

A spectrum of pathologies can affect the penis including benign disorders to cancers. There will be particular focus on interactive case based discussions highlighting the pit falls and controversies in management of penile diseases;

- The aetiology, diagnosis and medical management of the common penile diseases including inflammatory conditions of the penis.
- The medical and surgical management of HPV, BXO and pre-malignant conditions of the penis.
- The medical and surgical management of Peyronie's disease
- The course will also deal with the surgical management of these diseases including the surgical indications and surgical techniques used in penile reconstructive surgery.
- The management of penile carcinoma including the aetiopathogenesis, techniques/outcome of organ sparing surgery and surgical management of advanced disease including lymphadenectomy will be discussed.

14:30 - 17:30

Peyronie's disease

S.S. Minhas, London (GB)

14:30 - 17:30

Penile dermatology for the urologist

C. Bunker, London (GB)

14:30 - 17:30

Surgical management of penile diseases

S.S. Minhas, London (GB)

14:30 - 17:30

HPV, Premalignant lesions and penile cancer

S.S. Minhas, London (GB)

14:30 - 17:30

Management of penile cancer and lymph nodes

C. Protzel, Rostock (DE)

Surgery or radiotherapy for localised and locally advanced prostate cancer

ESU Course 31

Sunday, 26 March
14:30 - 17:30

Location: Room 14, Capital suite (level 3)

Chair: B. Djavan, Vienna (AT)

Aims and objectives of this presentation

The decision process towards surgery/active surveillance or radiation is a constantly evolving matter that requires a multitude of various information and inputs. In localised disease old habits have been jeopardised and surgical management seems to be fused with active surveillance in an increasing number of patients with good prognosticators. This course will summarise the decision process and indications for patients with clinically localised disease and help select the optimal treatment based on most recent oncological and functional data.

In locally advanced disease, growing evidence supports the notion of radical surgery to improve outcome. US and European data endorse this policy in a selected group of patients. New radiation protocols and strategies combined with hormone therapy offer as much adequate alternatives. In the second part of this course, controversies regarding the optimal management of locally advanced prostate cancer patients will be discussed and clear recommendations made to facilitate patient counselling and treatment.

14:30 - 17:30

Localised prostate cancer

14:30 - 17:30

Introduction

B. Djavan, Vienna (AT)

14:30 - 17:30

Treatment options and strategies in localised prostate cancer

B. Djavan, Vienna (AT)

14:30 - 17:30

How and when to use nomograms and networks

R.J.A. Van Moorselaar, Amsterdam (NL)

14:30 - 17:30

Oncology results of radiation therapy

A. Henry, Leeds (GB)

14:30 - 17:30

Oncological and functional results of radical prostatectomy

B. Djavan, Vienna (AT)

14:30 - 17:30

Advanced prostate cancer

14:30 - 17:30

Radiotherapy with or without hormonal treatment in advanced PCA

A. Henry, Leeds (GB)

14:30 - 17:30

Adjuvant therapies following radical prostatectomy: What is the standard and what is new?

R.J.A. Van Moorselaar, Amsterdam (NL)

14:30 - 17:30

Results of radical prostatectomy for T3 disease

B. Djavan, Vienna (AT)

14:30 - 17:30

Take home messages

B. Djavan, Vienna (AT)

Advanced vaginal reconstruction

ESU Course 32

Sunday, 26 March
14:30 - 17:30

Location: Room 15, Capital suite (level 3)

Chair: D. Pushkar, Moscow (RU)

Aims and objectives of this presentation

Clinicians involved in the care of female patients should know vaginal surgery. A specific goal of the faculty is to employ scientific principles, published information and clinical experience to describe and position newly developed techniques in current management of urinary incontinence. Special attention will be given to new techniques that use synthetic tapes in SUI surgery. This course will also cover the management of complications of surgery for stress incontinence and mesh complications. Treatment of recurrent urinary incontinence and incontinence with mixed symptoms also will be under discussion.

Management of vesicovaginal fistulas, urethral diverticulae and some rare conditions will be shown both during podium and video presentations. An interactive course means active participation by the audience and participants are encouraged to prepare and present interesting and challenging clinical cases for consultation by the faculty. After this course, participants should know how to apply the newest technique in patients with stress incontinence, urethral loss and iatrogenic injuries of lower urinary tract. This course will facilitate the decision making process for those who are just starting their careers and for advanced surgeons.

14:30 - 17:30

Introduction: Female Urology – improving functional outcome

D. Pushkar, Moscow (RU)

14:30 - 17:30

Stress urinary incontinence – approaching patient's expectations

T.J. Greenwell, London (GB)

14:30 - 17:30

Obstructive slings: What to do?

D. Pushkar, Moscow (RU)

K-D. Sievert, Salzburg (AT)

14:30 - 17:30

Autologous sling in 2016

T.J. Greenwell, London (GB)

14:30 - 17:30

Management of mesh complications

T.J. Greenwell, London (GB)

D. Pushkar, Moscow (RU)

K-D. Sievert, Salzburg (AT)

14:30 - 17:30

Urethral diverticulae surgery – tips and tricks

T.J. Greenwell, London (GB)

14:30 - 17:30

Urethral loss in females

D. Pushkar, Moscow (RU)

14:30 - 17:30

Vesico-vaginal fistulae repair from simple to complicated

D. Pushkar, Moscow (RU)

14:30 - 17:30

New slings for SUI – do you need one?

T.J. Greenwell, London (GB)

K-D. Sievert, Salzburg (AT)

14:30 - 17:30

Adjournment

Prostate cancer imaging: When and how to use it

ESU Course 33

Sunday, 26 March
14:30 - 17:30

Location: Room 16, Capital suite (level 3)

Chair: J. Walz, Marseille (FR)

Aims and objectives of this presentation

Recently new imaging technologies have been developed to improve the diagnosis and management of prostate cancer. These are multiparametric MRI, choline PET and new ultrasound based technologies.

The course's aim is to provide:

- An overview on the currently available imaging tools for prostate cancer
- Practical information about their use
- A critical assessment of their clinical performance and their limitations.

14:30 - 17:30

Introduction and objective of course

J. Walz, Marseille (FR)

14:30 - 17:30

Diagnosis of prostate cancer:

14:30 - 17:30

Standardization, acquisition and reporting of multiparametric MRI

B.M. Carey, Leeds (GB)

14:30 - 17:30

Reading of a prostate MRI and use of MRI for diagnosis of prostate cancer

B.M. Carey, Leeds (GB)

14:30 - 17:30

MRI guided biopsy and image fusion (mp MRI and Ultrasound)

J. Walz, Marseille (FR)

14:30 - 17:30

What are possible alternatives to multiparametric MRI?

J. Walz, Marseille (FR)

14:30 - 17:30

Staging of prostate cancer:

14:30 - 17:30

Staging with CT, MRI and bone scintigraphy

G. Villeirs, Ghent (BE)

14:30 - 17:30

MRI in local staging of prostate cancer

G. Villeirs, Ghent (BE)

14:30 - 17:30

Recurrent disease:

14:30 - 17:30

Use of PET in the management of prostate cancer (initial staging and recurrence)

J. Walz, Marseille (FR)

14:30 - 17:30

MRI in detection of locally recurrent prostate cancer

G. Villeirs, Ghent (BE)

14:30 - 17:30

When to do imaging of the prostate? Case discussion and current practical questions

B.M. Carey, Leeds (GB)
G. Villeirs, Ghent (BE)
J. Walz, Marseille (FR)

14:30 - 17:30

Closure and evaluation

Nerve-sparing cystectomy and orthotopic bladder substitution - Surgical tricks and management of complications

ESU Course 34

Sunday, 26 March
14:30 - 17:30

Location: Room 17, Capital suite (level 3)

Chair: A. Stenzl, Tübingen (DE)

Aims and objectives of this presentation

This course has over many years dealt with the technique of urethra- and nerve-sparing cystectomy and subsequent orthotopic bladder substitution in male and female patients. It will deal with indications, technique, possible complications and their prevention. Urologists with a vast experience in cystectomy and urinary diversion will present technical tips using videoclips, results in the literature as well as own data.

- Technique of nerve-sparing cystectomy
- Optimization of sphincter preservation for optimal continence results
- Technical tips and tricks in orthotopic neobladder surgery
- What to observe in male and female patients

14:30 - 17:30

Preoperative investigations and selection of patients for orthotopic bladder substitution

J.E. Gschwend, München (DE)

14:30 - 17:30

Arguments for nerve sparing cystectomy with orthotopic bladder substitution

A. Stenzl, Tuebingen (DE)

14:30 - 17:30

How to do a nerve-sparing cystectomy in male patients

H. Abol-Enein, Mansoura (EG)

14:30 - 17:30

Surgical tricks to avoid complications with orthotopic bladder substitution

J.E. Gschwend, München (DE)

14:30 - 17:30

Video on how to obtain good functional results in female patients

A. Stenzl, Tuebingen (DE)

14:30 - 17:30

Tips and Tricks: Male/female orthotopic urinary diversion

H. Abol-Enein, Mansoura (EG)

14:30 - 17:30

How to treat complications during follow-up

J.E. Gschwend, München (DE)

E-BLUS Exam

HOT13

Sunday, 26 March
15:30 - 16:30

Location: Room South America, Exhibition Hall (Level 1)

Aims and objectives of this presentation

The European training in basic laparoscopic urological skills (E-BLUS) is a programme offered to residents and urologists who want to improve the basic skills in laparoscopy. It is a unique opportunity to train with international experts in laparoscopy. The E-BLUS programme includes:

- Hands-on Training (HOT) courses of different levels carried out under the guidance of experienced tutors
- A set of training-box exercises developed and validated by the Dutch project Training in Urology (TiU) to train basic skills needed in urological laparoscopy
- E-BLUS examination and certification
- An online theoretical course

Improving outcomes in minimally invasive partial nephrectomy

Video Session 08

Sunday, 26 March
15:45 - 17:15

Location: eURO Auditorium (Level 0)

Chairs: To be confirmed
N. Barber, Camberley (GB)
C. Llorente, Madrid (ES)

Aims and objectives of this presentation

I would like to see up to date reports and demonstrations of advances and variation in techniques employed in performing partial nephrectomy that aim to improve the trifecta of outcome – that is, warm ischaemia time, blood loss and rate of positive margins

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

- *V58 **Purely off-clamp robotic partial nephrectomy**
By: Simone G., Misuraca L., Tuderti G., Minisola F., Ferriero M., Romeo G., Costantini M., Guaglianone S., Gallucci M.
Institutes:Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy
- *V59 **3D live surgical guidance for robot-assisted tumorectomy under superselective clamping**
By: Vuong N-S., Michiels C., Cornelis F., Grassano Y., Allenet C., Pasticier G., Robert G., Capon G., Bensadoun H., Ferrière J-M., Bernhard J-C.
Institutes:Bordeaux University Hospital, Dept. of Urology and Kidney Transplant, Bordeaux, France
- *V60 **Image guidance during robot-assisted partial nephrectomy: Results from a high volume centre**
By: De Groote R.¹, De Naeyer G.¹, Fossati N.², Umari P.³, Heinze A.⁴, Goossens M.¹, De Coninck V.¹, Schatteman P.¹, D'hondt F.¹, Mottrie A.¹
Institutes:¹OLV Ziekenhuis Aalst-Asse-Ninove, Dept. of Urology, Aalst, Belgium, ²URI; IRCCS Ospedale San Raffaele, Dept. of Oncology / Unit of Urology, Milan, Italy, ³University of Trieste, Ospedali Riuniti Di Trieste, Dept. of Urology, Trieste, Italy, ⁴Hospital Regional De Alta Especialidad De La Península De Yucatán, Dept. of Urology, Merida, Mexico
- *V61 **Robotic assisted laparoscopic tumor enucleation with artery hypothermic perfusion combined with neoadjuvant target therapy for a multifocal solitary kidney cancer**
By: Zhao X., Guo H.
Institutes:Nanjing Drum Tower Hospital, Medical School of Nanjing University, Dept. of Urology, Nanjing, China
- *V62 **Zero-ischemia partial nephrectomy using near-infrared fluorescence: Examples of complex tumors**
By: Lanchon C., Fiard G.F, Rambeaud J-J., Descotes J-L., Long J-A.
Institutes:CHU de Grenoble, Dept. of Urology, Grenoble, France
- *V64 **Combined robot-assisted salvage partial nephrectomy and cryotherapy after radiofrequency failure on a solitary kidney**
By: Michiels C.¹, Grenier N.², Grassano Y.¹, Cornelis F.², Capon G.¹, Vuong N-S.¹, Susperregui J.¹, Robert G.¹, Pasticier G.¹, Bensadoun H.¹, Ferriere J-M.¹, Bernhard J-C.¹
Institutes:¹Bordeaux University Hospital, Dept. of Urology, Bordeaux, France, ²Bordeaux University Hospital, Dept. of Radiology, Bordeaux, France
- *V65 **Robot assisted partial nephrectomy in a horse-shoe kidney with selective clamping guided by**

firefly fluorescence imaging

By: Volpe A.¹, Billia M.¹, Bondonno G.¹, Zacchero M.¹, De Angelis P.¹, Romani M.L.¹, Terrone C.²

Institutes:¹Maggiore Della Carità Hospital - University of Eastern Piedmont, Dept. of Urology, Novara, Italy, ²IRCCS Policlinico San Martino - University of Genoa, Dept. of Urology, Genova, Italy

Non muscle invasive bladder cancer: New standards in endoscopic management and adjuvant instillations

Poster Session 49

Sunday, 26 March
15:45 - 17:15

Location: Room Madrid, North Hall (Level 1)

Chairs: M. Babjuk, Prague 5 (CZ)
M. Brausi, Modena (IT)
M. Burger, Regensburg (DE)

Aims and objectives of this presentation

Non-muscle invasive bladder cancer (NMIBC) comprises a heterogeneous group in which tumour number, size, grade and pathological stage (pT) are important prognostic factors related to the risk of recurrence, progression and survival. Transurethral resection of bladder tumour (TURBT) is the reference treatment of NMIBC. The accepted standard for "correct" TURBT are complete macroscopic tumour clearance with specimens of tumour base and resection border sent separately. A key feature of the pathology report is the presence and/or invasion of lamina propria or muscularis propria, the latter being dependent upon the presence of detrusor muscle (DM) in the TURBT specimens. It is now well established that a "correct" TURBT positively influences recurrence and progression. This session aims to provide an overview of new techniques available to improve the quality of TURBT and the deliverance of adjuvant bladder instillations.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

*655

Active surveillance for non-muscle invasive bladder cancer (NMIBC): Result from bladder cancer Italian active surveillance (BIAS) project

By: [Hurle R.](#)¹, [Lazzeri M.](#)¹, [Saita A.](#)¹, [Forni G.](#)¹, [Buffi N.](#)¹, [Casale P.](#)¹, [Lughezzani G.](#)¹, [Pescechera R.](#)¹, [Pasini L.](#)¹, [Zandegiacomo S.](#)¹, [Benetti A.](#)¹, [Lista G.](#)¹, [Maffei D.](#)¹, [Cardone P.](#)¹, [Colombo P.](#)², [Guazzoni G.](#)¹

Institutes:¹Istituto Clinico Humanitas, Dept. of Urology, Rozzano, Italy, ²Istituto Clinico Humanitas, Dept. of Pathology, Rozzano, Italy

*656

Can the use of narrow-band imaging (NBI) reduce persistent bladder cancer rate during white-light classic trans-urethral resection of tumor (WLcTURBT)? A preliminary single-center experience in a large case series

By: [Giulianelli R.](#)², [Falavolti C.](#)¹, [Gentile B.C.](#)², [Mirabile G.](#)², [Tariciotti P.](#)², [Albanesi L.](#)², [Buscarini M.](#)³

Institutes:¹Villa Betania Hospital, Rome, Italy, ²Villa Claudia Clinic, Dept. of Urology, Rome, Italy, ³University Campus Bio-Medico, Dept. of Urology, Rome, Italy

*657

Monopolar versus bipolar transurethral resection for primary non-muscle invasive bladder cancer

By: [Liem E.](#)¹, [McCormack M.](#)², [Chan E.](#)³, [Matsui Y.](#)⁴, [Geavlete P.](#)⁵, [Choi Y.](#)⁶, [De Reijke T.](#)¹, [Farahat Y.](#)⁷, [Inman B.](#)⁸, [De La Rosette J.](#)¹, [Naito S.](#)⁹

Institutes:¹Academic Medical Center, Dept. of Urology, Amsterdam, The Netherlands, ²Centre Hospitalier De L'Universite De Montreal, Dept. of Urology, Montreal, Canada, ³The Chinese University of Hong Kong, Dept. of Urology, Hong Kong, China, ⁴Kyoto University, Dept. of Urology, Kyoto, Japan, ⁵Saint John Emergency Clinical Hospital, Dept. of Urology, Bucharest, Romania, ⁶Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, ⁷Sheikh Khalifa General Hospital, Dept. of Urology, Umm Al Quwain, United Arab Emirates, ⁸Duke University Medical Center, Dept. of Urology, Durham, United States of America, ⁹Harasanshin Hospital, Dept. of Urology, Fukuoka, Japan

- *659 **Is restaging transurethral resection (TUR) necessary in patients with non-muscle invasive bladder cancer (NMIBC) and focal lamina propria invasion?**
By: Audenet E.¹, Retinger C.¹, Chien C.², Benfante N.², Bochner B.¹, Donat M.¹, Herr H.¹, Dalbagni G.¹
Institutes:¹Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, ²Memorial Sloan Kettering Cancer Center, Dept. of Biostatistics, New York, United States of America
- *660 **Bladder endoscopic dissection of NMIBC procures better specimens for pathology than standard TURBT - the pathologists' perspective**
By: Daniel G.¹, Quintyn-Rant M-L.¹, Brierre T.², Roumiguié M.², Malavaud B.²
Institutes:¹Institut Universitaire Du Cancer, Dept. of Pathology, Toulouse, France, ²Institut Universitaire Du Cancer, Dept. of Urology, Toulouse, France
- *661 **Simultaneous transurethral resection of high grade bladder tumor and benign prostatic hyperplasia (BPH): Oncological safety**
By: Sionov B.V., Khunovich D., Benjamin S., Sidi A.A., Tsivian A.
Institutes:E. Wolfson M.C., Dept. of Urologic Surgery, Holon and The Sackler Faculty of Medicine Tel-Aviv University, Israel
- *662 **Safety and tolerability analysis of hyperthermic intravesical mitomycin to mitomycin alone in HIVEC I and HIVEC II: An interim analysis of 307 patients**
By: Tan W.S.¹, Palou J.², Kelly J.¹
Institutes:¹University College Hospitals London, Dept. of Surgery and Interventional Sciences, London, United Kingdom, ²Universitat Autònoma De Barcelona - Fundació Puigvert, Dept. of Urology, Barcelona, Spain
- *663 **Optimal diagnostic performance of photodynamic diagnosis (PDD) and Storz Professional Image Enhancement System (SPIES) is independent from surgeon experience**
By: Soria E., Rorato L.M., Pisano F., Allasia M., Pecoraro A., Filippini C., Zitella A., Gontero P.
Institutes:University of Turin, Città Della Salute E Della Scienza Di Torino, Dept. of Surgical Sciences, Division of Urology, Torino, Italy
- *664 **Recurrence and progression according to stage at re-tur in t1g3 bladder cancer patients treated with bcg: Not as bad as previously thought**
By: Palou J.¹, Gontero P.², Pisano F.², Joniau S.³, Oderda M.², Serretta V.⁴, Larré S.⁵, Di Stasi S.⁶, Van Rhijn B.⁷, Witjes A.J.⁸, Grotenhuis A.J.⁸, Colombo R.⁹, Briganti A.⁹, Babjuk M.¹⁰, Soukup V.¹⁰, Malmstrom P.U.¹¹, Irani J.¹², Malats N.¹³, Baniel J.¹⁴, Mano R.¹⁴, Cai T.¹⁵, Cha E.K.¹⁶, Ardelt P.¹⁷, Varkarakis J.¹⁸, Bartoletti R.¹⁹, Dalbagni G.²⁰, Shariat S.²¹, Xylinas E.¹⁶, Karnes R.J.²², Sylvester R.²³
Institutes:¹Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ²A.O. Città Della Salute E Della Scienza, University of Turin, Dept. of Urology, Turin, Italy, ³University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ⁴Paolo Giaccone General Hospital, Dept. of Urology, Palermo, Italy, ⁵John Radcliffe Hospital, University of Oxford, Dept of Surgical Science, Oxford, United Kingdom, ⁶Policlinico Tor Vergata-University of Rome, Dept of Urology, Rome, Italy, ⁷Netherlands Cancer Institute – Antoni Van Leeuwenhoek Hospital, Dept of Urology, Amsterdam, The Netherlands, ⁸Radboud University Nijmegen Medical Centre, Dept of Urology, Nijmegen, The Netherlands, ⁹Universit A Vita-Salute. Ospedale S. Raffaele, Dept of Urology, Milan, Italy, ¹⁰Motol Hospital, University of Praha, Dept of Urology, Prague, Czech Republic, ¹¹Cademic Hospital, Uppsala University, Dept of Urology, Uppsala, Sweden, ¹²Centre Hospitalier Universitaire La Mil Etrie, University of Poitiers, Dept of Urology, Poitiers, France, ¹³Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre, Dept. of Genetics, Madrid, Spain, ¹⁴Rabin Medical Centre, Dept. of Urology, Tel Aviv, Israel, ¹⁵Santa Chiara Hospital, Dept. of Urology, Trento, Italy, ¹⁶Weill Medical College of Cornell University, Dept. of Urology, New York, United States of America, ¹⁷Chirurgische Universitäts Klini, Dept. of Urology, Freiburg, Germany, ¹⁸Ismanoglio Hospital, University of Athens, Dept. of Urology, Athens, Greece, ¹⁹University of Florences, Dept. of Experimental and Clinical Medicine, Athens, Greece, ²⁰Memorial Sloan Kettering Cancer Center, New York, Dept. of Urology, New York, United States of America, ²¹Medical University of Vienna, Dept. of Urology, Vienna, Austria, ²²Mayo Clinic, Dept. of Urology, Rochester, United States of America, ²³ORTC Headquarters, Formerly Department of Biostatistics,, Brussels, Belgium

- *665 **Radiofrequency-induced thermo-chemotherapy effect plus mitomycin versus a second course of bacillus Calmette-Guérin (BCG) or institutional standard in patients with recurrence of non-muscle invasive bladder cancer following induction or maintenance BCG therapy (HYMN): A phase III, open-label, randomised controlled trial**
By: [Tan W.S.](#)¹, Buckley L.², Devall A.², Loubière L.², Pope A.², Feneley M.³, Cresswell J.⁴, Issa R.⁵, Mostafid H.⁶, Madaan S.⁷, Bhatt R.⁸, Mcgrath J.⁹, Sangar V.¹⁰, Griffiths L.¹¹, Page T.¹², Hodgson D.¹³, Datta S.¹⁴, Bilingham L.², Kelly J.¹
Institutes:¹University College London, Division of Surgery and Interventional Science, London, United Kingdom, ²University of Birmingham, Cancer Research UK Clinical Trials Unit, Birmingham, United Kingdom, ³University College London Hospitals, Dept. of Urology, London, United Kingdom, ⁴James Cook University Hospital, Dept. of Urology, Middlesbrough, United Kingdom, ⁵St George's Hospital, Dept. of Urology, London, United Kingdom, ⁶Basingstoke and North Hampshire Hospital, Dept. of Urology, London, United Kingdom, ⁷Darent Valley Hospital, Dept. of Urology, Dartford, United Kingdom, ⁸Queen Elizabeth Hospital, Dept. of Urology, Birmingham, United Kingdom, ⁹Royal Devon and Exeter Hospital, Dept. of Urology, Exeter, United Kingdom, ¹⁰Withington Hospital, Dept. of Urology, Manchester, United Kingdom, ¹¹Leicester General Hospital, Dept. of Urology, Leicester, United Kingdom, ¹²Freeman Hospital, Dept. of Urology, Newcastle, United Kingdom, ¹³Queen Alexandra Hospital, Dept. of Urology, Portsmouth, United Kingdom, ¹⁴University Hospital of Wales, Dept. of Urology, Cardiff, United Kingdom
- *666 **5-year outcomes of RITE thermochemotherapy for BCG unresponsive high risk non muscle invasive bladder cancer**
By: [Ayres B.](#), Sri D., Perry M., Issa R.
Institutes:St George's Hospital, Dept. of Urology, London, United Kingdom
- *667 **Comparison of pain, quality of life, lower urinary tract symptoms and sexual function between flexible and rigid cystoscopy in follow-up male patients with non muscle invasive bladder cancer: A randomized controlled cross section single blind study**
By: [Üçer O.](#), Temelta G., Yüksel M.B., Gümü B., Müezzino İ T.
Institutes:Celal Bayar University, Faculty of Medicine, Dept. of Urology, Manisa, Turkey
- 17:00 - 17:07 **Guidelines update**
M. Babjuk, Prague 5 (CZ)

Geriatrics in urological disorders

Poster Session 50

Sunday, 26 March
15:45 - 17:15

Location: Room Milan, North Hall (Level 1)

Chairs: J.L.H.R. Bosch, Utrecht (NL)
G.N. Thalmann, Bern (CH)
A. Wagg, Edmonton (CA)

Aims and objectives of this presentation

To explore the prevalence of urological disorders in the elderly and to evaluate the effect of various urological treatments in older people.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*668

The aging effect on the detrusor muscle serotonergic contraction in rats

By: [Takanashi A.](#)¹, [Sakai-Saitou A.](#)², [Hattori T.](#)³, [Katano Y.](#)², [Ishihata A.](#)²

Institutes:¹Juntendo University, Faculty of Health Care and Nursing, Urayasu, Japan, ²Yamagata University, Dept. of Theoretical Nursing and Pathophysiology, Yamagata, Japan, ³Asahi Kasei Pharma Corporation, Dept. of Medical Affairs, Tokyo, Japan

*669

Impact of lower urinary tract symptoms on mortality: A 15-year follow-up of Tampere Aging Male Urologic Study (TAMUS)

By: [Åkerla J.](#)², [Pesonen J.](#)¹, [Pöyhönen A.](#)², [Häkkinen J.](#)³, [Koskimäki J.](#)⁴, [Tammela T.](#)⁴, [Auvinen A.](#)⁵

Institutes:¹Päijät-Häme Central Hospital, Dept. of Surgery, Lahti, Finland, ²Central Finland Central Hospital, Dept. of Surgery, Jyväskylä, Finland, ³Turku University Hospital, Dept. of Urology, Turku, Finland, ⁴Tampere University Hospital, Dept. of Urology, Tampere, Finland, ⁵University of Tampere, School of Health Sciences, Tampere, Finland

*670

Management of lower urinary tract symptoms associated with benign prostatic hyperplasia in elderly patients with a new diagnostic, therapeutic and care pathway

By: [Carbone A.](#), [Fuschi A.](#), [Al Salhi Y.](#), [Velotti G.](#), [Leto A.](#), [Palleschi G.](#), [Pastore A.L.](#)

Institutes:Sapienza University of Rome, Dept. of Medico Surgical Sciences and Biotechnologies, Latina, Italy

*671

Recurrent urinary retention: Establishment of a multidisciplinary team board to improve alternative technics to the indwelling urinary catheter

By: [Rambaud C.](#)¹, [Gonfrier S.](#)¹, [Arlaud C.](#)¹, [Demonchy E.](#)², [Guerin O.](#)¹, [Durand M.](#)³

Institutes:¹University Hospital of Nice, Dept. of Geriatrics, Nice, France, ²University Hospital of Nice, Dept. of Infectiology, Nice, France, ³University Hospital of Nice, Dept. of Urology, Nice, France

*672

Geriatric assessment can predict outcomes of endoscopic surgery for benign prostatic hyperplasia in elderly patients

By: [Pichon T.](#)¹, [Culty T.](#)¹, [Lebdail S.](#)¹, [Launay C.P.](#)², [Collet N.](#)³, [Chautard D.](#)¹, [Cerruti A.](#)¹, [Hoarau N.](#)¹, [Brassart E.](#)¹, [Bigot P.](#)¹, [Beauchet O.](#)², [Azzouzi A-R.](#)¹

Institutes:¹Chu Angers, Dept. of Urology, Angers, France, ²Chu Angers, Dept. of Geriatric Medicine, Angers, France, ³CH Du Haut Anjou, Dept. of Geriatric Medicine, Chateau Gontier, France

*673

Pathophysiology of nocturnal lower urinary tract symptoms in older patients with urinary incontinence - a major role for nocturnal sodium excretion

By: [Denys M-A.](#)¹, [Decalf V.](#)¹, [Kumps C.](#)¹, [Petrovic M.](#)², [Goessaert A-S.](#)¹, [Everaert K.](#)¹

Institutes:¹Universitair ziekenhuis Gent, Dept. of Urology, Ghent, Belgium, ²Universitair ziekenhuis

Gent, Dept. of Geriatrics, Ghent, Belgium

- *674 **Psychological distress in patients undergoing surgery for urological cancer: A prospective single centre cross-sectional study**
 By: Pastore A.L.¹, Maruccia S.², Bou Mir A.³, Palleschi G.¹, Carbone A.¹, Camps Bellonch N.³, Palou J.⁴
Institutes:¹Sapienza University of Rome, Dept. of Medico Surgical Sciences and Biotechnologies, Latina, Italy, ²IRCCS Policlinico San Donato, Dept. of Urology, Milan, Italy, ³Fundació Puigvert, Dept. of Urology, Psychology Unit, Barcelona, Spain, ⁴Fundació Puigvert, Dept. of Urology, Barcelona, Spain
- *675 **Gait speed is a useful tool to evaluate frailty in urological cancer patients**
 By: Hatakeyama S., Narita T., Hagiwara K., Tanaka T., Noro D., Oikawa M., Tanaka Y., Imai A., Yoneyama T., Hashimoto Y., Koie T., Ohyama C.
Institutes:Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan
- *676 **Old patient, bad outcome? Prospective evaluation of preoperative assessments as predictors of outcome and functional recovery after major urologic tumour surgery. First results of a prospective single centre study.**
 By: Kahlmeyer A.¹, Losensky W.¹, Brammertz L.¹, Taubert H.¹, Wach S.¹, Keck B.¹, Ritt M.², Gassmann KG.², Wullich B.¹
Institutes:¹University of Erlangen-Nürnberg, Dept. of Urology, Erlangen, Germany, ²Geriatrics Centre Erlangen, Dept. of Internal Medicine III (Medicine of Ageing), Erlangen, Germany
- *677 **Aging risk of impaired ADL (activities of daily living) after nephrectomy and nephroureterectomy for malignancy among elderly including the aged over 80: Assessment based on 39649 cases**
 By: Sugihara T.¹, Yasunaga H.², Matui H.², Kinoshita Y.¹, Minami T.¹, Yamada Y.¹, Ishikawa A.¹, Fujimura T.³, Fukuhara H.³, Fushimi K.⁴, Homma Y.³
Institutes:¹Japanese Red Cross Medical Center, Dept. of Urology, Tokyo, Japan, ²The University of Tokyo, Dept. of Clinical Epidemiology and Health Economics, Tokyo, Japan, ³The University of Tokyo, Dept. of Urology, Tokyo, Japan, ⁴Tokyo Medical and Dental University, Dept. of Health Care Informatics, Tokyo, Japan
- *678 **The role of G8 screening tool in the assessment of surgical outcome of elderly patients (≥ 75 y.o.) with kidney tumours: A pilot study**
 By: Silvestri T., Pavan N., Chiapparrone G., Vedovo F., Di Cosmo G., Liguori G.
Institutes:University of Trieste, Dept. of Urology, Trieste, Italy
- *679 **A competing risks analysis for suicidal death in patients with bladder cancer: A 40+ year population-level analysis**
 By: Klaassen Z., Goldberg H., Chandrasekar T., Hamilton R.J., Fleshner N.E., Kulkarni G.S.
Institutes:University of Toronto, Princess Margaret Cancer Centre, Division of Urology, Toronto, Canada
- 17:00 - 17:07 **Summary**
 A. Wagg, Edmonton (CA)

Management of urological trauma and emergencies

Poster Session 51

Sunday, 26 March
15:45 - 17:15

Location: Room Paris, North Hall (Level 1)

Chairs: N.D. Kitrey, Ramat Gan (IL)
N. Lumen, Ghent (BE)
L. Martínez-Piñero, Madrid (ES)

Aims and objectives of this presentation

The aim of this session is to update on the management and long-term outcomes of urological trauma and emergencies

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *680 **Blunt renal trauma with rupture of the urinary tract: Are there still indications for endoscopic management?**
By: Overs C., Fiard G., Rambeaud J.J., Boillot B., Terrier N., Thuillier C., Pic G., Lee J.W., Peilleron N., Carnicelli D., Poncet D., Franquet Q., Lanchon C., Lefrancq J.B., Grisard S., Long J.A., Descotes J.L.
Institutes:Grenoble Teaching Hospital, Dept. of Urology, Grenoble, France
- *681 **Contemporary management of penetrating renal injuries: 11 year experience from two urban major trauma centres**
By: Hadjipavlou M.¹, Grouse E.², Gray R.³, Brown C.³, Sharma D.²
Institutes:¹St George's University Hospital, Dept. of Urology, London, United Kingdom, ²St George's Hospital, Dept. of Urology, London, United Kingdom, ³King's College Hospital, Dept. of Urology, London, United Kingdom
- *682 **Long-term complications after renal traumas: Results of a national multicentric study**
By: Dominique I.¹, Matillon X.⁴, Dariane C.⁵, Lebacle C.⁵, Pradere B.⁶, Olivier J.⁷, Freton L.², Langouet Q.⁸, Ruggiero M.⁹, Millet C.¹⁰, Bergerat S.¹¹, Panayatopoulos P.¹², Betari R.¹³, Chebbi A.¹⁴, Caes T.⁷, Patard P.M.¹⁵, Szabla N.¹⁶, Brichart N.⁸, Bohem A.⁶, Sabourin L.¹⁰, Guleryuz K.¹⁶, Rizk J.⁷, Gryn A.¹⁵, Madec F.X.¹⁷, Nouhaud F.X.¹⁴, Rod X.¹⁷, Hutin M.¹⁸, Fiard G.³, Peyronnet B.²
Institutes:¹CHU Lyon Sud, Dept. of Urology, Lyon, France, ²CHU Rennes, Dept. of Urology, Rennes, France, ³CHU Grenoble, Dept. of Urology, Grenoble, France, ⁴CHU Edouard Herriot, Dept. of Urology, Lyon, France, ⁵CHU Hôpital Européen Georges Pompidou, Dept. of Urology, Paris, France, ⁶CHU Tours, Dept. of Urology, Tours, France, ⁷CHU Lille, Dept. of Urology, Lille, France, ⁸CHU Orleans, Dept. of Urology, Orleans, France, ⁹CHU Kremlin Bicetre, Dept. of Urology, Paris, France, ¹⁰CHU Clermont Ferrand, Dept. of Urology, Clermont Ferrand, France, ¹¹CHU Strasbourg, Dept. of Urology, Strasbourg, France, ¹²CHU Angers, Dept. of Urology, Angers, France, ¹³CHU Amiens, Dept. of Urology, Amiens, France, ¹⁴CHU Rouen, Dept. of Urology, Rouen, France, ¹⁵CHU Toulouse, Dept. of Urology, Toulouse, France, ¹⁶CHU Caen, Dept. of Urology, Caen, France, ¹⁷CHU Nantes, Dept. of Urology, Nantes, France, ¹⁸CHU Montpellier, Dept. of Urology, Montpellier, France
- *683 **Renal trauma - what has changed in the past decade**
By: Eliseu M., Marques V., Antunes H., Tavares-Da-Silva E., Temido P., Nunes P., Figueiredo A.
Institutes:Coimbra Hospital and University Centre, Dept. of Urology and Renal Transplantation, Coimbra, Portugal
- *684 **Surgical management of iatrogenic ureteral injuries due to gynecological and/or radiological complications**
By: Hinev A.L.¹, Ivanov S.I.², Kosev P.A.¹, Kovachev E.G.²

Institutes:¹Varna Medical University, St. Marina University Hospital, Dept. of Urology, Varna, Bulgaria, ²Varna Medical University, Dept. of Obstetrics and Gynecology, Varna, Bulgaria

- *685 **Preventing urethral trauma from inadvertent inflation of catheter balloon in the urethra during catheterization: Evaluation of a novel safety syringe after correlating trauma with urethral distension and catheter balloon pressure**
By: Davis N.¹, Mooney R.², Cunnane C.³, Cunnane E.³, Thornhill J.¹, Walsh M.³
Institutes:¹Tallaght Hospital, Dept. of Urology, Dublin, Ireland, ²CABER, Dept. of Biomedical Engineering, Limerick, Ireland, ³CABER, Dept. of Biomedical Engineering, Limerick, Ireland
- *686 **Long-term outcome after urethral rupture: A comparison of different treatment modalities**
By: Furrer M.A., Paerli M., Thalmann G., Roth B.
Institutes:University Hospital Bern, Dept. of Urology, Bern, Switzerland
- *687 **Clinical risk factors for non salvageable testis in pediatric and adult testicular torsion patients**
By: Indradiputra I.M.U., Daryanto B., Seputra K.P., Satyagraha P., Nurhadi P.
Institutes:Medical Faculty Brawijaya University - Saiful Anwar Hospital, Departement of Urology, Malang, Indonesia
- *688 **Blunt scrotal trauma in adults: A multi-institution experience evaluating the American association for the surgery of trauma organ injury grading scale about 107 cases**
By: Sataa S.², Khouni H.¹, Boulma R.¹, Nawfel B.R.³
Institutes:¹Internal Security Forces Hospital La Marsa, Dept. of Surgery-Urology, La Marsa, Tunisia, ²Taher Maamouri University Hospital of Nabeul, Dept. of Surgery-Urology, Nabeul, Tunisia, ³Military Hospital, Dept. of Urology, Tunis, Tunisia
- *689 **Antithrombotic agents and haematuria: A systematic review**
By: Bhatt N., Davis N., Flynn R., Mcdermott T., Thomas A., Manecksha R.
Institutes:Adelaide and Meath Hospital, Dept. of Urology, Dublin, Ireland
- *690 **Pelvic fracture urethral injury – the nature of the causative injury correlates strongly with surgical treatment and outcome**
By: Bugeja S., Ivaz S., Frost A., Dragova M., Andrich D., Mundy A.
Institutes:University College Hospitals London, Dept. of Reconstructive Urology, London, United Kingdom
- *691 **Sex related penile fracture associated with urethral rupture: A retrospective multicentric study**
By: Quaresima L.¹, Gentile G.², Franceschelli A.³, Rolle L.⁴, Divenuto L.⁵, Rizzo M.⁶, Boschian R.⁶, Timpano M.⁴, Tiroli M.¹, Galosi A.B.¹, Liguori G.⁶, Vitarelli A.⁵, Frea B.⁴, Colombo F.³
Institutes:¹Polytechnic University of The Marche Region, Dept. of Urology, Ancona, Italy, ²University of Bologna, S. Orsola-Malpighi Hospital, Dept. of Urology, Bologna, Italy, ³Azienda Ospedaliero-Universitaria Di Bologna, Dept. of Andrology, Bologna, Italy, ⁴University of Turin, Città Della Salute E Della Scienza, Dept. of Urology, Turin, Italy, ⁵University of Bari, Dept. of Urology, Bari, Italy, ⁶University of Trieste, Dept. of Urology, Trieste, Italy

16:58 - 17:06

Associated video presentation Detachment of corpora cavernosa during anastomotic bulboprostatic reconstruction after pelvic trauma

L. Martínez-Piñeiro, Madrid (ES)

17:06 - 17:13

Summary

L. Martínez-Piñeiro, Madrid (ES)

Post-prostatectomy incontinence

Poster Session 52

Sunday, 26 March
15:45 - 17:15

Location: Room Amsterdam, North Hall (Level 1)

Chairs: R. Bauer, Munich (DE)
H.S. Son, Seoul (KR)
F. Van Der Aa, Leuven (BE)

Aims and objectives of this presentation

Despite considerable efforts in preserving continence after radical prostatectomy, PPI remains an important challenge.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*692

Previous incontinence surgery and surgical volume predict social continence and surgical revision: Results of a large multi-institutional study

By: Tutolo M.¹, Castagna G.², Ammirati E.³, Drake M.⁴, Thiruchelvam N.⁵, Tikkinen K.⁶, Bachmann A.⁷, Martinez-Salamanca J.⁸, Bozzini G.⁹, Bauer R.¹⁰, Heesakkers J.¹¹, Favro M.¹², Lee R.¹³, Larré S.¹⁴, De Nunzio C.¹⁵, Haab F.¹⁶, Ahyai S.¹⁷, Pichon T.¹⁸, Cornu J-N.¹⁶, Van Der Aa F.¹

Institutes:¹University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ²Urological Research Institute, IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, ³Azienda Ospedaliera Universitaria, Città Della Salute E Della Scienza, Ospedale Molinette, Università, Dept. of Urology, Turin, Italy, ⁴Spire Bristol Hospital, Dept. of Urology, Bristol, United Kingdom, ⁵Spire Cambridge Lea Hospital, Dept. of Urology, Cambridge, United Kingdom, ⁶Helsinki University Central Hospital and University of Helsinki, Dept. of Urology, Helsinki, Finland, ⁷University Hospital of Basel, Dept. of Urology, Basel, Switzerland, ⁸Hospital Ruber Internacional, Hospital Universitario Puerta De Hierro-Majadahonda, Dept. of Urology, Madrid, Spain, ⁹Humanitas Mater Domini, Dept. of Urology, Milan, Italy, ¹⁰Ludwig-Maximilian University, Dept. of Urology, Munich, Germany, ¹¹Radboud University Nijmegen MC, Dept. of Urology, Nijmegen, The Netherlands, ¹²Ospedale Maggiore Della Carità Di Novara, Dept. of Urology, Novara, Italy, ¹³NewYork-Presbyterian/Weill Cornell Medical Center, Dept. of Urology, New York, United States of America, ¹⁴CHU De Reims, Dept. of Urology, Reims, France, ¹⁵Azienda Ospedaliera Sant'Andrea, Dept. of Urology, Rome, Italy, ¹⁶CHU Charles Nicolle, Dept. of Urology, Paris, France, ¹⁷UNI-Klinikum Hamburg-Eppendorf Hamburg-Eppendorf Klinik Für Urologie, Dept. of Urology, Hamburg, Germany, ¹⁸Angers University Hospital, Dept. of Urology, Angers, France

*694

Preliminary outcomes of the European multicentre experience with the ZSI 375™ artificial urinary sphincter for treatment of stress urinary incontinence in men

By: Pottek T.¹, Ostrowski I.², Ciechan J.², Sledz E.², Dys W.², Golabek T.³, Przydacz M.³, Chlosta P.³, Blewniewski M.⁴, Von Heyden B.⁵, Neugart F.⁶, Carrieri G.⁷, Selvaggio O.⁷, Iori F.⁸

Institutes:¹Vivantes Klinikum Am Urban, Dept. of Reconstructive Urology and Genderincongruence, Berlin, Germany, ²Regional Specialistic Hospital, Dept. of Urology, Pulawy, Poland, ³Collegium Medicum of The Jagiellonian University, Dept. of Urology, Krakow, Poland, ⁴District Specialistic Hospital, Dept. of Urology, Lodz, Poland, ⁵Urology Practice, Dept. of Urology, Gaildorf, Germany, ⁶Klinikum Mittelbaden, Dept. of Urology, Baden-Baden, Germany, ⁷Foggia, Dept. of Urology, Foggia, Italy, ⁸Umberto I Hospital, Dept. of Urology, Rome, Italy

*695

Use of surgery for post radical prostatectomy urinary incontinence. Nationwide, population-based, study

By: Ventimiglia E.¹, Folkvaljon Y.², Akre O.³, Bratt O.⁴, Carlsson S.⁵, Johansson E.⁶, Peeker R.⁷, Volz D.⁵, Stattin P.⁶

Institutes:¹IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology; URI, Milan, Italy, ²Regional Cancer Centre Uppsala/Örebro, Department of Surgical Sciences, Uppsala, Sweden, ³Karolinska Institutet, Dept. of Urology, Stockholm, Sweden, ⁴Cambridge University Hospitals, Dept. of Urology/CamPARI Clinic, Cambridge, United Kingdom, ⁵Karolinska Institutet, Dept. of Molecular Medicine and Surgery, Section of Urology, Stockholm, Sweden, ⁶Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden, ⁷Sahlgrenska University Hospital, Dept. of Urology; Institute For Clinical Sciences, Gothenburg, Sweden

- *696 **Long-term outcomes after AMS 800 artificial urinary sphincter implantation in men with stress urinary incontinence: Review of 150 patients**
By: Sandri S., D'Urbano F.
Institutes:Hospital G. Fornaroli, Dept. of Urology, Magenta, Italy
- *697 **Quantitative assessment of nerve preservation improves the prediction of membranous urethral length on continence outcome after robot-assisted radical prostatectomy**
By: Grivas N.¹, Van Der Roest R.¹, Schouten D.², Cavicchioli F.³, Artibani W.³, Heijmink S.², Schoots I.², Van Der Poel H.²
Institutes:¹Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ²Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Radiology, Amsterdam, The Netherlands, ³Aouï Verona, Dept. of Urology, Verona, Italy
- *698 **MRI usefulness for prediction of urinary continence after radical prostatectomy**
By: Amoros-Torres A.², Durán-Rivera A.¹, Juan J.¹, Escudero E.², Nuño De La Rosa I.³, Ramos De Campos M.¹
Institutes:¹Valencia University General Hospital, Dept. of Urology, Valencia, Spain, ²Vinalopo University Hospital, Dept. of Urology, Elche, Spain, ³Elda General Hospital, Dept. of Urology, Elda, Spain
- *699 **Medium-term outcomes after transobturator sling placement for male post-prostatectomy urinary incontinence using a titanised mesh with De Leval technique**
By: Sacco E., Bientinesi R., Gandi C., Vaccarella L., Racioppi M., Pinto F., Totaro A., Palermo G., Bassi P.
Institutes:Agostino Gemelli Hospital Foundation, Catholic University, Dept. of Urology, Rome, Italy
- *700 **Early postoperative urinary retention as a prognostic factor for continence outcomes after insertion of transobturator sling for male stress urinary incontinence**
By: Chung A., Zuckerman J., Suarez O., Mccammon K.
Institutes:Eastern Virginia Medical School, Dept. of Urology, Norfolk, United States of America
- *701 **Efficiency and complications of the AMS AdVance™ Male Sling System for the treatment of male stress urinary incontinence: One prospective multicentric study**
By: Ye H.¹, Tonoli-Catez H.¹, M Bauer R.², De Ridder D.³, Haab F.⁴, Chauveau P.⁵, Arano P.⁶, Haillet O.⁷, Fassi-Fehri H.¹
Institutes:¹Hopital Edouard Herriot, Dept. of Urology, Lyon, France, ²Ludwig-Maximilians-University, Dept. of Urology, Munich, Germany, ³UZ Gasthuisberg, Dept. of Urology, Leuven, Belgium, ⁴Institution Tenon Hospital, Dept. of Urology, Paris, France, ⁵Clinique Jules Verne, Dept. of Urology, Nantes, France, ⁶Fundacion Puigvert, Dept. of Urodynamic, Barcelona, Spain, ⁷Hospital Bretonneau, Dept. of Urology, Tours, France
- *702 **ATOMS system for treatment of postprostatectomy urinary incontinence: A prospective single centre experience**
By: Dalpiaz O., Strini K., Ehrlich G., Pummer K., Primus G.
Institutes:LKH-Univ. Klinikum Graz, Dept. of Urology, Graz, Austria
- *703 **Mid-term follow up of the AdVance XP sling in the treatment of post-prostatectomy stress urinary incontinence – first 4-year results from a prospective multicenter trial**
By: Grabbert M.¹, Kretschmer A.¹, Klehr B.¹, Gozzi C.², Rehder P.³, May F.⁴, Homberg R.⁵, Gebhartl P.⁶, Stief C.G.¹, Bauer R.M.¹

Institutes:¹Ludwig-Maximilians-University Munich (LMU), Dept. of Urology, Munich, Germany, ²Marienlinik Bozen, Dept. of Urology, Bolzano, Italy, ³Medical University Innsbruck, Dept. of Urology, Innsbruck, Austria, ⁴Klinikum Dachau, Dept. of Urology, Dachau, Germany, ⁵St. Barbara Klinik Hamm, Dept. of Urology, Hamm, Germany, ⁶Klinikum Voecklabruck, Dept. of Urology, Voecklabruck, Austria

*704

Overactive bladder after artificial urinary sphincter implantation

By: Son H.S., Gamo M.B., Heo J.E., Oh K.T., Kim J.H.

Institutes:Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea

*705

ProACTTM device implantation after male sling failure for post-prostatectomy urinary incontinence: A monocentric experience

By: Baron M.G., Delcourt C., Nouhaud F-X., Pfister C., Grise P., Cornu J-N.

Institutes:Rouen University Hospital, Dept. of Urology, Rouen, France

Penile cancer - important details on surgical approaches

Poster Session 53

Sunday, 26 March
15:45 - 17:15

Location: Room Berlin, North Hall (Level 1)

Chairs: O.W. Hakenberg, Rostock (DE)
S. Horenblas, Amsterdam (NL)
V. Sangar, Manchester (GB)

Aims and objectives of this presentation

This session will update organ-sparing surgery in penile cancer from large series. In addition, guideline adherence and quality of care issues will be discussed.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

*706

The adherence to the EAU Guidelines on penile cancer treatment could influence the survival: Multicenter, retrospective study

By: Cindolo L.¹, Bada M.¹, Nyirády P.², Varga J.², Ditunno P.³, Boccasile S.³, Battaglia M.³, Chiodini P.⁴, Berardinelli F.¹, De Nunzio C.⁵, Tema G.⁵, Veccia A.⁶, Antonelli A.⁶, Simeone C.⁶, Puliatti S.⁷, Micali S.⁷, Schips L.¹

Institutes:¹ASL Abruzzo 2, Dept. of Urology, Chieti, Italy, ²Budapest Hospital, Dept. of Urology, Budapest, Hungary, ³University of Bari, Dept. of Emergency and Organ Transplantation, Bari, Italy, ⁴Second University of Naples, Medical Statistics Unit, Naples, Italy, ⁵S. Andrea Hospital, Dept. of Urology, Rome, Italy, ⁶Spedali Civili, Dept. of Urology, Brescia, Italy, ⁷University of Modena and Reggio Emilia, Dept. of Urology, Baggiovara, Italy

*707

Is the incidence of penile carcinoma in situ increasing in England and the rest of Europe?

By: Rodney S.¹, Arya M.², Muneer A.³

Institutes:¹University College London, Dept. of Interventional Science, London, United Kingdom, ²University College London Hospital, Dept. of Urology, London, United Kingdom, ³University College London Hospital, Dept. of Urology, London, United Kingdom

*708

The genomic profiling of penile carcinoma: DNA copy number aberrations and validation of candidate driver genes

By: La Touche S.¹, Lemetre C.², Lambros M.³, Stankiewicz E.¹, Ng C.², Weigelt B.², Rajab R.⁴, Tinwell B.⁴, Corbishley C.⁴, Watkin N.⁵, Berney D.¹, Reis-Filho J.²

Institutes:¹Barts Cancer Institute, Dept. of Molecular Oncology, London, United Kingdom, ²Memorial Sloan Kettering Cancer Centre, Dept. of Pathology, New York, United Kingdom, ³Institute of Cancer Research, Dept. of Molecular Pathology, London, United Kingdom, ⁴St Georges Hospital, Dept. of Pathology, London, United Kingdom, ⁵St Georges Hospital, Dept. of Urology, London, United Kingdom

*709

PIK3CA copy number aberration and activation of the PI3K-AKT-mTOR pathway in evolving disease states of penile cancer

By: Adimonye A.¹, Stankiewicz E.¹, Nicholson S.², Hall E.³, Kudahetti S.¹, Rajab R.⁴, Corbishley C.⁴, Lu Y-J.¹, Bahl A.⁵, Watkin N.⁶, Berney D.¹

Institutes:¹Barts Cancer Institute, Centre for Molecular Oncology, London, United Kingdom, ²Imperial College Healthcare NHS Trust, Dept. of Medical Oncology, London, United Kingdom, ³The Institute of Cancer Research, Clinical Trials & Statistics Unit, London, United Kingdom, ⁴St George's Hospital, Dept. of Histopathology, London, United Kingdom, ⁵Bristol Haematology and Oncology Centre, Dept. of Clinical Oncology, Bristol, United Kingdom, ⁶St George's Hospital, Dept. of Urology, London, United Kingdom

- *710 **A critical comparative analysis of operative complication and oncological outcome between robot assisted video endoscopic inguinal lymph node dissection and open inguinal lymph node dissection**
 By: Singh A., Shah S., Bansal P., Chatterjee S., Rawal S.
 Institutes: Rajiv Gandhi Cancer Hospital & Research Center, Dept. of Urology, Delhi, India
- *711 **Thulium laser treatment of early stage penile cancer: Initial results and functional outcomes**
 By: Musi G., Conti A., Russo A., Mistretta F.A., Serino A., Tringali V., Catellani M., Cozzi G., Bianchi R., Delor M., Ferro M., Matei V., De Cobelli O.
 Institutes: European Institute of Oncology, Dept. of Urology, Milan, Italy
- *712 **Predictive factors for local recurrence after glansectomy and neoglans reconstruction for penile squamous cell carcinoma**
 By: Albersen M.¹, Parnham A.², Sahdev V.², Christodoulidou M.², Nigam R.², Freeman A.², Jameson C.², Minhas S.², Ralph D.², Malone P.², Muneer A.²
 Institutes: ¹UZ Leuven, Dept. of Urology, Leuven, Belgium, ²University College London Hospitals, Dept. of Urology, London, United Kingdom
- *713 **The significance of close surgical margins in organ sparing surgery for penile squamous cell cancer**
 By: Sri D., Sujenthiran A., Lam W., Corbishley C., Yap T., Sharma D., Ayres B., Watkin N.
 Institutes: St Georges Hospital, Dept. of Urology, London, United Kingdom
- *714 **Prediction of postoperative complications after inguinal lymphadenectomy for penile cancer using a novel classification tool**
 By: Zhu Y.¹, Gu W-J.¹, Spiess P.², Ye D-W.¹
 Institutes: ¹Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China, ²H. Lee Moffitt Cancer Center, Dept. of Urology, FL, United States of America
- *715 **Is sarcopenia a useful prognostic indicator in patients with squamous cell carcinoma of the penis?**
 By: Christodoulidou M.¹, Attipa C.², Burden S.³, Ramachandran N.⁴, Gibson D.³, Mitra A.⁵, Lal S.⁶, Nigam R.⁷, Malone P.⁷, Richards T.⁸, Muneer A.⁷
 Institutes: ¹University College Hospitals London, Dept. of Urology, London, United Kingdom, ²University College London, London, United Kingdom, ³University of Manchester, Dept. of Dietetics, London, United Kingdom, ⁴University College London Hospital, Dept. of Radiology, London, United Kingdom, ⁵University College London Hospital, Dept. of Oncology, London, United Kingdom, ⁶University of Manchester, Dept. of Gastroenterology, London, United Kingdom, ⁷University College London Hospital, Dept. of Urology, London, United Kingdom, ⁸University College London, Division of Surgery and Interventional Radiology, London, United Kingdom
- *716 **Histopathologic and prognostic correlations regarding Human Papillomavirus (HPV) infection in penile squamous cell carcinomas (SCC) considering the novel 2016 WHO classification**
 By: Hölters S.¹, Khalmurzaev O.², Ueberdiek S.¹, Loertzer P.¹, Pfuhl T.³, Pryalukhin A.⁴, Hartmann A.⁵, Janssen M.¹, Loertzer H.⁶, Wunderlich H.⁷, Hauschild E.⁸, Bohle R.M.⁴, Smola S.³, Stöckle M.¹, Matveev V.², Junker K.¹
 Institutes: ¹Saarland University, Dept. of Urology and Paediatric Urology, Homburg, Germany, ²N.N. Blokhin Cancer Research Center, Dept. of Urology, Moscow, Russia, ³Saarland University, Institute of Virology, Homburg, Germany, ⁴Saarland University, Institute of Pathology, Homburg, Germany, ⁵Erlangen University, Institute of Pathology, Erlangen, Germany, ⁶Westpfalz-Klinikum GmbH, Dept. of Urology, Kaiserslautern, Germany, ⁷St Georg Klinikum, Dept. of Urology and Paediatric Urology, Blankenheim, Germany, ⁸Helios Clinics, Dept. of Urology, Blankenheim, Germany
- *717 **Does residual penile intraepithelial neoplasia (PeIN) require adjuvant chemotherapy after surgical excision?**
 By: Ziada M., Parnham A., Christodoulidou M., Freeman A., Bunker C., Muneer A.
 Institutes: University College London Hospital, Dept. of Urology, London, United Kingdom
- *718 **Dacomitinib (Daco) induction therapy for locally-advanced (LA) or metastatic penile squamous**

cell carcinoma (PSCC): An open label, single-arm, phase 2 study

By: [Necchi A.](#)¹, [Lo Vullo S.](#)², [Raggi D.](#)¹, [Giannatempo P.](#)¹, [Nicolai N.](#)³, [Piva L.](#)³, [Biasoni D.](#)³, [Catanzaro M.](#)³, [Torelli T.](#)³, [Stagni S.](#)³, [Calareso G.](#)⁴, [Togliardi E.](#)⁵, [Colecchia M.](#)⁴, [Busico A.](#)⁴, [Perrone F.](#)⁴, [Gloghini A.](#)⁴, [Sonpavde G.](#)⁶, [Mariani L.](#)⁷, [Salvioni R.](#)⁸

Institutes:¹Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, ²Fondazione IRCCS - Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy, ³Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, ⁴Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Radiology, Milan, Italy, ⁵Fondazione IRCCS - Istituto Nazionale Dei Tumori, Pharmacy Unit, Milan, Italy, ⁶UAB Comprehensive Cancer Center, Medical Oncology & Hematology, Birmingham, United States of America, ⁷Fondazione IRCCS Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy, ⁸Fondazione IRCCS Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy

*V90

Saphenous-sparing laparoscopic inguinal lymphadenectomy

By: [Chiapparrone G.](#)¹, [Rapisarda S.](#)², [De Concilio B.](#)³, [Zeccolini G.](#)³, [Trombetta C.](#)¹, [Celia A.](#)³

Institutes:¹University of Trieste, Dept. of Urology, Trieste, Italy, ²University of Catania, Dept. of Urology, Catania, Italy, ³San Bassiano Hospital, Dept. of Urology, Bassano Del Grappa, Italy

Improving standards through education and training

Poster Session 54

Sunday, 26 March
15:45 - 17:15

Location: Room Vienna, North Hall (Level 1)

Chairs: V.G. Mirone, Naples (IT)
D. Mitropoulos, Athens (GR)

Aims and objectives of this presentation

This session explores new ideas for improving standard of care through innovative education and training methods

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *719 **Is your career hurting you? The ergonomic consequences of surgery in 701 urologists worldwide**
By: Chung A.¹, Overbey D.², Sawyer M.³, Steinberg S.³, Williams D.⁴, Lloyd G.³
Institutes:¹University of Sydney and Concord Repatriation General Hospital, Dept. of Urology, Concord, Australia, ²University of Colorado School of Medicine, Dept. of Surgery, Denver, United States of America, ³University of Colorado School of Medicine and Veterans Administration Denver, Dept. of Urology, Denver, United States of America, ⁴University of Wisconsin School of Medicine, Dept. of Urology, Madison, United States of America
- *720 **Development of the novel endoscopic stone treatment step 1 (EST s1) assessment curriculum: EULIS, ESUT, YAUWP and ESU training research group collaboration**
By: Veneziano D.¹, Ahmed K.², Van Cleynenbreugel B.³, Goezen A.⁴, Breda A.⁵, Palou J.⁵, Sarica K.⁶, Liatsikos E.⁷, Sanguedolce F.⁸, Somani B.⁹
Institutes:¹University of Minho, School of Health Sciences, Braga, Italy, ²Guy's Hospital, Dept. of Urology, London, United Kingdom, ³University Hospital, Dept. of Urology, Leuven, Belgium, ⁴SLK Kliniken, Dept. of Urology, Heilbronn, Germany, ⁵Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ⁶Dr. Lutfi Kirdar R & T Hospital, Dept. of Urology, Istanbul, Turkey, ⁷University of Patras, Dept. of Urology, Patras, Greece, ⁸King's College Hospital, Dept. of Urology, London, United Kingdom, ⁹University Hospital Southampton, Dept. of Urology, Southampton, United Kingdom
- *721 **Consent in Urology: Are we doing it right?**
By: Khan S.², Ganta S.², Khastgir J.¹
Institutes:¹Morrison Hospital, Dept. of Urology, Swansea, United Kingdom, ²Walsall Manor Hospital, Dept. of Urology, Walsall, United Kingdom
- *722 **Urology teaching and exposure in foundation training and medical school: Is it enough?**
By: Luk A.C.O.¹, McConnell T.²
Institutes:¹Manchester Royal Infirmary, Dept. of Urology, Manchester, United Kingdom, ²Furness General Hospital, Dept. of Urology, Barrow-In-Furness, United Kingdom
- *723 **Validation of the European SIMULATE ureterorenoscopy training curriculum**
By: Aydin A.¹, Ahmed K.¹, Abe T.¹, Raison N.¹, Kunit T.², Brunckhorst O.¹, Ross T.¹, Wood T.¹, Al-Jabir A.¹, Iqbal M.¹, Aya H.¹, Brewin J.³, McIlhenny C.⁴, McCabe J.⁵, Rukin N.⁶, Patterson J.⁷, Marsh H.⁸, Dasgupta R.⁹, Samsuddin A.⁵, Khan A.¹⁰, Sievert K-D.², Khan M.S.¹, Dasgupta P.¹
Institutes:¹King's College London, Mrc Centre for Transplantation, London, United Kingdom, ²Paracelsus Medizinische Privatuniversität, Dept. of Urology, London, United Kingdom, ³Salisbury NHS Foundation Trust, Dept. of Urology, Salisbury, United Kingdom, ⁴NHS Forth Valley, Dept. of Urology, Glasgow, United Kingdom, ⁵St. Helens and Knowsley Teaching Hospitals, Dept. of Urology, Liverpool, United Kingdom, ⁶The Royal Wolverhampton NHS Trust, Dept. of Urology,

Wolverhampton, United Kingdom, ⁷Sheffield Teaching Hospitals NHS Foundation Trust, Dept. of Urology, Wolverhampton, United Kingdom, ⁸Medway NHS Foundation Trust, Dept. of Urology, Gillingham, United Kingdom, ⁹Imperial College Healthcare NHS Trust, Dept. of Urology, London, United Kingdom, ¹⁰King's College Hospital, Dept. of Urology, London, United Kingdom

- *724 **Measuring the impact on new surgical residents of undertaking a simulated ward round to test non-technical skills**
By: Mufti U.¹, Rajpal S.², Myatt A.³, Biyani C.S.¹, Jain S.¹
Institutes:¹St James' University Hospital, Leeds Teaching Hospitals NHS Trust, Dept. of Urology, Leeds, United Kingdom, ²Bradford Royal Infirmary, Bradford Teaching Hospitals NHS Foundation Trust, Dept. of Urology, Bradford, United Kingdom, ³Castle Hill Hospital, Hull and East Yorkshire Hospitals NHS Trust, Dept. of Urology, Hull, United Kingdom
- *725 **Learning of hand-assisted laparoscopic donor nephrectomy**
By: Tae B.S., Jeong C.W., Kwak C., Ku J.H., Kim H.H., Paick J-S.
Institutes:Seoul National University Hospital, Dept. of Urology, Seoul, South Korea
- *726 **Development and validation of a 3D-printed bladder model for laparoscopic and robot-simulated urethrovesical anastomosis training for radical prostatectomy**
By: Guo Y.¹, Hoogenes J.¹, Wong N.¹, Kim K.¹, Quantz M.², Shayegan B.¹, Matsumoto E.¹
Institutes:¹McMaster University, Dept. of Surgery/urology, Hamilton, Canada, ²University of Western Ontario, Dept. of Surgery, London, Canada
- *727 **Incidence, cost, complications and clinical outcomes of iatrogenic urethral catheterization injuries: A prospective multi-institutional study**
By: Davis N.¹, Quinlan M.², Bhatt N.², Browne C.¹, MacCraith E.¹, Manecksha R.², Walsh M.³, Thornhill J.², Mulvin D.¹
Institutes:¹St Vincent's University Hospital, Dept. of Urology, Co Dublin, Ireland, ²Tallaght Hospital, Dept. of Urology, Co Dublin, Ireland, ³CABER, Dept. of Biomedical Engineering, Co Dublin, Ireland
- *728 **New media for educating urology residents: A comparative interview study in Canada and Germany**
By: Salem J.¹, Borgmann H.², Macneily A.³, Boehm K.², Schmid M.⁴, Groeben C.⁵, Baunacke M.⁵, Huber J.⁵
Institutes:¹University Hospital Cologne, Dept. of Urology, Cologne, Germany, ²University Hospital Mainz, Dept. of Urology, Mainz, Germany, ³Vancouver General Hospital/University of British Columbia, Dept. of Urology, Vancouver, Canada, ⁴University Hospital Göttingen, Dept. of Urology, Göttingen, Germany, ⁵TU Dresden, Dept. of Urology, Dresden, Germany
- *729 **What do young adults know about the risk of urological disease in smokers?**
By: Fordyce W.¹, Birch B.²
Institutes:¹University of Southampton, Faculty of Medicine, Southampton, United Kingdom, ²University Hospital Southampton, Dept. of Urology, Southampton, United Kingdom
- *730 **Newsworthiness versus scientific impact: Are the most highly cited urology papers the most widely disseminated in the media?**
By: O'connor E.¹, Nason G.², O'Kelly F.³, Manecksha R.⁴, Loeb S.⁵
Institutes:¹St Vincent's Hospital, Dept. of Urology, Dublin, Ireland, ²Mater Misericordiae University Hospital, Dept. of Urology, Dublin, Ireland, ³Our Lady's Children's Hospital Crumlin, Dept. of Urology, Dublin, Ireland, ⁴St James's Hospital, Dept. of Urology, Dublin, Ireland, ⁵Laura & Isaac Perlmutter Cancer Center, Dept. of Urology and Population Health, New York, United States of America

Paediatric urology 3

Poster Session 55

Sunday, 26 March
15:45 - 17:15

Location: Room London, North Hall (Level 1)

Chairs: G. Bogaert, Leuven (BE)
K. Sarica, Istanbul (TR)
O. Telli, Çankaya/Ankara (TR)

Aims and objectives of this presentation

Paediatric urology update on paediatric stone management, obstruction and reconstructions.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *731 **Prenatal urinary tract anomalies leading to termination of pregnancy**
By: Verhovsky G.¹, Amos N.¹, Gabi K.², Maymon R.², Zisman A.¹
Institutes:¹Assaf Harofeh Medical Center, Dept. of Urology, Zrifin, Israel, ²Assaf Harofeh Medical Center, Dept. of Obstetric and Gynaecology, Zrifin, Israel
- *732 **Predictive factors for obstruction in severe uretero-pelvic junction obstruction like prenatal/postnatal USGs-prospective study**
By: Takvani A., Malaviya P.
Institutes:Takvani Kidney Hospital, Dept. of Urology, Junagadh, India
- *733 **Predictive value of cortical transit time on MAG3 for the need of surgery in antenatally detected unilateral hydronephrosis due to ureteropelvic junction stenosis**
By: Lee J.N., Lee Y.J., Chung J-W., Ha Y-S., Choi S.H., Kim B.S., Kim H.T., Kim T-H., Yoo E.S., Kwon T.G., Chung S.K., Kim B.W.
Institutes:Kyungpook National University School of Medicine, Dept. of Urology, Daegu, South Korea
- *734 **Laparoscopic transposition of lower-pole crossing vessels: Long-term follow-up of 33 patients at puberty**
By: Madec F.-X.¹, Faraj S.¹, Villemagne T.², Fourcade L.³, Lardy H.², Leclair M.-D.⁴
Institutes:¹Children University Hospital, Nantes, Dept. of Paediatric Surgery and Urology, Nantes, France, ²Children University Hospital, Tours, Dept. of Paediatric Surgery, Tours, France, ³Children University Hospital, Limoges, Dept. of Paediatric Surgery, Limoges, France, ⁴Children University Hospital, Nantes, Dept. of Pediatric Surgery and Urology, Nantes, France
- *735 **Metaphylaxis of uric acid nephrolithiasis in children: Continuous versus on-demand oral potassium citrate**
By: Abdel Aziz Elderwy A.¹, Safwat A.¹, Shahat A.¹, Almontaser H.², Hammouda H.¹
Institutes:¹Assiut University, Dept. of Urology, Assiut, Egypt, ²Assiut University, Dept. of Pediatrics, Assiut, Egypt
- *736 **Comparison of intermediate and low frequency shock wave lithotripsy for pediatric kidney stone**
By: Onur O., Kılıçarslan H., Mert A., Kordan Y.
Institutes:Uludag University, Dept. of Urology, Bursa, Turkey
- *737 **Comparison the results of 16 to 20 F percutaneous access dilatation of mini-PCNL in pediatric patients**
By: Baydilli N., Akınsal E.C., Sönmez G., Demirci D.

Institutes:Erciyes University Faculty of Medicine, Dept. of Urology, Kayseri, Turkey

*738

Experimental approach to advanced prostate cancer

Poster Session 56

Sunday, 26 March
15:45 - 17:15

Location: Room Stockholm, North Hall (Level 1)

Chairs: G. Attard, Sutton (GB)
C. Bevan, London (GB)
C. Thomas, Mainz (DE)

Aims and objectives of this presentation

Recent research has revealed several novel targets in prostate cancer. However, a single therapy approach will likely not be efficient in improving patient survival. For this reason, systemic pharmacology approaches have been developed in order to provide a scientific basis for novel therapies. The session will also address key issues of drug delivery in prostate cancer.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *746 **Identification and characterization of selective androgen receptor degraders (SARDs) for the treatment of enzalutamide unresponsive and/or resistant prostate cancer**
By: [Getzenberg R.](#)¹, Ponnusamy S.², Thiyagarajan T.³, Hwang D-J.³, He Y.³, Mcewan I.⁴, Watt C.⁴, Moldoveanu T.⁵, Miller D.⁶, Narayanan R.²
Institutes:¹Gtx Inc, Dept. of Prostate Cancer, Memphis, United States of America, ²University of Tennessee Health Science Center, Dept. of Medicine, Memphis, United States of America, ³University of Tennessee Health Science Center, Dept. of Pharmaceutical Sciences, Memphis, United States of America, ⁴School of Medicine, Institute of Medical Sciences, Aberdeen, United Kingdom, ⁵St. Judes Children's Research Hospital, Dept. of Structural Biology, Memphis, United States of America, ⁶University of Tennessee Health Science Center, Pharmaceutical Sciences, Memphis, United States of America
- *747 **Targeting enzalutamide-resistant prostate cancer using the novel androgen receptor inhibitor ODM-201**
By: [Borgmann H.](#), Ozistanbullu D., Beraldi E., Dalal K., Fazli L., Gleave M.
Institutes: Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada
- *748 **Targeting androgen receptor variants by niclosamide overcomes resistance to abiraterone and enzalutamide**
By: Liu C., Lou W., Pan C-X., Evans C., [Gao A.](#)
Institutes: University of California Davis, Dept. of Urology, Sacramento, United States of America
- *749 **The STAT3 inhibitor galiellalactone prevents prostate cancer cell induced generation of myeloid derived suppressor cells from monocytes ex vivo**
By: [Hellsten R.](#)¹, Leandersson K.², Johansson M.³, Bjartell A.¹
Institutes:¹Division of Urological Cancers, Dept. of Translational Medicine, Lund University, Malmö, Sweden, ²Cancer Immunology, Dept. of Translational Medicine, Lund University, Malmö, Sweden, ³Glactone Pharma AB, Helsingborg, Sweden
- *750 **The multi-kinase inhibitor EC-70124 delivers a double-hit to prostate cancer stem cells interfering with both STAT3 and NF-κB signaling**
By: Civenni G.¹, Shinde D.¹, Zoma M.¹, Albino D.¹, Costales P.², Moris F.², Carbone G.¹, [Catapano C.](#)¹
Institutes:¹IOR Institute of Oncology Research, Tumor Biology and Experimental Therapeutic, Bellinzona, Switzerland, ²Edificio Científico Tecnológico, EntreChem, EntreChem, Oviedo, Spain

- *751 **Dopamine hydrochloride relative nanoparticles in the treatment of prostate cancer**
 By: [Zhang C.](#), Zhao X., Lin T., Guo H.
 Institutes: Nanjing Drum Tower Hospital, Dept. of Urology, Nanjing, China
- *752 **ALK1Fc suppresses tumor growth by impairing proliferation of human prostate cancer cells in vitro and in vivo**
 By: [Astrologo L.](#)¹, Zoni E.¹, Karkampouna S.¹, Gray P.², Klima I.¹, Grosjean J.¹, Goumans M.J.², Hawinkels L.², Van Der Pluijm G.³, Ten Dijke P.², Spahn M.⁴, Thalmann G.⁴, Kruithof-De Julio M.¹
 Institutes:¹Urology Research Laboratory, Dept. of Clinical Research, Bern, Switzerland, ²Leiden University Medical Center, Dept. of Molecular Cell Biology, Leiden, The Netherlands, ³Leiden University Medical Center, Dept. of Urology, Leiden, The Netherlands, ⁴University Hospital Bern, Dept. of Urology, Bern, Switzerland
- *754 **Systems pharmacology and quantitative proteomics for developing targeted triple therapy**
 By: [Ebhardt H.A.](#)¹, Root A.², Beizaei A.¹, Liu Y.³, Gauthier N.⁴, Sander C.⁴, Aebersold R.³
 Institutes:¹University College Dublin, Systems Biology Ireland, Dublin, Ireland, ²Memorial Sloan-Kettering Cancer Center, Weill Cornell Graduate School of Medical Sciences, New York City, United States of America, ³ETH Zurich, Institute of Molecular Systems Biology, Zurich, Switzerland, ⁴Dana-Farber Cancer Institute, CBio Center At Dana-Farber, Boston, United States of America
- *755 **Transdermal delivery of leuprolide acetate with chitosan microneedles: A promising tool for androgen deprivation therapy**
 By: [Tsai Y-S.](#)¹, Chen M-Y.², Lan S-K.³, Tsai H-T.⁴, Chen M-C.⁵, Tzai T-S.⁶
 Institutes:¹National Cheng Kung University Hospital, Dept. of Urology, Tainan, Taiwan, ²Madou SinLau Hospital, Dept. of Urology, Tainan, Taiwan, ³Dalin Tzu-Chi Hospital, Dept. of Urology, Tainan, Taiwan, ⁴National Cheng-Kung University Hospital, Dept. of Urology, Tainan, Taiwan, ⁵National Cheng-Kung University, Dept. of Chemical Engineering, Tainan, Taiwan, ⁶Tainan An-Nan Hospital, Dept. of Urology, Tainan, Taiwan
- *756 **Co-treatment with L-methadone increases the efficacy of cytostatic drugs in prostate cancer cells**
 By: Stadlbauer B.¹, Kozian D.², Stief C.¹, [Buchner A.](#)¹
 Institutes:¹Ludwig-Maximilians-University Munich, Dept. of Urology, Munich, Germany, ²Sanofi-Aventis GmbH, Research Department, Frankfurt, Germany
- *757 **SEMA3C drives cancer growth and treatment resistance via cognate ligand-independent activation of multiple receptor tyrosine kinases**
 By: [Takeuchi A.](#)¹, Masaki S.¹, Peacock J.², Eto M.¹, Martin E G.², Ong C.²
 Institutes:¹Graduate School of Medical Sciences, Kyushu University, Dept. of Urology, Fukuoka, Japan, ²University of British Columbia, Vancouver Prostate Centre, Vancouver, Canada
- 16:58 - 17:08 **New approaches to overcome endocrine therapy resistance in prostate cancer**
 G. Attard, Sutton (GB)

Prostate cancer: Is the future focal?

Poster Session 57

Sunday, 26 March
15:45 - 17:15

Location: Room Munich, North Hall (Level 1)

Chairs: E. Barret, Paris (FR)
B. Hollenbeck, Ann Arbor (US)
M. Valerio, Lausanne (CH)

Aims and objectives of this presentation

The aim of this session is to update on the use of focal therapy and non-whole gland treatments

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *758 **Intra-prostatic injection of PRX302 to focally ablate clinically significant prostate cancer: An open label, phase 2a study**
By: Shanmugabavan Y.¹, Bass E.¹, Hulme A.², Freeman A.³, Brew-Graves C.¹, Potyka I.¹, Ramachandran N.⁴, Emberton M.¹
Institutes:¹University College London, Division of Surgery and Interventional Sciences, London, United Kingdom, ²Sophiris, Sophiris Bio Corporation, California, United States of America, ³University College London Hospital, Dept. of Histopathology, London, United Kingdom, ⁴University College London Hospital, Dept. of Radiology, London, United Kingdom
- *759 **Impact of the use of N2O for general anesthesia during high intensity focused ultrasound (HIFU) for the treatment of localized prostate cancer**
By: Potiron E.¹, Lacoste J.², Le Goguic G.², Rousseau T.², Nevoux P.²
Institutes:¹Clinique Urologique Nantes Atlantis, Dept. of , Saint Herblain, France, ²Clinique Urologique Nantes Atlantis, Dept. of, Saint Herblain, France
- *760 **Prospective comparative analysis of oncologic and functional outcomes between focal therapy and robotic radical prostatectomy**
By: Garcia Barreras S.¹, Sanchez-Salas R.¹, Sivararam A.², Secin F.³, Redondo C.¹, Velilla G.¹, Barret E.¹, Nunes-Silva I.¹, Srougi V.¹, Baghdadi M.¹, Galiano M.¹, Rozet F.¹, Cathala N.¹, Mombet A.¹, Prapotnich D.¹, Cathelineau X.¹
Institutes:¹Institut Mutualiste Montsouris, Dept. of Urology, Paris, France, ²Memorial Sloan Kettering, Dept. of Urology, New York, United States of America, ³CEMIC, Dept. of Urology, Buenos Aires, Argentina
- *761 **A phase III study comparing partial prostate ablation versus radical prostatectomy (PART) in intermediate risk prostate cancer – initial data from the feasibility study**
By: Leslie T.¹, Elliott D.³, Le Conte S.¹, Brewster S.², Sooriakumaran P.¹, Bryant R.¹, Dudderidge T.⁴, Rosario D.⁵, Catto J.⁵, Hindley R.⁶, Emberton M.⁷, Ahmed H.⁷, Donovan J.³, Hamdy F.¹
Institutes:¹Oxford University - Churchill Hospital, Dept. of Urology, Oxford, United Kingdom, ²Churchill Hospital, Dept. of Urology, Oxford, United Kingdom, ³University of Bristol, Dept. of Social and Community Medicine, Bristol, United Kingdom, ⁴University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom, ⁵Sheffield Teaching Hospitals, Dept. of Urology, Sheffield, United Kingdom, ⁶Basingstoke and North Hampshire Hospital, Dept. of Urology, Basingstoke, United Kingdom, ⁷University College London Hospital, Dept. of Urology, London, United Kingdom
- *762 **First repeated biopsy represents the most informative predictor of progression-free survival at 3**

years follow-up in patients included in an active surveillance protocol for low-risk prostate cancer

By: [Luzzago S.](#)¹, Suardi N.¹, Dell'oglio P.¹, Fossati N.¹, Capitanio U.¹, Gandaglia G.¹, Zaffuto E.¹, Mirone V.², Bertini R.¹, Damiano R.⁴, Freschi M.³, Gaboardi F.¹, Montorsi F.¹, Briganti A.¹

Institutes:¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²"Federico II" University, Dept. of Urology, Naples, Italy, ³Vita-Salute University San Raffaele, Dept. of Pathology, Milan, Italy, ⁴Magna Graecia University, Dept. of Urology, Catanzaro, Italy

*763

A nomogram for prediction of local cancer recurrence after primary prostate cryoablation

By: [El Shafei A.](#)¹, Tay K.J.², Ross A.³, Given R.⁴, Parsons J.K.⁵, Mouraviev V.⁶, Polascik T.², Jones J.S.¹

Institutes:¹Cleveland Clinic Foundation, Glickman Urological and Kidney Institute, Cleveland, United States of America, ²Duke Cancer Institute, Dept. of Urology, Durham, United States of America, ³The Johns Hopkins Medical Institution, Dept. of Urology, Baltimore, United States of America, ⁴Eastern Virginia Medical School, Dept. of Urology, Virginia, United States of America, ⁵UC San Diego Health System, Dept. of Urology, San Diego, United States of America, ⁶Global Robotics Institute, Dept. of Urology, Celebration, United States of America

*764

MRI-guided transurethral ultrasound ablation in patients with localized prostate cancer: 24-month outcomes of a prospective phase I clinical trial

By: [Chin J.](#)¹, Relle J.², Billia M.³, Siddiqui K.M.³, Kuru T.⁴, Hatiboglu G.⁴, Ionel V.P.⁴, Hafron J.², Matthias R.⁴, Mueller-Wolf M.⁴, Zahra K.⁴, Kibria F.⁵, Burtnyk M.⁵, Schlemmer H-P.⁴, Pahernik S.⁴

Institutes:¹Western University, Dept. of Urology, London, Canada, ²Beaumont Health System, Department of Urology, Dept. of Urology and Radiology, Royal Oak, United States of America, ³Western University, Dept. of Urology, London, Canada, ⁴German Cancer Research Center (DKFZ), Dept. of Urology and Radiology, Heidelberg, Germany, ⁵Profound Medical Inc., Dept. of Engineering, Toronto, Canada

*766

Neoadjuvant hormonal therapy for patients with low risk prostate cancer stimulates lymphvessel invasion and shorten biochemical recurrence-free survival periods

By: [Miyata Y.](#)¹, Mochizuki Y.¹, Shida Y.¹, Matsuo T.¹, Hakariya T.¹, Ohba K.¹, Furusato B.², Fukuoka J.², Sakai H.¹

Institutes:¹Nagasaki University Graduate School of Biomedical Sciences, Dept. of Urology, Nagasaki, Japan, ²Nagasaki University Hospital, Dept. of Pathology, Nagasaki, Japan

*767

Salvage prostate cryoablation in older men

By: Parsons K.², Ross A.³, [El Shafei A.](#)¹, Hatem A.¹, Cotta B.², Tay K.J.⁴, Polascik T.⁴, Given R.⁵, Mouraviev V.⁶, Jones J.S.¹

Institutes:¹Cleveland Clinic Foundation, Glickman Urological and Kidney Institute, Cleveland, United States of America, ²UC San Diego Health System, Dept. of Urology, San Diego, California, United States of America, ³The Johns Hopkins Medical Institution, Dept. of Urology, Baltimore, Md, United States of America, ⁴Duke Cancer Institute, Dept. of Urology, Durham, Nc, United States of America, ⁵Eastern Virginia Medical School, Dept. of Urology, Virginia, United States of America, ⁶Global Robotics Institute, Dept. of Urology, Celebration, Florida, United States of America

*768

Current national trends in the management of locally advanced prostate cancer with radical therapies: Results from the English National Prostate Cancer Audit

By: [Sujenthiran A.](#)¹, Nossiter J.¹, Charman S.¹, Aggarwal A.¹, Cathcart P.², Payne H.³, Clarke N.⁴, Van Der Meulen J.¹

Institutes:¹Royal College of Surgeons, Clinical Effectiveness Unit, London, United Kingdom, ²Guy's and St Thomas' NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ³University College London Hospitals, Dept. of Oncology, London, United Kingdom, ⁴The Christie and Salford Royal NHS Foundation Trusts, Dept. of Urology, London, United Kingdom

16:54 - 17:02

Associated video presentation MRI/US fusion office-based targeted cryoablation with local anesthesia

F.J. Bianco, Miami Lakes (US)

17:02 - 17:09

Summary

E. Barret, Paris (FR)

Renal cell carcinoma treatment: The search for the right strategy

Poster Session 58

Sunday, 26 March
15:45 - 17:15

Location: Room 7, Capital suite (level 3)
Chairs: S. Fernández-Pello Montes, Gijón (ES)
F. Porpiglia, Orbassano (turin) (IT)

Aims and objectives of this presentation

To discuss various aspects which impact the indication for RCC therapy

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *769 **Modified 5-item frailty index is associated with increased healthcare resource utilization following elective minimally invasive radical nephrectomy**
By: Xia L., Taylor B., [Guzzo T.](#)
Institutes:University of Pennsylvania, Perelman School of Medicine, Division of Urology, Dept. of Surgery, Philadelphia, United States of America
- *770 **Is a preoperative low ejection fraction a risk factor for complications and impaired survival in renal cancer patients who undergo surgery? Results from a propensity-score matching with non cardiopathic counterparts**
By: [Nini A.](#)¹, Larcher A.¹, Muttin F.¹, Zaffuto E.¹, Dell'oglio P.¹, Ripa F.¹, Carezzi C.¹, La Croce G.¹, Oppizzi M.², Fragasso G.², Montorsi F.¹, Capitanio U.¹, Bertini R.¹
Institutes:¹IRCCS San Raffaele, Dept. of Urology, Division of Oncology/Unit of Urology, URI, Milan, Italy, ²IRCCS San Raffaele, Dept. of Cardiology, Milan, Italy
- *771 **The ability of three comorbidity indexes to predict postoperative mortality in renal cell carcinoma patients: The impending need of a new disease-specific index**
By: [Dell'oglio P.](#), Larcher A., Muttin F., Fossati N., Nini A., Ripa F., La Croce G., Trevisani F., Carezzi C., Salonia A., Briganti A., Montorsi F., Bertini R., Capitanio U.
Institutes:IRCCS Ospedale San Raffaele, Urological Research Institute, Dept. of Oncology and Urology, Milan, Italy
- *772 **Should partial nephrectomy be considered an imperative indication in stage II chronic kidney disease?**
By: Hamilton Z.¹, Larcher A.³, Lane B.², Capitanio U.³, Hassan A-E.¹, Berquist S.¹, Dufour C.¹, Beksac A.T.¹, Wan F.¹, Proudfoot J.¹, [Derweesh I.](#)¹, Montorsi F.³
Institutes:¹Moore's Cancer Center, Dept. of Urology, La Jolla, United States of America, ²Spectrum Health, Dept. of Urology, Grand Rapids, United States of America, ³San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy
- *773 **Tumor size is associated with compensatory hypertrophy in the contralateral kidney before and after radical nephrectomy in patients with renal cell carcinoma**
By: [Park B.H.](#), Bae S.R., Lee Y.S., Kang S.H., Han C.H.
Institutes:Uijeongbu St. Mary's Hospital, Dept. of Urology, Uijeongbu-Si, South Korea
- *774 **Clinical application of calculated split renal volume using computed tomography-based renal volumetry after partial nephrectomy: Correlation with 99mTc-DMSA renal scan data**
By: Lee C.H., [Ku J.Y.](#), Ha H.K.
Institutes:Pusan National University Hospital, Dept. of Urology, Busan, South Korea

- *775 **Functional data as assessed by renal scintigraphy and volumetric assessment on CT-scan prior and after partial nephrectomy. Is there a correlation?**
By: Porpiglia F.¹, Bertolo R.¹, Amparore D.¹, Piramide F.¹, Checcucci E.¹, Angusti T.², Barrera M.³, Sardo D.³, Veltri A.³, Mele F.¹, Fiori C.¹
Institutes:¹San Luigi Hospital, Dept. of Urology, Turin, Italy, ²San Luigi Hospital, Dept. of Nuclear Medicine, Turin, Italy, ³San Luigi Hospital, Dept. of Radiology, Turin, Italy
- *776 **Characterisation of solid renal tumours with magnetic resonance elastography (MRE) at 3T: Integrating biomechanical, morphological and functional assessment**
By: Prezzi D.¹, Neji R.², Stirling J.¹, Jeljeli S.¹, Verma H.³, O'brien T.⁴, Challacombe B.⁴, Fernando A.⁴, Sinkus R.⁵, Goh V.¹
Institutes:¹King's College London, Dept. of Cancer Imaging, London, United Kingdom, ²Siemens Healthineers, Dept. of MR Research Collaborations, Frimley, United Kingdom, ³Guy's and St Thomas' NHS Foundation Trust, Dept. of Radiology, London, United Kingdom, ⁴Guy's and St Thomas' NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁵King's College London, Dept. of Biomedical Engineering, London, United Kingdom
- *777 **Discrimination of malignant and benign kidney tissue with 1064 nm dispersive Raman spectroscopy**
By: Haifler M.¹, Pence I.², Ristau B.¹, Greenberg R.¹, Chen D.¹, Smaldone M.¹, Kutikov A.¹, Viterbo R.¹, Uzzo R.¹, Zisman A.³, Mahadeven-Jensen A.², Patil C.⁴
Institutes:¹Fox Chase Cancer Center, Dept. of Urology, Philadelphia, United States of America, ²Vanderbilt University, Dept. of Biomedical Engineering, Nashville, United States of America, ³Assaf Harofe Medical Center, Dept. of Urology, Be'er Ya'akov, Israel, ⁴Temple University, Dept. of Biomedical Engineering, Philadelphia, United States of America
- *778 **Topographic distribution of sentinel lymph nodes in patients with renal tumours**
By: Kuusk T.¹, Grivas N.¹, Donswijk M.², Prevoo W.³, Horenblas S.¹, Bex A.¹
Institutes:¹Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ²Netherlands Cancer Institute, Dept. of Nuclear Medicine, Amsterdam, The Netherlands, ³Netherlands Cancer Institute, Dept. of Radiology, Amsterdam, The Netherlands
- *779 **The effect of anatomical location of retroperitoneal lymph node metastases on cancer specific survival in patients with clear cell renal cell carcinoma**
By: Nini A.¹, Larcher A.¹, Terrone C.², Volpe A.², Muttin F.¹, Ripa F.¹, Regis F.², Lucianò R.³, Briganti A.¹, Bertini R.¹, Montorsi F.¹, Capitanio U.¹
Institutes:¹IRCCS San Raffaele, Dept. of Urology, Division of Oncology, Milan, Italy, ²University Hospital Maggiore Della Carità, University of Piemonte Orientale, Dept. of Urology, Novara, Italy, ³IRCCS San Raffaele, Dept. of Pathology, Milan, Italy
- *780 **Lymph node dissection is not associated with increased 30-Day complications among patients undergoing radical nephrectomy for renal cell carcinoma: A propensity-score based analysis**
By: Gershman B.¹, Moreira D.², Thompson R.H.³, Boorjian S.³, Lohse C.⁴, Costello B.⁵, Cheville J.⁶, Leibovich B.³
Institutes:¹Rhode Island Hospital And The Miriam Hospital, Dept. of Urology, Providence, United States of America, ²University of Illinois, Dept. of Urology, Chicago, United States of America, ³Mayo Clinic, Dept. of Urology, Rochester, United States of America, ⁴Mayo Clinic, Health Sciences Research, Rochester, United States of America, ⁵Mayo Clinic, Dept. of Oncology, Rochester, United States of America, ⁶Mayo Clinic, Dept. of Pathology, Rochester, United States of America

16:56 - 17:04

Associated video presentation Laparoscopic inter-aorto-caval lymph-node dissection for RCC
 R. Bass, Holon (IL)

EBU Session: Postgraduate training and education in European urology

Special session

Sunday, 26 March
15:45 - 16:45

Location: Room 9, Capital suite (level 3)

Chairs: A.J. Figueiredo, Coimbra (PT)
A. Papatsoris, Marousi - Athens (GR)

Aims and objectives of this presentation

The common purpose of all urologists is the best care for the patient. The EBU in collaboration with the EAU and national urological organisations is concerned with the standards of training and education for urologists of the present and the future. The aim of this session is to explore current and future needs.

15:45 - 15:50

Introduction: The European Board of Urology and its role

A.J. Figueiredo, Coimbra (PT)
A. Papatsoris, Marousi - Athens (GR)

15:50 - 16:00

Standards for teaching and teachers in urology

J.D. Nawrocki, Brighton (GB)

16:00 - 16:10

Competence-based training and revalidation

A. Antoniewicz, Warsaw (PL)

16:10 - 16:20

Continuing medical education and professional development

To be confirmed

16:20 - 16:30

The Young Academic Urologist's (YAU) perspectives in training

M.S. Silay, Istanbul (TR)

16:30 - 16:40

Discussion

16:40 - 16:45

Conclusion

A.J. Figueiredo, Coimbra (PT)
A. Papatsoris, Marousi - Athens (GR)

E-BLUS Exam

HOT14

Sunday, 26 March
16:45 - 17:45

Location: Room South America, Exhibition Hall (Level 1)

Aims and objectives of this presentation

The European training in basic laparoscopic urological skills (E-BLUS) is a programme offered to residents and urologists who want to improve the basic skills in laparoscopy. It is a unique opportunity to train with international experts in laparoscopy. The E-BLUS programme includes:

- Hands-on Training (HOT) courses of different levels carried out under the guidance of experienced tutors
- A set of training-box exercises developed and validated by the Dutch project Training in Urology (TiU) to train basic skills needed in urological laparoscopy
- E-BLUS examination and certification
- An online theoretical course

Management of prostate cancer

Plenary session 05

Monday, 27 March
07:30 - 11:00

Location: eURO Auditorium (Level 0)

Chairs: A. Briganti, Milan (IT)
M. Wirth, Dresden (DE)

Aims and objectives of this presentation

The aim of this session is to discuss and debate about the role of screening, early detection and optimal treatment of localized prostate cancer. The role of screening based on the most updated results of prospective randomized studies will be debate and different PSA-based approaches will be discussed. In addition, strengths and limits of prostate MRI in improving our ability to detect of clinically significant prostate cancer will be covered. Finally, the optimal management of localized prostate cancer including local treatment and active surveillance will be discussed.

During the plenary sessions, French and Spanish translation will be provided. Please collect your headset in the session room prior to the start of the session and return it after the session.

Meet the speakers of the plenary session:

Delegates are able to meet the speakers of the plenary session immediately at the end of the session in the foyer of the eURO Auditorium (Level 0). Do not miss this opportunity to meet and greet the speakers and to consult them for any questions you may have.

07:30 - 08:00

EAU Consensus highlights and late breaking news

08:00 - 08:30

Debate Prostate cancer screening: Time to change recommendations for PSA testing?

08:00 - 08:15

Yes
J. Hugosson, Göteborg (SE)

08:15 - 08:30

No
G. Andriole, St. Louis (US)

08:30 - 09:00

State-of-the-art lecture MRI prior to biopsy – Results from the PROMIS trial

08:30 - 08:50

Presenter
H.U. Ahmed, London (GB)

08:50 - 09:00

Discussant
J. Walz, Marseille (FR)

09:00 - 09:30

Debate Should we change our strategy in primary prostate biopsy?

09:00 - 09:15

mpMRI targeted biopsies are sufficient
P.A. Pinto, Bethesda (US)

09:15 - 09:30

Systematic biopsy is essential
G. Ploussard, Toulouse (FR)

09:30 - 10:00 **State-of-the-art lecture** **Lessons from the ProtecT trial**

09:30 - 09:50 **Presenter**
F.C. Hamdy, Oxford (GB)

09:50 - 10:00 **Discussant: Putting ProtecT into context**
N. Mottet, Saint-Étienne (FR)

10:00 - 10:30 **Debate** **Active surveillance for Gleason 3+4 prostate cancer**

Moderator: A. Rannikko, Helsinki (FI)

10:00 - 10:15 **Pro (US)**
M.R. Cooperberg, San Francisco (US)

10:15 - 10:30 **Con (EU)**
M. Graefen, Hamburg (DE)

10:30 - 10:50 **State-of-the-art lecture** **Hereditary prostate cancer**
P.C. Walsh, Baltimore, MD (US)

10:50 - 11:00 **Late breaking news**

Functional urology

Plenary session 06

Monday, 27 March
08:00 - 10:30

Location: Room Copenhagen, North Hall (Level 1)

Chairs: F.C. Burkhard, Berne (CH)
D.J.M.K. De Ridder, Leuven (BE)

Aims and objectives of this presentation

Selected functional urology topics will be presented. The current state of the art on the role of the urothelium, the management of MS and BPS, the role of ISD and the EAU standpoint in the use of meshes for prolapse will be discussed.

During the plenary sessions, French and Spanish translation will be provided. Please collect your headset in the session room prior to the start of the session and return it after the session.

Meet the speakers of the plenary session:

Delegates are able to meet the speakers of the plenary session immediately at the end of the session in the foyer of the Room Copenhagen (North Hall, Level 1). Do not miss this opportunity to meet and greet the speakers and to consult them for any questions you may have.

08:00 - 08:15

State-of-the-art lecture Urothelium - The bladder's brain?

W.L.M. Everaerts, Leuven (BE)

08:15 - 09:00

Case discussion How to manage complex neuro-urological patients?

08:15 - 08:22

Case presenter

F. Van Der Aa, Leuven (BE)

08:22 - 08:32

Dementia

To be confirmed

08:32 - 08:42

Multiple sclerosis

B. Dybowski, Warsaw (PL)

08:42 - 08:52

Stroke

To be confirmed

08:52 - 09:00

Discussion

09:00 - 09:30

Case discussion Have new technologies superceded standard TURP?

09:00 - 09:15

Case presenter

A. Giannantoni, Perugia (IT)

09:15 - 09:30

Discussant

P. Dinis Oliveira, Porto (PT)

09:30 - 09:45

State-of-the-art lecture EAU standpoint on meshes

T. Tarcan, Istanbul (TR)

09:45 - 10:15

Debate Intrinsic sphincter deficiency: Is it worth diagnosing?

09:45 - 10:00

Pro

N.I. Osman, Sheffield (GB)

10:00 - 10:15

Con

G. Van Koeveringe, Maastricht (NL)

10:15 - 10:30

**Société Internationale d'Urologie (SIU) lecture Complications after treatment of prostate cancer:
How bladder function influences therapy and outcome**

M. Fisch, Hamburg (DE)

Leadership and the EAU

Special session

Monday, 27 March
08:30 - 11:30

Location: Room 9, Capital suite (level 3)

Chair: J.P.M. Sedelaar, Nijmegen (NL)

08:30 - 08:45

Welcome

J.P.M. Sedelaar, Nijmegen (NL)

08:45 - 09:45

Personal behaviour and leadership

08:45 - 09:45

Moderator:

H. Rijksen, Maarsbergen (NL)

What are my leadership styles?

What are the preferences?

Can I flex my style?

Am I effective?

09:45 - 10:15

Insights in your organisational patterns and symptoms

09:45 - 10:15

Moderator:

J. Zijlstra, Maarsbergen (NL)

Do we recognise our system?

Should I intervene?

What is my as a leader?

10:15 - 11:00

Ambidexterity

10:15 - 11:00

Moderator:

H. Rijksen, Maarsbergen (NL)

Management and leadership

The difference between leadership and management

On the floor and on the balcony

10:45 - 11:30

Adaptive challenges

10:45 - 11:30

Moderator:

J. Zijlstra, Maarsbergen (NL)

Theory adaptive leadership

When is it an adaptive challenge?

Why do we need a technical fix?

Am I effective?

The infertile couple - Urological aspects

ESU Course 35

Monday, 27 March
08:30 - 11:30

Location: Room 10, Capital suite (level 3)

Chair: W. Aulitzky, Vienna (AT)

Aims and objectives of this presentation

This course provides state-of-the-art information on urological aspects of diagnosis and therapy of modern reproductive medicine. Diagnostic procedures should be standardised and coordinated in a timely fashion for both partners, focusing on the possible urological, hormonal and genetic causes of male infertility. In terms of therapy, this course will provide updated information on evidence based data and will discuss the importance of varicoceles in male infertility. We will show microsurgical techniques on video and explain why proper training and skills perfection is key to successful case management. A successful IVF/ICSI outcome depends upon the use of state-of-the-art techniques for sperm retrieval and sperm preparation. We will also provide information on genetic aspects and stress the responsibility of the urologist as an adviser and gatekeeper for the treatment of the infertile couple.

08:30 - 11:30

Diagnostic work-up, medical treatment

A. Salonia, Milano (IT)

08:30 - 11:30

Pathophysiology, diagnosis and treatment of varicocele

W. Aulitzky, Vienna (AT)

08:30 - 11:30

Microsurgical refertilisation

W. Aulitzky, Vienna (AT)

08:30 - 11:30

Sperm retrieval techniques and genetic aspects of IVF/ICSI

A. Salonia, Milano (IT)

Ultrasound in urology

ESU Course 36

Monday, 27 March
08:30 - 11:30

Location: Room 11, Capital suite (level 3)

Chair: T. Loch, Flensburg (DE)

Aims and objectives of this presentation

Ultrasound is the basic imaging tool of the urologist and almost all urologists are using ultrasound in daily practice. Despite this, training and teaching of urological ultrasound is not provided in a satisfactory manner. The aim of the course is to provide the technical basics and standards for the use of ultrasound in urology. After the course the delegate should know the ideal settings for reliable and informative urological ultrasound as well as the normal and pathological findings.

- Covering urological organs: kidney, ureter, bladder, testis and penis
- Standard patient positioning
- Best choice of transducers and settings
- Standard operating procedures (SOP)
- Normal, benign and malignant pathologic findings
- Interventional and intraoperative ultrasound.

08:30 - 11:30

Technical basics and new technologies

T. Loch, Flensburg (DE)

08:30 - 11:30

Standardisation, tuning, acquisition and reporting of ultrasound exams

M. Ritter, Mannheim (DE)

08:30 - 11:30

Ultrasound of the kidney and ureter

M. Ritter, Mannheim (DE)

08:30 - 11:30

Ultrasound of the bladder

T. Loch, Flensburg (DE)

08:30 - 11:30

Ultrasound of the testis

T. Loch, Flensburg (DE)

08:30 - 11:30

Ultrasound of the penis

M. Ritter, Mannheim (DE)

Practical management of non-muscle invasive bladder cancer (NMIBC)

ESU Course 37

Monday, 27 March
08:30 - 11:30

Location: Room 12, Capital suite (level 3)

Chair: J.A. Witjes, Nijmegen (NL)

Aims and objectives of this presentation

This course was updated significantly in 2016 (more cases, other subjects and more interaction) which was evaluated in a very positive way by the participants. Therefore, we chose to keep the course unchanged in 2017.

After discussing diagnostic opportunities of NMIBC, we will spent considerable time on the technique of TUR, including tips, potential problems, en bloc resection, TUR in difficult situations and TUR with enhanced imaging. We will illustrate this with video's and discuss pitfalls with the audience.

Additional risk adapted intravesical treatment including new modalities, including limitations of these recommendations, will be discussed next.

After that, we will discuss daily problems with regard to complications during and after intravesical therapy and how to prevent and treat that.

Finally a topic that remains a clinical problem remains on the program: how to deal with abnormal cytology including locations outside the bladder.

Since we try to keep the course as practical in interactive as possible, with case discussions, videos, feedback and time for Q&A, we might not cover all topics as we experienced in 2016 in Munich. However, the lively discussions and interaction was highly appreciated.

In the end we hope that attendees will have updated their guideline knowledge, but also know what (not) to do in exceptional or complicated cases, and what alternatives could be.

08:30 - 11:30

Introduction

J.A. Witjes, Nijmegen (NL)

08:30 - 11:30

Diagnosis, markers and innovations

J. Palou, Barcelona (ES)

08:30 - 11:30

TUR technique: Tips and tricks, problems and bloc resection, TUR at difficult places, Re-TUR: Enhanced imaging (including many video's)

M. Babjuk, Prague (CZ)

08:30 - 11:30

Risk groups and guideline treatment: What is clearly established

J.A. Witjes, Nijmegen (NL)

08:30 - 11:30

Comments on guideline treatment including BCG shortage and new treatment modalities

M. Babjuk, Prague (CZ)

08:30 - 11:30

Complications of intravesical therapy

J.A. Witjes, Nijmegen (NL)

08:30 - 11:30

How to deal with abnormal cytology including locations outside the bladder (UUT and urethra) and its limitations

J. Palou, Barcelona (ES)

Percutaneous nephrolithotripsy (PCNL)

ESU Course 38

Monday, 27 March
08:30 - 11:30

Location: Room 14, Capital suite (level 3)

Chair: E. Liatsikos, Patras (GR)

Aims and objectives of this presentation

Aims

Aim of this course is to describe in detail the surgical techniques of all available treatment options in percutaneous surgery of renal stones. In addition, to tips and tricks aiming into improving the efficacy of the operation, the most common complications associated with the procedure will be reviewed focusing on their prevention and proper management.

Objectives

- Describe the basic percutaneous nephrolithotripsy techniques
- Provide tips to improve the efficacy of the operation
- Provide evidence on the comparison of percutaneous with ureteroscopic and extracorporeal treatment options; Which approach for which stone.
- Describe associate complications including their management

08:30 - 11:30

Guidelines on stone treatment

T. Knoll, Sindelfingen (DE)

08:30 - 11:30

PCNL instrumentation – Suite organisation, wires, dilators and lithotriptors

C.M. Scoffone, Turin (IT)

08:30 - 11:30

From Skin to Stone: Step-by-Step access using only fluoroscopy (Prone position)

E. Liatsikos, Patras (GR)

08:30 - 11:30

From Skin to Stone: Step-by-Step access using US and fluoroscopy (Supine position)

C.M. Scoffone, Turin (IT)

08:30 - 11:30

MiniPerc- Indications, equipment and technique

T. Knoll, Sindelfingen (DE)

08:30 - 11:30

Tips and tricks in PCNL

E. Liatsikos, Patras (GR)

08:30 - 11:30

Round Table: Complications of PCNL: Diagnosis, management, prevention

T. Knoll, Sindelfingen (DE)

E. Liatsikos, Patras (GR)

C.M. Scoffone, Turin (IT)

Small renal masses: From concepts to tips and tricks in daily management

ESU Course 39

Monday, 27 March
08:30 - 11:30

Location: Room 15, Capital suite (level 3)

Chair: P. Gontero, Turin (IT)

Aims and objectives of this presentation

- The course aims to address the multiplicity of treatment options for small renal masses.
- Essential concepts to guide the clinical decision making process will be interactively discussed with the help of clinical cases.
- Practical tips for a safe and effective treatment delivery will be provided on the current standard of ablative therapies and minimally invasive surgery.
- Attendees should become familiar on when and how to propose active surveillance in their daily clinical practice.

08:30 - 11:30

Introduction

P. Gontero, Turin (IT)

08:30 - 11:30

Active surveillance and discussion clinical cases

P. Gontero, Turin (IT)

08:30 - 11:30

Ablative therapies: Which technique and why?

J.J.M.C.H. De La Rosette, Amsterdam (NL)

08:30 - 11:30

Minimally invasive surgery in SRMs: How to safely do it when you get started

F. Keeley, Bristol (GB)

08:30 - 11:30

Indications for surgery vs ablative therapies

P. Gontero, Turin (IT)

08:30 - 11:30

Clinical case discussion

J.J.M.C.H. De La Rosette, Amsterdam (NL)

P. Gontero, Turin (IT)

F. Keeley, Bristol (GB)

Update renal, bladder and prostate cancer Guidelines 2017, what is changed?

ESU Course 40

Monday, 27 March
08:30 - 11:30

Location: Room 17, Capital suite (level 3)

Chair: H.G. Van Der Poel, Amsterdam (NL)

Aims and objectives of this presentation

During the course recent practice changing alterations in the guidelines will be discussed. Based on the clinical recommendations the highlights of the guidelines on prostate, renal and bladder cancer as changed in the 2016 updates will be presented and illustrated by clinical cases. A basic knowledge of the guidelines information is assumed for participating trainees.

08:30 - 11:30

Introduction

H.G. Van Der Poel, Amsterdam (NL)

08:30 - 11:30

Update renal cancer: Localized

A. Volpe

08:30 - 11:30

Discussion

08:30 - 11:30

Update renal cancer: Metastasized

A. Volpe

08:30 - 11:30

Discussion

08:30 - 11:30

Update bladder cancer: Non-muscle invasive

B.W.G. Van Rhijn, Amsterdam (NL)

08:30 - 11:30

Discussion

08:30 - 11:30

Update bladder cancer: Muscle invasive

B.W.G. Van Rhijn, Badhoevedorp (NL)

08:30 - 11:30

Discussion

08:30 - 11:30

Update prostate cancer: Localized

H.G. Van Der Poel, Amsterdam (NL)

08:30 - 11:30

Discussion

08:30 - 11:30

Update prostate cancer: Metastasized

H.G. Van Der Poel, Amsterdam (NL)

ESU/ESFFU Hands-on Training in Urodynamics

HOT07

Monday, 27 March
09:30 - 12:30

Location: Room South America, Exhibition Hall (Level 1)

Chair: H. Hashim, Bristol (GB)

Aims and objectives of this presentation

This course aims to provide a practical course offering an interactive “hands-on” environment for doctors, nurses and technicians to improve their skills in urodynamics, with an emphasis on practical aspects including equipment used, interpretation of traces, quality control and trouble-shooting. The use of recorded tests, access to equipment and small groups means that individual problems can be addressed. All the speakers are involved in similar “hands-on” courses, which have run successfully in the United Kingdom and abroad. The small group format has been shown to work well in addressing individual needs. Access to teaching aids and equipment will simulate the clinical scenario as much as possible within the constraints of the conference setting.

A. Gammie, Bristol (GB)

A. Garcia Mora, Mexico City (MX)

L. Thomas, Bristol (GB)

Lymph node surgery in uro-oncology: Semi-Live

Thematic session 10

Monday, 27 March
10:30 - 12:00

Location: Room Madrid, North Hall (Level 1)

Chair: M. Hohenfellner, Heidelberg (DE)

Aims and objectives of this presentation

Lymph node surgery in penile, prostate, bladder and kidney cancer. Preoperative diagnostics. Rationale of lymph node surgery in different urological malignancies. Intraoperative techniques and extend I templates. Tips and tricks to avoid complications. Morbidities. Adjuvant therapeutic consequences of positive nodes. Salvage lymph node surgery in prostate and bladder cancer including multimodal approaches.

10:30 - 12:00

Panel of commentators

J.E. Gschwend, München (DE)
R. Reiter, Los Angeles (US)
N. Suardi, Milan (IT)

10:30 - 10:50

Video presentation Radio-guided PSMA lymph node dissection in prostate cancer

T. Maurer, Munich (DE)

10:50 - 11:00

Panel discussion

11:00 - 11:20

Video presentation Endoscopic inguinal lymph node dissection in penile cancer

C. Schwentner, Stuttgart (DE)

11:20 - 11:30

Panel discussion

11:30 - 11:50

Video presentation Extended lymph node dissection in bladder cancer

S. Lerner, Houston (US)

11:50 - 12:00

Panel discussion

Complications: Radical cystectomy

Thematic session 11

Monday, 27 March
10:30 - 12:00

Location: Room Milan, North Hall (Level 1)

Chair: J. Rassweiler, Heilbronn (DE)

Aims and objectives of this presentation

Radical cystectomy with urinary diversion is one of the most challenging procedures in urology independent from the approach (open, laparoscopic, robot-assisted). We have subdivided this session discussing the most frequent complications, focussing on specific techniques, and emphasizing the role of optimize perioperative management presented by an experienced faculty. There will be room for discussion and interaction.

10:30 - 10:45

How I solve Vascular injuries

M.S. Michel, Mannheim (DE)

10:45 - 11:00

How I solve Intestinal injuries

P. Chlosta, Cracow (PL)

11:00 - 11:15

How I solve Extravasation

M. Fiedler, Heilbronn (DE)

11:15 - 11:30

How I solve Specific problems of robotic radical cystectomy

N.P. Wiklund, Stockholm (SE)

11:30 - 11:45

How I solve Specific problems of female neo-bladder

G. Gakis, Tübingen (DE)

11:45 - 12:00

How I solve Optimal perioperative management

P.Y. Wüthrich, Berne (CH)

Male hypogonadism - What role for Testosterone Replacement Therapy (TRT)?

Thematic session 12

Monday, 27 March
10:30 - 12:00

Location: Room Paris, North Hall (Level 1)

Chairs: F.M.J. Debruyne, Arnhem (NL)
V.G. Mirone, Naples (IT)

10:30 - 10:45

Case presentation

F.M.J. Debruyne, Arnhem (NL)

10:45 - 11:00

The urologist as primary gatekeeper of men's health

N. Sofikitis, Ioannina (GR)

11:00 - 11:15

Urological implications of male hypogonadism

G.R. Dohle, Rotterdam (NL)

11:15 - 11:30

The role of the urologist in TRT

A. Salonia, Milan (IT)

11:30 - 11:45

ReproUnion: Strategic partnership between EAU and the European Union

J.O.R. Sonksen, Herlev (DK)

11:45 - 12:00

Panel discussion

Panel: F.M.J. Debruyne, Arnhem (NL)
G.R. Dohle, Rotterdam (NL)
V.G. Mirone, Naples (IT)
A. Salonia, Milan (IT)
N. Sofikitis, Ioannina (GR)
J.O.R. Sonksen, Herlev (DK)

Kidney transplant and reconstructive surgery

Thematic session 13

Monday, 27 March
10:30 - 12:00

Location: Room Amsterdam, North Hall (Level 1)

Chairs: P. Kyzlasov, Moscow (RU)
E. Lledó García, Madrid (ES)

Aims and objectives of this presentation

I hope that our Session will be useful for practicing urologists. We will see new approaches to therapy, interesting clinical cases and ways how to solve them. And, above all, we would like to see new scientists who can develop our direction.

10:30 - 10:50

Video presentation **Robotic kidney transplantation with transvaginal graft insertion**
A. Alcaraz, Barcelona (ES)

10:50 - 11:00

Panel of commentators
R.K. Ahlawat
A. Breda, Barcelona (ES)
J.D. Olsburgh, London (GB)

11:00 - 11:20

Video presentation **Endoscopic resolution of surgical challenges after kidney transplantation**
F.J. Burgos Revilla, Madrid (ES)

11:20 - 11:30

Panel of commentators
A. Chkhotua, Tbilisi (GE)
A.J. Figueiredo, Coimbra (PT)
M.J. Ribal, Barcelona (ES)

11:30 - 11:50

Video presentation **Special technical considerations in penile prosthesis implant in the kidney transplant candidate/recipient**
R. Djinovic, Belgrade (RS)

11:50 - 12:00

Panel of commentators
P. Ditonno, Bari (IT)
I. Moncada, Madrid (ES)
N. Tomada, Porto (PT)

Rare and complex urogenital disease and conditions

Thematic session 14

Monday, 27 March
10:30 - 12:00

Location: Room Berlin, North Hall (Level 1)

Chairs: M. Batty, Sheffield (GB)
M. Fisch, Hamburg (DE)

Aims and objectives of this presentation

Rare and complex urogenital diseases and conditions will give an update of the new European Reference Network (ERN) policy and programs. The EAU ERN structure, developments and patient participation will be discussed.

10:30 - 10:45

State-of-the-art lecture European Reference Network (ERN) development in Europe and DG Sante
E. Terol, Brussels (BE)

10:45 - 11:00

State-of-the-art lecture The ERN eUROGEN
M. Batty, Sheffield (GB)

11:00 - 11:15

State-of-the-art lecture Rare uro-recto-genital anomalies
To be confirmed

11:15 - 11:30

State-of-the-art lecture Functional urogenital conditions and specialised surgery
M. Fisch, Hamburg (DE)

11:30 - 11:45

State-of-the-art lecture Rare urogenital tumors
V. Sangar, Manchester (GB)

11:45 - 12:00

European patient representative (ePAG)

MRI in prostate cancer: Optimising interpretation by urologists and radiologists

Thematic session 15

Monday, 27 March
10:30 - 12:00

Location: Room Vienna, North Hall (Level 1)

Chairs: H. Thoeny, Berne (CH)
A. Villers, Lille (FR)

Aims and objectives of this presentation

Prostate MRI is more and more frequently present in our patient evaluation for prostate cancer diagnosis, staging and treatment planning. As urologist we need to be confident in reading mpMRI, based on images and report from radiologists. This session will cover the PIRADS 2.0 scoring in clinical practice, the use of MRI guidance for prostate biopsy, and what to expect from your radiologist to get best mpMRI interpretation.

10:30 - 10:45

European Society of Urogenital Radiology (ESUR) lecture PI-RADS in clinical practice including differential diagnoses in prostate imaging

H. Thoeny, Berne (CH)

10:45 - 11:15

Reading and interpreting mpMRI: PIRADS 2.0

10:45 - 11:00

Presenter

M. de Rooij, Nijmegen (NL)

11:00 - 11:15

Discussant: Is PIRADS 2.0 standardised enough?

T. Polascik, Durham (US)

11:15 - 11:30

State-of-the-art lecture What do urologists need to know about mpMRI targeted biopsy?

S. Boxler, Bern (CH)

11:30 - 11:45

State-of-the-art lecture Levels of competence in mpMRI reporting

P. Puech, Lille (FR)

11:50 - 12:00

Discussion

Killer bacteria and viruses in urology

Thematic session 16

Monday, 27 March
10:30 - 12:00

Location: Room London, North Hall (Level 1)

Chairs: T.E. Bjerklund Johansen, Oslo (NO)
F.M.E. Wagenlehner, Giessen (DE)

Aims and objectives of this presentation

Infections have ever since accompanied mankind. It is only 80 years since infections have become successfully treatable diseases, by the development of effective anti-infective strategies.

In antibacterial treatment this success is going to be lost, by the increasing threat of antimicrobial resistance. This thematic session will focus on the current problems and evidence in treating infectious diseases in urology.

10:30 - 10:45

State-of-the-art lecture [How can microbiome affect the urinary tract?](#)
T.E. Bjerklund Johansen, Stavern (NO)

10:45 - 11:00

State-of-the-art lecture [Management strategies for urogenital tuberculosis](#)
E. Kulchavenya, Novosibirsk (RU)

11:00 - 11:15

State-of-the-art lecture [HPV vaccination in adolescents](#)
To be confirmed

11:15 - 11:30

State-of-the-art lecture [Antibiotic stewardship](#)
T. Cai, Trento (IT)

11:30 - 11:45

State-of-the-art lecture [Current trends in the management of urosepsis](#)
Z. Tandoş du, Newcastle Upon Tyne (GB)

11:45 - 12:00

State-of-the-art lecture [Antibiotic resistance and novel antibiotics](#)
To be confirmed

Controversies in metastatic prostate cancer

Thematic session 17

Monday, 27 March
10:30 - 12:00

Location: Room Stockholm, North Hall (Level 1)

Chair: M-O. Grimm, Jena (DE)

Aims and objectives of this presentation

This session will summarise most recent developments in castration sensitive and castration resistant metastatic prostate cancer. In particular, surgical resection of oligometastatic disease, new biomarkers and targets are to be discussed as part of individualised patient care. Furthermore, the upcoming role of immunotherapy in prostate cancer will be presented.

10:30 - 10:50

Debate Is there a role for local treatment of oligometastatic disease?

10:30 - 10:40

Yes

M. Spahn, Berne (CH)

10:40 - 10:50

No

B. Tombal, Brussels (BE)

10:50 - 11:05

State-of-the-art lecture EAU Guidelines on mCRPC - An update

P. Cornford, Liverpool (GB)

11:05 - 11:20

Society for Urologic Oncology (SUO) lecture Current and future biomarkers in castration resistant prostate cancer

C.P. Evans, Sacramento (US)

11:20 - 11:35

State-of-the-art lecture Next generation targets for individualised treatment

J. De Bono, Sutton (GB)

11:35 - 11:50

State-of-the-art lecture Update on immunotherapy - Revival of the fittest?

K. Fizazi, Villejuif (FR)

11:50 - 12:00

Associated abstract presentation

*748

Targeting androgen receptor variants by niclosamide overcomes resistance to abiraterone and enzalutamide

By: Liu C., Lou W., Pan C-X., Evans C., [Gao A.](#)

Institutes: University of California Davis, Dept. of Urology, Sacramento, United States of America

State-of-the-art lecture

Robotic assisted radical prostatectomy - Semi-Live Masterclass

Thematic session 18

Monday, 27 March
10:30 - 12:00

Location: Room Munich, North Hall (Level 1)

Chair: P. Albers, Düsseldorf (DE)

Aims and objectives of this presentation

The new format of semi-live surgical video presentations allows to compare and discuss different surgical techniques of robot-assisted radical prostatectomies. State-of-the art surgeons are challenged by other state-of-the art surgeons on an exquisite international level. Aim of this session is to practically demonstrate pros and cons of a personally preferred surgical technique to allow the auditorium to make up its own mind regarding special surgical tips and tricks.

10:30 - 10:50

Video presentation Conventional nerve-sparing robot assisted radical prostatectomy

A. Mottrie, Aalst (BE)

Aims and objectives of this presentation

The aim is to show the ORSI technique of antegrade nerve sparing during RARP. According to the preoperative data, the right plane of dissection can be chosen in an oncological safe way. This video-based presentation will show tips & tricks.

10:50 - 11:00

Panel discussion

11:00 - 11:20

Video presentation Retzius-sparing robot assisted radical prostatectomy

A. Bocciardi, Milan (IT)

Aims and objectives of this presentation

Retzius-sparing robotic prostatectomy has been developed in 2010. Since then, more than 1100 cases have been performed in Milan and several hundreds in other centers worldwide. The aim of this presentation are to provide a step-by-step guide to this kind of approach highlighting the functional advantages of the technique.

11:20 - 11:30

Panel discussion

11:30 - 11:50

Video presentation Management of inguinal hernias during robot assisted radical prostatectomy

A.E. Canda, Ankara (TR)

Aims and objectives of this presentation

This presentation focuses on repair of inguinal hernias during robotic radical prostatectomy (RARP). Types of inguinal hernias, diagnosis, indications and contraindications for repair at the time of the RARP procedure, types and use of mesh materials during repair, preoperative and postoperative precautions will be discussed.

11:50 - 12:00

Panel discussion

10:30 - 12:00

Panel of commentators

M.R. Cooperberg, San Francisco (US)

R. Rabenalt, Düsseldorf (DE)

K.H. Rha, Seoul (KR)

Post-surgical urinary incontinence in males

ESU Course 41

Monday, 27 March
12:00 - 14:00

Location: Room 10, Capital suite (level 3)

Chair: E. Chartier-Kastler, Paris (FR)

Aims and objectives of this presentation

- To review
 - o mecanisms of continence in men and
 - o mecanisms of post surgical incontinence in men
- To analyse symptoms and to indicate conservative treatment
- To be able to select one surgical treatment, referring to literature and guidelines
- To learn about long term follow-up of each surgical technique and to be able to deliver the best and objective information to patients

12:00 - 14:00

Introduction

E. Chartier-Kastler, Paris (FR)

12:00 - 14:00

Aetiology

F. Van Der Aa, Leuven (BE)

12:00 - 14:00

Workout of post-surgical incontinence

E. Chartier-Kastler, Paris (FR)

12:00 - 14:00

Conservative treatment for post-surgical incontinence

F. Van Der Aa, Leuven (BE)

12:00 - 14:00

Postsurgical LUTS

F. Van Der Aa, Leuven (BE)

12:00 - 14:00

Surgical treatment for post-surgical incontinence

E. Chartier-Kastler, Paris (FR)

Prostate biopsy - tips and tricks

ESU Course 42

Monday, 27 March
12:00 - 14:00

Location: Room 11, Capital suite (level 3)

Chair: P. Hammerer, Braunschweig (DE)

Aims and objectives of this presentation

- Provide an update on recent imaging techniques like TRUS, Elastography, Histoscanning, multiparametric magnetic resonance imaging (mpMRI) and nuclear imaging techniques for prostate cancer diagnosis.
- Explain standard reporting systems for ultrasound and mpMRI like PI-RADS
- Discuss different prostate biopsy techniques
- Tips and Tricks to reduce morbidity of prostate biopsies

12:00 - 14:00

Indications for TRUS and biopsy

P. Hammerer, Braunschweig (DE)

12:00 - 14:00

Practical aspects of TRUS and TRUS guided biopsies

P. Hammerer, Braunschweig (DE)

12:00 - 14:00

Indications for rebiopsy

V. Scattoni, Milan (IT)

12:00 - 14:00

Update on new technical developments

V. Scattoni, Milan (IT)

General neuro-urology

ESU Course 43

Monday, 27 March
12:00 - 15:00

Location: Room 12, Capital suite (level 3)

Chair: F. Cruz, Porto (PT)

Aims and objectives of this presentation

The course aims at introducing the basic principles of the diagnostic work-up and of the management of the most common neurological micturition dysfunctions to urologists and residents. The early identification of common neurological micturition dysfunctions will contribute to increase the longevity and the quality of life of neurological patients.

The main aims are:

- To refresh the terminology and the specific methods of investigation in Neuro-Urology
- To review the most important urodynamics patterns found in patients with neurogenic micturition dysfunction
- To analyse the pharmacological and surgical options available for the management of the neuro-urological patient
- To update the indications of botulinum toxin type A in the management of the neuro-urological patient.

12:00 - 15:00

Introduction

F. Cruz, Porto (PT)

12:00 - 15:00

Diagnostics

M.J. Drake, Bristol (GB)

12:00 - 15:00

Therapy

F. Cruz, Porto (PT)

12:00 - 15:00

Case discussions

Renal transplantation: Technical aspects, diagnosis and management of early and late urological complications

ESU Course 44

Monday, 27 March
12:00 - 14:00

Location: Room 14, Capital suite (level 3)

Chair: F.J. Burgos Revilla, Madrid (ES)

Aims and objectives of this presentation

Renal transplant is an essential part of Urology. The aims of the course are:

- To show surgical techniques of organ procurement in deceased and living donation settings
- To establish the basic principles for evaluation of candidates to donation and recipients of kidney graft
- To show the different approaches and surgical details of kidney transplant in conventional and complex recipients
- To review the algorithms for diagnosis and treatment of medical and surgical complications after kidney transplantation

12:00 - 14:00

Selection and urological preparation of transplant recipients; surgical aspects of nephrectomy in living and deceased donor

A.J. Figueiredo, Coimbra (PT)

12:00 - 14:00

Laparoscopic living donor nephrectomy: Technical aspects and controversies

F.J. Burgos Revilla, Madrid (ES)

12:00 - 14:00

Avoiding complications by proper techniques of renal transplantation; tricks and tips

A.J. Figueiredo, Coimbra (PT)

12:00 - 14:00

How to diagnose and manage postoperative and long-term complications following renal transplantation

F.J. Burgos Revilla, Madrid (ES)

Oligometastatic prostate cancer

ESU Course 45

Monday, 27 March
12:00 - 14:00

Location: Room 15, Capital suite (level 3)

Chair: R.J. Karnes, Rochester (US)

P. Ost, Ghent (BE)
A. Briganti, Milan (IT)

Competing technologies in BPO surgery

Video Session 09

Monday, 27 March
12:15 - 13:45

Location: eURO Auditorium (Level 0)

Chairs: To be confirmed
T.R.W. Herrmann, Hannover (DE)
G. Muir, Dorking (GB)

Aims and objectives of this presentation

To view competing and new technologies in LUTS surgery – comparing techniques and philosophies of tissue removal with final outcomes in mind.

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

- *V66 **The evolution of Green laser (532-nm) techniques in the treatment of benign prostatic obstruction: Not only for PVP**
By: [Rijo E.](#)¹, Lorente J.A.¹, Bielsa O.¹, Gomez-Sancha F.²
Institutes:¹Hospital Quiron Barcelona, Dept. of Urology, Barcelona, Spain, ²ICUA, Clinica CEMTRO, Dept. of Urology, Madrid, Spain
- *V67 **Transurethral anatomical endoscopic enucleation of the prostate using diode laser versus bipolar: Surgery technique with 12-month outcomes in a double-centre randomised controlled trial**
By: [Liu C.](#), Zou Z., Xu A., Chen B.
Institutes:Zhujiang Hospital of Southern Medical University, Dept. of Urology, Guangzhou, China
- *V68 **Holmium laser enucleation of the prostate with real-time intraoperative transrectal ultrasound navigation, initial experience**
By: [Abdeev R.](#)¹, Andrianov A.², Alekseev B.³, Apolikhin O.⁴, Kaprin A.⁵
Institutes:¹Scientific and Research Institute of Urology Named After N.A.Lopatkin, Dept. of Consultation and diagnosis, Moscow, Russia, ²Scientific Research Institute of Urology Named After N.A.Lopatkin, Dept. of Oncourology, Moscow, Russia, ³National Medical Research Radiological Centre of The Ministry of Health of The Russian Federation, M, Dept. of Oncourology, Moscow, Russia, ⁴Scientific and Research Institute of Urology Named After N.A. Lopatkin, Dept. of Urology, Moscow, Russia, ⁵National Medical Research Radiological Centre of The Ministry of Health of The Russian Federation, M, Dept. of Oncorology, Moscow, Russia
- *V69 **Robot-assisted simple prostatectomy (RASP) step by step procedure and results**
By: [Umari P.](#), Fossati N., Gandaglia G., Heinze A., De Groote R., Schatteman P., De Naeyer G., Mottrie A.
Institutes:Onze-Lieve-Vrouw Hospital, Dept. of Urology, Aalst, Belgium
- *V70 **Thulium laser enucleation of the prostate with en bloc technique (ThuLEP en bloc)**
By: [Dymov A.](#)¹, Glybochko P.¹, Alyaev Y.¹, Vinarov A.¹, Altshuler G.², Zamyatina V.³, Rapoport L.¹, Sorokin N.¹, Sukhanov R.¹, Enikeev D.¹, Lekarev V.¹, Proskura A.¹, Davydov D.¹, Hamraev O.¹
Institutes:¹I.m.sechenov First Moscow State Medical University, Dept. of Urology, Moscow, Russia, ²IPG Medical, Boston, United States of America, ³IRE-Polus, Fryazino, Russia
- *V71 **Laparoscopic simple prostatectomy for large volume benign prostatic hyperplasia (≥ 120 mL)**
By: [Pastore A.L.](#)¹, Palleschi G.¹, Al Salhi Y.¹, Leto A.¹, Fuschi A.¹, Velotti G.¹, Carbone A.¹, Celia A.²
Institutes:¹Sapienza University of Rome, Dept. of Medico-Surgical Sciences and Biotechnologies, Urology Unit, Latina, Italy, ²San Bassiano Hospital, Dept. of Urology, Bassano Del Grappa, Italy

- *V72 **Holmium laser enucleation of the prostate by an en-bloc and bladder neck preserved technique**
By: [Meng X.](#)
Institutes: The First Affiliated Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, China
- *V73 **Thulium laser enucleation of the prostate (ThuLEP): First results, efficacy, and complications**
By: Glybochko P.¹, Altshuler G.², Vinarov A.¹, Rapoport L.¹, Enikeev M.¹, [Enikeev D.](#)¹, Sorokin N.¹, Dymov A.¹, Khamraev O.¹, Sukhanov R.¹, Taratkin M.¹, Zamyatina V.³
Institutes:¹First Moscow State Medical University of I.M. Sechenov, Research Institute of Urology and Reproductive Health, Moscow, Russia, ²IPG Medical, Photonics, Oxford, United States of America, ³NTO IRE-Polus, Dept. of Photonics, Moscow, Russia

Partial nephrectomy: Improving outcomes

Poster Session 59

Monday, 27 March
12:15 - 13:45

Location: Room Copenhagen, North Hall (Level 1)

Chairs: P. Chlosta, Cracow (PL)
A. Minervini, Florence (IT)
A. Mottrie, Aalst (BE)

Aims and objectives of this presentation

To discuss how to improve outcomes of partial nephrectomy.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *781 **Perioperative morbidity of open versus minimally invasive partial nephrectomy: A contemporary analysis of the National Surgical Quality Improvement Program (NSQIP)**
By: Pereira J.¹, Renzulli J.¹, Pareek G.¹, Moreira D.², Golijanin D.¹, Gershman B.¹
Institutes:¹Rhode Island Hospital And The Miriam Hospital, Dept. of Urology, Providence, United States of America, ²University of Illinois At Chicago, Dept. of Urology, Chicago, United States of America
- *782 **Comparison of robot-assisted and open surgery partial nephrectomy: An observational prospective study on pathologic and early functional outcomes**
By: Larcher A.¹, Capitanio U.¹, Fossati N.¹, De Naeyer G.², De Groote R.², Umari P.², Trevisani F.¹, Guazzoni G.³, Salonia A.¹, Briganti A.¹, Bertini R.¹, Montorsi F.¹, Mottrie A.²
Institutes:¹IRCCS Ospedale San Raffaele, Urological Research Institute, Dept. of Oncology and Urology, Milan, Italy, ²Onze Lieve Vrouw Hospital, Dept. of Urology, Aalst, Belgium, ³Humanitas Clinical and Research Centre, Dept. of Urology, Milan, Italy
- *783 **Perioperative morbidity of clamp vs off-clamp robotic partial nephrectomy: Preliminary results from a multicentre randomized clinical trial (the CLOCK study)**
By: Antonelli A.¹, Cindolo L.², Sandri M.³, Furlan M.¹, Veccia A.¹, Palumbo C.¹, Simeone C.¹, Sessa F.⁴, Facchiano D.⁴, Serni S.⁴, De Concilio B.⁵, Zeccolini G.⁵, Celia A.⁵, Ingrosso M.², Giommoni V.⁶, Annino F.⁶, Pizzuti V.⁷, Nucciotti R.⁷, Dandrea M.⁸, Angelo P.⁸, Minervini A.⁹
Institutes:¹Spedali Civili Hospital of Brescia, Dept. of Urology, Brescia, Italy, ²San Pio Da Pietrelcina Hospital, Dept. of Urology, Vasto (chieti), Italy, ³University of Brescia, Data Methods and Systems Statistical Laboratory, Brescia, Italy, ⁴Careggi Hospital, Dept. of Urology, Florence, Italy, ⁵San Bassiano Hospital, Dept. of Urology, Bassano Del Grappa (vicenza), Italy, ⁶San Donato Hospital, Dept. of Urology, Arezzo, Italy, ⁷Misericordia Hospital, Dept. of Urology, Grosseto, Italy, ⁸Policlinico Di Abano, Dept. of Urology, Abano Terme (padova), Italy, ⁹Careggi Hospital, Dept. of Urology- On Behalf of The AGILE Group (italian Group For Advanced Laparo-Endoscopic Surgery), Florence, Italy
- *784 **Acute kidney injury after clampless partial nephrectomy: Incidence, predictors, and its low impact on intermediate-term renal function**
By: Kawamura N., Yokoyama M., Nakayama T., Tanaka H., Inoue M., Ito M., Kijima T., Yoshida S., Ishioka J., Matsuoka Y., Saito K., Kihara K., Fujii Y.
Institutes:Tokyo Medical and Dental University Graduate School, Dept. of Urology, Tokyo, Japan
- *785 **On-clamp versus off-clamp partial nephrectomy: Propensity score matched comparison of long term functional outcomes**
By: Simone G.¹, Capitanio U.², Larcher A.², Ferriero M.³, Misuraca L.¹, Tuderti G.¹, Romeo G.¹,

Minisola F.¹, Guaglianone S.¹, Muttin F.², Nini A.², Trevisani F.², Montorsi F.², Bertini R.², Gallucci M.¹
Institutes:¹Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ²San Raffaele Hospital, University Vita Salute, Dept. of Urology, Milan, Italy, ³Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy

- *786 **In the quest for better functional outcome after partial nephrectomy: Can comorbidities outweigh age?**
By: Santok G.D., [Kim L.H.](#), Abdel Raheem A., Chang K., Yoon Y.E., Han W.K., Choi Y.D., Rha K.H.
Institutes:Yonsei University College Of Medicine, Dept. of Urology, Seoul, South Korea
- *787 **Factors influencing renal volume and renal function after minimally-invasive partial nephrectomy. Preliminary results of a prospective study**
By: Porpiglia F.¹, [Bertolo R.](#)¹, Amparore D.¹, Piramide F.¹, Checcucci E.¹, Manfredi M.¹, Angusti T.², Barrera M.³, Sardo D.³, Veltri A.³, Fiori C.¹
Institutes:¹San Luigi Hospital, Dept. of Urology, Turin, Italy, ²San Luigi Hospital, Dept. of Nuclear Medicine, Turin, Italy, ³San Luigi Hospital, Dept. of Radiology, Turin, Italy
- *788 **Parenchyma volume and renal function after different types of nephron-sparing minimally invasive surgery in patients with renal cell carcinoma**
By: [Reva S.](#), Nosov A., Lushina P., Berkut M., Petrov S.
Institutes:N.N.Petrov Research Institute of Oncology, Dept. of Oncurology, Saint-Petersburg, Russia
- *789 **Comparisons of surgical outcomes between resection and the enucleation technique in robot assisted laparoscopic partial nephrectomy for renal tumors according to the surface-intermediate-base margin score**
By: [Toshio T.](#), Kondo T., Iizuka J., Tachibana H., Kobayashi H., Ishida H., Tanabe K.
Institutes:Tokyo Women's Medical University, Dept. of Urology, Tokyo, Japan
- *791 **Predictors of local recurrence after partial nephrectomy: Results from two-years follow up of a prospective multicentre study (RECORD 1 project)**
By: Minervini A.¹, [Mari A.](#)¹, Campi R.¹, Novara G.², Antonelli A.³, Bertolo R.⁴, Bianchi G.⁵, Fiori C.⁴, Furlan M.³, Longo N.⁶, Mirone V.⁶, Morgia G.⁷, Morselli S.¹, Porpiglia F.⁴, Schiavina R.⁸, Serni S.¹, Sessa F.¹, Simeone C.³, Terrone C.⁹, Vanacore D.¹, Carini M.¹
Institutes:¹Aou Careggi, Dept. of Urology, Florence, Italy, ²University of Padua, Dept. of Surgery, Padua, Italy, ³University of Brescia, Dept. of Urology, Brescia, Italy, ⁴University of Turin - San Luigi Gonzaga Hospital, Dept. of Urology, Turin, Italy, ⁵University of Modena and Reggio Emilia, Dept. of Urology, Modena, Italy, ⁶University of Naples Federico II, Dept. of Neurosciences, Science of Reproduction and Odontostomatology, Naples, Italy, ⁷University of Catania, Dept. of Urology, Catania, Italy, ⁸University of Bologna, Dept. of Urology, Bologna, Italy, ⁹University of Eastern Piedmont, Dept. of Urology, Novara, Italy
- *792 **Modified robot assisted simple enucleation with single layer suture technique versus laparoscopic enucleation in localized renal tumors**
By: [Zhao X.](#), Lu Q., Liu G., Xu L., Zhang G., Li X., Gan W., Guo H.
Institutes:Nanjing Drum Tower Hospital, Medical School of Nanjing University, Dept. of Urology, Nanjing, China

13:28 - 13:36

Associated video presentation Purely off-clamp robotic partial nephrectomy
 G. Simone, Rome (IT)

Active surveillance for low risk prostate cancer: What do we still need to know?

Poster Session 60

Monday, 27 March
12:15 - 13:45

Location: Room Madrid, North Hall (Level 1)

Chairs: M.R. Cooperberg, San Francisco (US)

N. Suardi, Milan (IT)

Aims and objectives of this presentation

The aim of this session is to highlight lights and shadows of active surveillance and how to improve current protocols

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*793

The spatial distribution of positive cores predicts outcomes of active surveillance in very low risk prostate cancer patients

By: Erickson A.¹, Vasarainen H.², Mirtti T.³, Rannikko A.²

Institutes:¹University of Helsinki, University of Helsinki, Institute for Molecular Medicine Finland, Helsinki, Finland, ²University of Helsinki, Dept. of Urology, Helsinki, Finland, ³University of Helsinki, Institute for Molecular Medicine Finland, Dept. of Pathology, Helsinki, Finland

Associated video presentation

*794

Variation in the use of active surveillance for low-risk prostate cancer

By: Löppenberg B.¹, Friedlander D.¹, Tam A.¹, Von Landenberg N.¹, Gild P.¹, Leow J.², Krasnova A.¹, Kibel A.¹, Noldus J.³, Menon M.⁴, Sun M.¹, Trinh Q-D.¹

Institutes:¹Brigham and Women's Hospital, Division of Urologic Surgery and Center For Surgery and Public Health, Boston, United States of America, ²Tan Tock Seng Hospital, Dept. of Urology, Singapore, Singapore, ³Marien Hospital Herne, Ruhr-University Bochum, Dept. of Urology, Herne, Germany, ⁴Henry Ford Health System, VUI Center for Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Detroit, United States of America

Associated video presentation

*795

PTEN status in diagnostic biopsies predicts active surveillance rebiopsy gleason upgrade, treatment change and adverse surgical histopathological findings

By: Erickson A.¹, Lokman U.², Vasarainen H.², Mirtti T.³, Rannikko A.²

Institutes:¹University of Helsinki, Institute for Molecular Medicine Finland, Helsinki, Finland, ²University of Helsinki, Dept. of Urology, Helsinki, Finland, ³University of Helsinki, Dept. of Pathology, Institute for Molecular Medicine Finland, Helsinki, Finland

Associated video presentation

*796

Risk-based selection for active surveillance: Results of the movember foundation's global action plan prostate cancer active surveillance (GAP3) initiative

By: Nieboer D.¹, Steyerberg E.¹, Bruinsma S.², Bangma C.², Roobol M.²

Institutes:¹Erasmus MC, Dept. of Public Health, Rotterdam, The Netherlands, ²Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands

Associated video presentation

- *797 **Pathological findings at radical prostatectomy after initial active surveillance in low-risk prostate cancer patients. Did we miss the chance to cure?**
By: [Suardi N.](#)¹, Luzzago S.¹, Dell'oglio P.¹, Fossati N.¹, Gandaglia G.¹, Zaffuto E.¹, Gaboardi F.¹, Doglioni C.², Freschi M.², Scattoni V.¹, Stabile A.¹, Montorsi F.¹, Briganti A.¹
Institutes:¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²Vita-Salute University San Raffaele, Dept. of Pathology, Milan, Italy
- Associated video presentation**
- *798 **Outcomes after deferred radical prostatectomy for men initially managed with active surveillance**
By: [Arnsrud Godtman R.](#)¹, Schafferer M.², Stranne J.², Hugosson J.²
Institutes:¹Institute of Clinical Sciences, Sahlgrenska Academy At The University of Göteborg, Dept. of Urology, Göteborg, Sweden, ²Institute of Clinical Sciences, Sahlgrenska Academy At The University of Gothenburg, Dept. of Urology, Gothenburg, Sweden
- Associated video presentation**
- *800 **Variation in prostate cancer care at commission on cancer designated facilities**
By: [Löppenberg B.](#)¹, Sood A.², Deepansh D.², Karaborn P.³, Sammon J.⁴, Vetterlein M.⁵, Noldus J.¹, Peabody J.², Trinh Q-D.⁶, Menon M.², Abdollah F.²
Institutes:¹Ruhr-University Bochum, Marien Hospital Herne, Dept. of Urology, Herne, Germany, ²Center For Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Henry Ford Hosp, Dept. of Urology, Detroit, United States of America, ³Henry Ford Hospital, Dept. of Public Health Sciences, Detroit, United States of America, ⁴Maine Medical Center, Division of Urology & Center For Outcomes Research, Portland, United States of America, ⁵University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, United States of America, ⁶Center For Surgery and Public Health, Brigham and Women's Hospital, Division of Urology, Boston, United States of America
- Associated video presentation**
- *801 **Multiparametric MRI represents an added value but not a substitute of follow-up biopsies in patients on active surveillance for low-risk prostate cancer**
By: [Luzzago S.](#)¹, Suardi N.¹, Dell'oglio P.¹, Cardone G.², Gandaglia G.¹, Esposito A.², De Cobelli F.², Cristel G.², Kinzikeeva E.¹, Freschi M.³, Gaboardi F.¹, Del Maschio A.², Montorsi F.¹, Briganti A.¹
Institutes:¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²Vita-Salute University San Raffaele, Dept. of Radiology, Milan, Italy, ³Vita-Salute University San Raffaele, Dept. of Pathology, Milan, Italy
- Associated video presentation**
- *802 **Introducing mpMRI into contemporary UK active surveillance for localised prostate cancer**
By: [Bryant R.](#)¹, Yang B.¹, Philippou Y.¹, Lam K.¹, Obiakor M.¹, Ayers J.B.¹, Gleeson F.², Macpherson R.², Verrill C.³, Roberts I.³, Leslie T.¹, Crew J.¹, Sooriakumaran P.¹, Hamdy F.¹, Brewster S.¹
Institutes:¹Oxford University Hospitals Nhs Foundation Trust, Dept. of Urology, Oxford, United Kingdom, ²Oxford University Hospitals Nhs Foundation Trust, Dept. of Radiology, Oxford, United Kingdom, ³Oxford University Hospitals Nhs Foundation Trust, Dept. of Pathology, Oxford, United Kingdom
- Associated video presentation**
- *803 **MRI as a follow up tool in active surveillance – results from an MRI-defined active surveillance cohort (387 men, median 5 year follow up)**
By: [Retter A.](#)¹, Giganti F.¹, Kirkham A.¹, Allen C.¹, Punwani S.¹, Emberton M.², Moore C.²
Institutes:¹University College London Hospital, Dept. of Radiology, London, United Kingdom, ²University College London Hospital, Dept. of Urology, London, United Kingdom

Associated video presentation

*804

Metastases and death after 15 year of follow-up in men with screen-detected low-risk prostate cancer treated with protocol based active surveillance, radical prostatectomy or radiotherapy

By: Verbeek J., Drost F-J., Bangma C., [Roobol M.](#)

Institutes: Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands

Associated video presentation

13:30 - 13:37

Summary

To be confirmed

Prostate cancer: Outcomes after radiotherapy and brachytherapy

Poster Session 61

Monday, 27 March
12:15 - 13:45

Location: Room Milan, North Hall (Level 1)

Chairs: A. Bossi, Villejuif (FR)
W.C. Loidl, Linz (AT)
C. Surcel, Bucharest (RO)

Aims and objectives of this presentation

To evaluate radiotherapy and brachytherapy protocols and oncological and functional results

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *805 **Optimization of assessment tool for lower urinary symptom flare in patients with localized prostate cancer treated with iodine-125 implant brachytherapy**
By: Miyake M.¹, Tanaka N.¹, Asakawa I.², Hori S.¹, Morizawa Y.¹, Tatsumi Y.¹, Nakai Y.¹, Anai S.¹, Hasegawa M.², Konishi N.³, Fujimoto K.¹
Institutes:¹Nara Medical University, Dept. of Urology, Nara, Japan, ²Nara Medical University, Dept. of Radiation Oncology, Nara, Japan, ³Nara Medical University, Dept. of Pathology, Nara, Japan
- *806 **Impact of ISUP new grading system on prognostic prediction in clinical stage T3 prostate cancer undergoing high-dose-rate brachytherapy**
By: Tsumura H.¹, Satoh T.¹, Tabata K-I.¹, Ishiyama H.², Ikeda M.¹, Kurosaka S.¹, Fujita T.¹, Hayakawa K.¹, Iwamura M.¹
Institutes:¹Kitasato University School of Medicine, Dept. of Urology, Sagamihara, Japan, ²Kitasato University School of Medicine, Dept. of Radiology and Radiation Oncology, Sagamihara, Japan
- *807 **Ten year outcomes of real time "4D" brachytherapy in prostates up to 100cc**
By: Rea A.¹, Rogers P.², Jones A.¹
Institutes:¹Royal Berkshire Hospital, Dept. of Urology, Reading, United Kingdom, ²Royal Berkshire Hospital, Dept. of Oncology, Reading, United Kingdom
- *808 **Long-term outcomes of permanent prostate brachytherapy**
By: Stone N.¹, Stock R.²
Institutes:¹The Icahn School Of Medicine At Mount Sinai, Dept. of Urology, New York, United States of America, ²The Icahn School Of Medicine At Mount Sinai, Dept. of Radiation Oncology, New York, United States of America
- *809 **Outcomes of treatment for localized prostate cancer in a single institution; comparison of radical prostatectomy vs radiation therapy -Propensity Score Matching Analysis-**
By: Hayashi N.¹, Yokomizo Y.¹, Kimito O.¹, Makiyama K.¹, Kondo K.¹, Nakaigawa N.¹, Yao M.¹, Taguri M.², Sugiura M.³, Ito E.³, Takano S.³, Mukai A.³
Institutes:¹Yokohama City University School of Medicine, Dept. of Urology, Yokohama, Japan, ²Yokohama City University School of Medicine, Dept. of Biostatistics, Yokohama, Japan, ³Yokohama City University School of Medicine, Dept. of Radiology, Yokohama, Japan
- *810 **Oncological outcomes of prostate cancer treated by radical prostatectomy versus radiotherapy: A multi-center study using propensity-matched and competing risk regression analyses**
By: Koo K.C.¹, Lee W.K.⁶, Kim J.C.¹, Bang W.J.², Lee S.H.³, Cho S.Y.⁴, Kim S.I.⁵, Kim S.J.⁵, Cho J.S.², Rha K.H.¹, Hong S.J.¹, Chung B.H.¹

Institutes:¹Yonsei University College of Medicine, Gangnam Severance Hospital, Dept. of Urology, Seoul, South Korea, ²Hallym University College of Medicine, Dept. of Urology, Chuncheon, South Korea, ³Yonsei University College of Medicine, Shinchon Severance Hospital, Dept. of Urology, Seoul, South Korea, ⁴Inje University College of Medicine, Dept. of Urology, Busan, South Korea, ⁵Ajou University College of Medicine, Dept. of Urology, Suwon, South Korea, ⁶Hallym University Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Dept. of Urology, Chuncheon, South Korea

- *811 **The hybrid method can cover an extensive area of planning target volume compared with the conventional method in prostate cancer patients who undergo of low-dose-rate brachytherapy**
By: [Tanaka N.](#)¹, Asakawa I.², Nakai Y.¹, Miyake M.¹, Anai S.¹, Fujii T.³, Hasegawa M.², Konishi N.³, Fujimoto K.¹
Institutes:¹Nara Medical University, Dept. of Urology, Kashihara, Japan, ²Nara Medical University, Dept. of Radiation Oncology, Kashihara, Japan, ³Nara Medical University, Dept. of Pathology, Kashihara, Japan
- *812 **Combined androgen deprivation and radiation versus either modality alone or observation after radical prostatectomy in patients with pathologic node-positive prostate cancer: Analysis of a national hospital cancer registry database**
By: Zareba P., Eastham J., Scardino P., [Touijer K.](#)
Institutes:Memorial Sloan Kettering Cancer Center, Dept. of Surgery and Urology, New York, United States of America
- *813 **What is the impact of diabetes mellitus on radiation induced proctitis after radical radiotherapy for adenocarcinoma prostate?**
By: [Paterson C.](#)¹, Alashkham A.⁴, Hubbard S.², Nabi G.³
Institutes:¹Ninewells Hospital, Dept. of Urology, Dundee, United Kingdom, ²University of Dundee, School of The Environment, Dundee, United Kingdom, ³University of Dundee, Dept. of Urology, Dundee, United Kingdom, ⁴University of Edinburgh, Centre for Human Anatomy, Edinburgh, United Kingdom
- *814 **Nationwide multicenter retrospective study on high-dose-rate brachytherapy as monotherapy for prostate cancer**
By: [Komiya A.](#)¹, Yoshioka Y.², Kotsuma T.³, Kariya M.⁴, Konishi K.⁵, Nonomura N.⁶, Fujiuchi Y.⁷, Kitamura H.⁷
Institutes:¹Chiba University Graduate School of Medicine, Dept. of Urology, Chiba, Japan, ²Osaka University Graduate School of Medicine, Dept. of Radiation Oncology, Osaka, Japan, ³Osaka National Hospital, Dept. of Radiation Oncology, Osaka, Japan, ⁴Kochi University Graduate School of Medicine, Dept. of Radiation Oncology, Osaka, Japan, ⁵Osaka Medical Center for Cancer and Cardiovascular Diseases, Dept. of Radiation Oncology, Osaka, Japan, ⁶Osaka University Graduate School of Medicine, Dept. of Urology, Osaka, Japan, ⁷Graduate School of Medicine and Pharmaceutical Sciences For Research, University of Toyama, Dept. of Urology, Toyama, Japan
- *815 **Ex vivo γ H2AX assay in prostate cancer patient-derived tumour samples reveals substantial differences in intrinsic radiation sensitivity**
By: [Neumann E.](#)¹, De Colle C.², Müller A-C.², Yaromina A.³, Hennenlotter J.¹, Stenzl A.¹, Scharpf M.⁴, Fend F.⁴, Ricardi U.⁵, Baumann M.⁶, Zips D.², Menegakis A.²
Institutes:¹Eberhard Karls University Tübingen, Dept. of Urology, Tübingen, Germany, ²Eberhard Karls University Tübingen, Dept. of Radiooncology, Tübingen, Germany, ³Maastricht University Medical Centre, Dept. of Radiation Oncology, Maastricht, The Netherlands, ⁴Eberhard Karls University Tübingen, Dept. of Pathology, Tübingen, Germany, ⁵University of Turin, Dept. of Radiation Oncology (Maastro), Turin, Italy, ⁶Faculty of Medicine and University Hospital Carl Gustav Carus, Dept. of Radiation Oncology, Dresden, Germany
- *816 **Pre-radiotherapy, (robot-assisted) laparoscopic sentinel node dissection and its impact on recurrence and progression of prostate cancer**
By: [Grivas N.](#)¹, Wit E.¹, Pos F.², De Jong J.³, Vegt E.⁴, Bex A.¹, Hendricksen K.¹, Horenblas S.¹, KleinJan G.⁵, Van Rhijn B.¹, Van Der Poel H.¹

Institutes:¹Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ²Netherlands Cancer Institute, Dept. of Radiation Oncology, Amsterdam, The Netherlands, ³Netherlands Cancer Institute, Dept. of Pathology, Amsterdam, The Netherlands, ⁴Netherlands Cancer Institute, Dept. of Nuclear Medicine, Amsterdam, The Netherlands, ⁵Leiden University Medical Center, Dept. of Radiology, Leiden, The Netherlands

13:28 - 13:38

Correct technique on radiation therapy

A. Bossi, Villejuif (FR)

e-Poster Abstract Session on New technologies: Urology and multimedia

Poster Session 62

Monday, 27 March
12:15 - 13:45

Location: Room Paris, North Hall (Level 1)

Chairs: P. Dasgupta, London (GB)
S. Loeb, New York (US)
H.G. Van Der Poel, Amsterdam (NL)

Aims and objectives of this presentation

To look at the current role of multimedia technology on various aspects of urological practice

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

12:38 - 12:48

The vanishing of printed journals

P. Dasgupta, London (GB)

12:48 - 12:58

The power of Twitter

S. Loeb, New York (US)

12:58 - 13:08

The danger of excessive information for patients

H.G. Van Der Poel, Amsterdam (NL)

*817

Mobile PSA -A novel tool for prostate cancer follow-up

By: Bergroth R., Matikainen M., Rannikko A.

Institutes:Helsinki University Hospital and Helsinki University, Department of Urology, Helsinki, Finland

*818

Developing HIGH-TECH bladder and bowel diary in innovative clinical informatics

By: Kitta T.¹, Ouchi M.¹, Kanno Y.¹, Moriya K.¹, Yamamoto T.², Shinohara N.¹

Institutes:¹Hokkaido University School of Medicine, Dept. of Urology, Sapporo, Japan, ²Hokkaido University, Dept. of Laboratory of Information Media Environment, Sapporo, Japan

*819

Electronic assistant in multi-disciplinary practice: A promising tool toward improved healthcare delivery

By: Zgheib J.¹, Mottrie A.², El Hajj I.³, El Salibi N.⁴, El Khoury F.¹

Institutes:¹University of Balamand, Dept. of Surgery and Urology, Beirut, Lebanon, ²OLV Robotic Surgery Institute, ORSI Academy, Melle, Belgium, ³Saint George Hospital University Medical Center, Dept. of General Surgery, Beirut, Lebanon, ⁴American University of Beirut, Dept. of Epidemiology and Population Health, Beirut, Lebanon

*820

Using social media and mobile technology for epidemic research of prostate cancer risk factors in Chinese population

By: Qin X., Dai B., Zhu Y., Ye D.

Institutes:Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

*821

Mapping the landscape of urology: A new media based cross-sectional analysis of public versus academic interest

By: Salem J.¹, Borgmann H.², Baunacke M.³, Boehm K.², Groeben C.³, Schmid M.⁴, Siegel F.⁵, Huber J.³

Institutes:¹University Hospital Cologne, Dept. of Urology, Cologne, Germany, ²University Hospital Mainz, Dept. of Urology, Mainz, Germany, ³TU Dresden, Dept. of Urology, Dresden, Germany, ⁴

University Hospital Göttingen, Dept. of Urology, Göttingen, Germany, ⁵University Medical Center Mannheim, Dept. of Urology, Mannheim, Germany

- *822 **Quantitative analysis of innovation in Urology**
By: [Bhatt N.R.](#)¹, Dalton D.M.², Davis N.F.¹, Mcdermott T.¹, Flynn R.J.¹, Thomas A.Z.¹, Manecksha R.P.¹
Institutes:¹Adelaide and Meath Hospital, Dept. of Urology, Dublin, Ireland, ²Royal College of Surgeons, Dept. of Surgery, Dublin, Ireland
- *823 **Consultant outcome publication: Surgeons opinions of a new mandatory health policy**
By: [Williams M.](#), Cotterill N., Drake M., Keeley F.
Institutes:Bristol Urology Institute, Dept. of Urology, Bristol, United Kingdom
- *824 **Use of digital media in daily clinical practice among urology residents**
By: [Salem J.](#)¹, Borgmann H.², Macneily A.³, Boehm K.², Schmid M.⁴, Groeben C.⁵, Baunacke M.⁵, Huber J.⁵
Institutes:¹University Hospital Cologne, Dept. of Urology, Cologne, Germany, ²University Hospital Mainz, Dept. of Urology, Mainz, Germany, ³Vancouver General Hospital/University of British Columbia, Dept. of Urology, Vancouver, Canada, ⁴University Hospital Göttingen, Dept. of Urology, Göttingen, Germany, ⁵TU Dresden, Dept. of Urology, Dresden, Germany
- *825 **What is #urology tweeting about? Strategic assessment of Twitter communication in urology**
By: [Borgmann H.](#)¹, Katz M.², Catto J.³, Weight C.⁴, Kutikov A.⁵
Institutes:¹University Hospital Mainz, Dept. of Urology, Mainz, Germany, ²Lowell General Hospital, Dept. of Radiation Medicine, Lowell, United States of America, ³University of Sheffield, Academic Urology Unit, Sheffield, United Kingdom, ⁴University of Minnesota, Dept. of Urology, Minneapolis, United States of America, ⁵Fox Chase Cancer Center, Division of Urologic Oncology, Philadelphia, United States of America
- *826 **Twitter is emerging as a big data tool and an essential source of information in urologic oncology and biomedical research**
By: [El-Bakri A.](#), Larré S.
Institutes:Robert Debré Teaching Hospital, Dept. of Urology, Reims, France
- *827 **Web promotion of da Vinci robotic prostatectomy exhibits varying sexual health information**
By: [Matsushita K.](#), Endo F., Shimbo M., Hattori K.
Institutes:St. Lukes International Hospital, Dept. of Urology, Tokyo, Japan
- *828 **Whatsapp Messenger as a tool for the multidisciplinary management in everyday clinical practice**
By: Di Maida F.¹, [Scalici Gesolfo C.](#)¹, Fazio I.², Mortellaro G.³, Blasi L.⁴, Borsellino N.⁵, Spada M.⁶, Ferrera G.⁴, Rinaldi G.⁷, La Paglia L.², Adamo M.S.⁸, Cicero G.⁷, Curti Giardina M.⁹, Di Trapani D.¹⁰, Serretta V.¹
Institutes:¹University of Palermo, Dept. of Urology, Palermo, Italy, ²"Macchiarella" Clinic, Dept. of Radiation Oncology, Palermo, Italy, ³ARNAS Civico Hospital, Dept. of Radiation Oncology, Palermo, Italy, ⁴ARNAS Civico Hospital, Dept. of Medical Oncology, Palermo, Italy, ⁵"Buccheri-La Ferla" Hospital, Dept. of Medical Oncology, Palermo, Italy, ⁶Fondazione Istituto G. Giglio, Dept. of Medical Oncology, Cefalù, Italy, ⁷University of Palermo, Dept. of Medical Oncology, Palermo, Italy, ⁸University of Palermo, Clinical Epidemiology and Cancer Registry, Palermo, Italy, ⁹A.S.P. 209, Dept. of Urology, Trapani, Italy, ¹⁰"Buccheri-La Ferla" Hospital, Dept. of Urology, Palermo, Italy
- *829 **Utilization of Facebook, Twitter, YouTube and Instagram in the prostate cancer community**
By: [Struck J.P.](#)¹, Salem J.², Siegel F.³, Kramer M.¹, Tsaour I.⁴, Heidenreich A.², Haferkamp A.⁴, Merseburger A.S.¹, Borgmann H.⁴
Institutes:¹University Hospital Luebeck, Dept. of Urology, Luebeck, Germany, ²University Hospital Cologne, Dept. of Urology, Cologne, Germany, ³University Hospital Mannheim, Dept. of Urology, Mannheim, Germany, ⁴University Hospital Mainz, Dept. of Urology, Mainz, Germany

Growth factors and receptors in urothelial tumors

Poster Session 63

Monday, 27 March
12:15 - 13:45

Location: Room Amsterdam, North Hall (Level 1)

Chairs: To be confirmed
T. Todenhöfer, Tübingen (DE)
E. Zwarthoff, Rotterdam (NL)

Aims and objectives of this presentation

Overexpression of peptide growth factors and their receptors have been reported in urothelium cancer. In addition, mutations in growth factor receptors occur and are associated with outcome of the disease. The session will focus on regulation of intracellular signalling, modification of gene expression and possibilities to improve specific targeting in urothelial tumors.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *830 **Role of the crosstalk between tumor cells, vascular endothelium and the coagulation cascade for the invasion of urothelial bladder carcinoma**
By: John A.¹, Schneider S.², Gorzelanny C.³, Bolenz C.¹
Institutes:¹University Hospital Ulm, Dept. of Urology, Ulm, Germany, ²University Hospital Hamburg, Dept. of Dermatology, Hamburg, Germany, ³Experimental Dermatology, Dept. of Dermatology, Mannheim, Germany
- *831 **Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma**
By: Ku J.Y.¹, Lee C.H.¹, Lee K.¹, Kim K.H.¹, Baek S.R.¹, Park J.H.¹, Lee J.Z.¹, Park H.J.¹, Han S.H.¹, Jeong I.Y.¹, Kwon M.J.¹, Ha H.K.¹, Jean P.T.²
Institutes:¹Pusan National University Hospital, Dept. of Urology, Busan, South Korea, ²National University of Singapore, Dept. of Urology, Singapore, Singapore
- *832 **Possible role of sonic hedgehog signaling and epithelial-mesenchymal transition in bladder cancer progression and invasion**
By: Shigemura K.¹, Kitagawa K.², Yamamichi F.³, Sung S-Y.⁴, Chen K.C.⁵, Nakano Y.¹, Fujisawa M.¹
Institutes:¹Kobe University Graduate School of Medicine, Dept. of Urology, Kobe, Japan, ²Kobe University Graduate School of Medicine, Dept of Internal Related, Kobe, Japan, ³Hyogo Prefectural Amagasaki General Medical Center, Dept. of Urology, Amagasaki, Japan, ⁴Taipei Medical University, College of Medical Science and Technology, Taipei, Taiwan, ⁵Taipei Medical University, Dept. of Urology, Taipei, Taiwan
- *833 **Lopinavir synergizes with ritonavir to induce bladder cancer apoptosis by causing histone acetylation and endoplasmic reticulum stress**
By: Sato A., Okubo K., Asano T., Isono M., Asano T.
Institutes:National Defense Medical College, Dept. of Urology, Tokorozawa, Japan
- *834 **Overexpression of PTP4A3 is associated with metastasis and unfavorable prognosis in urothelial carcinoma**
By: Yeh H-C.¹, Wu W-J.¹, Li C-C.¹, Huang C-N.², Ke H-L.², Li W-M.², Lee H-Y.¹, Li C-F.³
Institutes:¹Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Dept. of Urology, Kaohsiung, Taiwan, ²Kaohsiung Medical University Hospital, Kaohsiung Medical University, Dept. of Urology, Kaohsiung, Taiwan, ³Chi Mei Medical Center, Dept. of Pathology, Tainan, Taiwan

- *835 **Kaempferol modulates DNA methylation and up-regulates the expression of DAXX in bladder cancer**
By: [Qiu W.](#), Lin J., Zhu Y., Zhang J., Tian Y.
Institutes: Beijing Friendship Hospital, Capital Medical University, Dept. of Urology, Beijing, China
- *836 **The activity of intravesical hyaluronic acid and chondroitin sulfate administration on urothelial gene expression. Preliminary results on the Epidermal Growth Factor Receptor and Fibronectin gene expression evaluated in bladder washings of patients affected by non muscle-invasive bladder cancer**
By: Serretta V.¹, Di Maida F.¹, [Scalici Gesolfo C.](#)¹, Cangemi A.², Perez A.², Russo A.², Simonato A.¹
Institutes:¹University of Palermo, Dept. of Urology, Palermo, Italy, ²University of Palermo, Dept. of Medical Oncology, Palermo, Italy
- *837 **Frequency of subtypes in high grade urothelial carcinoma of the urinary bladder**
By: Scavuzzo A.¹, [Jimenez Rios M.A.](#)¹, Silva Morera C.², Pena L.², Moncada G.², Mendoza J.³, Cantu De Leon D.³, Perez Montiel D.²
Institutes:¹Instituto Nacional De Cancerologia, Dept. of Urology, Mexico City, Mexico, ²Instituto Nacional De Cancerologia, Dept. of Pathology, Mexico City, Mexico, ³Instituto Nacional De Cancerologia, Dept. of Clinical Research, Mexico City, Mexico
- *838 **Targeting ERBB2 mutations in urothelial carcinoma**
By: [Audenet F.](#)¹, Isharwal S.¹, Arcila M.², Funt S.³, Rosenberg J.³, Bajorin D.³, Bochner B.¹, Berger M.², Al-Ahmadie H.², Solit D.³, Iyer G.³
Institutes:¹Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, ²Memorial Sloan Kettering Cancer Center, Dept. of Pathology, New York, United States of America, ³Memorial Sloan Kettering Cancer Center, Dept. of Medical Oncology, New York, United States of America
- *839 **Long noncoding RNA H19 regulates Survivin expression in bladder cancer as sponge of miR-138-5p**
By: [Yang R.](#)¹, Qu S.², Liang H.², Chen X.², Zhang C.², Guo H.¹
Institutes:¹The Affiliated Drum Tower Hospital Of Nanjing University, School Of Medicine, Dept. of Urology, Nanjing, China, ²Nanjing University, Dept. of Biological Science, Nanjing, China
- *840 **M2 muscarinic receptors inhibit cell proliferation and migration in urothelial bladder cancer cells**
By: [Palleschi G.](#), Pastore A.L., Al Salhi Y., Fuschi A., Velotti G., Leto A., De Falco E., Calogero A., Petrozza V., Carbone A.
Institutes: Sapienza University of Rome, Dept. of Medico-Surgical Sciences and Biotechnologies, Urology Unit, Latina, Italy
- *841 **Panobinostat and ixazomib inhibit bladder cancer growth synergistically by increasing histone acetylation and inducing endoplasmic reticulum stress**
By: [Sato A.](#), Isono M., Asano T., Okubo K., Asano T.
Institutes: National Defense Medical College, Dept. of Urology, Tokorozawa, Japan
- 13:28 - 13:38 **Alterations in growth factor receptors in bladder cancer**
 E. Zwarthoff, Rotterdam (NL)

New therapeutic approaches in targeted therapy for renal cell carcinoma

Poster Session 64

Monday, 27 March
12:15 - 13:45

Location: Room Berlin, North Hall (Level 1)

Chairs: N. Kröger, Greifswald (DE)
A. Necchi, Milan (IT)
G. Stewart, Cambridge (GB)

Aims and objectives of this presentation

To discuss new therapeutic approaches based on basic research results

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *842 **Impact of intratumoral heterogeneity of renal cancer on drug response and development of resistance in patient derived xenografts**
By: Bedke J.¹, Flechsig S.², Hennenlotter J.¹, Wulf-Goldenberg A.², Jandrig A.³, Schostak M.³, Becker M.², Fichtner I.², Zeisig R.², Hoffmann J.², Schmees C.⁴, Stenzl A.¹
Institutes:¹University of Tübingen, Dept. of Urology, Tübingen, Germany, ²EPO GmbH, Berlin-Buch, Berlin, Germany, ³University of Magdeburg, Dept. of Urology, Magdeburg, Germany, ⁴Natural and Medical Sciences Institute, Dept. of Molecular Biology, Reutlingen, Germany
- *843 **Pathological and prognostic significance of densities of CD57+ (natural killer cells), CD68+ (macrophage), and mast cells in renal cell carcinoma tissues**
By: Mochizuki Y., Miyata Y., Yasuda T., Nakamura Y., Matsuo T., Oba K., Sakai H.
Institutes:Nagasaki University Hospital, Dept. of Urology and Renal Transplantation, Nagasaki, Japan
- *844 **A microplate co-culture assay allows individualised compound efficacy testing in patients derived 3D tumour spheroids and autologous immune cells**
By: Bedke J.¹, Bodenhöfer M.², Harland N.¹, Hennenlotter J.¹, Anderle N.², Schmees C.², Stenzl A.¹
Institutes:¹University of Tübingen, Dept. of Urology, Tübingen, Germany, ²Natural and Medical Sciences Institute At The University of Tübingen, Dept. of Molecular Biology, Reutlingen, Germany
- *845 **Enhanced RCC cell killing with natural killer cells generated from CD34+ hematopoietic progenitor cells combined with mAb cG250**
By: Oosterwijk-Wakka J.¹, Cany J.², Sabata Pérez H.¹, Dolstra H.², Mulders P.¹, Oosterwijk E.¹
Institutes:¹Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, ²Radboudumc, Dept. of Hematology, Nijmegen, The Netherlands
- *846 **Orthotopic sunitinib resistant renal cell carcinoma xenograft mouse model**
By: Frees S., Moskalev I., Raven P., D'costa N., Tan Z., Struss W., Chavez-Munoz C., So A.
Institutes:The Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada
- *847 **Inhibition of semaphorin 3C augments the anti-cancer effect of sunitinib in renal cancer**
By: Dejima T.¹, Takeuchi A.¹, Eto M.¹, Naito S.¹, Gleave M.², Ong C.²
Institutes:¹Kyushu University, Dept. of Urology, Fukuoka, Japan, ²The Vancouver Prostate Centre, Dept. of Urologic Sciences, Vancouver, Canada
- *848 **Expression pattern of immune checkpoint-associated molecules in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors**
By:

Takuto H., Miyake H., Nakano Y., Fujisawa M.

Institutes:Kobe University Graduate School of Medicine, Division of Urology, Dept. of Surgery Related, Kobe, Japan

*849 **Targeting heat-shock protein 27 enhances sensitivity to Sorafenib treatment in renal cancer in vitro and in vivo**

By: Frees S.¹, Chavez-Munoz C.¹, Zhou B.¹, Raven P.¹, Fazli L.¹, Chi K.¹, Lawson K.², Finelli A.², Gleave M.¹, So A.¹

Institutes:¹The Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada, ²University of Toronto, Dept. of Surgical Oncology,, Toronto, Canada

*851 **Panobinostat interacts with nelfinavir to inhibit renal cancer growth by causing endoplasmic reticulum stress**

By: Okubo K., Sato A., Asano T., Isono M., Asano T.

Institutes:National Defense Medical College, Dept. of Urology, Tokorozawa, Japan

*852 **Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma**

By: Abt D.¹, Kraus M.², Bader J.², Besse A.², Schmid H.-P.¹, Engeler D.S.¹, Driessen C.², Besse L.²

Institutes:¹Kantonsspital St. Gallen, Dept. of Urology, St. Gallen, Switzerland, ²Kantonsspital St. Gallen, Dept. of Medical Oncology and Hematology, St. Gallen, Switzerland

*853 **Ritonavir, a potent inhibitor of P-glycoprotein, enhances the anticancer effects of romidepsin in renal cancer cells**

By: Sato A., Asano T., Okubo K., Isono M., Asano T.

Institutes:National Defense Medical College, Dept. of Urology, Tokorozawa, Japan

*854 **Transcriptomic-metabolomic profiling revealed that fatty acid oxidation-induced stress causes cancer Cachexia**

By: Fukawa T.¹, Yan-Jiang B.C.⁴, Kanayama H.-O.², Teh B.T.³, Shyh-Chang N.⁴

Institutes:¹Tokushima University Graduated School, Dept. of Urology, Tokushima, Japan, ²Tokushima University Graduated School, Dept. Of Urology, Tokushima, Japan, ³National Cancer Centre Singapore, Laboratory of Cancer Epigenome, Singapore, Singapore, ⁴Genome Institute of Singapore, Agency For Science Technology and Research, Singapore, Singapore

13:30 - 13:37

Summary

G. Stewart, Cambridge (GB)

Stress incontinence in women

Poster Session 65

Monday, 27 March
12:15 - 13:45

Location: Room Vienna, North Hall (Level 1)

Chairs: T.J. Greenwell, London (GB)
M. Plata, Bogota (CO)
G. Van Koeveringe, Maastricht (NL)

Aims and objectives of this presentation

Primary and secondary SUI treatments will be reviewed

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *855 **Which one stands longer? 20 years experience in retropubic sub-urethral sling surgery for female stress urinary incontinence: Comparison between autologous fascia and prolene mesh**
By: [Chang Y-C](#), Fan Y-H., Lin A., Chen K-K.
Institutes: Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan
- *856 **Preventing early voiding problems after midurethral sling placement: Should we sleep on it?**
By: Bergman A.², Vrooman O.¹, [Van Balken M.](#)¹
Institutes:¹Rijnstate Ziekenhuis, Dept. of Urology, Arnhem, The Netherlands, ²Rijnstate Ziekenhuis, Dept. of Gynaecology, Arnhem, The Netherlands
- *857 **Management of urodynamic stress urinary incontinence in urethral diverticulum**
By: [Barratt R.](#), Spilotros M., Malde S., Pakzad M., Hamid R., Ockrim J., Greenwell T.
Institutes: University College London Hospital, Dept. of Urology, London, United Kingdom
- *858 **Comparative assessment of the efficiency of surgical methods of recurrent urinary incontinence**
By: [Kasyan G.R.](#), Stroganov R.V., Tupikina N.V., Gvozdev M.Y., Pushkar D.Y.
Institutes: Moscow State University of Medicine and Dentistry Named After A.I. Evdokimov, Dept. of Urology, Moscow, Russia
- *859 **Artificial urinary sphincter (AMS800) implantation in women: Rare indications and acceptable complications rate**
By: [Sayed Ahmed K.](#), Kaftan B., Olianias R.
Institutes: Luneburg Hospital, Dept. of Urology, Lüneburg, Germany
- *860 **Robot-assisted artificial urinary sphincter implantation in female patients: A multicenter study**
By: [Peyronnet B.](#)¹, Belas O.², Capon G.³, Manunta A.¹, Tondut L.¹, Allenet C.³, Desportes L.⁴, Vincendeau S.¹, Belas M.², Perrouin-Verbe M-A.⁵, Gobeaux N.², Callerot P.⁵, Pasticier G.³, Colla S.², Valeri A.⁵, Descazeaud A.⁶, Robert G.³, Fournier G.⁵
Institutes:¹CHU Rennes, Dept. of Urology, Rennes, France, ²Pole Santé Sud, Dept. of Urology, Le Mans, France, ³CHU Bordeaux, Dept. of Urology, Bordeaux, France, ⁴Pole Sante Sud, Dept. of Urology, Le Mans, France, ⁵CHU Brest, Dept. of Urology, Brest, France, ⁶CHU Limoges, Dept. of Urology, Limoges, France
- *861 **Artificial urinary sphincter implantation in women with stress urinary incontinence: Preliminary comparison of the robot-assisted and open approaches**
By: [Peyronnet B.](#)¹, Vincendeau S.¹, Tondut L.¹, Alimi Q.¹, Hascoet J.¹, Freton L.¹, Senal N.², Kerdraon J.², Bensalah K.¹, Manunta A.¹

Institutes:¹CHU Rennes, Dept. of Urology, Rennes, France, ²CHU Rennes, Dept. of Physical Medicine and Rehabilitation, Rennes, France

- *862 **Effect of bariatric surgery on urinary and fecal incontinence: Prospective analysis and one year follow up**
By: [Ait Said K.](#)¹, Leroux Y.², Menahem B.², Doerfler A.², Alves A.², Tillou X.¹
Institutes:¹CHU de Caen, Dept. of Urology and Transplantation, Caen, France, ²CHU de Caen, Dept. of Abdominal Surgery, Caen, France
- *863 **Five-years follow-up of tension-free vaginal tape (TVT) versus rectus sheath sling for surgical treatment of female stress urinary incontinence: A comparative study**
By: [Abou Hashem S.](#)¹, Mohamed Mostafa M.¹, Elbrombely W.²
Institutes:¹Zagazig University Hospital, Dept. of Urology, Zagazig, Egypt, ²Zagazig University Hospital, Dept. of Obstetrics and Gynecology, Zagazig, Egypt
- *864 **Three-month primary efficacy and six-month treatment arm results from the SUCCESS study of an intravesical balloon to treat female stress urinary incontinence (SUI)**
By: [Rovner E.](#)¹, Jacoby K.², Kalota S.³, Snyder J.A.⁴, Cline K.⁵, Robertson K.⁶, Rardin C.⁷, Kahan R.⁸, Green L.⁹, Elser D.¹⁰, Zuckerman J.¹¹, Mc Cammon K.¹¹
Institutes:¹Medical University of South Carolina, Dept. of Urology, Charleston, United States of America, ²Integrity Medical Research, Dept. of Urology, Mountlake Terrace, United States of America, ³Urological Associates of Southern Arizona, Dept. of Urology, Tucson, United States of America, ⁴Genitourinary Surgical Consultants, Dept. of Urology, Denver, United States of America, ⁵Regional Urology Associates, Dept. of Urology, Shreveport, United States of America, ⁶Chesapeake Urology Associates, Dept. of Urology, Shreveport, United States of America, ⁷Woman and Infants Hospital, Dept of Urogynecology, Providence, United States of America, ⁸WomanCare, Dept of Urogynecology, Arlington Heights, United States of America, ⁹Virginia Women's Center, Dept. of Urology, Richmond, United States of America, ¹⁰Women's Health Institute of Illinois, Dept of Urogynecology, Oak Lawn, United States of America, ¹¹Urology of Virginia, Dept. of Urology, Virginia Beach, United States of America
- *865 **Effectiveness of adjustable slings (Remeex system™) in women with stress urinary incontinence due to intrinsic sphincter deficiency**
By: [Plata M.](#)¹, Robledo D.¹, Castaño J.C.⁴, Osorio C.², Salazar M.³, Velásquez J.⁵, Trujillo C.¹, Caicedo J.¹, Cataño J.¹
Institutes:¹Hospital Universitario Fundación Santa Fe De Bogotá, Dept. of Urology, Bogotá, Colombia, ²Clínica Confamiliar De Risaralda, Dept. of Urology, Pereira, Colombia, ³Fundación Oftalmológica De Santander Clínica Carlos Ardila Lülle, FOSCAL, Dept. of Urology, Bucaramanga, Colombia, ⁴Clínica Universitaria CES, Dept. of Urology, Medellín, Colombia, ⁵Clínica Medellín and Universidad CES, Dept. of Urology, Medellín, Colombia
- *866 **Transurethral injections of polyacrylamide hydrogel (Bulkamid®) for treatment of female stress urinary incontinence (SUI) in DGH settings**
By: [Hamed A.H.](#), Bekarma H., Rewhorn M., Nair B.
Institutes:University Hospital of Ayr, Dept. of Urology, Ayr, United Kingdom
- *867 **The autologous fascia mid-urethral 'sling on a string', a viable and effective alternative to synthetic tape surgery**
By: [Hillary C.](#), Osman N., Inman R., Mangera A., Chapple C.
Institutes:Royal Hallamshire Hospital, Dept. of Reconstructive Urology, Sheffield, United Kingdom

Innovations in staging of prostate cancer

Poster Session 66

Monday, 27 March
12:15 - 13:45

Location: Room London, North Hall (Level 1)

Chairs: N. Fossati, Milan (IT)
M. Lardas, Nea Smirni-Athens (GR)
J. Hugosson, Göteborg (SE)

Aims and objectives of this presentation

Innovations in prostate cancer staging, prognostic groups, lymph nodes identification

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*869

11C-Choline versus 68ga-PSMA PET/CT scan for the detection of nodal recurrence from prostate cancer: Results from a large, multi-institutional salvage lymph node dissection series

By: Fossati N.¹, Briganti A.¹, Gandaglia G.¹, Suardi N.¹, Colicchia M.², Karnes J.², Haidl F.³, Porres D.³, Pfister D.³, Heidenreich A.³, Herlemann A.⁴, Gratzke C.⁴, Stief C.⁴, Battaglia A.⁵, Everaerts W.⁵, Joniau S.⁵, Van Poppel H.⁵, Aksenov A.⁶, Osmonov D.K.⁶, Juenemann K.P.⁶, Abreu A.D.L.⁸, Almeida F.⁸, Fay C.⁷, Gill I.⁷, Mottrie A.M.⁹, Montorsi F.¹

Institutes:¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²Mayo Clinic, Dept. of Urology, Rochester, Minnesota, United States of America, ³University of Cologne, Dept. of Urology, Cologne, Germany, ⁴Ludwig-Maximilians-University Munich, Dept. of Urology, Munich, Germany, ⁵University Hospitals Leuven, Urology, Dept of Development and Regeneration, Leuven, Belgium, ⁶University Hospital Schleswig Holstein, Dept. of Urology and Pediatric Urology, Campus Kiel, Germany, ⁷Catherine & Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern Cal, USC Institute of Urology, Los Angeles, California, United States of America, ⁸Phoenix Imaging Center, Dept. of Urology, Phoenix, Arizona, United States of America, ⁹OLV Ziekenhuis Aalst, Belgium ORSI Academy, Dept. of Urology, Melle, Belgium

*870

Introducing PSMA-Bone-PET-Index for quantitative assessment of osseous tumor burden in prostate cancer

By: Bieth M.², Krönke M.², Maurer T.¹, Tauber R.¹, Dahlbender M.¹, Retz M.¹, Gschwend J.¹, Nekolla S.², Menze B.², Eiber M.², Schwaiger M.²

Institutes:¹Klinikum rechts der Isar der Technischen Universität München, Dept. of Urology, Munich, Germany, ²Klinikum rechts der Isar der Technischen Universität München, Dept. of Nuclear Medicine, Munich, Germany

*871

Performance of 111In-PSMA-ligand radioguided surgery for identification of lymph node metastases: Correlation of tracer uptake and histopathology based on 310 single lymph nodes separated from lymphadenectomies in prostate cancer patients

By: Schaal K.¹, Mix M.², Stoykow C.², Bartholomä M.², Drendel V.³, Mäcke H.², Gourni E.², Wetterauer U.¹, Schultze-Seemann W.¹, Meyer P.T.², Jilg C.A.¹

Institutes:¹Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Germany, Department of Urology, Freiburg, Germany, ²Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Germany, Department of Nuclear Medicine, Freiburg, Germany, ³Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Germany, Institute For Pathology, Freiburg, Germany

*872

Prospective comparison of molecular and histopathologic detection of lymph node metastases in prostate cancer patients undergoing radical prostatectomy with extended pelvic lymph node dissection: Prediction of biochemical recurrence

By: Heck M.¹, Retz M.¹, Bandur M.¹, Souchay M.¹, Vitzthum E.¹, Weirich G.², Schuster T.³, Autenrieth M.¹, Kübler H.¹, Maurer T.¹, Thalgott M.¹, Herkommer K.¹, Gschwend J.¹, Nawroth R.¹

Institutes:¹Klinikum Rechts Der Isar, Technical University of Munich (TUM), Dept. of Urology, Munich, Germany, ²Klinikum Rechts Der Isar, Technical University of Munich (TUM), Dept. of Pathology, Munich, Germany, ³McGill University, Dept. of Family Medicine, Montreal, Canada

*873

Indication to pelvic lymph nodes dissection for prostate cancer: The role of prostate multiparametric MRI if the risk of lymph nodes invasion according to Briganti updated nomogram is

By: Porpiglia F.¹, Manfredi M.¹, Mele F.¹, Bertolo R.¹, Cattaneo G.¹, Passera R.², De Pascale A.³, Gned D.³, Veltri A.³, Regge D.⁴, Russo F.⁴, Cirillo S.⁵, Fiori C.¹

Institutes:¹San Luigi Hospital, Dept. of Urology, Turin, Italy, ²San Giovanni Battista Hospital, Dept. of Nuclear Medicine, Turin, Italy, ³San Luigi Hospital, Dept. of Radiology, Turin, Italy, ⁴IRCC Candiolo, Dept. of Radiology, Turin, Italy, ⁵Mauriziano Hospital, Dept. of Radiology, Turin, Italy

*874

Can we modulate the extent of nodal dissection according to the preoperative risk of lymph node invasion in prostate cancer patients undergoing radical prostatectomy?

By: Gandaglia G., Zaffuto E., Dell'oglio P., Fossati N., Scattoni V., Bianchi M., Gallina A., Capitanio U., Gaboardi F., Montorsi F., Briganti A.

Institutes:Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy

*875

Characteristics of MRI staging using PI-RADS version 2 and its predictive performance for biochemical recurrence after radical prostatectomy compared to PI-RADS version 1

By: Matsuoka Y.¹, Ishioka J.¹, Tanaka H.², Kimura T.², Inoue M.¹, Ito M.¹, Kijima T.¹, Yoshida S.¹, Yokoyama M.¹, Saito K.¹, Kihara K.¹, Fujii Y.¹

Institutes:¹Tokyo Medical and Dental University Graduate School, Dept. of Urology, Tokyo, Japan, ²Ochanomizu Surugadai Clinic, Dept. of Radiology, Tokyo, Japan

*876

Ability of a new clinical prognostic grouping to better predict disease mortality after treatment in primary non-metastatic prostate cancer

By: Gnanapragasam V.J.¹, Lophatananon A.⁴, Muir K.⁴, Stattin P.³, Bratt O²

Institutes:¹University of Cambridge, Academic Urology Group, Dept. of Surgery, Cambridge, United Kingdom, ²Addenbrookes Hospital, Dept. of Urology, Cambridge, United Kingdom, ³Umea University, Dept. of Surgical and Perioperative Science, Umea, Sweden, ⁴University of Manchester, Institute of Population Health, Manchester, United Kingdom

*877

Expression of tumor progression-associated genes in circulating tumor cells of patients with different stages of prostate cancer

By: Bier S.¹, Hennenlotter J.¹, Beger G.¹, Pavlenco L.¹, Feniuk N.², Hauch S.³, Rausch S.¹, Stenzl A.¹, Todenhöfer T.¹

Institutes:¹Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany, ²Qiagen, Dept. of Research and Development, Hilden, Germany, ³Qiagen, Dept. of Research and Development, Hilden, Germany

*878

Current and projected prevalence of prostate cancer according to risk-categories. A nation-wide and population-based study

By: Folkvaljon Y.¹, Garmo H.², Ventimiglia E.³, Holmberg L.², Stattin P.⁴

Institutes:¹Regional Cancer Centre Uppsala/örebro, Dept. of Surgical Sciences, Uppsala, Sweden, ²King's College London, Faculty of Life Sciences and Medicine, Division of Cancer Studies, London, United Kingdom, ³IRCCS Ospedale San Raffaele, Division of Experimental Oncology/Unit of Urology; URI, Milan, Italy, ⁴Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden

*879

Are the results of the protect trial applicable to contemporary prostate cancer patients treated at two high-volume European Institutions?

By: Gandaglia G.¹, Zaffuto E.¹, Fossati N.¹, Dell'oglio P.¹, Cucchiara V.¹, Pompe R.², Suardi N.¹, Rigatti P.³, Graefen M.², Montorsi F.¹, Tilki D.², Briganti A.¹

Institutes:¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²Martini-Klinik Prostate Cancer Center, Dept. of Urology, Hamburg, Germany, ³Advanced Urotechnology Center,

Scientific Institute "Istituto Auxologico Italiano, Dept. of Urology, Milan, Italy

*880

External validation of a new clinical prognostic grouping to improve prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer

By: Gnanapragasam V.¹, Bratt O.², Stattin P.³, Lee L.⁵, Huang H.⁵, Muir K.⁴, Lophatananon A.⁴

Institutes:¹University of Cambridge, Academic Urology Group, Dept. of Surgery, Cambridge, United Kingdom, ²Addenbrookes Hospital, Dept. of Urology, Cambridge, United Kingdom, ³Umea University, Dept. of Surgical and Perioperative Science, Umma, Sweden, ⁴Institute of Population Health, Manchester, United Kingdom, ⁵Singapore General Hospital, Dept. of Urology, Singapore, Singapore

*881

Do more granular Gleason categorizations lead to better prognostic accuracy over time?

By: Fankhauser C.¹, Wilson K.⁴, Rider J.⁵, Penney K.⁴, Peisch S.⁶, Fiorentino M.⁷, Kantoff P.⁸, Moch H.², Mucci L.⁴, Gerke T.³

Institutes:¹University Hospital Zurich, Dept. of Urology, Zurich, Switzerland, ²University Hospital Zurich, Dept. of Pathology and Molecular Pathology, Zurich, Switzerland, ³Moffitt Cancer Center, Dept. of Epidemiology, Tampa, United States of America, ⁴Harvard T.H. Chan School of Public Health, Dept. of Epidemiology, Boston, United States of America, ⁵Boston University, Dept. of Epidemiology, Boston, United States of America, ⁶Brigham and Women's Hospital/Harvard Medical School, Channing Division of Network Medicine, Dept. of Medicine, Boston, United States of America, ⁷S. Orsola-Malpighi Hospital, Addarii Institute, Dept. of Pathology, Bologna, Italy, ⁸Dana-Farber Cancer Institute, Harvard Medical School, Dept. of Medical Oncology, Boston, United States of America

13:32 - 13:39

New methods in staging of prostate cancer

M. Lardas, Nea Smirni-Athens (GR)

Rare... but important diseases

Poster Session 67

Monday, 27 March
12:15 - 13:45

Location: Room Stockholm, North Hall (Level 1)

Chairs: K. Ghani, Ann Arbor (US)
G. Pourmand, Tehran (IR)
K. Thomas, London (GB)

Aims and objectives of this presentation

7% of the population have one Today's rare and difficult diseases will remain tomorrow's rare and difficult diseases Unless we research, study and teach about them.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *882 **Shorter telomere length increases age-related risk of kidney cancer in von Hippel-Lindau disease**
By: [Wang J.Y.](#), Peng S.H., Ning X.H., Li T., Liu J.Y., Liu S.J., Gong K.
Institutes: Peking University, Institute of Urology, Dept. of Urology, Beijing, China
- *883 **Integrated analysis of microrna and mrna expression profiles in tuberous sclerosis complex angiomyolipoma**
By: [Yi C.](#), Li H., Zhang Y.
Institutes: Peking Union Medical College Hospital, Dept. of Urology, Beijing, China
- *884 **Nephron-sparing surgery for renal angiomyolipomas with high nephrometry scores**
By: [Huang T.H.](#), Chang Y-H., Chung H-J., Lin A.T-L.
Institutes: Taipei Veterans General Hospital, Dept. of Urology, Taipei City, Taiwan
- *886 **Clinicopathologic features and survival outcomes of primary renal sarcoma: A 20-year experience and the largest cohort study from Taiwan**
By: [Liao C-C.](#), Tai H-C., Chen C-H., Wang S-M., Huang C-Y., Pu Y-S., Huang K-H.
Institutes: National Taiwan University Hospital, Dept. of Urology, Taipei, Taiwan
- *887 **Male urinary status, fertility and sexuality in complex exstrophy epispadias: A descriptive study**
By: [Reynaud N.](#)¹, Charvier K.², Ruffion A.³, Mouriquand P.⁴, Morel-Journel N.³, Courtois F.⁵, Terrier J-E.³
Institutes: ¹University Hospital of Saint-Etienne, Dept. of Urology, Saint-Etienne, France, ²Henry Gabrielle Hospital, University Hospital of Lyon, Dept. of Neuro Perineal and Sexology Rehabilitation, Lyon, France, ³South Lyon Hospital, University Hospital of Lyon, Dept. of Urology, Lyon, France, ⁴Woman Mother Child Hospital, University Hospital of Lyon, Dept. of Urogenital Surgery, Visceral, Thoracic, Newborn and Transplantation, Lyon, France, ⁵University of Québec, Dept. of Sexology, Montréal, Canada
- *888 **HIPEC with cytoreductive surgery can cure patients with limited peritoneal carcinomatosis from adenocarcinoma of the urachus**
By: [Behrendt M.A.](#)¹, Mehta A.², Boot H.³, Fransen Van De Putte E.¹, Van Der Heijden M.⁴, Horenblas S.¹, Moonen L.⁵, Verwaal V.⁶, Meinhardt W.¹, Van Rhijn B.¹
Institutes: ¹Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ²Basingstoke and North Hampshire Hospital, Dept. of Colorectal Surgery, Hampshire, United Kingdom, ³Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Surgical Oncology, Amsterdam, The Netherlands, ⁴Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Oncology, Amsterdam, The Netherlands, ⁵Netherlands

Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Radiotherapy, Amsterdam, The Netherlands, ⁶Catharina Ziekenhuis, Dept. of Surgical Oncology, Eindhoven, The Netherlands

- *889 **Encapsulating peritoneal sclerosis, a serious complication of peritoneal dialysis**
By: Pourmand G.¹, Alatab S.¹, Najafi I.², Hosseini M.³, Ahmadbeigi N.⁴
Institutes:¹Tehran University of Medical Sciences, Urology Research Center, Tehran, Iran, ²Tehran University of Medical Sciences, Shariati Hospital, Nephrology Research Center, Tehran, Iran, ³Tehran University of Medical Sciences, School of Public Health, Tehran, Iran, ⁴Tehran University of Medical Sciences, Digestive Disease Research Institute, Liver and Pancreatobiliary Diseases Research Center, Tehran, Iran
- *890 **Female sexual function after intravesical therapy in patients with interstitial cystitis/bladder pain syndrome**
By: Arslan B.¹, Cilesiz N.C.¹, Onuk O.², Cetin B.¹, Yazıcı G.¹, Hazar A.I.¹, Aydin M.¹
Institutes:¹Gop Taksim Training and Research Hospital, Dept. of Urology, Istanbul, Turkey, ²Yeniüzyıl University, Dept. of Urology, Istanbul, Turkey
- *891 **Effect of Brimapitide on acute and chronic cystitis model induced by cyclophosphamide in conscious rats**
By: Abadie C.¹, Chabot S.², Augé C.², Deloche C.¹, Lluet P.², Combette J-M.¹
Institutes:¹Solid Drug Development, Geneva, Switzerland, ²UROsphere, Toulouse, France
- *892 **Withdrawn**
By:
Institutes:
- *893 **Time-dependent changes in urine markers in patients with interstitial cystitis**
By: Furuta A.¹, Yamamoto T.², Koike Y.¹, Suzuki Y.³, Gotoh M.², Egawa S.¹, Yoshimura N.⁴
Institutes:¹Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, ²Nagoya University Graduate School of Medicine, Dept. of Urology, Nagoya, Japan, ³Tokyo Metropolitan Rehabilitation Hospital, Dept. of Urology, Tokyo, Japan, ⁴University of Pittsburgh School of Medicine, Dept. of Urology, Pittsburgh, United States of America
- *894 **The natural history of Leydig cell testicular tumours: An analysis of the National Cancer Registry in Ireland**
By: Nason G., Redmond E., Considine S., Izzeldin S., Sweeney P.
Institutes:Mercy University Hospital, Dept. of Urology, Cork, Ireland

BLEXIT - best oncological outcomes from cystectomy

Poster Session 68

Monday, 27 March
12:15 - 13:45

Location: Room Munich, North Hall (Level 1)

Chairs: J.E. Gschwend, München (DE)
F. Saad
P. Zehnder, Luzern (CH)

Aims and objectives of this presentation
optimising oncological outcomes

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

*895

Clinical and outcome characteristics of the cancer genome atlas (TCGA) bladder cancer cohort: Is it representative?

By: Seiler B.¹, Black P.¹, Thalmann G.², Stenzl A.³, Todenhöfer T.³

Institutes:¹University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ²University of Bern, Dept. of Urology, Bern, Switzerland, ³University Hospital, Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany

*896

Does associated CIS with MIBC impact on neoadjuvant chemotherapy? Results of an International consortium

By: Vasdev N.¹, Zagar H.², Noel J.³, Suleyman N.¹, Thorpe A.⁴, Mir M.C.⁶, Ercole C.E.⁶, Zargar-Shoshtari K.⁷, Fairey A.S.⁸, Mertens L.S.⁹, Dinney C.P.¹⁰, Krabbe L.M.¹¹, Cookson M.S.¹², Jacobsen N.E.¹³, Gandhi N.M.¹⁴, Griffin J.¹⁵, Montgomery J.S.¹⁶, Yu E.Y.¹⁷, Xylinas E.¹⁸, Campain N.J.¹⁹, Veeraterpillay R.⁴, Kassouf W.²⁰, Dall'Era M.A.²¹, Seah J.A.²², Horenblas S.⁹, Sridhar S.S.²², McGrath J.S.¹⁹, Aning J.²³, Shariat S.F.²⁴, Wright J.L.¹⁷, Morgan T.M.¹⁶, Holzbeierlein J.M.¹⁵, Bivalacqua T.J.¹⁴, North S.²⁵, Barocas D.A.²⁶, Lotan Y.¹¹, Garcia J.A.², Grivas P.², Shah J.B.¹⁰, Van Rhijn B.W.⁹, Daneshmand S.⁸, Spiess P.E.⁷, Li J.², Stephenson A.J.², Black P.⁵

Institutes:¹Lister Hospital Stevenage, Division of Robotic Urology, Department of Urology, Stevenage, United Kingdom, ²Glickman Urological and Kidney Institute and Taussig Cancer Center, Cleveland Clinic, Cleveland, United States of America, ³Division of Robotic Surgery, Dept. of Urology, Stevenage, United Kingdom, ⁴Freeman Hospital, Dept. of Urology, Newcastle, United Kingdom, ⁵University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ⁶Cleveland Clinic, Glickman Urological and Kidney Institute and Taussig Cancer Center, Cleveland, United States of America, ⁷H. Lee Moffitt Cancer Center and Research Institute, Dept. of Genitourinary Oncology, Tampa, United States of America, ⁸University of Southern California, USC/Norris Comprehensive Cancer Center, Institute of Urology, Los Angeles, United States of America, ⁹The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ¹⁰MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ¹¹University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ¹²University of Oklahoma College of Medicine, Dept. of Urology, Oklahoma City, United States of America, ¹³University of Alberta, Edmonton, Alberta, Canada, ¹⁴The James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, Dept. of Urology, Baltimore, United States of America, ¹⁵University of Kansas Medical Center, Dept. of Urology, Kansas City, United States of America, ¹⁶University of Michigan Health System, Dept. of Urology, Ann Arbor, United States of America, ¹⁷Division of Oncology, University of Washington School of Medicine and Fred Hutchinson Cancer Research, Dept. of Medicine, Seattle, United States of America, ¹⁸Weill Cornell Medical College, Presbyterian Hospital, Dept. of Urology, New York, United States of America, ¹⁹Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Trust, Dept. of Surgery, Exeter, United Kingdom, ²⁰McGill University Health Center, Dept. of Surgery (Division of Urology), Montreal, Canada, ²¹University of California at Davis, Davis Medical

Center, Dept. of Urology, Sacramento, United States of America, ²²Princess Margaret Cancer Center, Dept. of Urology, Toronto, Canada, ²³Freeman Hospital, Dept. of Urology, New Castle upon Tyne, Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Trust, Dept. of Surgery, Exeter, United Kingdom, ²⁴Weill Cornell Medical College, Presbyterian Hospital, New York, Medical University of Vienna, Vienna General Hospital, Dept. of Urology, Vienna, Austria, ²⁵Cross Cancer Institute, Edmonton, Alberta, United States of America, ²⁶Vanderbilt University Medical Center, Dept. of Urologic Surgery, Nashville, United States of America

- *897 **Bladder-sparing protocol consisting of low-dose chemoradiotherapy and consolidative partial cystectomy against muscle-invasive bladder cancer: A comparison of oncological outcomes between primary and progressive diseases**
By: Nakamura Y., Tanaka H., Fujii Y., Inoue M., Ito M., Kijima T., Yoshida S., Yokoyama M., Ishioka J., Matsuoka Y., Saito K., Kihara K.
Institutes: Tokyo Medical and Dental University Graduate School, Dept. of Urology, Tokyo, Japan
- *898 **The B4GALT1 expression is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with muscle-invasive bladder cancer**
By: Xie H.¹, Zhou L.², Zhu Y.¹, Wang Z.³, Fu Q.³, Zhu Y.¹, Shen Y.¹, Xu J.³, Ye D.¹
Institutes:¹Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China, ²Zhongshan Hospital, Fudan University, Dept. of Urology, Shanghai, China, ³School of Basic Medical Sciences, Fudan University, Biochemistry and Molecular Biology, Shanghai, China
- *899 **Pattern of positive node metastases in patients treated with extended and super extended pelvic lymph node dissection and radical cystectomy due to bladder cancer**
By: Moschini M.¹, Colombo R.¹, Suardi N.⁴, Burgio G.¹, Bandini M.¹, Zaffuto E.¹, Damiano R.², Mattei A.³, Shariat S.⁴, Briganti A.¹, Montorsi F.¹, Gallina A.¹
Institutes:¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²Magna Graecia University of Catanzaro, Dept. of Urology, Catanzaro, Italy, ³Klinik Für Urologie, Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, ⁴Medical University of Vienna, Dept. of Urology, Vienna, Italy
- *900 **Circulating tumor cells do not correspond with clinicopathological characteristics of muscle-invasive bladder cancer patients undergoing radical cystectomy: Interim results of the CirGuidance study**
By: Boormans J.L.¹, De Kruijff I.², Beije N.², Kraan J.³, Te Slaa E.⁴, Wijburg C.⁵, Van Der Hoeven J.⁶, Van Der Heijden A.G.⁷, Somford R.⁸, Klaver O.S.⁹, Van N.M.³, Martens J.W.³, Sleijfer S.²
Institutes:¹Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, ²Erasmus MC, Dept. of Medical Oncology, Rotterdam, The Netherlands, ³Erasmus MC, Dept. of Medical Oncology and Cancer Genomics, Rotterdam, The Netherlands, ⁴Isala Klinieken, Dept. of Urology, Zwolle, The Netherlands, ⁵Rijnstate Hospital, Dept. of Urology, Arnhem, The Netherlands, ⁶RDGG, Dept. of Urology, Delft, The Netherlands, ⁷Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, ⁸CWZ, Dept. of Urology, Nijmegen, The Netherlands, ⁹Maasstadziekenhuis, Dept. of Urology, Rotterdam, The Netherlands
- *901 **Muscle invasive bladder cancer: A single sample patient assay to predict molecular subtypes and benefit of neoadjuvant chemotherapy**
By: Seiler R.¹, Ashab H.A.D.², Erho N.², Van Rhijn B.W.³, Winters B.⁴, Douglas J.⁵, Van Kessel K.⁶, Fransen Van De Putte E.³, Sommerlad M.⁵, Wang Q.⁷, Choerung V.⁷, Gibb E.⁷, Palmer-Aronsten B.⁷, Lam L.⁷, Buerki C.⁷, Davicioni E.⁷, Sjö Dahl G.⁸, Kardos J.⁹, Hoadley K.⁹, Lerner S.¹⁰, Mcconkey D.¹¹, Choi W.¹¹, Kim W.⁹, Kiss B.¹², Thalmann G.¹², Todenhöfer T.¹, Crabb S.¹³, North S.¹⁴, Zwarthoff E.⁶, Boormans J.⁶, Wright J.⁴, Dall'era M.¹⁵, Van Der Heijden M.³, Black P.¹
Institutes:¹University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ²GenomeDx, Biosciences, Vancouver, Canada, ³Netherlands Cancer Institute, Dept. of Surgical Oncology, Division of Urology, Amsterdam, The Netherlands, ⁴University of Washington School of Medicine, Dept. of Urology, Seattle, United States of America, ⁵University Hospital of Southampton, Dept. of Urology, Hampshire, United Kingdom, ⁶Erasmus MC, University Medical Center Rotterdam, Dept. of Pathology, Rotterdam, The Netherlands, ⁷GenomeDx, Dept. of Biosciences, Vancouver, Canada, ⁸Department of Translational Medicine, Lund University, Division of Urological Research, Malmö, Sweden, ⁹University of North Carolina At Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, United States of America, ¹⁰Baylor College of Medicine, Dept. of Urologic

Oncology, Houston, United States of America, ¹¹University of Texas MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ¹²University of Bern, Dept. of Urology, Bern, Switzerland, ¹³University Hospital of Southampton, Dept. of Medical Oncology, Hampshire, United Kingdom, ¹⁴University of Alberta Edmonton, Cross Care Institute, Dept. of Oncology, Alberta, Canada, ¹⁵University of Sacramento, UC Davis Comprehensive Cancer Center, Sacramento, United States of America

- *902 **Preoperative double-J stenting increases the risk of upper urinary tract (UUT) recurrence after radical cystectomy**
 By: Kiss B.¹, Furrer M-A.¹, Wuethrich P.², Burkhard F.¹, Thalmann G.¹, Roth B.¹
 Institutes:¹University Hospital Bern, Dept. of Urology, Bern, Switzerland, ²University Hospital Bern, Dept. of Anesthesiology, Bern, Switzerland
- *903 **Impact of perioperative transfusion of red blood cells and fresh frozen plasma on recurrence-free survival of patients after radical cystectomy for bladder cancer**
 By: Schubert T., Schmid M.A., Renninger M., Lütfnrenk T., Stenzl A., Gakis G.
 Institutes:University Hospital of Tuebingen, Dept. of Urology, Tuebingen, Germany
- *904 **Fate of patients undergoing pulmonary metastasectomy for metastatic urothelial carcinoma**
 By: Hoshi S.¹, Fukui I.², Kageyama Y.³, Kawashima K.⁴, Narita S.⁵, Ono K.⁶, Numahata K.¹, Sato M.⁸, Morozumi K.⁸, Kuromoto A.⁸, Ozawa M.⁸, Hoshi K.⁷, Bilim V.⁷, Sasagawa I.⁷
 Institutes:¹Yamagata Prefectural Central Hospital, Dept. of Urology, Yamagata, Japan, ²Cancer Institute Hospital, Dept. of Urology, Tokyo, Japan, ³Saitama Prefectural Cancer Center, Dept. of Urology, Saitama, Japan, ⁴Tochige Prefectural Cancer Center, Dept. of Urology, Tochigi, Japan, ⁵Akita University Hospital, Dept. of Urology, Akita, Japan, ⁶Ishinomaki Redcross Hospital, Dept. of Urology, Ishinomaki, Japan, ⁷Yamagata Tokushukai Hospital, Dept. of Urology, Yamagata, Japan, ⁸Yamagata Prefectural Central Hospital, Dept. of Urology, Yamagata, Japan
- *905 **Characterization of genomic aberrations of circulating, cell-free DNA in bladder cancer patients treated with radical cystectomy using multiplex ligation-dependent probe amplification: A new and efficient profiling method**
 By: Soave A.¹, Chun F.¹, Rink M.¹, Weisbach L.¹, Maurer V.¹, Gild P.¹, Steinbach B.², Fisch M.¹, Pantel K.², Schwarzenbach H.²
 Institutes:¹University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ²University Medical Center Hamburg-Eppendorf, Dept. of Tumor Biology, Hamburg, Germany
- *906 **Perioperative allogeneic blood transfusion does not adversely impact survival after radical cystectomy for urinary bladder cancer – a competing-risks analysis from a multi-institutional European series**
 By: Gild P.¹, Vetterlein M.¹, Kluth L.A.¹, Gierth M.², Fritsche H-M.², Burger M.², Protzel C.³, Hakenberg O.³, Von Landenberg N.⁴, Roghmann F.⁴, Noldus J.⁴, Nuhn P.⁵, Rink M.¹, Chun F.¹, May M.⁶, Fisch M.¹, Aziz A.¹
 Institutes:¹Universitätsklinikum Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ²Caritas St. Josef Medical Center, University of Regensburg, Dept. of Urology, Regensburg, Germany, ³University of Rostock, Dept. of Urology, Rostock, Germany, ⁴Marien Hospital Herne, Ruhr-University Bochum, Dept. of Urology, Herne, Germany, ⁵University Hospital Mannheim, Dept. of Urology, Mannheim, Germany, ⁶St. Elisabeth Medical Center Straubing, Dept. of Urology, Straubing, Germany
- *907 **A propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic**
 By: Kulkarni G.¹, Hermanns T.¹, Wei Y.¹, Bhindi B.¹, Satkunasingam R.¹, Athanasopoulos P.¹, Bostrom P.¹, Kuk C.², Li K.¹, Templeton A.³, Sridhar S.³, Van Der Kwast T.⁴, Chung P.⁵, Bristow R.⁵, Milosevic M.⁵, Warde P.⁵, Fleshner N.⁶, Jewett M.⁶, Bashir S.⁷, Zlotta A.⁸
 Institutes:¹Princess Margaret Cancer Centre, University Health Network, Dept. of Surgery, Toronto, Canada, ²Mount Sinai Hospital, Dept. of Surgery, Toronto, Canada, ³Princess Margaret Cancer Centre, University Health Network, Dept. of Medical Oncology, Toronto, Canada, ⁴Toronto General Hospital, University Health Network, Dept. of Pathology, Toronto, Canada, ⁵Princess Margaret

Hospital, University Health Network, Radiation Medicine Program, Toronto, Canada, ⁶Princess Margaret Cancer Centre, University Health Network, Dept. of Surgery (urology), Toronto, Canada, ⁷Princess Margaret Cancer Centre, University Health Network, Dept. of Biostatistics, Toronto, Canada, ⁸Mount Sinai Hospital, Dept. of Surgery (urology), Toronto, Canada

*908

Outcome of patients undergoing radical cystectomy for urothelial cell carcinoma of the bladder with evidence of distant metastases. Results of a single center study

By: Grimm T., Buchner A., Schneevoigt B-S., Kretschmer A., Grabbert M., Jokisch F., Schulz G., Stief C.G., Karl A.

Institutes:LMU-Klinikum der Universität München, Urology, München, Germany

*909

The accuracy of sequential urethral frozen sections and its impact on urethral recurrence after radical cystectomy

By: Schubert T., Schmid M.A., Renninger M., Lütfnik T., Stenzl A., Gakis G.

Institutes:University Hospital of Tuebingen, Dept. of Urology, Tuebingen, Germany

ESU/ESFFU Hands-on Training in Urodynamics

HOT08

Monday, 27 March
13:00 - 16:00

Location: Room South America, Exhibition Hall (Level 1)

Chair: H. Hashim, Bristol (GB)

Aims and objectives of this presentation

This course aims to provide a practical course offering an interactive “hands-on” environment for doctors, nurses and technicians to improve their skills in urodynamics, with an emphasis on practical aspects including equipment used, interpretation of traces, quality control and trouble-shooting. The use of recorded tests, access to equipment and small groups means that individual problems can be addressed. All the speakers are involved in similar “hands-on” courses, which have run successfully in the United Kingdom and abroad. The small group format has been shown to work well in addressing individual needs. Access to teaching aids and equipment will simulate the clinical scenario as much as possible within the constraints of the conference setting.

M. Belal, Birmingham (GB)
A. Gammie, Bristol (GB)
A. Garcia Mora, Mexico City (MX)
L. Thomas, Bristol (GB)

Minimally invasive reconstructive surgery

Video Session 10

Monday, 27 March
14:00 - 15:30

Location: eURO Auditorium (Level 0)

Chairs: S.A. Ahyai, Göttingen (DE)
G. Al Edwan, Amman (JO)
P-T. Piéchaud, Bordeaux (FR)

Aims and objectives of this presentation

Demonstration of reconstructive procedures with novel approaches which seem promising because they still obey the principles of classic reconstructive urology or show convincing data with follow up and evidence.

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

- *V74 **Laparoscopic management of congenital, acquired and iatrogenic diseases of the upper urinary tract**
By: Fuschi A., Al Salhi Y., Leto A., Velotti G., Palleschi G., Pastore A.L., Carbone A.
Institutes: Sapienza University of Rome, Dept. of Medico-Surgical Sciences and Biotechnologies, Urology Unit, Latina, Italy
- *V75 **Minilaparoscopic single-site (MILESS) pyeloplasty: The best compromise between surgeon's ergonomomy and patient's cosmesis (IDEAL phase 2a)**
By: Greco F.¹, Pini G.³, Alba S.¹, Altieri V.¹, Verze P.², Mirone V.²
Institutes:¹Romolo Hospital, Dept. of Urology, Rocca Di Neto, Italy, ²Federco II University, Dept. of Urology, Naples, Italy, ³Uroclinic, Minimally Invasive Robotic Center, Stockholm, Sweden
- *V76 **Robotic ureteral reimplantation for uretero-enteric anastomotic strictures in different urinary diversions**
By: Simone G.¹, Fay C.², Freitas D.², Chopra S.², Misuraca L.¹, Tuderti G.¹, Ferriero M.¹, Guaglianone S.¹, Gill I.², Berger A.², Desai M.², Goh A.³, Gallucci M.¹, Aron M.²
Institutes:¹Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ²Keck School of Medicine, University of Southern California, USC Institute of Urology, Los Angeles, United States of America, ³Methodist Hospital, Dept. of Urology, Houston, United States of America
- *V77 **Laparoscopic ureteral substitution with cecal appendix**
By: Cavalli A.², Hota T.¹, Slongo L.², Gouveia D.³, Souza V.³
Institutes:¹Hospital de clínicas, Federal University of Parana, Dept. of Urology, Paraná, Brazil, ²University Federal of Parana, Dept. of Urology, Curitiba, Brazil, ³Hospital Nossa Senhora Das Graças, Dept. of Urology, Curitiba, Brazil
- *V79 **Left-sided ureteroplasty with appendix**
By: Popov S.¹, Orlov I.¹, Vyazovtsev P.¹, Galliamov E.², Novikov A.³, Sergeev V.⁴
Institutes:¹City Hospital Saint Luka / No18, Dept. of Urology, Saint Petersburg, Russia, ²Civil Aviation Hospital, Dept. of Urology, Moscow, Russia, ³Central Bank Medical Center, Dept. of Urology, Moscow, Russia, ⁴Moscow Oncological City Hospital #62, Dept. of Urology, Moscow, Russia
- *V80 **Robot-assisted implantation of artificial urinary sphincter in women: Standardization of the surgical technique**
By: Peyronnet B., Vincendeau S., Pradere B., Tondut L., Alimi Q., Fretton L., Hascoet J., Bensalah K., Manunta A.

Institutes:CHU Rennes, Dept. of Urology, Rennes, France

*V81

The novel technique of pelvic organ prolapse treatment: Apical sling and subfascial colporrhaphy

By: Shkarupa D., Pisarev A., Zaytseva A., Shapovalova E., Kubin N.

Institutes:University Clinic of Saint Petersburg State University, Dept. of Urology, Saint-Petersburg, Russia

Sophisticated approaches to advanced RCC

Poster Session 69

Monday, 27 March
14:00 - 15:30

Location: Room Copenhagen, North Hall (Level 1)

Chairs: J.I. Martínez Salamanca, Majadahonda (ES)
V. Matveev, Moscow (RU)
M.C. Mir Maresma, Cleveland (US)

Aims and objectives of this presentation

To discuss different surgical aspects of nephrectomy for advanced RCC

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

*910

Renal tumor management in Scandinavia: A multi-institutional survey

By: Nisen H.¹, Jarvinen P.¹, Lund L.², Ljungberg B.³, Kromann-Andersen B.⁴, Gudmundsson E.⁵, Sundqvist P.⁶, Fovaeus M.⁷, Nilsen F.⁸, Beisland C.⁹

Institutes:¹HUCH Helsinki University Central Hospital, Dept. of Urology, Helsinki, Finland, ²Odense University Hospital, Dept. of Urology, Odense, Denmark, ³Umeå University, Dept. of Surgical and Perioperative Sciences, Umeå, Sweden, ⁴Herlev University Hospital, Dept. of Urology, Copenhagen, Denmark, ⁵Landspítali, Dept. of Urology, Reykjavik, Iceland, ⁶Örebro University Hospital, Dept. of Urology, Örebro, Sweden, ⁷Sahlgrenska University Hospital, Dept. of Urology, Göteborg, Sweden, ⁸Akershus University Hospital, Dept. of Urology, Oslo, Norway, ⁹Haukelan University Hospital, Dept. of Urology, Bergen, Norway

*911

Multicenter analysis of oncologic and renal functional outcomes of radical and partial nephrectomy in stage II renal cell carcinoma

By: Hamilton Z.¹, Correa A.², Larcher A.⁴, Khene Z.³, Fero K.¹, Han D.¹, Bloch A.¹, Field C.¹, Peyronnet B.³, Capitanio U.⁴, Montorsi F.⁴, Bensalah K.³, Uzzo R.², Derweesh I.¹

Institutes:¹Moores Cancer Center, Dept. of Urology, La Jolla, United States of America, ²Fox Chase Cancer Center, Dept. of Urology, Philadelphia, United States of America, ³University of Renne, Dept. of Urology, Renne, France, ⁴San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy

*912

Partial versus radical nephrectomy in patients with renal cell carcinoma and renal or caval thrombus: Oncological and functional outcomes from an individual matched cohort analysis

By: Marra G.¹, Gontero P.¹, Brattoli M.¹, Filippini C.², Linares Espinos E.³, Capitanio U.⁴, Montorsi F.⁴, Daneshmand S.⁶, Huang W.C.⁷, Martínez-Salamanca J.I.⁸, McKiernan J.M.⁹, Scherr D.S.¹⁰, Zigeuner R.¹¹, Libertino J.A.⁵

Institutes:¹San Giovanni Battista Hospital, Dept. of Urology, Turin, Italy, ²San Giovanni Battista Hospital, Dept. of Urology, Turin, Italy, ³Hospital Universitario Puerta De Hierro-Madrid, Dept. of Urology, Madrid, Spain, ⁴San Raffaele Hospital, Dept. of Urology, Milan, Italy, ⁵Lahey Clinic, Dept. of Urology, Burlington, United States of America, ⁶USC/Norris Comprehensive Cancer Center, Dept. of Urology, Los Angeles, United States of America, ⁷University School of Medicine, Dept. of Urology, New York, United States of America, ⁸Hospital Universitario Puerta de Hierro-Majadahonda, Universidad Autónoma de Madrid, Dept. of Urology, Madrid, Spain, ⁹Columbia University College of Physicians and Surgeons, Dept. of Urology, New York, United States of America, ¹⁰Weill Cornell Medical Center, Dept. of Urology, New York, United States of America, ¹¹Medical University of Graz, Dept. of Urology, Graz, Austria

*913

Comparison of different surgical approaches for the management of renal cell carcinoma invading the renal vein

By: Hanna N., Ingham M., Seisen T., Chang S.

Institutes:Brigham and Women's Hospital, Dept. of Urology, Boston, Canada

- *914 **Robot assisted radical nephrectomy and inferior vena cava thrombectomy: Surgical technique, perioperative and oncologic outcomes**
By: Simone G.¹, Hatcher D.², Ferriero M.¹, Minisola F.¹, Misuraca L.¹, Tuderti G.¹, Guaglianone S.¹, De Castro Abreu A.L.², Aron M.², Desai M.², Gill I.S.², Gallucci M.¹
Institutes:¹Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ²Keck School of Medicine, University of Southern California, Institute of Urology, Los Angeles, United States of America
- *916 **Comparison between laparoendoscopic single site nephrectomy and conventional laparoscopic nephrectomy: A randomized control single institution experience**
By: Eltemamy M., Abdel Hakim M., El-Feel A., Abdel Wahab M., Abdallah A., Elshafei A., Omar A.-R.
Institutes:Cairo University, Dept. of Urology, Cairo, Egypt
- *918 **The efficacy of neoadjuvant targeted therapy in treatment of localized RCC**
By: Voylenko O., Vitruk I., Stakhovskyi O., Kononenko O., Pikul M., Stakhovsky E.
Institutes:National Cancer Institute, Dept. of Plastic and Reconstructive Oncological Urology, Kiev, Ukraine
- *919 **Clinical benefit of presurgical axitinib therapy in renal cell carcinoma patients with thrombus extending to inferior vena cava**
By: Tanaka Y., Hashimoto Y., Hatakeyama S., Hosogoe S., Noro D., Oikawa M., Tanaka T., Narita T., Hagiwara K., Tobisawa Y., Yamamoto H., Yoneyama T., Yoneyama T., Koie T., Ohyama C.
Institutes:Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan
- *920 **Phase II study of axitinib for downstaging cT2a to cT1 renal tumors for allowing partial nephrectomy (AXIPAN)**
By: Lebacle C.¹, Bernhard J.C.², Bensalah K.³, Baumert H.⁴, Lang H.⁵, Jacqmin D.⁵, Duclos B.⁶, Ravaud A.⁷, Laguerre B.⁸, Albiges L.⁹, Arnoux A.¹⁰, Escudier B.⁹, Patard J.J.¹
Institutes:¹Bicêtre University Hospital, Dept. of Urology, Le Kremlin-bicêtre, France, ²Pellegrin Hospital, Dept. of Urology, Bordeaux, France, ³Pontchaillou University Hospital, Dept. of Urology, Rennes, France, ⁴Saint-Joseph Hospital, Dept. of Urology, Paris, France, ⁵Hôpitaux Universitaires De Strasbourg, Nouvel Hôpital Civil, Dept. of Urology, Strasbourg, France, ⁶Hôpitaux Universitaires De Strasbourg, Hôpital Hautepierre, Dept. of Oncology, Strasbourg, France, ⁷Saint-André Hospital, University Hospital, CHU Bordeaux, Dept. of Medical Oncology, Bordeaux, France, ⁸Eugène Marquis Center, Dept. of Oncology, Rennes, France, ⁹Gustave Roussy Université Paris-Saclay, Dept. of Medicine, Villejuif, France, ¹⁰Bicetre University Hospital, Dept. of Statistics, Le Kremlin-Bicêtre, France
- *921 **Meta-analysis of upfront VEGF targeted therapy prior to nephrectomy in metastatic clear cell renal cancer**
By: Szabados B.¹, Gomez De Liano Lista A.¹, Wimalasingham A.¹, De Bruijn R.², Haanen J.³, Blank C.³, Hall P.⁴, Staehler M.⁶, Chowdhury S.⁵, Hopkins T.⁴, Powles T.⁴, Bex A.²
Institutes:¹Barts Health Nhs Trust St Bartholomew's Hospital, Dept. of Oncology, London, United Kingdom, ²The Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ³The Netherlands Cancer Institute, Dept. of Oncology, Amsterdam, The Netherlands, ⁴Barts Health NHS Trust St Bartholomew's Hospital, Dept. of Oncology, London, United Kingdom, ⁵Guy's, King's and St Thomas' Hospitals, Dept. of Oncology, London, United Kingdom, ⁶University Hospital Munich-Grosshadern, Dept. of Urology, Munich, Germany
- *922 **S-TRAC adjuvant sunitinib phase 3 trial in patients with high risk renal cell carcinoma: Subgroups analyses by risk factors**
By: Staehler M.¹, Patard J.-J.², Pantuck A.³, Ravaud A.⁴, Motzer R.⁵, Pandha H.⁶, George D.⁷, Chang Y.-H.⁸, Escudier B.⁹, Donskov F.¹⁰, Magheli A.¹¹, Carteni G.¹², Laguerre B.¹³, Tomczak P.¹⁴, Breza J.¹⁵, Gerletti P.¹⁶, Lechuga M.¹⁶, Lin X.¹⁷, Casey M.¹⁸, Patel A.¹⁹
Institutes:¹University Hospital of Munich, Dept. of Urology, Munich, Germany, ²Bicêtre Hospital, Paris-Saclay University, Dept. of Urology, Le Kremlin Bicêtre, France, ³Ronald Reagan UCLA Medical Center, Dept. of Urology, Los Angeles, Ca, United States of America, ⁴Bordeaux University

Hospital, Dept. of Medical Oncology, Bordeaux, France, ⁵Memorial Sloan Kettering Cancer Center, Dept. of Oncology, New York, Ny, United States of America, ⁶University of Surrey, Dept. of Clinical and Experimental Medicine, Surrey, United Kingdom, ⁷Duke Cancer Center, Dept. of Oncology, Durham, Nc, United States of America, ⁸Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan, ⁹Institut Gustave Roussy, Dept. of Medical Oncology, Villejuif, France, ¹⁰Aarhus University Hospital, Dept. of Oncology, Aarhus, Denmark, ¹¹Charité Universitaetsmedizin Berlin, Dept. of Urology, Berlin, Germany, ¹²Azienda Ospedaliera Di Rilievo Nazionale A. Cardarelli,, Dept. of Oncology and Urology, Naples, Italy, ¹³Centre Eugene Marquis, Dept. of Medical Oncology, Rennes, France, ¹⁴Klinika Onkologii Oddzial Chemioterapii, Dept. of Oncology, Poznan, Poland, ¹⁵Slovak Medical University In Bratislava, Dept. of Urology, Bratislava, Slovakia, ¹⁶Pfizer S.r.L, Dept. of Oncology, Milan, Italy, ¹⁷Pfizer Inc, Dept. of Oncology, La Jolla, Ca, United States of America, ¹⁸Pfizer Inc, Dept. of Oncology, New York, Ny, United States of America, ¹⁹Spire Roding Hospital, Dept. of Urology, London, United Kingdom

15:15 - 15:22

Summary

M.C. Mir Maresma, Cleveland (US)

Complications and functional outcomes after radical prostatectomy

Poster Session 70

Monday, 27 March
14:00 - 15:30

Location: Room Madrid, North Hall (Level 1)

Chairs: M. Graefen, Hamburg (DE)
G. Ploussard, Toulouse (FR)

Aims and objectives of this presentation

The aim of this session is to evaluate peri-operative complications and functional outcomes after radical prostatectomy

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *923 **Pre-discharge predictors of readmissions and post-discharge complications in robot-assisted radical prostatectomy**
By: Xia L., Taylor B., [Guzzo T.](#)
Institutes:University of Pennsylvania Perelman School Of Medicine, Division of Urology, Dept. of Surgery, Philadelphia, United States of America
- *924 **Impact of metabolic syndrome on robotic assisted radical prostatectomy outcomes: Stratification by number of metabolic risk factors**
By: [Bonet Puntí X.](#), Ogaya G., Woodlief T., Hernández-Cardona E., Ganapathi H., Rogers T., Dinatale R., Coelho R., Rocco B., Patel V.
Institutes:Global Robotics Institute, Florida Hospital - Celebration Health, Dept. of Urology, Celebration, United States of America
- *925 **Detailed analysis of the impact of robotic-assisted radical prostatectomy on lower urinary tract symptoms**
By: [Mackenzie K.](#)¹, Fabricius M.², Mccoll E.², Johnson M.¹, Soomro N.¹, Harding C.¹, Aning J.¹
Institutes:¹Newcastle Upon Tyne Hospitals Nhs Foundation Trust, Dept. of Urology, Newcastle Upon Tyne, United Kingdom, ²University of Newcastle, Institute of Health and Society, Newcastle Upon Tyne, United Kingdom
- *926 **Predictors of continence after Retzius-sparing robot-assisted radical prostatectomy**
By: [Kim L.H.](#), Abdel Raheem A., Santok G.D., Chang K., Lee S.H., Ham W.S., Choi Y.D., Rha K.H.
Institutes:Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea
- *927 **Risk stratification model for post-operative urinary continence based on pre-operative patient's factors and preservation of the neurovascular bundles during robot-assisted radical prostatectomy**
By: Morizane S., Yumioka T., Yamaguchi N., [Iwamoto H.](#), Masago T., Hikita K., Honda M., Takenaka A.
Institutes:Faculty of Medicine, Tottori University, Dept. of Urology, Yonago, Japan
- *928 **Association between early urinary continence and erectile function recovery after robot-assisted radical prostatectomy: Development of a novel postoperative risk score to optimize patient counseling and follow-up**
By: [Gandaglia G.](#)¹, Suardi N.¹, Gallina A.¹, Dell'oglio P.¹, Fossati N.¹, Cucchiara V.¹, Moschini M.¹, Bandini M.¹, Zaffuto E.¹, Salonia A.¹, Gaboardi F.¹, Damiano R.³, Mirone V.², Montorsi F.¹, Briganti A.¹
Institutes:¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²University of Naples

'Federico II', Dept. of Urology, Naples, Italy, ³Magna Graecia University, Dept. of Urology, Catanzaro, Italy

- *929 **Comparison of the limited and extended lymphadenectomy during robot-assisted radical prostatectomy for prostate cancer: Does the extended lymphadenectomy affect the complications?**
 By: Morizane S.¹, Fukasawa S.², Komaru A.², Inokuchi J.³, Eto M.³, Shimbo M.⁴, Hattori K.⁴, Kawano Y.⁵, Noma H.⁶, Takenaka A.¹
 Institutes:¹Faculty of Medicine, Tottori University, Dept. of Urology, Yonago, Japan, ²Chiba Cancer Center, Dept. of Urology, Chiba, Japan, ³Graduate School of Medical Sciences, Kyushu University, Dept. of Urology, Fukuoka, Japan, ⁴St. Luke's International Hospital, Dept. of Urology, Tokyo, Japan, ⁵Faculty of Life Sciences, Kumamoto University, Dept. of Urology, Kumamoto, Japan, ⁶The Institute of Statistical Mathematics, Dept. of Data Science, Tokyo, Japan
- *930 **Contemporary complications after radical prostatectomy**
 By: Pompe R.S.¹, Beyer B.¹, Gild P.¹, Karakiewicz P.², Leyh-Bannurah S-R.¹, Schlomm T.¹, Steuber T.¹, Huland H.¹, Graefen M.¹, Tilki D.¹
 Institutes:¹Universitätsklinikum Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ²University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada
- *932 **Return to work following robot assisted laparoscopic- and open retropubic radical prostatectomy: A single center cohort study to compare duration of sick leave**
 By: Beyer B., Von Mechow S., Tennstedt P., Graefen M.
 Institutes:Universitätsklinikum Hamburg-Eppendorf, Martini-Clinic, Prostate Cancer Center, Hamburg, Germany
- *933 **Outcomes of preventive vs delayed ligation of dorsal vascular complex during RARP: Preliminary results of a randomized trial**
 By: Palumbo C., Antonelli A., Mittino I., Francavilla S., Lattarulo M., Sodano M., Furlan M., Peroni A., Simeone C.
 Institutes:ASST Spedali Civili Hospital of Brescia, Dept. of Urology, Brescia, Italy
- *934 **Adjustable transobturator male system with pre-attached scrotal port for the treatment of male stress urinary incontinence**
 By: Angulo J.¹, Arance I.¹, Esquinas C.¹, Dorado J.F.², Marcelino J.³, Martins F.³
 Institutes:¹Hospital Universitario de Getafe, Dept. of Urology, Getafe, Spain, ²Pertica, Dept. of Statistics, Getafe, Spain, ³Hospital De Santa María, Dept. of Urology, Lisbon, Portugal
- *935 **Incidence, risk factors, management and complications of rectal injuries during radical prostatectomy**
 By: Mandel P.¹, Linnemannstöns A.², Chun F.³, Schlomm T.¹, Rosenbaum C.¹, Ludwig T.³, Dahlem R.³, Fisch M.³, Graefen M.³, Salomon G.², Huland H.², Tilki D.¹, Steuber T.¹
 Institutes:¹University Hospital Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center; Department of Urology, Hamburg, Germany, ²University Hospital Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center, Hamburg, Germany, ³University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany
- *936 **Urinary continence, sexual function and biochemical recurrence 12 months following robot-assisted radical prostatectomy: A randomized controlled study comparing the Bocciardi and Menon techniques**
 By: Menon M., Dalela D., Prasad M.-A., Jamil M., Abdollah F., Sood A., Sammon J., Simone A., Jeong W.
 Institutes:Vattikuti Urology Institute, Dept. of Urology, Detroit, United States of America
- *937 **Long term complications and quality of life after pure versus robot-assisted laparoscopic prostatectomy: Results of a prospective randomised controlled trial**
 By: Fiori C.¹, Bertolo R.¹, Manfredi M.¹, Mele F.¹, Poggio M.¹, Garrou D.¹, Checcucci E.¹, De Luca S.¹,

Passera R.², Scarpa R.M.¹, Porpiglia F.¹

Institutes:¹San Luigi Hospital, Dept. of Urology, Turin, Italy, ²San Giovanni Battista Hospital, Dept. of Nuclear Medicine, Turin, Italy

Survivorship in prostate cancer: "Its all about patients"

Poster Session 71

Monday, 27 March
14:00 - 15:30

Location: Room Milan, North Hall (Level 1)

Chairs: R. Kirby, London (GB)
S. MacLennan, Aberdeen (GB)
B. Tombal, Brussels (BE)

Aims and objectives of this presentation

To assess patients perspective and expectation during treatment and follow-up

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *938 **Prostate cancer-specific anxiety in long-term survivors after radical prostatectomy**
By: Meissner V.H.¹, Dinkel A.², Marten-Mittag B.², Gschwend J.¹, Herkommer K.¹
Institutes:¹Klinikum Rechts Der Isar, Technical University of Munich, Dept. of Urology, Munich, Germany, ²Klinikum Rechts Der Isar, Technical University of Munich, Dept. of Psychosomatic Medicine and Psychotherapy, Munich, Germany
- *939 **Patients' perspectives on the risks of localized prostate cancer treatments prior to making the treatment decision**
By: Van Stam M-A.¹, Van Der Poel H.², Aaronson N.³, Horenblas S.², Tillier C.², Bosch J.⁴
Institutes:¹University Medical Center Utrecht, Dept. of Urology, Utrecht, The Netherlands, ²NKI-AvL, Dept. of Urology, Amsterdam, The Netherlands, ³NKI-AvL, Division of Psychosocial Research & Epidemiology, Amsterdam, The Netherlands, ⁴Umc Utrecht, Dept. of Urology, Utrecht, The Netherlands
- *940 **Elderly prostate cancer patients in the Netherlands have a worse prognosis than younger patients: A population-based study**
By: Vernooij R.¹, Van Oort I.², De Reijke T.³, Aben K.¹
Institutes:¹Netherlands Comprehensive Cancer Organisation, Dept. of Research, Utrecht, The Netherlands, ²Radboud University Medical Centre, Dept. of Urology, Nijmegen, The Netherlands, ³Academic Medical Centre, Dept. of Urology, Amsterdam, The Netherlands
- *941 **A multimodal supportive care intervention in men and their partners/carers affected by metastatic prostate cancer: A randomised controlled feasibility study**
By: Paterson C., Primeau C.P., Nabi G.N
Institutes:Ninewells Hospital, Dept. of Urology, Dundee, United Kingdom
- *942 **Perioperative patient education improves long-term satisfaction rates of low-risk prostate cancer patients after radical prostatectomy**
By: Kretschmer A., Buchner A., Grabbert M., Sommer A., Herlemann A., Stief C.G., Bauer R.M.
Institutes:LMU-Klinikum der Universität München, Dept. of Urology, Munich, Germany
- *943 **Impact of the perception of relationship cohesion (dyadic adjustment) on the quality of life (QoL) of patients with prostate cancer (PCa) receiving gonadotropin-releasing hormone (GnRH) agonist therapy**
By: Droupy S.¹, Pello-Leprince-Ringuet N.², Perrot V.², Descazeaud A.³
Institutes:¹Chu Carêmeau, Dept. of Urology Androlgy, Nîmes, France, ²Ipsen Pharma, Dept. of Urology, Boulogne-Billancourt, France, ³University Hospital, Dept. of Urology, Limoges, France

- *944 **Impact of implementing a goal directed holistic needs clinic on quality of life after robotic radical prostatectomy**
By: [Calleja E.](#), Ferguson J., Aning J.
Institutes:Freeman Hospital, Dept. of Urology, Newcastle Upon Tyne, United Kingdom
- *946 **Psychosocial interventions to improve the quality of life for men with prostate cancer: A Bayesian network meta-analysis of 31 randomised controlled trails**
By: [Shi Q.](#), Xiang T., Liangren L., Zhenhua L., Lu Y., Qiang W.
Institutes:West China Hospital - Sichuan University, Dept. of Urology, Chengdu, China
- *947 **Safety and benefits of group based exercise in daily clinical practice for men with prostate cancer undergoing androgen deprivation therapy**
By: [Ostergren P.B.](#)¹, Ragle A-M.², Jakobsen H.¹, Klausen T.W.³, Vinther A.², Sønksen J.¹
Institutes:¹Herlev and Gentofte University Hospital, Dept. of Urology, Herlev, Denmark, ²Herlev and Gentofte University Hospital, Dept. of Rehabilitation, Herlev, Denmark, ³Herlev and Gentofte University Hospital, Dept. of Haematology, Herlev, Denmark
- *948 **How do changes in erectile functioning affect self-esteem in older men with localized prostate cancer?**
By: Hilger C., Burkert S., [Kendel F.](#)
Institutes:Charité - Universitätsmedizin Berlin, Dept. of Medical Psychology, Berlin, Germany
- *949 **Estimation of outcomes of artificial urinary sphincter implantation - A multicenter prospective observational study**
By: [Kaiho Y.](#)¹, Masuda H.², Takei M.³, Hirayama T.⁴, Mitsui T.⁵, Yokoyama M.², Kawamorita N.¹, Nakagawa H.¹, Iwamura M.⁴, Shinohara N.⁵, Arai Y.¹
Institutes:¹Tohoku University Graduate School of Medicine, Dept. of Urology, Sendai, Japan, ²Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, ³Harasanshin Hospital, Dept. of Urology, Fukuoka, Japan, ⁴Kitasato University School of Medicine, Dept. of Urology, Kanagawa, Japan, ⁵Hokkaido University Graduate School of Medicine, Dept. of Renal and Genitourinary Surgery, Sapporo, Japan
- 15:15 - 15:22 **Personal perspective**
R. Kirby, London (GB)

Management of recurrence after local treatment

Poster Session 72

Monday, 27 March
14:00 - 15:30

Location: Room Paris, North Hall (Level 1)

Chairs: S. Joniau, Leuven (BE)
N. Mottet, Saint-Étienne (FR)
K. Touijer, New York (US)

Aims and objectives of this presentation

To evaluate the imaging and markers for recurrence and adjuvant or salvage treatments results

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*950

External validation of a TCP model predicting PSA relapse after post-prostatectomy radiotherapy

By: Broggi S.², Galla A.³, Saracino B.⁴, Faiella A.⁴, Fossati N.⁵, Gabriele D.³, Maggio A.³, Sanguineti G.⁴, Di Muzio N.¹, Briganti A.¹, Cozzarini C.¹, Fiorino C.²

Institutes:¹San Raffaele Scientific Institute, Dept. of Radiotherapy, Milan, Italy, ²San Raffaele Scientific Institute, Dept. of Medical Physics, Milan, Italy, ³Candiolo Cancer Institute - FPO, IRCCS, Dept. of Radiotherapy, Candiolo, Italy, ⁴Regina Elena National Cancer Institute, Dept. of Radiotherapy, Rome, Italy, ⁵San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy

*951

Genomic classifier augments the role of pathological features in identifying optimal candidates for adjuvant radiation therapy in patients with prostate cancer: Development and internal validation of a multivariable prognostic model

By: Dalela D.¹, Santiago-Jimenez M.², Yousefi K.², Karnes J.³, Ross A.⁴, Den R.⁵, Freedland S.⁶, Schaeffer E.⁷, Dicker A.⁵, Menon M.¹, Briganti A.⁸, Abdollah F.¹

Institutes:¹Henry Ford Health System, Vattikuti Urology Institute, Detroit, United States of America, ²GenomeDx Biosciences, GenomeDx Biosciences, Vancouver, Canada, ³Mayo Clinic, Dept. of Urology, Rochester, United States of America, ⁴Johns Hopkins Hospital, James Buchanan Brady Urological Institute, Baltimore, United States of America, ⁵Sidney Kimmel Cancer Center, Thomas Jefferson University, Dept. of Radiation Oncology, Philadelphia, United States of America, ⁶Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Dept. of Surgery, Division of Urology, Los Angeles, United States of America, ⁷Northwestern University, Feinberg School of Medicine, Dept. of Urology, Chicago, United States of America, ⁸Vita Salute San Raffaele Hospital, Dept. of Urology, Milan, Italy

*952

Natural history of patients treated with salvage radiation therapy for rising PSA after radical prostatectomy: A long-term survival analysis

By: Briganti A.¹, Fossati N.¹, Karnes J.², Boorjian S.², Colicchia M.², Bossi A.³, Cozzarini C.⁴, Fiorino C.⁴, Noris Chiorda B.⁴, Dell'oglio P.¹, Gandaglia G.¹, Wiegel T.⁵, Shariat S.⁶, Goldner G.⁷, Joniau S.⁸, Battaglia A.⁸, Haustermans K.⁹, De Meerleer G.⁹, Fonteyne V.¹⁰, Ost P.¹⁰, Van Poppel H.⁵, Montorsi F.¹

Institutes:¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²Mayo Clinic, Dept. of Urology, Rochester, United States of America, ³Gustave Roussy Institute, Dept. of Radiation Oncology, Villejuif, France, ⁴Vita-Salute University San Raffaele, Dept. of Radiotherapy, Milan, Italy, ⁵University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany, ⁶Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁷Medical University of Vienna, Dept. of Radiation Oncology, Vienna, Austria, ⁸University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ⁹University Hospitals Leuven, Dept. of Radiotherapy, Leuven, Belgium, ¹⁰Ghent University Hospital, Dept. of Radiotherapy, Ghent, Belgium

- *953 **Identifying the optimal candidate for salvage lymph node dissection for nodal recurrence of prostate cancer: Results from a large, multi-institutional analysis**
By: Suardi N.¹, Briganti A.¹, Fossati N.¹, Dell'oglio P.¹, Gandaglia G.¹, Colicchia M.², Karnes J.R.², Haidl F.⁸, Pfister D.⁸, Porres D.⁸, Heidenreich A.⁸, Gratzke C.⁷, Herlemann A.⁷, Stief C.⁷, Battaglia A.⁵, Everaerts W.⁵, Joniau S.⁵, Van Poppel H.⁵, Aksenov A.⁴, Osmonov D.K.⁴, Juenemann K.P.⁴, Abreu A.D.L.³, Almeida F.³, Fay C.⁶, Gill I.⁶, Mottrie A.M.⁹, Montorsi F.¹
Institutes:¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²Mayo Clinic, Dept. of Urology, Rochester, Minnesota, United States of America, ³Phoenix Imaging Center, Dept. of Urology, Phoenix, Arizona, United States of America, ⁴Department of Urology and Pediatric Urology, University Hospital Schleswig Holstein, Campus Kiel, Dept. of Urology, Kiel, Germany, ⁵University Hospitals Leuven, Urology, Dept of Development and Regeneration, Leuven, Belgium, ⁶Keck School of Medicine, University of Southern California, USC Institute of Urology, Catherine & Joseph Aresty Department of Urology, Los Angeles, California, United States of America, ⁷Ludwig-Maximilians-University, Dept. of Urology, Munich, Germany, ⁸University of Cologne, Dept. of Urology, Cologne, Germany, ⁹OLV Ziekenhuis Aalst, Belgium ORSI Academy, Dept. of Urology, Melle, Belgium
- *954 **Selection criteria for surveillance in patients with biochemical recurrence after radical prostatectomy**
By: Mikami H., Numao N., Yamamoto S., Hagiwara K., Uehara S., Takeda H., Inoue T., Ogawa M., Yuasa T., Masuda H., Fukui I., Yonese J.
Institutes:Cancer Institute Hospital, Japanese Foundation for Cancer Research, Dept. of Urology, Koto-ku, Japan
- *955 **Adjuvant versus early salvage radiation therapy in node positive prostate cancer patients: A long-term survival analysis**
By: Fossati N.¹, Karnes R.J.², Boorjian S.², Colicchia M.², Bossi A.³, Cozzarini C.⁴, Fiorino C.⁴, Chiorda B.N.⁴, Gandaglia G.¹, Dell'oglio P.¹, Wiegel T.⁵, Shariat S.⁶, Goldner G.⁷, Joniau S.⁸, Battaglia A.⁸, Haustermans K.⁹, De Meerleer G.⁹, Fonteyne V.¹⁰, Ost P.¹⁰, Van Poppel H.⁵, Montorsi F.¹, Briganti A.¹
Institutes:¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²Mayo Clinic, Dept. of Urology, Rochester, United States of America, ³Gustave Roussy Institute, Dept. of Radiation Oncology, Villejuif, France, ⁴Vita-Salute University San Raffaele, Dept. of Radiotherapy, Milan, Italy, ⁵University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany, ⁶Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁷Medical University of Vienna, Dept. of Radiation Oncology, Vienna, Austria, ⁸University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ⁹University Hospitals Leuven, Dept. of Radiotherapy, Leuven, Belgium, ¹⁰Ghent University Hospital, Dept. of Radiotherapy, Ghent, Belgium
- *956 **Salvage external beam radiation therapy (EBRT) for local recurrence after high intensity focused ultrasound (HIFU) failure versus salvage HIFU for local recurrence after EBRT failure: A long term analysis**
By: Lee J-W., Crouzet S., Soria J., Gelet A.
Institutes:Hospices Civils De Lyon, Dept. of Urology and Transplantation, Lyon, France
- *957 **Predictive factors of positive 68Ga-PSMA PET/CT in patients with PSA recurrence following radical prostatectomy**
By: Tosco L.¹, Joniau S.¹, Witters M.¹, Battaglia A.¹, Cromphout L.², Goffin K.², Gheysens O.², Deroose C.², Oyen R.², Van Laere K.²
Institutes:¹Uz Leuven - Campus Gasthuisberg, Dept. of Urology, Leuven, Belgium, ²Uz Leuven - Campus Gasthuisberg, Dept. of Nuclear Imaging, Leuven, Belgium
- *958 **Clinical impact of 68Ga-PSMA PET/CT in prostate cancer patients with rising PSA after treatment with curative intent: Preliminary analysis of a multidisciplinary approach**
By: Albisinni S.¹, Artigas C.², Aoun F.¹, Biaou I.¹, Gil T.³, Hawaux E.¹, Limani K.¹, Otte F.X.⁴, Peltier A.¹, Sideris S.³, Sirtaine N.⁵, Flamen P.², Van Velthoven R.¹
Institutes:¹Institut Jules Bordet, Dept. of Urology, Brussels, Belgium, ²Institut Jules Bordet, Dept.

of Nuclear Medicine, Brussels, Belgium, ³Institut Jules Bordet, Dept. of Oncology, Brussels, Belgium, ⁴Institut Jules Bordet, Dept. of Radiotherapy, Brussels, Belgium, ⁵Institut Jules Bordet, Dept. of Pathology, Brussels, Belgium

- *959 **68Ga-PSMA PET/CT improves biochemical response after salvage lymph node dissection for nodal recurrence in prostate cancer patients**
By: Herlemann A.¹, Kretschmer A.¹, Buchner A.¹, Karl A.¹, Tritschler S.¹, El-Malazi L.¹, Wenter V.², Ilhan H.², Bartenstein P.², Stief C.¹, Gratzke C.¹
Institutes: ¹Ludwig-Maximilians-University Munich, Dept. of Urology, Munich, Germany, ²Ludwig-Maximilians-University Munich, Dept. of Nuclear Medicine, Munich, Germany
- *960 **The comparison of prognoses between radiotherapy and radical prostatectomy in patients with high risk localized or locally advanced prostate cancer treated with neoadjuvant hormonal therapy**
By: Joung J.Y.¹, Kim S.H.¹, Seo H.K.¹, Chung J.¹, Cho K.H.², Park W.S.³, Lee K.H.¹
Institutes: ¹National Cancer Center, Dept. of Genitourinary Cancer Branch, Goyang, South Korea, ²National Cancer Center, Proton Therapy Center, Dept. of Radiation Oncology, Goyang, South Korea, ³National Cancer Center, Dept. of Pathology, Goyang, South Korea
- *962 **Stereotactic radiotherapy for bone and nodal oligometastases: Patterns of relapse in a prospective clinical trial**
By: Siva S.², Udovich C.¹, Shaw M.², Violet J.², Chander S.², Bressel M.³, Goad J.¹, Lawrentschuck N.¹, Foroudi F.¹, Murphy D.¹
Institutes: ¹Peter MacCallum Cancer Centre, Dept. of Urology, Melbourne, Australia, ²Peter MacCallum Cancer Centre, Dept. of Radiation Oncology, Melbourne, Australia, ³Peter MacCallum Cancer Centre, Dept. of Biostatistics and Clinical Trials, Melbourne, Australia
- *963 **Assessing the risk of early and late toxicity of post-prostatectomy radiation therapy: A long-term multi-institutional analysis**
By: Briganti A.¹, Fossati N.⁵, Karnes J.², Boorjian S.², Colicchia M.², Bossi A.³, Cozzarini C.⁴, Fiorino C.⁴, Noris Chiorda B.⁴, Dell'oglio P.⁵, Gandaglia G.⁵, Wiegel T.⁶, Shariat S.⁷, Goldner G.⁸, Joniau S.⁹, Battaglia A.⁹, Haustermans K.¹⁰, De Meerleer G.¹⁰, Fonteyne V.¹¹, Ost P.¹¹, Van Poppel H.⁹, Montorsi F.⁵
Institutes: ¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²Mayo Clinic, Dept. of Urology, Rochester, United States of America, ³Gustave Roussy Institute, Dept. of Urology, Villejuif, France, ⁴Vita-Salute University San Raffaele, Dept. of Radiotherapy, Milan, Italy, ⁵Vita-Salute University San Raffaele, Dept. of Oncology and Urology, Milan, Italy, ⁶University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany, ⁷Medical University of Vienna, Dept. of Oncology and Urology, Vienna, Austria, ⁸Medical University of Vienna, Dept. of Radiation Oncology, Vienna, Austria, ⁹University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ¹⁰University Hospitals Leuven, Dept. of Radiotherapy, Leuven, Belgium, ¹¹Ghent University Hospital, Dept. of Radiotherapy, Ghent, Belgium

Immune therapy and targeted therapy in urothelial cancer

Poster Session 73

Monday, 27 March
14:00 - 15:30

Location: Room Amsterdam, North Hall (Level 1)

Chairs: Y. Allory, Creteil (FR)
A. Sato
A. Vlahou, Athens (GR)

Aims and objectives of this presentation

Not all patients respond to BCG therapy for urothelium tumors. Immunological mechanisms relevant to a possible improvement of BCG treatment will be discussed in this session. In addition, novel functions of growth factors which are highly expressed in bladder cancer will be presented.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*964

Immune responsiveness to tuberculin in vitro may predict clinical outcome of intravesical BCG immunotherapy in bladder cancer

By: Jallad S.¹, Thomas D.², Thomas P.³, Newport M.⁴, Kern F.⁴

Institutes:¹Brighton and Sussex Medical School, Dept. of Urology, Brighton, United Kingdom, ²Brighton and Sussex Medical School, Division of Medicine, Brighton, United Kingdom, ³Brighton and Sussex University Hospitals, Dept. of Urology, Brighton, United Kingdom, ⁴Brighton and Sussex University Hospitals, Division of Medicine, Brighton, United Kingdom

*965

Evaluation of pro- and anti-tumor effect induced by three colony-stimulating factors, G-CSF/GM-CSF/M-CSF using a human bladder cancer xenograft model: Is G-CSF a friend of cancer cells?

By: Hori S., Miyake M., Tatsumi Y., Morizawa Y., Nakai Y., Goto D., Onishi K., Iida K., Onishi S., Tanaka N., Fujimoto K.

Institutes:Nara Medical University, Dept. of Urology, Kashihara, Japan

*966

Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells

By: Ferreira-Teixeira M.², Parada B.¹, Paiva-Oliveira D.², Alves V.³, Sousa V.⁴, Chijioke O.⁵, Münz C.⁵, Reis F.⁶, Rodrigues-Santos P.⁷, Gomes C.⁶

Institutes:¹Coimbra University Hospital (CHUC), Urology and Renal Transplantation, Coimbra, Portugal, ²University of Coimbra - Faculty of Medicine, Institute For Biomedical Imaging and Life Sciences (IBILI), Coimbra, Portugal, ³University of Coimbra - Faculty of Medicine, Institute of Immunology, Coimbra, Portugal, ⁴University of Coimbra - Faculty of Medicine, Institute of Anatomical and Molecular Pathology, Coimbra, Portugal, ⁵University of Zurich, Viral Immunobiology, Institute of Experimental Immunology, Zurich, Switzerland, ⁶University of Coimbra - Faculty of Medicine, Laboratory of Pharmacology and Experimental Therapeutics, Institute For Biomedical Imaging and Life Sciences (IBILI), Coimbra, Portugal, ⁷University of Coimbra - Center For Neurosciences and Cell Biology (CNC), Immunology and Oncology Laboratory, Coimbra, Portugal

*967

Double positive IFN γ /IL17 CD4+ lymphocytes play a pathogenic role in bladder cancer

By: Ariaifar A.¹, Faghih Z.², Zeighami S.¹, Sarkarian M.¹, Abtahi S.², Ghaderi A.²

Institutes:¹Shiraz University of Medical Sciences, Urology-Oncology Research Center, Dept of Urology, Shiraz, Iran, ²Shiraz Institute for Cancer Research, Dept. of Immunology, Shiraz, Iran

*968

IFN alpha modulates the response to BCG immunotherapy in bladder cancer patients with specific

CTLA4 and CD28 single nucleotide polymorphisms

By: Esuvaranathan K., Rahmat J., Tham S.M., Lim Y.K., Sng J.H., Raman L., Ma Z.M., Chan Y.H., Tsang W.C., Chiong E., Mahendran R.

Institutes: National University Singapore, Dept of Urology, Singapore, Singapore

*969

Inhibition of LIM-SH3 domain protein 1 (LASP1) augments the anti-cancer effect of cisplatin in bladder cancer

By: Dejima T.¹, Takeuchi A.¹, Shiota M.¹, Black P.², Eto M.¹, Naito S.¹, Gleave M.², Ong C.²

Institutes:¹Kyusyu University, Dept. of Urology, Fukuoka, Japan, ²The Vancouver Prostate Centre, Dept. of Urologic Sciences, University of British Columbia, Vancouver, Canada

*970

HGF-MET-MMP and VEGF-C signaling as a potential target for invasive bladder cancer therapy

By: Shintani T., Daizumoto K., Fukawa T., Nakatsuji H., Fukumori T., Takahashi M., Kanayama H.

Institutes: Institute of Biomedical Sciences, Tokushima University Graduate School, Dept. of Urology, Tokushima, Japan

*971

The novel checkpoint kinase 1 inhibitor MK-8776 strongly sensitizes bladder cancer cells to gemcitabine

By: Isono M.¹, Sato A.¹, Asano T.¹, Okubo K.¹, Hoffmann M.², Schulz W.², Asano T.¹

Institutes:¹National Defense Medical College, Dept. of Urology, Tokorozawa, Japan, ²Heinrich Heine University, Dept. of Urology, Düsseldorf, Germany

*972

T-DM1, a novel HER2 antibody-cytotoxic drug conjugate, has anti-metastatic potential and is a promising targeted therapy for bladder cancer with HER2 IHC score 2+/3+

By: Hayashi T.¹, Oo H.², Jäger W.², Kobatake K.¹, Goriki A.², Seiler R.², Todenhöfer T.², Li N.², Fazli L.², Matsubara A.¹, Black P.²

Institutes:¹Hiroshima University, Dept. of Urology, Hiroshima, Japan, ²Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada

*973

Pathological significance and prognostic roles of c-Fes expression in bladder cancer differ depending on the grade

By: Asai A., Miyata Y., Yasuda T., Nakamura Y., Matsuo T., Ohba K., Sakai H.

Institutes: Nagasaki University Graduate School of Biomedical Sciences, Dept. of Urology, Nagasaki, Japan

*974

Reduced expressions of 4N1K-peptide derived from thrombospondin-2 is associated with malignant aggressiveness and prognosis in bladder cancer

By: Mochizuki Y.¹, Miyata Y.¹, Yasuda T.¹, Nakamura Y.¹, Matsuo T.¹, Ohba K.¹, Furusato B.², Fukuoka J.², Sakai H.¹

Institutes:¹Nagasaki University Graduate School of Biomedical Sciences, Dept. of Urology, Nagasaki, Japan, ²Nagasaki University Hospital, Dept. of Pathology, Nagasaki, Japan

*975

Compound A inhibits urothelial tumorigenesis via both glucocorticoid receptor and androgen receptor pathways

By: Ide H.², Inoue S.³, Zheng Y.², Kashiwagi E.⁴, Kawahara T.⁵, Miyamoto H.¹

Institutes:¹University of Rochester, Dept. of Pathology, Urology and Oncology, Rochester, United States of America, ²Johns Hopkins University, Dept. of Pathology and Urology, Baltimore, United States of America, ³University of Rochester, Dept. of Pathology and Oncology, Rochester, United States of America, ⁴Kyushu University, Dept. of Urology, Fukuoka, Japan, ⁵Yokohama City University Medical Center, Dept. of Urology and Renal Transplantation, Yokohama, Japan

15:13 - 15:20

New targets in urothelial cancer

Y. Allory, Creteil (FR)

Oncogenes, tumor suppressor genes and molecular markers in renal cell carcinoma

Poster Session 74

Monday, 27 March
14:00 - 15:30

Location: Room Berlin, North Hall (Level 1)

Chairs: A. Bex, Amsterdam (NL)
K. Junker, Homburg (DE)
M. Uemura, Toyonaka Osaka (JP)

Aims and objectives of this presentation

To discuss the molecular biology of renal tumors

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *977 **Risk assessment for ccRCC patients based on alterations in specific chromosomal regions**
By: Grimm J.¹, Janssen M.¹, Wagenpfeil S.², Hartmann A.³, Stöhr C.³, Kunath F.⁴, Stöckle M.¹, Junker K.¹
Institutes:¹Saarland University Medical Center, Dept. of Urology and Pediatric Urology, Homburg/saar, Germany, ²Saarland University Medical Center, Institute of Medical Biometry, Epidemiology and Medical Informatics, Homburg/saar, Germany, ³University Hospital Erlangen, Institute of Pathology, Homburg/saar, Germany, ⁴University Hospital Erlangen, Dept. of Urology, Homburg/saar, Germany
- *978 **Overexpression of miR-27a-3p is an independent prognostic factor for recurrence in clear cell renal cell carcinoma**
By: Uemura M., Nakata W., Kawashima A., Ujike T., Nagahara A., Fujita K., Nonomura N.
Institutes:Osaka University Graduate School of Medicine, Dept. of Urology, Suita, Osaka, Japan
- *979 **Validation and target identification of metastasis-associated miRNAs as prognostic markers in clear cell renal cell cancer**
By: Heinzelmann J.¹, Hoelters S.¹, Arndt M.¹, Pleyers R.¹, Fecher-Trost C.², Schalkowsky P.², Janssen M.¹, Pryalukhin A.³, Stoeckle M.¹, Junker K.¹
Institutes:¹Saarland University, Dept. of Urology and Pediatric Urology, Homburg, Germany, ²University of The Saarland, Experimental and Clinical Pharmacology and Toxicology, Homburg, Germany, ³University Hospital of Saarland, Institute of Pathology, Homburg, Germany
- *981 **The activation of mTOR independent autophagy in kidney carcinoma cells by the upregulation of miR501-5p occurs through the decrease of mitochondrial calcium uptake**
By: Dell'Atti L.¹, De Stephanis L.², Patergnani S.³, Galosi A.B.⁴, Ippolito C.¹, Pinton P.³, Aguiari G.²
Institutes:¹University Hospital "St. Anna", Dept. of Urology, Ferrara, Italy, ²University of Ferrara, Dept. of Biomedical and Specialty Surgical Sciences, Ferrara, Italy, ³University of Ferrara, Dept. of Morphology, Surgery and Experimental Medicine, Ferrara, Italy, ⁴Marche Polytechnic University, Dept. of Urology, Ancona, Italy
- *982 **Functional variants in the low-density lipoprotein receptor gene are associated with clear cell renal cell carcinoma susceptibility**
By: Zhang G-M.¹, Wang M-Y.², Zhu Y.³, Gu C-Y.³, Wan F-N.³, Wei Q-Y.², Ye D-W.³
Institutes:¹The Affiliated Hospital of Qingdao University, Dept. of Urology, Qingdao, China, ²Fudan University Shanghai Cancer Center, Cancer Institute, Shanghai, China, ³Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

- *983 **Tumor suppressor versus oncogenic role of the new N-hydrolase DNPH1 in kidney and prostate cancers**
By: Danilin S.¹, Amiable C.², Coquard C.¹, Kaminski P-A.², Paoletti J.², Rothhut S.¹, Hamaidi I.³, Lindner V.⁴, Lang H.⁵, Pochet S.², Massfelder T.¹
Institutes:¹Inserm U1113, Team 3, Dept. of Cellular Signalisation and Communication In Kidney and Prostate Cancers, Strasbourg, France, ²Pasteur Institute, Biocatalyse and Chemistry Unit, Paris, France, ³Inserm U1113, Team 3, Cellular Signalisation and Communication In Kidney and Prostate Cancers, Strasbourg, France, ⁴Strasbourg University Hospital, Dept. of Pathology, Strasbourg, France, ⁵Strasbourg University Hospital, Dept. of Urology, Strasbourg, France
- *985 **Systematic expression analysis of the mitochondrial complex III subunits identifies UQCRC1 as biomarker in clear cell renal cell carcinoma**
By: Ellinger J.¹, Gromes A.¹, Poss M.¹, Brüggemann M.¹, Schmdit D.¹, Ellinger N.², Tolkach Y.³, Dietrich D.³, Kristiansen G.³, Müller S.C.¹
Institutes:¹Universitätsklinikum Bonn, Dept. of Urology, Bonn, Germany, ²Universitätsklinikum Bonn, Dept. of Anesthesia and Intensive Care, Bonn, Germany, ³Universitätsklinikum Bonn, Dept. of Pathology, Bonn, Germany
- *986 **LOXL2 status correlates with tumor stage and regulates integrin levels to promote tumor progression in ccRCC**
By: Uemura M.¹, Hase H.², Kawashima A.¹, Ujike T.¹, Nagahara A.¹, Fujita K.¹, Tsujikawa K.², Nonomura N.¹
Institutes:¹Osaka University Graduate School of Medicine, Dept. of Urology, Suita, Osaka, Japan, ²Osaka University Graduate School of Pharmaceutical Sciences, Laboratory of Molecular and Cellular Physiology, Suita, Osaka, Japan
- *987 **Validation of BRCA1 associated protein-1 (BAP-1) as an adverse prognostic factor and investigations into the impact of BAP1 loss on the vascular endothelial growth factor (VEGF) pathway in clear cell renal cell carcinoma (ccRCC)**
By: Skibbe M.², Guenther K.², Kapur P.³, Huang J.⁴, Belldegrün A.⁵, Burchardt M.¹, Zimmermann U.¹, Gu Y-F.⁶, Wolff N.⁶, Brugarolas J.⁶, Lillig C.², Pantuck A.⁵, Kroeger N.¹
Institutes:¹Ernst-Moritz-Arndt University Greifswald, Klinik und Poliklinik für Urologie, Greifswald, Germany, ²Ernst-Moritz-Arndt University Greifswald, Institute of Medical Biochemistry and Molecular Medicine, Greifswald, Germany, ³University of Texas Southwestern Medical Center, Dept. of Pathology, Dallas, United States of America, ⁴David Geffen School of Medicine, University of California-Los Angeles, Dept. of Pathology and Laboratory Medicine, Los Angeles, United States of America, ⁵David Geffen School of Medicine At The University of California Los Angeles, The Institute of Urologic Oncology, Department of Urology, Los Angeles, United States of America, ⁶University of Texas Southwestern Medical Center, Dept. of Internal Medicine, Dallas, United States of America
- *988 **Targeting Lim1 oncogene has a therapeutic potential in advanced human renal cell carcinoma**
By: Hamaidi I.¹, Danilin S.², Dormoy V.³, Rothhut S.¹, Coquard C.¹, Barthelmebs M.¹, Béraud C.⁶, Lindner V.⁴, Lang H.⁵, Massfelder T.¹
Institutes:¹Inserm U1113 Team 3, Dept. of Urology, Strasbourg, France, ²FIRALIS, Dept. of Urology, Hunningue, France, ³Inserm UMRS 903, Dept. of Urology, Reims, France, ⁴HUS, Hôpital De Hautepierre, Dept. of Pathology, Strasbourg, France, ⁵HUS, Nouvel Hôpital Civil, Dept. of Urology, Strasbourg, France, ⁶Urolead, Dept. of Urology, Strasbourg, France
- *989 **Receptor activator of NF- κ B (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma**
By: Steven A.¹, Kroeger N.², Leisz S.³, Fussek S.², Nowroozizadeh B.⁴, Huang J.⁴, Brandstetter D.⁵, Dougall B.⁵, Burchardt M.², Belldegrün A.⁶, Seliger B.³, Pantuck A.⁶
Institutes:¹Martin Luther University Halle/wittenberg, Medical Immunology At, Halle, Germany, ²Ernst-Moritz-Arndt University, Dept. of Urology, Greifswald, Germany, ³Martin Luther University Halle/wittenberg, Medical Immunology At, Halle, Unknown, ⁴David Geffen School of Medicine At The University of California, Dept. of Pathology and Laboratory Medicine, Los Angeles, United States of America, ⁵Amgen Inc., Dept. of Hematology and Oncology Research, Seattle, United States of America, ⁶David Geffen School of Medicine At The University of California, Los Angeles,

Pelvic floor reconstruction and pelvic organ prolapse

Poster Session 75

Monday, 27 March
14:00 - 15:30

Location: Room Vienna, North Hall (Level 1)

Chairs: W. Artibani, Verona (IT)
E. Costantini, Perugia (IT)

Aims and objectives of this presentation

The treatment of POP and of mesh complications is a hot topic at this time? Also other reconstructive procedures such as fistula treatment have made progress.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

14:23 - 14:33

EAU position paper on mesh and tapes

W. Artibani, Verona (IT)

*990

The longterm functional outcomes of vesico-vaginal fistula repair

By: Grewal M., Beardmore-Gary A., Pakzad M., Hamid R., Ockrim J., Greenwell T.

Institutes: University College London Hospital, Dept. of Urology, London, United Kingdom

*991

Laparoscopic repair of female genitourinary fistulae: Single-center single-surgeon experience

By: Abdel-Karim A., Aboelfotoh A., Elsalmy S.

Institutes: Alexandria University, Dept. of Urology, Alexandria, Egypt

*992

Comparison of autologous pubovaginal sling, abdominal sacrocolpopexy and laparoscopic sacrocolpopexy in the management of symptomatic pelvic organ prolapse

By: Cormio L., Mancini V., Liuzzi G., D'altilia N., Carrieri G.

Institutes: Urology and Renal Trasplant Unit, Dept. of Uro-Nephrology, University of Foggia, Ospedali Riuniti, Foggia, Italy

*993

Removal of synthetic tapes and meshes: Surgical indications and outcomes

By: Ismail S., Chartier-Kastler E., Bitker M-O., Rouprêt M., Phé V.

Institutes: Pitié-Salpêtrière Academic Hospital, Dept. of Urology, Paris, France

*994

Urethrovaginal fistula repair: Long-term outcomes

By: Herschorn S.

Institutes: Sunnybrook Health Sciences Centre, Dept. of Surgery and Urology, Toronto, Canada

*995

Laparoscopic versus robotic assisted sacrocolpopexy: A randomized, controlled trial

By: Illiano E.¹, Di Biase M.¹, Di Tonno P.², De Rienzo G.², Zucchi A.¹, Mearini L.¹, Maglia D.¹, Costantini E.¹

Institutes:¹University of Perugia, Dept. of Urology, Perugia, Italy, ²University of Bari, Dept. of Urology, Bari, Italy

*996

Laparoscopic sacrocolpopexy in treatment of pelvic organ prolapse: Learning curve analysis

By: Carracedo Calvo D., López-Fando Lavallo L., Sánchez Gallego M.D., Jimenez Cidre M.A., Gómez De Vicente J.M., Burgos Revilla F.J.

Institutes: Ramón Y Cajal University Hospital, Dept. of Urology, Madrid, Spain

*997

Abdominal vs laparoscopic sacrocolpopexy a subanalysis of a randomized controlled trial

By: Illiano E., Mearini L., Di Biase M., Zucchi A., Costantini E.

Institutes: University of Perugia, Dept. of Surgical and Biomedical Science , Urology and Andrology Clinic, Perugia, Italy

*999

Changes in vesico-sphincter function after surgery for pelvic organ prolapse

By: Giannantoni A., Salvini E., Rossi De Vermandois J., Turco M., Pietropaolo A., Gubbiotti M.

Institutes: University of Perugia, Dept. of Surgical and Biomedical Sciences, Urology and Andrology Section, Perugia, Italy

*1000

Combined mus and anterior colporrhaphy vs. mus alone in the treatment of sui, randomized controlled trial

By: Taha D-E., Wadie B., El-Hefnawy A., Gaballah m

Institutes: Urology and Nephrology Center, Dept. of Urology, Mansoura, Egypt

Kidney transplantation: All about the graft and donation

Poster Session 76

Monday, 27 March
14:00 - 15:30

Location: Room London, North Hall (Level 1)

Chairs: A. Alcaraz, Barcelona (ES)
M. Stöckle, Homburg (DE)
C. Terrone, Turin (IT)

Aims and objectives of this presentation

This session covers different aspects on kidney donation and grafts including:

- donor and kidney selection
- development and treatment of tumors in the graft
- experience with non-heartbeating donors

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *1003 **Role of polyomavirus BK in the carcinogenesis of urothelial and renal tumours in kidney transplant recipients**
By: Poletti F.¹, Borgogna C.², Billia M.¹, Zacchero M.¹, Boldorini R.³, Cantaluppi V.⁴, Gariglio M.², Volpe A.¹
Institutes:¹University of Eastern Piedmont, Dept. of Urology, Novara, Italy, ²University of Eastern Piedmont, Virology Unit, Novara, Italy, ³University of Eastern Piedmont, Dept. of Pathology, Novara, Italy, ⁴University of Eastern Piedmont, Dept. of Nephrology and Renal Transplantation, Novara, Italy
- *1004 **De novo functional renal graft carcinomas: Are they a different entity ?**
By: Tillou X.¹, Bensadoun H.², Bessede T.³, Bigot P.⁴, Boutin J-M.²⁸, Bouyé S.⁵, Codas R.⁶, Cognard N.⁷, Coffin G.⁸, De Fortescu G.⁹, Devonec M.⁶, Erauso A.¹¹, Gaudez F.¹⁰, Gigante M.¹⁸, Hubert J.¹², Karam G.¹³, Laurent G.¹⁴, Lechevallier E.¹⁵, Mousson C.¹⁶, Rerolle J-P.¹⁷, Sallusto F.¹⁹, Salomon L.²⁰, Sénéchal C.²¹, Terrier N.²², Timsit M-O.²³, Thuret R.²⁴, Toupance O.²⁹, Verhoest G.²⁵, Viart L.²⁶, Doerfler A.²⁷
Institutes:¹CHU Caen, Dept. of Urology and Transplantation, Caen, France, ²CHU De Bordeaux, Dept. of Urology and Transplantation, Bordeaux, France, ³CHU Kremlin Bicêtre, Dept. of Urology and Transplantation, Paris, France, ⁴CHU D'Angers, Dept. of Urology and Transplantation, Angers, France, ⁵CHRU De Lille, Dept. of Urology and Transplantation, Lille, France, ⁶CHU De Lyon, Dept. of Urology and Transplantation, Lyon, France, ⁷CHU De Strasbourg, Dept. of Urology and Transplantation, Strasbourg, France, ⁸CHU Pitié-Salpêtrière, Dept. of Urology and Transplantation, Paris, France, ⁹CHU De Rouen, Dept. of Urology and Transplantation, Rouen, France, ¹⁰CHU Saint Louis, Dept. of Urology and Transplantation, Paris, France, ¹¹CHU De Brest, Dept. of Urology and Transplantation, Brest, France, ¹²CHU De Nancy, Dept. of Urology and Transplantation, Nancy, France, ¹³CHU De Nantes, Dept. of Urology and Transplantation, Nantes, France, ¹⁴CHU De Clermont Ferrand, Dept. of Urology and Transplantation, Clermont Ferrand, France, ¹⁵CHU De Marseille, Dept. of Urology and Transplantation, Marseille, France, ¹⁶CHU De Dijon, Dept. of Urology and Transplantation, Dijon, France, ¹⁷CHU De Limoge, Dept. of Urology and Transplantation, Limoge, France, ¹⁸CHU De Nice, Dept. of Urology and Transplantation, Nice, France, ¹⁹CHU Rangeuil, Dept. of Urology and Transplantation, Toulouse, France, ²⁰CHU Henri Mondor, Dept. of Urology and Transplantation, Paris Créteil, France, ²¹CHU Point À Pitre, Dept. of Urology and Transplantation, Guadeloupe, France, ²²CHU De Grenoble, Dept. of Urology and Transplantation, Grenoble, France, ²³HEGP, Dept. of Urology and Transplantation, Paris, France, ²⁴CHU De Montpellier, Dept. of Urology and Transplantation, Montpellier, France, ²⁵CHU De Rennes, Dept. of Urology and Transplantation, Rennes, France, ²⁶CHU D'Amiens, Dept. of Urology and

Transplantation, Amiens, France, ²⁷CHU De Caen, Dept. of Urology and Transplantation, Caen, France, ²⁸CHU De Tours, Dept. of Urology and Transplantation, Tours, France, ²⁹CHU De Reims, Dept. of Nephrology, Tours, France

- *1005 **Urothelial carcinoma after kidney transplant: A heterogeneous entity in terms of diagnosis, treatments and oncological outcomes**
By: [Hevia V.](#), Lorca J., Gómez V., Donis F., Brasero J., Alvarez S., Díez V., Jiménez M.A., Burgos F.J.
Institutes: Hospital Universitario Ramón y Cajal, Dept. of Urology IRYCIS, Madrid, Spain
- *1006 **Our experience in the management of prostate cancer in renal transplant recipients**
By: [Narváez Barros A.](#), Riera Canals L., Fernández-Concha Schwalb J., Suarez Novo J., Castells Esteve M., Vigués Julià F.
Institutes: Bellvitge University Hospital, Dept. of Urology, Barcelona, Spain
- *1007 **Effectiveness and safety of minimally invasive laparoscopic live donor nephrectomy in comparison with standard laparoscopic live donor nephrectomy**
By: Abdelwahhab M., [Ghoneima W.](#), El Shenoufy A., Morsi H., Abo El Fettouh H., El Gammal M.
Institutes: Cairo University Hospitals, Dept. of Urology, Cairo, Egypt
- *1008 **Impact of an additional trocar on clinical outcome, inflammatory cytokines, and cosmetic satisfaction in laparoendoscopic single-site donor nephrectomy**
By: Saito M.¹, [Inoue T.](#)¹, Narita S.¹, Tsuruta H.¹, Maeno A.¹, Numakura K.¹, Satoh S.², Habuchi T.¹
Institutes:¹Akita University School of Medicine, Dept. of Urology, Akita, Japan, ²Akita University School of Medicine, Center For Kidney Disease and Transplantation, Akita, Japan
- *1009 **Visceral obesity in living kidney Asian donors significantly impacts on renal function after donor nephrectomy**
By: [Pek X.W.G.](#)¹, Ngoh L.Y.C.², Teo B.W.³, Vathsala A.³, Goh Y.S.B.⁴, Yong H.R.C.⁵, Raman L.N.M.⁴, Tiong H.Y.⁴
Institutes:¹University College Dublin, UCD School of Medicine and Medical Sciences, Dublin, Ireland, ²National University Hospital, Dept. of Medicine, University Medicine Cluster, Singapore, Singapore, ³National University Hospital, Dept. of Nephrology, University Medicine Cluster, Singapore, Singapore, ⁴National University Hospital, Dept. of Urology, University Surgical Cluster, Singapore, Singapore, ⁵National University Hospital, Dept. of Diagnostic Radiology, Singapore, Singapore
- *1010 **Local sildenafil accelerate renal regeneration after ischemia/reperfusion injury in canine model**
By: [Zahran M.](#)¹, Barakat N.², Khater S.³, Awadalla A.³, Mosbah A.², Nabeeh A.², Shokeir A.²
Institutes:¹Urology and Nephrology Center, Mansoura, Egypt, ²Urology and Nephrology Center, Dept. of Urology, Mansoura, Egypt, ³Urology and Nephrology Center, Dept. of Pathology, Mansoura, Egypt
- *1011 **Impact of renal graft volume in the renal function of patients who undergo kidney transplantation**
By: [Ordones F.](#)¹, Kawano P.², Guerra R.³, Yamamoto H.³, Modelli De Andrade L.G.⁴, Amaro J.L.³
Institutes:¹Royal Adelaide Hospital, Dept. of Urology, Adelaide, Australia, ²Botucatu Medical School - Sao Paulo State University, Dept. of Urology, Botucatu, Brazil, ³Botucatu Medical School - Sao Paulo State University - UNESP, Dept. of Urology, Botucatu, Brazil, ⁴Botucatu Medical School - Sao Paulo State University - UNESP, Dept. of Nephrology, Botucatu, Brazil
- *1013 **Kidney transplantation from uncontrolled donation after circulatory death (Ila): Organ procurement and renal harvested over a ten year period**
By: [Medina Polo J.](#), Justo-Quintas J., Gil-Moradillo J., De La Rosa-Kehrmann F., Pamplona-Casamayor M., Rodríguez-Antolín A., Duarte-Ojeda J.M., Tejido-Sánchez A., Villacampa-Aubá F., Sopeña-Sutil R., Benitez-Sala R., Guerrero-Ramos F., Andrés-Belmonte A., Passas-Martínez J.B.
Institutes: Hospital Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain
- *1014 **Initial experience and results in kidney transplants in controlled asystolia donors in a single institution**

By: Calaf Perisé O.¹, Areal Calama J¹, González Satué C¹, Juega Mariño J², Pérez Mir M², Ibarz Servio L.¹

Institutes:¹Hospital Universitari Germans Trias i Pujol, Urologia, Badalona, Spain, ²Hospital Universitari Germans Trias i Pujol, Nefrologia, Badalona, Spain

*1015

Implementation of a donation and trasplantation after controlled cardiac death (ccd) program in a Spanish university hospital. Results on renal graft and recipient survival

By: Trilla Herrera E.¹, Sandiumenge A.², Lorente D.¹, Moreso F.³, Perelló M.³, Mazo C.⁴, Chamoun B.³, Ruiz-Rodriguez J.C.⁴, Gracia R.M.⁴, Espinel E.³, Pont T.², Morote J.¹

Institutes:¹Hospital Universitari Vall d'Hebron, Dept. of Urology, Barcelona, Spain, ²Hospital Universitari Vall d'Hebron, Dept. of Trasplant Coordination, Barcelona, Spain, ³Hospital Universitari Vall d'Hebron, Dept. of Nephrology, Barcelona, Spain, ⁴Hospital Universitari Vall d'Hebron, Dept. of Intensive Care, Barcelona, Spain

Urethral strictures and reconstructions

Poster Session 77

Monday, 27 March
14:00 - 15:30

Location: Room Stockholm, North Hall (Level 1)

Chairs: S.J. Hosseini, Tehran (IR)
R. Inman, Sheffield (GB)
S.S. Kariev, Tashkent (UZ)

Aims and objectives of this presentation

Urethral strictures are a major problem for our patients and new updates will be presented.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *1016 **Delayed anastomotic urethroplasty in children and adolescence with pelvic fracture urethral injury (PFUI): Experiences in two centers of reconstructive urethral surgery in Indonesia**
By: [Satyagraha P.](#)¹, [Adi K.](#)², [Daryanto B.](#)¹, [Seputra P.](#)¹, [Indradiputra I.M.U.](#)¹, [Agil A.](#)²
Institutes:¹Saiful Anwar General Hospital, Dept. of Urology, Malang, Indonesia, ²Hasan Sadikin General Hospital, Dept. of Urology, Bandung, Indonesia
- *1017 **Pelvic fracture injuries of the female urethra**
By: [Ivaz S.](#), [Frost A.](#), [Bugeja S.](#), [Dragova M.](#), [Andrich D.](#), [Mundy A.](#)
Institutes:UCLH NHS Foundation Trust, Dept. of Urology, London, United Kingdom
- *1018 **The early and midterm outcomes of ventral only buccal mucosal graft substitution urethroplasty for female urethral stricture**
By: [Mukhtar B.](#), [Spilotros M.](#), [Fairbanks J.](#), [Pakzad M.](#), [Hamid R.](#), [Ockrim J.](#), [Greenwell T.](#)
Institutes:University College London Hospital, Dept. of Urology, London, United Kingdom
- *1019 **Female urethral reconstruction: Etiology and outcomes**
By: [Kasyan G.](#)¹, [Diakov V.](#)¹, [Pushkar D.](#)²
Institutes:¹Moscow State University of Medicine and Dentistry, Moscow, Russia, ²Moscow State University of Medicine and Dentistry, Dept. of Urology, Moscow, Russia
- *1020 **Correlation of MRI features of urethral diverticulum and stress urinary incontinence**
By: [Seth J.](#)¹, [Naaseri S.](#)², [Solomon E.](#)¹, [Pakzad M.](#)¹, [Hamid R.](#)¹, [Ockrim J.](#)¹, [Greenwell T.](#)¹
Institutes:¹University College London Hospital Nhs Trust, Dept. of Urology, London, United Kingdom, ²University College London Hospital Nhs Trust, Dept. of Uro-Radiology, London, United Kingdom
- *1021 **Re-operative abdomino-perineal reconstructive surgery**
By: [Frost A.](#), [Ivaz S.](#), [Bugeja S.](#), [Dragova M.](#), [Andrich D.](#), [Mundy A.](#)
Institutes:University College Hospitals London, Dept. of Reconstructive Urology, London, United Kingdom
- *1022 **Predictive factors of Sachse endoscopic urethrotomy failure**
By: [Soligo M.](#), [Franchini G.](#), [Morlacco A.](#), [Zattoni F.](#), [Dal Moro F.](#), [Beltrami P.](#), [Calpista A.](#), [Zattoni F.](#)
Institutes:Università di Padova - Azienda Ospedaliera, Padova, Italy
- *1023 **Sclerosis and severe fibrosis as a predictive factor for restricture after bulbar urethroplasty**
By: [Olsen Ekerhult T.](#)¹, [Lindqvist K.](#)¹, [Grenabo L.](#)¹, [Kåbjörn C.](#)², [Peeker R.](#)¹
Institutes:¹Sahlgrenska University Hospital, Dept. of Urology, Gothenburg, Sweden, ²Sahlgrenska

University Hospital, Dept. of Pathology, Gothenburg, Sweden

- *1024 **Effect of patient and surgical characteristics on treatment failure in 491 one-stage ventral onlay buccal mucosal graft urethroplasties**
By: [Vetterlein M.](#), Rosenbaum C., Gild P., Meyer C., Loewe C., Ludwig T., Chun F., Engel O., Dahlem R., Fisch M., Kluth L.
Institutes: University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany
- *1025 **The effect of closure versus non-closure of the buccal mucosa donor site during substitution urethroplasty on oral pain and morbidity: Final findings of a randomized controlled trial**
By: [Soave A.](#)¹, Dahlem R.¹, Pinnschmidt H.², Ahyai S.³, Rink M.¹, Langetepe J.¹, Engel O.¹, Kluth L.¹, Reiss P.¹, Fisch M.¹
Institutes:¹University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ²University Medical Center Hamburg-Eppendorf, Medical Biometry and Epidemiology, Hamburg, Germany, ³University Medical Center Goettingen, Dept. of Urology, Goettingen, Germany
- *1026 **Development of improved tissue engineered buccal mucosa for treatment of urethral strictures**
By: [Jimiek A.](#)¹, Bullock A.², Roman S.², Chapple C.³, Macneil S.⁴
Institutes:¹University of Sheffield/ Royal Hallamshire Hospital, Dept. of Female and Reconstructive Urology/Materials Science & Engineering, Sheffield, United Kingdom, ²University of Sheffield, Dept. of Materials Science & Engineering, Sheffield, United Kingdom, ³Royal Hallamshire Hospital, Dept. of Female and Reconstructive Urology/Materials Science & Engineering, Sheffield, United Kingdom, ⁴University of Sheffield, Materials Science and Engineering, Sheffield, United Kingdom
- *1027 **Off the shelf tissue-engineered material for urethral reconstruction**
By: [Vythilingam G.](#)¹, Larsson H.M.², Pinnagoda K.², Vardar E.³, Balet E-M.³, Thambidorai R.¹, Kamarul T.⁴, Hubbell J.⁵, Frey P.⁶
Institutes:¹University Malaya, Dept. of Surgery, Kuala Lumpur, Malaysia, ²Centre Hospitalier Universitaire Vaudois, Dept. of Pediatrics, Lausanne, Switzerland, ³École Polytechnique Fédérale de Lausanne, Institute of Bioengineering, Lausanne, Switzerland, ⁴University Malaya, Dept. of Orthopedic, Kuala Lumpur, Malaysia, ⁵University of Chicago, Institute for Molecular Engineering, Chicago, United States of America, ⁶École Polytechnique Fédérale De Lausanne, Institute of Bioengineering, Lausanne, Switzerland
- *1028 **Outcomes of hypospadias retrieval surgery in adults, after failed childhood hypospadias surgical repair**
By: [Aldamanhori R.](#), Inman R., Chapple C.
Institutes: Sheffield Teaching Hospital, Dept. of Urology, Sheffield, United Kingdom
- *1029 **Smoking and stricture recurrence after one stage bulbar urethroplasty – results from a large contemporary cohort**
By: [Meyer C.](#), Vetterlein M., Loewe C., Rink M., Chun F., Dahlem R., Fisch M., Kluth L.
Institutes: University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany
- *1030 **The positive impact of subspecialist training in urethral reconstruction**
By: [Adi K.](#)¹, Chee J.²
Institutes:¹Hasan Sadikin Hospital, Dept. of Urology, Bandung, Indonesia, ²Murac Health, Dept. of Urology, Melbourne, Australia

Upper urinary tract tumor: Let's manage it endoscopically!

Poster Session 78

Monday, 27 March
14:00 - 15:30

Location: Room Munich, North Hall (Level 1)

Chairs: A. Breda, Barcelona (ES)
M. Rink, Hamburg (DE)
O. Traxer, Paris (FR)

Aims and objectives of this presentation

The rise in clinical awareness about upper tract urothelial carcinomas (UTUCs) is in part due to the significant technological improvement in endoscopes used to examine the upper urinary tract. The development of small calibre, fibre optic flexible digital ureteroscopes has expanded the management options for UTUC. Advances in distal-tip deflection and scope durability, combined with improved laser technology, have enhanced the role of flexible ureteroscopy from a diagnostic to a therapeutic procedure. No longer can radical nephroureterectomy (RNU) be considered the 'gold standard' treatment for all UTUCs. The challenge is to identify pre-operatively which patients and tumours would be more appropriately managed in a conservative manner via endoscopic techniques and laser ablation or segmental ureterectomy in certain cases. Based on the available evidence UTUC patients with contralateral normal kidney can be classified at time of diagnosis as having "low-risk UTUC" or "high-risk UTUC". Patients with low-risk disease should be offered (as default) endoscopic management with laser ablation and topical MMC or BCG as an option. The aim of this session is to review available data to better select UTUC suitable for kidney-sparing treatment.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*1031

Assessment of clinical screening criteria and point of care testing for lynch syndrome-associated upper tract urothelial cancer

By: Metcalfe M.¹, Rao P.², Mork M.³, Xiao L.⁴, Broaddus R.², Matin S.¹

Institutes:¹University of Texas Md Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ²University of Texas Md Anderson Cancer Center, Dept. of Pathology, Houston, United States of America, ³University of Texas Md Anderson Cancer Center, Dept. of Genetics, Houston, United States of America, ⁴University of Texas Md Anderson Cancer Center, Dept. of Statistics, Houston, United States of America

*1032

Ureteroscopic biopsy of upper tract urothelial carcinoma is associated with increased intravesical recurrences on follow-up: A multi institutional Suture group study

By: Anbarasan T.¹, Shaikh N.², Mcluckie S.¹, Shams-Uddin A.³, Alcorn J.⁴, Jain S.⁵, Biyani C.S.⁴, Nabi G.¹

Institutes:¹University of Dundee, School of Medicine, Academic Section of Urology, Division of Cancer Research, Dundee, United Kingdom, ²United Lincolnshire NHS Trust, Pilgrim Hospital, Dept. of Urology, Lincolnshire, United Kingdom, ³Imperial College Healthcare NHS Trust, Charing Cross Hospital, Dept. of Urology, London, United Kingdom, ⁴Mid Yorkshire Hospitals NHS Trust, Dept. of Urology, Wakefield, United Kingdom, ⁵Leeds Teaching Hospitals NHS Trust, Dept. of Urology, Leeds, United Kingdom

*1034

Is ureteroscopy essential prior to nephroureterectomy for upper tract transitional cell carcinoma?

By: Veeratterapillay R.¹, Thompson E.², Shakoor R.², Gandiya T.², Rogers A.², Thomas D.²

Institutes:¹Freeman Hospital, Dept. of Urology, Newcastle Upon Tyne, United Kingdom, ²Freeman Hospital, Dept. of Urology, Newcastle Upon Tyne, Unknown

- *1035 **Diagnostic ureteroscopy for upper tract urothelial carcinoma is independently associated with intravesical recurrence after radical nephroureterectomy**
 By: [Li X-S.](#), Zhou L., Su X., Liu P., Fang D.
 Institutes: Peking University First Hospital, Dept. of Urology, Beijing, China
- *1036 **Fluorescence in situ hybridization for upper urinary tract urothelial carcinoma - an important diagnostic tool in clinical practice**
 By: Bonaventura A, Jung V., Ohlmann C.-H., Stöckle M., [Junker K.](#)
 Institutes: Saarland University Medical Center, Dept. of Urology, Homburg, Germany
- *1038 **CT urography understages, and URS with biopsy undergrades upper tract urothelial carcinoma in the preoperative evaluation before nephroureterectomy**
 By: [Almas B.](#)¹, Loe A.¹, Reisaeter L.², Halvorsen O.J.³, Beisland C.¹
 Institutes: ¹Haukeland University Hospital, Dept. of Urology, Bergen, Norway, ²Haukeland University Hospital, Dept. of Radiology, Bergen, Norway, ³Haukeland University Hospital, Dept. of Pathology, Bergen, Norway
- *1039 **Positive predictive value of CT urography for upper tract urothelial carcinoma diagnosis using diagnostic ureteroscopy as the reference standard**
 By: [Mintz L.](#)¹, Reshetnyak O.¹, Kabha M.¹, Chang C.T.², Sophie B.³, Diego M.³, Mabweesh N.¹, Matzkin H.¹, Liao J.², Sofer M.¹
 Institutes: ¹Tel Aviv Sourasky Medical Center, Tel-Aviv University, Dept. of Urology, Tel-Aviv, Israel, ²Stanford Health Care, Stanford University, Dept. of Urology, Stanford, United States of America, ³Tel Aviv Sourasky Medical Center, Tel-Aviv University, Dept. of Radiology, Tel-Aviv, Israel
- *1040 **Results of second line topical therapy for upper tract urothelial carcinoma (UTUC)**
 By: Balasubramanian A., Metcalfe M., Wagenheim G., Xiao L., Papadopoulos J., Navai N., Davis J., Karam J., Kamat A, Wood C., Dinney C., [Matin S.](#)
 Institutes: University of Texas Md Anderson Cancer Center, Dept. of Urology, Houston, United States of America
- *1041 **Clinical application of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in upper tract urothelial carcinoma**
 By: [Lu C.C.](#)¹, Yen R.F.¹, Huang C.Y.², Tsai Y.C.³, Pu Y.S.²
 Institutes: ¹National Taiwan University Hospital, Dept. of Nuclear Medicine, Taipei, Taiwan, ²National Taiwan University Hospital, Dept. of Urology, Taipei, Taiwan, ³National Taiwan University Hospital, Dept. of Oncology, Taipei, Taiwan
- *1042 **A systematic review of the impact of pre-operative diagnostic ureteroscopy on bladder recurrence after nephroureterectomy for upper tract transitional cell carcinoma**
 By: [Birks T.](#), Jenkins J., Davenport K.
 Institutes: Cheltenham General Hospital, Dept. of Urology, Cheltenham, United Kingdom
- *1043 **Statin use and prognosis of the upper tract urothelial carcinoma in a Finnish population-based cohort**
 By: Hurskainen H.², Kotsar A.³, Tammela T.¹, [Murtola T.](#)¹
 Institutes: ¹Tampere University Hospital, Dept. of Urology, Tampere, Finland, ²University of Tampere, School of Medicine, Tampere, Finland, ³Tartu University Hospital, Dept. of Urology, Tartu, Estonia

Laparoscopic and robot-assisted laparoscopic radical cystectomy

ESU Course 46

Monday, 27 March
14:30 - 17:30

Location: Room 10, Capital suite (level 3)

Chair: N.P. Wiklund, Stockholm (SE)

Aims and objectives of this presentation

The course is Video based. The steps in the surgical treatment of muscle invasive bladder cancer by conventional laparoscopy and robot-assisted technique will be described. The surgical technique to perform Male and female cystectomy, lymph node dissection, urinary diversion with extracorporeal and intracorporeal technique, conduits as well as orthotopic neobladders, will be shown. Indications, contraindications, outcomes and handling of complications will be discussed.

- The surgical steps in nerve sparing and non-nerve sparing male cystectomy
- The surgical steps in female cystectomy with and without organ sparing technique
- The surgical steps in lymph node dissection during cystectomy
- The technique in urinary diversion, conduit and neobladder, with intra and extracorporeal technique
- Indications, outcomes and complications after minimally invasive cystectomy
- The handling of the most common complications after minimally invasive cystectomy.

14:30 - 17:30

Laparoscopic cystectomy in males (video based teaching)

14:30 - 17:30

Conventional laparoscopy

R.F. Van Velthoven, Brussels (BE)

14:30 - 17:30

Robot-assisted technique with nerve sparing technique

N.P. Wiklund, Stockholm (SE)

14:30 - 17:30

Laparoscopic cystectomy in Females (video based teaching)

14:30 - 17:30

Conventional cystectomy

J. Rassweiler, Heilbronn (DE)

14:30 - 17:30

Robot-assisted cystectomy with organ preservation

N.P. Wiklund, Stockholm (SE)

14:30 - 17:30

Laparoscopic lymph node dissection (video based teaching)

J. Rassweiler, Heilbronn (DE)

14:30 - 17:30

Laparoscopic urinary diversion (video based teaching)

14:30 - 17:30

Intracorporeal urinary diversion

R.F. Van Velthoven, Brussels (BE)

14:30 - 17:30

Intracorporeal urinary diversion

N.P. Wiklund, Stockholm (SE)

14:30 - 17:30

Extracorporeal urinary diversion

J. Rassweiler, Heilbronn (DE)

| | |
|---------------|---|
| 14:30 - 17:30 | Controversies in laparoscopic and robotic cystectomy challenge the expert |
| 14:30 - 17:30 | Oncological outcomes in laparoscopic cystectomy - Challenger R.F. Van Velthoven, Brussels (BE) |
| 14:30 - 17:30 | Oncological outcomes in laparoscopic cystectomy - Pro N.P. Wiklund, Stockholm (SE) |
| 14:30 - 17:30 | Complications and functional outcomes in laparoscopic cystectomy - challenger J. Rassweiler, Heilbronn (DE) |
| 14:30 - 17:30 | Complications and functional outcomes in laparoscopic cystectomy - Pro N.P. Wiklund, Stockholm (SE) |

Robot renal surgery

ESU Course 47

Monday, 27 March
14:30 - 17:30

Location: Room 11, Capital suite (level 3)

Chair: A. Mottrie, Aalst (BE)

Aims and objectives of this presentation

This course will cover all principal indications for robotic surgery of the upper urinary tract. The standard techniques will be explained on a video-based fashion and will be followed by discussing advanced cases as well as troubleshooting and complication management. On top of that, technical innovations and new applications will be discussed as well.

Don't miss this course, a must for all robotic surgeons!:

- Videobased step-by-step approach
- Standard techniques
- Complex cases
- Troubleshooting and complication management
- Technical innovations: What's new in robotics?

14:30 - 17:30

Introduction

A. Mottrie, Aalst (BE)

14:30 - 17:30

Patient positioning, trocar positioning, trans- and retroperitoneal access in renal robotic surgery

B.J. Challacombe, London (GB)

14:30 - 17:30

Robotic pyeloplasty: Multichannel or single technique

N. Buffi, Milan (IT)

14:30 - 17:30

Renal surgery: Nephrectomy and nephroureterectomy: How I do it

B.J. Challacombe, London (GB)

14:30 - 17:30

Partial nephrectomy I: Step 1: Isolation of renal hilum; Step II: Mobilisation of the kidney; Step III: Clamping of renal pedicle: Different techniques

N. Buffi, Milan (IT)

14:30 - 17:30

Partial nephrectomy II: Step IV: Different tumouresection techniques

A. Mottrie, Aalst (BE)

14:30 - 17:30

Partial nephrectomy III: Step V: Different renorrhaphy techniques

B.J. Challacombe, London (GB)

14:30 - 17:30

Partial nephrectomy IV: Special & difficult indications

A. Mottrie, Aalst (BE)

14:30 - 17:30

Partial nephrectomy V: Complication management and new tools

A. Mottrie, Aalst (BE)

14:30 - 17:30

Wrap up and conclusions

B.J. Challacombe, London (GB)

Paediatric urology for the adult urologist - 2

ESU Course 49

Monday, 27 March
14:30 - 17:30

Location: Room 14, Capital suite (level 3)

Chair: G. Bogaert, Leuven (BE)

Aims and objectives of this presentation

The primary aim of this course is to provide participants with the core skills needed to provide an evidence-based solution to clinical problems that may arise in everyday urological practice. These skills include understanding the precise nature of the clinical problem, asking the appropriate question in order to address it, having the ability to identify, collate, synthesise, interpret and summarise the best available evidence in a transparent, systematic and reproducible manner and being able to reliability assess its quality in order to inform and guide clinical practice.

- Understand the fundamentals of evidence-based medicine
- Learn how to construct a structured and answerable clinical question to solve a clinical problem (i.e. PICO approach) and understand the basic strategies to search for evidence in the literature
- Understand the processes involved in undertaking a systematic review, learn how to critically appraise a study and understand the basic principles of the GRADE approach
- Learn how to perform a meta-analysis

14:30 - 17:30

Disorders of sex development

C. Radmayr, Innsbruck (AT)

14:30 - 17:30

Congenital malformations of the external genitalia: What do we need to know regarding sexual function and fertility in adolescence and adulthood?

G. Bogaert, Leuven (BE)

14:30 - 17:30

Urinary incontinence from childhood into adolescence

G. Mosiello, Rome (IT)

14:30 - 17:30

Discussion

Metastatic prostate cancer

ESU Course 50

Monday, 27 March
14:30 - 17:30

Location: Room 15, Capital suite (level 3)

Chair: K. Pummer, Graz (AT)

Aims and objectives of this presentation

The three lectures of ESU course 48 will provide comprehensive state-of-the-art information about currently available therapies for hormone-naïve and castration resistant prostate cancer, such as various forms of primary androgen deprivation, immunotherapy, chemotherapy, and therapies approved for CRPC. After the course, attendees should be able to adequately treat patients with metastatic prostate cancer at all disease stages.

14:30 - 17:30

Treatment of kastration-sensitive metastatic prostate cancer

K. Miller, Berlin (DE)

14:30 - 17:30

What is the role of chemotherapy and immunotherapy in patients with CRPC?

G. Mickisch, Bremen (DE)

14:30 - 17:30

Treatment of mCRPC – sequence or combination?

K. Pummer, Graz (AT)

14:30 - 17:30

Case discussion

G. Mickisch, Bremen (DE)

K. Miller, Berlin (DE)

K. Pummer, Graz (AT)

Dealing with the challenge of infection in urology

ESU Course 52

Monday, 27 March
14:30 - 17:30

Location: Room 17, Capital suite (level 3)

Chair: F.M.E. Wagenlehner, Giessen (DE)

Aims and objectives of this presentation

This ESU course on infection diseases provides a broad, up to date coverage of the most important and recent problems of infectious diseases in urology. Antimicrobial resistance is one of the biggest worldwide challenges in medicine and gains increasing importance in urology. The management of infections in general and of urogenital tract infections especially, has been compromised by this rapid and continuous increase of antimicrobial resistance. Basic biologic principles and strategies to treat urogenital tract infections from benign infections to life threatening infections will be discussed in this workshop:

- Classification of UTI and surgical field contamination categories as a basis for treatment and prophylaxis
- Diagnosis, treatment and prophylaxis strategies of urogenital tract infections
- Uncomplicated and recurrent cystitis
- Complicated urinary tract infections
- Urosepsis and Fournier gangrene
- Male genital tract infections

14:30 - 17:30

Introduction

F.M.E. Wagenlehner, Giessen (DE)

14:30 - 17:30

Classification of UTI and surgical field contamination categories as a basis for treatment and prophylaxis

Z. Tandođ du, Newcastle Upon Tyne (GB)

14:30 - 17:30

Low grade and recurrent UTI

F.M.E. Wagenlehner, Giessen (DE)

14:30 - 17:30

Male genital infections: Prostatitis, epididymitis and urethritis

B. Köves, Budapest (HU)

14:30 - 17:30

Hospital acquired UTI and antibiotic resistance

Z. Tandođ du, Newcastle Upon Tyne (GB)

14:30 - 17:30

Perioperative prophylaxis with special focus on prostate biopsies, stone surgery and prosthesis implantation

B. Köves, Budapest (HU)

14:30 - 17:30

Sepsis and Fournier's gangrene

F.M.E. Wagenlehner, Giessen (DE)

Video and imaging urodynamics

ESU Course 48

Monday, 27 March
15:30 - 17:30

Location: Room 12, Capital suite (level 3)

Chair: G. Van Koeveringe, Maastricht (NL)

Aims and objectives of this presentation

This course aims to convey the additional value of the combination of imaging techniques with a urodynamic investigation. In addition to Radiological imaging, also other imaging techniques such as ultrasound will be discussed. The logistic requirements, equipment, preparation and personnel will be pointed out. The interpretation of the acquired data and trouble shooting tips and tricks will be explained by speakers experienced in the field of functional and neurourology.

M. Oelke, Hanover (DE)

How will immunotherapy change the multidisciplinary management of urothelial bladder cancer

ESU Course 51

Monday, 27 March
15:30 - 17:30

Location: Room 16, Capital suite (level 3)

Chairs: A. Necchi, Milan (IT)
J.P. Bedke, Tübingen (DE)

Aims and objectives of this presentation

Early results from immunotherapy trials in the salvage setting of advanced/metastatic urothelial bladder cancer (UBC) paved the way of a revolutionary road in the treatment of this disease.

Atezolizumab, an anti-programmed cell death ligand-1 (PD-L1) antibody, was recently granted conditional approval by the U.S. Food and Drug Administration (FDA) for the treatment of advanced or metastatic UBC after platinum chemotherapy (IMvigor 210 study). Pembrolizumab, an anti-PD-1 antibody, has just demonstrated, for the first time in this disease, overall survival advantage compared to active therapy in a phase 3, multicenter, randomized trial (Keynote-045 study) of salvage therapy.

Other immune checkpoint inhibitors have been positively investigated, and a myriad of clinical trials are being developed in UBC worldwide in different clinical settings, including the non-muscle invasive disease.

Consequently, urologists are asked to understand the background of immunotherapy in UBC, the achievable results and side effects, and to know which are the ongoing and future therapeutic options for their patients, provided either inside or outside of clinical trials.

In brief, the aims will be the following:

- To provide urologists with the state-of-the art with the use of immune-checkpoint inhibitors in UBC.
- To provide urologists with the next clinical trials in the setting of non-muscle invasive and muscle invasive metastatic disease, and in the perioperative setting (before or after surgery).
- To provide an overview of the immunological background of the mode of action of checkpoint inhibitors in bladder carcinoma
- To discuss the optimal clinical management of patients receiving immune checkpoint inhibitor treatment, including side effects.

15:30 - 17:30

State of the art of immune checkpoint inhibitors in urothelial bladder cancer – advanced disease
A. Necchi, Milan (IT)

15:30 - 17:30

State of the art of immune checkpoint inhibitors in urothelial bladder cancer – early stages
J.P. Bedke, Tübingen (DE)

15:30 - 17:30

Ongoing clinicals trials in the EU and future developments
J.P. Bedke, Tübingen (DE)
A. Necchi, Milan (IT)

15:30 - 17:30

Case discussion 1: When should we consider immune-checkpoint inhibitors in UBC treatment
J.P. Bedke, Tübingen (DE)
A. Necchi, Milan (IT)

15:30 - 17:30

Case discussion 2: How to manage treatment with immune-checkpoint inhibitors in UBC
J.P. Bedke, Tübingen (DE)
A. Necchi, Milan (IT)

Advanced reconstructive surgery

Video Session 11

Monday, 27 March
15:45 - 17:15

Location: eURO Auditorium (Level 0)

Chairs: C. Imbimbo, Naples (IT)

F. Van Der Aa, Leuven (BE)

Aims and objectives of this presentation

Reconstructive surgery is one of the most complex surgeries. Every case is a real challenge because it is not always easy to predict clinical situation. Often there isn't a standard technique and the surgeon must combine various techniques as we shall see in this video session which brings us an up-to-date on the latest knowledge and practices in this field.

All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.

- *V82 **Redo bulbo-prostatic anastomotic (BPA) urethroplasty for recurrent pelvic fracture-related urethral strictures**
By: [Fes Ascanio E.](#)¹, Bugeja S.², Ivaz S.³, Frost A.³, Campos F.⁴, Andrich D.³, Mundy A.³
Institutes:¹Hospital Can Misses, Dept. of Urology, Eivissa, Spain, ²St Luke's Hospital, Dept. of Urology, San Luka, Malta, ³University College London Hospitals, Dept. of Urology, London, United Kingdom, ⁴Marques De Valdecilla University Hospital, Dept. of Urology, Santander, Spain
- *V83 **Urethral centralisation after partial penectomy**
By: [Parnham A.](#)¹, Albersen M.², Kranz J.³, Sahdev V.¹, Ziada M.¹, Nigam R.¹, Muneer A.¹, Malone P.¹
Institutes:¹University College London Hospitals, Dept. of Andrology, London, United Kingdom, ²University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ³St. Antonius Hospital, Dept. of Urology, Eschweiler, Germany
- *V84 **Detachment of corpora cavernosa during anastomotic bulboprostatic reconstruction after pelvic trauma**
By: [Martínez-Piñeiro L.](#)¹, Ríos E.², Sánchez J.², Díez J.², López-Tello J.², Alvarez M.¹
Institutes:¹La Paz University Hospital, Dept. of Urology, Madrid, Spain, ²Infanta Sofía University Hospital, Dept. of Urology, Madrid, Spain
- *V87 **Suture-free sealing of tunical defect with collagen fleece after partial plaque excision in Peyronie's disease: Long-term outcomes of the sealing technique**
By: [Hatzichristodoulou G.](#)¹, Fiechtner S.¹, Gschwend J.¹, Kübler H.¹, Lahme S.²
Institutes:¹Technical University of Munich, Dept. of Urology, Munich, Germany, ²Siloah St. Trudpert Hospital, Dept. of Urology, Pforzheim, Germany
- *V88 **Corporoplasty using bovine pericardium graft in Peyronie's disease**
By: [Ruiz-Hernandez M.](#)¹, Fraile-Poblador A.², Donis-Canet F.¹, Martínez-Salamanca J.I.³, Martínez-Arcos L.M.¹, Sanz-Mayayo E.¹, Rodríguez-Patrón R.¹, Burgos-Revilla F.J.¹
Institutes:¹Hospital Universitario Ramón y Cajal, Dept. of Urology, Madrid, Spain, ²Hospital Universitario Ramón y Cajal and Centro de Urología Médico-Quirúrgico CUMQ-LYX, Dept. of Urology, Madrid, Spain, ³Centro de Urología Médico-Quirúrgico CUMQ-LYX, Madrid, Spain
- *V89 **One-stage preputial island tubularized flap repair for cripple hypospadias in adults. A step-by-step technique**
By: [Ploumidis A.](#)¹, Pappas A.¹, Lumen N.², Hoebeke P.², Spinoit A-F.²
Institutes:¹Athens Medical Center, Dept. of Urology, Athens, Greece, ²Ghent University Hospital,

Dept. of Urology, Ghent, Belgium

Challenges in minimally invasive partial nephrectomy

Poster Session 79

Monday, 27 March
15:45 - 17:15

Location: Room Copenhagen, North Hall (Level 1)

Chairs: M. Gallucci, Rome (IT)

G. Novara, Padova (IT)

Aims and objectives of this presentation

Exchange of experiences with challenging minimally invasive partial nephrectomies

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *1044 **MIC and Trifecta in robot-assisted partial nephrectomy in highly complex tumors – similar results in comparison with tumors of low and intermediate complexity**
By: Harke N.N.¹, Wagner C.², Schiefelbein F.³, Trabs G.³, Roosen A.⁴, Ubrig B.⁴, Schoen G.³, Witt J.²
Institutes:¹University of Rostock, Dept. of Urology, Rostock, Germany, ²St. Antonius Hospital, Prostate Center Northwest, Dept. of Urology, Pediatric Urology and Urologic Oncology, Gronau, Germany, ³Missionsaerztliche Klinik, Dept. of Urology, Wuerzburg, Germany, ⁴Augusta-Kranken-Anstalt, Dept. of Urology, Bochum, Germany
- *1046 **Histopathological analysis of peritumoral pseudocapsule infiltration and surgical margin status after enucleative robot-assisted partial nephrectomy (RAPN) for malignant renal tumors**
By: Campi R.¹, Mari A.¹, Sessa F.¹, Tellini R.¹, Rudi X.¹, Sforza S.¹, Vanacore D.¹, Tuccio A.¹, Serni S.¹, Carini M.¹, Raspollini M.R.², Minervini A.¹
Institutes:¹Aou Careggi, Dept. of Urology, Florence, Italy, ²Aou Careggi, Dept. of Pathology, Florence, Italy
- *1047 **Adherent perinephric fat in Asian patients: Predictors, and impact on perioperative outcomes of partial nephrectomy**
By: Kawamura N., Saito K., Inoue M., Ito M., Kijima T., Yoshida S., Yokoyama M., Ishioka J., Matsuoka Y., Kihara K., Fujii Y.
Institutes: Tokyo Medical and Dental University Graduate School, Dept. of Urology, Tokyo, Japan
- *1048 **Robotic-assisted partial nephrectomy for hilar and non-hilar tumours: Perioperative outcomes**
By: Lu S-Y.¹, Chung H-J.², Huang Y-H.², Lin T-P.², Lin A.², Chen K-K.²
Institutes:¹Dept. of Urology, Taipei city, Taiwan, ²Taipei Veterans General Hospital, Dept. of Urology, Taipei city, Taiwan
- *1049 **Is retro the way forward? Retroperitoneal robotic-assisted partial nephrectomy: Single institution experience**
By: Hussain M., Oakley J., Muller G., Emara A., Barber N.
Institutes: Frimley Park Hospital, Dept. of Urology, Surrey, United Kingdom
- *1051 **Perioperative outcomes between open and robot-assisted partial nephrectomy for cystic masses: An international multicentric study**
By: Pradere B.¹, Peyronnet B.², Delporte G.³, Manach Q.⁴, Khene Z.², Rischk J.³, Moulin M.⁷, Benoit T.⁵, Brichtart N.⁶, Beauval J.B.⁵, Bex A.⁸, Roupert M.⁴, Bensalah K.², Bruyère F.⁹
Institutes:¹CHRU de Tours, Hôpital Bretonneau, Dept. of Urology, Tours, France, ²CHU Rennes, Dept. of Urology, Rennes, France, ³CHRU Lille, Dept. of Urology, Lille, France, ⁴Hopital Pitié-Salpêtrière, Dept. of Urology, Paris, France, ⁵CHU Toulouse, Dept. of Urology, Toulouse, France, ⁶CHR Orléans, Dept. of Urology, Orléans, France, ⁷CHU Dijon, Dept. of Urology, Dijon, France, ⁸

Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ⁹CHRU Tours, Dept. of Urology, Tours, France

- *1052 **Robot-assisted partial nephrectomy for complex cases (Padua score \geq 10): Results from a multicenter experience at three high-volume centers**
By: [Lughezzani G.](#)¹, [Buffi N.](#)¹, [Lista G.](#)¹, [Maffei D.](#)¹, [Forni G.](#)¹, [Larcher A.](#)², [Fossati N.](#)², [Lazzeri M.](#)¹, [Casale P.](#)¹, [Saita A.](#)¹, [Hurle R.](#)¹, [Guazzoni G.](#)¹, [Porter J.](#)³, [Motttrie A.](#)²
Institutes:¹Istituto Clinico Humanitas, IRCCS, Dept. of Urology, Milan, Italy, ²OLV Vattikuti Robotic Center, Dept. of Urology, Aalst, Belgium, ³Swedish Medical Center, Dept. of Urology, Seattle, United States of America
- *1053 **3d versus 2d laparoscopic partial nephrectomy: Feasibility and advantages**
By: [Varca V.](#), [Benelli A.](#), [Gregori A.](#)
Institutes:G. Salvini Hospital, Dept. of Urology, Milan, Italy
- *1054 **Intraoperative dual-modality imaging in clear cell renal cell carcinoma using Indium-111-DOTA-girentuximab-IRDye800CW**
By: [Hekman M.](#)¹, [Rijpkema M.](#)², [Oosterwijk E.](#)³, [Langenhuijsen H.](#)³, [Boerman O.](#)², [Oyen W.](#)², [Mulders P.](#)³
Institutes:¹Radboudumc, Dept. of Urology and Dept. of Radiology & Nuclear Medicine, Nijmegen, The Netherlands, ²Radboudumc, Dept. of Radiology & Nuclear Medicine, Nijmegen, The Netherlands, ³Radboudumc, Dept. of Urology, Nijmegen, The Netherlands
- *1055 **Partial nephrectomy in the treatment of renal tumors with concomitant venous tumor thrombosis (VTT) of renal vein branches: Retrospective, multi-center analysis of perioperative, functional, and oncologic outcomes**
By: [Zattoni Fa.](#)¹, [Thompson R.](#)², [Capitano U.](#)³, [Crestani A.](#)⁴, [Ficarra V.](#)⁴, [Kutikov A.](#)⁵, [Larcher A.](#)³, [Lane B.](#)⁶, [Leibovich B.](#)², [Mcintosh A.](#)⁵, [Montorsi F.](#)³, [Moon D.](#)⁷, [Mulwijk T.](#)⁸, [Murray K.](#)⁹, [Noyes S.](#)⁶, [Russo P.](#)¹⁰, [Uzzo R.](#)⁵, [Van Poppel H.](#)⁸, [Yang D.](#)², [Zattoni F.](#)¹¹, [Motttrie A.](#)¹², [Novara G.](#)¹¹
Institutes:¹University of Padua and University of Udine, Dept. of Surgery, Oncology, and Gastroenterology - Urology Clinic, University of Padua - Department of Experimental and Clinical Medical Sciences - Urologic Clinic, University of Udine, Padua and Udine, Italy, ²Mayo Clinic, Dept. of Urology, Rochester, Mn, United States of America, ³URI, IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology, Milan, Italy, ⁴University of Udine, Italy, Dept. of Experimental and Clinical Medical Sciences - Urologic Clinic, Udine, Italy, ⁵Fox Chase Cancer Center, Temple University Health System, Division of Urologic Oncology, Department of Surgical Oncology, Philadelphia, Pa, United States of America, ⁶College of Human Medicine, Michigan State University, Division of Urology, Spectrum Health, Grand Rapids, Michigan, United States of America, ⁷Peter MacCallum Cancer Centre, Epworth Healthcare, University of Melbourne, Division of Cancer Surgery, Melbourne, Australia, ⁸University Hospitals,Leuven, Dept. of Urology and Radiation Oncology, Leuven, Belgium, ⁹University of Missouri, Dept. of Surgery-Urology Division, Columbia, Mo, United States of America, ¹⁰Memorial Sloan Kettering Cancer Center, Urology Service, New York, Ny, United States of America, ¹¹University of Padua, Dept. of Surgery, Oncology, and Gastroenterology - Urology Clinic,university of Padua - Department of Experimental and Clinical Medical Sciences - Urologic Clinic, University of Udine, Padua, Italy, ¹²Onze Lieve Vrouweziekenhuis Hospital, Dept. of Urology, Aalst, Belgium
- *1056 **Simple enucleation for selected renal tumours \leq 7 cm**
By: [Lu Q.](#)¹, [Zhao X.](#)¹, [Ji C.](#)¹, [Guo S.](#)², [Liu G.](#)¹, [Zhang S.](#)¹, [Li X.](#)¹, [Gan W.](#)¹, [Guo H.](#)¹
Institutes:¹Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Dept. of Urology, Nanjing, China, ²Nanjing Medical University, School of Public Health, Nanjing, China
- 17:00 - 17:07 **Summary**
 To be confirmed

Improving prostate cancer staging and outcomes after radical prostatectomy

Poster Session 80

Monday, 27 March
15:45 - 17:15

Location: Room Madrid, North Hall (Level 1)

Chairs: G. Gandaglia, Milan (IT)
D. Murphy, Melbourne (AU)
G. Palapattu, Ann Arbor (US)

Aims and objectives of this presentation

The aim of this session is to discuss on how to improve prostate cancer staging and outcomes after surgery

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *1057 **Lymphadenectomy trends in Gleason 7 prostate cancer: A population-based study**
By: [Chandrasekar T.](#), Goldberg H., Klaassen Z., Hamilton R., Fleshner N., Kulkarni G.
Institutes: University Health Network, Division of Urology, Dept. of Surgical Oncology, Toronto, Canada
- *1058 **Population-based analysis: Changes in the natural history of low risk localized prostate cancer**
By: [Helgstrand J.T.](#)¹, Klemann N.¹, Toft B.G.², Vainer B.², Røder M.¹, Iversen P.¹, Brasso K.¹
Institutes:¹Copenhagen University Hospital, Rigshospitalet, Copenhagen Prostate Cancer Center, Dept. of Urology, Copenhagen, Denmark, ²Copenhagen University Hospital, Rigshospitalet, Dept. of Pathology, Copenhagen, Denmark
- *1059 **Non-prostate cancer mortality following radical prostatectomy or radiotherapy in men with localized and locally advanced prostate cancer: An analysis using propensity score matching**
By: [Kim S.I.](#)¹, Kim S.J.¹, Choo S.H.¹, Cho D.S.²
Institutes:¹Ajou University School of Medicine, Dept. of Urology, Suwon, South Korea, ²Bundang Jesaeng Hospital, Dept. of Urology, Seongnam, South Korea
- *1060 **Oncologic long-term outcome in patients with pathologic Gleason 3+3 score at radical prostatectomy**
By: [Mandel P.](#)¹, Graefen M.², Pompe R.², Chun F.³, Salomon G.², Huland H.², Tilki D.¹
Institutes:¹University Hospital Hamburg-Eppendorf, Martini-Clinic Prostate Cancer Center, Department of Urology, Hamburg, Germany, ²University Hospital Hamburg-Eppendorf, Martini-Clinic Prostate Cancer Center, Hamburg, Germany, ³University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany
- *1061 **Preoperative characteristics of the P.R.O.S.T.A.T.E. scores: A novel predictive tool for the risk of positive surgical margin after radical prostatectomy**
By: [Xu B.](#)
Institutes: Peking University First Hospital, Dept. of Urology, Beijing, China
- *1062 **Cost effectiveness comparison between neoadjuvant chemo-hormonal therapy and extended lymph node dissection in patients with high-risk prostate cancer**
By: [Hagiwara K.](#)¹, Hatakeyama S.¹, Tobisawa Y.¹, Yoneyama T.¹, Imai A.¹, Yoneyama T.¹, Hashimoto Y.¹, Koie T.¹, Tsuchiya N.², Habuchi T.³, Arai Y.⁴, Ohyama C.¹
Institutes:¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Yamagata University, Faculty of Medicine, Dept. of Urology, Yamagata, Japan, ³Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan, ⁴Tohoku University Graduate School of Medicine, Dept. of Urology, Sendai, Japan

- *1063 **Retrograde perfusion sphinterometry to evaluate efficacy of autologous 6-branch suburethral sling to properly restore sphincteric apparatus during robotic assisted radical prostatectomy (RALP)**
By: [Cestari A.](#), Lolli C., Ghezzi M., Sangalli M., Zanoni M., Fabbri F., Sozzi F., Zanni G., Dell'acqua V., Rigatti P.
Institutes: Istituto Auxologico Italiano, Dept. of Urology, Milan, Italy
- *1064 **Transurethral catheter removal on postoperative day 2 after robot-assisted laparoscopic radical prostatectomy: A feasibility study from a single high-volume referral centre**
By: [Brassetti A.](#), Emiliozzi P., Cardi A., De Vico A., Iannello A., Pansadoro A., Scapellato A., Riga T., D'elia G.
Institutes: San Giovanni Addolorata Hospital, Dept. of Urology, Rome, Italy
- *1065 **Visibility of characterized periprostatic nerve distributions for nerve-sparing radical prostatectomy**
By: [Sievert K-D.](#)¹, Hennenlotter J.², Dillenberg T.², Kuehs U.², Wollner J.³, Kunit T.⁴, Zweers P³, Andersson K-E.⁵, Pannek J.³, Amend B.²
Institutes:¹Paracelsus Private Medical University of Salzburg, Dept. of Urology and Andrology, Salzburg, Austria, ²University of Tübingen, Dept. of Urology, Tübingen, Germany, ³Swiss Paraplegic Center, Dept. of Neuro-Urology, Nottwil, Switzerland, ⁴SALK, Dept. of Urology, Salzburg, Austria, ⁵Aarhus University, Dept. of Clinical Medicine, Aarhus, Denmark
- *1066 **Oncological and functional outcome after radical prostatectomy in men \geq 45 years of age**
By: [Mandel P.](#), Angerer M., Haese A., Salomon G., Rosenbaum C., Veleva V., Graefen M., Huland H., Tilki D.
Institutes: University Hospital Hamburg-Eppendorf, Martini-Klinik Prostate Cancer Center; Dept. of Urology, Hamburg, Germany
- *1067 **A randomized control trial on the impact of regional hypothermia: Ad hoc analysis on short term recovery of sexual function after robot-assisted radical prostatectomy (RARP)**
By: Ko Y-H.², Osann K.³, Skarecky D.¹, Morales B.¹, [Ahlering T.](#)¹
Institutes:¹University of California, Irvine, Dept. of Urology, Orange, United States of America, ²Yeoungnam University, Dept. of Urology, Yeoungnam, South Korea, ³University of California, Irvine, Dept. of Medicine, Orange, United States of America
- *1068 **The prognostic role of sentinel node dissection on biochemical recurrence-free survival rate of prostate cancer patients after robot-assisted radical prostatectomy**
By: [Grivas N.](#)¹, Wit E.¹, Bex A.¹, Hendricksen K.¹, Horenblas S.¹, Kleinjan G.¹, Van Rhijn B.¹, Vegt E.², Van Der Poel H.¹
Institutes:¹Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ²Netherlands Cancer Institute, Dept. of Nuclear Medicine, Amsterdam, The Netherlands
- *1069 **Fluorescence supported lymph node dissection in robot-assisted radical prostatectomy – a prospective randomized clinical trial**
By: [Harke N.N.](#)¹, Wagner C.², Schuette A.², Addali M.², Urbanova K.², Fangmeyer B.², Witt J.H.²
Institutes:¹University of Rostock, Dept. of Urology, Rostock, Germany, ²St. Antonius Hospital, Prostate Center Northwest, Dept. of Urology, Pediatric Urology and Urologic Oncology, Gronau, Germany
- 17:00 - 17:07 **Summary**
D. Murphy, Melbourne (AU)

Primary treatment of prostate cancer: Balancing benefits and side effects

Poster Session 81

Monday, 27 March
15:45 - 17:15

Location: Room Milan, North Hall (Level 1)

Chairs: G.M. Ahlgren, Malmö (SE)
G. Giannarini, Udine (IT)
R.C.N. Van Den Bergh, Amsterdam (NL)

Aims and objectives of this presentation

The aim of this session is to discuss on oncological and functional outcomes on primary treatments for prostate cancer

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *1070 **The BAUS radical prostatectomy audit 2014/2015 – an update on current practice and outcomes by centre and surgeon case volume**
By: [Khadhoury S.](#)¹, Miller C.¹, Mcneill A.², Hounscome L.³, Fowler S.⁴, Mcgrath J.¹
Institutes:¹Royal Devon and Exeter Hospital, Dept. of Urology, Exeter, United Kingdom, ²Western General Hospital, Dept. of Urology, Edinburgh, United Kingdom, ³Public Health England, Dept. of Public Health, London, United Kingdom, ⁴BAUS, Dept. of Surgery, London, United Kingdom
- *1071 **Efficacy of local treatment in prostate cancer patients with clinically pelvic lymph node-positive disease at initial diagnosis**
By: [Seisen T.](#)¹, Vetterlein M.¹, Karabon P.¹, Jindal T.¹, Sood A.¹, Nocera L.¹, Nguyen P.², Choueiri T.³, Trinh Q-D.⁴, Menon M.¹, Abdollah F.¹
Institutes:¹Henri Ford Hospital, Dept. of Urology, Detroit, United States of America, ²Brigham and Women Hospital, Dept. of Radiation Oncology, Boston, United States of America, ³Dana Farber Cancer Institute, Dept. of Genito-Urinary Medical Oncology, Boston, United States of America, ⁴Brigham and Women's Hospital, Dept. of Urology, Boston, United States of America
- *1072 **Oncological and functional outcomes of laparoscopic versus robot-assisted radical prostatectomy: Five years results of a prospective randomised controlled trial**
By: Porpiglia F.¹, [Fiori C.](#)¹, Bertolo R.¹, Manfredi M.¹, Mele F.¹, Garrou D.¹, Cattaneo G.¹, De Luca S.¹, Passera R.², Scarpa R.M.¹
Institutes:¹San Luigi Hospital, Dept. of Urology, Turin, Italy, ²San Giovanni Battista Hospital, Dept. of Nuclear Medicine, Turin, Italy
- *1073 **Contemporary extended pelvic lymph node dissection for prostate cancer in the UK – an analysis of national practice**
By: Calleja E., Fowler S., Mcgrath J., Sooriakumaran P., [Aning J.](#)
Institutes:BAUS Section of Oncology, British Association of Urological Surgeons, London, United Kingdom
- *1074 **Applicability of Briganti nomogram: Is it an absolute requirement before lymph node dissection in intermediate-risk prostate cancer? Assessment of the external applicability**
By: [Pradere B.](#), Roumiguié M., Sanson S., Gas J., Patard P.M., Huyghe E., Rischmann P., Gamé X., Thoulouzan M., Doumerc N., Soulié M., Beauval J.B.
Institutes:CHU Toulouse, Dept. of Urology, Toulouse, France
- *1075 **More extensive lymph node dissection at radical prostatectomy is associated with improved outcomes after salvage radiotherapy for rising PSA after surgery: A long-term, multi-institutional analysis**

By: Fossati N.¹, Karnes R.J.², Colicchia M.², Bossi A.³, Cozzarini C.⁴, Fiorino C.⁴, Noris Chiorda B.⁴, Gandaglia G.¹, Dell'oglio P.¹, Wiegel T.⁵, Shariat S.⁶, Goldner G.⁷, Joniau S.⁸, Battaglia A.⁸, Haustermans K.⁹, De Meerleer G.⁹, Fonteyne V.¹⁰, Ost P.¹⁰, Van Poppel H.⁵, Montorsi F.¹, Briganti A.¹, Boorjian S.A.²

Institutes:¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²Mayo Clinic, Dept. of Urology, Rochester, United States of America, ³Gustave Roussy Institute, Dept. of Radiation Oncology, Villejuif, France, ⁴IRCCS Ospedale San Raffaele, Dept. of Radiotherapy, Milan, Italy, ⁵University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany, ⁶Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁷Medical University of Vienna, Dept. of Radiation Oncology, Vienna, Austria, ⁸University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ⁹University Hospitals Leuven, Dept. of Radiotherapy, Leuven, Belgium, ¹⁰Ghent University Hospital, Dept. of Radiotherapy, Ghent, Belgium

*1076 **The CPC risk calculator app: A validated tool to predict recurrence after radical prostatectomy.**

By: Røder M.A.¹, Berg K.D.¹, Loft M.D.², Gerds T.A.³, Ferrari M.², Thomsen F.B.¹, Gruschy L.¹, Kurbegovic S.¹, Rytgaard H.C.³, Kjær A.⁴, Brasso K.¹, Iversen P.¹, Brooks J.²

Institutes:¹Rigshospitalet, Copenhagen Prostate Cancer Center, Dept. of Urology, Copenhagen, Denmark, ²Stanford University Medical Center, Dept. of Urology, Stanford, United States of America, ³University of Copenhagen, Dept. of Biostatistics, Copenhagen, Denmark, ⁴Rigshospitalet, Dept. of Clinical Physiology, Nuclear Medicine & PET and Cluster For Molecular Imaging, Copenhagen, Denmark

*1077 **Obesity was associated with improved metastases-free survival after surgery in 13,667 prostate cancer patients**

By: Tennstedt P.¹, Salomon G.¹, Tilki D.¹, Budäus L.¹, Pompe R.¹, Leyh-Bannurah S-R.², Haese A.¹, Heinzer H.¹, Huland H.¹, Graefen M.¹, Schiffmann J.³

Institutes:¹University Medical Center Eppendorf, Martini-Klinik, Hamburg, Germany, ²University Medical Center Eppendorf, Department of Urology, Hamburg, Germany, ³Academic Hospital Braunschweig, Department of Urology, Braunschweig, Germany

*1078 **Functional outcomes and complications of a multicentre series of open versus robot-assisted salvage radical prostatectomy**

By: Gontero P.¹, Marra G.¹, Alessio P.¹, Oderda M.¹, Palazzetti A.¹, Pisano F.¹, Battaglia A.¹, Munegato S.¹, Frea B.¹, Munoz F.², Filippini C.³, Linares E.⁴, Sanchez-Salas R.⁴, Goonewardene S.⁵, Dasgupta P.⁵, Cahill D.⁵, Challacombe B.⁵, Popert R.⁵, Gillatt D.⁶, Persad R.⁶, Palou J.⁷, Joniau S.⁸, Smelzo S.⁹, Piechaud T.⁹, De La Taille A.¹⁰, Roupert M.¹¹, Albisinni S.¹², Van Velthoven R.¹², Morlacco A.¹³, Vidit S.¹³, Gandaglia G.¹⁴, Mottrie A.¹⁴, Smith J.¹⁵, Fiscus G.¹⁵, Van Der Poel H.¹⁶, Tilki D.¹⁷, Karnes R.J.¹³

Institutes:¹San Giovanni Battista Hospital, Dept. of Urology, Turin, Italy, ²Pasini Hospital, Dept. of Radiotherapy, Aosta, Italy, ³San Giovanni Battista Hospital, Dept. of Statistics, Turin, Italy, ⁴Institut Mutualiste Montsouris, Dept. of Urology, Paris, France, ⁵Guy's Hospital, Dept. of Urology, London, United Kingdom, ⁶North Bristol NHS Foundation Trust, Dept. of Urology, Bristol, United Kingdom, ⁷Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ⁸Leuven University Hospitals, Dept. of Urology, Leuven, Belgium, ⁹Clinique Saint Augustin, Dept. of Urology, Bordeaux, France, ¹⁰CHU Mondor, Dept. of Urology, Créteil, France, ¹¹Pitié Salpêtrière Hospital- University Paris 6, Dept. of Urology, Paris, France, ¹²Institut Jules Bordet, Université Libre De Bruxelles, Dept. of Urology, Bruxelles, Belgium, ¹³Mayo Clinic, Dept. of Urology, Rochester, Mn, United States of America, ¹⁴OLV Hospital, Dept. of Urology, Aalst, Belgium, ¹⁵Vanderbilt University, Medical Center North, Dept. of Urology, Nashville, Tnt, United States of America, ¹⁶Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ¹⁷Martini Klinik, Dept. of Urology, Hamburg, Germany

*1079 **Impact of type of radical prostatectomy on outcomes reported by men with prostate cancer 18 months post-diagnosis: Results from the English National Prostate Cancer Audit (NPCA)**

By: Nossiter J., Sujenthiran A., Charman S., Cathcart P., Aggarwal A., Payne H., Clarke N., Van Der Meulen J.

Institutes:Royal College Of Surgeons Of England, Clinical Effectiveness Unit, London, United Kingdom

*1080 **Functional results of PROPENLAP: Prospective multicentric study comparing open and mini-**

invasive radical prostatectomy

By: Salomon L.¹, Bastuji-Garin S.², Soulie M.³, Devonec M.⁴, Boutin E.⁵, Mandron E.⁶, Benoit G.⁷, Richman P.³, Mottet N.⁸, Gasman D.⁹, Irani J.¹⁰, Zerbib M.¹¹, Vaessen C.¹², Dore B.¹⁰, Leuret T.¹³, Colombel M.⁴, Lechevallier E.¹⁴, Gregoire L.¹⁵, Allory Y.⁵, Abbou C-C.¹

Institutes:¹CHU Henri Mondor, Dept. of Urology, Créteil, France, ²CHU Henri Mondor, Santé Publique, Créteil, France, ³Hôpital De Toulouse, Dept. of Urology, Toulouse, France, ⁴Hôpital De Lyon, Dept. of Urology, Lyon, France, ⁵CHU Henri Mondor, Anapath, Créteil, France, ⁶HEGP, Dept. of Urology, Paris, France, ⁷Hôpital Bicêtre, Dept. of Urology, Kremlin Bicêtre, France, ⁸Hôpital De Saint Etienne, Dept. of Urology, Saint Etienne, France, ⁹Clinique De Longjumeau, Dept. of Urology, Longjumeau, France, ¹⁰Hôpital De Poitiers, Dept. of Urology, Poitiers, France, ¹¹Hôpital Cochin, Dept. of Urology, Paris, France, ¹²CHU Pitié Salpêtrière, Dept. of Urology, Paris, France, ¹³Hôpital Foch, Dept. of Urology, Suresnes, France, ¹⁴Hôpital De Marseille, Dept. of Urology, Marseille, France, ¹⁵CHU Henri Mondor, CIC, Créteil, France

*1081 **Randomized study evaluating postoperative outcomes in patients with complex anastomosis during da Vinci prostatectomy**

By: Pushkar D., Kolontarev K., Govorov A., Rasner P.

Institutes: Moscow State Medico Stomatological University, Hospital 50, Dept. of Urology, Moscow, Russia

*1082 **Surgical expertise is the major determinant of decreased complication rates in contemporary patients treated with robot-assisted radical prostatectomy**

By: Dell'Oglio P.¹, Stabile A.¹, Zaffuto E.¹, Gandaglia G.¹, Fossati N.¹, Bandini M.¹, Moschini M.¹, Fallara G.¹, Dehò F.¹, Guazzoni G.², Gallina A.¹, Suardi N.¹, Gaboardi F.¹, Montorsi F.¹, Briganti A.¹

Institutes:¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²Humanitas Clinical and Research Center, Dept. of Urology, Milan, Italy

*1083 **Characterization of the "one-pad patient" at long-term follow-up after radical prostatectomy**

By: Löppenber B., Müller G., Bach P., Von Bodman C., Brock M., Roghmann F., Noldus J., Palisaar J.

Institutes: Ruhr-University Bochum, Marien Hospital Herne, Dept. of Urology, Herne, Germany

Testicular cancer - new approaches in surgery and systemic treatment

Poster Session 82

Monday, 27 March
15:45 - 17:15

Location: Room Paris, North Hall (Level 1)

Chairs: M. Jewett, Toronto (CA)
D.L. Nicol, London (GB)
N. Nicolai, Milan (IT)

Aims and objectives of this presentation

This session will update the audience with new indications and outcome results from surgical approaches together with new systemic treatment options for patients with advanced germ cell cancer. In addition, quality of care issues will be discussed based on large registries.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *1084 **Non-guideline concordant treatment of testicular cancer**
By: [Paffenholz P.](#), Pfister D., Heidenreich A.
Institutes: University Hospital Cologne, Dept. of Urology, Cologne, Germany
- *1085 **Testicular cancer in patients with learning disabilities in England from 2001-2015: A national cohort study**
By: [Afshar M.](#)², [Jackson-Spence E.](#)¹, De-Santis M.³, Tanner J-R.⁴, Evison F.⁵, James N.³, Selby P.⁶, Patel P.⁷
Institutes:¹University of Birmingham, Medical School, Birmingham, United Kingdom, ²St George's University Hospitals NHS Foundation Trust, Dept. of Urological Oncology, London, United Kingdom, ³University of Warwick, Cancer Research Unit, Coventry, United Kingdom, ⁴University Hospitals Birmingham NHS Foundation Trust, Dept. of Oncology, Birmingham, United Kingdom, ⁵University Hospitals Birmingham NHS Foundation Trust, Dept. of Informatics, Birmingham, United Kingdom, ⁶University of Leeds, Leeds Institute of Cancer & Pathology, Leeds, United Kingdom, ⁷University of Birmingham, School of Cancer Sciences, Birmingham, United Kingdom
- *1086 **Reliability of frozen section examination in a large cohort of testicular masses: What did we learn?**
By: [Vartolomei M.D.](#)¹, Matei D.V.², Renne G.³, Tringali V.M.², Ferro M.², Bianchi R.², Russo A.², Cozzi G.², De Cobelli O.⁴
Institutes:¹University of Medicine and Pharmacy, Targu Mures, Romania and European Institute of Oncology, Dept. of Cell and Molecular Biology and Dept. of Urology, Milan, Italy, ²European Institute of Oncology, Dept. of Urology, Milan, Italy, ³European Institute of Oncology, Dept. of Pathology, Milan, Italy, ⁴European Institute of Oncology and University of Milan, Dept. of Urology, Milan, Italy
- *1087 **Diagnostic value of frozen section examination (FSE) during inguinal exploration in patients with inconclusive testicular lesions**
By: [Fankhauser C.](#)¹, Beyer J.², Roth L.¹, Sulser T.¹, Bode K-P.³, Moch H.³, Hermanns T.¹
Institutes:¹University Hospital Zurich, University of Zurich, Dept. of Urology, Zurich, Switzerland, ²University Hospital Zurich, University of Zurich, Dept. of Oncology, Zurich, Switzerland, ³University Hospital Zurich, University of Zurich, Dept. of Pathology and Molecular Pathology, Zurich, Switzerland
- *1090 **Primary retroperitoneal lymph node dissection (RPLND) in Stage II A/B seminoma patients without adjuvant treatment: A phase II trial (PRIMETEST)**
By: [Lusch A.](#), Gerbaulet L., Winter C., Albers P.

Institutes:Düsseldorf University, Dept. of Urology, Düsseldorf, Germany

- *1091 **Surgical resection of residual tumours after adjuvant chemotherapy of germ cell (GC) tumour**
By: Gonzalez F.¹, Bossavy J-P.¹, Otal P.², Quintyn-Rant M-L.³, Roumiquié M.⁴, Chevreau C.⁵, Malavaud B.⁴
Institutes:¹Chu Toulouse Rangueil, Dept. of Vascular Surgery, Toulouse, France, ²Chu Toulouse Rangueil, Dept. of Radiology, Toulouse, France, ³Institut Universitaire Du Cancer, Dept. of Pathology, Toulouse, France, ⁴Institut Universitaire Du Cancer, Dept. of Urology, Toulouse, France, ⁵Institut Universitaire Du Cancer, Dept. of Medical Oncology, Toulouse, France
- *1092 **Complications and adjunctive surgical procedures in post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) to define a tertial referral center**
By: Lusch A., Gerbaulet L., Winter C., Albers P.
Institutes:Düsseldorf University, Dept. of Urology, Düsseldorf, Germany
- *1093 **Bone metastases in germ cell tumours: Surgical management and outcomes**
By: Nini A.¹, Konieczny M.², Winter C.³, Lusch A.³, Krauspe R.², Albers P.³
Institutes:¹, IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²University Hospital Düsseldorf, Heinrich-Heine University Medical Faculty, Dept. of Orthopedic Surgery, Düsseldorf, Germany, ³University Hospital Düsseldorf, Heinrich-Heine University Medical Faculty, Dept. of Urology, Düsseldorf, Germany
- *1094 **Retinal toxicity after cisplatin-based chemotherapy in patients with testicular cancer**
By: Gild P.¹, Vetterlein M.¹, Dieckmann K.P.², Matthies C.³, Wagner W.³, Ludwig T.¹, Meyer C.¹, Soave A.¹, Dulz S.⁴, Asselborn N.⁴, Oechsle K.⁵, Bokemeyer C.⁵, Becker A.¹, Fisch M.¹, Hartmann M.¹, Chun F.¹, Kluth L.A.¹
Institutes:¹University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ²Albertinen Hospital, Dept. of Urology, Hamburg, Germany, ³Bundeswehr Medical Center Hamburg, Dept. of Urology, Hamburg, Germany, ⁴University Medical Center Hamburg-Eppendorf, Dept. of Ophthalmology, Hamburg, Germany, ⁵University Medical Center Hamburg-Eppendorf, Dept. of Medical Oncology, Hamburg, Germany
- *1095 **The features and management of late relapse of non-seminomatous germ cell tumours**
By: Jay A., Aldiwani M., Wijayarathna S., Huddart R., Mayer E., Nicol D.
Institutes:Royal Marsden Hospital, Dept. of Urology, Chelsea, United Kingdom
- *1096 **Incidence of secondary malignancies (SM) in patients (pts) with germ cell tumors (GCT) who received high-dose chemotherapy (HDCT): A retrospective study from the European Society for Blood and Marrow Transplantation (EBMT) database**
By: Necchi A.¹, Rosti G.², Badoglio M.³, Giannatempo P.⁴, Secondino S.², Lanza F.⁵, Pedrazzoli P.²
Institutes:¹Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, ²Fondazione IRCCS Policlinico San Matteo, Dept. of Medical Oncology, Pavia, Italy, ³EBMT, EBMT Study Offices, Paris, France, ⁴Fondazione IRCCS Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milano, Italy, ⁵Hospital of Ravenna, Dept. of Hematology, Ravenna, Italy
- *1097 **Pazopanib (PZP) in germ cell tumors (GCT) after chemotherapy (CT) failure: Final results of the open label, single-group, phase 2 Pazotest trial**
By: Necchi A.¹, Lo Vullo S.², Giannatempo P.¹, Raggi D.¹, Calareso G.³, Togliardi E.⁴, Crippa F.⁵, Pennati M.⁶, Zaffaroni N.⁶, Perrone F.⁷, Colecchia M.⁷, Nicolai N.⁸, Mariani L.², Salvioni R.⁸
Institutes:¹Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, ²Fondazione IRCCS - Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy, ³Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Radiology, Milan, Italy, ⁴Fondazione IRCCS - Istituto Nazionale Dei Tumori, Pharmacy Unit, Milan, Italy, ⁵Fondazione IRCCS - Istituto Nazionale Dei Tumori, Nuclear Medicine - PET Unit, Milan, Italy, ⁶Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Experimental Oncology and Molecular Medicine, Milan, Italy, ⁷Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Pathology, Milan, Italy, ⁸Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy

Topnotch new technologies for tissues and bacterial cultures: New wireless diagnostics and new techniques in training

Poster Session 83

Monday, 27 March
15:45 - 17:15

Location: Room Amsterdam, North Hall (Level 1)

Chairs: T.E. Bjerklund Johansen, Oslo (NO)
Y.S. Kyung, Seoul (KR)
E. Liatsikos, Patras (GR)

Aims and objectives of this presentation

To identify new technologies for training, diagnosing infections and wireless diagnostics for urological applications

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *1098 **Dynamic imaging of urine flow at bladder neck during voiding by wireless capsule endoscopes in vivo**
By: [Yamamoto T.](#)¹, Mizuno H.¹, Soh S.², Funanishi Y.¹, Matsukawa Y.¹, Nakamura M.³, Gotoh M.¹
Institutes:¹Nagoya University Graduate School of Medicine, Dept. of Urology, Nagoya, Japan, ²Dokkyo Medical University, Dept. of Urology, Koshigaya, Japan, ³Nagoya University Graduate School of Medicine, Dept. of Gastroenterology, Nagoya, Japan
- *1099 **Wireless micro-robots for endoscopic applications in urology**
By: [Adams F.](#)¹, Qiu T.², Mark A.², Melde K.², Palagi S.², Miernik A.¹, Fischer P.²
Institutes:¹University Hospital Freiburg, Dept. of Urology, Freiburg, Germany, ²Max Planck Institute For Intelligent Systems, Micro Nano and Molecular Systems, Stuttgart, Germany
- *1100 **Measures of pelvic floor strength by age and parity using the Elvie device**
By: Coggins J.¹, [Cartwright R.](#)², Bergmann J.³
Institutes:¹Chiaro Technology Ltd., Data Science Department, London, United Kingdom, ²Imperial College London, Faculty of Medicine, School of Public Health, London, United Kingdom, ³University of Oxford, Institute of Biomedical Engineering, Oxford, United Kingdom
- *1101 **Experimental study on establishing tissue engineered bionic urethra by cell sheet technology and labeled by ultrasmall super-paramagnetic iron oxide (USPIO) for full-thickness urethral reconstruction**
By: Fu Q., [Zhou S.](#)
Institutes:Shanghai Sixth People's Hospital, Dept. of Urology, Shanghai, China
- *1102 **Modifying the surface chemistry of biomaterials designed for surgical treatment of stress urinary incontinence to reduce bacterial adhesion**
By: [Roman S.](#)¹, Mangir N.¹, Chapple C.², McArthur S.L.³, Macneil S.¹
Institutes:¹University of Sheffield, Dept. of Material Science and Engineering, Sheffield, United Kingdom, ²Royal Hallamshire Hospital, Dept. of Urology, Sheffield, United Kingdom, ³Swinburne University of Technology, Biointerface Engineering Group and Polymer Nanointerface Engineering Group, Melbourne, Australia
- *1103 **Surface acoustic waves prevent bacterial colonization in indwelling urinary catheters**
By: [Rosenblum J.](#)¹, Markowitz S.², Goldstein M.³
Institutes:¹Shaarei Zedek Medical Center, Dept. of Urology, Bet Shemesh, Israel, ²Shaarei Zedek Medical Center, Dept of Urology, Bet Shemesh, Israel, ³Private Practice, Dept. of Urology, Bet

Shemesh, Israel

- *1104 **Photodynamic therapy's use in reduction in vitro of prevalent bacteria in Fournier's gangrene**
By: [Pereira N.](#), Feitosa L., Navarro R., Kozusni-Andreani D., Carvalho N.
Institutes:Unicastelo, Dept. of Biomedical Engineering, São Paulo, Brazil
- *1105 **Analysis of errors in 3D printing phantoms for partial nephrectomy**
By: Kyung Y.S.¹, [Choi S.Y.](#)³, Kim G.B.², Song H.K.², Kim H.², You D.³, Jeong I.G.³, Homg J.H.³, Kim N.², Kim C-S.³
Institutes:¹University of Ulsan College of Medicine, Asan Medical Center, Dept. of Health Screening and Promotion Center, Seoul, South Korea, ²University of Ulsan College of Medicine, Asan Medical Center, Dept. of Biomedical Engineering Research Center, Seoul, South Korea, ³University of Ulsan College of Medicine, Asan Medical Center, Dept. of Urology, Seoul, South Korea
- *1106 **Feasibility and safety of augmented reality-assisted urological surgery**
By: [Rodríguez Socarrás M.E.](#)¹, Tortolero Blanco L.², Salem J.³, Tsaur I.⁴, Gomez-Rivas J.⁵, Barret E.⁶, Borgmann H.⁴
Institutes:¹University Hospital Alvaro Cunqueiro, Dept. of Urology, Vigo, Spain, ²University Hospital Vinalopo, Dept. of Urology, Elche, Spain, ³University Hospital Cologne, Dept. of Urology, Cologne, Germany, ⁴University Hospital Mainz, Dept. of Urology, Mainz, Germany, ⁵University Hospital La Paz, Dept. of Urology, Madrid, Spain, ⁶Institut Montsouris, Université Paris-Descartes, Dept. of Urology, Paris, France
- *1107 **Video analysis of skill and technique (VAST): Machine learning to assess the technical skill of surgeons performing robotic prostatectomy**
By: [Ghani K.](#)¹, Liu Y.², Law H.², He D.², Miller D.¹, Montie J.¹, Deng J.²
Institutes:¹University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ²University of Michigan, Dept. of Computer Science & Engineering, Ann Arbor, United States of America
- *1108 **During endoscopic surgery, eye fatigue in surgeons can be reduced by wearing polarized lens glasses**
By: [Iwabuchi T.](#), Kawano Y., Narumi S., Oiwa Y., Ottomo T., Yokoyama H., Noda Y., Ishikawa S., Watanabe H., Uetani M., Yamamoto R., Hriu K., Minowada S.
Institutes:Tokyo Nephro Urology Center, Yamato Hospital, Dept. of Urology, Tokyo, Japan
- *1109 **Folic acid-conjugated AuAg nanoparticles combined surface enhanced Raman spectroscopy for rapid detection of bladder cancers in urine**
By: [Chuang T.Y.](#)¹, Chiu Y.C.¹, Yang Y.T.², Lin C.H.³, Liao M.Y.⁴, Huang C.C.³
Institutes:¹Taipei City Hospital, Zhongxiao Branch, Dept. of Urology, Taipei, Taiwan, ²National Pingtung University, Dept. of Applied Chemistry, Pingtung, Taiwan, ³Center For Micro/Nano Science and Technology and Advanced Optoelectronic Technology Center, National, Dept. of Photonics, Tainan, Taiwan, ⁴National Cheng Kung University, Medical Laboratory Science and Biotechnology, Tainan, Taiwan
- 16:56 - 17:03 **Summary**
 E. Liatsikos, Patras (GR)

Basic science in sexual medicine: Pathophysiology and new treatment options

Poster Session 84

Monday, 27 March
15:45 - 17:15

Location: Room Berlin, North Hall (Level 1)

Chairs: M. Albersen, Leuven (BE)
F. Castiglione, Milan (IT)
L. Lund, Odense (DK)

Aims and objectives of this presentation

This session will provide the audience with latest news regarding pathophysiological mechanisms behind erectile dysfunction. Furthermore, evidence from in vitro- and animal studies on possible new treatment options for erectile dysfunction, peyronies disease and hypogonadism will be presented. The audience will walk away with an idea of the future direction in the world of andrology.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *1110 **Functional brain imaging shows a correlation between distended seminal vesicles and specific brain activity in young men**
By: Weisstanner C.², Wapp M.², Schmitt M.³, Puig S.⁴, Mordasini L.⁵, Wiest R.², Thalmann G.³, [Birkhäuser F.](#)¹
Institutes:¹Hirslanden Klinik St. Anna, Dept. of Urology St. Anna, Luzern, Switzerland, ²University Hospital Bern, Dept. of Diagnostic and Interventional Neuroradiology, Bern, Switzerland, ³University Hospital Bern, Dept. of Urology, Bern, Switzerland, ⁴University Hospital Bern, Dept. of Diagnostic, Pediatric and Interventional Radiology, Bern, Switzerland, ⁵Luzerner Kantonsspital, Dept. of Urology, Luzern, Switzerland
- *1111 **Immune modulation with etanercept on hypogonadism induced by hyperprolactinemic status**
By: [Huang W.](#)¹, Wang Z-L.², Yang L-Y.³, Chen H-H.², Lin H-H.², Tsai Y-T.²
Institutes:¹National Yang-Ming University Taipei Veterans General Hospital, Dept. of Urology and Physiology, Taipei, Taiwan, ²National Yang-Ming University, Dept. of Physiology, Taipei, Taiwan, ³National Yang-Ming University, Taipei Veterans General Hospital, Dept. of Pediatrics, Taipei, Taiwan
- *1112 **Development and validation of a phenotypic high-throughput, cell-based assay for anti-myofibroblast activity in Peyronie's disease**
By: [Ilg M.M.](#)¹, Mateus M.¹, Stebbeds W.², Ameyaw B.², Raheem A.³, Spilotros M.³, Capece M.³, Parnham A.³, Garaffa G.³, Christopher N.³, Muneer A.³, Cellek S.¹, Ralph D.³
Institutes:¹Anglia Ruskin University, Faculty of Medical Science, Chelmsford, United Kingdom, ²Cranfield University, Cranfield Health, Bedfordshire, United Kingdom, ³University College London Hospital, Dept. of Andrology, London, United Kingdom
- *1113 **Androgen receptor (AR) gene (CAG)n and (GGN)n length polymorphisms and symptoms in young males with long-lasting adverse effects after finasteride use against androgenic alopecia**
By: [Chiriaco G.](#)¹, Cauci S.², Cecchin E.³, Toffoli G.³, Xodo S.⁴, Stinco G.⁵, Trombetta C.¹
Institutes:¹Azienda Ospedaliero Universitaria di Trieste, Dept. of Urology, Trieste, Italy, ²University of Udine, Dept. of Medical and Biological Sciences, Udine, Italy, ³CRO Aviano National Cancer Institute, Experimental and Clinical Pharmacology Unit, Aviano, Italy, ⁴University Hospital Santa Maria Della Misericordia, University of Udine, Udine, Italy, ⁵University Hospital Santa Maria Della Misericordia, Dept. of Dermatology, Udine, Italy

- *1114 **The efficacy of human testicular stromal cell and neuronal precursor cell in a mouse model of cavernous nerve injury**
By: Choi K.H.¹, Ki B.S.², Lee S.R.¹, Hong Y.K.¹, Park D.S.¹, Lee D.R.²
Institutes:¹CHA University, Dept. of Urology, Seongnam, South Korea, ²CHA University, Dept. of Biomedical Science, College of Life Science, Seongnam, South Korea
- *1115 **Erectile Dysfunction (ED) secondary to radical prostatectomy is associated with selective down-regulation of nitergic innervation in human cavernosal tissue**
By: Martínez-Salamanca J.J.¹, Martínez-Salamanca E.², La Fuente J.², Pepe-Cardoso A.², Louro N.², Carballido J.A.¹, Angulo J.²
Institutes:¹Hospital Universitario Puerta de Hierro-Majadahonda, Dept. of Urology, Majadahonda, Spain, ²Hospital Universitario Ramón Y Cajal, IRYCIS, Madrid, Spain
- *1116 **Restoration of erectile function with intracavernous injections of smooth muscle progenitor cells after bilateral cavernous nerve injury in rats**
By: Chiang B.J.¹, Liao C-H.¹, Chiang H-S.², Wu Y-N.²
Institutes:¹Cardinal Tien Hospital, Dept. of Urology, New Taipei City, Taiwan, ²Fu-Jen Catholic University, Dept. of Urology, New Taipei City, Taiwan
- *1117 **Additive pro-erectile effect of Low intensity-Shockwave Therapy (Li-ESWT) delivered by Aries® combined with sildenafil in spontaneously hypertensive rats (SHR)**
By: Assaly-Kaddoum R.², Giuliano E.¹, Compagnie S.², Bernabé J.², Behr-Roussel D.²
Institutes:¹Université De Versailles Saint-Quentin-En-Yvelines, AP-HP Raymond Poincaré Hospital-Dept. of Neurological Rehabilitation, Garches, France, ²Université De Versailles Saint-Quentin-En-Yvelines, Pelvipharm, Montigny-Le-Bretonneux, France
- *1118 **Resveratrol restores erectile function in irradiated rats: Role on SIRT-1 and nNOS protein expressions**
By: Uner T.E.¹, Tavukcu H.H.², Atasoy B.M.³, Cevik O.⁴, Kaya O.T.⁵, Cetinel S.⁶, Degerli A.³, Tinay I.¹, Simsek F.¹, Akbal C.¹, Sener G.⁵
Institutes:¹Marmara University School of Medicine, Dept. of Urology, Istanbul, Turkey, ²Istanbul Bilim University, Istanbul Florence Nightingale Hospital, Dept. of Urology, Istanbul, Turkey, ³Marmara University, School of Medicine, Dept. of Radiation Oncology, Istanbul, Turkey, ⁴Cumhuriyet University, School of Pharmacy, Dept. of Biochemistry, Sivas, Turkey, ⁵Marmara University, School of Pharmacy, Dept. of Pharmacology, Istanbul, Turkey, ⁶Marmara University, School of Medicine, Dept. of Histology & Embryology, Istanbul, Turkey
- *1119 **Role of PI3K/AKT in the erectile dysfunction from metabolic syndrome rats**
By: Li R., Wang T., Yang J., Zhang Y., Ruan Y., Li H., Cui K., Wang S., Rao K., Liu J.
Institutes:Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Dept. of Urology, Wuhan, China
- *1120 **Activation of Nrf2 improves endothelial function in corpus cavernosum from aged rats and in corpus cavernosum and penile arteries from ED patients**
By: Martínez-Salamanca J.J.¹, El Assar M.², Fernández A.², Sánchez-Ferrer A.², Fraile A.³, Rodríguez-Mañas L.⁴, Carballido J.A.¹, Angulo J.²
Institutes:¹Hospital Universitario Puerta de Hierro-Majadahonda, Dept. of Urology, Majadahonda, Spain, ²Hospital Universitario Ramón Y Cajal, IRYCIS, Madrid, Spain, ³Hospital Universitario Ramón Y Cajal, Dept. of Urology, Madrid, Spain, ⁴Hospital Universitario De Getafe, Dept. of Geriatrics, Madrid, Spain
- *1121 **Preserved erectile function in the hyperhomocysteinaemia transgenic rat harboring human tissue kallikrein 1**
By: Cui K., Tang Z., Luan Y., Rao K., Wang T., Chen Z., Liu J.
Institutes:Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Dept. of Urology, Wuhan, China

17:00 - 17:07

Summary

M. Albersen, Leuven (BE)

Innovations in urodynamics and diagnostics

Poster Session 85

Monday, 27 March
15:45 - 17:15

Location: Room Vienna, North Hall (Level 1)

Chairs: H. Hashim, Bristol (GB)
P.F.W.M. Rosier, Utrecht (NL)
A. Tubaro, Rome (IT)

Aims and objectives of this presentation

Advances and innovations in urodynamics and LUTD diagnosis are highlighted in this session.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *1122 **Prospective simultaneous comparison of fluid filled versus air filled pressure systems during clinical cystometry**
By: [Rosier P.](#)
Institutes: UMC Utrecht, Dept. of Urology, Utrecht, The Netherlands
- *1123 **Comparing a novel hand held device (Peritron+) to standard urodynamics in measuring intravesical pressure**
By: [Radomski S.](#)¹, [Ruzhynsky V.](#)¹, [Bitzos S.](#)², [Goping I.](#)²
Institutes: ¹Toronto Western Hospital, University Health Network, Dept. of Urology, Toronto, Canada, ²Laborie Medical Technologies Canada ULC, Clinical Research, Mississauga, Canada
- *1125 **Does videourodynamic classification depend on patient positioning in patients with stress urinary incontinence?**
By: [Ecclestone H.](#), [Soloman E.](#), [Pakzad M.](#), [Hamid R.](#), [Wood D.](#), [Greenwell T.](#), [Ockrim J.](#)
Institutes: University College Hospital London, Dept. of Urology, London, United Kingdom
- *1126 **Validation of the TOTO Flowsky® uroflowmetry device**
By: [Tsang W.C.](#)¹, [Raman L.](#)², [Wai Z.](#)², [Guo H.](#)², [Consigliere D.](#)², [Chiong E.](#)²
Institutes: ¹NUHS National University Health System, Dept. of Urology, Singapore, Singapore, ²National University Health System, Dept. of Urology, Singapore, Singapore
- *1127 **Routine enema before urodynamics has no impact on the quality of abdominal pressure curves: Results of a prospective controlled study**
By: [Peyronnet B.](#)¹, [Rigole H.](#)², [Dampousse M.](#)², [Senal N.](#)², [Brochard C.](#)³, [Manunta A.](#)¹, [Kerdran J.](#)², [Tondut L.](#)¹, [Alimi Q.](#)¹, [Hascoet J.](#)¹, [Siproudhis L.](#)³, [Bonan I.](#)²
Institutes: ¹CHU Rennes, Dept. of Urology, Rennes, France, ²CHU Rennes, Dept. of Physical Medicine and Rehabilitation, Rennes, France, ³CHU Rennes, Dept. of Gastrology, Rennes, France
- *1128 **Brain areas involved in urinary urge sensation using 7 Tesla functional magnetic resonance imaging of the human brain**
By: [Rahnama'i M.S.](#)¹, [Van Den Hurk J.](#)², [Drossaerts J.](#)³, [Koeveringe G.](#)³
Institutes: ¹Maastricht UMC+, Dept. Urology, Maastricht, The Netherlands, ²Scannexus, Scannexus, Maastricht, The Netherlands, ³Maastricht UMC+, Dept. of Urology, Maastricht, The Netherlands
- *1129 **Concordance of urodynamic definitions of female bladder outlet obstruction**
By: [Solomon E.](#), [Yasmin H.](#), [Duffy M.](#), [Malde S.](#), [Ockrim J.](#), [Greenwell T.](#)
Institutes: University College London Hospital, Dept. of Urology, London, United Kingdom

- *1130 **A wearable biosensor for the bladder: Study of awake bladder urodynamics in large animal model**
By: Soebadi M.A.¹, Bakula M.², Weydts T.², Van Der Aa F.³, Puers R.², De Ridder D.³
Institutes:¹Universitas Airlangga, Dept. of Urology, Surabaya, Indonesia, ²KU Leuven, ESAT-MICAS, Leuven, Belgium, ³KU Leuven, Dept. of Development and Regeneration, Leuven, Belgium
- *1131 **Anterior pelvic prolapse evaluation by dynamic MRI and ultrasound. Clinical correlation with Pop-q staging system**
By: Garcia Ibanez J., Duran Rivera A., Sánchez-Ballester F., Cayuelas Rubio C., Mitjana Biosca S., Monzó A., Ramos De Campo M., López-Alcina E., Juan J.
Institutes:Hospital General Universitario, Dept. of Urology, Valencia, Spain
- *1133 **Comparison of neurogenic lower urinary tract dysfunctions in open vs. closed spinal dysraphism: Results observed in a prospective cohort of 395 patients**
By: Peyronnet B.¹, Brochard C.², Hascoet J.¹, Jezequel M.³, Menard H.³, Senal N.⁴, Bonan I.⁴, Siproudhis L.², Kerdraon J.⁴, Game X.⁵, Manunta A.¹
Institutes:¹CHU Rennes, Dept. of Urology, Rennes, France, ²CHU Rennes, Dept. of Gastrology, Rennes, France, ³CHU Rennes, Referral Center For Spina Bifida, Rennes, France, ⁴CHU Rennes, Dept. of Physical Medicine and Rehabilitation, Rennes, France, ⁵CHU Toulouse, Dept. of Urology, Toulouse, France
- *1134 **Neurogenic detrusor overactivity leak-point pressure (NDO-LPP), urodynamic findings and vesico-ureteral reflux in patients with spinal cord injury (SCI)**
By: Topazio L.¹, Amato I.¹, Iacovelli V.¹, Miano R.¹, D'amico A.², Vespasiani G.¹, Finazzi Agrò E.¹
Institutes:¹Policlinico Tor Vergata Roma, Dept. of Experimental Medicine and Surgery, Roma, Italy, ²Fondazione Santa Lucia, Neuro-Urology, Roma, Italy
- *1135 **Development of new and non-invasive diagnostic markers on urothelial cells in voided urine for the lower urinary tract symptoms / lower urinary tract dysfunction**
By: Shimura H.¹, Ihara T.¹, Mochizuki T.¹, Imai Y.¹, Kira S.¹, Nakagomi H.¹, Sawada N.¹, Mitsui T.¹, Takeda M.¹, Miyamoto T.²
Institutes:¹University of Yamanashi, Dept. of Urology, Chuo-City, Japan, ²Fujiyoshida Municipal Medical Center, Dept. of Urology, Fujiyoshida-City, Japan

How to optimize kidney transplantation

Poster Session 86

Monday, 27 March
15:45 - 17:15

Location: Room London, North Hall (Level 1)

Chairs: A.J. Figueiredo, Coimbra (PT)
E. Lledó García, Madrid (ES)
J.D. Olsburgh, London (GB)

Aims and objectives of this presentation

To discuss surgical results of kidney transplantation including robot assisted kidney transplantation.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *1136 **Robot assisted kidney transplantation: A centres first experiences**
By: Tugcu V.¹, Sahin S.¹, Atar F.A.¹, Yavuzsan A.H.¹, Eksi M.¹, Sener N.C.³, Akbay F.G.², Apaydin S.²
Institutes:¹Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Dept. of Urology, Istanbul, Turkey, ²Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Dept. of Nephrology, Istanbul, Turkey, ³Adana Numune Training and Research Hospital, Dept. of Urology, Adana, Turkey
- *1137 **Robotic renal transplant with more than one year follow up: Preliminary results**
By: Bruyere F.¹, Brichtart N.¹, Boutin J.M.¹, Pradere B.¹, Faivre D'arcier B.¹, Buchler M.²
Institutes:¹CHRU De Tours - Hôpital Bretonneau, Dept. of Urology, Tours, France, ²CHRU De Tours - Hôpital Bretonneau, Nephrology, Tours, France
- *1139 **Feasibility and perioperative outcomes of robot-assisted renal transplantation: An initial experience**
By: Pradere B.¹, Lesourd M.¹, Roumiguié M.¹, Beauval J.B.¹, Binhazaa M.¹, Rischmann P.¹, Soulié M.¹, Kamar N.², Gamé X.¹, Sallusto F.¹, Doumerc N.¹
Institutes:¹CHU Toulouse, Dept. of Urology, Toulouse, France, ²CHU Toulouse, Dept. of Nephrology, Toulouse, France
- *1140 **Renal graft implantation on vascular prosthesis: A large multicenter study**
By: Nedelec M., Glemain P., Chowanec Y., Geudry P., Robine E., Madec F.X., Lefevre M., Rigaud J., Karam G., Branchereau J.
Institutes:CHU Nantes, Dept. of Urology, Nantes, France
- *1141 **Long term follow up of patients performed enterocystoplasty and Ureterocystoplasty before kidney transplantation: A single center experience**
By: Mahdavi Zafarghandi M.R., Tavakkoli M., Ghoreifi A., Mahdavi Zafarghandi M.
Institutes:Mashhad University of Medical Sciences, Dept. of Urology, Mashhad, Iran
- *1142 **Kidney transplantation in patients with bladder augmentation: Long term outcomes**
By: Yamaçake K., Piovesan A., Falci R., Messi G., Kanashiro H., Antonopoulos I., Nahas W.
Institutes:University of Sao Paulo, Dept. of Urology, Sao Paulo, Brazil
- *1143 **Safety of dual kidney transplantation compared to single kidney transplantation from expanded criteria donors: A single center cohort of 39 recipients**
By: Mendel L.¹, Yandza T.¹, Albano L.², Jourdan J.¹, Quintens H.¹, Tibi B.¹, Durand M.¹, Amiel J.¹, Chevallier D.¹

Institutes:¹University Hospital of Nice, Dept. of Urology, Nice, France, ²University Hospital of Nice, Dept. of Nephrology, Nice, France

*1144 **Kidney transplantation with grafts from old donors: Is there a difference in term of complications and survival outcomes?**

By: Medina Polo J.¹, Sopeña-Sutil R.¹, Benítez-Sala R.¹, De La Rosa-Kehrmann F.¹, Pamplona-Casamayor M.¹, Rodríguez-Antolín A.¹, Duarte-Ojeda J.M.¹, Tejido-Sánchez A.¹, Villacampa-Aubá F.¹, Alonso-Isa M.¹, Justo-Quintas J.¹, Gil-Moradillo J.¹, Andrés-Belmonte A.², Passas-Martínez J.B.¹

Institutes:¹Hospital Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain, ²Hospital Universitario 12 de Octubre, Dept. of Nephrology-Transplant Coordination, Madrid, Spain

*1145 **Does nighttime renal graft increases the risk of post-operative complications?**

By: Treacy P.J., Imbert De La Phalecque L., Bentellis I., Regnier P., Bodokh Y., Roustan F.R., Haider R., Prader R., Tibi B., Chevallier D., Amiel J., Durand M.

Institutes:University Hospital of Nice, Dept. of Nice, Nice, France

*1146 **Comparison of DCE-MRI renography, SPECT renography and endogenous creatinine clearance rate in kidney transplant recipients**

By: Jun T., Ruoyun T., Zhijian H., Xiaobing J., Wanli Z., Yudong Z., Min G.

Institutes:The First Affiliated Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, China

Functional aspects of reconstructive surgery

Poster Session 87

Monday, 27 March
15:45 - 17:15

Location: Room Stockholm, North Hall (Level 1)

Chairs: H. Abol-Enein, Mansoura (EG)
E. Chartier-Kastler, Paris (FR)
M. Hohenfellner, Heidelberg (DE)

Aims and objectives of this presentation

To assess the functional results of various bladder reconstruction techniques

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *1147 **Ureteric injury is rarer than previously reported in association with developed world vesico-vaginal fistulae**
By: Seth J., Kiosoglous A.J., Pakzad M.H., Hamid R., Ockrim J.L., Shah P.J.R., Greenwell T.J.
Institutes: University College London Hospital, Dept. of Urology, London, United Kingdom
- *1148 **Attempted nerve sparing has a lifelong impact on urinary continence in patients with an orthotopic bladder substitute**
By: Furrer M.A., Gross T., Thalmann G., Studer U., Nguyen D.
Institutes: University Hospital Bern, Dept. of Urology, Bern, Switzerland
- *1149 **Functional outcomes after radical cystectomy with ileal neobladder**
By: Von Landenberg N.¹, Hanske J.², Berg S.², Schmidt J.², Brock M.², Palisaar J.², Von Bodman C.², Roghmann F.², Noldus J.²
Institutes: ¹Ruhr-University Bochum, Marien-Hospital Herne and Brigham and Women's Hospital, Harvard Medical Scho, Dept. of Urology, Herne, Boston, Germany, ²Ruhr-University Bochum, Marien-Hospital Herne, Dept. of Urology, Herne, Germany
- *1150 **Functional outcomes of Turin pouch: A novel ileocecal cutaneous continent urinary diversion**
By: Muto G.¹, Altobelli E.¹, Mastroianni R.¹, Giacobbe A.², Castelli E.², Papalia R.¹
Institutes: ¹Campus Bio-Medico University, Dept. of Urology, Rome, Italy, ²San Giovanni Bosco Hospital, Dept. of Urology, Turin, Italy
- *1151 **Is the rectosigmoid-pouch (Mainz-Pouch-II) still a valid option for children and adolescents?**
By: Huck N.F.¹, Ewald S.², Neisius A.², Thüroff J.¹, Stein R.³
Institutes: ¹UMM Universitätsmedizin Mannheim, Dept of Urology, Mannheim, Germany, ²Universitätsmedizin Mainz, Dept of Urology, Mainz, Germany, ³UMM Universitätsmedizin Mannheim, Zentrum für Kinder- und Jugendurologie, Mannheim, Germany
- *1152 **Continent ileovesicostomy after bladder neck closure as salvage procedure for intractable incontinence**
By: Kranz J.¹, Anheuser P.², Rausch S.³, Fechner G.⁴, Braun M.⁵, Müller S.⁶, Steffens J.¹, Kälble T.⁷
Institutes: ¹St.-Antonius-Hospital Eschweiler, Dept. of Urology and Pediatric Urology, Eschweiler, Germany, ²Albertinen Krankenhaus, Dept. of Urology, Hamburg, Germany, ³Universitätsklinikum Tübingen, Dept. of Urology, Tübingen, Germany, ⁴Facharztzentrum Euskirchen, Dept. of Urology, Euskirchen, Germany, ⁵Klinikum Leverkusen, Dept. of Urology, Leverkusen, Germany, ⁶Universitätsklinikum Bonn, Clinic and Polyclinic for Urology and Pediatric Urology, Bonn, Germany, ⁷Klinikum Fulda, Dept. of Urology and Pediatric Urology, Fulda, Germany

- *1153 **Pregnancy after urinary diversion at young ages: Risks and outcome**
By: [Huck N.F.](#)¹, Schweizerhof S.², Honeck P.¹, Neisius A.², Thüroff J.¹, Stein R.³
Institutes:¹UMM Universitätsmedizin Mannheim, Klinik für Urologie, Mannheim, Germany, ²Universitätsmedizin Mainz, Klinik für Urologie, Mainz, Germany, ³UMM Universitätsmedizin Mannheim, Zentrum Für Kinder- Und Jugendurologie, Mannheim, Germany
- *1154 **Managing pregnancy in those who have undergone complex urological reconstruction**
By: Rajendran S.¹, [Sihra N.](#)¹, O'brien P.², Wood D.¹
Institutes:¹University College London Hospital, Dept. of Urology, London, United Kingdom, ²University College London Hospital, Dept. of Obstetrics and Gynaecology, London, United Kingdom
- *1155 **Does the use of recreational Ketamine pose a challenge on bladder reconstruction?**
By: [Sihra N.](#), Rajendran S., Ockrim J., Wood D.
Institutes:University College London Hospital, Dept. of Urology, London, United Kingdom
- *1156 **A step toward scarless surgery: Robot-assisted laparoendoscopic single-site versus mini-laparoscopic pyeloplasty**
By: [Fiori C.](#), Bertolo R., Manfredi M., Mele F., Amparore D., Cattaneo G., Garrou D., Piramide F., Toso S., Scarpa R.M., Porpiglia F.
Institutes:San Luigi Hospital, Dept. of Urology, Turin, Italy
- *1157 **Chemical ablation of the bladder urothelium and intestinal de-epithelialization and its effect on mucous secretion in augmentation cystoplasty: An experimental study**
By: [Abou Hashem S.](#)
Institutes:Zagazig University Hospital, Dept. of Urology, Zagazig, Egypt
-
- 16:52 - 17:00** **Associated video presentation The novel technique of pelvic organ prolapse treatment: Apical sling and subfascial colporrhaphy**
D. Shkarupa, St. Petersburg (RU)
-
- *V91 **Robot assisted repair of a vesicovaginal fistula with a peritoneal flap**
By: [Papadoukakis S.](#), Poth S., Horstmann M.
Institutes:MKH St. Josefshospital, Dept. of Urology, Krefeld, Germany
Associated video presentation
- 17:04 - 17:11** **Summary**
M. Hohenfellner, Heidelberg (DE)

Upper urinary tract tumor: Outcomes after radical surgery & peri-operative chemotherapy

Poster Session 88

Monday, 27 March
15:45 - 17:15

Location: Room Munich, North Hall (Level 1)

Chairs: To be confirmed
To be confirmed
E. Xylinas, Paris (FR)

Aims and objectives of this presentation

To date, however, radical surgery represents the only potentially curable therapeutic intervention for patients with urothelial carcinoma of the upper tract (UTUC). Although the role of lymphadenectomy in these tumors has not yet been clarified, recent evidence has shown that in patients with locally advanced tumors, it improves staging and consequently could help in selecting patients for adjuvant chemotherapy. UTUC and bladder carcinomas, are considered to be relatively chemosensitive. In fact, most of the data regarding the clinical efficacy of chemotherapy in the neoadjuvant and adjuvant settings are based on outcomes from the treatment of bladder UC. Contrary to what has been demonstrated for bladder cancer, there have been no convincing reported effects of neoadjuvant chemotherapy for UTUCs. Adjuvant chemotherapy achieves a remission rate of up to 50% but has minimal impact on survival.

Systemic recurrences are common in this disease, however, and it is therefore reasonable to consider perioperative chemotherapy in an effort to decrease a patient's risk of recurrence. The aim of this session is to discuss modern outcomes after radical nephroureterectomy and peri-operative chemotherapy.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *1158 **Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper tract urothelial carcinoma**
By: [Seisen T.](#)¹, Krasnow R.¹, Bellmunt J.², Rouprêt M.³, Leow J.¹, Lipsitz S.¹, Vetterlein M.¹, Preston M.¹, Hanna N.¹, Kibel A.¹, Sun M.¹, Choueiri T.², Trinh Q-D.¹, Chang S.L.¹
Institutes:¹Brigham and Women Hospital, Dept. of Urology, Boston, United States of America, ²Dana Farber Cancer Institute, Dept. of Genito Urinary Medical Oncology, Boston, United States of America, ³Hôpitaux Universitaires La Pitié-Salpêtrière, Dept. of Urology, Paris, France
- *1159 **Integrated comprehensive genomic characterization of upper tract urothelial carcinoma (UTUC)**
By: Moss T.³, Qi Y.³, Xi L.², Peng B.³, Mosqueda M.⁵, Guo C.⁶, Ittman M.⁴, Wheeler D.², Matin S.⁷, [Lerner S.](#)¹
Institutes:¹Baylor College of Medicine, Scott Dept. of Urology, Houston, United States of America, ²Baylor College of Medicine, Human Genome Sequencing Center, Houston, United States of America, ³MD Anderson Cancer Center, Dept. of Bioinformatics and Computational Biology, Houston, United States of America, ⁴Baylor College of Medicine, Dept. of Pathology, Houston, United States of America, ⁵MD Anderson Cancer Center, Institute for Personalized Cancer Therapy, Houston, United States of America, ⁶MD Anderson Cancer Center, Dept. of Pathology, Houston, United States of America, ⁷MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America
- *1160 **Perioperative chemotherapy does not improve disease free survival in upper tract urothelial carcinoma: A population based analysis**
By: [Goldberg H.](#), Klaassen Z., Chandrasekar T., Hamilton R., Kulkarni G., Fleshner N.

Institutes:Princess Margaret Hospital, Division of Urology, Department of Surgical Oncology, Toronto, Canada

- *1161 **Association of PD-L1 expression with cancer-specific survival in upper tract urothelial carcinoma**
By: Zhang B.¹, Yu W.¹, Feng X-R.², Zhao Z.¹, Fan Y.¹, Meng Y-S.¹, Hu S.¹, Cui Y.¹, He Q.¹, Zhang H.³, Li D.³, Zhou L-Q.¹, He Z-S.¹, Jin J.¹, Han W-K.¹
Institutes:¹Peking University First Hospital, Dept. of Urology, Beijing, China, ²Peking University First Hospital, Dept. of Geriatrics, Beijing, China, ³Peking University First Hospital, Dept. of Pathology, Beijing, China
- *1162 **Comparing oncological outcomes of laparoscopic versus open nephroureterectomy for the treatment of upper tract urothelial carcinoma: A propensity match analyses**
By: Moschini M.¹, Seisen T.², Roupret M.², Foerster B.¹, Abufaraj M.¹, Colin P.³, De La Taille A.⁴, Peyronnet B.⁵, Bensalah K.⁵, Herout R.⁶, Wirth M.P.⁶, Novotny V.⁶, Czech A.⁷, Bianchi M.⁸, Briganti A.⁹, Romeo G.¹⁰, Simone G.¹⁰, Gallucci M.¹⁰, Matsumoto K.¹¹, Karakiewicz P.¹², Shariat S.¹
Institutes:¹Medical University of Vienna, Dept. of Urology, Vienna, Austria, ²Pitié-Salpêtrière, Assistance-Publique Hôpitaux De Paris, Dept. of Urology, Paris, France, ³Hôpital Privé De La Louvière, Générale De Santé, Dept. of Urology, Lille, France, ⁴Hopital Mondor, Dept. of Urology, Creteil, France, ⁵CHU Rennes, Dept. of Urology, Rennes, France, ⁶Technische Universität Dresden, Dept. of Urology, Dresden, Germany, ⁷Jagiellonian University, Dept. of Urology, Krakow, Germany, ⁸Urological Research Institute, Vita-Salute University, San Raffaele Scientific, Dept. of Urology, Milan, Italy, ⁹Urological Research Institute, Vita-Salute University, San Raffaele Scientific, Dept. of Urology, Milan, Italy, ¹⁰"Regina Elena" National Cancer Institute, Dept. of Urology, Rome, Italy, ¹¹Kitasato University School of Medicine, Dept. of Urology, Kanagawa, Japan, ¹²University of Montreal, Dept. of Urology, Montreal, Canada
- *1164 **Trends of lymphadenectomy in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: The impact of surgical technique**
By: Moschini M.¹, Seisen T.², Roupret M.², Colin P.³, De La Taille A.⁴, Peyronnet B.⁵, Bensalah K.⁵, Foerster B.¹, Herout R.⁶, Abufaraj M.¹, Wirth M.P.⁶, Novotny V.⁶, Chlosta P.⁷, Bandini M.⁸, Briganti A.⁸, Simone G.⁹, Gallucci M.⁹, Romeo G.⁹, Matsumoto K.¹⁰, Karakiewicz P.¹¹, Shariat S.¹
Institutes:¹Medical University of Vienna, Dept. of Urology, Vienna, Austria, ²Pitié-Salpêtrière, Assistance-Publique Hôpitaux, Dept. of Urology, Paris, France, ³Hôpital Privé De La Louvière, Dept. of Urology, Lille, France, ⁴Hopital Mondor, Dept. of Urology, Creteil, France, ⁵CHU Rennes, Dept. of Urology, Rennes, France, ⁶Technische Universität Dresden, Dept. of Urology, Dresden, Germany, ⁷Jagiellonian University, Dept. of Urology, Krakow, Poland, ⁸Vita-Salute University, San Raffaele Scientific, Dept. of Urology, Milan, Italy, ⁹Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ¹⁰Kitasato University School of Medicine, Dept. of Urology, Kanagawa, Japan, ¹¹University of Montreal, Dept. of Urology, Montreal, Canada
- *1165 **Clinical benefit of platinum-based neoadjuvant chemotherapy for locally advanced upper tract urothelial carcinoma**
By: Hatakeyama S., Hosogoe S., Kusaka A., Hamano I., Imai A., Yoneyama T., Hashimoto Y., Koie T., Ohyama C.
Institutes:Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan
- *1166 **Significance of butyrylcholinesterase before chemotherapy as an independent predictor of overall survival in patients with advanced upper-tract urothelial cancer**
By: Yoneyama T., Oikawa M., Hagiwara K., Toshikazu T., Narita T., Imanishi K., Yoneyama T., Mori K., Imai A., Hatakeyama S., Hashimoto Y., Koie T., Ohyama C.
Institutes:Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan
- *1167 **1000 retroperitoneoscopic procedures of the upper urinary tract: analysis of complications**
By: Klap J., Cholley I., Masson-Lecomte A., Defontaine J., Vordos D., Hoznek A., Yiou R., Abbou C-C., De La Taille A., Salomon L.
Institutes:Chu Henri Mondor, Dept. of Urology, Créteil, France
- *1168 **Comparative effectiveness of different surgical approaches for nephro-ureterectomy for the**

treatment of upper tract urothelial carcinoma

By: [Hanna N.](#), Ingham M., Seisen T., Chang S.

Institutes: Brigham and Women's Hospital, Harvard Medical School, Dept. of Urology, Boston, Canada

*1169

Impact of adjuvant chemotherapy in high-risk patients with upper tract urothelial carcinoma treated with radical nephroureterectomy: A multi-institutional retrospective study

By: [Ikeda M.](#)¹, Matsumoto K.¹, Hirayama T.¹, Koguchi D.², Murakami Y.³, Matsuda D.⁴, Okuno N.⁵, Utsunomiya T.³, Taoka Y.², Irie A.⁶, Iwamura M.¹

Institutes:¹Kitasato University School of Medicine, Dept. of Urology, Kanagawa, Japan, ²Kitasato University Medical Center, Dept. of Urology, Saitama, Japan, ³Kanagawa Prefectural Federation of Agricultural Cooperatives For Health and Welfare Sagamihara Kyodo, Dept. of Urology, Kanagawa, Japan, ⁴Higashiyamato Hospital, Dept. of Urology, Tokyo, Japan, ⁵National Hospital Organization Sagamihara Hospital, Dept. of Urology, Kanagawa, Japan, ⁶Kitasato University Kitasato Institute Hospital, Dept. of Urology, Tokyo, Japan

*1170

Ability of early ureteral ligation to prevent intravesical recurrence after radical nephroureterectomy for upper urinary tract urothelial carcinoma: A prospective single-arm multicenter clinical trial

By: [Yamashita S.](#)¹, Ito A.¹, Mitsuzuka M.¹, Aizawa A.², Ioritani N.², Ishidoya S.³, Ikeda Y.⁴, Numahata K.⁵, Orikasa K.⁶, Tochigi T.⁷, Soma F.⁸, Namima T.⁹, Saito H.¹⁰, Sato M.¹¹, Katoh S.¹², Ota S.¹³, Kyan A.¹⁴, Takeda A.¹⁵, Kaiho Y.¹, Arai Y.¹

Institutes:¹Tohoku University Graduate School Of Medicine, Dept. of Urology, Sendai, Japan, ²Japan Community Health Care Organization Sendai Hospital, Dept. of Urology, Sendai, Japan, ³Sendai City Hospital, Dept. of Urology, Sendai, Japan, ⁴Osaki Citizen Hospital, Dept. of Urology, Osaki, Japan, ⁵Yamagata Prefectural Central Hospital, Dept. of Urology, Yamagata, Japan, ⁶Kesenuma City Hospital, Dept. of Urology, Kesenuma, Japan, ⁷Miyagi Cancer Center, Dept. of Urology, Natori, Japan, ⁸Hachinohe City Hospital, Dept. of Urology, Hachinohe, Japan, ⁹Tohoku Rosai Hospital, Dept. of Urology, Sendai, Japan, ¹⁰Sendai Medical Center, Dept. of Urology, Sendai, Japan, ¹¹Senenrifu Hospital, Dept. of Urology, Rifu, Japan, ¹²Ogachi Central Hospital, Dept. of Urology, Yuzawa, Japan, ¹³Japanese Red Cross Sendai Hospital, Dept. of Urology, Sendai, Japan, ¹⁴Shirakawa Kosei General Hospital, Dept. of Urology, Shirakawa, Japan, ¹⁵Iwate Prefectural Iwai Hospital, Dept. of Urology, Ichinoseki, Japan

*1171

Robotic radical nephroureterectomy is associated with poorer oncological outcomes than open and laparoscopic radical nephroureterectomy

By: [Peyronnet B.](#)¹, Brichart N.², Bruyere F.³, Seisen T.⁴, Alimi Q.¹, Vanalderwerelt V.³, Rammal A.², Mathieu R.¹, Tondut L.¹, Pradere B.³, Colin P.⁵, Verhoest G.¹, Roupret M.⁶, Bensalah K.¹

Institutes:¹CHU Rennes, Dept. of Urology, Rennes, France, ²CH Orleans, Dept. of Urology, Orleans, France, ³CHU Tours, Dept. of Urology, Tours, France, ⁴Pitié Salpêtrière Hospital, Dept. of Urology, Paris, France, ⁵CHU Lille, Dept. of Urology, Lille, France, ⁶Pitié Salpêtrière Hospital, Dept. of Urology, Paris, France

Stones

Plenary session 07

Tuesday, 28 March
08:00 - 13:30

Location: eURO Auditorium (Level 0)

Chairs: T. Knoll, Sindelfingen (DE)
A. Stenzl, Tübingen (DE)

Aims and objectives of this presentation

This plenary covers all aspects of urinary stone disease, from epidemiology and pathogenesis to the whole range of interventions. Well-known experts in the field will present what is state-of-the-art and discuss what is on the horizon.

During the plenary sessions, French and Spanish translation will be provided. Please collect your headset in the session room prior to the start of the session and return it after the session.

08:00 - 08:15

State-of-the-art lecture **The Swiss kidney stone cohort: Unraveling the cause of renal stones**
B. Roth, Bern (CH)

08:15 - 08:30

State-of-the-art lecture **Stones and cardiovascular disease: More than a coincidence?**
R.J. Unwin, London (GB)

08:30 - 09:00

Debate **The patient in pain: How to approach the ureteral stone?**

Moderator: T. Knoll, Sindelfingen (DE)

08:30 - 08:35

Emergency ESWL
S. Picozzi, Milan (IT)

08:35 - 08:40

Emergency URS
J. Galan Llopis, Alicante (ES)

08:40 - 08:45

Alpha-blockers
T.B. Lam, Aberdeen (GB)

08:45 - 08:50

Stenting
A.J. Gross, Hamburg (DE)

08:50 - 09:00

Discussion

09:00 - 09:15

Confederación Americana de Urología (CAU) lecture **Percutaneous nephrolithomy in high-volume centers: All lessons learnt?**
J. Gutierrez, Winston Salem (US)

09:15 - 09:45

Debate **Small asymptomatic renal stones: Treat or observe?**

Moderator: O. Traxer, Paris (FR)

09:15 - 09:25

Treat

M. Monga, Cleveland (US)

09:25 - 09:35

Observe

A. Miernik, Freiburg (DE)

09:35 - 09:45

Discussion

10:00 - 10:45

Case discussion Complex cases made simple

Moderator: K. Sarica, Istanbul (TR)

10:00 - 10:45

Case presenter and challenger

P.J.S. Osther, Fredericia (DK)

10:00 - 10:45

Discussants:

M.R. Desai, Naidad (IN)

G. Giusti, Milan (IT)

S. Lahme, Pforzheim (DE)

E. Liatsikos, Patras (GR)

B.W. Turney, Oxford (GB)

10:45 - 11:15

State-of-the-art lectures Urolithiasis 2017: New technology, same old difficulties?

10:45 - 10:52

ESWL

G.G. Tailly, Brasschaat (BE)

10:53 - 11:00

Mini and micro-PNL

U. Nagele, Hall in Tirol (AT)

11:01 - 11:08

Robotic URS

J-T. Klein

11:08 - 11:15

Lasers

P.M. Kronenberg, Lisbon (PT)

11:15 - 11:30

Late breaking news

11:30 - 13:30

Souvenir session By the EAU Scientific Committee
